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ABSTRACT
Regulation of the heterogeneous cell types and mediators that constitute the
immune system is achieved, in part, by the activity of CD4+ T lymphocytes.
Their effector functions are induced following ligation of antigen specific
receptors expressed on the cell surface of the CD4+ T cells by peptides
bound to major histocompatibility complex class II proteins, in conjunction
with costimulatory signals provided by antigen presenting cells. Qualitative
and quantitative differences in CD4+ T cell effector functions allow the
immune system to maintain homeostasis through its ability both to induce
tolerance and promote productive immunity. The failure of CD4+ T cells to
recognise antigen or stimulate inappropriate immune responses also
influences the outcome of immunity, the resolution of inflammation and,
therefore, in some circumstances may compromise the host.
The research reported here investigates the biology and regulation of
CD4+ T cell responses to antigens capable of inducing inflammation of the
respiratory tract. Initially, T cell recognition of the respiratory pathogens,
influenza virus and mycobacteria, is described. CD4+ T cells also contribute
to chronic airway inflammation that occurs in susceptible individuals when
they are exposed to environmental allergens and the characteristics of
allergen reactive T cells are defined for responses to house dust mite derived
allergens. Molecular studies complete the research on T cell antigen
recognition and provide the scientific basis for the development of both in
vitro and in vivo experimental models of CD4+ T cell targeted immunotherapy
which are then described. The observations from this analysis has potential
practical applications in the regulation of allergic inflammation.
In summary, the research reported here explores the biology of CD4+
T cells specific for different antigens associated with respiratory inflammation
and their potential to act as targets in the induction of protective immunity or
the modulation of unwanted immune responses.
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CHAPTER 1
CD4+ T CELL ANTIGEN RECOGNITION
1.1 INTRODUCTION
CD4+ T lymphocytes regulate many aspects of innate immunity, such as
macrophage activation, as well as those of the adaptive immune system, for
example the induction of cytotoxic T cells and the regulation of antibody
synthesis. The research described in this thesis focuses on the
characterisation and regulation of CD4+ T cells activated by stimulation with
different antigens that can lead to inflammation of the airways. As examples
of respiratory pathogens, capable of inducing either acute or chronic
inflammation, CD4+ T cell responses to influenza virus and mycobacteria
were investigated. These findings are compared to the CD4+ T cell
repertoire that is induced following the inhalation of non-pathogenic
environmental antigens, such as allergens derived from house dust mite
(HDM). HDM is the most common source of aeroallergens and causes
symptoms that range from atopic dermatitis and rhinitis to asthma.
Therefore, in light of its clinical importance HDM allergy was selected for
investigation as an example of unwanted chronic immunity generated by
inhaled non-pathogenic antigens.
Collectively influenza, mycobacterial infection and HDM induced
allergic disease, all of which can effect the respiratory tract, constitute a
major global health problem. Through immune regulation in the form of
vaccination the severity of the symptoms caused by these agents may be
reduced or prevented. However, current vaccines for influenza and
mycobacteria need improvement and as an initial step in the design of new
vaccines detailed information on the immune responses against these
pathogens is required. CD4+ T cells play an important role in immunity to
influenza and mycobacterial infection, therefore, detailed analysis of the T
cell repertoire in both individuals with disease and those who are protected
will provide valuable information. As regards HDM induced airway
inflammation CD4+ T (Th2) cells promote specific IgE synthesis and the
differentiation and activation of eosinophils. Thus, the aim of specific
vaccination in this situation is to inhibit the function of Th2 cells that promote
allergic inflammatory responses. Therefore, characterisation of these cells
may contribute to the development of improved allergen immunotherapy.
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In the first section of this chapter T cell recognition of influenza,
mycobacteria and HDM derived antigens in health and disease is
investigated with respect to antigen (sections 1.2.1 to 1.2.3) and MHC class II
restriction (section 1.3) specificity. This is followed in section 1.4 by
publications reporting experiments which were designed to explore the
molecular interactions formed between T cell antigen receptor (TCR), MHC
class II molecules and antigenic peptides or superantigens. The information
obtained from the results of these experiments form, in part, the scientific
basis of the different approaches to immunotherapy specifically designed to
target CD4+ T cells (chapter 2).
1.2 ANALYSIS OF THE ANTIGEN SPECIFICITY OF T CELL RESPONSES
1.2.1 INFLUENZA VIRAL ANTIGENS
1.2.1.1 Introduction
Influenza virus induces acute infection that results in the recruitment
and expansion of both viral specific CD4+ and CD8+ T cells, as well as the
production of neutralising antibodies, which are predominantly directed
against the cell surface glycoprotein, haemagglutinin (HA). CD8+ T cells,
which tend to target cross reactive antigens, such as matrix protein (MP) and
nucleoprotein (NP), also contribute to protection against and recovery from
influenza infection. However, it appears that humoral immunity may play the
more important role in protection and this is illustrated in experimental models
of influenza virus infection where it has been demonstrated that passively
transferred anti-HA antibodies alone can mediate protection. Therefore, in
the analysis of the influenza virus specific CD4+ T cell repertoire reported
here recognition of HA was of particular interest. These studies were
extended to determine the effects of both natural infection and subunit
vaccination on the specificity of the HA reactive T cell repertoire. Although
much emphasis has been placed on HA specific responses CD4+ T cell
recognition of neuraminidase (NA) and the core proteins (MP and NP) was
also investigated .
Lamb JR, Eckels DD, Lake P, Johnson AH, Hartzman RJ, Woody JN:
Antigen specific human T lymphocyte clones: induction, antigen specificity,
and MHC restriction of influenza virus-immune clones. J Immunol 1982,
128:233-238.
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1.2.1.2 Summary
Analysis of the antigen specificity of human CD4+ T cell responses by clonal
analysis in an adult following recent infection with influenza A revealed that
cells reactive with HA, NA, MP and NP were present in the peripheral
repertoire. Of the 11 T cell clones investigated 5 were specific for NA, 4 for
MP, one was specific for NP and one for HA. The HA specific T cells were
subtype specific responding to all the H3N2 influenza viruses tested, whereas
the NA specific cells recognised H3N2 and H2N2 influenza viruses. Analysis
of the MP and NP reactive T cell clones using different viral subtypes
demonstrated that they were broadly cross reactive amongst the influenza A
viruses.
In order to explore the HA reactive human CD4+ T cell repertoire in
greater depth T cell lines and clones were induced with affinity purified H3
and their specificity analysed using different viruses representative of the
different viral subtypes together with synthetic peptides. The results of these
experiments revealed T cell epitopes within residues 1-38, 105-140, 200-228
and 306-318 of HA1 of which 306-318 was immunodominant at least for the
HLA-DR1, 3 haplotype. This latter region is conserved for the H3 subtypes.
Only a single T cell clones was identified that was uniquely specific for H3 of
A/Texas/1/77 the inducing antigen. Other T cells revealed varying levels of
cross reactivity.
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In more recent studies CD4+ T cell recognition of HA from
A/Beijing/32/92 was examined in 3 groups of unrelated adults of different
HLA haplotypes. Those in group 1 were naturally infected with A/Beijing.
Group 2 comprised of subjects with no history of influenza virus infection or
vaccination 4 years prior to the study. The final experimental group
contained individuals that were vaccinated with trivalent influenza subunit
vaccine containing HA from A/Beijing/32/92. Using synthetic peptides
covering the entire HA1 and HA2 subunits the specificity of CD4+ T cell
responses were investigated. Following natural infection T cell responses
are directed towards highly conserved regions, with all subjects responding to
epitopes within sequences 295-328 and 407-442. Vaccination boosted the
response to conserved epitopes and promoted the expansion of cross
reactive T cells. Although T cell recognition of HA epitopes was strongly
influenced by HLA class II the affinity of the binding of particular peptides did
not necessarily mean that these specificites would dominant the T cell
response.
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1.2.2 MYCOBACTERIAL ANTIGENS
1.2.2.1 Introduction
In contrast to influenza, infection with mycobacteria may result in chronic
inflammation that may fail to resolve and one of the primary target organs
affected is the lung. Evidence suggests that immunological protection
against mycobacteria is dependent on the effector function of specific CD4+
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T cells, representative of the Th1 functional phenotype, perhaps with some
contribution from CD8+ T cells. However, it seems that humoral immunity
offers minimal protection if any at all. Therefore, in view of the quantitative
differences in protective immunity to influenza and mycobacterial infection it
was of interest to contrast the nature of CD4+ T cell responses to these
pathogens as regards recognition of specific and/or cross reactive
determinants in their target antigens.
The prinicipal aims of the studies on CD4+ T cell recognition of
mycobacterial components (section 1.2.2) were two fold. Firstly, to determine
if T cells could be identified that recognised antigenic determinants that are
expressed in Mycobacterium tuberculosis and not Mycobacterium bovis
(BCG). Secondly, to explore from the analysis of the pattern of antigen
specific T cell recognition in family contacts and patients with mycobacterial
infection if there was any indication of those antigens that may be associated
with protective immunity or susceptibility to disease. Collectively, this
information might be of value in the design of skin test reagents to distinguish
BCG vaccinated individuals from those with active disease, such as
tuberculosis and contribute to the development of subunit vaccines.
A major hurdle in the analysis of the antigen specificity of T cells
reactive with mycobacterial antigens has been the restricted availability of
antigens in a purified form. The number of proteins in M. tuberculosis that
are potential candidates of T cell recognition is extensive. While the use of
different strains of mycobacteria, affinity purified antigens, recombinant
proteins and peptides synthesized from predicted protein sequences can
provide some information it is limited and allows only a proportion of the T
cell repertoire to be investigated. In order to circumvent this problem a solid-
phase an assay using nitrocellulose immunoblots was developed to screen
fractionated mycobacteria and recombinant libraries. The diversity of CD4+
T cell responses to mycobacterial antigens was explored and the
immunodominance of cross-reactive epitopes established. In addition, it was
observed that several of the antigens that were targets of T cell recognition
were stress proteins, which have human homologues. Cross reactive
immunity to these antigens may provide a link between infectious and
autoimmune diseases.
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1.2.2.2 Summary
From analysis of polyclonal T cell populations and T cell clones it appeared
that the major component of the human CD4+ T cell repertoire was cross
reactive recognising antigens that are present in M. tuberculosis, M. bovis
BCG and other strains of mycobacteria. Where possible, T cell recognition
was further examined at the epitope level using the combination of truncated
recombinant proteins and synthetic peptides. Several of the target antigens
of T cell responses induced by mycobacteria are common bacterial proteins,
for example the 65 kDa heat shock protein. There are vertebrate homologues
of bacterial heat shock proteins. Thus, interest was generated in the
possiblity that expression of human heat shock proteins, following trauma or
cell death, may reactivate T cells initially primed with mycobacterial heat
shock proteins. A theoretical consequence of this T cell cross reactivity is
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the potential to induce or exacerbate autoimmune diseases, such as
rheumatoid arthritis. However, rather than being the direct cause of specific
autoimmune immune diseases it is likely that these cross reactive immune
responses are present as a non-specific component characteristic of chronic
inflammation in general.
Despite the molecular and serological definition of a variety of
mycobacterial proteins, many remain that are uncharacterised and could be
targets of the T cell response. In order to investigate this component of the
repertoire mycobacterial antigens were fractionated, immunoblotted and used
in solid-phase assays to analyse the antigen specificity of T cell responses.
Using this approach an antigen in the molecular weight region of 52-55 kDa,
which was distinct from known monoclonal antibody defined antigens, was
identified as a T cell target. The antigen was present in M. tuberculosis but
not M.bovis BCG. This technique was applied to the analysis of T cell
repertoire reactive with M. leprae and M. tuberculosis in family contacts and
patients with leprosy and provided a lead for the identification of
immunodominant antigens. Although the pattern of T cell recognition was
complex and influenced by HLA haplotypes, again there was evidence to
suggest that distinct epitopes present in different strains of mycobacteria are
recognised by T cells. Nevertheless, the major component of the T cell
repertoire in the patients and control subjects was cross-reactive. With
technical advances the molecular characterisation of strain specific T
epitopes is becoming easier to realise and, therefore, more candidate
vaccines will become available for evaluation.
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1.2.3 HOUSE DUST MITE DERIVED ALLERGENS
1.2.3.1 Introduction
The inhalation of non-pathogenic environmental antigens has opposing
immunological outcomes in individuals who are susceptible to allergen
induced respiratory inflammation and those who are not. In the latter
population inhaled antigen does not prime productive immunity but on the
contrary induces non-responsiveness. In those individuals who suffer from
allergic disease of the airways a hallmark of inflammation is the presence of
CD4+ T cells expressing a Th2-dominant cytokine profile, the infiltration of
eosinophils and, in many instances, the production of specific IgE antibodies.
It is believed that eosinophils contribute to airway hyperresponsiveness in
asthma through epithelial damage mediated by basic granule proteins, and
that similar mechanisms may also contribute to upper airway inflammation in
rhinitis. The induction of IgE and the recruitment of eosinophils are mediated
by CD4+ T cells. A primary step in the development of CD4+ targeted
immunotherapy for HDM induced allergy is to characterise the allergen
specific T cell repertoire. Here, the specificity and biological activity of T cells
reactive with HDM derived allergens were investigated for polyclonal and
monoclonal cell populations as an example of chronic inflammatory disease.
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1.2.3.2 Summary
Analysis of antigen specificity revealed that human CD4+ T cell responses to
influenza virus and mycobacteria are predominantly cross reactive amongst
different strains of the respective pathogens. Cross reactivity may occur as
the result of repeated exposure leading to the selection of particular epitopes
that may be more abundant, processed more efficiently or bind to MHC class
II with higher affinity. Alternatively, it may arise from recognition of common
antigens that are present in different microorganisms.
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The situation is different for T cell responses to HDM derived allergens
in allergic individuals. Although there is extensive cross reactivity of
antibodies for the different species of HDM, the T cell repertoire was specific
for only the inducing species despite extensive sequence homology. The
studies were extended and epitope maps were generated for T cell
responses to the group 1 (Der p 1) and 2 (Der p 2) allergens of
Dermatophagoides pteronyssinus. From the results of experiments using
overlapping peptides to examine polyclonal T cell responses to Der p 2 it
appeared that for individual donors multiple epitopes were recognised,
although selected regions of the protein were immunodominant. There was
no evidence to suggest that particular epitopes were associated with T cell
responses observed only in atopic individuals and it appeared that epitope
recognition reflected MHC haplotype rather than disease status.
Furthermore, the functional phenotype of the T cell repertoire in atopics was
that of Th2/Th0 cells and for non-atopics, who also are capable of mounting
T cell responses to HDM derived allergens, the Th1/Th0 phenotype was
dominant. Human CD4+ T cell responses to Der p 1 were directed primarily
towards epitopes located within the region 100-130, although other amino
and carboxyl terminal regions were also immunogenic. These observations
have bearing on the potential of peptide based immunotherapy for HDM
induced allergic diseases at the population level. However, analysis of
peripheral TCR repertoire within the same HDM atopic individual over a
period spanning 6 years revealed that Va8 and Vp3 sequences were
dominant and that identical junctional regions were present implying that
chronic allergen exposure selects for long-lived T cell clones in vivo.
H-2b (C57BL/6J) mice are high responders to Der p 1 and, although,
the region 110-130 contains the immunodominant determinants, responses to
minor epitopes (residues 15-29, 81-102 and 197-212) were also observed.
The ability of Der p 1 to induce CD4+ T cells that proliferate to residues 15-
29 ( p1, 15-29) of Der p 1 and to the murine MHC class ll-associated
invariant chain derived peptide (CLIP) was demonstrated. In the absence of
p 1, 15-29 or exogenously added CLIP, T cells from Der p 1 primed mice
could be expanded on wild type H-2b spleen cells and they retained
specificity for both p 1, 15-25 and CLIP. This finding implies that naturally
presented self peptides may maintain T cell memory to foreign antigens and
in the case of HDM allergen contribute to the chronicity of the disease.
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Chronic exposure to HDM induces a long-lived stable population of
CD4+T cells that is largely species specific and not cross reactive which is in
contrast to the human T cell repertoires reactive with either influenza or
mycobacterial antigens.
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1.3 ANALYSIS OF RESTRICTION SPECIFICITY BY MAJOR
HISTOCOMPATIBILITY COMPLEX CLASS II PROTEINS
1.3.1 Introduction
Activation of CD4+ T cells depends upon the interaction of TCR with
complexes formed by peptides bound to class II MHC proteins expressed on
the surface of APCs. The recognition of these complexes is both restricted
to particular MHC class II molecules and specific for a limited number of
pepides. The experiments described here were designed to examine the
restriction specificity of human CD4+ T cell recognition of influenza,
mycobateria and HDM derived antigens. The practical application of this
information would be in the development of subunit vaccines.
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1.3.2. Summary
For T cell responses to influenza it was demonstrated that DRB1 gene
products were the most frequently used restriction elements in the
recognition of HA, NA, MP and NP. Similarly CD4+ T cell responses to
mycobacterial antigens were restricted most commonly by HLA-DR
molecules. Nevertheless, rare examples of influenza specific T cells
restricted by DQ and DP were recorded. Peptide/ MHC class II protein
interactions have a strong influence on the specificity of T cell responses.
However, by analysing in parallel the class II binding affinity of HA peptides
with immunodominance at the level of T cell proliferation it was apparent that
there is not always a direct relationship. These findings suggest that antigen
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processing, intracellular competition for HLA binding, the TCR repertoire and
perhaps the level of antigen exposure may all determine immunodominance.
Extensive heterogeneity in the HLA class II restriction elements used
by T cells for the recognition of HDM derived allergens was observed. In
addition to DRB1, it was apparent that DRB3 gene products were also
functional. Likewise, HDM specific T cell recognition restricted by HLA-DP
and -DQ molecules was observed. Furthermore, there were examples of T
cell restriction of a single T cell epitope by either HLA-DR or -DQ in the same
individual. These observations may help to explain why it has proven
difficult to establish HLA class II disease associations for HDM allergy.
However, the practical advantage of promiscuity of HDM peptide binding
when paralleled with immunodominance of the T cell response is in the
design of subunit (peptide) vaccines.
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1.4 MOLECULAR INTERACTIONS BETWEEN TCR, MHC CLASS II AND
PEPTIDE OR SUPERANTIGEN MOLECULES
1.4.1 Introduction
Knowledge of the structural basis of the interactions formed between TCR,
MHC class II, peptide or superantigen molecules has the potential to facilitate
the enhancement, abrogation or selective modulation of T cell activation and
effector function. This premise underlies the experiments described in the
publications included in this section of the thesis. Much of the work reported
here has focused on the interaction of the influenza HA peptide 306-318 with
HLA-DRB1*0101 (DR1) which is recognised by the CD4+ T cell clone HA1.7.
By the introduction of structural changes in the peptide ligand through amino
acid substitutions and in MHC class II and TCR by site directed mutagenesis
the nature of the interactions between these molecules has been
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investigated. The subsequent resolution of the three dimensional structure of
DR1/306-318 and DR1/SEB complexes by crystallography has helped in the
interpretation of the results reported here which were derived from the
combination of functional and cell surface binding assays.
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1.4.2 Summary
The first approach used to probe the interactions between peptide and MHC
class II molecules was based on analysing the effect of structural
modification of the peptide ligand. In brief, this was achieved in several
ways. Firstly, by synthesizing peptides truncated from the amino and
carboxyl terminal ends. Secondly, by generating hybrid peptides formed by
exchanging residues between two DR1 restricted epitopes (HA and MP) and
determing the effects on the proliferative response of MP and HA specific T
cell clones. Thirdly, by introducing single amino acid substitutions, radical
and conservative, sequentially at each position and investigating the effect on
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the ability of the peptide analogues both to bind to cell surface expressed
MHC class II molecules and to induce T cell proliferation.
The existence of natural polymorphisms affecting a single or limited
number of amino acids at known locations within MHC class II proteins, for
example subtypes of DR4, allowed the role of residues at defined positions in
T cell recognition to be investigated. Alternatively, substitutions can be made
at selected residues by site directed mutagenesis and the mutant MHC class
II molecules expressed in murine fibroblasts and their function determined. It
is also possible to mutate residues at selected positions in the a and p chains
of TCR and evaluate whether or not those changes abrogate or enhance
antigen recognition. The TCR-a chain of cloned T cells reactive with the HA
peptide 307-319 was mutated with E at position 94 substitued by A or K and
both of these changes resulted in a loss antigen recognition. From molecular
modelling it was predicted that TCR-a E94 would contact 316K in the HA
peptide, however peptide analogues in which the residue at this position had
been substituted failed to restore responsiveness. Thus, using a combination
of technical approaches, it was possible to define residues within peptide,
MHC class II and TCR molecules that influence antigen recognition.
Superantigens are presented by MHC class II proteins and although
their recognition by T cells exhibits some degree of allele specificity they are
not genetically restricted in the same way as conventional antigenic peptides.
They stimulate T cells in an oligoclonal manner that is dependent on the
expression of particular variable region gene elements in the TCR-p chain
(Vp). The possibility that T cell responses in certain diseases are associated
with the expansion of particular TCR-Vp families has attracted much
attention. The potential to specifically regulate such "disease associated" T
cell populations prompted the analysis of superantigen interactions with TCR
and class II MHC proteins. The principal finding of this analysis was that
unlike conventional peptides superantigens can form complexes with TCR in
both the presence and absence of class II MHC molecules.
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CHAPTER 2
MODULATION OF CD4+ T RESPONSES
2.1 INTRODUCTION
In this chapter the focus is on CD4+ T cell targeted immunotherapy in the
regulation of unwanted immune responses to inhaled non-pathogenic
environmental antigens. Antigen independent adhesion between APCs and
T cells is the primary event in CD4+ T cell activation and, therefore, the
ability to disrupt this union may facilitate the inhibition of T cell responses. In
the first section of the chapter experiments are performed to determine if the
activation of HDM reactive ThO, Th1 and Th2 cells exhibit the same
dependence on the functional activity provided by LFA-1 and CD4.
The initial interaction between T cells and APCs is followed by ligation
of the TCR by complexes of antigenic peptides bound to class II MHC
molecules expressed on the surface of APCs. Antigenic peptides are
generated as the result of the processing of intact proteins, nevertheless,
soluble peptides are able to bind directly to a small fraction of empty class II
MHC molecules present on the cell surface. In principle, this subset of class
II molecules is a possible target for immunotherapy since they can be used to
present peptides delivered exogenously. Non-stimulatory peptides could
potentially be used as antagonists to compete with the binding of "disease
associated" T cell epitopes to cell surface class II MHC on the APCs. The
potential of peptide competition at the level of antigen presentation to inhibit
polyclonal and and clonal T cell responses to HDM derived allergens was
investigated.
Subtle structural changes in antigenic peptides by the introduction of
conservative amino acid substitutions can result in the generation of ligands
which act as partial agonists. Peptides analogues with these characteristics
are termed altered TCR ligands and, through their ability to differentially
signal via the TCR, are capable of inducing selective T cell effector functions.
The effects of altered TCR ligands on proliferation and cytokine production by
HDM specific T cells was the principle focus of section 2.3.2 in chapter 2.
Ligation of the TCR by MHC class li/peptide complexes alone is
insufficient to drive clonal expansion and additional costimulatory signals are
required. To date it appears that the interaction of the B7 family of ligands
(CD80 and CD86) with their receptors CD28 and CTLA-4 provides
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costimulation. The presentation of antigen in the absence of costimuiation
leads to the induction of anergy and here an experimental model for the
analysis of T cell anergy in vitro in human CD4+ T cells is described. The
principal observation is that following exposure to a supraoptimal
concentration of peptide in the absence of APCs T cells fail to respond to
antigenic restimulation but remain responsive to exogenous IL-2. This basic
finding is extended and questions are addressed which include the influence
of antigen structure on tolerance induction as well as transcriptional
regulation and phenotypic modulation in anergic T cells. The information that
can be obtained from in vitro models has obvious limitations, therefore, the
ability of allergen derivatives to modulate specific immune responsiveness
was analysed in vivo in a mouse model of HDM induced immunity. The
observation that inhalation of the immunodominant peptide of Der p 1
induces tolerance that can be transferred by CD4+ T cells prompted the
analysis of regulatory (inhibitory) T cells (section 2.4).
Presentation of allergen under conditions that promote Th1-dominant
immune responses offers an alternative to the induction of T cell tolerance for
downregulating Th2 cytokine mediated immunity. In the final section the
ability of different antigen delivery systems for HDM allergens and their
effects on the qualitative nature of allergen immunity are investigated.
2.2 MODULATION OF ACCESSORY/CO-RECEPTOR MOLECULES
2.2.1 Introduction
The adhesion molecule LFA-1 and the coreceptor CD4 both enhance
adhesion between and contribute to T cell activation. Antibodies against
LFA-1 and CD4 can inhibit responses and, furthermore, the administration of
non-depleting anti-CD4 antibodies in the presence of specific antigen leads to
the induction of long-lasting T cell tolerance. There is some evidence that
this phenomenon results in a "reprogramming" of the immune response
mediated by the production of inhibitory and/or Th2 cytokines. The
experiments reported here were designed to determine if the dependence of
HDM specific Th2 cells on the costimulatory/coreceptor properties of LFA-1
and CD4 was different to that of ThO and Th1 cells.
Faith A, Higgins JA, O'Hehir RE, Lamb JR: Differential dependence of ThO,
Th1 and Th2 CD4+ T cells on co-stimulatory activity provided by accessory
molecule LFA-1. Clin Exp Allergy 1995, 25:1163-1170.
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Lamb JR, Faith A, Higgins JA, Verhoef A, Schneider P, Yssel H, O'Hehir RE:
Clonal analysis of CD4 mediated accessory function on the effector activity of
human CD4+ T cell subsets. Clin Exp Allergy 1995, 25:839-847.
2.2.2 Summary
Human Th2 cells exhibited a greater requirement for the costimulatory activity
of LFA-1 than either ThO or Th1 cells. Similarly, functional modulation by
anti-CD4 antibodies has different effects the various functional subsets of
CD4+ T cells. Antigen induced IL-4 production was more resistant than IFN-y
to inhibition by anti-CD4 antibodies and certain antibodies were able to
dissociate IFN-y and IL-4 production and could inhibit IFN-y without blocking
antigen dependent proliferation. No evidence was obtained from these in
vitro studies to suggest that anti-CD4 antibodies were able to induce T cell
anergy.
2.2.3 Related publications
Faith A, O'Hehir RE, Malkovsky M, Lamb JR: Analysis of the basis of
resistance and susceptibility of CD4+ T cells to HIV-gp120 induced anergy.
Immunology 1992, 76:1-8.
Faith A, O'Hehir RE, Yssel H, Lamb JR: Reversal of the inhibitory effects of
HIV-gp120 on CD4+ T cells by stimulation through the CD28 pathway. Clin
Exp Immunol 1996, 105:225-230.
2.3 ANTIGEN MEDIATED MODULATION OF T CELL FUNCTION
2.3.1 INHIBITION OF T CELL PROLIFERATION
2.3.1.1 Introduction
The ability of certain peptides to bind with high affinity to selected class II
MHC molecules has drawn attention to their potential to inhibit the
presentation of "disease associated" epitopes. Competitor peptides can
prevent experimental autoimmune encephalomyelitis (EAE) triggered by
immunisation with myelin basic protein. Furthermore, in EAE it has been
reported that T cells capable of mediating the disease have restricted TCR
usage and that peptides derived from the CDR2 domain of the appropriate
TCR-Vp gene segment can prevent the induction and progression of disease.
However, whether this treatment is effective in the human disease (multiple
sclerosis) is not clear. Here the results of experiments are reported in which
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both competitor peptides and TCR-Vp derived peptides were investigated for
their ability to inhibit the in vitro response of human CD4+ T cells from atopic
and non-atopic individuals to HDM.
O'Hehir RE, Busch R, Rothbard JB, Lamb JR: An in vitro model of peptide-
mediated immunomodulation of the human T cell response to
Dermatophagoides spp. (house dust mite). J Allergy Clin Immunol 1991,
87:1120-1127.
Hawrylowicz CM, Jarman ER, Guida L, O'Hehir RE, Lamb JR: T-cell receptor
peptides that inhibit the T-cell response to allergen induce transforming
growth factor-pi production. J Allergy Clin Immunol 1996, 97:707-709.
2.3.1.2 Summary
In the first of the two papers presented here peptide competition at the level
of MHC class II was investigated. An analogue of the influenza HA peptide
(HA 307-319) with 309Y replaced by S was non-stimulatory in polyclonal T
cell cultures and inhibited the proliferation of DRB1 and DRB3 restricted HDM
specific T cell clones. Furthermore, the analogue downregulated polyclonal T
cell responses induced by HDM but not other recall antigens.
From the analysis of TCR usage in HDM allergy a peptide based on the
CDR2 of Vp3 (see section 1.2.3.2) was synthesized and demonstrated to
inhibit HDM induced polyclonal T cell responses. T cell responses to
mycobacterial antigens were unaffected by the addition of the peptide.
While these approaches are of theoretical interest it is unlikely that
they will have any practical application in allergen immunotherapy.
2.3.1.3 Related publications
Eckels DD, Gorski J, Rothbard JB, Lamb JR: Peptide mediated modulation of
T cell allorecognition. Proc Natl Acad Sci USA 1988, 85:8191-8195.
2.3.2. ALTERED T CELL RECEPTOR LIGANDS
2.3,2.1 Introduction
Generating peptide analogues with partial agonist activity in that they induce
only selected T cell effector functions, for example cytokine production in the
absence of proliferation, can be achieved by the substitution of conservative
amino acids. The substitution of residues that make contact with either TCR
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or MHC class II have been associated with the modulation of T cell effector
function. ThO cells are a marked component of the allergen specific T cell
repertoire in allergic as well as normal individuals. Thus, the capacity to
signal allergen specific ThO cells to promote the production of IFN-y and not
Th2 cytokines may contribute to the downregulation of allergic inflammation.
In the experiments reported here the ability of altered TCR ligands to
modulate cytokine production by human ThO cells was investigated in
different antigen systems.
Tsitoura DC, Verhoef A, Gelder CM, O'Hehir RE, Lamb JR: Altered T cell
ligands derived from a major house dust mite allergen enhance IFN-y but not
IL-4 production by human CD4+ T cells. J Immunol 1996, 157:2160-2165.
Tsitoura DC, Gelder CM, Kemeny DM, Lamb JR: Regulation of cytokine
production by human ThO cells following stimulation with peptide analogues:
differential expression of TGF-p in activation and anergy. Immunology 1997,
92:10-19.
2.3.2.2 Summary
In the first of the papers, analogues of an immunodominant epitope of Der p
2, residues 28-40 were synthesized with sequential alanine substitutions and
their effect on proliferation and cytokine production evaluated for both ThO
and Th2 cells. Certain analogues could dissociate proliferation from IL-4
production by Th2 cells. There were examples in which analogues could
inhibit proliferation and cytokine production by ThO cells. The p 2, 28-40
peptide analogues with A at positions 34 and 36 altered the IFN-y:IL-4 ratio of
ThO cells by selectively enhancing IFN-y secretion.
In addition to promoting Th1 cytokine production there is evidence to
suggest that altered TCR ligands may selectively induce the synthesis of
inhibitory cytokines. The second paper in this section addressed this issue.
It was observed for human ThO cells reactive with HA306-318 that certain
amino acid substitutions, which failed to induce proliferation, stimulated TGF-
P production. At present no in vivo studies in experimental models have
been carried out in order to establish if altered TCR ligands can modulate




Lamb JR, Higgins JA, Hetzel C, Hayball JD, Lake RA, O'Hehir RE: The
effects of changes at peptide residues contacting MHC class II or TcR on
antigen recognition and human ThO cell effector function. Immunology 1995,
85:447-455.
2.3.3 ANALYSIS OF IN VITRO ANTIGEN-INDUCED SPECIFIC ANERGY
2.3.3.1 Introduction
The clonal distribution of antigen specific receptors on lymphocytes offers the
potential to tolerise selected population of cells. A principal aim of specific
immunotherapy is to vaccinate with allergen or its derivatives under
conditions that will inhibit the allergen specific response leaving the
remainder of the immune system functionally intact. With this in mind an in
vitro model using human CD4+ T cells was developed to investigate
protocols for inducing antigen specific unresponsiveness. In this section of
thesis, following the description of the model, characterisation of the cellular
and molecular basis of T cell anergy is reported. The influence of ligand
structure and the requirement for class II MHC was investigated for anergy
mediated by conventional peptide antigens and bacterial superantigens. The
effects of anergy on the expression of T cell surface proteins and the
modulation of the functional phenotype, namely cytokine production are
reported. The final three papers report on biochemical changes and
transcriptional regulation in T cell anergy.
Lamb JR, Skidmore BJ, Green N, Chiller J, Feldmann M: Induction of
tolerance in influenza virus-immune T lymphocyte clones with synthetic
peptides of influenza haemagglutinin. J Exp Med 1983, 157:1434-1447.
Tsitoura DC, Holter W, Cerwenka A, Gelder CM, Lamb JR: The induction of
anergy in human ThO cells by stimulation with altered T cell antigen receptor
ligands. J Immunol 1996, 156:2801-2808.
O'Hehir RE, Lamb JR: Induction of specific clonal anergy in human T
lymphocytes by Staphylococcus aureus enterotoxins. Proc Natl Acad Sci
USA 1990, 87:8884-8888.
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Lamb JR, Feldmann M: Essential requirement for major histocompatibility
complex recognition of T-cell tolerance induction. Nature 1984, 308:72-74.
Higgins JA, Lamb JR, Hayball JD, Marsh S, Tonks S, Rosen-Bronson S,
Bodmer JA, O'Hehir RE: Peptide-induced non-responsiveness of HLA-DP
restricted human T cells with Dermatophagoides spp. (house dust mite). J
Allergy Clin Immunol 1992, 90:749-756.
Hewitt CRA, Lamb JR, Hayball J, Hill M, Owen MJ, O'Hehir RE: MHC
independent clonal T cell anergy by direct interaction of Staphylococcus
aureus enterotoxin B with the T cell antigen receptor. J Exp Med 1992,
175:1493-1501.
Zanders ED, Lamb JR, Feldmann M, Green N, Beverley PCL: Tolerance of
T-cell clones is associated with membrane antigen changes. Nature 1983,
303:625-627.
Lamb JR, Zanders ED, Sewell W, Crumpton MJ, Feldmann M, Owen MJ:
Antigen-specific T cell unresponsiveness in cloned helper T cells mediated
via the CD2 or CD3/Ti receptor pathways. Eur J Immunol 1987, 17:1641-
1644.
O'Hehir RE, Yssel H, Verma S, de Vries JE, Spits H, Lamb JR: Clonal
analysis of differential lymphokine production in peptide and superantigen
induced T cell anergy. Int Immunol 1991, 3:819-826.
Schall TJ, O'Hehir RE, Goeddel DV, Lamb JR: Uncoupling of cytokine mRNA
expression and protein secretion during the induction phase of T cell anergy.
J Immunol 1992, 148:381-387.
Essery G, Feldmann M, Lamb JR: lnterleukin-2 can prevent and reverse
antigen-induced unresponsiveness in cloned T lymphocytes. Immunology
1988, 64:413-417.
Lake RA, O'Hehir RE, Verhoef A, Lamb JR: CD28 mRNA rapidly decays
when activated T cells are functionally anergized with specific peptide. Int
Immunol 1993, 5:461-466.
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Zanders ED, Feldmann M, Lamb JR: Biochemical events initiated by
exposure of human T lymphocyte clones to immunogenic and tolerogenic
concentrations of antigen. Eur J Immunol 1985, 15:302-305.
Wotton D, Higgins JA, O'Hehir RE, Lamb JR, Lake RA: Differential induction
of NF-AT complex during restimulation and induction of T-cell anergy. Human
Immunol 1995, 42:95-102.
2,3.2.2 Summary
Following exposure to supraimmunogenic concentrations of peptide in the
presence and absence of APCs human cloned CD4+ T cells become
unresponsive to antigenic restimulation and fail to prolferate or provide B cell
help. The loss proliferation is not due to cell death since the T cells remain
responsive to exogneous IL-2 after peptide treatment. The induction of
anergy can be blocked with anti-MHC class II antibodies confirming the
requirement for MHC class II dependent antigen recognition. This
observation suggested that peptide may bind initially to class II MHC and
then is presented to surrounding T cells of the same specificity and in the
absence of the appropriate costimulatory signals induces unresponsiveness.
In contrast, superantigen mediated anergy is independent of MHC binding
and occurs through direct interaction with the TCR but mediates the same
functional outcome.
The induction of anergy was associated with complex changes in the
cell surface phenotype, most notably TCR and CD28 were downregulated,
whereas CD25 and CTLA-4 were upregulated. No change in the expression
of CD40L, CD80 or CD86 was observed. As regards changes in the
functional phenotype these are also complex. Based on the measurement of
cytokine specific transcripts in T cells undergoing activation, tolerance or that
were in a resting state it appeared that hyperresponsiveness precedes the
induction of anergy. However, release of the soluble protein did not always
parallel mRNA levels and this was well illustrated from the analysis of IL-8
production. These experiments were extended and the production of
cytokines was analysed when T cells pretreated with anergising
concentrations were rechallenged with antigen and APCs. In this situation
the synthesis of the majority of the cytokines analysed was inhibited with the
exception of IFN-y, TGF-|3 and IL-10. Although the immunosuppressive
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activity of TGF-p and IL-10 could account for the functional inhibition
observed, however, it appears that their production alone is not sufficient and
cell contact was also required.
CD28 transduces an efficient costimulatory signal for the activation of
T cells and in the absence of which ligation of TCR by peptide/MHC class II
complexes results in anergy. In addition, CD28 expression is differentially
regulated during activation and the induction of anergy. The induction of
anergy in resting and fully activated CD4+ T cells was accompanied by a
profound down regulation of mRNA and surface expression of CD28. The
ligation of CD28 affects IL-2 synthesis by the generation of a nuclear factor
complex, CD28RC, that increases transcription from the IL-2 gene promoter.
The modulation of this and other selected transcription factors that regulate
expression of the TCR-p chain and IL-2 genes during the induction of anergy
and restimulation of anergic T cells was investigated. The results of these
experiments revealed that NF-AT was markedly lower in anergic than
activated cells, however, this may be a consequence of reduced calcium
signalling.
2.3.2.3 Related publications
Zanders ED, Feldmann M, Green N, Lamb JR: Direct evaluation of antigen
binding to human T lymphocyte clones: involvement of major
histocompatibility complex products in antigen binding. Eur J Immunol 1984,
14:1101-1105.
Lamb JR, Feldmann M, Green N, Lerner RA: Influence of antigen structure
on the activation and induction of unresponsiveness in cloned human T
lymphocytes. Immunology 1986, 57:331-335.
Bal A, Mclndoe A, Denton G, Hudson D, Lombardi G, Lamb JR, Lechler R:
Antigen presentation by keratinocytes induces tolerance in human T cells.
Eur J Immunol 1990, 20:1893-1899.
O'Hehir RE, Aguilar BA, Schmidt TJ, Gollnick SO, Lamb JR: Functional
inactivation of Dermatophagoides spp. (house dust mite) reactive T cell
clones. Clin Exp Allergy 1991, 21: 209-215.
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Yssel H, Faster S, Lamb JR, de Vries JE: Induction of non-responsiveness in
human allergen specific Th2 cells. CurrOpin Immunol 1994, 6:847-852.
O'Hehir RE, Lake RA, Schall TJ, Yssel H, Panagiotopolou E, Lamb JR:
Regulation of cytokine and chemokine transcription in human Th2 cells
during the induction phase of anergy. Clin Exp Allergy 1996, 26:20-28.
Holan V, Lamb JR, Malkovsky M: Immunological tolerance and lymphokines.
CRC Crit Rev Immunol 1991, 10:481-493.
2.3.4 INDUCTION OF PERIPHERAL TOLERANCE IN VIVO
2.3.4.1 Introduction
Although in vitro models are useful in the analysis of T cell unresponsiveness
they have obvious limitations and, therefore, the tolerogenic activity of
peptides was investigated in vivo in a murine model of specific immunity to
HDM.
Analysis of responses to Der p 1 revealed that H-2b mice were high
responders with the immunodominant T cell epitope contained within
residues 110-131 (p 1, 110-131). Weaker responses were observed to the
sequences 15-29, 81-102 and 197-212, which were termed minor
determinants. The ability of peptides to induce peripheral T cell tolerance
following intranasal administration was investigated and papers that describe
the cellular characterisation and address the molecular mechanisms of
tolerance are included. The final paper in the section reports a clinical study
in which the effect of grass pollen immunotherapy on proliferative responses
and IL-5 cytokine production was examined to examine whether or not
tolerance and/or immune reprogramming contributed to successful
immunotherapy.
Hoyne G, O'Hehir RE, Wraith DG, Thomas WR, Lamb JR: Inhibition of T cell
and antibody responses to house dust mite allergen by inhalation of the
dominant T cell epitope in naive and sensitized mice. J Exp Med 1993,
178:1783-1788.
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Hoyne GF, Askonas BA, Hetzel C, Thomas WR, Lamb JR: Regulation of
house dust mite responses by intranasaily administered peptide: transient
activation of CD4+ T cells precedes the development of tolerance in vivo. Int
Immunol 1996, 8:335-342.
Hoyne GF, Jarnicki AG, Thomas WR, Lamb JR: Characterisation of the
specificity and duration of T cell tolerance to intranasaily administered
peptides in mice: a role for intramolecular epitope suppression. Int Immunol
1997, 9:1165-1173.
Till S, Walker S, Dickason R, Huston D, O' Brien F, Lamb J, Kay AB,
Corrigan C, Durham S: lnterleukin-5 production by allergen-stimulated T cells
following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp
Immunol 1997, 110:114-121.
2.3.4.2 Summary
The intranasal administration of the immunodominant peptide p 1, 110-131 in
H-2b mice induced profound antigen specific peripheral T cell tolerance that
was long-lasting. There was a reduction in all T cell derived cytokines and
modulation of delayed type hypersensitivity in the tolerant mice. Tolerance to
p 1, 110-131 inhibited the response of T cells reactive with all epitopes on
Der p 1 provided that tolerant mice were immunised with the intact protein.
This phenomenon is termed linked suppression has been described for other
models of peripheral tolerance to transplantation and self-antigens. The
nature of the signals that mediate linked suppression and are poorly
understood and it has been proposed that it arises from antigen dependent
production of inhibitory cytokines derived from regulatory T cells that
suppress the response of naive T cells. However, T cells isolated from
tolerant mice failed to produce immunosuppressive cytokines when
restimulated with antigen in vitro suggesting that linked suppression is
mediated through an alternative mechanism, perhaps involving direct cell
contact (see section 2.4). Serological inhibition in vitro, the induction of
tolerance in CD8 gene deficient mice together with the ability of CD4+ T cells
to transfer the effect to naive recipients all imply that regulatory cells were
induced and that the phenomenon of linked suppression was mediated by a
subset of CD4+ T cells.
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There are two additional aspects of this model of peptide mediated
tolerance induced via the mucosa of the airways that warrant comment in the
context of clinical immunotherapy. Firstly, transient T cell activation occurs
before tolerance develops. Secondly, T cells from tolerant mice were unable
to support HDM specific antibody production in vitro cultures of T cells,
however, in vivo IgE responses were unaffected. Several clinical trials of
allergen immunotherapy have demonstrated that specific IgE is elevated at
the start of therapy but may remain at relatively high levels even though the
patients report an improvement in symptoms.
In the clinical study reported here it was observed that grass pollen
immunotherapy in patients who had received 6 to 7 years of continuous
conventional immunotherapy or had received 3 to 4 years of conventional
immunotherapy followed by 3 years of placebo treatment abogated the
cutaneous late phase responses. However, this was not accompanied by a
reduction in IL-5 production or proliferation by peripheral blood mononuclear
cells (PBMCs), neither was IFN-y synthesis enhanced. Thus, clinical efficacy
of immunotherapy may require only modulation of the local Th2 immunity.
2.3.3,3 Related publications
Hoyne GF, Kristensen NM, Yssel H, Lamb JR: Peptide modulation of allergen
specific immune responses. CurrOpin Immunol 1995, 7:757-761.
2.3.4 INDUCTION OF REGULATORY (INHIBITORY) CELLS
2.3.4,1 Introduction
Understanding the mechanisms of peripheral tolerance to inhaled antigens
has attracted attention in respect to defining and regulating chronic
respiratory inflammation. It now appears that regulatory (inhibitory) cells may
contribute to the induction immunological tolerance in the airways. The
phenotype of these cells is controversial. In some reports the inhibition is
mediated by CD8+ T cells, expressing either a,p or y8 TCR, whereas in others
the regulatory cells are a subset of CD4+ cells.
Here two sets of studies are described. In the first with human
PBMCs as responder cells and autologous cloned T cells as stimulator cells
regulatory cells were isolated and characterised. In addition, human PBMCs
from atopic and non-atopic individuals were stimulated with TCR-Vp CDR2
derived peptides (see section 2.3.1). The second study focuses on the in
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vivo selection of regulatory CD4+ T cells induced in mice rendered tolerant
to Der p 1 by intranasal delivery of peptides (see section 2.3.3).
Lamb JR, Feldmann M: A human suppressor T cell clones which recognizes
an autologous helper T cell clone. Nature 1982, 300:456-458.
Jarman ER, Hawrylowicz CM, Panagiotopolou E, O'Hehir ER, Lamb JR:
Inhibition of human T-cell responses to house dust mite allergens by a T-cell
receptor peptide. J Allergy Clin Immunol 1994, 94:844-852.
Hoyne GF, Dallman MJ, Lamb JR: Linked suppression in peripheral T cell
tolerance to the house dust mite derived allergen Der p 1. Int Arch Allergy
Immunol 1999, 118:122-124.
2.3,4.2 Summary
In order to establish if regulatory T cells can be detected in peripheral T cell
repertoire in man PBMCs were cultured with autologous T cells. In this way it
was possible to generate T cells that could inhibit the response of autologous
CD4+ helper T cells. In addition, as described above (section 2.3.1.1), a
TCR-VP3 CDR2 derived peptide can inhibit HDM induced proliferation of
polyclonal T cells from atopic individuals. Analysis revealed that this effect
was mediated by CD8+ T cells that produced TGF-p, but not the other
immunosuppressive cytokines IL-4 or IL-10.
Intranasal administration of the immunodominant peptide (p 1, 110-
131) resulted in the induction of tolerance that can be transferred to naive
recipients by CD4+ T cells and, furthermore, these cells mediated linked
suppression. It has been proposed in other systems of peripheral tolerance
in which linked suppression is also observed that the secretion of inhibitory
cytokines may provide the negative signals that mediate this effect.
However, the failure to detect the production of these cytokines in mice
tolerised by intranasal peptide suggested alternative mechanisms may
operate which are dependent on direct cell contact between regulatory and
naive T cells. Cognate interactions involving the Notch signalling pathway
were demonstrated to mediate linked suppression.
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2.3.4.3 Related publications
Lamb JR, Eckels DD, Ketterer EA, Sell TW, Woody JN: Antigen specific
human T lymphocyte clones: mechanisms of inhibition of proliferative
responses by xenoantiserum to human non-polymorphic HLA-DR antigens. J
Immunol 1982, 129:1085-1090.
Naor D, Essery G, Tarcic N, Kahan M, Lamb JR, Feldmann M: Specific
interactions between a human CD4+ clone and autologous bifunctional
immunoregulatory clones. Immunol Rev 1990, 116: 63-85.
2.3.5 SELECTIVE ANTIGEN PRESENTATION BY VACCINE VECTORS
2.3.5.1 Introduction
An alternative approach to the induction of tolerance presentation of allergen
under conditions that promote Th1 cytokines may facilitate the
downregulation of allergic inflammation. For these experiments two distinct
vector systems were selected because they have already been used in man.
Firstly, particulate antigen presentation based on the Ty p1 protein, which
forms virus-like particles (VLPs) when expressed in yeast was analysed.
VLPs are efficient in generating both specific CD4+ Th1-type and CD8+
cytotoxic T cell (CTL) responses.
The second vector analysed is mycobacteria. They are known to be
highly immunostimulatory and through their uptake and presentation by
macrophages favour the stimulation of Th1-type responses by the production
of IL-12 and IFN-y. Therefore, mycobacteria were an appropriate live vaccine
vector to investigate for the expression and presentation of HDM genes with
which to induce Th1 cells.
Harris SJ, Roth J-F, Savage N, Woodrow SA, Hoyne GF, Lamb JR, Layton
GT: Prediction of murine MHC class I epitopes in a major house dust mite
allergen and induction of T1-type CD8+ T cell responses. Int Immunol 1997,
9:273-280.
Lamb JR: Peptide-mediated regulation of allergen-specific immune
responses. Res Immunol 1998,149:235-240.
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Hetzel C, Janssen R, Ely SJ, Kristensen NM, Bunting K, Cooper JB, Lamb
JR, Young DB, Thole J: An epitope delivery system for use with recombinant
mycobacteria. Infect Immun 1998, 66:3643-3648.
2.3.5.2 Summary
Immunisation of H-2b mice with VLPs expressing p 1, 111-139 induced Th1-
type CD4+ T cells that responded in vitro to both the specific peptide and the
native Derp 1 protein. Furthermore, p 1, 111-139-VLPs stimulated a 111-
119 specific H-2Db restricted CD8+ CTL response that was long-lasting. Both
Der p 1 specific CTL and T helper cells produced high levels of IFN-y. The
role of specific CD8+ T cells in the regulation of allergic responses in man is
unclear, although there are reports of that the number of CD8+ T cells in the
periphery increases following desensitisation.
Antigenic determinants from HDM proteins were engineered into an
extended loop of the superoxide dismutase molecule of M. tuberculosis, and
expressed in M. vaccae, a non-pathogenic species. H-2b mice that were
primed with recombinant M. vaccae expressing p 1,111-139 (rM. vaccae -Der
p 1) generated specific immunity predominantly of the Th1 phenotype, with
little or no IL-5 detectable. These experiments were extended and mice
injected with rM. vaccae -Der p 1 were subsequently immunised with peptide
to induce a specific Th2-dominant response. Enhanced levels of IFN-y
together with a reduction in IL-5 synthesis were observed in these mice
compared to the controls. This indicated that the pretreatment with rM.
vaccae -Der p 1 had primed mice for Th1 immunity that was reactivated when
the mice were rechallenged with antigen under conditions selected to induce
Th2 responses.
2.3.5.3 Related publications
Abou-Zeid C, Gares M-P, Inwald J, Janssen, R, Zhang Y, Young DB, Hetzel
C, Lamb JR, Baldwin SL, Orme IM, Yeremeev V, Nikonenko, BV, Apt AS:
Induction of a type 1 immune response to a recombinant antigen from
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ANTIGHN-SPECIRC HUMAN T LYMPHOCYTE CLONES: INDUCTION, ANTIGEN
SPECIFICITY, AND MHC RESTRICTION OF INFLUENZA VIRUS-IMMUNE CLONES1
JONATHAN R. LAMB,2 DAVID D. ECKELS, PHIL LAKE, ARMEAD H. JOHNSON, ROBERT J. HARTZMAN.3
AND JAMES N. WOODY3
From the Division of Immunologic Oncology, Deparrmeafof Pediatncs. and the Vincent T. Lombard Cancer Research Center. Georgetown
University School of Medicine, Washington. DC 20007 and-the Naval Medical Research Institute. Bethesda. MD 20014
Human peripheral blood lymphocytes from an HLA-
Dw1,3 individual were primed in vitro with influenza A
virus (A/Texas/1-77/x-49) and subsequently cloned by
limiting dilution in TCGF. Of the 96 TLCs originally ob¬
tained, nine were characterized in detail. TLCs were
antigen specific, responding to influenza A virus, not to
influenza S, TGAL, GAT, tetanus toxoid, or KLH, and only
when antigen was presented by cells unable to form
rosettes with AET-treated SRBC. Presentation of antigen
by unseparated PBL often resulted in significant "back
stimulation," probably via production of growth factors.
The MHC requirements for the induction of TLC prolifer¬
ation were analyzed. Of four representative clones ana¬
lyzed, three required Dw1;DR1 compatibility for success¬
ful presentation of viral antigens by a panel of antigen-
presenting cells. In contrast, one TLC showed an unusual
pattern of response that could not be correlated to a
particular HLA haplotype. Monoclonal anti-T cell antibody
analysis of the surface phenotype of two TLCs main¬
tained in continuous culture for 5 mo indicated that they >
were 0KT3"", 4.~, and 8~, consistent with an inducer/
helper phenotype. To confirm the clonal nature of TLCs,
data on the functional properties of TLC subclones are
also presented.
The analysis at the molecular level of T call interactions in
the regulation of immune function requires expanded popula¬
tions of monoclonal T lymphocytes. A number of approaches
have been utilized, to ootain enriched populations: for example,
antisera reactive with cell-surface determinants have defined
the characteristics of some T lymphocyte subsets both in
mouse (1, 2) and in man (3-5). By using such arrtisera. and by
either positive or negative selection, certain T cell types can be
enriched (6-8), although these techniques fail to isolate mon¬
oclonal populations. In another approach, somatic cell hybrid¬
izations between normal murine T cells and thymomas resulting
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in-T call hybrids with specific suppressor (9) or helper (TO)
activity have been reported. However, such techniques are nor
sufficiently developed to allow the monoclonal expansion of all
T cell subsets and are currently not available for analyzing
human T lymphocyte function. Recently, the recognition that
supematants from mitogerv-sbmuiated lymphocyte cultures,
which contain T cell growth factor (TCGF).3 can maintain the
growth- of T lymphocytes in vitro (11, 12) has allowed the
expansion and maintenance of functional antigen-specific T
cell subpopuiations in long-term culture (13-15). Conse-
ouently, in the mouse it has been possible to preoare antigen-
reactive clonse of T cells that recognize specific alloantigenic
determinants (16). particulate antigens such as sheep eryth¬
rocytes (SRBC) (17). or soluble protein antigens (18).
In the human, the majority of early studies utilized prolifera¬
tion of peripnerai blood mononuclear cell (PBL) populations to
antigens such as purified protein derivative (PPD) to analyze
ceil interactions (19, 20). More recently, long-term cultures of
, "human T lymphocytes that are dependent on TCGF for contin¬
ued growth and that are antigen specific have been reported
(21, 22). Furthermore, it has also been demonstrated that
human T cell lines specific for soluble antigens (23, 24.) or
alloantigens (25) can be cloned. In human studies evidence
has accumulated that HLA-O'.DR sharing is reauired between
T lymphocytes and antigen-presenting calls (APC) in order for
antigen-specific proliferation to occur (20. 22. 26, 27). As
shown recently, the use of clones of human T lymphocytes
eliminates the problem of ailoreactivity (24), making possible
the analysis of genetic requirements for the induction of T ceil
response using allogeneic panels of cell donors. In the studies
reported here, we describe the system for the generation and
characterization of T lymphocyte clones (TLC) that have anti¬
gen specificity for influenza viral proteins. In addition, we
present evidence that the majority of TLC and subclones stud¬
ied require HLA-O/DR-identicai APC in addition to virus in
order for triggering to occur. However, for one antigen-specific
TLC an unusual pattern of genetic restriction was observed.
MATERIALS AND METHODS
Celts. PBL were obtained from wnole blood diluted witn an soual volume
ot RPMI 1640 (Grand Island Biological Comoany, Grand Island, NY) and
1 Abtirevianons used In On paoer: AET-SRBC. S-2-emtnoemyksothiouronrum
Oromtde-oeetea SRBC: APC. antigen-preaanting call: DNV. aouote normalized
value: E. erythrocyte: E~. mononuclear emits mat torm rosettes with AET-SRBC;
E". norv-AET-SRBC loeetxa lormeiq celts: GAT. LrgluUmtc aad^-aiamne^'.L-
tyrosme'l^HTdR. mttatedmetnytttiyrmdine: HEPES.-M2-hycroxyetnylM-oiDer-
azxne-etnane sulfonic acid: HLA. human MHC: HTC. homozygous typing cell:
KLH. Keynote limpet hemocyemn: MHC. major htstocomoatitiillty complex: PBL.
pertonerai blood mononuclear cans: PWM. pokeweed mitogen: TCGF. T cell
growth lector TGAL. (jL-tyroamex-glutamK: acid) poly Dc-eianinedX>»Y-i.-lysine:
TLC. T lymphocyte done; T. Tax., tetanus toxoid: HAU. hemaggluBnanng umts:- -
FTTC. rtuoreacevi isothtocyanate.
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canrnhjgodovac Ftcxau-Hypaou«<Sgma Giomca! CLmoany. 3L ' MO.
ana Wmtnreo Laooratonox. Now Yorx. NY) at *00 x G tor 30 rrnn. Attar
wM«ng. mo-coll* www- musomnaaa to lO'/m* in RPMI 16AO mocttum-
suopum—M with 10* oooMd human A" sarum. 2 mM c-glutamma. 25
mM HEPES* burtw. 50 pg/mtgamamicxn. 25 lU/mt sodium naoarm. 1 mM
soatum pyruvate. and 7.5%-v/v flgnatfiytamfcttnOa at A*C. Tha caUs warn
trozan at for 2D mm usng a rata comreUact fraazar (Cryson.
Associated Siomadic Syatamx. Buttaio. NYL tnan at -50*C/imn down to
—30"C. Attar thts ortscaoura. ma catts wara rranstarrad to tha vaoor pnasa
or a ilaux) introgsu fraazar <MVE Gryogarncs. Naw Prague. MN) and stored
at — 180*C untH reouxrao.
Antirjam. Attanuaiad influenza A (A/Taxas/1-77/x-A9) and B (B/SIn-
gaoora/222/79) strain viruses wara Kindly pmoxrsd 0y M. Phaten and W.
E Berttttow. Division at Virology. Bureau at Biologies. NIH. Betneaaa. MO.
The polymers L-giutarrac aad*aru-aianwwiab_-fyrosinai0 (GAT) and (u-ryro-
smaa.-giutain»c acid) petty au-aranm»:poiy«.-iys«na (TGAL Lot MC8) wara
purcnaaeo tram MUas Laooratonac. inc^ MRes Rasaarcn Division. ElkftarT.
IN. Keynote- llmoat hemocyantn (KLH) was ttte generous gift of Or. M.
Rlttanoarg. Portland. OR. Tetanus toxoid (T. Tax.) was pmuiaaod from
Masaacfti—<ta Rlotogical Laooratona*. Boston. MA.
Amtgmn xavmoan at PBL PBL at 5 x 10* cans/ml in RPMI 18AO
(GIBCO) containing 10% screened, poolad human A" sarum. 2 mM u-
gtutamtna. 25 mM HEPSS buttar. 50 hQ/tt« gantanucm. 25 lU/ntt Na-
haoann. aad 1 mM Na-pyruvata wara somuiaied witft influenza A virus at 5
hemaggtuonaong units (HAU)/rm. Tha concantranon at virus raouired to
produce uuuitai stimulation at PHL assayed by incorporation, of trtttatad
mamyitftynadlna (JHTdR). varied for aitlarmnt virus praoaranons. Put was
always in ma range of 2 to 5 HAU/mt. Attar mixing. 0.2-ml aliouots of tha
ceil suspensions ware plated into 36-watt. 'J-Pottom tissue culture- tnrys
(Linpro Scientific Company. Mamaen. CT) and incuoaied for 6 days at 37*C
in a 5% CD»/airmixture.
T cMi groaen /actor (TCGF). PBL from screened donors ware cultured at
1 x l0*/«nl in RPMI 1 SAO supplemented with 0.1% ounfled phytonemag-
gsutinin-P (PWA-Pr Difco Laooratones. OetroiL MO and 1% autologous
plasma (281 Attar 4-8 hr. suoamatants ware harvested, passed tttrougn
0.22-um fitters. and assayed for than- aOttity to suooort tha growth of a
TCGP-daoanoant call line assayed by 3HTdfl incorporation. Acceotaoie lots
at TCGF vwre stored at A*C or diluted as raauired to 20% v/v in 10% AB
piasma and suopiememed RPMI 16AQ.
Cooing at iartuanza-soaa/k: lyrrronocyTBs. After 5 days culture in the
presence <X influenza virus, calls ware narvesied. resusoended over 35 to
AO% Reread (Phsrmeoa. Uppsala. Sweden) in 12 x 75 mm stanle test tunes
(Falcon Qfcaaion. Bac:on Oicxinson and Comparry. Cocxeysville. M0). and
cemntugad for 20 mm at 200 X G. Calls at ma interface ware ennched
two- to five fold for lymonootasts and. composed 50 to 70% of the calls
counted. ISast-ennuied suspensions ware diluted to 33% calls/ml of me¬
dium contaeang 20% TCGF and placed in 1 D-m aiipuots in stente 60 wail
Microtear a trsys (Feicon). Ten thousand aupiogous ceils ware gamma
irradiated C2500 red. ,a/Cs). comoined with optimal concentrations of influ¬
enza virus, aad acdad to walla containing blasts in 10-ui aliauocs. Cultures
ware mcunatad for 7 days in humxtiftea cramoars at 37*C in 5% CO*/air.
attar wmcn growing waHs ware translarred to frasn medium (0.2 mi) con¬
taining 20% TCGF. irradiated autologous feeders (5 X lOVmf). and inttu-
errza virus« 9«-we«f ftai-oortom trays. After seven additional days of culture,
the dorms ware transferred to 2* wail trays (Linoro Scientific Company.
Hamdan. CD containing tha aooropnate concentrations of TCGF. autolo¬
gous leaders, and irrttuanza m a total volume of 2 mi. Cultures received
fresh TCGF every 3 to -4 days, alternating with pooled irradiated feeders (5
X 10*/mO vatftout virus, and ware thus maintained throughout the course
at the szomimT,tents. dons- wsra allcwsc to grow 5 to 3 days after asettion
of feeder cats oetore testing in proliferative assays, for the oreiimrnary
screening or influanza-resoonsive clones, mdrviaual clones from 24-wall
trays ware cflcueci l :200. and the proliferative resoonse in me presence of
autologous ganvna-vraoiatad PBL and influenza A virus was determined by
me tncoiummon of JHTdfl.
ProlUeraoon assays. Rve- thousand TLC catts in 10% A" sarum ana
suopiemenmd-medium were added to 96-wett. U-dottonr trays in 0.1-mi
aliauots. rracaonaad or unrracaonated autologous PBL as a source of
APC. ware suspended in medium containing iQ% a" serum and outinium
cortcentraaons of antigen, and-ware disoensed in 0.1 -mi auouats to wells
containing TLC catts. Cultures were irtcuoaxed for 12 to i aa. hr. pulsed for
3 to 18 hr axtt 1.0 uCI of JHTdR (New England Nudear. Boston. MA), ana
harvested onto giasa-flber filters. Proliferation, as correlated with 3HTdR
incorporation, was measured by fiouid corraltanon soecttoscooy. The re¬
sults are expressed as the mean counts per mmute (com) — standard error
of the mean (SEM) for tnoecate cultures.
rracoonaaon of lymonoc/tB ooomaoons Dy SFBC rozettmg. Erythrocyte
(0 rosettes were formed with SRBC treated with S-2-arranoetnyiisomiou-
romum browede hycrooronede (AET: Calhiocnem. San Qiego. CA) as pre¬
viously deeenbed (29). One volume at packed SRBC was incuDated with 5
vol ot AET (40.2 mg/rnl in disolled HtO. pH 9.0) for 20 mtn at 37*C. One
volume of PBL. ax i Q' catts/mi .was mixed with 2 vol of 2% AE7-SRBC ana
0.5 volumes of fetal caIt serum (FC3). The suspension wea centnfuged ar
250 x G tor 10 mm and Pieced on ice for QQ mm. After or the
petteta by gertOe rotation, tna saoaratfon of-E roaattaMormmg (ED from
nonrosatttng (ED lymonocytae was achieved by centrttugaoon (1SOO x G.
IS mm) aver Percoll (p — 1.08O g/mtt Pharmacia). Tha S" JOro
recovered from tha interface and tha E" catts from tha pattet by lysis ot
SRBC with Gey's namotyoc solution (3D). Tha £~ call poouiauon contained
less than 1% E* catts. m proliferaDon assays, cultures were- reconstituted
with 5 x ID* ED 2D x 10* ED or 25 x lO* E" and E" cetta. Comparaoie
cultures were reconstituted with 25 X 1D4 imuttered PBL aa a source or
APC.
HLA (yptrrj. APC from panel members were serotyoeo according ro HLA
worxsnoD soacxfkatiaa approved by the W. H. Q. Nomenclature Commrttee
for HLA wontsnoo soecfiattee as well aa for MB and MT usmg more man-
4Q0 sera. The typing teenrwduee used are oaecnoed in n^ry»i ateewoere
(3D. The farmttee and many panel memoers have been cnaracterrzed in at
least one international Histocompatibility Worxsnoo. HLA-O typing was
performed utilizing homozygous typmg cells (HTC5 from the- 7ttt and 8tn
Worxsnoo as well as local HTC. Cans were asa^ned asoedflaty (Dwl-tO)
it they were typed with two defined HTC with an average ONV ot leea than
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PTranoryvtc anmfyaa at TLC. Gonad T catts were petteied by cerrmfuga-
tton at 300 to G for 10 mm at a*C and than resusoended to 10' catts/ml in
medium supplemented with 10% FCS and 1 mg/ml Na azide at a'C. To
10O-ui aliauots at cetti. 5 pJ of manodand antltxxfy were aodad. ana the
mixture was incuoated for 30 mm with agttaoon every 10 mm. After two
waanae in cold medium. 10 nl of countarstaimng reagent (eUhar fluorescein
iaothiocyanate- (HTC} HaOr^neeo antt-mouse-igG. Caooal LaPoraxones.
Cocrtranville. PA. car RTC-cnnfugated awdin) were added, incubated for 30
mm on ice with agitation, and weaned twice. Ceils were reausoenoed in 2
rm of medium and analyzed for fluoreecence on an Ormo Cytoftucrograon.
model 50H (Ortno Olegnosncs, Boston. MA). The munne monoaonai anti¬
bodies and reagents used in these characzenzations were as follows:
0KT3.A.8.8 (Ormo): biomvconiugaxed Leu 2A.3A. DR. RTC-avidln. and
FTTC-Leu 1 (Becton GicJarrson. Sunrrwaie. CA): HLA-fremeworK (Betnesaa
Research Laboratories. 3ethesd2L M0): FTTC-conrugated. pooled goat anti-
human—g (Raffij (Kaileszad Laooraronas. Inc^ Chasxa. MN).
Suocfomng. Suodonea were induced using cloning procedures de-
scnoed above. T ceils were plated at 0-2 calls/weli in Terasexi plates with
autologous irradiated PBL and influenza A virus in supplemented RPMI
18AO containing 20% TCGF. Cultures showing positive growth at 7 days
were transierred to 96-wil trays and finally to tissue culture ftasxs as
described above.
Staasacai methods. In order to obiecsveiv classify negative and positive
responses, we have employed the Kurrosis test for outliers as suggested by
Sheeny (33). This analysis was amy applied to the maior histocompatibility
complex (MHC) restnepon experiments.
RESULTS
Expansion and preliminary screening for influenza respon¬
sive clones. After initial stimulation with virus. Iymphooiasts
were plated in Terasaki plates and 12% of the wells contained
growing ceils after 7 days. Because the biast-ennched ceils
were plated at one call every third well, approximately 25% of
the total number of seeded cells proliferated. Furthermore,
upon subsequent transfer to 96-well trays. 100% of the clones
were still growing after seven additional days in culture.
A total of 96 individual TLC were cultured in the absence of
TCGF with autologous irradiated PBL as a source of APC. ana
their resoonsiveness to influenza A virus was determined by
3HTdR incorporation. In order to concentrate aur efforts, oniy
TLC that showed proliferation in excess of 10.000 com were
investigated further. Indeed. 15 TLC were distributed within
this category, wnereas the remainder incorporated less than
10.000 com in the presence of influenza virus. To indicate that
the lack of responsiveness of negative clones was not cue to
ceil death. TLC were also cultured with TCGF. The proliferative
resoonse of a selecsd group of clones is snown in Table I. By
fulfillment of the requirements outlined aoove. TLC 18. 50. 76.
and 77 were considered negative, wnereas the remainder (TLC
6. 24. 37. 52. 71. 69. 72. and 88) were considered positive.
The clones selected from the preliminary screening were
cultured with APC and influenza A virus, and the proliferative
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kinetics was determined by 3HTdR incorporation at 12 to 144-
hr alter initiation of the culture (data nor shown). Of the positive
clones selected, ail reached maximum *HTdR incorporation
between 72 and 96 hr, and by 144 hr proliferation was not
significantly above background. The magnitude of the specific
response at 72 hr was fivefold greater than the nonspecific
response to TCGF. TLC '50, however, responded much more
vigorously to TCGF than specific antigen, suggesting that the
done was truly negative and that its failure to respond did not
reflect call death. The response of TLC to medium alone
remained below 100 cpm.
Antigen specificity af T lymphocyte clones. The antigenic
specificity of individual TLC was assayed* by cuitunng dones
with irradiated autologous PBL and various antigens (Table II).
Although all positive dones (TLC 6. 24. 26, 37. 53, and 71)
proliferated vigorously to influenza A virus, each TLC was also
restimuiated by at least one apparently unrelated antigen. Such
andllary reactions were generally less than 10% of the re¬
sponse to influenza A; however, they were significantly above
TABLE I
Distribution of intkjmnza TLC into hip/». intarmadimta and low reeoonderr*
Clone no.
- - Hu ♦ Flu •— PBL OR) 4. TCGF ii»aiuw
CSMX^EM
50 222(587* 10(2) 24(3) 8.492(1.126) 39(14)
76 219(387 11 (1) 15(4) 4.S70C218) 15(2)
18 1.280 (242) 13(1) 34(3) 4.427 (889) 17(1)
77 2.105(4167 14(1) 18(5) 5281 (754) 13(3)
89 4.136(1.068) 14(1) 112(28) 3^78 (7477 33(5)
88 4.774 (3857 9(3) 28(77 3.753 (847) 13(1)
6 36.149 (2-39*) 23(5) 134(44) 10.845 (1527 17(5)
24 12.005(1.883) 18(2) 118(43) 2.078(32) 20(5)
26 14.243(3.414) 16(2) 32(8) 3.837 (954) 17(5)
37 24.534 (5-397) 16(4) 639(163) 7.142(404) 5(1)
53 27.051 (4.555) 13(1) 1.549 (335) 7.870(1240) 17(2)
71 32.889(7.629) 11 (4) 2248(392) 7.703 (490) 37(3)
72 152587 (3.059) 18(1) 42(11) 1275 (202) 25(1)
Controls: PBL OR)
4. Flu -*■ PWM 4- PHA Alone
11 C3) 18(3) 16(3) 8(2)
* Umrecnoneted PBL tromahign rasoonoerware stimulated wrtti influenza A
virus and cloned by tontfln d4u»on 96 TLCa ware selected and ixoanded in
limed cutejre_A 1200 Oiutlon of 13 TLCx were sOr o'I1I
background controls. Whan antigen was presented by irradi¬
ated AET-SRBC E~ cells. TLC responded to specific antigen
with virtually no cross-reactivity to unrelated antigens (Table
lll-rt). The presence of peripheral blood T ceils in ttie prasent-
ing-cell population, however, induced nonspecific proliferation
of the TLC. Representative results of the nonspecific stimula¬
tion of TLC by contaminating T calls in the presenting-ceil
population are shown for TLC S3 (TaOle IH-8). Without excep¬
tion, TLC were not reactive to unrelated antigens when pre¬
sented in the absence of T calls.
Presentation of antigen by HLA-D region-related and -unre¬
lated cell types. A panel of E~ APC were tested for their
capacity to present influenza virus to T lymphocyte responOer
clones (Table IV). TLC 6, 37, and 53 were effectively restimu¬
iated only in the presence of virus and APC bearing HLA-Qwl;
DPT. Proliferation induced by APC that did not express Dwl \
DPT was less than 100 cpm and was not significantly different
from negative controls of TLC cultured with antigen alone or
medium. One other done did not appear to be restricted by a
known D;CR-type (Table IV). TLC 71 responded to influenza
virus presented by APC from LNAT (autologous), DSMO,
□BUD, and MLAU. No consistently common HLA antigen was
found on these four cells. This pattern of presentation to TLC
71 was reproducible. TLC 50 was induded as a negative,
nonspecific control and was never induced to proliferate by
TABLE II
Response of infiuanxa A nrus inducmd TLC to soaohc and unraiatad anbQans*
Anepen
PmWecwne n>>Pow o« TLC Qone Ko.
« 2* 2fl 37 S3 71 72 SO
Influenza A (5 73.707* 9.549 77i935 77.049 8.730 9.473 3.797 67
HA/ml)
influenza B (5 720 33 45 778 59 101 32 55
HA/mi)
GAT (500 no/ 19 25 25 67 22 68 40 85
ml)
TGAL (1 mg/ 28 18 18 747 33 58 722 298
ml)
T. Toxoid (0.1 424 200 730 985 870 7.593 37 64
LF/ml)
KLH (80 >42/ 81 28 21 68 47 795 42 23
ml)
Medium 21 10 15 14 19 38 12 18
TCGF 2.197 689 1288 1.143 1213 2.011 363 1.476
Influenza A in a 72-trr *WTdR incorporation assay in tt»e
irradiated C2500 rads) autologous PBL. Controls of
cultured wttft influenza A. PWM. and PHA aremown.
1 as tnaan com (2: SEM) of tnpirare
k* of 25 x 10*
autologous PBL
* 5 x 10* T cafls from 8 TLC ware somuiatad wrtti influenza A (5 HA unto/
ml), influenza B (5 MA units/mi). GAT (500 ea/ml). TGAL (1 mg/mf). T. Tox (0.1
LF/mO or KLH (80 pg/ml) togetner witft 25 X 10* autologous irradiated PBL.
Stimulation was aaressad by me incorporation of *HTdR in a 72-hr assay,
a com 5-iotd or ureater over bacxground.
TABLE 111
EtfacT of anooan presenting emu population on ctana ssmdficxtY*
TLC AFC Flu A Hue OAT TOAL T. Tax. Km UMMW TCGF
coats:
A -8 E~ 72.587 (239)* 171 (135) 82(84) 16(2) 30(4) 29(11) 22(4) 7.943 (53)
'24 E~ 7.442 (750) 35(27) 14(3) 62 C2) 10(2) 19(4) 17(4) 701 (141)
26 E" 5.858(830) 19(7) 13(1) 28(14) 37(7) 6(0) 37(29) 1.271 (190)
37 E~ 6.308 (390) 289(57) 41 (27) 20(0) 57(25) 46(9) 15(1) 1.339 (281)
71 E~ 2.757 (332) 18(8) 10(12) 30(4) 37(11) 420(188) 27(1) 2.117 (490)
72 E" 7.824 (728) 16(2) 16(4) 73(57) 38(2) 43(10) 18(3) 404 (8)
50 E" 23(3) 50(38) 26(0) 11 (1) 124 (34) 39 Q) 202(184) 7.872 1720)
B 53 _ 17(9) 24(4) 16(0) 10 (4) 25(7) 33(7) 28(2) 7.385 (94)
53 PBL 8270(353) 59(27) 22(6) 33(15) 810(717) 47(10) 19(5) —
53 E* 32(10) 24(3) 49(3) 10(0) 39(8) 37(1) 22(2) —
53 E" 5-542 (590) 28(7) 51 (47) 25(1) 59(14) 43(12) 19(3) —
53 r + r 8284(997) 86(8) 24 (16) 48(13) 787 (195) 37(3) 11 (3) -
* A. 5 X TO* T cab* from TLC ware sbmuiated w*n influenza A. influenza B. GAT. TGAL. T. Tox. or KLH tisgatner witn 5 x 10* autotogoia irradiated sneeo
erymocyte rosette negative (£") caiia. B. 5 x 1O* T cafls from TLC S3 were cultured wan influenza A. influenza B. GAT. TGAL. T. Tox. or KLH in tfta presence of 25
x 10* autologous irradiated E~ cells or 20 x 10*E" togamerwun 5 x 10* E~ cadsas a source of antigan presenting calta (APQ. Stimulation of bom irradiated and
unirradiated APC tracaona by antigens alone was iasa man 100 com. incorporation of *MTdR waa.measured at 72ftr.
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influenza virus and APC. although it did resoond to TCGF. TLC
cultured with incompatible APC from panel members in the
acsence of virus gave responses of less than 50 com (data not
shown). "
.
SuD&anrng. To ensure that the properties at the TLC ana¬
lyzed in thts study were those of true clones. TLC 6 was plated
in Terasaki trays at 0.3 cells/well in the presence of autologous
feeder cells, influenza A virus, and 20% TCGF. The subclones
of TLC 5 were exoanded and subsequently characterized.
Representative subclones (TLC 6.1, 6.2. 6.4., 6.7) possessed
identical antigenic specificity and HLA-O region restriction be¬
tween T call done and APC as onsen/ed with the parent clone
TLC 6 (Table V). All subdones responded in the presence of
APC to influenza A but not the unrelated antigens, influenza S.
GAT. TGAL. T. Tax., or KLH (Table V-A). Furthermore, the
presentation of specific antigen observed in the reduced panel
of APC of related and unrelated HLA-O region pnenotypee was
identical for the suxxsones and parent ceil in that restriction to
HLA-OW7 :OR7 was observed (Table V-3). Control responses
of TLC 6 and its subclones to APC in the adsenca of vims-was
<20 cpm and confirmed that the response was not due to
stimulation by ailoantigens.
Immunofluorescence analysis of TLC phanotypa. The phe-
notypes of TLC 6 and 37. wnich had been maintained in
continuous culture for 5 mo. were characterized using a panei
of monoclonal ano-T cell antibodies (Table VI). Both donas
TABLE (V
y at vwus inaucma oro&fmoon at TLC » HLA-O/DP
OW OR a 37 S3 71 so
LNAT* 1/3 1/3 27.95J (3.520)*-* 0.205 (1.02*) 4.588 (320) • 349 (37) 40(14)
MLAU 1/1 1/1 ■*2.732 (9*1) 9.237 (2.03*) 10.952(2.070) 2.020 (54) nf
GAR0 1/1 1/1 11.5*7(1.072) 3.637 (577) *.007 (023) . .36(123 nt
JSAU t/3 1/3 16.703 (3.1*7) 37.727 (1.5* 7) nt 24 (4) TOO (18)
JLM8 via 1/4 1 *.073 (3.190) 1.779(77) 5.90* (2.678) 50 (223 24(12)
EKET 1/7 1/5 20.552 (307J 1 7.097 (2.4 75) 13.135(1.07*) 55(10) 15(5)
GHOV 3/3 3/7 2* (4) 15(3) 23(3) 20 (83 23(183
3MIN 3/7 3/7 232 (2*2) 331 (83) nt 31 (53 m
OSMO 3/5 3/5 315 (177) 68 (4) 271 (37) 5.281 (858) 40 (11)
RKEL 3/Q 3/w6.1 23(1) 22(10) nt 173 (71) 32 (4)
• KCAR 2/2 2r 13.(1) 19(1) nt 28 (12) 17(1)
RCAR 2/7 2/7 17(4) 17(1) nt 18 (2) 81 (373
□BUO 4/0B3 */? 25 (8) 12 (0) nt 1.37* (173) 37 (9)
Ag alone 34(4) 21 (4) 28 (4) 21 (1) 17(2)
Medium 38 (6) 27 (8) 27 (5) 28 (8) 17 (3)
TCGF 4. 780 (350) 3.187 (200) 2.425(127) 5.339 (333) 1.773(273)
' 5 x iQJ TLC calls were snmuuiM witn 5 HA units/rm of influenza A virus in tn» presence ol 5 x IT irradiated E" cwis from a panel of HLA-O region rotated
and unretarea Conors. TLC cultured witn APC in trie aosence of influenza virus gave resoortses less man 60 com. Stimulation was assessed in a 72-nr 'HTcR
incorporation assay.
*
Autologous control from wrncn TLC were derived.
' Values exoresseo as meen com (— SEM) of trroecare cultures. •
' men red values indicate oostfrve reeoonsea.
* Mot tested.
TABLE V
A/rogen-soea/icify and MHC rastrtcaon or cudciones of TLC 3*
HUA-0R pntnoryp*
A/mean
cm aanm OW on s a.i SJ: 3.4 a.7
A. Flu A LNAT* 1/3 1/3 13.372 (1.262) 11.736(555) 12.0*2 (898) 13.285 (698) 74,405 (239)
Flu 8 4- 19(83 15 (2) 17(1) 14 (6) 27(53
GAT 4. 19(4) 23 (4) 18(2) 18(3) 12(3)
TGAL 4- 31 (53 29(12) 28 (8) 23 (4) 17(2)
T. Tax - 28 CIO) 23 (2) 15(2) 25 (4) 33(10)
KLH - 17(1} 19(3) 15 (4) 15 (1) 14(2)
2. Ru A LNAT 1/3 1/3 17.9*7(755) 13.083 (597) 11.330(105j 12.077 (255) 13.921 (999)
— — 25 (4)" 11 (5) 17 (J ) 19 (3) 15(7)
— MLAU 1/1 1/1 22.569(1.990) 19.199 (1.02*1 19.287(020) 28.083 (239) 23.917(359)
- — 24 (23 17(4) 15 (4) 19(2) 17(2)
w JLMB 1/10 1/4 5.895(231) 5.9*3 (ASO) 5.607 (354) 4. 788 (209) 5.021 (138)
— — 15(53 19(33 21 (53 17(2) 13(3)
— EXET 1/7 1/5 12.319 (1.095) 13.098 (890) 17.937 (7.137) 10.730 (*39) 13.007 (987)
- — 13 (4) 13 (23 17(8) 18(2) 17(2)
— GHOV a/3- 3/7 22(2) 12 (5) 13 (3) 15 (2) 17(5)
— ■— 14(2) 22(33 18 (1) 19(2) 11 (1)
- RCAR 2/7 2/7 32(4) 14(2) 11 (4) 23(73 17(1)
— - 15(2) 14(03 13(2) 19 (4) 13(2)
* RKEL 3/6 3/wfi.l 17(4) 17(3) 15 (S3 18 (4) 13(1)
— — 13(2) 21 (3) 15 (3) 10(3) 18(3)
Ag alone 19(1) 15(1) 11 (4) 23(7) 17(1)
Medium 21 (4)
. 10(3) 13(4) 14 (2) 21 (7)
TCGF 5.732 (7*3) 8.21 7 (282) 7,1*7 (793) 6,697 (1.723) 8.279 (3*1)
' A. 5 x id* T cans from TLC 6 or suooonee 6.1. SPL a.—. 5.7 were snmuiaxeo witn soeartc and unrelated antigen in tne oreaence of 5 x id irradiated
autologous £~. B. 5 xh01 T cans from TLC S or suooonem o. J. 8J3. 3.4. 8.7 were somtuaieo vein imtuenza A vtrns in tne presence of 5 x id irradiated E~ ceils from
HLA-O regron related and unrelated donors. Sttomaaoon was isseeseq witn 72-dr ^HTdH ii
* Values expressed as mean com <= SEM) or trtoecate cultures.
' Iraiicxzed vaiues indicate positive resoonseo.
'
Autologous control from wmcn TLC were derived.
* Response of TLC and E" cess culture in me acsence of Influenza A virus.
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TABLE VI
PhmnetyuKi anmtyurn of TIC
8* 37*
*






Leu 1 90 3
Lau 2A <J <1
Lau 3A 80 100
«*0 <7 <1
' Each TLC formed >«fi% £ rommttmm.
were positive with OKT3 (pan-T cell) as wed as for HLA- and
DR-framework antigens. Furthermore, both TLC were reactive
with 0KT4 and Leu 3A, which detect an inducer/helper
marker. Cells from neither done were stained by OKT6 (thy¬
mocytes). OKT 8, or Leu 2A (suppressor/cytotoxic ceils) or
anti-surtace Ig (B cells). Interestingiy, Leu 1. a pan-7-reagent
which is similar to OKT3, but which detects a different cell
surface molecuJe, was found on TLC 6 but not on TLC 37.
Each TLC formed more than-95% E-rosettes.
DISCUSSION
The in vitro generation of discrete subsets of human T ceils
with different functions, such as help, suppression, cytotoxidty.
and proliferation, has been reported for a variety of antigens
(27, 34-36). Furthermore, it is known that long-term cultures
of human T cells with spedfidty for allogeneic (25, 28) or
soluble antigens (22—24) can be maintained using TCGF. In
the present study we report the generation, maintenance, and
characterization of doned human T calls that proliferate spe¬
cifically in response to influenza A virus. .
The unfractionated PBL from a high responder to influenza
A virus were cultured with a single pulse of influenza A vims to
induce blast transformation, of T cells. These ceils were sub¬
sequently doned by limiting dilution, thus making it possible to
select for antigen spedfidty before donai-expansion (25-27).
Murine (18) and human (24) proliferating T cefl dones. selected
for antigen specificity before clonal expansion in TCGF, have
also been reported, whereas other techniques have centered
on enriching for specific cells by repeated antigenic stimulation
and culture in the presence of TCGF (14. 15). A potential
problem with the latter approach is that thecells that grow well
in vitro in response to TCGF are not necessarily those cells
that are functionally significant in vivo.
In the smrties reported here, the frequencyof growing dones
after plating at one ceil every three wells was approximately
35%. Different plating efficiencies have bean reported by dif¬
ferent investigators in a variety of systems (22, 25). Such
differences may reflect the nature of the antigens used, the
presence of both specific and nonspecific secruitabie T ceils,
quantitative or qualitative differences in theTcell subsets found
in peripheral blood compared with lymphaticorgans, ormerely
variations in technical procedures. From theonset, there were
concerns as to whether or not these cais were dones. By
Poisson probabilities. 99% of the wells stxadd have contained
one or fewer calls, and the functional data obtained were
consistent with this observation. However. Ivy subdoning and
analyzing the antigenic specificity and MHCrastnction of both
the suddones and the parent cell line as shown in Table V. the
true clonal nature of the TLC could be exanened. The reaction
of TLC 6 subclones, as anticipated, was absolutely identical
with that of the parent done.
The stimulation of the influenza virus-induced dones with a
panel of antigens resulted in significant proliferation of the
done in response to the inducing-antigen. Additionally, at least
one other unrelated antigen always restimulated when irradi¬
ated autologous PBL were used as a source of APC. In an
attempt to resolve this problem, different fractions of PBL were
assayed for their ability to act as APC. Itwas observed that the
addition of an irradiated E~ fraction consisting primarily of B
ceils, and monocytes resulted in the proliferation of TLC when
stimulated with influenza A, but not with unrelated antigen.
Thus, one likely explanation for the apparent cross-reactivity
of influenza A-spedflc TLC was that it was due to the presence
of an irradiation-resistant T call population that upon antigen
stimulation released TCGF or other growth promoters, which in
turn induced nonspecific proliferation ("back stimulation") of
the TLC. This is supported by the report that irradiation-resist¬
ant T cells can release TCGF after mitogen stimulation (28).
Thus, all of the reactive dones analyzed in this report were
antigen specific, in that they responded to influenza virus strain
A, the indudng the antigen, but not to influenza strain B or
other unrelated protein antigens. This confirms two previous
observations of antigen-epedfic human T cell dones (23. 24).
The detailed analysis of the viral recognition pattern of the
influenza virus-immune TLC is reported elsewhere.8
For the majority of TLC tested, induction of antigen-specific
proliferation required that the APC and the responding TLC
share HLA-D region specificities. This was documented in
experiments in which recognition of antigen by three of five
TLC was restricted to those APC from unrelated individuals
Rearing DwV.DRI antigens and confirmed for the subdones of
TLC 6. These particular results confirm the findings of many
laboratories (22,24, 26,27). However, in contrast to the other
dones. antigen presentation to TLC 71 was not restricted by
any obvious HLA antigens and suggests that the human HLA-
D region may show complexity analogous to that of the murine
la-region provided that many dones are assayed on large
enough panels of presenting calls.
In contrast to other reports (18, 24) TCGF is used in our
system only for expanding TLC cultures and is not required
during proliferation assays. Interestingly, murine cytotoxic
dones require the continuous presence of both TCGF and "
feeders for proliferation (37). Furthermore, the-T-helper cell,
which is capable of indudng cytotoxic T ceil proliferation,
appears to be restricted by class II la region antigens (38, 39).
Thus, human T cell dones that show TCGF dependency as
well as antigen spedfidty may be cytotoxic cells or their
precursors.
To determine with which subset of T lymphocytes the influ¬
enza virus-epedfic TLC were associated, by their cell-surfaca
phenotypes, were analyzed using monodonai anti-human T
call reagents (4, 5). Two dones, TLC-6 and 37, which had
been maintained in continuous culture for 5 mo, were charac¬
teristic of activated T cells in that they were OKT3"\ DR", and
surface lg~. Furthermore, they appear to belong to the inducer/
helper subset as opposed to the suppressor/cytotoxic ceil
subset, in that they were QKT4"~. Lau3A"", 0KT8", and
Leu2A~. Kumick etal. (23) have reported that antigen-specific
T call dones that proliferate strongly and cooperate with B
• Lamo. J. R~ P. P. Ecteia. M. Ptielan. J. N. Wootty. and P. Late. Antigen-.
spaahe human T lympnocyw donas; Viral specificity ol-influanza virus immune
clones. SuDmtftad tor puoiication.
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cells in the production of antibody are also OKT4.~.
Finally, human antigen-specific T cell clones are a powerful
tool and snould allow the detailed analysis of many functional
asoects of lymphocyte interaction and elucidation of the fine
specificity of genetically restricted responses previously im¬
possible with conventional cell-culture tecnniaues.
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ANTIGEN-SPECIFIC HUMAN T LYMPHOCYTE CLONES: VIRAL ANTIGEN SPECIFICITY OF
INFLUENZA VIRUS-IMMUNE CLONES'
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Human T iymohocyte clones (TLC) specific for type A
(A/Texas/1 /77) influenza virus and maintained in contin¬
uous culture with T ceil growth factor, were analyzed to
define the cellular specificity pattern of virus recognition.
A panel of TLC were stimulated with strains of serologi¬
cally characterized type A influenza subtypes, rive TLC
recognized all the viral subtypes; the remaining clones
recognized only subtypes that shared serologically de¬
fined determinants with the immunizing subtype. In ad¬
dition, the 11 TLC were analyzed for their fine antigenic
specificity by using the purified viral components hemag¬
glutinin (HA), neuraminidase (NA), matrix protein (MP),
and nucleoprotein (NP). Five TLC proliferated in response
to NA, four to MP, one to HA, and one to NP. None of the
clones responded to the unrelated B strain influenza
virus, B/Singapore. Furthermore, the fine specificity of
an MP-reactive TLC was confirmed by sObciomng.
Infection of mice with type A influenza virus can prime both
humoral and cell-mediated immunity directed at other subtypes
withtn the strain, a p»enomenon termed heterotypic immunity
(1-3). Furthermore, antibody responses to influenza virus vac¬
cines are ennanced by previous infection with heterotypic
influenza viruses as shown in hemagglutination innibition (HI)3
assays (1, 4). Such cross-protection was demonstrated for
influenza A subtypes with unrelated hemagglutinin (HA) and
neuraminidase (NA) suounits, but not between strain A and
strain 8 influenza viruses. As HA is a 7-oepencenr antigen (5).
this suggests that a hapten-carner effect (6, 7) may occur in
the production of specific antibody. This is supported by recent
reports that T cells that recognize matrix protein (MP), an
internal component of the influenza virion, can cooperate with
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5 Aooreviations used in this Daper: AET, S-2-Aminoetnviisotniouronium oro-
mioe nvorooromide: HA. hemagglutinin: HAU. nemagglutmating units: HI. hemag¬
glutination inmoition: HEPES. -iH:2-hydroxyetnyi>-i-oioerazine-etnanesuifonic
acid: S~. sneeo erytnrocyie rosene-oositive mononuclear cells: S~. sneeo erytn-
rocyte rosette-negative mononuclear cells: MP. matrix orotein: NA. neuramini¬
dase: NP. nucieoorotem: TC3F. T ceil growtn factor (interieuKin 2): TLC. T
lymDnocyte clone: iH-7dR. 'H-tnymidme.
3 calls that recognize HA to ennance the HI antibody response
(8. 9). The internal antigens MP, nucieoprotem (NP). and P
proteins of various influenza A strain suDtypes are cross-re¬
active (10). although minor differences in their antigenicity
have been reported (11). The possibility that these common
proteins snared antigenic determinants recognized by T helper
cells may help to explain the mechanisms that underlie heter¬
otypic immunity.
The viral specificity of cytotoxic T cell responses to influenza
virus has Oeen analyzed in detail (2. 3, 12-1 8, reviewed in 1 9).
Immunization of mice with subtypes of influenza A virus gen¬
erates two distinct subpopuiations of H-2-restnc:ed cyrotoxic
T lympnocytes. One population was specific for the immunizing
virus (12. 13). recognizing the HA sudunit (14. 15); the other
exnibited a high degree of cross-reactivity with other suotypes
by virtue or its specificity for MP (16. 1 7). However, the cross-
reactivity was restricted to strain A subtypes, and no reaction
witn strain 5 influenza virus was ooserveo (13). Recent analysis
of cloned lines of munne infuenza virus-specific cytotoxic T
lympnocytes demonstrated recognition patterns that were
either specific for the immunizing virus, subtype-specific in that
they reacted with determinants common to viruses of the same
subtype as the immunizing virus, or were cross-reactive with
all influenza A subtypes (18). In man, the secondary response
of a polyclonal population of cytotoxic T cells to influenza A
viruses has been directed against cross-reactive determinants
of-the strain A subtypes expressed on the target (20).
Recently we described tne induction and properties of influ¬
enza virus-immune numan T iympnocyte clones CTLC) (21), the
genetic requirements for antigen presentation to TLC. and here
we report the viral recognition pattern of these clones deter¬
mined by proliferation assays. Two maior groups of TLC were
ODserved. one mat recognizes antigenic determinants common
to all influenza A viruses and tne orner mat responds only to
determinants within a given subtype. The precise nature of the
antigens recognized by the TLC was determined by their re¬
sponses to purified viral components.
MATERIALS AND METHODS
Cells. Mononuclear ceils from oeriDnerai biooa (P5L) were ootainea from
a neaitny aault aonor ana seoaratea by flotation on FicoH-Hyoacue (22) anc
cryoDreservea as oreviousiy aescrtDea (21).
Antigens. The influenza type A viruses usea for tnis stuay were: A/Puerto
Rico/8/34. (HiNi), A/Swine/76/31 (H,N,). A/Omacni/1/53 (H.N,). A/
USSR/92/77 (H.N,). A/FW/1/50 (H.N,). A/FuKUsnima/ 103/78 (H.N,).
A/Japan/305/ 57 (H7N-»), A/Japan/170/62 (H?N?). A/Taiwan/1 /6a
(H7N7), A/uaorn/304/72 (H,N7). A/'Porr Chamoers/1/73 (H3N7).
A/Victorta/3/75 (H?N?). A/Texas/1/77 (H,N?). A/Bangxok/1 /79.
(H3N7) ana 8/Singaoore/222/ 79. The viruses were grown in tne allantoic
cavity or emoryonatea cmcxen eggs, immunocnemicaily ouritiea HA (A •
3angKOK/1 /79). NA (Papau New Guinea/1 /75). ana MP (A/Bangkok/1 /
79) were generously proviaea oy Or. 3. G. Weoster. St. Juae Chnaren s
Researcn Hospital. Mempnis. TN. Purified NP (A/ Hong Kong/X31) was tne




7 cell growxn factor (TCGF). PBL were cultured at i x lOVmi in RPMi
16^0 medium suooiementeo witn 2 mM i_-giutamine. 50 ug/mi gentamicm.
25 mM HEPES4 Durter. 25 lU/mi sodium neoarin. 1 % autologous oiasma.
and 0.1 "to v/v onytonemaggiuiinm-P (PHA-P: Oitco Laooratories. Detroit.
Ml; 22). The suoernatants were narvesteo atter 48 n. passed tnrougn 0.22-
um filters, anc assayed tor their aDility to suoDort tne growth ot a TC3F-
aeoenaent line as determined Dy tntiated tnvmidine (3H-7dR) incorooration.
Acceotaole lots of TCGF were stored at a°C and were usee as reouired.
Fractionation ot lymonocyre ooouiations Dy sneeo erytnrocyte rosettmg.
Erythrocyte (E) rosettes were formed with sneeo red Dtooo cells (SRBC)
treated witn AET (S-2-aminoetnynsotniouronium oromide nyorooromioe.
CaiDiocnem. San Diego. CA) as descnoed (21). One volume of oacKed
SRBC was mcuoated with 5 vol of AET (40.2 mg/mi in distilled H?0. dm
9.0) tor 20 mm at 37°C. One voiume of PBL at 10' cells/mi was mixed with
2 vol of 2% AET-SRBC and 0.5 vol of fetal calf serum. The suspension was
centrifuged at 250 x G for 10 mm and was Diaced on ice tor 60 mm. After
resusoension of tne pellets Dy gentle rotation, tne separation of E roserte-
rormmg (E") from nonrosemng (E") iymonocytes was acmeved Dy centrif-
ugation (1500 x G. 15 mm) over Percoit (p — 1.080 g/ml; Pharmacia.
Piscataway. NJ). The E" cells were recovered from the interface and
contained less tnan 1% E* cells, in proliferation assays, cultures were
reconstituted witn 5 x 10J E". as a source of antigen-oresentmg cells.
Inouction anO assay ot antigen-sDecific T lymonocyte clones (TLC).
Human T cells specific for influenza A virus were induced as oescrioed (21).
Briefly. 106 PBL/mi were cultured in medium supplemented with 10% A*
serum and 5 nemaggiutmating units (HAU)/mi of attenuated influenza virus
(A/Texas /1/77). After 5 days, responding cells were enncned on a 25 to
40% Percoli gradient, resuspenoed at a concentration of 22 'h cells/mi in
medium containing 20% TCGF. ano were plated at one cell every tnird well
in Terasaki trays with 10* irradiated autologous PBL and tne optimal
concentration of influenza A virus. After 7 days, growing clones were
transterred to 96-wel! flat-ooftomed trays and suoseauently to 24-well
plates ano were then expanded in 25-cm* tissue culture flasxs. Suoctones
were induced Dy using tne same initial cloning procedure, namely 7LC cells
were piated at 0.3 cells/well in TerasaKi plates with irradiated autologous
PBL ano influenza virus in tne presence of 20% TCGF. The cultures snowing
positive growtn at 7 days were expanded as already descrioeo. Fresn 20%
TCGF was aooed every 3 to 4 oavs and irradiated oooieo feeders (5 x
10s/mi) were aooec every 7 cays. Before use m proliferation assays. TLC
were rested 6 to 7 cays after tne addition of ieeoers.
TLC were examined tor antigen-specific proliferation in a 72-n assay Dy
using JH-7dR incorporation. Five thousand TLC were cultured witn irradiated
E" ceils (5 x 10-1) and antigen in a total volume of 200 ul. After 72 n.
cultures were ouised with 1.0 uCi of ^H-TdR and were harvested 8 to i 6 h
later, incorporation of raoioiaDet®d thymidine was measured Dv hauid scin¬
tillation spectroscopy. Results are expressed as tne mean counts per minute
(cpm) = i standard error of tne mean (SEM) for triplicate cultures or as tne
percent of tne response to tne immunizing virus.
RESULTS
Pattern of influenza virus recognition exnioitea oy virus-soe-
cific TLC. A panel of 11 TLC. seiecred for tneir aDility to
proliferate in response to the inducing antigen (A/Texas/1/
77. H3N2). were cultured with irradiated E~ lymphocytes, as a
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source of antigen-presenting cells, in the presence of appro¬
priate virus strains representative of the major type A influenza
virus suDtypes. Also included were swine influenza (A/Swine/
76/31. HiN,) and the unrelated influenza B strain. B/Singa-
pore/222/79. Taoie I snows the results of this analysis. Of the
11 TLC induced and seiectec with A/Texas/l /77. oniy one
cione (TLC 11) proliferated wnen cultured only with the H3N?
suDtypes (A/Uoorn/304./72: A/Port Champers/1 /73: A/Vic-
toria/3/75; ano A/BangkoK/1 /79). This result suggests that
TLC 11 recognizes an antigenic determinant on the HA mole¬
cule snared Dy tne H3N? suDtypes. rive TLC (26. 53. 57. 71.
and 95) proliferated in response to all H3N7 and H2N2 suDtypes
but failed to proliferate wnen cultured with any of the H,N,
suDtypes (A/PR/8/34; A/Swine/1 976/31; A/FW/1/50: A/'
Omacni/1/53: A/USSR/92/77; and A/FuKushima//l03/
78). Thus. TLC 26. 53. 57. 71. and 95 were specific for NA;
only A strain suDtypes bearing N2 were able to stimulate these
five ciones. The remaining five clones (TLC 6. 37. 39. 72. and
83) proliferated in the presence of viruses representative of all
strain A influenza virus subtypes. Therefore, these TLC rec¬
ognize an antigen sucn as MP or NP that is shared by all the
suDtypes. None of the TLC analyzed snowed antigenic speci¬
ficity restricted to only the inducing suDrype A/Texas/1 /77)
ano they were unresponsive to strain 3 influenza virus (TaDle
I). Also, in the absence of E~ antigen-presenting cells, none of
the TLC responded to any of the virus strain A subtypes (data
not shown).
Reactivity of virus-SDecific TLC with influenza virus compo¬
nents. The same panel of 11 TLC was analyzed for reactivity
with influenza virus components (TaDie II). Each TLC was
stimuiatea witn tne purified components, HA (0.1 ,ug/ml), NA
(10~3 v/v). MP (0.1 ag/ml). and NP (0.1 ug/ml). The antigens
were used at the optimal concentration for inducing maximum
proliferation of unfractionated PBL of the donor whose cells
were cloned. In addition to viral components, the TLC were
stimulated with the intact inducing virus (A/Texas/1 /77) anc
tne unrelated strain B influenza virus (B/Singaoore/222/79).
TLC 11 proliferated wnen cultured with HA but failed to
responc to NA ano MP. Although the MP preparation may
contain residual HA (R. G. Weoster. personal communication),
it is cieariy not present in sufficient ouantities to elicit a re¬
sponse from TLC 11. Five TLC (26, 53. 57. 71. and 95)
proliferated only in response to the viral component NA. Of the
remaining clones, four (6. 37. 39. anc 72) proliferated wnen
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Recognition oattern ot mhuenza vircz strain A suotypes cv ~ ivncnocvte Clones'
Clone no
Virus Suorvoe H N
11 26 53 57 71 35 6 37 39 72 33
A/Texas/l /77 2 2 100 100 100 100 100 100 100 100 100 100 100
A/Udorn/304/72 3 2 100° 98 102 107 1 14 122 131 132 11 1 138 107
A/Pr. Chalmers/1/73 3 2 109 122 113 99 120 108 1 1 7 120 103 1 15 100
A/Victoria/3/75 2 2 129 118 101 91 133 99 1 23 126 l 13 94 74
A/BanaxoK/1/79 3 2 124 106 117 131 98 103 ns 99 98 102 113
A/japan/305.57 2 2 100 121 34 63 98 108 98 99 1 14 37
A/japan/170/62 2 2 2 94 92 102 99 109 120 1 10 102 96 101
A/Taiwan/1 /64 2 2 2 108 131 11 1 100 90 53121 64 35 91 1 15
A/FW/1 /50 1 1 1 1 2 1 101 72 106 103 34
A/Omacni/1 /53 1 1 <1 <1 1 2 1 16 76 119 32 100
A/USSR/92/77 1 2 1 2 1 57 SO 95 124 108
A/Fuiutsntma/ 103/78 1 1 1 1 3 1 93 100 105 59 127
A/PR/8/34 1 1 2 2 t 2 4 107 34 110 86 98
A/Sw.ne/1976/31 1 2 1 3 2 2 52 22 11.' 73
= /Singapore/222/75 t <1 <1 <1 <1 <1 1 <• 1
* A panel ot 11 T lymonocyte ciones (2.5 x iC'.'mi) was cuitureo witn 16 influenza viruses at final dilutions ot l / 1000 ana 1 /5000 in tne presence ot autologous
irradiated £" cells (2.5 x iCVmi). Stimulation was assessed Dy tne incorporation ot 'H-invmioine in a 72-nr assav.
3 Results expressed as tne percent proliferation ot tne mean response or eacn TLC to A/Texas/1 /77. Control responses ot eacn TLC to virus in tne aosence ot
E" was <50 com as was tne response to virus of E" ceils atone.
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cultured with MP but not with HA or NA. wnereas TLC 83 failed
to resDono to HA. NA. or MP. However, when cultured with
NP. TLC 83 proliferated vigorously (Taole II). To ensure that
the antigenic specificity of the TLC analyzed in this study were
those of true clones. TLC 5 was suocloned by limiting dilution.
The specificity of representative subclones (TLC 6.1. S.3. 3.4.,
5.5. and 3.7) was identical to that of the parent TLC 3 in that
they responded to MP but not to any of the other influenza viral
components tested.or to influenza strain 8 (Table III).
DISCUSSION
The results presented in this report suggest that the specific¬
ity of proliferative responses by human T lympnocytes to influ¬
enza virus are highly heterogeneous. At the clonal level, it is
evident that proliferating clones with several distinct soecific:-
ties of influenza virus recognition are present. Analysis of the
clones on a panel of strain A virus subtypes revealed two
patterns of response. Firstly, clones that recognizes ail strain
A subtypes are evident, and secondly, those that responded to
determinants snared by viruses of the same subtype as the
immunizing virus are found as well. However. TLC in neither
group cross-reacted with influenza B virus.
Similar reports of suotype-specific and cross-reactive pop¬
ulations exist for human cytotoxic T ceils pnmeo with type A
influenza (20, 24., 25). Our observation that T cell clones
recognize specific and snared type A viral antigenic determi-
TABLE II
Soecificity of virus-immune T ivmonocvte clones to ourifiea viral comoonents*
11 28 53 57 71 95 s 37 39 72 83
Influenza A strain (A/Texas/1/ 7962ac 7812 74tg 8542 3570 5550 5343 18191 5635 7739 5358
77: 5 HAU/ml) (400) (1728) (705) (582) (2018) (876) (504) (479) (595) (263) (1266)
Influenza 3 strain (8/Singaoore: 37 16 47 23 24 1 4 45 20 26 21 37
5 HAU/ml) (14) (1) (6) (4) (8) (5) (8) (2) (2) (1) (is)
Hemagglutinin (0.1 ug/ml) 5467 19 54 10 28 17 70 41 43 17 16
(925) (1) (21) (2) (14) (4) (30) (5) (20) (2) (2)
Neuraminidase (10~J v/v) 3 3680 7123 4213 5291 4031 21 19 52 15 19
(4) (34a) (709) (382) (1249) (612) (1) (5) (13)
'
(3) (7)
Matrix orotem (0.1 ug/ml) 16 19 37 23 27 19 4132 9752 4668 6666 21
(2) (2) (9) (7) (8) (2) (751) (1677) (710) (777) (2)
Nucieoorotein (0.1 ug/mi) 18 22— 29 41 25 33 57 7T 25 = 7 4581
- (2) (S) (o) (5) (8) (10) (27) (27) (7) (10) (539)
Medium 15 23 35 19 1 4 16 146 30 21 39 27
(4) (3) (16) (4) (3) (4) (45) (6) (2) (4) (4)
TCGF 4375 5039 7283 3679 2741 2387 4725 10987 3242 4915 5695
- (255> (769) (281) (721) (507) (27) (295) (1 159) (252) (675) (126)
' Sacn TLC at 2.5 x iCVmi vvas stimuiatea witn ma. ma. M° and MP in me sresence or 2.:
by JH-TdP incorDoration in a 72-nr assay.
3 Proliferation exoressea as mean com (xSEM).
e Unaertine indicates com greater tnan 230-fold over background.
TABLE III
Viral comoonenr soecificity of suociones of TLC 6'
x 10" autologous irraciatec E" cells/ml. Stimulation was assessea
Clone Suociones
Viral Comoonents
5 5.1 5.3 5.4 5.5 s.r
influenza a strain (A/Texas/1 /77: 5 13134"c 16137 13960 21092 i 6483 •367~
HAU/ml) (815) (127) (1266) (198) (400) (1222)
Influenza 3 strain (B/Singaoore: 5 35 22 27 40 20 30
HAU/ml) (5) (2) (14) (1) (3) (6)
Hemagglutinin (0.1 ug/mi) 27 22 15 26 1 4 34
(8) (8) (5) (6) (2) (11)
Neuraminidase (10"1 v/ v) 45 32 19 33 27 • 7
(20) (2) (4) (14) (4) (2)
Matrix crotein (0.1 ug/mi)
' '550 '■2155 12166 24953 i 2sc5 10375
'407) (230) (833) (825) (772) (585)
Nucieccrotein (0.1 ug/mi) ZZ 2=
(3i (19) (14) (2) (4)
Medium 24 25 30 16 15 19
(4) (4) (7) (4) (5) (1)
TCGF 3225 4222 7131 3431 4Q68 4840
(516) (276) (629) (662) (127) (413)
' TLC 5 or suocicnes of TLC S at 2.5 x i0- 'mi were stimulated witti HA. MA. MP. and NP in tne oresence of 2.5 x 10* autologous irradiated c ceiis/mi.
Stimulation was assessed by JH-TdR mcorooration in a 72-hr assay.
5 °ronferation exoressed as mean com (±SEM).
'
Underline indicates com greater man 20-foid over oacxgrouno.
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nants confirms and extends earlier reports of two distinct
populations of influenza-reactive, cytotoxic T cells (12-15).
However, none of the TLC reported here proliferated only in
response to the inducing virus A/Texas/1 /77. findings similar
to those reported for cloned mouse lines of anti-mfluenza-
specific cytotoxic 7 lymonocytes (26). This is contrary to an¬
other report of the specificity of cloned mouse lines of influenza
virus-specific cytotoxic cells, in which six of 1 2 clones analyzed
appeared specific for only the immunizing subtype (18). This
inference, however, was based on specificity analyses in wnich
only two H?N? subtypes were used. Furthermore, the fine
specificity of two cytotoxic clones, one specific for the immu¬
nizing virus and the other subtype-specific was investigated. It
was interesting that both of these clones appeared to recognize
viral HA as determined by their reaction with two recombinant
virus strains. This may imply that subtype-specific clones may
recognize a "common" region of HA. Our failure to observe
clones uniauely specific for the priming virus may be due to
exposure of the donor to particular viral antigens during a
previous natural infection with influenza A virus. Thus it is likely
that we have cloned primed T cells in vivo. Furthermore,
because there is evidence to suggest that the numan secondary
cytotoxic T ceil response to influenza viruses is predominantly
directed against cross-reactive determinants (20. 25), cell spe¬
cific only for the immunizing strain may aopear at too low a
freauency in the peripneral blood to be cloned.
Whereas the specificity of cytotoxic Tlymphocytes has been
reported to be directed predominantly against HA (J4) and MP
(1 6. 1 7). the majority of human proliferative TLC responded to
eitner NA or MP. Although cytotoxic T lympnocytes specific for
NA have not been demonstrated directly, our eviaence ma: NA
can be recognized by T cells suggests this antigen aoes
participate in cell-mediated ynmune responses, -ft is possible
that cytotoxic cetts specific for NA may be present in vivo, but
at a- mucn lower freauency than killer cells directed at otner
viral antigens and iower than is observed for proliferating T
cells, indeed. Koszinowski er a!. (27) describee influenza A-
scecific, cross-reactive, cytotoxic T cells that may recognize
NA on target cells fused with mixed influenza/Senoai lipo¬
somes lacking MP. Thus, functionally distinct T cell subsets
may show biased reactivity to viral components.
That MP determinants are recognized by cross-reactive lym¬
pnocytes. as reported previously (3, 16. 17), is somewnat
uncertain since analysis of virus-infected targets, using a panel
of monoclonal anti-NP antibodies, demonstrated that NP was
expressed on the cell surface at concentrations 10-fold nigner
tnan those of MP. This implies that cross-reactive killer cells
may also recognize NP (28). Alternatively, it has been sug¬
gested that cross-reactive cytotoxic T cells recognize the viral
glycoproteins (27). The present study snows that MP-soecific
T cells are a significant component of the infiuenza-soecific. T
cell repertoire, ana suggests that this antigen may be recog¬
nized by other effector cell subsets. The MP-specific TLC
reoorted here may be important in cellular collaboration during
production of HA-soecific antibodies as nas been describee for
carrier effect, may oe operating in the production of anti-HA
antibodies in man.
Detailed analyses of the antigenic specificity of T cell re¬
sponses to influenza virus have been made with the use of
cytotoxic T cells (18. 19. 25. 26). in this report we have
analyzed the fine specificity of human influenza A-specific T
lympnocyte clones selected for their ability to proliferate. This
approach should ailow a precise analysis of the interrelation¬
ship of viral antigenic sites recognized by accessory, inducer,
or suppressor cells and the mechanisms controlling immuno-
genicity of antigenic determinants recognized by effector T and
B cells.
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These cell lines. like CTCL-3 -r.d CTC-16, were established
from .tile peripheral blood of patients with leukaemia or iym-
oma involving relatively mature T cells. An example of the
immunofluorescence obtained using monoclonal anti-pl9 anti¬
body on MT-l and MT-2 cells and a positive control cell line,
done A9, is shown in Fig. 2.
A specific competition radioimmunoassay has been described
for the HTLV core protein. p24', which can detect as little as
0.05 ng of p24. This precipitation assay uses 1X3I-labeiled
homogeneous HTLV p24 and a hyperimmune rabbit antiserum
against detergent-disrupted HTLV. Competition is observed
only with proteins from disrupted HTLV or HTLV-producing
cells. As shown in Fig. 3a, cell extracts from both MT-l and
the HTLV-producing cell line, done B-2, competed in the
HTLV p24 radioimmunopredpitation assays. The competition
with IdUrd-induced MT-l cells was about 10-fold higher than
with untreated MT-l cells, and the slope and end point of the
competition curves with done B2 and induced MT-l were the
same. The p24 determinants of HTLV and ATLV which are
recognized by this antiserum are thus indistinguishable No
competition was observed with extracts from HTLV-negative
control cells, which induded cultured human normal mature T
cells and leukaemic T-cell lines previously shown to be HTLV
negative. -
The kinetics of induction of expression of pl9 and p24 were
analysed in parallel after treatment of MT-1 cells with IdUiti.
for 24 h. As shown in Fig. 3b. the induction of both proteins
was time-dependent and increased with increasing concentra¬
tions of inducer. There was a slight increase in the expression
of both pl9 and p24 immediately following the 24-h treatment
of MT-l cells with IdUrd. However, a substantial increase in
the expression of both proteins was observed 48 h after IdUrd
treatment At the highest IdUrd "concentration tested
(60 ugmT'), the p!9 expression increased about 8-foid while
a 16-foid increase was detected for p24 compared with the
untreated control ceils. The expression of both these proteins
therefore increased simultaneously on IdUrd treatment of
MT-1 cells. It is therefore likely that the'adultT-cell leukaemia-
associated antigen' or 'ATLA' in MT-ceils detected following
induction with IdUrd and using natural antibodies in seta of
Japanese ATL patients3, represents one of these previously
described HTLV proteins''10.
We have previously shown that >90% of tested Japanese
patients with ATL also contained antibodies to HTLV p24"~*.
A subsequent more extensive screen of a large number of sera
of Japanese ATL patients has substantiated the earlier finding"*.
In addition. 25% of dose relatives of ATL patients and about
10% of individuals in the area endemic for ATL also have
antibodies to HTLV p24. In contrast, none of 40 normal ran¬
dom sera from the non-endemic regions of Japan had anti-
HTLV p24 antibodies.
We condude from the data presented here that the antigens
reacting with the antibodies in the sera of most Japanese ATL
patients are highly cross-reactive with HTLV proteins p 19 and
p24. Two cell lines from such patients (MT-l andMT-2), which
contain ATLV RNA and proviral DNA3, also contain viral
nudeotide sequences which are virtually indistinguishable from
those of HTLV. MT-l (which produces ATLV3) expresses two
antigenic determinants indistinguishable from those of HTLV
p24 and p 19. Virtually all MT-2 cells (which produce ATLV)
express HTLV p!9. Moreover, three other Japanese ATL cell
lines established in our laboratory (M.P. er at., in preparation)
and two other similar lines established in Japan (S. Morikawa,
personal communication) also express antigenic determinants
indistinguishable from those of HTLV p24 and pl9. The wide¬
spread occurrence of antibodies in the Japanese AIL sera
strongly reactive with HTLV p24 further strengthens our con-
dusion that the retrovirus associated with Japanese ATL is.
identical or very dosely related to previously described strains
of HTLV'—1* which have been isolated and characterized from
patients in the US with leukaemias and lymphomas involving
mature T cells, and establish ATLV within the HTLV group.
We thank M. Jarvis, E. Richardson and E. Shepard for
technical assistance. Fixed cells from MT-2 were provided by
Dr Y. Hinuma. M.P. was a redpient of the American Cancer
Soriety, Eleanor Roosevelt International Cancer Fellowship
awarded by the International Union Against Cancer.
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Human T-cell clones recognize
chemically synthesized
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The continual variation in the antigenic structure of the haemag-
giutinin (HA) molecule is associated with the appearance of
new epidemics or pandemics of influenza in immune popula¬
tions1. The detailed analysis of HA structure has provided the
molecular basis of this phenomenon3"* and -while foarantibody-
binding sites have been suggested*, the epitopes of HA that
are recognized by T cells remain undefined. Using chemically
synthesized peptides corresponding to sequences of the HA
moiecnie5, we have investigated the antigenic determinants
recognized by long-term T-lymphocyte iines and clones induced
with HA and maintained in T-<eil growth factor (TCGF or
interienidn-2, IL-2). The data suggest that HA-spedfic T-cell
peptides analysed. However, when responses are analysed at
the clonal level, one peptide located at the carboxy-terminns
of the HA1 moiecnie and discrete from the proposed antibody-
binding sites'1 seems to be immunodominant.
* To «mm corrapomttnci ikooid b« xbdrtwd.
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Peripheral blood lymphocytes (PBL) from adult volunteers
selected for icnown responses to strain A. influenza virus
(A/Texas/1/77; HjN-j) were cultured with HA isolated from
this subtyoe. After 6 days, cultures were either cicned by
limiting diludon in the presence or'TCGF, irradiated autologous
PBL and specific antigen as previously described6, or main¬
tained as ceil lines. The T lymphocyte clones and lines were
maintained in continuous culture for 8 weeks and then assayed
for responsiveness to specific antigen in the presence of antigen-
presenting ceils as determined by tndated thymidine (JH-TdR)
incorporation.
Normal PBL responded to the intact virus and to the HA
moiecuie of A/Texas/1/77, as did long-term influenza and HA
lines induced with the same viral subtype (Table 1). The anti¬
genic specificity of these- lines was confirmed by their failure to
respond to the unrelated strain B influenza virus. B/Singa¬
pore/222/79. Both normal PBL and T-cell lines in the
presence of antigen-presenting cells responded to each of the
synthetic peptides (Fig. 1) tested over a- dose range of-
0.01-10 figml"1. Although these peptides were synthesized
according to the sequences of influenza strain X.-47 (ref. 7), in
most cases they were identical to corresponding regions of
A/Texas/1/77 (ref. 8). Both viruses are H3N2. and comparison
of their sequences reveals only a few amino acid differences.
It is evident that peptide 20, which corresponds to the carboxy-
terminus of HAi, induced.the marimiim proliferative response
(Table 1). Interestingly, this peptide is distant from the four
proposed antibody-binding sites. Although these sites are able
T*bi« 1 Reicnon of normal peripheral blood lymphocyte* and initnrrm A virus-
and HA-«pednc long-term T-ceil lines with synthetic peptides at the HAI
moiecuie
Synthetic peptides Lymphocytes
of HA-1 moiecuie Normal PBL Influenza A line HA line
2 2J88 (206) 10J08( 1.737) 1.797 (326)
a 3.461 (171) 1.008 (387) 22216(321)
7 6.204 (494) 7.885 (515) 1.497 (296)
10 3.924 (583) 7.287 (1.005) 2.088 (64)
11 5.960 (926) 11.359 (2.179) . 1-349(321)
16 2J59(639) 9.173 (780) 1.439 (366)
17 1.667 (186) 6.683 (566)
%
1.470(2641
19 2J167 (334) 10.091 (25) 1.131 (381)
20 9.061 (1.737) 30.266 (6.240) 3-549 (272)
21 2.460 (373) 5.871 (764) 1.622(196)
22 4.733 (445) 2.065 (245) 1-378(174)
22 3.017 (308) 8.743 (952) 2.094(140)
HA molecule
| A/Texas/1/77; H,) 6.514 (512) 16.792(1.308) 2J26 (452)
Intact virus
i A/Texas/1/77) 16.017(2^16) 40.645 (9.307) 9.173 <1.072)
Influenza 8 strain
B,'Singapore/222/79) 22.085 (4.969) 57(10) 27(16)
Meoium alone 21 15) 20(6) 21 (6)
TCGF — 3.481 13651 1.329(52)
Normal human penpnerai blood lymphocytes (PBL. 2.5 xlO'" ml"') were cul¬
tured with either the synthetic peptides of the HAI molecule, the punned HA
molecule igift of Dr R. G. Wetosteri. or intact influenza A (A/Texas/1 /77) or B
(B/Singapore/222/79) strain virus for 6 days in RPMI-1640 iGibcoi supple¬
mented with 10% pooled A* serum. The concentration of anugen used for the
symhenc peptides and HA was 0.01-10 ugml"'. and 0.05-50 hicmaggiunnaong
units i HAU) ml"' for the intact viruses. To induce T-ceil lines. PBL were cultured
'nth intact A/Texas/1/77 or the punned HA molecule of A/Texas, and after 6
davs the lymphotriasa were enriched on a discontinuous Percoll gradient. These
blast cells (101 ml"') were expanded as long-term T-cell lines with filler ceils
'irradiated (2-500 rad) autologous PBL at 5x 10* ml"') and specific anugen in
the presence of T-ceil growth factor. TCGF was prepared by cuiturmg PBL
ll * 10* mi"') with 0.1% ptinfied phytohaemaggiuunin-P (PHA-P: Difcoi in
RPMI-I640 supplemented with 1% autologous plasma'7. After -^8 h. super¬
natant! were collected and assayed for their ability to support growth of a
TCGF-dependem line as described previously*. The lines were maintained wuh
filler cells and anugen every 7 days and TCGF every 3 days. Influenza A virus
md HA-specific T-ceil lines (2^x Iff* mi"') were cultured with the panel of
anugens in the presence of irradiated autologous PBL 11.25 x 10* ml": J for 72 h.
poised for 8-16 h with 1.0 uX2 of trmaied methyl thymidine (JH-TdR: MEN) and
collected on to glass fibre filters. Proliferation, as correlated with JH-TdR incor¬
poration. was measured by liquid scintillation spectroscopy*. Results are
exorcised as mean c.p.m. Iss.ejn.j of triplicate cultures. Only the highest prolife¬
rative resoonsc in the antigen dose-<esportse. curve is shown. As controls, the
responses to medium alone; TCGF and B/Singapore were determined.










FTg. 1 Amino acid sequence of tbe HAI moiecuie ot X-47 as
predicted, from the nucleotide sequence . The regions of the
moiecuie- synthesized are underlined and numbered. C and Y at
the end of the peptide indicate, respectively, the addition of a
cysteine or tyrosine not present in the primary sequence.
to induce proliferation, it appears that they are not the
— immimnrinminant region of the HA molecule for T-ceii
responses; In comparison, studies on immune responses to
myoglobin in mice have demonstrated that the Ave antigenic"
sites recognized by antibody are also the primary inducers of
T-ceil proliferation in ceil populations'*10 and long-term cul¬
tures11. Furthermore, itwas reported that peptides representing
B-ceil non-antigenic parts of the molecule were unable to
induce proliferation10, which may reflect the fact that regions
of myoglobin are phyiogeneticaily conserved and are thus
immunologically silent. However, our findings demonstrate that
the entire HA moiecuie as denned by the synthetic peptides
used in these studies can induce T-ceil proliferation with none
of the peptides behaving as nommmunogens. as was observed
in myoglobin10, or actively inducing suppression, as has been
reported for lysozyme12*13. Analysis of the activity of smaller
peptides of HA. however, may allow such regions to be
identified.
The fine specificity of antigen recognition by HA-sperific T
ceils was investigated at the clonal level using chemically synthe¬
sized peptides of HAI ITable 2). One of the four T-lymphocyte
clones (HA 1.9) proliferated in response to the HA moiecuie
and the intact influenza A virus, but failed to respond to
3/Singapore or to the panel of synthetic peptides. Presumably,
this cione recognizes determinants that reside in the sequences
not covered by overlapping peptides iFig. 1). The remaining
three clones analysed (HALA HA 1.7 and HA2.43) responded
oniy to peptide 20 and not to the predominant antibody-binding
sites. Comparable to this observation is a report on the cionai
analysis of T-cell recognition of the antigenic determinants of
myoglobin, where two clones specific for the fragment 1-55
failed to respond to peptide 15-22. which contains the only
antibody-binding site11.
To define the epitope specificity of T-cell antigen recognition,
clones HA 1.4. HA 1.7 and HA2.43 were cultured with the
intact viruses A/Japan/305/57 (H2N2) and A/Texas/1/77
(H3N2). Neither clone HA1.4 nor HA 1.7 responded to
A/Japan, but both proliferated in response to stimulation with
A/Texas (Table 3), suggesting that these two clones recognize
a variant region of the carboxy-terminus of HAI. Any one of
the amino acid substitutions between A/Japan and A/Texas
occurring within the sequence of peptide 20 at residues
312-314, 316. 321 and 326-329 (Fig. 2) would be abie to
confer the specificity of these clones for A/Texas as opposed
to A/Japan, as it has been reported that T-ceii activation may
68 Letters to Nature
Table 2 Recognition of synthetic peptides by HA-speaftc human T-lyrapnocyte clones
Symheac peptides done no. -
of HA1 molccme HA1.4 HA 1.7 HA1.9 HA2.43
2 61 (55-92 (16) 17 (6)—59413) 25 (11)-J7(15) 17(55-57(14)
4 24(21-54(14) 17 (1>—31 (11) 25 (5)-37 (9) 49(95-81 (95
7 ' 33 (75-136 (50) 13 (45-38(1) 16(85-51(19) 10(15-61(75
to 31 (95-96 (72) 27 (3>—38 (5) 26(95-52(14) 28(45-74(95
11 15 (3>—47 (5) 19 (5)-81 (25) 14(35-37(1) 17 (45-37 (9)
16 16(45-^5 (45) 15 (4V-26 (10) 14(85-93 (51) 15 (45-43 (8)
17 24(5>-40 (8) 20 <5>—45 (23) 20 (5)-45 (23) 18(75-19(2)
19 27 C5>—51 (4) 27 (5V-67 pi4) 14(2)-19(12) 31 (55-61 (14)
20 69 (465-3.591 (22) 25(41-2^46(158) 33 (155-83 (23) 886 (305-13.662(1.514)
21 21 (25-48(2) 22(2)—44(15) 16(45-13 (7) 17(25-31(6)
22 18(45-14. (7) 19 (45-39 (7) 16 (25-28 (4) 11(35-21 (35
23 12(l)-22 (3) 4«(9)-63(6) 21 (35-52(16) 9(25-39(35
HA molecule (A/Texas/1/77; H,) 2.607 .232) 3.073 (ISO) 10.440 '566) 12.038 (2305
Intact virus (A/Texas/1/77) 7.772.732) 3.009 (99) 22.289 (6.751) 14.401 (926)
influenza B strain (B/Singapore/222/79) 37(11) 29.2) 43 (6) 18 (21
Medium alone 20(1) 27 (4) 27 (45 29(2)
TCGF 3.813 (366) 1.018 (29) 8.099 (521) L276 (25)
HA-«pecific human T-lympnocyte clones were isolated as described previously for influenza A virus*. Briefly PBL were cultured for 6 days with 0.1 ugmi-1 HA.
The lympbobiasts enriched on a discontinuous Percoii gradient and rcsuspendcd at 33^ ceils ml""' in RPMi—1640 supplemented with 10% A" serum and 20% TCGF.
were plated out at one cell every third well in Terasaki trays with 10* irradiated autologous PBL and 0.1 ugmi'1 HA. After 7 days, growing clones were transferred
•to 96-weii microntre trays and then to 24-well trays. Then they were expanded in 25-cm" tissue culture flasks. At each transfer the T-iympnocyte acmes received
fresh TCGF and irradiated autologous PBL. together with specific antigen. The clones were maintained with 20% TCGF every 3—1 days and irradiated autologous
PBL and HA were added every 7 days. Before use in proliferation assays, the clones were allowed to rest for 6-7 days after the addition of filler ceils. HA-specific
clones (2^x 10* ml"') were cultured with the rynthenc peptides of HA1 molecule (0.01-10 ugmi"'), HA molecule (0.01-10 ugmi"'). A/Texas/1/77 (0.05-
50 HAU mi"') or 3/Sing*pore/222/79 (0.05-50 HAUmi"') in the presence of irrauiaxed autologous sheep erythrocyte rosette-neganve (EH ceils (2-5 x 10* ml"')
for 72 h. and proliferation measured by JH-TdR irmv|inr»nnn. E~~ *'« were fracsonated as described previously*. Results are expressed as mean c.pun. (•cs.r m.)
of triplicate cultures. Both the lowest and highest proliferative responses for the antigen concentrations used are shown for the synthetic peptides. "—i
■<-TabU 3 Specificity of T-ceii denes for A/Japan/305/57 (H2N2) and A/Texas/1/77 (H3N2) subtypes of influenza A virus
Gone no. -c
•• Antigen *" HAl.4 : HALT HA2.43 •-
Peptide 20 1.145 (1385-15.265 (L356) 1.047 (2075-17.408 (1.799) 620 (655-3.373 (481)
A/Texas/1/77 645(1345-15^61(438) W 975 (251>-17.406 (822) 472 (109>-3.089 (3965 ■j-
A/Japan/305/57 ~ 55(295-91(21) 63 (495-123 (16) 274(285-2.620 (229)
B/Singapore/222/79 19 (5)-42 (6) 4.. 25 (35-56(2) 27(35-49(9)
Medium alone 21(3) 55 (23) 11(3)
TCGF 1.409(24) 1.982(57) 1.472(139)
HA-spesific clones (2-5 x 10* ml"4) were cultured with peptide 20 (0.Q1-IQ ugmi"'), A/Texas/1/77. A/Japan/305/57 or B/Singapore/222/79 in the presence of
irradiated autologous E~ ceils (2J.x 10* mi"') fot^72 h. The intact influenza viruses were at concentrauons of 0.05-50 HAU ml"'. Proliferation was determined
by the incorporation of JH-TdR. Results are expressed as described in Table 2 legend.
Ci i ^ ■ m.Ii
UMMWDKI O—-»^n.1.
Fig. 2 Amino aad substitutions between A/Japan/305/57 and
A/Texas/1/77 occumng within the sequence of peptide 20. The
sequence comparison was derived from Gething et at.". The
sequence nmnoeimg a according to Min Jou et aL' in order to
conform with our peptide designations. The boxed areas indicate
substitutions.
be sensitive to a single amino acid substitution1*"13. In contrast
to clones HLA1.4 and HA1.7, clone HA2.43 recognized both
viral subtypes, which implies that it recognizes an invariant
sequence or peptide 20, or less likely that the amino arid
substitutions between A/Japan and A/Texas are insufficient to
cause modification of the moiecuie to influence T-ceil antigen
recognition1*.
The findings reported here do not resolve the issue of the
nature of T-ceil recognition in terms of a denned amino aad
sequenceor its dependency on tertiary structure16. In an attempt
to define the epitope sequence, subunits of peptide 20 were
generated with the four carboxy-tcrminai amino acids and
increasing the subunit sequence progressively by four amino
acids until the complete peptide was synthesized, Uniikc the
intact_peptide, however, none of the subumts induced prolifer¬
ation of the clones (data not shown). This result does not
distinguish whether the amino terminus of peptide 20 is the
precise sequence recognized or whether it dictates the confor¬
mation of the native peptide necessary for T-ceil recognition.
An alternative explanation is that the subunits themselves can¬
not adopt the same conformation as in the intact peptide,
therefore they are no longer recognized by the T cells.
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Duchenne muscular dystrophy (DMD) is one of the most com¬
mon and serious human X-linked disorders. It occurs at a
frequency of up to 1 in 5,000 newborn males in most popula¬
tions studied, with about one-third of ail cases due to new
mutations1. The primary biochemical defect remains unknown,
and no proven prenatal diagnostic test exists, although raised
serum creatine kinase levels act as a somewhat eqnivocai guide
to carrier females1. Previous studies have shown no measurable
genetic linkage of the DMD locus- with any X-chromosome
marker1"*. Therefore, if a cioned sequence of the X chromosome
could be used to. define the locus, and to provide a closely
linked set of markers, it would be of considerable importance
in the prediction and prevention of DMD. as weil as a step
towards identifying the basic biochemical defect earning the
disease. We present here evidence of an X-chromosome
sequence, defined by its restriction enzyme polymorphism, that
is* loosely linked to DMD, at a distance of approximately 10
centimorgans. as determined by studies on nine informative
families..The polymorphism occurs in 29% of women in a
control London population and in 22% of carriers for DMD.
The linkage data support cytogenetic evidence that DMD is
on the short arm of the X chromosome. The object of this letter
is to encourage others to make use of our probe, which seems
to be linked to the DMD locus.
Restriction fragment length variation results from changes
in the primary DNA sequence, such as single base changes
introducing or deleting a restriction site, or sequence deletions,
additions or translocations affecting the length of DNA between
sites. These DNA sequence polymorphisms are inherited in a
menaeiian fashion ana may be used in conventional linkage
studies"-*. Variations in restriction sites around the human
/3-giobin genes have been estimated to occur once in every 100
base pairs'. Polymorphisms are sufficiently frequent in the
human genome to assume that one will be found adjacent to
any random cioned DNA probe several kilobases (kbj in iength.
A set of such sequences can be used to construct a linkage map
of the entire human genome, or of a particular chromosomal
region6-10"'3.
We have previously cloned a collection of sequences from
the human X chromosome in A phage after sorting using a
cvtofluonmeter: aoproximateiv 50.000 clones were obtained,
sufficient to ensure that >90% of sequences from the X chromo¬
some are represented in the library1*.
Single-copy sequences were identified in the X-chromosome
library using Benton-Davis screening13 to total labelled human
DNA; clones containing repetitive elements present at >100
copies in the genome hybridize and are labelled in the reanneai-
ing conditions used16. One of the singie-copy clones obtained,
given the laboratory acronym ARCS, was characterized by
Fig. I Localization of ARC3 to the region Xp21-Xp223 using
EcoRI-digested DNA from a panel of rodent-human cell hybrids.
Positioned above each lane is a representation of the human X
chromosome, shaded to show the portion which is present in the
hybrid ceil line from which the DNA was obtained (from left to
right): Chinese hamster parental cell line, mouse parental cell line:
hybrids containing part or all of the human X chromosome:
Xpter-Xqter. Xp223-Xqter. Xp21-Xqter, Xql2-Xqter, Xq21-
Xqter. Xq22-Xqter. Xq26-Xqter. Xq28-Xqter. fibroblast ceil line
(F). These ceil lines were characterized cytogeneucaily and bv
isozyme markers in the department of Genetics. University of
Freiburg. High molecular weight total DNA was extracted,
digested and analysed by Southern blotting as previously
described23,2*. Blots were washed in lxSSC at 65°C'and
' -**•* ~ autoradiograpned at —70*C for 72 h. -•
hybridization- to ircpRI-digested human DNA.. DNA from
various rodent-human' hybrid ceil lines containing X chromo¬
somes or fragments as the only human genome component,
and mouse DNA using Southern blots17. ■ .
This: clone. contains a'6.1-kb insert of human DNA and
hybridizes to a singie 6.1-kb band in EcoRI-digested human
genomic DNA, and DNA from HORL9.X ceils (a mouse-
human hybrid ceil line in which the only human chromosome
is the X chromosome), but not to.mouse DNA (Fig. 1). It
hybridizes to 46XY, 46XX and 48XXXX genomic DNAs with
an intensity relative to the number of X chromosomes present
(not shown), demonstraang that it is X-chromosome specific.
In hybridizations to total human DNA it gives a slight back¬
ground after moderate stringency washes 11 x SSO which dis¬
appears after washing filters at a higher stringency (0.1 xSSO
and does not interfere with the analysis reported here.
Somatic cell hybrids were used to locate the DNA sequence
cloned in ARC3 to a region of the X chromosome. Hybridization
of the clone to DNA samples from various rodent-human ceil
lines containing portions of the human X chromosome localized
ARCS to the region Xp21-Xo223 (Fig. I). There was no correla¬
tion between hybridization and the spectrum of autosomes
present in these ceil lines.
Table L Linkage data tor Duchennc muscular dystrophy, prooe A RCS.
Xg blood group and colour blindness (C3)
DMD-A RC3 DMD-Xg DMD-C3 A RC3-Xg
H n =»9 n =» L0 n = 3 n =4
0.01 -0.393 -13.403 -9.781 -0.711
0.05 +1.535 -6.667 • -5.018 -0.099
0.10 -t-1.766 -3.986 -3.082 -0.090
0.15 -1.715 -2.573 -2.023 -0.050
0.20 -1.543 -1.683 — 1.343 -0.161
0.25 -1.305 -i.085 -0.365 —0.144
0.30 -1.033 -0.675 -0.524 -0.115
0.35 -0.753 -0.394 -0.283 -0.078
0.40 -0.481 -0.203 -0.123 -0.046
0.45 -0.229 -0.078 -0.030 -0.017
Results are expressed as lod scores (log of the oddsi for different
values of recombination fracnon (0). The numoer of kindreds informa¬
tive for each comparison is indicated (n i.
0023-1836 ?:.44<-i#)9— o) '.9MC Macmnlan Journals L:a
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The human CD4"*" T-cell repertoire of responses to hemagglutinin (HA) of influenza virus A/Beijing/32/92
was examined 3 to 6 months after natural infection by using a panel of 16-mer peptides overlapping by 11
residues. Short-term CD4"t" T-cell lines were derived by using full-length HAs of virus A/Beijing/32/92 from 12
unrelated, major histocompatibility complex (MHC) class I and II haplotyped adults with a history of influenza
in November and December 1993 and from 6 adults with no history of influenza during the preceding 4 years
but who responded to HA. In contrast to recent murine studies, the human CD4"* T-ceil repertoire of responses
was dominated by the recognition of highly conserved epitopes. The HA2 subunit, widely regarded as nonim-
munogenic, induced strong responses in every donor. This resulted in functional cross-reactivity among
influenza A viruses. Our study included one pair of unrelated donors expressing identical HLA DRB1* and
DQB1* alleles and two pairs of donors sharing low-resolution MHC class H types. These pairs responded to
identical peptides; furthermore, clearly identifiable patterns of response were seen in donors sharing single
class II haplotypes, irrespective of the presence of other alleles and exposure history. Two conserved regions
which induced responses in 17 of 18 donors were identified (residues 295 to 328 and 407 to 442). Possible
implications for cross-reactive T-cell vaccines are discussed.
Influenza virus type A remains a major cause of human
morbidity and mortality. Humoral immunity is hindered by
antigenic shift and. drift of the viral surface coat proteins (2).
The major surface glycoprotein hemagglutinin (HA), which
consists of two subunits, HA1 and HA2, produced by enzy¬
matic cleavage of a precursor molecule,*HA0, is responsible for
virus-host cell fusion. The HA1 subunit contains both highly
conserved and variable regions located at five main sites on the
surface of the molecule (36); these are the targets of the host
neutralizing antibodies. HA2 is conserved in structure among
H3 influenza A viruses and has homology with influenza type
A HI and H2 viruses. CD4* T-ceil help is required for the
production of neutralizing antibody (1, 34), and HA is a major
antigen for both the murine and the human CD44" T-cell re¬
sponses to influenza virus (14, 16, 20, 24).
Murine studies have demonstrated that CD4*" T cells rec¬
ognize both conserved and variable regions of HA, depending
on the experimental system used (reviewed in reference 37).
Thomas and associates have shown, in a series of detailed
experiments, that following nasal priming with live virus, strong
CD4*" T-ceil responses to epitopes closely related to the highly
variable, antibody-neutralizing sites of HA occur (3, 4, 10, 15,
24, 32), indicating that murine T- and B-cell epitopes can
overlap (4).
Very few studies of the human CD4*" T-ceil response to
influenza A virus HA have been undertaken, and the responses
of CD4"*" T cells derived from only a single donor have been
mapped in detail (19, 21); even this study employed an incom¬
plete panel of peptides derived from only the HA1 sequence of
* Corresponding author. Mailing address: Infection and Immunity
Section. Department of Biology, Imperial College of Science. Tech¬
nology and Medicine, Prince Consort Rd.. London SW7 2BB, En¬
gland. Phone: 171-594-5405. Fax: 171-584-9075.
a viral strain that had not circulated for 10 years. However, the
indication from this study and two other studies using T-cell
clones derived from single donors and panels of influenza
viruses (14) or HAs (31) is that the human response may be
directed, at least in part, towards conserved regions of HA.
In order to obtain detailed information about the human
CD4^ T-cell repertoire of responses after recent natural in¬
fection, we investigated the responses of CD4"*" T cells from a
panel of 12 unrelated major histocompatibility complex
(MHC) class I- and II-typed adult donors with a history of
influenza virus infection during the winter of 1993 to 1994
(recent influenza virus donors). We employed HA and pep¬
tides derived from influenza virus A/Beijing/32/92. the main
H3 influenza virus circulating at the time of our recent influ¬
enza virus donors' illnesses. We aimed to examine the balance
of conserved and variable epitope recognition following natu¬
ral infection, to examine the CD4"1" T-ceil response to both the
HA1 and the HA2 subunits, and to investigate the MHC ge¬
netics of peptide recognition. We decided to study the re¬
sponses of CD4^ T-ceil lines rather than T-cell clones because
the use of clones would have severely restricted the number of
donors examined, would have led to the selection of a small
number of dominant epitopes that were not necessarily repre¬
sentative of the CD4^ T-ceil repertoire, and might therefore
have introduced bias in favor of conserved-epitope recogni¬
tion. We employed a panel of CD4"" T-ceil lines selected with
full-length HA for 2 to 3 weeks and examined their prolifera¬
tive responses to HA from virus A/Beijing/32/92 and HA de¬
rived from the prototype H3 subtype virus A/Aichi/68. Epitope
recognition was mapped by using a panel of 118 16-mer pep¬
tides, overlapping by 11 residues, spanning the entire sequence
of A/Beijing/32/92 HA.
In order to compare the results obtained within 6 months
after infection with longer-term CD4"*" T-ceil memory, we also
studied a panel of six unrelated adult volunteers who had been
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recoveryMHC class I MHC class II
A 35 F A2.68. B 18.44. CW7.7/8V DRB1"0101.11. DRB3*01/02/03, DQB1*0301.05 7 7.9
B 55 F Al. B 18.27, CWI.7 DRBl-0101.il. DRB3"01/02/03. DQB1*0301,05 14 4.5
C 35 M AC3. B7.44. CW5.7 DRB1 *0401.15. DRB4-01. DRB5*01. DQB1 *0301,0601/2 10 13.3
D 24 F A1.72. B7.37. CW6.7 DRB1*0408.15, DRB4-01. DRB5*01, DQB 1*0301,0601/2 10 4.7
E 25 F A2. B44/63. CW15 DRB1 *0101.0401, DRB4-01. DQB1*0301.05 10 4.5
F 21 F A2J. B7.44, CW5.7 "DRB1 "03.04. DRB3*01/02/03. DRB4*01. DQBl*02,,d 14 4.4
G 40 F A2. B15.65. CW3.10 DRB1 *10,1302, DRB3"01/02/03, DQB1 *05.0604-8 14 13.4
H 24 F A11.24. B52.75, CWND DRB1*0403.12. DRB3*01/02/03. DRB4-01. DQB1 *0301,0302 14 8.1
I 25 M A2. B14. CW5 DRB1 *0102.07. DRB4-01. DQB1"0Z05 14 10.4
J 24 M A1,2. B8-52. CWND DRB1 *15.0301, DRB3*01/02/03. DQB1*02.0601/2 7 3.6
K 25 M A24. B55.62, CW9 DRBI *1302. DRB3"01/02/03, DQB1 *02,06 7 4.4
L 25 F A30.68, B4L51, CW(1501-3),(41-42) DRB1* 1301.1303/4, DRB3*01/02/03, DQB1 *0301.603 5 7.0
M 38 M A2J. B7.51. CW1.7 DRB1"0101. DQB1*05 0 1.2
N 30 M A2.66. B27.51. CW1.7 DRB1"0103.08, DQB1 *0301,04 0 0.7
O 42 M A2J1. B51.60. CW4.10 DRB 1*0101,0402. DRB4*01. DQB1 *0302.05 0 0.6
P 34 M A2LI8. B7.17. CW6.7 DRB1 "15,07. DRB4-01. DRB5*01. DQB1 "0303.601/2 0 0.6
Q 36 F A2.19. B14.18. CWND DRB1 *0101.12. DRB3*01/02/03, DQB1 *0301.05 0 11
R 28 M NDe DRB1 *0101.07. DRB4"01. DQB1*0Z05 0 1.5
° Subjects A to L had a history of inhuenza dunng Novemoer and Decemoer 1993; subjects M to R had no history of influenza during tne preceding 4 years.
b F. female; M. male.
c Ratio of cells recovered at day 21 in culture to number of PBMC initially seeded, calculated as follows: (number of cells recovered on day 7/number of PBMC
originally seeded) x (number recovered on day 14/number seeded on day 7) x (number recovered on day 21/number seeded on day 14).
" Subject F was class II typed serologically oniv. with the typing reported in molecular typing nomenclature for comparison.
* ND. not done.
found to make polyclonal responses to HA but who gave no
history of influenza dunng the preceding 4 years (control do¬
nors).
MATERIALS AND METHODS
Subject selection. Twelve unrelated healthy adult donors (ages. 21 to 55 years)
with a history of influenza virus infection during November and. December of
1993 were studied (recent influenza donors, subjects A to L) 3 to o months after
infection. None had ever been vaccinated against influenza virus. A positive
history was taken to be fever, headache, sore throat, myalgia, and severe lassitude
lasting several days during a period when A/Beijing/32/92-like strains were cir¬
culating. Many of the subjects had extended periods of lassitude lasting several
months and/or perststent cough. Three of the donors (D. G. and I) had been
examined for responses to HA during the summer of 1993 and were found to be
nonresponders.
An additional group of six healthy subjects (ages. 23 to 42 years), with no
history of influenza-like illness dunng the previous 4 years but who made a strong
polyclonal T-ceil response to HA. were studied as a companson (control donors.
M to R). Subject details are summarized in Table I.
MHC typing. MHC class I typing was performed by a combination of sero¬
logical typing at the Tissue Typing Laboratory, Sl Mary s Hospital. London.
United Kingdom (33), and molecular typing using sequence-specific pnmers
(PCR-SSP) at the Tissue Typing Laboratory, Churchill Hospital. Oxford. United
Kingdom (9. 30). MHC class II typing*was performed by molecular typing using
PCR-SSP at the Tissue Typing Laboratory, Churchill Hospital (26), with the
exception of one donor (F) who was typed serologically at St. Mary s Hospital.
All donors tissue types are presented in the format recommended in "'Nomen-
clature for Factors of the HLA. System. 1994" (6).
Antigens. X117 recombinant A/Beiiing/32/92 HA was the generous gift of R.
Brands. Solvav Duphar. Weesp. The Netnerlands. The preparation was egg
derived and contained the entire HA1 and HA2 suounits. The preparation was
contaminated with a trace of nucleoprotein. HA from A/Aichi/68 was the gen¬
erous gift of A. Hay and J. Skenel. National Institute for Medical Research. Mill
Hill. London. United Kingdom, ana was obtained by bromelain cleavage (7). A
series of overlapping peptides were derived from the nucleotide seauence of the
HA1 subunit of A/Beijing/32/92 and the HA2 subunit of the closely related virus
.A/Hong Kong/90, as sequence information for the HA2 subunit of A/Beijing/
32/92 was unavailable at the time of peptide synthesis. Unpublished sequence
information for both viruses was kindly supplied by N. Cox (Centers for Disease
Control and Prevention. Atlanta. Ga.). Peptides were synthesized by using F-moc
cnemistry on a Muitipeotide Synthesis block BT7400 (Camondge Research Bio-
cnemicais. Wirrai. United Kingdom) with Pepsvn KB resins by the method of
Fairchiid et al. (13). In brief, couplings were performed by using F-moc side
chain protected pentafluorophenyl or oxobenzotnazme ammo acid esters in the
presence of l-nydroxybenzotnazoie. Full-length peptides were deprotected with
tnfluoroacetic acid-phenol-thioanisoie-ethanedithiol in the ratio of 94:2:2:2 and
cleaved with 0.4 M NaOH. Thfc resulting solutions were neutralized with HQ to
yield peptides in saline solution. The peptides were 16 residues iong, overlapping
normally by 11 ammo acids. The composite primary ammo acid sequence used to
synthesize the peptides and individual peptide sequences are shown in Fig. 1.
which also shows the residue changes between the HAs from A/Aichi/68 and
A/Beijing/32/92 as an indication of the variable regions of H3 HA. The numoer-
ing of peptides used in this study is based on the precursor molecuie HAO.
Establishment of CD4* T-ceil lines. Venous blood was collected between 3
and 6 months after infection, and peripheral blood mononuclear ceils (PBMC)
were separated by Ficoil-Hypaque density centrifugauon. A total of 25 x 10°
PBMC were cultured for 7 days in 24-well tissue culture piates at 37°C with 5%
CO; with HA from A/Beiiing/32/92 (0.1 ng/ml) at a density of 5 x 10" ceils per
weil. in 2 mi of complete medium (RPMI 1640 supplemented with 2 mM l-
giutamine. 100 IU of penicillin-streptomycin (Gibco. Life Technologies. Paisley,
Scotland) per ml. and 5% screened, inactivated human AB"" serum (Sigma.
Poole. Dorset. England]). The remaining PBMC were stored in iiquid N; and
suosequentiv used as antigen-presenting cells (APCs).
At day 7. 4 x K^T cells were used to analyze the response to HA and peptides
as described below and the remaining T cells were restimuiated. at a density of
1.0 x 10° per well, with equal numbers of irradiated (3.000 rads) autologous
PBMC premcubated at 37®C in 5% CO= in complete medium for 1 h with HA
from A/Beijing/32/92 (0.01 to 0.1 jtg/nil). At 24 and 72 h. the lines were supple¬
mented with a source of intcrieukm 2 (Lymphocult T; Biotest Foiex, Frankfurt.
Germany) (10%. vol/vol). The T-cell lines were maintained in culture for 3 to 4
weeks as described above, with the addition of fresh, irradiated autologous
prepulsed PBMC every 7 days.
Analysis of T-cell specificities by using overlapping peptides. Autologous,
irradiated (3.000 rads) PBMC (4 x lCPAvell) were incubated with whole anttgen
(HA from A/Beijing/32/92 [0.01 to 0.1 uug/ml) or HA from A/Aichi/68 (1.0
jxg/ml]) or peptide pools (five peptides each at a concentration of 10 ttg/ml) for
1 h at 37°C in 5% C02 in complete medium and subsequently cultured with 4 x
104 responder T cells per well in round-bottommed 96-well piates. At 48 h. the
ceils were pulsed with [JH]thymidine (1 p.Ci per well: Amersham Intemauonal
PLC Amersham. United Kingdom) and harvested 16 n later. Proliferation, as
correlated with [3H)thymidine incorporauon. was measured by iiquid scintilla¬
tion spectroscopy. Responses of at least five times the geometric mean of the
background (T cells, autologous irradiated PBMC. and medium) were scored as
positive. Mapping with individual pepudes (10 ji.g/ml) was conducted at day 21 or
28 as described above.
MHC class II restriction studies. Monoclonal anti-HLA-DR (L243) (22).
anti-HLA-DP (B7/21) (35). and anti-HLA-DQ (SPV-L3) (a gift from H. Spitz.
DNAX. Palo Alto. Calif.) antibodies were isolated from hybndoma culture
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2 a a 2 s
A/BEIJING QK L PGNDNS TAT LCLGHHAVPNGTLVKT I TNDQ I EVTNATE LVQSSSTGR
A/AiCHI O OK
2 s 8 a I
A/BEIJING ICDSPHRI L DGKNCTL I DALLGDPHCDGFQCKEWDLFVERS KAYSNCYPY
A/AICHI N N 10 VET F
2 5 s 9 I
A/BEIJING DVPQYASLRS LV ASSGTLEF I NEOFNWTGVAQQGGSY ACKRGSVNS F FSR
A/AICHI TOT T N N P O 5 0
i s i S I
A/BEIJING LNWLHKSEYKYPALNVTMPNNGKFDKLY I WG VHHPSTDRDQTS UYVRASG
A/AICHI T E GST V ON I N O E 0
s S S 2 2
A/BEIJING RVTVSTKRSQQTVTPNIGSRPWVRGQSSR I S I Y WT IVKPGDI LLINSTGN
A/AICHI P I I L v v N
1 5 8 Z 3
A/BEIJING LI APRGYFK I RNGKSS I MRS O A P IGTCSSECI TPNGS I PNDKP FQNVNRI
A/AICHI M r 0 1 K
2 g g | 2
A/BEIJING TYGACPRYVKQNTLKLATGMRNVPEKQTRG I FGAIAGF I ENGWEGMVDGW
A/AICHI K L I
5 5 8 2 3
A/HK YGFR HQNSEGT-GQAADLKSTQAA I DQI NGKLNR L IEKTNEKFHQ I EKEFS
A/AICHI
2 a a | s
A/HK EVEGR IQDL E KYVEDTK IDLWSYNAE LLVALENQHT I D LTDS EMNKLFEK
A/AICHI
I % I ? 3
A/HK TR KQ LRENA E D MG NGCF K IYHKCONAC I GS I R N GTY DHDVYRDEALNNRF
A/AICHI E
A/HK Q I KGVELKSGYKDWILWISFA I SCFL LCVVLLG F IMWACQKGN I RCN I C
A/AICHI *
FIG. I. Sequences of HA from A/Beijing/32/92 and peptides used in this study. The amino acid sequence used for peptide synthesis, based on the putative sequence
of HAO. is shown. The HA1 subunit (residues 1 to 328) is based on A/Beijing/32/92. The HA2 subunit (residues 330 to 550) is based on the closely related A/Hong
Kong/90, as no sequence information on the HA2 subunit of A/Beijing/32/92 was available at the time of synthesis. Sequence differences between A/Beijing/32/92 and
A/Aichi/68 HAs (in italics below main sequence) are indicated. A/Beijing, A/Beijing/32/92 HA: A/Aichi. A/Aichi/68 HA: A/HK. A/HongKong/90 HA.
supernatants and purified with protein A-Sepharose. Autologous irradiated
(3.000 rads) PBMC (4 x lO'Vweil). were incubated for 30 min with 10 jxg of
antibody per ml before the addition of antigen (1 and 5 of individual peptides
per ml). After 1 h of incubation at 37°C in round-bottomed 96-weil plates in
complete medium. T ceils (4 x IffVweil) were added. The cells were cultured,
pulsed, and harvested as described above.
Cross-reactivity of T-cell lines among a panel of influenza A viruses. The
following freeze-dried viruses were kind gifts of P. Chakraverty. Public Heaith
Laboratory Service, Colindaie. London. United Kingdom: H1N1. A/Formosa/1/
47. .A/Taiwan/1/86. and A/Fiji/2/88: H2N2. A/Singapore/1/57; and H3N2. A/Vic-
toria/3/75. A/Bangkok/1/79. and A/England/427/88. Between 1 and 10 hemagglu-
tinating units of virus was preincubated with autologous irradiated APCs for 1 h.
which were then cultured with T ceils as described above.
Fluorescence flow cytometry. T-ccil lines were stained directly with saturating
concentrations of fluorescein isothiocvanate-conjueated murine monoclonal an¬
tibodies anti-Leu-4 (CD3), anti-Leu-3a (CD4), and anti-Leu-2a (CD8) (Becton
7500 GELDER ET AL. J. Virol.
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FIG. 2. DeveloDmcnt of HA response by CD4~ T-ceil line derived from donor A and selected for 3 weekswith A/Beiiing/32/92 HA (a to d), plus response of control
MTSE-specinc CD4~ T-cell lines to HA and peptides (e). T-cell proliferation in resoonse to A/Aicni/68 HA A/Beijing/32/92 HA and peptide pools was tested at 7 (a).
14 (b). and 21 (c) days by using irradiated autologous prepulsed PBMC as APCs. At 4$ h. the T-cell lines were pulsed with [JH)thymidine, and they were harvested
16 h later. The v axis represents individual data for each well of a triplicate: C. control (proliferative response ofT-cell line to complete medium and autologous APCa);
A response of T-ccil line to A/Aichi/68 HA (1.0 p.g/ml); B. response to A/Beij ing/32,'92 HA (0.1 pijj/ml). Peptide poois are labelled according to the number of the first
residue of the first peptide in the pool (five peptides per pool. 10 of each peptide per ml). The .v axis represents counts per minute, (d) More-oetaiied mapping with
single peptides (10 uLg/u-1) conducted at day 28. (e) Response of MTSE-specific T-cell line to HA and peptides used in this study. The CD4" T-cell line was derived
from a donor nonresponsive to A/Beijing/32/92 HA by stimulating PBMC with 5 pj$ of MTSE per mi. Bar MTSE. response to 5 jig of MTSE per ml.
Dickinson Immunocytometry Systems. San Jose. Calif.). Viable cells, identified
by their ability to exclude proDidium iodide, were anaivzed By flow cytometry
with an Epics Profile II (Coulter Electronics. Luton. Beds. United Kingdom).
The cell population was analyzed by gating on the volume and light scatter
characteristics.
RESULTS
Subjects. The panel of donors with a history of influenza
during November and December 1993 (recent influenza virus
donors) had a wide range of MHC class II hapiotypes (Ta¬
ble 1). One pair, donors A ana B. snared MHC HLA DRB1*
and DQB1* hapiotypes (DRB1*0101.11. DRB3*01/02/03. and
DQB1* 0301,05). A second pair, donors C and D. had identical
low-resolution MHC class II types (DRB1*04.15, DRB4"01.
DRB5*01, and DQBI*0301.0601/2) and differed oniv in HLA
DRB1*04 subtype. Three donors (D, G, and I) did not prolif¬
erate in response to HA from A/Aichi/68 during the summer of
1993 but recognized both A/Beijing/32/92 and A/Aichi/68 HAs
after influenza-like illness in November and December 1993
(not illustrated).
The second panel of donors, with no history of influenza
during the preceding 4 years (control donors), also had a range
of MHC class II hapiotypes. although four shared the DRB1*
0101 allele (Table 1). Donor O shared low-resolution HLA DR
ana DQ types with donor E. who had a history of recent
influenza.
In total, of the 18 donors in the two groups. 7 shared the
DRB1*0101 DQB1*05 haplotvpe, 5 shared the low-resolution
HLA DRBI*04 type (but had several different subtypes), 4
shared the DRB1*15 hapiotype, 3 shared the DRB1*13 hap-
lotvpe. 2 shared the DRB1"07 hapiotype. and 2 shared the
DRB1*11 hapiotype. In addition, the responses of donors with
HLA DRB1*0102. -0103. -03, -08, -10. and -12 hapiotypes were
examined.
Lack ofmitogenicity of HAs and peptides. The antigens used
in this study were tested for mitogenicity by using a human
CD4~ T-cell line specific for Mycobacterium tuberculosis solu¬
ble extract (MTSE). No mitogenicity (greater than three times
the geometric mean) was induced by A/Beijing/32/92 or A1
Aicni/68 HA or any of the synthetic peptides (Fig. 2e).
Characteristics of T-ceii iines. T-ceii iines derived from the
recent influenza virus donors and selected with A/Beijing'32'92
HA expanded at least fourfold in culture over 3 weeks, in
contrast to those derived from the control donors, which, with
the exception of donor Q's T-cell line, showed no significant
expansion (data in Table 1).
Analysis of two T-ceil lines by flow cytometry showed that
the ratio of CD4~ cells to CD8~ cells progressively increased
from days 7 to 21. Six T-cell lines tested at 21 days were >90%
CD3T 78 to 88% CD4~, and 2 to 10% CD8" (not illustrated).
Examples of the proliferative responses obtained from do¬
nor A at 7. 14. and 21 days in culture are shown in Fig. 2 (a to
c). The dominant responses are to peptide poois 97-128. 183-
217. 295-328. 384-418. and 407-442. while the background pro¬
liferation progressively drops with time. In general, the pat¬
terns of response to major epitopes remained stabie. though
there was some loss of response to minor epitopes. Figure 2d
shows the results of more-detailed analysis of epitope recog¬
nition by this line using singie peptides at 28 days. Because of
the increased ratio of CD4"~ T cells and low background pro-
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liferation. we chose to analyze peptide specificity at 21 days
whenever possible.
Responses of CD44" T-ceil lines derived from unrelated do¬
nors with a history of recent influenza to HA and peptides. The
recent influenza virus donors responded to both A/Beijing/
32/92 and A/Aichi/68 HAs (Fig. 3). Marked differences in
patterns of peptide recognition were seen berween individual
T-cell lines from donors differing in MHC class II haplotvpe.
Without exception, every CD4T T-cell line mounted a signifi¬
cant proliferative response to the HA2 subunit.
When results for individual recent influenza virus donors
during the second and third weeks of culture were combined,
we found that almost the entire protein sequence as repre¬
sented by the peptide pools could induce proliferative re¬
sponses. Three regions of HA. represented by peptide pools
97-128. 295-328. and 407-442. were recognized by 10 of 12. 12
of 12. and 11 of 12 donors, respectively, during the second
and/or third weeks. A further three regions (pools 183-217,
357-393. and 384-418) were recognized by 8 of 12 donors.
Studies with single peptides within the dominant regions
showed that the responses usually localized to identical indi¬
vidual peptides or a pair of overlapping peptides, representing
regions of HA that have been structurally conserved over many
years among H3 influenza A viruses (not illustrated). Pool
407-442 was found to contain at least two immunogenic re¬
gions.
Responses of CD4"*" T-cell lines from adult donors with no
history of influenza during the preceding 4 years to HA and
peptides. The responses of the six control donors (M to R)
were, in general, to regions of HA similar to those of the recent
influenza virus donors, though not as strong (Fig. 4). Once
again, every T-cell line responded to the HA2 subunit. Pools
97-128. 295-328, and 407-442 were recognized by four, five, and
six of six donors, respectively.
Influence of MHC class II on T-celI«recognition of HA pep¬
tides. It is striking that the responses of donors A and B (shar¬
ing DRBP0101.il, DRB3"*01/02/03. and DQBP0501.0301) to
the peptide pools were very similar: both responded to pools
97-128. 183-217. 295-328. and 407-442. and studies with single
peptides demonstrated that the responses were localized to
identical peptides or pairs of overlapping peptides within the
pools (not illustrated). Donors C and D (DRB1*04,15. DRB4*
01. DRB5'Ol. DQBP0301.0601/2) differed in DRBP04 sub¬
type (0401 and 0408, respectively), but both T-cell lines re¬
sponded strongly to pools 1-25. 25-59. 97-128. 273-305. 295-
328. 407-442. and 456-488. An additional response to 252-283
was made by donor D. and again, when single-peptide studies
were undertaken, dominant responses were found to be di¬
rected to identical individual peptides. Donors E and O. who
differed in historv of exposure to influenza virus but shared
low-resolution hla DRBP01,04, DRB4*01, and DQBP03,
05 types, made strong responses to identical peptide pools,
though there were differences in the relative strengths of their
responses.
Similarities in patterns of response were also seen between
individuals who shared a single MHC class II haplotvpe. This
was particularly evident for HLA DRBI*0101 for subject E,
who shared DRB1*0101 and DQB1*0301.05 with subjects A
and B ana responded to pools 97-128. 183-217, 295-328. 384-
418. and 407-442. The responses of cell lines from subjects M.
O. and R. who had no history of recent influenza and who
shared the MHC class II alleles DRBl*0101 and DQB1*05.
were very similar to those of subjects A, B. and E. with all six
lines responding stronglv to peptide pools 97-128. 295-328. and
407-442. Subject Q (DRBT0101.12. DRB3*01/02/03. DQB1*
0301,05) responded to pools 295-328 and 407-442 but not to
pool 97-128.
In contrast, marked differences were seen in response pat¬
terns of donors with different subtypes of HLA DRBI*01:
neither donor I (DRB1*0102) nor donor N (DRB1*0103) fol¬
lowed the pattern seen for the DRB1*0101 donors.
Results of studies with anti-MHC class II antibodies. The
results of the MHC restriction studies using antibodies to
MHC class II on two T-cell lines are shown in Fig. 5. The
majority of responses by both donors were inhibited by anti-
HLA-DR antibody and were therefore HLA DRB1* re¬
stricted. Interestingly, donor D showed some increase in pro¬
liferative response to peptide pairs 20/25, 97/100. and 303/308
following preincubation with anti-HLA-DP antibodies.
Influenza virus cross-reactivity. Six T-cell lines from the
recent influenza virus donors, including ail three donors (D, G.
and I) who were nonresponsive to A/Aichi/68 HA prior to
November or December 1993. were examined for cross-reac¬
tivity among a panel of HI. H2. and H3 influenza A viruses
(Fig. 6). All were cross-reactive, although the relative strengths
of responses to HI. H2. and H3 viruses varied considerably.
T-cell line I showed a stronger response to H3 viruses than to
the HI or H2 viruses. This T-cell line was dominated by re¬
sponses to HA2. Studies with single peptides localized the
response to regions 384 to 399. 403 to 422. 427 to 442. and 463
to 483 (not illustrated). In three of these four regions, radical
changes (residue 388. T to M: 404. G to K and R: 412. Y to K:
417, F to K: 430. A to L: and 440. T to H) which probably
account for these observed differences in response occur be¬
tween H3 and HI and H2 influenza A viruses.
DISCUSSION
We report the first major study of the human CD4" T-cell
repertoire of responses to HA after recent natural infection.
004^ T-cell lines were derived from a panel of 12 unrelated
MHC class I- and Il-haplotvped adult donors with a history of
influenza during November and December 1993 (recent influ¬
enza virus donors) and a panel of 6 adult donors who re¬
sponded to HA but who had no history of influenza in the past
4 years (control donors). CD4~ T-cell lines were selected by
using full-length HA from A/Beijing/32/92 and epitope recog¬
nition mapped by using a panel of 16-mer peptides, overlap¬
ping by 11 residues, covering the entire sequence of HA1 and
HA2. Cross-reactivity was investigated by using the original
1968 H3 influenza A virus HA and a panel of influenza A
viruses. Results have been interpreted in the context of the
donors' MHC class II haplotvpes.
HA was highly immunogenic in all cases. We expected MHC
class II to play an important role in HA epitope selection in
association with an individual's exposure history and other
factors. It is remarkable, however, that proliferative responses
bv the short-term T-cell lines from unrelated donors A and B.
who are both DRBl*0101.il. DRB3*01/02/03. DQB1*0301.
05. were both directed predominantly to peptide pools 97. 183.
295. 384. and 407. with only some quantitative differences.
Analysis using single peptides revealed that their responses
were to identical peptides or pairs of overlapping peptides (not
illustrated). Donors E and O, who share low-resolution HLA
DR and DQ types but differ in exposure history, also recog¬
nized identical peptide pools. This similarity' in pattern of re¬
sponse was not limited to donors with such close MHC class II
matches, as ail seven donors who expressed DRB1*0101 and
DQB1*05 alleles, irrespective of differences in their history of
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FIG. 4. HA responses ot' CD4* T-cell lines from donors with no history of inriuenza during the last 4 years. For details, see the legend to Fig. 2. Three donors had
previously been frequently exposed to inriuenza virus, donors N and P. who were practicing physicians, and donor O. who had worked extensively with H3 inriuenza
A viruses 10 years previously.
II alleles, showed similar patterns of T-cell recognition (except
for donor Q, who failed to respond to pool 97-128).
.As predicted by peptide binding studies (11, 12), the subjects
who expressed other subtypes of HLA DR1. donors I (DRB1 *
0102) and N (DRBl*0103), in peptide recognition differed from
both the DRB1*0101 donors and each other. There are only
limited structural differences between these alleles (changes of
V to A at residue 85 and of G to V at residue 86 for DRB1*
0102 and changes of L to I at residue 67, Q to D at residue 70.
and R to E at residue 71 for DRB 1*0103). Six donors shared
the low-resolution HLA DRB1*04 haplotvpe: two of them,
donors C (DRB1*0401) and D (DRB1*0408), also shared
DRB1*15 and had very similar patterns of peptide responsive¬
ness. The variations between these donors may reflect the slight
difference between DRB1*0401 and DRB1*0408 (change at
position 71 from K to R). Identifiable patterns of response are
also evident for HLA DRB 1*07. with donors P. I. and R all
responding strongly to pool 456-488.
Most interestingly, HA2 (residues 330 to 550), which has
been regarded as largely nonimmunogenic (5), induced strong
responses in every donor. Furthermore, with the exception of
the N and C termini of HA2, every peptide pool representing
HA2 induced a response in at least 3 of 12 recent influenza
virus donors. One conserved region (residues 407 to 442) in¬
duced responses in 11 of 12 recent influenza virus donors
during the second or third week in culture: this region is un¬
changed among H3 influenza A viruses and has homology with
HI and H2 viruses. Two additional highly conserved regions
(residues 357 to 393 and 384 to 418) were recognized by 8 of 12
recent influenza virus donors. We are aware of only one pre¬
liminary study of the human CD4" T-cell response to HA2:
unselected PBMC were derived from 14 donors, who were not
tissue typed, and limiting dilution analysis showed T-ceil re¬
sponses to at least three regions of HA2 (29). One murine
study has demonstrated cross-reactive CD4 T-ceil recogni¬
tion of HA2 after nasal infection with live virus (though no
epitopes were determined) (18). A second murine study dem¬
onstrated responses to HA2 following vaccination with HA2
alone and characterized two epitopes (residues 425 to 437 and
499 to 511) (17).
Regarding the HA1 subunit (residues 1 to 328). two regions,
residues 97 to 128 and 295 to 328. were the most frequently
recognized, inducing responses in 10 of 12 and 12 of 12 recent
influenza virus donors, respectively. Studies with single pep¬
tides localized the majority of responses to residues 100 to 115
and 306 to 323. which are conserved among H3 influenza A
viruses (not illustrated). The second region has sequence ho¬
mology with HI and H2 viruses and is closely related to the
dominant epitope originally described by Lamb et al. (who
used a different panel of peptides) (19. 21). One peptide pooi
which contained a variable region within the H3 influenza A
viruses, pooi 183-217, induced responses in 8 of 12 donors. The
majority of responses localized within this region were to res¬
idues 192 to 212, which have been relatively conserved during
7504 GELDER ET AL. J. Virol.
FIG. 5. Effeci of MHC class II blocking antibodies on the response to dominant peptides. Autologous PBMC were incubated with 10 y.g of anti-HLA-DP.
ann-HLA-DQ. or anti-HLA-DR antibodies per mi or with medium (control). Individual pepudes or pairs of peptides (1 and 5 p.g/ml) were added to the PBMC and
incubated at 37°C for I h prior to addition of responder CD*~ T ceils. Further experimental details are described for Fig. 2. Numbers on thex axis refer to the individual







the past decade (changes: residue 193, S to N; 197, Q to R; 201,
R to K; and 207, K to R). Responses of CD4* T-ceil lines
derived from control donors M to R were examined as a
comparison of results after 3 to 6 months and longer-term
CD4~ T-ceil memory. The two groups recognized similar pep¬
tide pools, though the responses of the control panel were
generally weaker. Interestingly, the control lines demonstrated
an expansion in vitro which was severaifoid iower than those of
the recent influenza virus donors (Table 1). The most likely
explanation is a lower T-ceil precursor frequency, implying a
decline in circulating CD4^ T-ceil memory after infection. A
similar decline in circulating influenza virus-specific CD8" T-
cell memory has been reported (23), and both findings are in
agreement with early epidemiological surveys which showed
protection from influenza virus following natural infection de¬
clining after 4 years (28).
It is interesting that viral infection induces recognition of
several conserved HA epitopes by a large proportion of the
population. Our findings concur with the original human
CD4" T-ceil studies (which were limited to single donors) in
which, with the exception of one done specific for a variable
region of an H2 influenza A virus (8), the responses were
either cross-reactive between H3 influenza A viruses (and
sometimes HI and H2 viruses) (14, 20) or localized to con¬
served regions of the HA1 subunit (21). This contrasts with
recent murine studies of live-virus infection which have dem¬
onstrated strong CD4" T-ceil responses to epitopes closely
related to the antibody-neutralizing sites (3, 4. 10, 15, 24, 32).
Several explanations for these apparent species differences
are possible. First, our donors may have been infected with
viral strains differing from A/Beijing/32/92. However, the ma¬
jority of influenza A virus strains isolated in London in No¬
vember and December 1993 were similar to A/Beijing/32'92:
four conservative substitutions (residue 75, H to N: 145. N to
£L 201, R to K; and 208, R to K), three intermediate substi¬
tutions (residue 189, R to S; 214. T to I; and 276, T to N), and
three nonconservative substitutions (residue 157, S to L; 219. S
to F; and 226, Q to L) were recorded (12a). These changes
offer an explanation for the low frequency of response to pools
137-171 and 208-243 which was seen but do not account for the
dominance of CD4"" T cells recognizing HA regions conserved
within the H3 subtype. Alternatively, repeated exposure to
influenza A viruses in humans may bias the CD4~ T-ceil re¬
sponse towards recognition of conserved HA epitopes. There
is evidence for this phenomenon in the human B-ceil response
to HA (27).
We were fortunate that three donors (D, G, and I) failed to
mount detectable proliferative responses to A/Aichi/68 HA
during the summer of 1993. Following influenza-like illness in
November and December 1993. ail three donors made strong
responses to both A/Aichi/68 and A/Beijing/32/92 HAs, dem¬
onstrating the induction of significant cross-reactivity.
Finally, differences in antigen presentation between I-A.
which is equivalent to human HLA DQ, and HLA DR (equiv¬
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RG. 6. Responses of six CD4 T-cell lines to a panel of influenza A viruses. Autologous irradiated PBMC were prepulsed for 1 h with 1 to 10 hemagglutinacing
units of virus prior to the addition of 3-week CD4~ T-cell lines selected bv A/Beijing/32/92 HA. C. control (T ceils plus APCs). Viruses: Fm/47, A/Formosa/1/47; Tw/86.
A/Taiwan/1/86; Fj/88. A/Fiji/2/88 (ail H1N1); Sng/57. A/Singapore/1/57 (H2N2); Vc/75. A/Victona/3/75: Bk/79, A/Bangkok/1/79; and Eng/88, A/England/427/88 (ail
H3N2).
ingiy, Burt and coworkers have reported I-E-restricted re¬
sponses directed towards more-conserved regions of HA1 (10).
Influenza virus vaccination achieves a reduction of approx¬
imately 50% in hospital admissions due to influenza and pneu¬
monia among the elderly during an epidemic (25). Because of
the persistence of antigenic variation in HA, complete protec¬
tion is strain specific and generally short-lived. The partial
protection obtained from vaccination may be due in pan to the
induction of a cross-reactive CD4"*" T-cell response. This is
supported by our preliminary observations of the human
CD4"" T-cell response to HA following vaccination. As a few
conserved regions of HA were recognized by a large propor¬
tion of our donors, it may be possible to design specific CD4"t*
T-cell vaccines to boost cross-reactive protection.
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We have examined human CD4"*" T-cell recognition of influenza A/Beijing/32/92 (H3N2) virus hemagglutinin
following influenza virus HANA subunit vaccination. CD4"*" T-ceil repertoires were dominated by recognition
of epitopes located in conserved regions of the molecule, in a major histocompatibility complex class II
haplotype-dependent manner, analogous to that observed following natural infection.
Influenza A virus remains a major cause of human morbidity
and mortality. Influvac, an influenza virus HANA subunit vac¬
cine, is widely used for immunoprophylaxis. It is safe and induces
satisfactory levels of neutralizing antibodies (11). However, be¬
cause of continual antigenic variation in virus coat glycoproteins
(4, 13. 14), protection by neutralizing antibodies is generally
short lived. Subunit influenza virus vaccines are poor inducers
of human CD8"1" T-ceil responses (10), and until now there has
never been a systematic investigation of human CD4^" T-cell
responses to influenza virus following any form of influenza
virus vaccination. CD4"*" T cells play a crucial role in the con¬
trol of influenza virus infection, as the production of neutral¬
izing antibody, immunoglobulin class switching, and affinity
maturation are all CD4"1" T-celf dependent (1, 6, 12). In addi¬
tion, CD4"" T cells amplify CD8*" T-ceil cytotoxic responses (3,5,
9) and may participate in viral clearance more directly by the
secretion of gamma interferon (2).
We recently demonstrated that in the polymorphic human
population, adult CD4"*" T-cell repertoires to hemagglutinin
(HA) at 3 to 6 months following natural infection with influ¬
enza virus A/Beijing/32/92 (H3N2)-like strains are dominated
by the recognition of regions of the HA1 and HA2 subunits
that are highly conserved among human influenza A virus H3
isolates and that this results in cross-reactive recognition of









MHC class I MHC class II Prevaccination ^ost
vaccination
A 31 F No A3.23: B7.44; C4.0702 DRB1*1501,0701; DRB4*01: DRB5*01;
DQB1 *010601/2
16 4.4
B 34 M No A26J1; B38: C0701.1203 DRB1 "0301/4,1302; DQB1*06 1.2 7.2
C 31 M No A2.66; B27.51; Cl,7 DRB0103.080X; DQB1'0301.04 0.7 17.5
D 28 M No A2.29; B44.35; C4.1601 DRB1 *0101.0701; DRB4'01; DQBl'02.05 1.7 10.7
E 33 M No A2.3; B65.51; C5.0802 DRBI"0101.1301; DRB3*01/02/03;
DQB1 "0501,0603
1.7 10.7
F 42 M No A2.31; B51.60; C4.10 DRB1 "0101,0402; DRB4*01; DQB1"0302,05 0.6 5.5
G 55 M - A2J0; B44.51 DRBl'1501,0701; DRB4"01 DRB5*01;
DQB1 "02,0601/2
8.1 7.4
H 40 F Yes A2; B15.65; C3.10 DRB1"100X,1302; DRB3*01/02/03;
DQB1 "05,0604-8
13.4 17.4
" F. female: M. male.
b
—. donor G. on the basis of our previous results, is likely to have had a recent subclinical infection (see the text). Donors B, F, and G had received influenza virus
vaccines more than 5 years previously.
c Cell yield is the ratio of ceils recovered at day 21 in culture to the number of peripheral blood mononuclear ceils initially seeded: {number of ceils recovered on
day 7/number of peripheral blood mononuclear cells originally seeded) x (number recovered on day 14/number seeded on day 7) x (number recovered on day
21/number seeded on day 14).
*
Corresponding author. Present address: Department of Medicine.
University of Wales College of Medicine. Llandough Hospital, Pen-
arth, Cardiff CF64 4XN, United Kingdom. Fax: 44-1222-712284.
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FIG. 1 HA responses by CD4~ T-ceil lines derived from donors G and H. Donor H had a history of inriuenza during December 1993. and donor G. on the basis
of our previous results, may have had recent suoclinical intiuenza. The results are shown for samples obtained before (open columns) and 3 to 4 montns following
(striped columns) vaccmauon with Iniiuvac. For details, see the iegend to Fig. I.
oiher human influenza A viruses (8). These findings prompted
us to investigate CD4~ T-ceil recognition of HA following
virus subunit vaccination. In order to allow a direct comparison
between the studies, we vaccinated eight unrelated, major his¬
tocompatibility complex (MHC)-cvped. adult donors with a
subunit influenza virus vaccine containing A/Beijing/32/92.
HA-specific CD4~ T-cell lines were derived before and at 3 to
4 months following subunit vaccination. Details about the do¬
nors are given in Table I. Donors A to G had no history of
influenza for at least 5 years (though donor G may have had a
recent subclinical influenza virus infection [see beiowj). Donor
H had a history of influenza during December 1993. Subjects
received 0.5 ml of Influvac, containing 15 jxg each of HA from
influenza A/Beijing/32/92 and A/Singapore/6/86 (H1N1) vi¬
ruses and influenza B/Panama/45/90 virus, according to the
manufacturer's instructions. All other experimental details
have been previously described (8). In brief. CD4' T-ceil lines
(75. 88% CD4"") were selected for 3 weeks with a full-length
HA sequence of influenza A/Beijing/32/92 virus. Detailed HA
recognition was examined at days 14 and 21 with a panel of 16
amino acid peptides, overlapping by 11 residues, spanning the
entire sequence of the A/Beijing/32/92 HA. Peptide prolifera¬
tive assays were initially performed with pools of five peptides,
ana then responses were further localized with individual pep¬
tides. Peptides are numbered according to the N-terminai
ammo acid residue. Peptide pools are numbered by the N-
terminai amino acid of the N-terminai peptide. Possible cross-
reactivity among H3 influenza A virus HAs was investigated
with HA derived from A/Aichi/68 (H3N2).
Prior to subunit vaccination. CD4~ T-ceil lines derived from
donors A to F expanded 0.6- to 2.6-foid in the presence of
antigen (Table 1) and had A/Aichi/68 and A/Beijing/32''92 HA-
specific proliferative responses of less than 12.000 cpm (Fig. 1).
Two donors (C and E) mounted negligible responses to HA. In
marked contrast. CD4" T-ceil lines derived from donors G and
H expanded at least eightfold during culture and had higher
levels of HA-specmc proliferation (Fig. 2). Donor H had a
history of influenza during November and December of 1993.
whereas donor G had no recollection of an influenza-like ill¬
ness during the past 5 years. We have previously reported a
marked difference in the relative in vitro expansion of CD4"
T-ceil lines derived from donors recently exposed to influenza
(7.2-foid expansion during 21 days of culture) compared with
those from adults with no recent history of influenza (1.1-fold
expansion during 21 days of culture) (8). We therefore believe
that donor G had a recent subclinical influenza virus infection.
Following vaccination, CD4" T-cell lines derived from do¬
nors A to F showed increases in both in vitro ceil expansion
(Table I) and AyBeijing/32/92 ana A/Aichi/68 HA-specinc pro¬
liferation (Fig. 1). Vaccination cieariv boosted the proliferative
responses of donors A to F to the HA peptide pools (Fig. 1).
Serum from each donor recognized at least one of the poois
representing the highly conserved HA2 subunit (residues 329
to 550). Furthermore, the majority of responses to the HA1
subunit localized to regions conserved among influenza A virus
H3 strains (individual peptide data not shown), with oniv two
major exceptions: donor E responded to residues 146 to 61.
which included one conservative substitution between A/Ai¬
chi/68 and A/Beijing'32/92 (G-146 to S) and five nonconserva-
tive substitutions (T-155 to H. E-156 to K. G-158 to E. S-159 to
Y. and T-160 to K), and donor F responded to residues 137 to
157, which included four conservative substitutions (S-143 to P.
FIG. 1. CD4~ T-cell lines were derived from donors A to F before (open columns) and 3 months following (striped columns) vaccination with Inriuvac. Ceil lines
were selected with the full-length HA sequence trom intiuenza AyBeiiing/32/92 (H3N2) virus. T-ceil proliferation responses to A/Aichi/68 (H3N2) HA 11.0 u.g/mi).
A/Betjing/31'92 HA (0.1 n.g/mi). and peottde poois (five peptides per pooi: 10 ug of each peptide per mil were tested at 14 or 21 days of culture with irradiated
autologous preouised peripheral blood mononuclear ceils as antigen-presenting ceils. At 48 h. T-cell lines were pulsed with (JH {thymidine and harvested 16 h iater.
The .r axis represents the geometric mean of triplicate weiis. Control (Cent), proliferative response of T-ceil lines to comoiete medium and autologous antieen-
presenttng ceils: Aicni. response of T-ceil line to A/Aichi/68 HA (1.0 u.g/ml): Beii. response to A/Beijing/32/92 HA (0.1 txg/mi). Peptide pools are iabeiled according
to the number of the N-terminai residue of the N-terminai peptide ;n the pool (live peDtiaes per pool: 10 u.g of each peptide per mil.
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S-145 to N, G-146 to S, and T-155 to H) and three noncon-
servative substitutions (N-137 to Y, G-144 to V, and E-156 to
K) (7).
Donors G and H showed no marked increase in the ceil
expansion of their CD4"" T-ceil lines following vaccination.
The magnitudes of their anti-A/Aichi/68 and anti-A/Beijing/
32/92 HA-specihc proliferative responses did increase but were
associated with a much smaller overall rise in the A/Beiiing/
32/92 HA-specific peptide response. In both donors, the HA2
subunit was recognized, and the great majority of their re¬
sponses to HA1 were directed to conserved regions.
As the vaccine contained HA derived from an HI influenza
A virus, we were not able to directly examine the cross-reac¬
tivity of response with HI and H2 influenza A viruses. How¬
ever, because donors A, D, F, G, and H responded to residues
463 to 473 of HA and donors B and E responded to residues
442 to 462 and both regions are highly conserved among hu¬
man influenza A virus subtypes, such cross-reactivity is Iikeiy.
Following natural infection we identified two conserved re¬
gions ofHA. residues 303 to 323 and 407 to 428. which induced
CD4~ T-cell responses from 17 of 18 unrelated donors, despite
differences in their MHC class II hapiotypes (8). Following
subunit vaccination, these regions were recognized by 8 of S
and 6 of 8 donors, respectively, though the magnitudes of
individual donors' responses varied.
Clear MHC class H hapiotype-associated recognition pat¬
terns of HA were evident. Donors A and G, who express
identical DRB1" and DQ1* alleles, responded to the same
pepride pools, despite differences in their prevaccination re¬
sponses. Furthermore, donors D, E, and F, who share the
DRBI "0101- and DQBl'05-containing MHC class II hapio-
type, responded to pepride pools 97, 183, 295, and 407. Our
study of natural infection (8) included several donors with this
haplotype, allowing a direct comparison. For the two groups,
identical pepride pools were recognized, and the responses
within these pools were localized ta identical individual pep¬
tides or pairs of peptides (data not shown). Overall, the levels
of proliferative response by the two groups were similar. We
are currently investigating whether these results also reflect
similar patterns of cytokine production.
In conclusion, influenza virus subunit vaccination enhances
CD4"" T-ceil recognition of conserved HA epitopes in a man¬
ner analogous to that observed following natural infection. At
present influenza virus vaccines are offered to high-risk groups
on an annual basis. It will therefore be important to monitor
CD4" T-ceil responses after repeated annual vaccinations and
to define the optimal interval between vaccinations for the
maintenance of strong CD4~ T-ceil responses to conserved
HA epitopes.
Wc are most grateful to K. I. Welsh for help and advice regarding
HLA typing, R. Brands and Solvay Duphar tor the gift of highly
purified A/Beijing/32/92 HA and Influvac, A. Hay and J. J. Skehel for
the gift of A/Aichi/68 HA. and all our volunteer donors.
This sluay was supported by the Wellcome Trust.
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Immunological Activity of a 38-Kilodalton Protein Purified from
Mycobacterium tuberculosis
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A 38-kiIodalton (kDa) protein antigen fromMycobacterium tuberculosis was purified by monoclonal antibody
TB71-based affinity chromatography. This molecule carries two nonoveriapping epitopes recognized by
monoclonal antibodies TB71 and TB72, which are expressed substantially more strongly by M. tuberculosis
than by Mycobacterium bovis. However, cross-reactive determinants between these two species were revealed
on the 38-kDa protein by a rabbit anti-BCG serum. An immunoradiometric assay based on the TB71 and TB72
antibody pair specifically determined 38-kDa-antigen concentrations in mycobacterial extracts. Antibodies in
sera from tuberculosis patients estimated by binding to 38-kDa-antigen-coated microliter plates were positively
correlated with TB72 competing titers. Unlike antibodies, T-cell proliferative responses.to the 38-kDa protein
were expressed equally by 60% of tuberculosis patients and healthy BCG-vaccinated subjects. Similarly,
deiayed-type hypersensitivity skin reactions were elicited in both M. tuberculosis- and M. bovis-sensitized
guinea pigs. The results suggest the immunodominance of the species-specific B-cell and cross-reactive T-cell
stimulatory epitopes.
Purified mycobacterial antigens are required as essential
structural probes for dissecting the basic mechanisms of the
immune response to mycobacteria. They also have potential
applications as specific skin-test and serodiagnostic re¬
agents. Although the immune reaction to crude mixtures of
mycobacterial proteins such as tuberculin preparations has
been extensively investigated over the past several decades,
analysis of the activity of particular components has been
frustrated by the technical difficulties encountered in identi¬
fying and purifying proteins from mycobacterial extracts (3).
Antigens which were previously isolated from Mycobacte¬
rium tuberculosis include a 9.7-kiIbdaiton (kDa) protein
purified by ion-exchange chromatography (9), a 10-kDa
protein purified by monoclonal antibody-based chromatog¬
raphy (11), and antigen 5 isolated by using a polyclonal
antibody preparation (5). All these antigens were equally
represented in M. tuberculosis and M. bovis and conse¬
quently no more specific as skin-test reagents than tubercu¬
lin.
The monoclonal antibody (MAb) technology opened the
way toward the molecular definition of mycobacterial anti¬
gens. Two MAbs, TB71 and TB72, were reported to bind
specifically to several strains ofM. tuberculosis when com¬
pared with M. bovis and 20 other species of mycobacteria (4,
8). These two MAbs selectively discriminate in competition
assays between the sera of patients with active pulmonary
tuberculosis and the sera of control subjects (6, 7). In a
recent comparative survey of 31 MAbs from nine separate
laooratories, a total of seven distinct antigens were identified
(H. D. Engers and V. Houba, Letter, Infect. Immun.
51:718-720). However, only two molecules, one of 38 kDa
(identified by MAbs TB71 and TB72) and a 14-kDa protein,
were reported to carry epitopes restricted to the M. tuber-
culosis-M. africanum-M. bovis complex. In view of these
results and the previous data indicating that under appropri-
" Corresponding author.
ate experimental conditions antibodies to both identified
epitopes of the 38-kDa antigen distinguished between M.
tuberculosis and M. bovis (4. 8), we preceded with the
purification and characterization of this protein.
MATERIALS AND METHODS
Bacteria. M. tuberculosis H37Rv was grown for 8 weeks
as a surface pellicle on Sautons medium. Bacilli were re¬
moved by centrifugation and the culture supernatant was
sterilized by passing it through a filter (0.45-qm pore size:
Millipore Corp., Bedford, Mass.). Soluble extracts were
prepared by disruption of 2.5 mrad ^Co-irradiated orga¬
nisms by using a Braun MSK ceil disintegrator at 4,000 rpm
for 2 min at 5 to 10°C. Bacterial debris was removed by
centrifuging at 100,000 x g for 60 min. and the supernatant
was passed through a filter (0.45-p.m pore size) before it was
applied to immunoaffinity columns.
Immunoaffinity chromatography. The globulin fraction
precipitated by 18% Na2S04 from the ascitic fluid of hvbna-
oma TB71 was coupled to CNBr-activated Sepharose 4B
(Pharmacia, Inc., Piscataway. N.J.) as recommended by the
manufacturers by using a concentration of 7.5 mg of protein
perml of gel. The column (6 ml) was washed with phosphate-
buffered saline (PBS) and eiution buffers before use and
stored at 0 to 4°C in PBS with 0.1% (wt/vol) sodium aziae.
Crude antigen (culture filtrate or soluble extract of M.
tuberculosis) was passed through the column at room tem¬
perature with a flow rate of approximately 30 ml/hr, and the
column was washed with PBS until the eluate had no
detectable A^go* Bound material was then eiuted with 4-
coiumn volumes each of a succession of three eiution
buffers, containing (i) 1.0 M NaCl, (ii) 0.1 M giycine-HCl
(pH 2.5), and (iii) 10 % (vol/vol) dioxan in 0.1 M glycine-HCl
(pH 2.5). The column was then reequilibrated with PBS and
stored. Fractions (5 ml) were collected during the eiution
procedure and assayed for 38-kDa protein by enzyme-linked
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immunosorbent assay (EI.TSA) or by antigen capture assay.
Fractions containing anugen were neutralized, diaiyzed, and
concentrated by freeze-drying. Protein concentrations were
determined with bovine serum aibumin (BSA) as the stan¬
dard.
Antibody ELISA. The antigens were coated to Dynatech
Immuion I microliter piates (Dynatech Industries, Inc.,
McLean, Va.) by overmght incubation at 0 to 4°C in Q.l M
bicarbonate buffer (pH 8.3). The piates were washed three
times with PBS (pH 7.2) containing 0.05% (vol/vol) Tween
20 (PBST), and 1% BSA in PBST was added for 30 min at
37°C to block nonspecific binding. Antibody samples (sera or
MAbs) diluted in 1% BSA-PBST were added for a 1-h
incubation at 37"C. The piates were washed three times with
PBST, and peroxidase-conjugated secondary antibody was
added for a further 1-h incubation at 3772. Peroxidase-
conjugaied antibodies were affinity-purified goat anti-mouse
immunoglobulin G (Bio-Rad Laboratories, Richmond,
Calif.), affinity-purified goat anti-rabbit immunogiobuiin G
(Bio-Rad), ana affinity-purified goat anti-human immuno¬
giobuiin G- (gamma chain) (Sigma Chemical Co., St. Louis,
Mo.) diluted in 1% BSA-PBST at 1:2.000, 1:3.000. and
1:1.000, respectively. After further washing with PBST,
tetramethyibenzidine (dihydrochloride) (Aldrich Chemical
Co.. Inc., Milwaukee, Wis.) was added at 0.1 mg/mi in 0.1 M
citrate buffer (pH 5) containing 0.03% HiOi- After 10 min at
room temperature, the reactions were stopped by adding
acid and the A«jo was measured. The results were corrected
for any color development in the absence of primary anti¬
body or coating anugen. Hyperimmune rabbit anti-Af. bovis
BCG, anti-Af. paratuberculosis, and anti-Af. duvaiii sera
were obtained from Dako Ltd., High Wycombe, Bucking¬
hamshire,- United Kingdom.
Antigen detection by tandem immunoassay. MAb TB71 or
TB72 was diluted to 10 pg/ml and coated to polyvinyl
chloride microliter piates by incubation for 2 h at 37°C. The
plates were washed three times with PBST and blocked for
30 min with 1% BSA-PBST. Anugen samples diluted in 1%
BSA-PBST were added to the wells followed by detector
MAb (103 com per well) labeled with as described
previously (6). After 1 h at 37*C, the plates were washed with
PBST and bound radioactivity was determined in an LKB
gamma counter (LKB Instruments. Inc., Rockville, Md.).
The counts were corrected for any radioactivity bound in the
absence of anugen or coating antibody.
Serum antibody competition test. Antibody titers inhibitory
for the binding of ^I-labeied TB72 and TB71 murine MAbs
were determined essentially by the ■previously described
technique (6). Briefly, polyvinyl chloride microhter piates
coated with the soluble extract of. H37Rv were incubated
with serial dilutions of human sera for 4 h followed by the
addition of ^I-labeied MAbs and further incubation for 20 h
at 4"C. The radioactivities in the washed weils were cor¬
rected for background, and the 50% inhibitory serum dilu¬
tions were derived from graphic plots.
Immunobkit technique. Anugen samples were analyzed by
sodium dodecyl sulfate (SDSPpolyacryiamide gel electro¬
phoresis under reducing conditions by using a minigel elec¬
trophoresis system (Bio-Rad). After electrophoresis, the
proteins were transferred to nitrocellulose by blotting for 1 h
at 50 V (13). The nitrocellulose membranes were washed
with 0.1% Triton X-100 in PBS, and nonspecific binding was
blocked by incubation with 1% BSA in PBS-Triton. MAbs
(2-5 ug/ml), rabbit anti-Af. bovis BCG antibodies (1:10,000),
or human sera (1:100) diluted with 1% BSA in PBS-Triton
were added to the membranes, and they were incubaied with
Infect. Immun.
shaking for 1 h at room temperature. After the membranes
were washed with PBS-Tnton, peroxiaase-conjugated sec¬
ondary antibodies were added as described above for the
ELISA. Color development was accomplished by incubating
washed membranes in diaminobenzidine dihydrochloride
(Q.l mg/mi; Sigma) in 0.1 M citrate buffer (pH 5) with 0.03%
H3O2. After 5 min, the membranes were thoroughly washed
with deionized water and allowed to dry. For the localization
of total protein, the mtroceiluiose membranes were stained
with amido black immediately after electrobiotling. Alterna¬
tively, bound MAbs were detected with mI-labeied affinity-
purified rabbit anti-mouse antibody. Autoradiographs were
then prepared by exposing the washed membranes with
X-ray films for 1 to 3 days at —70°C.
Human T-lymphocyte proliferation assay. Peripheral blood
mononuclear leukocytes were isolated on a Ficoll-Hypaque
density gradient and suspended (5 x HP/ml) in microliter
trays in RPMI-1640 supplemented with 2 raM L-giutaminc.
100 IU of penicillin-streptomycin perml, and 10% A" human
serum. The soluble extract ofH37Rv. purified protein deriv¬
ative (PPD) (Evan Medical Ltd., Greenford, Middlesex,
England), or 38-kDa protein were added at the initiation of
these cultures over a concentration range of0.01 to 10 ug/ml.
After 6 days of incubation, the cultures were pulsed with 1.0
u.C: of triuated methyl thymidine (3H-TdR: Amersham In¬
ternational, Amersham, Buckinghamshire, United King¬
dom) for 16 h and harvested onto glass fiber filters. Prolifer¬
ation, as correlated with 3H-TdR incorporation, was mea¬
sured by liquid scintillation spectroscopy. The results are
expressed as the mean count per minute = standard error of
the mean for triplicate cultures.
DTH assay. For the deiayed-type hypersensitivity (DTH)
assay, guinea pigs of the Hartley strain (female, 250 to 300 g)
were sensitized with.killec (2-5 mrad "'Co-irradiated) BCG
or soluble extracts of mycobacteria in incomplete Freund
adjuvant by subcutaneous injection into three sites at the
back of the neck. Skin reactions were elicited 26 days after
sensitization by intracutaneous injection. Two diameters of
induraiion at 90" were measured 24 h later. (For the dosages
of used maierials. see Table 4.)
RESULTS
Demonstration of two nonoveriapping epitopes (TB71 and
TB72) on the 38-kDa protein from Af. tuberculosis. A Western
blot analysis of the reactivity of MAbs TB71 and TB72 with
a soluble extract from Af. tuberculosis indicated that both
MAbs recognized a single band with a molecular weight of
38.000 (Fig. 1A). Each MAb was previously tested for its
ability to compete with the binding of the other MAb in
labeled antibody compention assays, and neither produced
cross-competition, indicating that they were recognizing
spatially separate epitopes (6). To confirm that the two
epitopes were located on the same protein moiecuie, a
tandem immunoassay was set up in which one antibody was
bound to microuter piates and used to capture the antigen,
which was then detected by using the alternative antibody
labeled with ^I. The performance of the tandem assav with
[^1X1372 (Fig. 2A) or [^ITTB?! (Fig. 2B) as the detector
antibody was compared by using soluble extracts from Af.
tuberculosis or Af. bovis BCG as the source of the antigen.
The positive results in this assay demonstrate that the two
epitopes are indeed locaied on the same protein moiecuie. It
is of interest that doses ofAf. bovis soluble extract at least 10
times higher than those of Af. tuberculosis soluble extract
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FIG. 1. Western blot analysis of the 38-kDa protein. (A) Soluble extract from M. tuberculosis H37Rv (10 p.g per lane) was run in an
SDS-polyacrylamide gel and transferred to nitrocellulose by electroblotting. Membranes were developed with MAbs TB71 andTB72 and then
with a radiolabeled secondary antibody. (B) Soluble extract (10 p.g) from M. tuberculosis H37Rv (left lane) and 0.3 p.g of purified 38-kDa
protein (right lane) were run in an SDS-poiyacrylamide gel (12.5% acrylamide) and transferred to nitrocellulose by electroblotting. Membranes
were developed with MAb TB71 (1), serum from a tuberculosis patient (2), rabbit anti-A/. bovis BCG (3), or amido black staining (4).
were needed to obtain the same level of binding in the assay.
This quantitative difference between M. tuberculosis and M.
bovis is consistent with previous results concerning the
specificities of these two MAbs (4, 8).
Isolation and characterization of the affinity-purified 38-kDa
antigen. The outcome of the purification of a 30-mi sample of
culture filtrate from M. tuberculosis H37Rv by immunoaf-
finitv chromatography on TB71-Sepharose is summarized in
Table 1. The 38-kDa-antigen content in the purification
samples was estimated by using the tandem immunoassay
with TB72 as the detector antibody. Antigen-containing
samples were titrated in the assay, and the amount of the
sample required to produce 50% of the maximum (plateau)
binding level obtained by adding excess antigen in the assay
was determined. Results are expressed in terms of protein
concentrations based on use of a standard curve generated
with the purified 38-kDa antigen in the tandem assay (Fig.
2C). The amount of the purified 38-kDa protein required to
give 50% activity in the assay varied from 1 to 2 ng in
different experiments using freshly isolated preparations.
Repeated freezing and thawing of purified protein caused a
reduction in antigenicity, with 3 to 5 ng required for 50%
pg protein/ml ug protein/ml Mg protein/ml
FIG. 2. Detection of the 38-kDa antigen bv tandem immunoassav. (A and B) 38-kDa-antigen activity in soluble extracts from M.
tuberculosis (MTSE. •. ■) or M. bovis (MBSE. O, □) with [l23HTB72'( A) or [123I]TB71 (B) as the detector MAb. (O TB71 affinity-purified
protein. #. TB71 capture with [123I]TB72 detector MAb; ■. TB72 capture with [123I]TB71 detector MAb.
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Starting 30 1.38 41.4 14.0 420 1.01
material
Filtrate 100 0.37 37.0 0.6 60 0.16




serum (103) giving an





Anti-/Vf. bovis BCG 0.70 0.50 200 10.0
Anti-/W. paratuberculosis 0.70 <0.01 200 NA°
Anti-M. duvalii 0.75 <0.01 200 NA
Nonimmune 0.30 <0.01 0.2 NA
0 Antisera were tested in an ELISA. as described in the text, at dilutions
ranging from 1:200 to 1:625.000.
* Soluble extract from M. tuberculosis H37Rv.
6 NA. Not applicable.
tuberculosis patients and healthy controls"
SI
Subjects No. tested
2 to 4>4 <2
Tuberculosis patients 10 6 1 3
Healthy controls 18 11 2 5
" The starting material was culture filtrate from M. tuberculosis H37Rv
.grown on Sautons medium. The filtrate fraction contained the material which
passed through the column without binding along with the initial PBS wash.
The 38-kDa antigen was eluted from the column by 10% dioxan in 0.1 M
giycine-HCl buffer.
6 The concentration of the 38-kDa protein was estimated by using the
antigen capture assay with [,2JI]TB72 as the detector antibody. The amount of
pure protein required to give 50% activity in the assay was calculated as 5 ng
from the standard curve shown in Fig. 2C.
c The 38-kDa protein as a percentage of the total protein present in each
fraction.
d Determined after freeze-drying.
activity in the case of preparations stored for several
months.
The content of the 38-kDa antigen per mg of protein was
increased 100-fold during the purification procedure, with
74% of the original antigen recovered in the purified fraction
eluted in the,presence of 10% dioxan in giycine-HCI buffer
(pH 2.5) (Table 1). Optimal results were obtained by im-
munoaffinity chromatography of culture filtrates ofM. tuber¬
culosis. The specific antigen contents of soluble extracts
from M. tuberculosis were similar to those found in culture
filtrates, but immunoaffinity chromatography was less satis¬
factory with such preparations, with less than 50% of the
antigen binding to the column even after repeated passage.
The purity of the 38-kDa antigen preparation was investi¬
gated by using SDS-polyacrylamide gel electrophoresis
along with a variety of detection methods. Direct silver
staining of gels (2) or amido black staining of nitrocellulose
blots showed a single band of protein with a molecular
weight of 38.000 (Fig. IB, panel 4). Similarly, autoradiogra¬
phy of gels run with antigen labeled with 123I showed a single
band at the same molecular weight. To screen for low
amounts of antigenic contaminants. Western blots of the
purified antigen were screened with polyvalent antisera
having high activities against mycobacterial antigens. Exam¬
ples of such blots with sera from a tuberculosis patient and a
rabbit hyperimmunized with M. bovis BCG are shown in
Fig. IB (panels 2 and 3). Although extensive reaction with
multiple molecular weight bands in crude M. tuberculosis
TABLE 2. Analysis of 38-kDa protein with polyclonal
rabbit antisera
" Peripheral blood mononuclear cells (2 x lOVml) were cultured for 7 days
with a range (0.01 to 10.0 jj.g/ml) of 38-kDa protein concentrations. The
maximal proliferative response was obtained for each donor from the dose-
response curve. The SI was calculated by using this value and the counts per
minute obtained in unstimulated cultures. A similar distribution was also
obtained if responsiveness was expressed as the difference in maximum
stimulated counts per minute minus the counts per minute in unstimulated
controls (Acpm) and ranked as high (Acpm. <5.000), medium (Acpm. 2.000 to
5.000). and low (Acpm. <2,000) responsiveness.
extracts was observed (Fig. IB, panels 2 and 3, left lanes),
only a single band of reactivity was seen with the purified
antigen (right lanes). Analysis of purified antigen prepara¬
tions with MAbs recognizing proteins with molecular
weights at 65,000. 23,000, 19,000, and 14.000 (4; Engers and
Houba. Letter. 1986) failed to show detectable levels of
contaminating protein in an ELISA or a dot blot (14) assay.
Recognition of the 38-kDa antigen by anti-mycobacterial
antisera was further investigated by testing rabbit antisera to
M. bovis BCG. M. paratuberculosis, and M. duvalii in
ELISAs with M. tuberculosis soluble extract or purified
38-kDa protein as the coating antigen. All of the antisera
bound to the crude extract with comparable reactivities in
terms of maximum absorbance and serum titer, whereas
only the anti-M. bovis BCG serum reacted with the 38-kDa
protein (Table 2).
Application of purified 38-kDa antigen for serological test¬
ing of human sera. Sera from 14 patients with active pulmo¬
nary tuberculosis were examined for binding to 38-kDa-
antigen-coated plates (Fig. 3). The sera were ranked accord¬
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38Kd antigen binding - OD
FIG. 3. Detection of 38-kDa-antigen-binding antibodies by
ELISA. Microliter plates coated with 0.05 p.g of 38-kDa protein
were reacted with human sera and peroxidase-anti-human immuno¬
globulin G conjugate, y axis: binding titers represent serum dilutions
giving 0.2 OD450; competing titers represent 50% inhibitory serum
dilutions. TB71 50% inhibitory serum dilution, >1/10. x axis:
38-kDa-antigen-bmding OD45o at a fixed 1/5 serum dilution.
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[OD.jJ) al a 1/5 serum dilution on the x axis, and the
quantitatively determined 38-kDa binding tilers and
[^nTBTT competing titers fix., 50% inhibitory serum dilu¬
tions) on the y axis were compared. The 38-kDa protem-
binding antibody tilers of most tested sera were positively
correlated with the TB72-compering titers. Only one 38-kDa-
binding positive (titer. 50) serum had TB72 competmg activ¬
ity 10 tunes lower. Conversely, three sera with less than 0.2
0D4» values showed significant (liters. 14 to 15) TB72
competition. These results suggest that the antibody re¬
sponse of tuberculosis patients is directed predominantly
against the TB72 epitope of the 38-kDa antigen. Only three
sera (21%) revealed TBTl-competing activity.
T-ceil m ngiillinn of 38-kDa protein. The proliferative
response of peripheral blood T lymphocytes to the 38-kDa
protein was determined. A positive response (stimulation
index fSn, > 4) was obtained with lymphocytes from 6 of 10
patients with active pulmonary tuberculosis and also with
those from U of 18 individuals vaccinated with BCG but
having no clinical history of tuberculosis (Table 3). The
remaining subjects produced either no sumuiauon (SI. <2)
or a margmai increase of the lymphocyte response (SI. 2 to
41. Thus, the frequency of significant lymphocyte responses
to the 38-kDa antigen was similar in tuberculosis patients
and BCG-vaccinated controls. Examples of posidve and
negauve responses to the 38-kDa protein by tuberculosis
patients are shown in Fig. 4A and B. The 38-kDa protein was
required at a concentration of 3 agrml to induce maximal
stimulation, equivalent to the plateau elicited by PPD and
H37Rv. Increasing the concentration of the 38-kDa protein
to 10 qgiml resulted in a mild reduction of proliferation, in
contrast to the increased activation induced by PPD and
H37Rv ai that concentration. Furthermore, at concentra¬
tions of <0.1 ug/'ml. both PPD and H37Rv sumuiated T-ceil
proiiferauon. whereas the 38-kDa protein failed to do so
(Fig. 4A). While the 38-kDa protein over the concentration
range tested (0.01 to 10.0 ugrmi) failed to stimulate the T
lympnocytes of the nonresponder population (Fig. 4B). PPD
and H37Rv induced proliferation, with an overall pattern
similar to that observed m the rT«.|viimrr population (Fig. 4A).
Skm DTH response of guinea pig. The potency of the
38-kDa protein to evoke a skin DTH reaction was oeter-
mined in guinea pigs presensitized with BCG or with soiuble
extracts from either M. tuberculosis or M. bovis. The results
showed weak reactions to the 38-kDa anugen. 4.0 to 6.0 mm
mean diameter, as compared with 8.8- to 10.5-mm reactions
to PPD and 13.0- to 17.7-mm reactions to M. tuberculosis
soiuble extract. The positive reactions in the M. bovis-
sensiuzed groups suggested that cross-reactive epitopes of
the 38-kDa -protein were recognized by DTH-effective T
ceils.
DISCUSSION
Purification of protein antigens either from mycobacterial
extracts as described here or possibly from Escherichia coii
containing recombinant DNA (IS) is a prerequisite for the
detailed analysis of the role of each of these components in
the immune response to mycobacteria. Immunoafihuty chro¬
matography using MAb TB71 provided a simple one-step
purificauon procedure for the 38-kDa protein ofM. tubercu¬
losis. The successful outcome could have been predeter¬
mined by the lack of complexing of the antigen with other
molecules in the starting preparation, as well as by the
suitable affinity of the used TB71 MAb. The use of high-salt-
concentrauon and iow-pfi buffers before edition of the
Anupan m cuitur* tugSnf]
FIG. 4. Stimulation of human lymphocytes with the 38-kDa
protein. Pcnpncrai blood mononuclear ceils of a responder (A) ana
nonresponder (B) at 2 x lOVmJ were stimulated with outer M.
tuoercuiosis soluble extract (• PPD (O). or the 38-kDa protein (A)
ai a range of concentrauona. Proliferation as correlated with 3H-TdR
incorporation was determined after 7 days of culture. The results are
expressed as the mean counts per minute = the standard error, with
the counts per minute of the control unstimulated cultures sub¬
tracted. The background response of the control cultures was less
than 2-500 cpm. The peripheral blood mononuclear ceils were tested
for in vitro proliferative responses 7 days after. the addition of
anugen by the incorporation of JH-TdR. The results are expressed
as the mean counts per minute = the standard error nanus the
counts per minute (2.1*4 = 198) incorporated in control unstimul¬
ated penonera! blood mononuclear cells.
anugen with a hydrophobic solvent at low pH probably
contributed to the purity of the final preparation.
It seemed mandatory for the subsequent analysis of spec¬
ificity and immunological activity of the 38-kDa protein to
ascertain the purity of the obtained preparation. Compelling
evidence demonstrating that the obtained preparation was
substantially free of other antigenic components was pro¬
vided by the immunoblor technique by using a hyperimmune
poiyspecific antiserum to M. bovis BCG. This antiserum,
directed toward multiple antigens in M. tuberculosis soluble
extract, detected only a single 38-kDa band in the affinity-
purified material. Furthermore, no significant binding was
revealed by immunoassay with MAbs ML30 and ML34
directed to antigens which were contaminating previously
reported affinity-purified fractions (8).
The binding of both TB71 and TB72 MAbs to the TB71
affinity-coiumn-eiuted fraction showed unequivocally that
they represent two distinct epitopes on the 38-kDa molecule.
Consequently, it was possible to use this pair of MAbs as
capture and detector reagents, respectively, in a tandem
immunna<gty. This assay is eminently suitable for the spe¬
cific quantitative estimation of 38-kDa-antigen concentra¬
tions in crude bacterial extracts. There is a particular advan¬
tage in this technique as compared with a roaring of antigen
onto solid phase, in which binding values can be masked by
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other abundant antigens (Engers and Houba. Letter. 1986).
Comparative analysis of soiuoie extracts from M. tubercu¬
losis ana M. bovis BCG by the tanacm assay cieariy dem¬
onstrated at ieast 10-fold-higher expression of both tne
epitopes of the native 38-kDa protein in M. tuberculosis.
This is consistent with the original soiid-phase immunoassay
results (4) ana with the previous demonstration of weak M.
bovis cross-reacnviry by methods which involved a certain
degree of protein aenaturation (8: Engers and Houoa. Let¬
ter, 1986). However, the presence of a 38-kDa homologous
protein in M. bovis was suggested by the presence of
cross-reactive antibodies in a Hyperimmune rabbit anti-Af.
bovis BCG scrum. These antibodies may be directed to
cross-reactive determinants wnich are either distinct or
stencaily related to the TB71 and TB72 epitopes. However,
hyperimmune anusera to M. paraiuberculosis and M. duvaiii
of comparable titer to the anti-Af. bovis serum aid not bind to
the 38-kDa protein.
Previous analysis of the antibody repertoire in active
pulmonary tuberculosis by the scrum competition test
snowed activity toward tne TB72 epitope in tne majority of
patients and activity toward tne TB71 epitope in the minor¬
ity. out neither was present in healthy BCG-vaccinated
controls (6). In the present study, it was of interest to
examine human sera antibodies for binding to purified 38-
kDa-anugen-coated poiyvinyi chloride piates whicn seemed
to offer possible technical advantages over the competition
test. The results of a pilot study on sera from 14 tuoercuiosis
patients snowed a positive correlation between TB72 com¬
petition titers ana total 38-kDa-protein binding. This is
consistent with the conclusion that in tuberculosis patients
the TB72 epitope is the mam immunodominant epitope of the
38-kDa antigen. Thus, it is not surprising that marginally
positive sera couia be detected with greater sensitivity by
tne T372 competition test. However, more extensive ^eval¬
uation of the 38-kDa-antigen-based assay for the serology of
tuocrcuiosis is reauired.
in view of the presence of the two serologically active M.
tuberculosis-specific epitopes on the 38-kDa orotcir.. it was
of considerable interest to examine the T-cell stimulatory
activity of the afiinitv-purined antigen in numans and in
guinea pigs. Uniike B-cell responses, the T-ceil-proiircrative
in vitro assay was stimulated by the 38-kDa antigen in aoout
eauai proportions (60%) of tuoercuiosis patients and healthy
BCG-vaccinated controls. Furthermore, DTK skin reactions
elicited by the 38-kDa antigen were not significantly different
wnen guinea pigs sensitized with M. tuoercmosis ana M.
oovis were compared. Tne reiativeiv nigh 38-kDa-anugen
concentration (when compared with that of PPD) requirea
for the ODtrmai stimulation of human ivmpnocytes couia
nave applied aiso for guinea pigs and therefore may explain
their iow skin-test response. Nevertheless, this result docs
not need to impiy a wcaK immunogenicity of the 38-kDa
antigen, consiaenng that the superior potency of PPD :s
probably due to its complexity of antigens which stimulate T
ceils of multiple specificities. Taken together, tnese results
suggest tnat the immunoaominant T-ceil stimulatory deter¬
minants of the 38-kDa protein are snared berwecn M.
tuberculosis ana M. bovis. The ooservation that the im¬
munodominant determinant for the antibody response ap-
pears to be species-specific whereas the immunoaominant
T-cell determinant is cross-reactive with M. bovis suggests
that the 38-kDa protein may be useful as a diagnostic reagent
for serological testing but is uniikeiy to be a specific skin-test
reagent. Information on any protective effect of the T-ceil
response to the 38-kDa protein, and consequently any po¬
tential application towards vaccine development, is an im¬
portant subject for further study.
Although it is generally accepted that B ana T lympho¬
cytes recognize distinct structural determinants on anugens
(10. 12), so far little is known about tne pairing of the
respective constitutive epitopes on proteins (1). These reia-
uonsmps are not at all understood when the anugens are
parts of an even more complex bacterial structure. How¬
ever, the obtained oata indicate that the B-ceil responses
toward the M. tuoercuiosis-svczihz epitopes of the 38-kDa
antigen probably use cross-reactive neipcr T celis. Finally, it
is conceivable that the search for truiy specific reagents for
skin testing will require the use of peptiaes containing single
epitopes of desired specificity rather than wnoie protein
molecules.
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Two complementary approaches were used to determine the
epitope specificity of clonal and polyclonal human T lympho¬
cytes reactive with the 65-kd antigen ofMycobacterium leprae.
A recombinant DNA sublibrary constructed from portions
of the 65-kd gene was used to map T ceil determinants within
amino acid sequences 101—146 and 409—526. Independently,
potential T ceil epitopes within the protein were predicted bas¬
ed on an empirical analysis of specific patterns in the amino
acid sequence. Of six peptides that were predicted and subse¬
quently symbesised. two (112—132 and 437—459) were shown
to contain human T ceil epitopes. This corroborated and refin¬
ed the results obtained using the recombinant DNA
sublibrary. Both of these regions are identical in M. leprae
and M. tuberculosis and are distinct from the known B cell
epitopes of the 65-kd protein. This combination of recombi¬
nant DNA technology and peptide chemistry may prove
valuable in analysis of the cellular immune response to in¬
fectious agents.
Key words: epitopes/mycobacreria/peptides/recombinant DNA/T
cells
Introduction
Identification of antigenic determinants within protein molecules
is of theoretical importance in understanding the fundamental
interactions involved in immune responses and of potential prac¬
tical value in the design of 'summit' vaccines and specific
diagnostic reagents. Information has arnimn'mrrrl recently on the
architecture of both antibody binding sites and T ceil epitopes
for a number of structurally well-defined proteins such as
lysozyme and myogiobuiin (Benjamin et aL, 1984) and con¬
siderable interest has been shown in the use of synthetic pep¬
tides for modulation of antibody responses to infectious agents
(Lerner, 1984). Several predictive methods have been describ¬
ed for the identification of potential B ceil epitopes (Hopp and
Woods, 1981; Tamer et aL, 1984; Westfaof et aL, 1984; Bariow
et aL, 1986). Because an effective immune response to many
pathogens, such as intracellular parasites, is dependent on T ceil
activation (Hahn and Kaufman, 1981), it is also necessary to
develop strategies to identify T ceil determinants. The observa¬
tion that T ceil determinants generally consist of short linear pep¬
tide sequences has stimulated the development of predictive
theories for T ceil epitopes that are based on analysis of amino
acid sequence (DeLisi ana Berzofsky, 1985; Rothbard, 1986).
Pathogenic mycobacteria are the cause of widespread chronic
diseases, particularly in developing countries, with an estimated
30 million individuals suffering from tuberculosis and a further
10—15 million individuals -with leprosy (Bloom and Godai,
1983). The outcome of mycobacterial infection is thought to be
determined by the interaction of mycobacterial antigens with T
ceils (Mackaness, 1964) and recent studies have identified some
of the mycobacterial proteins which are involved in recognition
by human T ceils (Emmrich et aL, 1986; Mustafa et aL, 1986;
Ottenhoff et aL, 1986; Young et aL, 1986; Lamb and Young,
1987; Oftung et aL,-1987).
The gene for a major mycobacterial antigen, the 65-kd pro¬
tein, has been cloned from Mycobacterium tuberculosis (Young
et aL, 1985a; Husson and Young, 1987) and from M. leprae
(Young et aL, 1985b). Sequence data shows that this antigen is
highly conserved in the two mycobacteria (Mehra et aL, 1986;
Shinmck. 1987). The 65-kd protein is recognised by a high pro¬
portion of the many differrair mnrjnff monoclonal antibodies raised
against mycobacterial extracts (Engers et aL, 1985,1986), sug¬
gesting that the antigen is important in the B ceil response to
mycobacteria. A recombinant DNA expression method has been
used to map the epitopes recognised by six of these monoclonal
antibodies (Mehra et aL, 1986).
The 65-kd antigen is also involved in the T ceil response to
infection, and T ceil clones from patients with tuberculosis or
leprosy have been shown to proliferate in response to the 65-kd
protein (Ernmnch eraL, 1986; Lamb et aL, 1986; Oftung et aL,
1987). However, the precise location of the T ceil determinants
within the molecuie has not yet been established.
In this paper we have exploited two new techniques to map
human T ceil epitopes within the 65-kd protein, one based on
recombinant DNA expression (Mehra et.aL, 1986) and the other
based on the synthesis of peptides whose sequences are predicted
to constitute T ceil determinants (Rothbard, 1986).
Results
Expression of antigens by recombinant DNA clones
Construction of a set of recombinant DNA clones containing
overlapping.fragments of the structural gene of a protein can be
used to determine the location of antigenic sites within the
molecule. Screening of such a sublibrary with monoclonal anti¬
bodies has been used to identify six B ceil epitopes in the 65-kd
protein (Mehra et aL, 1986) and we have used an analogous ap¬
proach to locate T ceil determinants. Figure 1 illustrates the
regions of the gene covered by each of the recombinant DNA
clones.
Expression of antigens in lysogenic strains derived from the
phage ciones listed in Figure 1 was analysed by Western blot¬
ting as shown in Figure 2. The phage clone which was used for
construction of the sublibrary (Y3178) contains a DNA insert
coding for the entire 65-kd prtxem ofM. leprae butwith an onen-
tanon reversed wnh respect to-the lacZ gene (Mehra et aL, 1986).
The antigen expressed by this clone has a moi. wt of —65 kd
and is dearly not fused to /3-gaiactosidase (lane 8). An analogous












Fig. 1. Map snowing area* of the 65-icd picxpu covered by- DNA suolibrary
clones ana synmeoc peoodes. The ammr* sad resdocs of the 65-icd prnmn
(1—588. based oa proooscd SL Levra* cm™ seauence) are snown on the
scale cuoog the top. The upper pornoo of the diagram snows toe area* of
the gene covered by the DNA suoiibrary aones, wniie the lower pornon
snows the synthetic peoaaes. The snppted areas correspond to the regions
recognised by T ceils.
•jr-CJi'i..-
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Fig. — Exnressioo of myrooactenai anngen- by recomoinam DNA clones.
Lvsogens preoared in E. coii Y1089 using the Xgtll pnages snown in
Figure 1 wen- grown ana induced as described in the "-n Western bioa
were preoarea ana acveiopeo with maooaonai .imiimiiw Cl.l (lanes 1—41.
HH9 (lane 5) ana IICS (lanes 6—81. f 1 contained lysogexx ("'>■» clone
Y3150: lane 2. Y3222; lane 3. Y32Q3; lane 4. Y32A3: lane 5. Y3246:
Lane 6. Y324Q; lane 7, Y3189: lane 8. Y3178. On the nght-nand of
the figure is shown the migration posmou of szanaaxd orotem maixers with
moi. wa (in kn) as i
simanon exists for clone Y3150 which exnresses the 65-icd pro¬
tein ofM. nwercuiosis (lane 1). In contrast, ail of the sublibrarv
clones used in this study have insert DNA oriented with the ZacZ
gene (Media, eraL, 1986) and Western bioranalysis riwwmmran-s







Fig. 3. T ceil recogmnon of onagers expressed by recomoinant DNA
clones. Unfracaomrrd rtscmc iynxpnocyics were snrmnircd with .exiraas
from Y3150. Xgill icontrol iysogen with no insert DNA). Li. L2. L2. LA.
L5. L6 (ail at 30 ug protem/mi) ana MTSE (1 n% protein/ml). Proliferation
as corrnarrri with (JH]TdR mcorooranon w«* dcterminea at day 6. The
results are exoirssed as mean c.p.m. s SEM of trroiicaie cultures. The
resoonse of T ceils to medium aiooe w*s 575 as 10 c.p.m. as SEM.
T ceils of done P77 were szzmuiatea with the same antigens as aoove in the
presence of autologous uraniatrrt PBMC as a source of APC. Proliferation
was determined at 72 h. Tho coatroi lestxxtse of P77 to APC in the aoscnrr
of antigen was 325 = -i C-p.m. as SEM.
pressed as a high moi. wt fusion ljtotem linicrd to d-gaiactosiaase
(Figure 2. ianes 2—7);
After uitrasomcanon. the fusion protein from each clone-was
found to be present in approximately equai amounts in the solu¬
ble and insoiubie fmcnons. Adriinon of ammonium suipiiare to
the soluble tfacaon (finai concentration. 50% saturation at
0-4°C) resulted in complete precrpimnon of fusion proteins as
judged by Western blot analysis. Previous experiments (data not
shown) have :nriirarrh that coii exuams have a non-specific
inhibitory effect on T ceil proliferation .assays which can be
substantially riecr^s^ by this simple ammonium suiohaie frac¬
tionation step.
T ceil recognznon of fusion proteins from 65-kri. sublibrary
Products expressed by the intact 65-kd gene (Y3150) and the
subiforary clones L2 (residues 1-185), L3 (67—246) ana L5
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Fig. 4. Response of T cell clone P77 to synthetic peptides of 65-kd antigen.
T cells of clone P77 were stimulated with peptides 112—132 (O). 163 — 184
(V). 200-218 (□), 227 -243 (A). 242 - 266 (•), 437-459 (■) in the
presence of autologous irradiated EBV-B ceils. Proliferation was determined
at 72 h.
3H-TdR cpm lid3







Fig. 5. Polyclonal T cell response to synthetic peptides of 65-kd antigen.
Ururactionated ascitic lymphocytes were stimulated with peptides 112 — 132,
200—218. 437 —459. 470—485, MTSE or alone in medium. Proliferation
was determined at day 6. The results show the- maximum proliferation of a
dose—response curve for each antigen.
(408—570) induced a proliferative response in the polyclonal T
ceils of the ascitic effusion as compared to the control of a lysogen
prepared using Xgtll without insert DNA (Figure 3). The
response to LI, L4 and L6 was <2-foid higher than that of the
background control of the Xgtl 1 lysogen. This suggested that at
the polyclonal level at least two regions of the 65-kd protein
(residues 101 — 146 and 409—526) contained T cell epitopes
(Figure 1). The response of the ascitic T cells to MTSE served
as a positive control (Figure 3).
The pattern of recognition of the 65-kd sublibrary fusion pro¬
teins by T cells of clone P77, isolated from the ascitic effusion
and previously repotted to be specific for the 65-kd anugen (Lamb





Fig. 6. Annuo acid satuence of residues 112—132 and 437 —459 of the
65-kd protein. Amino acids arc represented by the single, lem-r code. The
underlined residues represent the rhnnw-ff^^rjf- patterns a<crv-mn-vf with the
presence of predicted T ceil epitopes (Rothbard, 1986).
ei aL, 1986), was also determined. Clone P77 proliferated in
response to L2 and 13 but not to the adjacent sequences LI and
LA. In contrast to the response observed with ascitic T ceil popula¬
tion, clone P77 was not stimulated by extracts from the recom¬
binant clones covering the carboxyi terminus of the protein (L5
and L6) (Figure 3). The cloned T ceils responded to the intact
65-kd protein (Y3150) and to MTSE but not to the control ex¬
tract from a lysogen prepared from Xgtl 1 without insert DNA.
This suggests that the epitope recognised by P77 is located within
residues 101 — 146.
Mapping of T cell epitopes with synthetic peptides
A high proportion of the peptides which have been reported to
function as T ceil determinants contain a distinctive pattern within
their amino acid sequence (Rothbard, 1986). This pattern con¬
sists of a charged, or a glycine residue, followed by two or three
consecutive hydrophobic residues, and terminating with a poiar
amino acid. The 65-kd antigen was analysed for the presence
of such sequences and six peptides containing patterns similar
to those in previously defined epitopes were identified and syn-
thesised. Figure 4 lists the six peptides along with a control pep¬
tide (470—484) which contains a known B cell epitope (Mehra
et al., 1986) but lacks the characteristic T cell pattern.
Each peptide was tested with both the T cell clone and with
the polyclonal population using the proliferation assay. T cells
of clone P77 proliferated in a dose-dependent manner when
stimulated with peptide 112— 132 in the presence of antigen
presenting ceils, but not with the control peptides 163— 184.
200 -218, 227 -243, 242 -266 and 437 -459 all from the 65-kd
protein (Figure 4). The proliferation was equal to that elicited
by preparations containing the intact protein or any of the
fragments produced by the subiibrary clones, thus allowing us
to conclude that this peptide did indeed contain the epitope for
clone P77.
When the response of the uncioned T ceils to the peptides was
analysed, the same peptide (112 — 132) was found to be stimu¬
latory and there was also a substantial response to the peptide
437—459 (Figure 5). By means of six peptides we were able
to identify two distinct regions of the 65-kd protein that were
stimulatory for the ascitic T cells of the donor selected in this
study. These two peptides are located within the same two regions
of the protein which were identified as immunostimulatory by
the recombinant sublibrary approach. The amino acid sequences
of the two stimulatory peptides are shown in Figure 6, with the
residues corresponding to the predictive patterns underlined.
Discussion
The approach used here for mapping of epitopes recognised by
T cells using a Xgtll subiibrary prepared from the gene coding
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for the 65-kd. armgen is analogous to that previously used to iden¬
tify monoclonal anhbody binding sites on the same protein (Menra
et aL, 1986). Although recognition of antigens in Ivsares from
Escherichia coii by T ceil clones has been reported (Lamb et
aL, 1986; Mustafa et aL, 1986) we have been able to*extend
this technique to identify regions within a moiecuie which
stimulate proliferation of both clonal and uncloned T ceils. It is
important to note tha? both 'free' antigens and antigens expressed
as 3 gaiacmsidase fusion prtxems were recognised in these assays,
although ir is conceivable that a fusion point very close to the
T ceil epitope couid cause a 'false-negative' result if it leads to
an alteration in antigen processing mechanisms. The polyclonal
T ceil population used in this study was obtained from an ascitic
effusion and is highly enriched in T ceils reactive with myco¬
bacteria. Proliferation of polyclonal T ceil preparations in
response to E. coii lysaies is quite variable; only preparations
with strong responses to specific antigen and low background
responses to £L coii itselfwill be suitable for this type ofanalysis.
The second strategy we have used to identify T ceil epitopes
is to test the ability of peptide antigens directly to stimulate T
ceils. Rotfabarri (1986) has identified a common pattern in the
amino acid sequence of peptides containing known T ceil epitopes
and it is possible that the presence of such a pattern can be used
to identify novel T ceil epitopes. As a prototype, we have used
the 65-kd. antigen to test the possibility of using this approach
to predicrpreviously undefined T cell epitopes in a reianveiy iarge
open reading frame. Because- the known T ceil epitopes are still
quite email in number, the power of such an empirical predic¬
tion must, however, remain iimhrd at the present tune. Nonethe¬
less we were able to identify two stimulatory epitopes in a
polyclonal population, by synthesising six peptides containing
predicted T ceil epitopes without knowledge of the- results ob¬
tained using the recombinant DNA subiibrary. The twQ
stimulatory peptide sequences fell within the regions of the pro¬
tein identified by subiibrary mapping:
Both sequences 112 —132 and 437—459 of the 65-kd protein
are identical in M. leprae and M. tuberadosis, (Menra er aL,
1986; Shinnick, 1987) and this is consistent with the cross -
reactivity observed at.the clonal level for T cells specific for this
protein (Emmrich etaL, 1986; Lamb etaL, 1986). Usmg mouse
monoclonal antibodies, both species-specific and cross-reactive
B ceil epitopes have been identified on the 65-kdantigen (Mehra
et aL, 1986) and it is interesting to note thai none of these B
ceil epitopes overlap with the two T ceil epitopes described here.
Previous analysis of other protein antigens also suggests thaL T
and B ceil epitopes within a moiecuie need not overlap (Lamb
ana Green, 1983; Benjamin etaL, 1984). Whether T ceils bin¬
ding to the cross-reactive epitopes are able to function as helper
ceils to sumuiaie procincnon of antibodies to adjacent specific
or cross-reactive B ceil epitopes remains to be investigated.
Whether the two regions of the 65-kd protein within which
we have identified. T ceil epitopes are immunodominant at the
population level or reflect the repertoire of restriction elements
that this individual is able to use requires further investigation.
The latter has been found to be true for the human, cytotoxic T
ceil response to influenza vims where residues 335—349 of
nucieoprotein. are recognised only in the context of HLA-B37
(McMichael etaL, 1986). Each of the peptides contains two sets
of predictive patterns as shown by the underlined residues in
Figure 6 (118— 121/122— 125 and 443—446/449—453). It may
therefore be necessary to test the effect of ammo acid substitu¬
tion at particular residues in order to analyse the association of
these peptides with HLA-encoded determinants.
The experimental observations reported here show that a
recombinant DNA subiibrary can be used for initial localisation
of T ceil epitopes within a protein. Determination of the
nucleotide sequence of subiibrary clones allows derivation of an
amino acid sequence which can be analysed for identification of
potential T ceil epitopes. The complementary strategy of using
predicted pepade aimgens verified and refined the results obtained
using the recombinant DNA subiibrary. The combination of the
two techniques leads to a rapid identification of the immunolog¬
ically important sites within protein antigens. This approach to
analysis of T' cell recognition of the 65-kd protein from
mycobacteria may be generally applicable to the invest!ganon
of other infectious agents and may allow production of simpie
defined peptide antigens which can be used as probes for detail¬
ed analysis of cellular immune responses.
Materials and methods
Amzgsns
Mycobacterium tuberculosis H37RV was. grown for 8 weeks as a surface pelli¬
cle on Samoa's medium. A soluble extract (MTSE) was prepared by disruption
of cxxMir-iiraaiareo organisms using a Braun MSK cell disintegrator at 4000 r.p.m.
for 2 mm at 5— 10*C. Bacrmai aeons was removed by cenuifuganon at 30 000 g
for 1 h. ana supernatant material filtered tnrougn a 0.4-5-rrucron filter. Protein
concentrations m the soluble extracts were determined by tbe metnod of Lowry
et aL (1931) witb bovine serum albumin as a standard.
Preparation of anagen from recombinant DNA clones
Preparation and enaraeensanon of a Xgtl 1 subiibrary from me DNA insert of
clone Y3178 (M. Leprae 65-kd armgetp has been described previously by Menra
(1986). The subiibrary clones used m me present study are shown in Figure 1
along with their relationship to me amino Qf tbe 65-kd pnxein as
deduced from the insert endnomt analysis (Menra et aL. 1986). Other recombi¬
nant clones used in this study were Y3178 (M. Leprae 65-kd antigen: Young et
aL. 1985b) and Y3150 (M. nibercuiosis 65-kd anngen: Young et aL. 1985a).
Lysogens were prepared from phage clones in £. coii Y1089 as described by
Huynh et aL (1985). After growth m L-broth at 37*C to an absoroance of 025
at 600 nm, lysogens were induced bV incuoanoa for 20 mm at 45*C, followed
by addition of Lsoorooy 1-d-D-miogaiacmpyranoside (IPTG) to 10 raM and fur¬
ther inaionnoo at 38°C for 1 h. Ceils were harvested by cemnfiiganoa. resuspeno-
ed in one-tenm volume of pnospnaie-buffeted saline (PBS), and lysed by sonic
ciisrupoon using a Rinco B1070 ultrasonic prooe at-a maximum output for 20 s.
Bacrenai debns was removed by centnruganon at 10 000 g for 20 nun. and an
equal volume of saturated ammonium suipnate soiunon was added with vigorous
mixing to the supernatant fracnons. .After I h at 0—4°C, precipitate material was
collected by cemnfuging at 10 000 g for 20 nun and resuspenoed in PBS. The
protein concentration in the 50% ammonium suipnate fractions was determined
by the metnod of Lowry et aL (1951).
Expression of mycocacrenai antigenic determinants in recomotnant lysaies was
analysed by Western blotting using monoclonal antibodies CL1 (Mehra et at..
1986). IIH9 and IIC3 (Giilis and Buchanan. 1982). Bacterial pellets andsamnies
from the soiuole and insoluble portions ootainea after soracanon of E. coil strains
were mixed with samrne buffer tor SDS—poivacryiannde gel ciecnopnoresis nrmrr
reducing conditions (Larrrtmli. 1970) and incuoawa oa a boding water bam for
2 mm. Samutes ( — 5 wg of procem per lane) were applied to SDS—potyacryianube
gets (6% w/v, final acryiamide concentration) ana subjected to eiectropooresis
at 15 mA per gel for 50 nun usmg a mini-gel system supplied by Hoerfer Scien¬
tific instruments (San Francisco. CA). Nitrocellulose blots were prepared from
gets by electroblomng at 50 V for 1 h (Towoin et aL. 1979). Blots were wasned
with 021% Triton X-100 in PBS and non-specific binding was blocred by carry¬
ing out subsequent incubanorts in the presence of 5 % dnea rmik powder m
PBS—Triton. Deveiomeni of Western blots , with monoclonal antibodies and
horseradish peroxidase conjugated secondary annboay was penbrmeo as describee
previously (Young et aL. 1986).
Syntnetic peptides
The synthetic peptides were prepared using soiid-phase methods on an Applied
Biosvstems 430 A peptide synthesiser as previously described (Townsena et aL.
1986). The canicular regions of the protein mat were symnesisea were seiectea
on the basis of tbe presence of a panrm of either four orfive amino acids (charg¬
ed/glycine foilowca by two or three hyaropaooic residues aixl then a polar aimnn
acid) (Rothbaid. 1986). These two patterns have a high statistical correlation with
known helper and cytotoxic T ceil epitopes. The 65-kd protein contains 25 pat¬
terns of four amino acids and 12 patterns of five, which couid be oraered by
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analysing the amino acid sequence in comparison with preyiously defined T cell
epitopes.
Preparation of lymphocytes
Mononuclear leucocytes reactive with M. tuberculosis were isolated from
peripheral blood (PBMC) and the ascitic effusion of a panent by centnfuganon
on a discontinuous density gradient of Fkoll—Hypaque were resuspended in com¬
plete medium. RPMI 1640 supplemented with A-r- serum. 2 mM L-giutamine
and 100 lU/ml penicillin/streptomycin.
Isolation of human T lymphocyte clones
Human T cell clones reactive with. M. tuberculosis were isolated as previously
described (Lamb and Young, 1987). Briefly, ascitic lymphocytes (2J x 10*/ml)
were stimulated with MTSE (l./zg protein/ml) in 96-well. round-boaom miuutme
plates (Nunc, Rosiriide, Denmark) in complete medium. Lymphoblasts were
ennched on Ficoil—Hypaque and cloned by limiting dilution (03 cells/weil in
Terasaki plates) in the presence of autologous irraaiated (3000 rads) PBMC mixed
(1:1) with ascitic lymphocytes (5 x lOVmi), MTSE (1 jig/ml) and 10% (v/v)
interieukm-2 (IL-2; Lymphocult T. Biotest-Senim Insdmte GmbH. Frankfurt.
FRG) (Lamb etaL. 1982). At day 7, growing clones were transferred to 96-well.
flat-bottom microtitrc plates and subsequently to 24-well plates. At each transfer
the clones received filler cells, antigen and IL-2. The clones were expanded and
Maintained by the addition of fresh IL-2 every 3—4 days, and filler cells together
with specific antigen every 7 days. Before use in proliferation assays the T cell
clones were rested for 6—8 days after the Last addition of filler cells.
Proliferation assays
Cloned T-lymphocytes (5 x lOVrnl) were cultured with soluble antigen in the
presence or autologous irradiated PBMC (1.25 x lO^/ml) or EBV transformed
B ceils (5 x 10"*/ml) in a total volume of 200 jd in 96-well. round-bottom piates
as previously described (Lamb and Young, 1987). After 72 h incubation [3H]-
methyl thymidine (1 /tCi; [3HTTdR; Amersham intemanonai. Amexsham. UK) was
added to the cultures for 8—16 h, and then harvested onto glass-fibre filters.
Unrractionated lymphocyte cultures (1 x 106/mi) were pulsed with [3H]TdR
after 6 days mcubanon. Proliferation as correlated with [3HJTdR incorporation
was measured by liquid scintillation spectroscopy. The results arc expressed as
the mean counts per minute (c.p.m.) ± % error of the mean for triplicate cultures.
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summary
Current approaches to the anaivsis oi' antigens involved in the cellular immune response to
mycobacterial infection reiv on the initial identification and isolation ofmoiecuiar components using
monoclonal antibodies. In order to overcome the constraints of this approach, we have utilized a
procedure involving T-ceil recognition ofantigens fractionated by poivacryiamide gel electrophoresis
(SDS-PAGE) and added to proliferation assays after blotting onto nitrocellulose membranes.
Analysis ofhuman T-ceii responses to Mycobacterium tuberculosis ana Mycobacterium bovis BCG by
this procedure reveaiea distinctive patterns of reactivity to different moiecuiar weight components
indicative of the selective recognition of immunodominant and species-specific determinants. Human
T-ceil clones were subsequently aenved. ana SDS-PAGE immunobiotting was used to identify the
antigen recognized by each clone. Three epitopes denned by individual T-ceil clones were identified
on separate polypeptides with moiecuiar weights '6.000-18.000 (clone P53). 18.000-20.000 (done
P57) and 52.000-55.000 (clone P35). This stuay demonstrates the potential application of T-ceil
cioning in conjunction with SDS-PAGc immunobiotting for the dissection and anaivsis of the
ceiluiar immune response to pathogenic agents during human infection.
introduction
A considerable effort has been made overmany years to identify
moiecuiar components of pathogenic mycobacteria that are
involved in stimulation or suppression of the human immune
response during infection (Brennan. !984; Daniei. 1984). The
potential rewards of such research are the development of novel
diaenosuc reagents and the production of vaccines effective in
oiling diseases such as leprosy and tuberculosis (Arnon.
1984). The generation and characterization of mouse mono¬
clonal antibodies directed towards mycobacterial antigens nave
representee a significant advance in this area of resarcn i E.ngers
1985. 1986: Ivanvi. Morns 8c Keen. 1985*) and. as a resuit of
these studies, a limited number of protein antigens of Mycobac¬
terium tuberculosis and Mycobacterium leprae have been identi¬
fied. The independent generation of many monoclonal anti¬
bodies with overlapping specificities in separate iaboratones
suggests that these proteins represent immunodominant mvco-
bactenal antigens with respect to the murine antiboav response
(Engers. 1985. 1986). Representative monoclonal antibodies
from workshops organized by the Worid Heaith Organisation
(Engers. 1985. 1986) have been used with considerable success to
Abbreviations: 3CG. Bacillus caimette-guenn: (JH]TuR. truiaied
methyi thymidine: IL-2. inteneukin-2: MBSE. M. bovis soiuoie extract:
MTSE. .V/. tuberculosis soiubie extract: SDS-PAGE: souium doaecyi-
suipnate-poiyacrylamiae gel electrophoresis.
Correspondence: Dr J. R. Lamb. MRC Tuberculosis ana Related
Infections Unit. Hammersmith HosDitai. Ducane Road. Lonaon W12
OHS. U.K.
screen for expression of these major antigens in recombinant
DNA libraries (Thoie et al.. 1985: Young et ai.. 1985a. b). Since
protection from mycobacterial infection is a function of the cell-
mediated immune system (Hahn & Kaufmann. 1981), several
laboratories have initiated studies involving characterization of
the human T-ceil response to these antigens (Mustafa et ai..
1986: Ottenhorf et at.. 1986: E.mmnch et al.. 1986: Young et ai..
1986).
Whiie it seems likely that the monoclonal antibody-denned
proteins are immunoaominant for murine B ceils (Engers. 1985.
1986: Ivanyi et ai.. 1985), it is not clear that the same pattern of
immunodommance will be redectea in the human T-eeii re¬
sponse to mycobacteria. It is possible, for example, that antigens
that cause marked T-ceil proliferation during infection may
stimulate little or no antibody formation following immuniza¬
tion with a mycobacterial extract. There is therefore a neea to
supplement the present monoclonal antiboav-based approach
to antigen identification with an approach that directly identi¬
ties antigens recognized by human T ceils. The recent develop¬
ment of an SDS-PAGE assay for screening T-ceil clones (Young
8c Lamb. 1986) provides the possibiiitv ofsuch an approach, ana
we aesenbe here its application to the identification of antigens
of M. tuberculosis involved in the human T-ceil response.
materials and methods
Antigens
Mycobacterium tuberculosis H37Rv and Mycobacterium bovis
BCG were grown for 8 weeks as a surface pellicle on Sauton s
I
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medium. Soluble extracts were prepared by disruption ofcobalt-
irradiated organisms using a Braun MSK cell disintegrator at
4000 r.p.m. for 2 min at 5-10°. Bacterial debris was removed by
centrifugation at 30.000£ for 1 hr. and supernatantmaterial was
filtered through a 0-45 micron filter. Protein concentrations in
the soluble extracts were determined by the method of Lowry et
al. (1951) with bovine serum albumin as standard.
Preparation of immunoblots
Dot blots and SDS-PAGE immunoblots were prepared as
described previously (Young & Lamb. 1986). Samples of
mycobacterial extracts for electrophoresis contained 20 pg of
protein per lane. Polyacryiamide gels were run on a 'mini-gel*
apparatus (Hoeffer Scientific Instruments. San Francisco, CA)
to a total length of 2 cm (Table 2) or 4 cm (Figs 1 and 2), or on a
full-sized gel apparatus (BioRad Instruments. Richmond, CA)
to a total length of 15 cm (Fig. 2. insert). Proteins were
transferred to nitrocellulose by electroblotting as described
elsewhere .(Young & Lamb, 1986).
Preparation of lymphocytes
Mononuclear leucocytes isolated from peripheral blood
(PBMC) and the ascitic effusion of a pauent reactive with M.
tuberculosis by centrifugation on a discontinuous density gra¬
dient of Ficoll-Hypaque (Boyum, 1968) were resuspended in
complete medium, RPMI-1640 supplemented with 10% pooled
AH- serum, 2 mM L-glutamine and 100 IU/ml penicillin/
streptomycin.
Isolation of human T-lvmphocyte lines and clones
Ascitic lymphocytes (2-5 x 105/ml) were stimulated for 6 days
with a soluble extract of Mycobacterium tuberculosis strain
H37Rv (MTSE; 1 pg protein/mi) in 96-well round-bottomed
microtitre plates (Nunc. Roskilde. Denmark) in* complete
medium. The activated lymphocytes were isolated on Ficoil-
Hypaque and expanded as a long-term T-ceil line (P anti-Rv)
with autologous irradiated (3000 rads) PBMC mixed (1 : l)with
ascitic lymphocytes (5x 105/ml) and MTSE (1 ,ug/ml) in the
presence of 10% interleukin-2 (IL-2; lvmphocuit T, Biotest-
Serum Institut GmbH. Frankfurt, FRG) or cloned by limiting
dilution as previously described (Lamb et al., 1982). T-ceil
clones reactive with mycobacterial antigens were isolated as
follows. Ascitic T lvmphobiasts were diluted [0*3 cells/weil in
Terasaki piates (Nunc)] in the presence of irradiated autologous
PBMC mixed (1:1) with ascitic lymphocytes (5 x 10s/ml), 10%
IL-2 and MTSE (1 /ig/ml). Growing clones at Day 7 were
transferred to 96-weil flat-bottomed microtitre plates and
subsequently to 24-well plates then 25 cm; flasks. At each
transfer the clones received filler cells, antigen and IL-2. The
clones were expanded ana maintained by the addition of fresh
IL-2 every 3-4 days, and filler cells together with specific antigen
every 7 days. Before use in proliferation assays the T-cell clones
were rested 6-8 days after the last addition of filler cells.
Proliferation assays
T-iymphocvte clones and long-term lines (5 x lOVml) were
cultured with soluble or nitrocellulose-bound antigen in the
presence of autologous irradiated PBMC,'ascitic lymphocytes
(5 x I0sml) in 96-weil flat-bottomed microtitre plates as pre¬
viously described (Young & Lamb 1986). Briefly, after 72 hr
incubation the cultures were resuspended and the nitrocellulose
strips discarded prior to the addition of tritiated methyl
thymidine (1 pCi; [3H-]TdR: Amersham International. Amer-
sham, Bucks) for 8-16 hr and then harvested onto giass fibre
filters. The duration of unfractionated lymphocyte cultures
(1 x 106/mi) was 5 days. Proliferation as correlated with [3H]-
TdR incorporation wasmeasured by liquid scintillation spectro¬
scopy. The results are expressed as the mean counts per minute
(c.p.m.)±% standard error of the mean for triplicate cultures.
RESULTS
T-cell proliferation in response to nitrocellulose-bound antigen
T lymphocytes obtained from ascitic effusions or from the
peripheral blood of tuberculosis patients were found to prolifer¬
ate in response to M. tuberculosis extract supplied either as
soluble antigen or in the form of a solid-phasp antigen bound to
nitrocellulose. Table 1 shows a representative experiment
demonstrating proliferation of a T-cell line derived from an
ascitic effusin. As described previously for the clonal respo- )
a viral antigen (Young & Lamb, 1986), a higher concentration of
solid-phase antigen was required to stimulate an equivalent
response to that obtained with soluble antigen. No proliferation
was observed in the absence of accessory cells, and the
nitrocellulose itself was not mitogenic (Table 1).
Differential pattern of reactivity on the polyclonal T-ceil response
to SDS-PAGE immunoblots of M. tuberculosis and \l. bovis
In order to identify the molecular weight of the components
stimulating the proliferative response of the polyclonal T-ceil
population, mycobacterial extracts were subjected to SDS-
PAGE and, following transfer to nitrocellulose membrane, the
different antigen factions were tested in proliferation assays.
Figure I shows the response of ascitic T cells to M. tuberculosis
and M. bovis BCG extracts examined in this manner. A distinct
Table 1. Activated T lymphocytes recognize antigens blotted on
nitrocellulose
Response (f3HTTdR incorporation c.p.m. — SEM)
T cells APC Antigen Nitrocellulose bound Soluble
375^14
180 ±9 286r 23
5482 ±10 24.197 ±21
21.445-16 30.997 ±35
31.620 ± 1 55.381 = 20
— 22.478 — ! 8
— 36.474 ±36
H37Rv-reactive T-cell line (P anti-Rv 5 x 10*/ml) was stimulated
with MTSE as soluble antigen or nitroceilulose-bound as dot-blots
together with irradiated autologous ascitic lymphocytes and PBMC
("5 x 105 ml) as a source of antigen-presenung ceils (APC). Proliferation
as correlated with (3H]TdR incorporation was determined at 72 hr. The
results are expressed as the mean c.p.m. ± SEM of triplicate cultures.
Control responses of T ceils to (*) medium, (t) APCs without antigen,
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Figure 1. Differential pattern of reactivity of the polyclonal T-ceii
response to SDS-PAGE antigens on immunobiots of A/. tuberculosis
and A/, bovis BCG. Unfractionated ascitic lymphocytes (I x 10° mi)
were cultured for 5 days with M. tuberculosis and A/, bovis BCG on
nitrocellulose biots (20 fractions) or as soluble antigen. Proliferation
was determined as described in the legend to Table 1. The response to
s'-' He A1. tuberculosis and A/, bovis BCG (1 tig protem mi) was
i r 11 — 15 ana '1.246 — 9 c.p.m. - SENT respectively. Background
proliferation of the T cells to nitrocellulose or to medium alone were
637 — 14 and 587 — 22c.p.m. — SEM. (a) M. tuberculosis and (b ) M. horis
BCG extracts (20 ug protein per lanei were preprea and run on SDS-
poiyacrylamiae geis. ana proteins were blotted onto nitrocellulose: (ci A
representative gei stained with Coomassie blue: Lane 1. A/, tuberculosis
extract: Lane 2. A/, bovis BCG extract: Lane 3. moiecuiar weight
markers.
pattern of peaks ana troughs in the proliferative response to \i.
tuberculosis extract was observed (Fig. la) with peaks particu¬
larly in the moiecuiar weight regions of 51.000-66.000. 24.000-
23.000. ana 12.000-! 8.000. Whiie the overall response of this T-
cell population to M. bovis BCG extract at ljug/ml (71.246 3; 15)
was comparable to the M. tuberculosis response (112.411 ± 15).
quantitative and qualitative differences in response to the two
extracts were observed during analysis by SDS-PAGE immuno-
blotting (Fig. la ana b). The higher moiecuiar weight fractions
from M. bovis BCG (51.000-66*000 and 24.000-28.000) stimu¬
lated a lower response than those from W. tuberculosis.
although comparable proliferation in response to the low
moiecuiar weight material (< 20.000) was observed. Visual
inspection of poivacrvlamide geis stained for total protein (Fig.
lc) did not indicate a marked difference in the concentration of
proteins in these moiecuiar weight regions between the two
mycobacterial extracts.
Analysis by T-ceil cloning
In order to earn/ out a more detailed analysis of the T-ceil
response to the antigens of different moiecuiar weights, a set of
T-cell clones was established from the T-ceil population shown
in Fig. I. Nine of the clones were selected for detailed analysis
and these are listed in Tabie 2.
All of the clones proliferated in response to the \f.
tuberculosis extract, whiie several showed little or no response to
,V/. bovis BCG. Seven strongly proliferative clones ( > 10.000
c.p.m. to .Vf. tuberculosis-soluble extract) showed a cieariv
positive response to nitroceiluiose-bound antigen, whiie the
remaining two clones (P2 and P56) showed oniv a weak
proliferation to solid-phase antigen. All of the clones were testea
for recognition of high, medium or low moiecuiar weight
fractions obtained from 2-cm mini-immunobiots. and positive
results (proliferation > 1000 c.p.m.) were observed with hve of
the clones (Table 2). Clones P35. P53 and P57 were then
analysed using 4-cm SDS-PAGE immunobiots divided into 20
fractions each (Fig. 2). Clone P35 responded to two adjacent
fractions in the high moiecuiar weight region (50.000-60.000
( Fig. 2) and subsequent more detailed analysis using 70-fraction
immunobiots indicated a moiecuiar weight of 52.000-55.000 for
the antigen recognized by this clone i Fig. 2a. insert). The other
two ciones 1 P53 and P57) that both showed some proliferation
in response to M. bovis BCG recognized antigens with moiecuiar
weight 16.000—18.000 (Fig. 2b) ana 18.000-20.000 (Fig. 2cj.
respectively.
DISCUSSION
The results presented in this paper demonstrate a novei ana
important approach to the moiecuiar analysis of the antigens of
a microbial pathogen that interact with the human ceiluiar
immune system. It is possible to use SDS-PAGE immunobiot-
ting to analyse the contribution of antigens of different
moiecuiar weight to the overall polyclonal T-ceil response to a
mycobacterial extract. The extension of this analysis to screen
the polyclonal response of tuberculosis patients ana normal
individuals to extracts prepared from different mycobacteria
represents a potential approach to the identification of species-
speciffc antigens and of antigens that are recognized as immuno¬
dominant during infection. Since the concentration of protein in
each fraction of the gei has not at this stage been assayed, it
cannot be stated whether the immunodominance represented by
the peaks is a reflection of the concentration of particular
antigens or of the concentration of T ceils with appropriate
specificities. Visual inspection of gels stained for total protein
does not demonstrate the occurrence of particularly nigh
concentrations of protein in sections of the gei stimulating
maximum T-ceil proliferation, ana immunoaominance basec
on immune recognition rather than on relative antigen concen¬
tration wouia therefore appear more likely. Occurrence 01
antigens causing a suppression of T-ceil proliferation in the
4 J. R. Lamb & D. B. Young
Table 2. Specificity pattern of MTSE-induced T-ceil clones for immunoblotted M. tuberculosis
Gone no.
P2 P35 P48 P53 P56 P57 P65 P77 P83
(A) Soluble antigen
I. MTSE 7251 28.115 11.584 45.507 8998 19.053 13.772 12.020 25.851
2. MBSE 818 406 1804 14.902 279 13.466 895 805 3155
3. IL-2 response 36.798 83.042 64.290 29.105 39.019 88.258 37.818 61.611 51.867
4. APC control 283 273 121 113 95 176 155 127 346
5. Medium control 86 109 105 75 55 176 74 103 83
(B) Nitrocellulose-bound antigen
1. MTSE 1387 9195 4108 19.175 1441 9388 2804 7069 7868
2. Immunoblot > 50.000 221 5778 739 2039 380 575 167 351 479
3. Immunoblot 35.000-50.000 345 399 2580 4944 276 586 298 238 464
4. Immunoblot 20.000-35.000 533 430 231 699 126 464 353 252 497
5. Immunoblot 20.000 431 568 1387 7553 356 2431 884 538 1226
6. Nitrocellulose control 451 352 214 137 128 159 252 237 * 457
Cloned T ceils (2-5 x 104/ml) were stimulated with MTSE or M. bovts BCG soluble extract. MBSE (1 ng.
protein/ml) as a soluble antigen (Al. A2) or the same concentration of MTSE bound to nitrocellulose (Bl).
Each done was also tested with four sections prepared from 2-cm MTSE immunoblots corresponding to
the approximate molecular weight ranges listed for samples B2-B5. Results from the major reactive section
are underlined for each clone. Controls included medium alone (A5). with antigen-presenting cells (A4) and
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Figure 2. Identification of antigens recognized by M. luoercuiosts-
reactive T-ceil clones using immunoblot analysis. T ceils of clones P35.
53 and 57 (2-5 x lO^'ml) were cultured with SDS-PAGE-separated
immunoblots (20 fractions) together with irradiated PBMC.'ascitic
lymphocytes and assayed as described in the legend to Table I. The
specificity ol done P35 was analysed in more aetaii using the MW
fractions (40.000-60.000) of a 15-cm (75 fractions) immunobiot (insert
in (a)]. Results are shown as the mean of triplicate assays, the standard
error for peak samples was less than 15% in each case.
areas of the gei corresponding to the troughs cannot be
dismissed at this stage. It is also possible that the immunodomi-
nance apparent by this techniquemay reflect other properties of
the proteins such as their degree of binding to nitrocellulose and
the efficiency of processing and presenting particular antigens
from the soiid phase. While being aware of these reservations,
analysis by SDS-PAGE immunobiotting does offer the poten¬
tial of obtaining considerably more information than simple
proliferation assays with unfractionated extracts, and this
approach may be expected to lead to the identification of
immunodominant antigens of important biological function of
specificity in complex antigen mixtures.
In addition to the analysis of polyclonal responses, SDb-
PAGE immunobiotting allows a new roie for T-cell clones in the
identification and analysis of mycobacterial antigens. Several
authors have described the generation of human T-cell clones
recognizing mycobacterial extracts (Mustafa ei al., 1986: Otten-
hoff ei al., 1986; Emmrich et al., 1986) and. in some cases,
particular clones have been shown to respond to individual
antigens identified using mouse monoclonal antibodies (Otten-
hoff et al.. 1986), or by recombinant DNA techniques in
association with the same antibodies (Mustafa et al.. 1986:
Emmnch et al.. 1986). In this paper we have demonstrated a
direct approach to the identification of the antigen specificity of
human T-ceil clones that is not dependent on an antibody-based
analysis. Two of the T-cell clones described here (P53 and P57)
recognize antigens in a molecular weight range 16.000-20.000
that overlaps with the 19.000 antigen recognized by known
monoclonal antibodies (Engers. 1986) and further analysis to
determine whether the T-cell antigen in either case is identical to
the 19.000 protein will be of interest. A third clone (P35)
recognizes an antigen in the molecular weight region 52.000-
T-ceil sites in M. tuberculosis
55.000. which is well separated from the monocional antibodv-
derined proteins at 65.000 and 38.000 (Engers. 1986). This
suggests that the T- and B-ceil repertoires as regards their
specificity for mycobacterial antigens need not be identical as
has been reported for other antigens (Berzofskv, Richman <it
Kiion. 1979: Lamb & Green. 1983). It is interesting to note that
this clone, which did not respond to M. bovis BCG. recognized
an antigen in the molecular weight range that appeared to be
relatively rich in M. tuberculosis-specific antigens. Of the 33
monoclonal antibodies analysed during the WHO workshop on
antibodies to M. tuberculosis. none was found to discriminate
compietelv between tubercle bacilli and M. bovis BCG (Engers.
1986). This study therefore not only demonstrates a novel
approach to the analysis of antigen specificity of T-cell clones,
but has also resulted in the identification of an M. tuberculosis
antigen that is not represented in the previous set of monoclonal
antibody-defined proteins. Not all of the T-cell clones investi¬
gated in these experiments recognized the SDS-PAGE immuno-
blots. ana therefore this procedure may not be applicable for all
T " subsets or for those T cells with low-aifinity receptors.
FuiUiermore. where T-ceil clones responded to more than one
fraction of the four fraction (2-cm) immunobiots. this- may
result from inadequate separation of the determinants, or it may
be that one determinant can exist on multiple molecular weight
proteins as evidence by monoclonal antibodies recognizing the
65.000 "multiple band' antigen of mycobacteria (Ivanyi et al..
1985). Therefore, further analysis of the T-ceil clones described
in this paper using extracts from different strains of mycobac¬
teria ana using Escherichia coii clones expressing recombinant
mycobacterial DNA (Young et al.. 1985a. b) is currently in
progress.
Thus, the experiments described here indicate two poten¬
tially important areas for the application of SDS-PAGE
immunoblotting to further research orrthe molecular analysis of
mycobacterial immunity. These are the analysis of immuno¬
dominant antigens by screening of polyclonal responses, and the
identification of novei antigens and epitopes using T-ceil clones.
A panei of well-characterized human T-ceil clones recognizing
different mycobacterial antigens couid prove useful in comple¬
menting the set of antigens previously defined by mouse
r. clonal antibodies (Engers. 1985. 1986). Screening of
recombinant DNA libraries I Thole er al.. 1985: Young et al..
1985a. b) with such T-cell clones could provide an approach
towards the isolation of the relevant antigens in quantities
suitable for thorough immunological analysis.
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MOLECULAR STUDY OF THE T CELL REPERTOIRE IN FAMILY CONTACTS
AND PATIENTS WITH LEPROSY
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The specificity of lymphocyte proliferative re¬
sponses of 22 family contacts and 7 patients with
leprosy were analyzed using Ag fractions from sol¬
uble extracts of Mycobacterium Leprae and Myco¬
bacterium cubercuLosis. Fractions 10-100 kDa m.w.
from each extract were separated by SDS-polyacryl-
amide gei electrophoresis, electroblotted to nitro¬
cellulose membrane and soiubilized for use in lym¬
phocyte culture. The main immunogenic fractions
for both contacts and patients had m.w. of 12.000
to 22.000. 35.000 to 40.000. and 65.000. Determi¬
nants which were either distinct or shared by the
two extracts were active in each of the immunogenic
fractions. Lymphocyte proliferation following stim¬
ulation with separated Ag was found also in rive
subjects who failed to respond to the whole soluble
extracts. Stimulatory synthetic peptides were iden¬
tified for the 65 kDa protein Ag. This technique has
permitted the screening of the T ceil immune rep¬
ertoire for the identification of the immunodomi¬
nant Ag which merit further purification and molec¬
ular characterization.
It is generally believed thac the nature ofT ceil mediated
immune responses to Mycobacterium leprae determine
whether the infection will be self-limiting or pachogenic
to the host. Moreover, the clinical spectrum from the
tuberculoid to the lepromatous pole is represented by a
change from pronounced reactions to T cell anergy in
response to M. leprae Ag. This information is based on
delayed type hypersensitivity and in vitro lymphocyte
proliferation co crude soiuble extracts from M. Leprae {1-
3). The role of individual Ag in protective or pathogenic
host interactions and hence the spectrum of the disease
is not yet understood. Eariier studies which reported
anergy to M. leprae but responsiveness to tuberculin
stimulated the interest in .Vf. ieprae-specific constituents
with putative suppressor function for the response to che
common mvcobactenai Ag (4-6). Cloned T cells of defined
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specificity have been described (7. 8), but without knowl¬
edge about their relative representation in the immune
repertoire in relation to M. Leprae infection or disease.
Nevertheless, functional studies ascribed putative sup¬
pressor activity to certain T cell clones (9. 10).
This study analyzes the specificity of polyclonal T ceil
proliferation responses of leprosy contacts and patients.
Ag contained in soluble extracts of .Vf. Leprae and .Vf.
tuberculosis were separated on the basis of m.w. within
the range of 10 to 100 kDa by SDS-PAGE and were used,
after electroblotting and solubilization for lymphocyte
stimulation in vitro (11. 12). The specific aims of the
study were: a) to investigate the most frequent immuno¬
genic fractions: b) to compare che responses of patients
with family contacts: and c) co find out if separated
fractions are able to stimulate responses of lymphocytes
which fail to proliferate in che presence of whole soluble
extracts. Parallel analysis was performed on the specific¬
ity of serum antibodies.
MATERIALS AND METHODS
Patients ana contacts. 3Idoa in citrate-dextrose was obtained
from seven pacients with leprosy and 22 of chetr family contacts.
Informed consent being obtained from themselves or their parents/
guardians. The disease was classified, according to the criteria ot
Ridley and Jooilng [131. Patients (3 male. 4 female) aged between 21
to 60 years had been caking antl-mycooactenai chemotherapy for 4
to 17 years. All patients had lived formany years in leprosy-endemic
areas of the Indian Subcontinent except for patient C3-c wno origi¬
nated in che Yemen. None of che 12 contacts aged 17 years or less
had spent more than a few weeks in leorosv-enaemic areas but ail
8 older contacts had lived In endemic areas for a numoer of years
and could nave been exposed to .Vf. leprae from other mtectious
cases.
Mycobacterial extracts. MLSE. a filtered sonicate of .Vf. leprae
obtained from infected armadillo livers ibatcn CD521. was a gift from
Dr. R. J. W. Rees. National Institute for Medical Researcn. London.
(J.K. .Vf. tuberculosis strain H37Rv bacilli grown on Sauton s me¬
dium and killed by 2.5 Mrad from a i9Co source were dlsrupced In a
Braun MSK ceil homogenizer and the MTSE. batch 5. was ootained
by centnfugatlon for 60 mm at 47.000 x g.
Agfractions. MLSE or MTSE (50 or 100 ug per gel) were applied,
using a blank comb with a single reference well for m.w. markers
(Sigma Chemical Co.. Pooie. Dorset. U.K.). Protein bands were sepa¬
rated using SDS-PAGE (12% w/v acrylamide in the running gel ana
4.8% in the stacking gel) under reducing conditions at 15 mA per gel
for 50 mm in a Mlnigel electropnoresis system (SE 250 Hoeifer
Scientific Instruments. San Francisco. CA). 3oth mycooactenai ex¬
tracts contained several protein constituents, apparently following
seaming with Coomassie blue.
The proteins were electropnoretlcailv transferred to nitrocellulose
paper in the TE22 Apparatus (Hoet'fer Scientific instruments. San
Francisco. CA) using 0.02 M Tns-glycine buffer (pH 8.3) containing
20% methanol for i h at 50V. Nitrocellulose memoranes (7.5 mm x
40 mmi were cut into 20 honzoncai sections each 2 mm wide,
corresponding co 12 to 92 kDa m.w. fractions. Stnos were then
solubtllzed as aescnPed previously (12) by incubation and intermit-
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cent mixing for I h with 500 ui DMSO and nitrocellulose particles
were orecipitatetl by the addition of 500 ui sterile 0.05 M caroonate-
bicaroonate buffer wmle vortexmg the mixture vigorously. The ni¬
trocellulose particles were susocnoed in 0.5 ml of RPMI 1640 (Flow
Laooratones. Rtucmansworth. Herts.; alter removal of OMSO by
reoeated wasnmg and centnfugauon with PBS. The emulsified frac¬
tions from 16 reoilcate nitrocellulose memorunes were pooled, and
aiiauoted at —20*C for use in proliferation assay. M.w. were assigned
to fractions using markers (Sigma; which were stained following
separation with amido black.
Lymphocyte proliferation assays. P3MC were isolated on a Fl-
coli-Hypaque density gradient and stored in liouid N-». Thawed cells
were susDended (101 or 5 x 10* mi) in 96-well microutre trays in
RPMI-1640 suopicmented with 2 mM L-glutamme. 100 IU of peni¬
cillin. 100 ug of streptomycin per ml and 10%• human A" serum: 20
Mi of Che 20 separate fractions were added co each well at the
initiation of these cell cultures. After seven days of Inclination. the
cultures were pulsed with 1.0 » CI of cnuated methyl thymidine
(aHTdR: Amersnam international: so. act.. 25 Cl/mmoi) for 8 to 16
h and harvested onto glass-fibre filters. Proliferation, as correlated
with 'HTdR-tncorocration, was measured by liquid scintillation
spectroscopy. Mean councs perminute — standard error of the mean
for triplicate Ag-containing cultures were converted to stimulation
indices (SI) in relation co tne saline control culture.
Antibody assay. .Nitrocellulose memoranes orepared by blotting
of SOS-PACE separated fractions of MLSE or MTSE were cut verti¬
cally into 3 mm stnos. and were wasned with 0.1 % Triton X-100 in
PBS. Non-specific binding was blocked by incubation with 5% recon¬
stituted dried skimmed milk in PBS-Tnton. Strips were mcuoaced
with sera diluted 1:100 in PBS-Tnton for I h at 20"C with snaxing.
Afterwasnmgwith Tnton X-100 in PBS perexidase-taoelleo affinity-
punfied goat antt-numan igG (gamma chain) or anti-human igA
(aiona cnaini (Slgmai diluted 1:1000 in PBS-Tnton was added to the
individual nitrocellulose stnps and incubated for I h at 20*C. After
color development (5 mini using dlaminooenzidlne dlhyarocnionoe
(0.1 mg/mi. Slgmai in 0.1 M citrate buffer (pH 5) with 0.01% rf?Oi.
stnos were waanea and dried.
The functional viability of Che lymphocytes following
frozen scorage/chawmg was evaluated by 'heir ?HA re¬
sponsiveness. Sausfactory responses with mean 22.S —
2.52 x 10"° cpm were obtained. Background proliferation
tn Che presence of emuislfied nitrocellulose without Ag
varied from 200 co 2000 cpm. All lymphocytes were
tested wtth fractions prepared from gels loaded with
either 50 or 100 ug soiubie extract. The results obtained
at che two Ag doses were in most instances comparable
boch in che pattern and magnitude of che proliferation. A
representative example of chis is demonstrated in Figure
i. Responses co individual fractions, corrected for che
corresponding background control, were considered pos¬
itive when thymidine uptake was fivefold and strongly
positive when it was cenioid Che control. The results from
ail tested patients and contacts evaluated on this basis
are snown tn Figure 2. The obtained patterns of re-
SDonses co fractions derived from SDS-PAGE fractionated
MLSE (left columnl and MTSE (right column) indicate
chat almost ail stimulatory actiyltles couid be classified
into three regions: 55 kDa. 25 co 40 kDa and a broader
12 to 22 kDa region. The latter low rn.w. fractions clearly
contained Che most frequently immunogenic Ag: how¬
ever. polypeptide fragments from larger native molecules
may have partly contributed co this activity. The immu-
nodormnance of the separated fractions snowed a similar
pattern for contacts and patients.
The role of species-specific and cross-reactive deter¬
minants from each m.w. fraction can be at least partly
ascertained by che comparison between MLSE and
MTSE-derived fractions (Table I). The results suggested
chat both species-restricted epitopes and chose cross-
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Figure i. ReoroauciOilltv oi iymonocvte summation oaltems at :wo
aoao oi Ag. Reaoonsea at" one aonor 'C3-91 to concurrently separated Ag
fractions. .
immunogenic and contributed in about equal proportions
when comparing che individual responaers. This was
ooserved with the 55. 35 co 40 as well as che <22 kDa
fractions. Although che response patterns showed con-
sineraoie individual differences, che frequency oi re¬
sponaers co che chree main immunogenic regions was
similar when comparing iecrosy patients ana contacts.
All lymphocyte samples were also examined tor proili-
erative resoonses co Che wnoie soiubie extracts. MLSE
and MTSE. Two patients and five contacts failed co give
a pronounced (SI > 5) proliferation response co che mix-
cure of Ag contained in both extracts. While cwo or these
contacts (LL-t and BL-II source case; also failed to responc
to che Ag fractions, lymphocytes from che other chree
contacts and cwo patients did respond significantly co at
least one of che <22 kDa fractions: four of these aonors
responded aiso co 55 kDa ana cwo donors co che 35 kDa
fraction. Representative patterns snowing che amplified
proliferation in cultures -with fractions wnen compared
with wnoie soiubie extract are demonstrated in Figure 3.
It was of interest co examine che possibility chat Ag
when presented from nitrocellulose are more stimulatory
wnen compared with che native soiubie extracts. Soiubie
mvcooactenai extracts were incubated in sampie buffer
ana poivacryiamiae reagents, eiectrooiocted onto nitro¬
ceiluiose and prepared as emulsified particles under con¬
ditions corresponding with che cecnmque used tor che
eiectropnoretlcailv seoarated fractions. Graced amounts
of processed ana soiuoie preparations were Chen tested
for their stimulatory potency in culture, using che PMBC
T CELL REPERTOIRE
Figure 2. The pattern 01" proliferative re¬
sponses to fractionated 30tuPie extracts.
Donors: patients (LL. BL. or TT) are listed
wtth their respective contact (CI children icj.
soouae (si or other (o| relatives. Fractions
were derived from SDS-PAGE-seoarated
MLSE (ML) or MTSE (MT) applied to SDS-
PAGE at the 100 ^/mt concentration.
Counts of [JH!TdR uptaxe are given for sa¬
line and PHA (10 >*g/mll-containing cul¬
tures. '-Vhole soluDle extracts (MLSE. MTSE1
vere added at 100 ug per ml culture. ■ — 31
> 10. 3. - SI 3-10: Q SI < 5. Source case
;BT| lymonocvtes for contacts CI7-18 and





(YR1 X 10 X 10
ML MT
LL-l 39 0.6 55.6 □ □
c:-c 17 2.1 37.1 C 0
C2-c 16 1.2 32.3 a a
C 13 0.3 35.7 0 a
C5-o 16 0.3 92.3 0 B
cs-» 36 0.2 39.3 GG
ll-ii 57 0.3 64.4 G 3
C7-c 16 0.8 74.0 a c
C3-« 16 l.l N.T. a a
u.-ai 34 i.3 N.T. a a
C9-» 32 0.2 N.T. a a
ClO-c 10 0.3 21.1 □ a
3L-; 60 1.2 N.T. B B
C12-c 25 1.2 N.T. a G
C13-c 33 0.3 18.7 0 a





31-23 32-19 17-13 13-12
—w » T1U I -1U.V1I V4U.V4I
sac cc aa cc cc cc cc aa cc oz
GG GG GG GG GG CC GG GG GG CG
GG CD CC CD CC CD GD CC GG CG
DC GD CM GD CD GD GG B0 GG GS
CG sea ■■ GG ■■ SB GC ■■ GG 20
GG CG CG CG GC GC CG GG GG CG
CG GC 2G CD C0 CC GC CC 3D CC
GG GC CM GG. GC CC GD GG GG GG
GD GD CD 2G GD CG CG 0G G0 23
Cm GG GG.CD GG CC G0 CC GD GG
GG GD BG CD GC BG GG CC C2 BG
GD GC 0B GD GG CC GC BB Bfl 2B
CG CC CC GC CC CG CC CC GG GG
GC CG CC CG CG 2C CC GG GC GC
GG CC ZC CG GG GC GG GB GB G0
CC CG CG CG GG CB GG BC CG GC
8L-a 35 0.6 14.2 G G GG CG 90 CC GC CG GG 90 GG GG
CI6-* 33 0.2 29.3 G G GG GC GG CC CG CG GG GG GG GG
C27-o 45 1.1 N.T. ■ m GG CG GC GG GG 39 GG 39 222 GG
C18-o 37 0.3 116.2 C 22 GG GG GC GG GG G9 GG 22G GG GG
C20-c 5 0.3 12.0 m 9 GG GG 20 GG G0 222 0C 22 223 2G
C21-c 3 0.4 3.1 GG GC C0 GG GG GC GG CG 232 GG GG
C22-I 23 0.9 30.8 GG GG GG CG GG GG 022 GC 022 20 GG
TT-I 55 0.9 N.T. <2 9 GG GD GG GG CG GG GC 2C 20 2G
C23-* 47 0.4 N.T. ■ 9 GG GG 90 GG C2 99 GG 99 10 GG
TT-II 48 0.3 N.T. 9 9 GG GG GG GG GG CG GG 2S G2 00
C24-c 15 0.3 4.1 GG CG GG 2C GG CC GG GG 20 G2 GG
CGI-c 10 1.5 N.T. G 0 GG CG GG GG G9 G2 GG G0 GG GG
CZ6-c 5 U N.T. 9 G CG GG CG GG 2G GG GG 22 G0 G2




Numoer o i Rooonaen"1
Contacts i22\ Pauents (71
(kOai MLSE MTSE MLSE MLSE MTSE MLSE
omv onlv plus MTSE only onlv plus MTSE
Proliferation o5 3 2 5 o 0 2
40-30 3 6 6 0 I I
22-i 9 3 3 10 2 2 3
17-15 0 5 5 2 2 I
13-12 3 3 3 1 I t
whoie extract 3 4 10 1 I 3
Ancibody >92 3 0 0 4 0 0
70 0 3 0 0 1 0
65-55 0 12 0 0 4 0
40-30 6 2 5 2 0 3
14 0 3 0 0 3 0
" Proliferation: SI > 5: Antibody: bands demonstrate by lmmunoolottlng.
from a patient with tuberculoid leprosy (Fig. 4). The
results showed an approximately twofold amplification
of proliferation with the tested two lower doses of proc¬
essed MTSE whereas the responses to the two tested
MLSE preparations were equivalent.
PBMC from contacts C9-s. ClO-c. C23-s. C13-c and
C7-c ail reactive 'with the recombinant 65 kDa Ag were
analyzed for their ability to recognize synthetic peptides
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?'.qu.re 3. Demonstration of" amDilfiea proliferation with seoaratea an¬
tigens compared to wnote sotuole extracts. L/monocyte donors: see figure
derived from che sequence of .Yf. leprae 65 kDa procem
(14). Of che five subjects tested oniv three responded to
che peptides and in each individual the pattern of recog¬
nition was different (Table II). Donor C9-s responded to
peptides corresponding to che sequences 65 co 35. 153 co
171 and 195 co 219. This latter sequence was recognized
Ccncernraoon . ug / culture.
F'.gure 4. Comoanson of proliferative resDonsea co processed and soi-
uDle mycooactenai extracts. Sacn extract (100 ugj was processed under
conditions corresponding :o '.he preparation of SDS-PAGE :'raction3.
Mean proliferative rcsDonses of ?SMC from tnoiicate -veils are presented.
by P9MC from ClO-o and C23-s chat aiso responded co
residues 390 co 412 and 65 co 35 respectively. None of
che individuals cesced responded co sequence ISO co 196.
The specificity of serum antibodies from ail lymphocyte
donors was determined by the immunobioc technique.
The m.w. of demonstrable bands on MLSE and MTSE
blocs are presented in Tabie I. The majority of che tested
sera reacted with MTSE ana fewer reactions were de¬
tected with MLSE. There was no correlation in che m.w.
of che antibody binding and T ceil stimulatory fractions
when comparing individual contacts ana patients. It is oi
particular interest chat six contacts snowed binding to a
35 'xDa band with specificity for ,Vf. leprae. However,
additional testing by competition assay (161 using the
ML04 mAb (anti-35 kDa) showed positive values oniv in
LL ana 3L patients, thus confirming che selective im-
munoaominance of this epitope for muitlbacillary leprosy
(results not snowni.
DISCUSSION
In view of the complexity of the T ceil proliferative
repertoire in leprosy, we piaced emphasis on che analysis
of che responsiveness of heaithv family contacts, hoping
chat their responses might be limited co fewer Ag. This
study also had che advantage of being earned out in a
non-endemic country (UK) where the potential source oi
infection was a single household member and there was
relatively limited stimulation by environmental mvcobac-
tena. For che analysis of che specificity of the T reper¬
toire. SDS-PAGE fractionated Ag (MTSE and MLSE) was
transferred co nitrocellulose ana added co T ceil prolifer¬
ation assavs as an emuision (121. This technique has che
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TABLE II
T cell recognition of peptides from ctxe 65 kDa protein of mycoOactena
DONOR meaiurn 8S kDa" 85-33# 116-137 153-171 180-196 195-219 390—M2
C9-s 0.2* 5.2 10.7 0.4 13.4 0.5 10.5 0.8
CiO-c 0.3 3TTT "33 0.7 "373 0.5 T3 3.7
C23-9 0.4 577 4.6 2.5 0.7 0.9 273 377
CI3-c . 0.5 57T 373 33 0.3 0.5 T7T 0.2
CT-c aa 33 04 05 0.7 0T 06 0.7
" Recombinant 65 kOa protein l'rom £. coll (211.
" Peptides synthesized from the sequence of M. leprae 65 kDa protein (221. Ag were added to the cultures at 1 or 10 ng/
ml and the highest proliferation induced with either concentration is shown.
c Results are expressed as mean cpm x 10"^ of triplicate cultures with SEM <20%. Responses >5-fold over background
are underlined.
advantages that extensive biochemicai purification of
individual Ag components is not required and that there
is no pre-seiection of Ag based on other forms of immu¬
nodetection such as serology. The results demonstrated
clear resolution between Ag when separated tnto 20 frac¬
tions of 12 to 92 kDa.m.w. The main technical advance,
which considerably helped the standardization of the
analysis, was the pooling of fractions from replicate runs
into batches which provided identical stimulants for as
many as 400 lymphocyte cultures.
Recent results of lymphocyte proliferative patterns to
SDS-PAGE separated fractions in healthy staff with ex¬
tensive occupational contact wtth leprosy patients
showed most frequent responsiveness to low m.w. ma¬
terial in the region of 11 to 16 kDa from Mycobacterium
bovis and 22 to 26 kDa from Af. leprae (17]. Evaluation
of responses in our study showed three main prolifera¬
tion-inducing fractions with 19 to 22. 35 to 40 and 65
kDa m.w. individual donor lymphocytes proliferated wtth
fractions from Af. leprae or Af. cubercuLosts alone orwtth
corresponding fractions from both soluble extracts. This
could reflect the Immunogenicity of both common and
distinct epitopes in the genetically polymorphic human
population, although such a conclusion is limited by the
possibility that homologous proteins might be of slightly
different m.w. Polypeptides resulting from partial degra¬
dation of native molecules could have contributed to the
marked stimulatory activity in the <22 kDa m.w. frac¬
tions observed. However, the paucity of stimulation by
fractions in 40 to 65 kDa region was surprising consid¬
ering that the 65 kDa protein is particularly susceptible
to enzymatic proteolysis (18). It is possible that the frag¬
mentation of the 65 kDa protein had disrupted or modi¬
fied sites involved either in T ceil recognition or distinct
functional sites that may influence selective processing
of the protein. Alternatively, non-specific inhibitors of T
ceil proliferation co-migrating in that region could have
overridden the stimulatory effects. Previous studies have
demonstrated that lipoarabtnomannan which co-mi-
grates at a similar m.w. is able to inhibit non-specifically
T ceil proliferative responses to protein Ag (19).
The patterns of proliferation found in this study
showed a considerable degree of individual variation, but
without a significant difference in pattern between con¬
tacts and patients (Table I). Overall, the patterns of Ag
reactivity observed within and between the families may
reflect in part the polymorphism in the MHC genes of the
individuals investigated. It would be of particular interest
to know if there are any associations between the form
of leprosy or family relationship with the Ag specificity.
It appeared that responses to the 65 kDa fractions pre¬
vailed in both case and contacts of families with a lep-
romatous (11/18) rather than tuberculoid (3/11) source
case. In contrast, responses to the 22-19 and 17-15 kDa
fractions were more frequent in tuberculoid than in lep-
romatous families. However, these apparent associations
on the present limited number of examined cases did not
attain statistical significance. It will be of interest to
ascertain whether any of the observed differences are
attributable to lymphocyte priming or to differences in
Ag presentation by the respective accessory ceils. Fur¬
thermore. the role of donor HLA hapiotype which is
known to control certain responses to mycobacterial Ag
(20) would need to be evaluated.
The finding of proliferation in response to individual
Ag In five donors who failed to respond to the whole
soluble sonicate is of considerable interest. One possible
explanation for this could be that SDS-PAGE/nitroceilu-
lose/DMSO-processed Ag have enhanced stimulatory po¬
tency compared with soluble Ag. This interpretation was
indicated by the previously reported 20 to 30 fold en¬
hancement of responses by separated particles (12). al¬
though in comparable experiments in this paper only a
modest enhancement of proliferation was observed wtth
particulate MTSE and none with MLSE. Whether en¬
hancement or inhibition of the response to unfractlon-
ated Ag presented in particulate form is observed for a
particular individual will depend on the summation of
the different effects for the various Ag components and
MHC hapiotype of the individuals However, the procedure
can lead also to loss of antigenic activity, at least for
certain Ag (21). Therefore, an alternative interpretation
may be the abolition of a "suppressor' constituent by the
technical processing or separation of the soluble extract.
The latter mechanism, which had been considered in
other studies (4. 9. 10. 17) would need to be examined by
more detailed investigation.
Previous serological studies have consistently shown
elevated antibody levels in muitibacillary forms of leprosy
only (22). Antibodies to the ML04 epitope of the 35 kDa
protein were previously detected by competition assay in
only a few (4%) of leprosy contacts (23) but in themajority
of volunteers vaccinated with 5 x 10d killed Af. leprae
(24). In this study, several of the contact sera reacted
with a 35 kDa band of Af. leprae: since these sera were
negative by theML04-competitlon assay, the data suggest
that antibodies were directed to additional epitopes on
the 35 kDa molecule. Immunobiotting demonstrated
binding to a band >92 kDa of Af. leprae which may
correspond to the 98 kDa band noted by other investiga¬
tors (17) and as yet not identified by mAb.
Since T ceils specific for the 65 kDa protein appear to
represent a major component 01 the T ceil repertoire
reactive with mycobacteria, the fine specificity was in-
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vcstigaced using synthetic peptides denved from this pro¬
tein. Selection 01" these peptides vas based on the pres¬
ence ot' sequences similar to chose identified in previously
defined T ceil epitopes (14). Since it is likely that each 3
peptide may contain more than a single T cell epitope
ana chat Class II MHC proteins are able to bind a variety
of pepcldes (25) it was not surprising that some individ¬
uals. C3-s and C2C-S recognized multiple peptides. Fur¬
thermore. the failure of the T cells from two of the inai-
10.
•/lduais co respond co any ot the six peptides cested.
although reactive with the recombinant procein suggests
chat as yet other undefined epitopes are present in Che , {
65 kDa protein.
The presented results illustrate che complexity of T cell
Ag recognition but also represent a lead for che identlfl-
cation of immunodominant epitopes at the population
level. The fractionated Ag represents a distinct advance
over che use of whole soluble extract from .Vf. Leprae for [2.
che analysis of che T cell repertoire in M. leprae infected
subjects. It is apparent however, chat the physical form '4'
of presentation may be important and could have distinct
characteristics for each of che relevant Ag. Antibody and 1S-
T ceil proliferation patterns did not overlap at the level
of che individual, indicating chat other Chan helper func¬
tion is exercised bv che T ceils. Therefore, additional
16.
assays .'or lymDhoKme secretion combined with the Ag
specificity will be of interest in future studies.
17.
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The 65kDa antigen of mycobacteria - a
common bacterial protein?
The 65 kilodalton antigen of Mycobacterium tuberculosis ana
M. leorae is a well-characterized, strongly immunogenic pro-
1in eliciting antibody and T-cell responses in infected pavents.
cent studies have disclosed regions of cross-reactivity be-
ween the 65kDa antigen and proteins in many other bacterial
species. These include the product of the arms gene in E. coii
wnicn is involved in the processing of RNA. Here Dougias
Young and his colleagues discuss these ooservations, the
significance of the 55kDa antigen and its possible roie in the
pathogenesis of mycobactenal and other diseases.
The challenge of understanding the mechanisms under¬
lying the immune response to mycobactena has be\.i
taken up by successive generations of scientists ana
renewed efforts are currently underlay to use improved
methods for analysis of mycobactenal antigens and for
isolation and characterization of T cells. The effective
immune response is thought to involve recognition
of mycobactena! antigens by helper T lymphocytes,
followeo by activation of macropnages and pernaps
stimulation of cytotoxic T ceils. A key area of research is
therefore to identify mycobactena! antigens wnicn are
voived in recognition by T ceils.
A major advance in the identification of mycobacterial
.rotein antigens was accomplished by monoclonal anti¬
bodies directed to components from Mycobacterium
tuberculosis and Mycobactenum leprae'. One of the
antigens which was identified by a high proportion of
monocionai antibodies - particularly those raisea against
M. leprae- has been generally referred to as the '65kDa
antigen' Monoclonal antibodies directed to this antigen
frequently bina to bands with multiple molecular
weights dunng western blotting of extracts from M.
tuberculosis and M. leprae, although this banding pat¬
tern seems to be less marked in the case of more rapidly
growing mycobacteria'. The most likeiy origin of the
multiple banding is that an original protein of aoout 65
kOa undergoes progressive proteolytic degradation to
multiple fragments each containing a subset of the total
antibody binding sites of the full length molecuie.
MRC Tuoerculosis and Related infections Unit, Royal Postgraduate
Meoicai School, Hammersmith Hospital. Ducane Road. Lonoon W12
0HS. UK
Douglas B. Young, Juraj Ivanyi. Josephine H.
Cox and Jonathan R. Lamb
Monocionai antibodies recognizing epitopes situated
towards the N terminus of the molecule (for example.
Y1.2 - see Fig. 2) show very limited recognition of low
molecular weight bands and this would be consistent
with an initial site of proteolysis being locateo near to the
N terminus. Antibodies binding in the C terminal region
(e.g. IIIC8) do show extensive 'multi-banding'.
The 65kDa antigen has been described as 'cell-wall-
associated'2 since much of the antigen is found in the
insoiubie fraction remaining after disruption of the
mycooactena! cells. Other authors have proposed a
'perioiasmic' location for this antigen and have demon¬
strated release of the molecule into culture supernatants
during growth of Mycobactenum bovis under conditions
of zinc deficiency3. Since the amino acid sequence of the
protein (see beiow) contains no strikingiy hydrophobic
regions, a close association of such a molecule with the
lioid-rich cell wall of mycobactena seems unlikely. While
immuno-electron microscopy may be expected to pro-
vioe definitive information on the location of the 65kDa
antigen, an interaction with ribosomes would be consis¬
tent with some of the data discussed below.
Cloning of the 65kDa antigen
Most of the mycobacterial antigens recognized by
monoclonal antibodies have been expressed from M.
leprae and M. tuberculosis genomic libraries using the
\gt11 system-4-5. Recombinant clones expressing all, or
portions, of the 65kDa antigen were found at a particu¬
larly high frequency. It has been shown that the gene for
the 65kDa protein can be expressed in E. coii regaroless
of its onentation with respect to promoters on the
cioning vector, suggesting that, in contrast with some
other mycobacterial enzymes6, the mycobacterial pro¬
moter for this gene can be. recognized by E. coii7-9. The
proteins from M. leprae and M. tuberculosis contain a
striking degree of sequence homology, diffenng in only
26 amino aad substitutions3-9. From the primary se-
auence it can be predicted that the 65kDa antigen
contains extensive a-heiical secondary structure with no
marxed hydrophobic regions and no cysteine residues. 215
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Manping of antibody enrages
Comoetrave binding assays showed that monodonai
antibodies recognize at least Id. soatiailv seoarate eoi-
tooes on the obkDa oroteini0. iVIost of the monodonai
antiboaies bina to the 65kDa antigens from ooth M.
leprae and M. tuberculosis but antibodies IIIE9 and IVD8
recognize an eoitope whicn is unique to the leorosv
baailus11, wniie TB78 recognizes an eoitODe present oniy
in M. tuberculosis and M. bovis'2. By screening a DNA
suolibrary prepared by doning fragments of the SSkDa
gene in \gt11, it was possible to determine the amino
aco seouence wnicn constrtutes the epitope for six of
the monodonai antibodies — induoing the M. leorae-
soecrnc antibody I1IE9 (Ret. 8) (Fig. 1).
The comoiete success of the sublibrary maoDing
aoDroacn was unexoected, in that one mignt have
preaicteo that many of the antibodies wouid be oirectea
to non-iinear determinants ana would therefore faii to
bind to the antigen fragments. The ooserved rugn fre-
auenc/ of monodonai anoboaies airecteo to linear
determinants on the 65kDa antigen couio be the result
of the fragmented nature of the antigen preoarations
useo for immunizaoon. Altemativeiy, the fact that many
of the invesngators useo western blot analysis for onarac-
tenzaoon of the monodonai antiboaies may have
favoured seiecoon of antiboaies aole to bind to dena¬
tured antigen. A thira possible exoianaoon wouid be that
some structural feature of the 65kDa Drotein particuiany
promotes binding of antiboaies to linear determinants.
This might be the case, for example, if tne moiecuie
exists in a preoominantty unfolded configuration with a
high proportion of surface-exoosed residues. Such a
structure mignt also be consistent with the enhanced
sensitivity of this anogen to attack by proteolytic en¬
zymes. Preliminary analysis of sera from tuoercuiosis
patients by subiibrary mapping suggests that non-linear
eprtooes may be important in the poiydonai antiboay
response to the 65kDa protein.
Mapping of T-ceil epitopes
Several grouos have reported the isolation of human
T-cell dones reactive with the SSkDa antigen13-15 ana
the purified protein eiiats a strong aeiayed-type
hypersensitivity response in immunized guinea pigs3.
Two of the epitooes recognized by human T lymphocytes
have been mapped by combining \gt11 sublibrary
screening with a second approach which invoivea analy¬
sis of the 65k0a antigen for die presence of sequence
motifs with similanty to previously aefinea T-ceil
epitopes1*. Based on this analysis, six peptides were
synthesized and two were shown to contain T-ceil
epitopes (Fig. 1). While tnese two epitcoes were recog¬
nized by the individual used in this parncuiar study, more
7-ceil epitooes may be founa on the SSkDa antigen once
die analysis is broadened to indude inaiviauals witn
diffenng HLA types.
Cross-reactivity with £ ooff
When extracts from dones containing recpmoinant
DNA were screened on western blots, some of tne
monodonai antibodies directed to tne 65kDa antigen of
mycoDactena reacted with an aaditional band with a
moiecuiar weight of SSkDa in the control £ coii extracts.
This benaviour is shown by three monodonai anobodies
whicn map at different regions along the protein (Fig. 2)
and paraai purification of the cross-reacove anogen from
£ coll suggests that the same protein is recognized in
eaci case. Raooit antisera raised against syntnetic peo-
tiaes from different regions of tne 65kDa seouence aiso
reacted in western blots, again with an £ coii protein of
SSkDa (Fig. 2!. This anaiysis suggests that regions of
cross-reactivity between tne SSkDa antigen ana an £ coii
protein occur along most of the lengtn of the molecule.
Other monodonai antibodies do not react with £ coii.
indicating that these cross-reacove regions are inter-
SDersed with eoitcoes wnici snow varying oegrees of
species soedficty.
Cross-reacdvity witn £ coii aiso occurs at tne ievei of
T-ceil recognition. Human T-cell lines generated to dif-
monoaonaJ antibodies raoDit arrasera
65kDa^
58kOa^ "i f ir r
^35kDa
^ SSkDa
Y1.2. D7C 11 ICS PZ Pa. pa
Fig. 2. Cvss-reacuvtty of anvboay eatooes.
Western blot analysis ofM. ruoefcuioas (lefthand lane) and 6. coii (rrgnt hand
lanei. Monoaonai anuoooies (asauc fluid were •jseo at a aiiuuon of 1:20 000
(YLZ IIIC3) or l : 100 000 (D7Q. Sera from racms immunized with syntneuc
Denudes P2. P* or P6 were >jseo at a amnion of I : 2500 for M. tuoerauosts ana
I : JO 000 for E. coii. Sera from unrmmunizec raDbits snowed no oinamg unaer
uiese conaiuons.
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ferenx peptides from 65kDa sequence were tested for
proliferation in response to extracts of E. coli fractionated
by SDS-gel electrophoresis'6 (Fig. 3). A T-cell line whicn
recognizes peptide 2 does not react with E. coli, wnile a
line recognizing peptide 5 reacts with an E. coli com¬
ponent which has a molecular weight coincident witn
that of the protein identified by antibody cross-reactivity.
Whiie some of the T-cell aeterminants of the 65kDa
antigen are cross-reactive with E. coli, others are more
restricted in their distribution and a T-cell clone whicn
discriminates between the 65kDa antigens of M. leorae
and M. tuberculosis has oeen reported15.
Homology with the £. coliams gene
Mutation in the ams gene results in an extended
half-life for messenger RNA in E. coli and a gene
encoding a protein which complements this mutation
has been cloned and sequenced17. Residues 296-420 of
the mycobacterial 65kDa orotein show a 65% homology
with the sequence derived from the ams gene (Fig. 4).
This sequence homology includes the region of the
65kDa antigen recognized by monoclonal antibody D7C
as well as peptide 6 which has an associated T and B cell
cross-reactivity. The 17kDa molecular weight of tne ams
gene product17 is not. however, consistent with the
western blot data and does not account for the more
extensive cross-reactivity associated with other parts of
the molecule. It is possiole that the clone which has oeen
seouenced may code for only a portion of the complete
ams protein. Translation of the nucleotide sequence
before the proposed AUG start signal in the ams gene17
would result in a protein sequence in whicn six out of
nine amino acids were identical to the corresponding
region of the 65kDa antigen.
Cross-reactivity with other bacteria
The extent of the observed sequence homology be¬
tween organisms as distantly related as mycobacteria
and E. coli suggests that at least portions of the 65kDa
antigen are under strong selective pressure for conserva¬
tion and it is therefore anticipated that simiiar structures
will be found in a wide range of bacteria. Quantitative
analysis of cross-reactive oinding of anti-65kDa mono¬
clonal antibodies to soiuble extracts from several non-
mycobacterial genera showed marked differences be¬
tween the tested species (Table 1). It is interesting that
the variation in antigenic homology was expressed for
the individual epitopes in most parts of the protein
seouence.
Molecular weight (kDal
Fig. 3. Cross-reactivity of '-ceil epitopes.
Proliferative resDonse of T-cell lines reactive witn svntnetic peptiaes P2 ana P5
to Different moiecuiar weight comoonents of E. coli.
Nitrocellulose strips coated witn differentmolecularweignt fractions from an E.
con attract were oreoared ov electroolomng'6 ana aaaea to proliferation assays
after conversion to microoamculate form22 T-cell lines reactive vvttn oeotiaes P2
ana P6 were generated rem tne ascnc effusion of a tuoercuiosis oatient23
Proliferation as correlated with uotane of mated tnymidine is shown as me
mean of tnoiicaie wells for each fraction. The broken line snows thymidine
uDtake ir. control wells without antigen. Thymidine uptake in response to tne
nomoiogous oeonoe ana to an extract of M. tuDercuiosis was 7884 z 23 Ic.o.m.
z semi ana I' 258 z 15 for line P2, ana I6698 z3 and 14494 - 19 for line P6.
Significance of the 65kDa antigen
While T lymphocytes capable of recognizing the
65kDa antigen are readily demonstrable, it is not known
whether these cells play any role (stimulatory or suppres¬
sive) in protective immunity to mycobacteria! infection or
in the immunopathology of the disease. Analysis of the
effect of the 65kDa antigen in animal modeis using the
cloned gene in vaccinia virus and attenuated Salmonella
vectors will provide important data in this respect.
From the standpoint of immune recognition, tne
65kDa antigen of mycooacteria has become one of the
most thoroughly characterized bacterial proteins. Its
antigenic determinants are as well studied as those of
the .intensively studied bacterial toxins and adhesion
factors'8 The fact that many individuals appear to have
primed T cells which recognize peptide sequences from
the 65kDa antigen makes it an attractive mooe! for
carrying out basic research into the human immune
response to intracellular bacteria in a manner compara¬
ble with that in wnich, for example, haemagglutinin and
ribonucleoprotein from the influenza virus have been
used as model studies for viral antigens (reviewed in Ref.
i 9). Some of the questions which studies of the 65kDa
antigen may be able to answer include: Is recognition of
particular epitopes uniquely associated with specific HLA
types? Do epitopes recognized by antibodies, neiper T
cells and cytotoxic T cells overlap, or are particular
epitooes associated with single immune functions? Can
a single epitope induce heiper or suppressive effects in
different individuals? 217
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in view at tne deotn of knowledge aoout the 55kDa
protein as an antigen. it is exciting to have an indication
of the possible r'unction of this protein within tne
oactenai ceils. 7ne marxec seauenca homology witn the
E. coii ams gene product strongly suggests that :ne
65kOa protein may be Involved in the processing of a
messenger RNA and an association witn riboscmes and
translation mecnanisms seems possibie.
Why aoes the 65kOa antigen eiict sucn strong
•mmune responses? Is this a direct ccnsecuence of ts
presence in a diverse range of bacteria with constant
restimuiation of helper T ceils ounng contact with normal
bactenai fiora? Or is there seme particular feature of tnis
protein wnicn renders it strongly ^antteenic? If the
mmune response :s due to pnming by a cross-reactive
cactenai antigen it wouic be apDroonate to consider
wnat effect exposure to otner bactsna iaenoemic areas
mignt have on the immune response to mvcocacteriai
infection ano how such factors mignt mfiuence the
effectiveness of 3CG vaccination20, it may aiso oe cues-
tionec whether priming of responses to the 55kOa
antigen dunng mycooactenai infection or 3CG vaccina¬
tion has an effect on the suosecuent immune response
to challenge with other environmental bacte.na. s t
possibie that an inoiviouai wno has been higniv primec
to the mycocactenai 55k0a antigen may mount an
exagceratea ano potentially narmfui response to ccss-
-ii
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Fig. P. Homology with tne i. coii arm gene.
The smote ietrer amino aaa cooe for a ooruon of tneM. leorae 65kDa qene° is
snown (uoDer line) along 'wim me sequence aerrveo for tne c. coii ams gene'7
lower line). Pesaues in meM. tuaercuiosrs 65xDa crown* wnicn differ from me
M. ieorae seovence are snown aoove me uooer fine. P.esiaues cenotea bv smaii
-tiers are outv/irn me crcooseo transa tea region of tne ams gene"' 5ect/ence
nomoioay is snown oy tne oaxea rescues.
reaenve antigens trcm otner essen-
naiiy non-patnogenic bactsna? Sucn
a phenomenon couid provice an
ICS :IIC3 explanation for the occurrence of
autoimmune diseases witn no
oovous aetioiogy, ano wouid be
_ consistent witn the reported associa¬
tion of T-ceil responses to mycooac-
tenai antigens with rheumatoid
artnntis21.
A furtner application of the identi¬
fication of a defined bactenai anti-
~
gen with the aoiiity to stimulate oro-
liferation of heioer T cells wouid be
to use portions of this protein as a
~
'earner' for imducng immune
;%) to responses to other antigenic deter¬
minants. For example, a peotiae of
the 55kDa antigen wntcn stimulates
heioer T ceils coula be ccuoieo to oeotiaes from other
proteins containing the epitopes recogmzea by particular
antibodies or cytotoxic T cells. Sucn a strategy mav
provioe a oasis for developing efficient 'suounit vaccines
cacacie of pnming or eiicnna tne appropriate arms of
the immune response.
The existing detailed information aoout the 55kDa
antigen provides an oooorrunity to asx r'unaamentai
Questions aoout the human immune response to n-
traceiiuiar bacteria wnicn nave applications well beyono
tne 'mmeoiate fleid of mycocactenai aisease.
We are grateful to R.A. Harnson and A. Vyakarnan -'or
carr/ing out tne seouence homology searcn: to R.A. vcung "*cr
providing \at1* suoiibrarv clones: to j.3. Rotnoarn for prepara¬
tion of svntnetic peotiaes: to T.M. 3ucnanan ana 3.R. Bloom
for providing monoconai anticoaies: ana to r. Soiisour/ ;or
providing cactenai species.
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Antibody-mediated graft versus host
reactions in renal transplantation
Graft versus host reactions (GvHR) are freauent and
severe complications of bone marrow transplantation.
Although the major symptoms of GvHR in these patients
are thought to be mediated through T lymphocytes, both
clinical and experimental ODservations indicate that anti¬
body production also is stimulated by GvHR. in animal
models of GvHR, Gleichmann and colleagues' have
demonstrated a range of antlbody-mediatec lesions,
which become more pronounced when the antigenic
differences between donor and host favor stimulation of
heiper T lymphocytes and a chronic disease process.
Only limited attention has been given to the possibility
that 'passenger lymphocytes' in soiid tissue transplants
may cause GvHR. In 1953 Simonsen suggested that the
plasma cells he observed in the interstitium of trans¬
planted canine kidneys were possibly of donor origin, Put
he abandoned this hypothesis when radiolabelling ex¬
periments demonstrated that cells of host origin infil¬
trated skin and kidney allografts (reviewed in Ref. 2). Vet,
sporadic cases have been reported of unexDected
hemolytic episodes following the transplantation of kid¬
ney, liver or lung from a donor who is Rh negative or O
blood group to a patient whose erythrocytes bear Rh, A,
B, or AB antigens3-10 One report suggested that irradia¬
tion of the donor kidney prevented antibody production
to the recipient's erythrocytes3, and in a few cases
antibodies that were eiuted from the recipients' erythro¬
cytes have been shown to be of donor allotype3-1'; thus
substantiating the hypothesis that the hemolytic epi¬
sodes reflect GvHR. Some investigators3-6." nave argued
that this phenomenon may be more frequently encoun¬
tered when cydosporine A (CyA) is used as an immuno¬
suppressive agent, because selective effects of CyA on T
lymphocytes mignt prevent rejection of the donor 8-
lympnocytes but not suppress antibody production by
these lymphocytes. Several recent reports have
documented the longitudinal titers of circulating anti¬
bodies to recipient A, B or Rh antigens in CyA treated
renal transplant recipients. These antibodies have been
detected within 1 to 3 weeks after transplantation and
they can persist for months6, even after immunosuppres¬
sion is discontinued8. Both IgG and IgM antibodies have
been detected in the serum ana in eluates from the
recipients' erythrocytes by the indirect antiglooulin test
Transblant Laooratory, Deoartment or Pathology, DuKe University and
VA Medical Centers. Durnam. NC 27710, USA
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wnich has a detection limit of about 10-200 ng/ml (Ref.
12). Assuming that a B iymphocyte can secrete about 2
x 10s IgG molecules (or 0.05 ng immunogioDuiin) per
day13, then about 106—107 B lymonocytes with the
appropriate specificity would be required to produce
detectable levels of hemagglutinins in the circulation.
Hemoloytic anemia as a result of antiboov production
appears to be more freauent following transplants of
liver than kidney7-"; this may simply reflect a dose effect
of passenger B lymphocytes related to the size of the
organ that is transplanted.
While antibodies that cause hemolysis have obvious
practical consequences for some patients wno receive an
ABO or Rh incompatible transplant, the oasic observation
that B-lymphocytes which are passively transferred in a
transplant can expand and produce clinically significant
amounts of antibodies has broader implications. Anti¬
bodies to widely distributed antigens of a recipient sucn
as those to HLA-A or -B antigens, might be aosorbed
from the circulation without causing specific clinical
effects. Alternatively they could form soluole immune
complexes that might deposit in the renal transplant and
ultimately contribute to the peculiar form of allograft
reaction described as transplant glomerulopathy15-16
Antibodies to antigens with a more restricted distribution
mignt impair the function or reduce the number of
certain ceil populations. For example, antibodies directed
against recipient class II MHC antigens might decrease
the number of activated T lymphocytes or certain host
antigen presenting cells. Even more specific antibodies
such as anti-idiotypic antibodies could inhibit responses
of certain critical clones of lymphocytes in the recipient.
Indeed some of these antibody responses by donor
lymphocytes may be responsible for the variable results
observed in association with blood transfusions to kidney
donors17'19.
Antibodies of donor origin which are not directed to
the recipient's own antigens mignt aiso be of import¬
ance. Misleading serological data could be caused oy
antibodies produced by donor lymphocytes to viral anti¬
gens. Based on increases in titers to cytomegalovirus
(CMV), for example, it is generally believed that renal
transplants from donors who are serologically positive
for CMV almost always transmit CMV infections to the
recipient20, but some of these recipients have no symp-
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Stress proteins may provide a link between
the immune response to infection and
autoimmunity
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Abstract
Stress proteins are frequently the target of humoral and cell-mediated immune responses to
infection. These proteins belong to highly conserved gene families and there is substantial
sequence homology between antigens produced by pathogenic organisms and the corresponding
proteins from mammalian cells. Human T cells from sites of infectious and autoimmune lesions
proliferate in response to stress proteins, and mapping of antigenic determinants on a
mycobacterial stress protein shows that both species specific and highly conserved, self-like',
regions of the molecule can take part in immune recognition. It is proposed that the lymphocyte
population induced in response to stress proteins of pathogens during infection includes cells
capable of autoimmune recognition of the corresponding self protein. Local accumulation of self
stress proteins—in response to viral infection, for example—may subsequently provide a stimulus
for proliferation of such autoreactive lymphocytes, thereby triggering a cycle of events which
may contribute to the pathological damage associated with autoimmune disease.
Introduction
Exposure of cells to stress stimuli, such as an increase in
temperature or exposure to toxic chemicals, results in induction
of the synthesis of stress, or 'heat-shock', proteins (1). Stress
proteins and structurally related proteins are also synthesized
constitutively and perform essential functions during normal cell
growth. Members of the 70 kilooaiton heat-shock protein family
(hsp70) are involved in membrane translocation (2.3), and the
90 kilodalton heat-shock protein (hsp90) has been found to
associate with steroid hormone receptors (4.5). The product of
the groEL gene of Escherichia coli is a maior stress protein whicn
belongs to a class of proteins, termed molecular chaoerones.
which assist in the assembly of multi-subunit complexes (6). Stress
proteins have been highly conserved during evolution ano
members of each of the three protein families—hsD70. hsp90
and GroEL—are found in all cells, from bacteria to man
(1.6.7-10).
Analysis of cell-mediated and humoral responses to a variety
of bacterial and parasitic pathogens has shown that members
of stress orotein families are often strongly immunogenic during
infection (11 -18). Proteins involved in antibody responses to
parasitic diseases (maiaria. schistosomiasis, leishmaniasis,
trypanosomiasis and filanasis) have been identified as members
of the hsp70 and hsp90 gene families, and antigens belonging
to hsp70 and GroEL families have been shown to play a role
in T cell ano B cell recognition during bacterial infections including
leprosy, tuberculosis and Q fever. Immune responses to stress
proteins have also been reported during autoimmune diseases.
The mycobacterial GroEL stress protein has been identified as
the target of a T cell clone capable of causing autoimmune
disease in a rat model of adjuvant-induced arthritis (19), and
elevated responses to the same protein have been found by
testing T ceils from the synovial infiltrates of rheumatoid arthritis
Corresoondence to: 0. 3. Young, address as above
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patients (20). Autoantibodies to hsp90 have been reported in
systemic lupus erythematosus (SLE) (21) and elevated antibody
responses to nso70 and GroEL stress proteins have been found
in SLE and in rheumatoid arthritis (22).
These reports indicate that stress proteins provide particularly
attractive targets for immune recognition. Since stress proteins
from different pathogens possess a high degree of sequence
homology, it can be "proposed that their apparent immuno-
dominance is a reflection of repeated challenge to the immune
system resulting in a high frequency of lymphocytes directed to
conserved antigenic determinants. On the other hand, since these
antigens share extensive sequence identity with the corres¬
ponding host cell proteins, their immune recognition must be
influenced by mechanisms of 'self-non-self discrimination, and
it would be anticipated that response to conserved determinants
will be excluded by tolerance. In order to evaluate the significance
of immune responses to stress proteins during infection and
autoimmune disease, it is important to establish whether or not
conserved elements in these proteins can take part in immune
recognition. In this paper we describe analysis of the cross-
reactivity of T cell responses to stress proteins, and demonstrate
the presence of human T cells capable of autoimmune recog¬
nition of conserved determinants. A model is proposed in which
immune responses to stress proteins provide a link between
infectious and autoimmune diseases.
Materials and methods
Preparation of antigens
Mycobacterial GroEL—the 65 kilodaiton antigen (11)—was
isolated from a recombinant E.coli strain (23) and was a gift from
Dr Jan van Emooen (RIVM. Bilthoven. The Netherlands). E.coli
GroEL was purified from a recombinanant strain transformed with
plasmid pND5 (11) using an adaptation of the method described
by Chancrasekhar ef al. (24). Purity was assessed by non-
denaturing and SDS-poiyacrylamide gel electrophoresis. Human
GroEL was partially purified from heat-shocked peripheral blood
mononuclear cells (PBMC) using DEAE-Sephacei and Sephacryl
S200 chromatography. It was identified by its molecular weight
under non-denaturing conditions (- 850 kiiodaltons), its subunit
molecular weight (- 60 kiiodaltons). and by its cross-reactivity
with antisera to E.coli GroEL and Tetrahymena hsp58 (9).
The hsp70 Drotems were obtained from (a) a recombinant E.coli
strain whicn overexpressed the mycobacterial 71 kilooalton an¬
tigen (25), (b) E.coli strain TG1, and (c) heat-shocked human
PBMC. The proteins were purified using a modification of the
ATP-agarose affinity chromatography procedure of Welch and
Feramisco (26) and purity was assessed by SDS-polyacrylamide
gel electrophoresis and Western blotting as described previously
(25).
Synthetic peptides cerresponding to T cell epitopes on ihe
mycobacterial GroEL protein were selected and prepared by
solid phase synthesis as described previously (27).
Isolation and cloning of human T cells
Human T cell lines (T1. T2. T3 and T6) specific for peptides
corresponding to sequences from the mycobacterial GroEL
Drotein (pi. residues 65-85; p2. 116- 137: p3. 153 - 171: 06
390-412) were isolated from the ascitic effusion of a patient
reactive with M.tuberculosis as described previously (27.28).
Lymphoblasts. activated with peptide (10 micrograms/ml) for
7. oays ana enriched on a Ficoll-Paque gradient, were
restimulated with peptide and autologous irradiated (5000 Rads)
EBV-transformed B cells (1 x 10%nl), and maintained in culture
as long-term lines. A T cell clone (T5) was isolated from PBMC
(2.5 x 10s) stimulated for 7 days with synthetic peptide p5
(corresponding to residues 195-219) (3 micrograms/ml) by
limiting dilution in the presence of peptide, autologous irraaiatea
(2500 Raas) PBMC and inteneuKin-2 (Lymphocult T. Biotest-
Serum Institut GmbH, Frankfurt. FRG) (29). Before use in
proliferation assays, the T cell clone and lines were rested for
6-8 days after the last addition of antigen-presenting cells (APC)
and antigen.
In proliferation assays, T cells (5x 104/ml) were stimulated with
antigen in the presence of autologous irradiated PBMC
(1.25 x 105/ml) or EBV-transformed B cells (5x104/ml) in
complete medium (RPMI 1640 supplemented with 2 mM
glutamine. 100 lU/ml penicillin and streptomycin) containing 5%
screened A+ serum. After 3 days incubation, tritiated methyl
thymidine ([3H]-TdR) (1 microcurie/well: Amersham Interna¬
tional. Amersham. Bucks) was acaea and the cultures harvested
onto giass fibre filters 8- 16 h later. Proliferation, as correlated
with (3H]-TaR incorporation, was measured by liquid scintillation
spectroscopy.
The proliferative response of lymphocytes isolated from the
synovial fluid of patients with arthritis was tested by resuspenaing
cells at 5 x 104 cells per well in complete medium plus antigen
and measuring uptake of [3H]-TdR as described above except
that cultures were incubated for 6 days prior to addition of
thymidine.
Results
T cell recognition of defined epirooes on the mycobacterial GroEL
antigen
The ascitic effusion of patients suffering from tuberculosis infection
is a rich source of lymphocytes reactive with antigens from
M.tuberculosis including the mycobacterial GroEL stress protein
(27,28). Synthetic peptides corresponding to regions of the
GroEL seauence carrying motifs related to known T ceil epitopes
(27) were used to stimulate proliferation of lymphocytes isolated
from the ascitic fluid of a single individual and T cell lines (T1.
T2. T3 and T6) directed to four separate epitopes were obtained
(Table 1). Each of the lines was stimulated by the eliciting peptide
and by the purified mycobacterial protein, but the cells snowed
no response to the heterologous peptides. In addition to the T cell
lines shown in Table T, lines were also raised from the same
ascitic fluid to peptides p4 (residues 180-196) and p5
(195-219). Proliferation of the remaining two nnes occurred in
the presence of antigen-presenting cells alone and was
independent of the addition of exogenous antigen. A T cell clone
(T5) showing a specific proliferative response to the p5 peptide
was derived from peripheral blooo mononuclear cells of a olood
donor with no known history of mycobacterial or autoimmune
disease ana is included in Table 1.
These results are in agreement with previous reports indicating
that the mycobacterial GroEL antigen contains a broac array of
epitopes available for recognition by human T lymphocytes
Table 1. Mapping of species specific and conserved ~ ceil epitopes on the mycobacterial GroEL stress protein
Antigen T ceil-response (Sit
Tf T2 T3 T5 T6
pf 65 85
mycobacteria Y — K ! G A E L V K E V A K K 7 □ □ V A G 2.8 1.1 0.9 0.2 7
E.coli F * N M * Q M * * * * * S * A N * A * *
human * K N * * * K * * Q 0 * * N N * N £ c * *
p2 116 137
mycobacteria K R G I E K A V 0 K V 7 £ 7 L L K 0 A K E V 1.0 8.1 1.7 0.5 1.
E.coli * * * * O * * * 7 A A V * E * K A L S V P. C
human R * * V M L # * * A * I A E * K * Q s * P *
p3 153 1171
mycbbacteria D Q S I G D L I A E A M D K V G N E G o.a 0.8 15.9 0.4 1."
E.coli * E 7 V * K * * * * * * * # * * K * *
human * K E # * N I * S 0 * * K * * * R K *
p5 195 219
mycobacteria K G Y I S G Y F V T 0 A E R Q E A V L E E P Y I L 1.0 1.4 0.9 12.9 1.
E.coli R * * L * P # * I N K P * 7 G A V E * * S * F * *
human R * * * * P # * I N r S K G * K C E F Q D A # V *
p6 390 412
mycobacteria R K H R I E D A V R N A K A A V £ c G I V A G 0.8 1.4 0.9 1.3 33.
E.coii K * A * V * * * L H A T R * * * * * * V * # *
human K * D * V 7 # * L N A T R * * * * * * * » L ♦
mycobacterial GroEL 4.0 3.1 5.7 9.4 8.1
E.coii GroEL 1.0 0.7 4.2 9.2 4.4
human GroEL 1.1 1.0 0.7 9.6 8.9
'Five epitopes involved in human T cell recognition of the mycooacteriai GroEL protein were mapped using syntnettc oeptides. Two T cell lines
(T1 and T2) were specific for the mycobacterial antigen, while T cell line T3 was also able to recognize the related protein from E.coli. In addition
to the bacterial GroEL antigens. T cell line T6. and T cell clone T5. were stimulated by the related orotein purified from human ceils.
The sequence of eacn epitooe is shown using the single letter code for amino acios along with the corresponding regions of E.coli GroEL (6t
and a memoer of the GroEL family from human mitochondria (10). Residues identical to the mycobacterial protein are shown as an asterisk.
Maximum proliferation in a dose resDo'nse curve (0.3 -30 micrograms/ml) is shown. Results are expressed as stimulation index (SI).
SI = (T cells - APC - antigenl-(T ceils - APCVfT cells-APC)
(27,30). An unexpected finding is tfjat T cells capable of
recognition of many different determinants (at least four out of
the six peptides tested) ceuld be isolated from a single individual.
Cross-reactivity of T cell responses
Having established a panel of lymphocyte populations responsive
to individual defined epitopes on the mycobacterial GroEL
antigen, it was of interest to determine whether or not the
homologous stress proteins purified from other organisms could
stimulate these ceils. The proliferative response of each T cell
preparation was therefore tested using GroEL purified from E.coli
and a partially purified preparation of a GroEL protein from
human ceils.
The corresponding GroEL protein from E.coli was recognized
by T cells directed to epitopes defined by synthetic peptides p3.
po and p6. with the latter two determinants aiso being conserved
in GroEL extracted from human cells. A human mitochondrial
protein (PI) has recently been seauenceo. and comparison with
the mycobacterial GroEL sequence indicates that P1 belongs
to the GroEL family (10). Comparison of amino acid sequences
in the regions of each of the three GroEL proteins corresponding
to T cell epitopes (Table 1) shows that immunological cross-
reactivity does not require complete sequence identity, but
presumably reflects conservation of key residues involved in inter¬
actions with components of the maior histocompatibility complex
(MHC) and with the T cell receptor. A synthetic peptide cor¬
responding to the appropriate sequence of the related human
protein stimulated proliferation of the T cell clone directed to the
p5 epitope (residues 195-208) of mycobacterial GroEL (Fg. 1)
thus confirming the autoreactive associated with this area of the
protein.
Recognition of stress proteins by T cells during autoimmune
disease
An association between rheumatoid arthritis and lymphocyte
responses to mycobacterial extracts has been reported (31) and
we therefore tested for recognition of stress proteins by T cells
from arthritis patients. Lymphocytes obtained from synovial
infiltrates showeo strong responses to stess proteins (Table 2):
oerionera! blood lymphocytes from the same patients gave only
weak proliferation (data not shown). The response couid be
inhibited by addition of arra-CD3 antibodies, showing that it was
an indication or T cell proliferation. Stress proteins (hsp70 and
GroEL) from mycobacteria were most effective in stimulating T ceil
proliferation, but the same ceils also responded to the
homologous proteins from E.coli. Lower, but cleariy detectable
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Fig. 1. A human T cell clone responds to a synthetic peptide
corresponding to a sequence from the human GroEL protein. The epitope
recognized by T cell clone T5 was localized within the region defined
by residues 195 - 208 of the mycobacterial GroEL. A synthetic peptide
corresponding to the equivalent region of the human GroEL sequence
was prepared and shown to stimulate a proliferative response comparable
to that induced by the mycobacterial peptide. Only 6 of the 14 residues
are identical between the two peptides.
Table 2. Lymphocytes isolated from the synovial effusion of
arthritis patients proliferate in response to stress proteins
Antigen Source T cell response (thymidine uptake)
patient number
hsD70 mycobacteria 5095 19 244 2679
E.coli 4205 13 006 2048
human 2209 5891 1143
GroEL mycobacteria 8077 22 076 2189
E.coli 1095 7447 1285
medium control 847 562 522
The proliferative response to stress proteins was tested using lymphocytes
isolated from the synovial effusion of two patients with rheumatoid arthritis
(patients 1 and 3), and one patient with reactive arthritis (patient 2). Patients
2 and 3 were typed as HLA DR2.5 and HLA DR2.3 respectively. The
tissue type of patient 1 has not been determined. All of the patients showed
a strong response to the mycobacterial stress proteins and, particularly
in the case of patient 2. marked response to the corresponding human
hso70 protein was also observed.
The results are expressed as mean counts per minute (cpm) for triplicate
cultures. The standard errors were less than 20%. The maximum
response in a dose response curve was obtained at 10 micrograms
protein/ml and is shown
responses were observed when hsp70 from human cells was
used as an antigen. No response to human hsp70 was found
when testing penpheral blood lymphocytes from normal donors.
Preliminary experiments using lymphocytes from osteoarthritis
patients showed no elevated responses to stress proteins
(B. R. Bloom, personal communication). These results demon¬
strate that stress proteins are recognized by patients with autoim¬
mune disease and that a portion of the T cell population involved
in the human immune response to stress proteins is capable of
recognizing the homologous 'self proteins.
Discussion
Iri assessing the significance of immune responses to highly
conserved antigens such as the stress proteins, it is important
to determine whether the determinants involved in immune
recognition are made up of conserved or variable amino acid
residues. Species specific epitopes can be recognized as foreign
antigens, but epitopes from conserved regions of the protein
should be seen as 'self and should not elicit an immune
response. We report here that, in the case of the mycobacterial
GroEL-stress protein, the determinants available for human T cell
recognition include both species specific ana conserved elements
and conclude that the mechanisms of self - non-self discrimi¬
nation are not sufficiently stringent to exclude T cell recognition
of self-like' epitopes of stress proteins.
The relative contribution of conserved and variable deter¬
minants to the overall immune response has not yet been
assessed and it is possible that, as has been reported for antibody
responses to stress proteins (32), the normal cellular response
to such antigens is dominated by recognition of species specific
epitopes. An autoreactive component is. however, detectable in
the proliferative response of bulk lymphocytes isolated from the
synovial fluid of arthritis patients. Antigen recognition by T cells
requires interaction with an MHC molecule on the surface of an
antigen-presenting cell, and specificity associated with the
antigen-binding site on the MHC molecule will result in preferential
recognition of different epitopes on stress proteins by individuals
with different MHC haplotypes. The relative frequency of
presentation of variable and cbnserved epitopes will therefore
be regulated in part by MHC polymorphism.
The presence of T cells capable of responding to a self protein
need not necessarily result in autoimmune pathology. Indeed,
the T cell clone (T5) recognizing the self peptide from the GroEL
protein was isolated from an individual with no clinical history
of autoimmune disease. Proliferation of autoreactive T cells may
be restricted in vivo by the action of regulatory pathways perhaps
involving suppressor or cytotoxic cells. Alternatively, the self
protein may not be efficiently processed and presented at
sufficiently high antigen concentration for lymphocyte recognition
in vivo. If the latter mechanism plays a role in tolerance to self
proteins, then stimuli which cause increased synthesis of stress
proteins may lead to antigen concentrations sufficient to stimulate
autoreactive lymphocytes. A variety of physiological events, such
as viral infection (33^36) or possibly stresses occurring within
inflamed joints (37), could increase the local condentrations of
stress proteins in this way. Alternatively, localized changes in the
level of expression of MHC molecules could result in increased
presentation of self stress proteins (38).
Based on three distinctive features of stress proteins—
immunogenicity, sequence conservation and differential
expression—we propose that there may be a link between their
role in infection and a possible involvement in autoimmunity.
Immune responses to stress proteins are generated during
bacterial and parasitic infections. This response will be directed
primarily to variable epitopes but. under some circumstances
(possibly related to the nature of the infection and to the MHC
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haDiotype) an immune response to self-like determinants may
also oe induced. A subsequent local increase in synthesis of the
corresponding self stress protein, for example in response to viral
infection, could activate the autoreactive lymphocyte population
and provide a focus for generation of autoimmune pathology.
This mooei may provide an explanation for the reported links be¬
tween autoimmune disease and-a diversity of bacterial and viral
infections (39). and could also be relevant in understanding the
immunooathoiogy which is often associated with chronic bacterial
ano parasitic diseases.
This report demonstrates that a human T cell response to self
stress proteins does occur. In order to validate the mooei
proposed above it will be necessary to show that alterations of
stress protein synthesis in vivo can result in activation of this
potentially autoreactive T cell population. Animal models of
autoimmune disease (19) provide a possible approach to further
evaluation of this model.
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com counts per minute
E3V Epstein Barr virus
hspTO 70 kilodaiton neat-shock protein family
hso90 90 kilodaiton heat-shock protein family
MHC major histocompatibility comoiex
P3MC oenoherai blood mononuclear cells
SDS sodium dodecyi suiohate
SLE systemic lupus erythematosus
TdR thymidine
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SUMMARY
In this report. T-ceil and B-cell recognition of the house dust mite Dermatophagoidesfarinae (D.far.)
is compared. Nitrocellulose immunoblots of polyacrylamide gel electrophoresis (SDS-PAGE)-
fractionated D.far. were added to proliferation assays to map the antigen specificity ofcloned human
helper T cells and a long-term line induced with D. Jar. T-cell recognition was of a polypeptide of
molecular weight 9000-13.000. that migrates with the serologically defined allergen DerfII (12.500
MW). Since the cloned T cells, unlike the polyclonal response, failed to respond to Dermatophagoides
pteronvssinus (D. pier.), this suggests that they recognize a species-specific epitope. In contrast,
analysis of the B-cell response using Western blotting demonstrated that, in addition to Derf II.
antibodies reactive with the major allergens Derf I (26.000 MW) and Der f III (29,000 MW) were
present in the serum. Similar specificities were seen in the antibody response to D. pter.. and while it
has been reported that the B-cell response to D. far. and D. pter. are predominantly cross-reactive,
our observations suggest that species-specific CD4-positive T cells are present in the overall cellular
response to D. far.
INTRODUCTION
The T-ceil dependency and reaginic activity of IgE in ciinical
allergy is weil documented and. unlike other classes of immuno¬
globulin, rather than being protective is responsible for allergic
sensitivity in atopic individuals (Ishizaka. 1984). Eariv studies
(Orange. Austen 8c Austen. 1971) demonstated that ailergen-
IgE antibody reactions in the human lung induce chemical
mediators that cause the symptoms of respiratory allergy.
In contrast, the antigen specificity and functional roie of T
lymphocytes in the induction and regulation of allergic respira¬
tory diseases remain ill defined, with current research restricted
largely to phenotvpic analysis (Metzger et al., 1987). Recogni¬
tion of allergens such as ragweed (Meuer et al., 1983), pollen
(Brostoff, Greaves 8c Roitt. 1969) and Dermatophagoides
(Rawie. Mitchell & Platts-Mills. 1984: Lanzavecchia a/.. 1983)
by the T cells of atopic individuals has been reported. Rawle et
al. (1984) observed that helper T cells from atopic but not
Abbreviations: APC, antigen-presenting cell: D. Jar., Dermatopha¬
goides farinae: D. pter.. Dermatophagoides pteronyssinus: [3H]TdR.
tritiated methvi thymidine: PBMC. peripheral blood mononuclear
leucocytes: PBS. phosphate-buffered saiine: SDS-PAGE. sodium aode-
cyisulpnate polvacryiamiae gel electrophoresis.
Correspondence: Dr R. E. O'Hehir, Dept. of Allergy and Clinicai
Immunology, Caraiothoracic Institute. Brompton Hospital. Fulham
Road. London SW3 6HP. U.K.
control individuals responded to the purified major allergen pi
from the house dust mite D. pter. Lanzavecchia et al. (1983)
isolated HLA-DR-restricted T-cell lines and clones reactive
with the aeroailergen D. pter. They subsequently used alloreac-
tive T-helper clones for the in vitro stimulation of IgE produc¬
tion (Lanzavecchia 8c Parodi. 1984).
Investigation of the antigenic structures of the house dust
mites D. pter. and D.far. suggest that Derp I and DerfI. both
of molecular weight 24.000. are the major allergens i Chapman
8c Platts-Mills. 1980: Hevmann. Chapman 8c Platts-Mills.
1986). Others have reported major allergens of slightly different
molecular weights, but it has been accepted generally that the
most allergenic fractions were distributed in the range of
20.000-30.000 (Dandeu et al., 1982: Stewart 8c Turner, 1980).
Additionally. DerfII. a major allergen (12.500 MW), and other
minor allergens have also been described (Hevmann et ai..
1987). However, the identification of these antigens was based
on monoclonal antibodies, and since T and B cells may
recognize different components of D. Jar., this should be
supplemented by a direct approach for the analysis of T-ceil
antigen recognition.
In this study, in order to investigate the roie of cell-mediated
immunity in the ailergic response to house dust mite, T-cell lines
and clones reactive with D. far. were isolated. Using the SDS-
PAGE immunoblot assay system for T-ceil antigen recognition
(Young 8c Lamb. 1986) the fine specificity could be mapped to
d.iterminants present in the molecular range of 9000-13.000 and









Figure 1. SDS-poiyacryiamidegei oCD. far. and D.pier. extracts. D. far
extract (10? BU protein per lane) was prepared and run on SDS-
polyacrviamide cel. and proteins were blotted onto nitrocellulose. A
representative gel stained with Coomassie blue is shown with molecular
weight markers. D. pier, extract was run in parallel (D. pier.. Lane 3: D.
far.. Lane 2: molecular weight markers. Lanes 1 and 4).
was specific for D. far., showing no recognition of the closely
related genus D. pier. In contrast, the IgE antibody response to
Derf II was cross-reactive.
MATERIALS AND METHODS
Antigens
Lvophiiized extracts of D. far.. Timothy grass, five-grass mix
and Parietana were kindly provided by Pharmacia (Uppsala.
Sweden). D. pier, was the generous gift of Bencard (Brentford.
Middlesex).
Antibodies
Monoclonal antibodies reactive with T-cell surface antigen. Leu
2a. Leu 3a. Leu 4. HLA-DR ana IL-2 receptor were purchased
from Becton-Dickinson. Sunnyvale. CA.
Preparation of immunoblots
SDS-PAGE immunoblots were prepared as described pre¬
viously (Young &. Lamb. 1986). Briefly, antigen was boiled in
the presence of SDS and 2-mercaptoethanoi and separated by
SDS-polvacrylamide gel electrophoresis in a 'mini-gel* appara¬
tus (Hoeffer Scientific. San Francisco. CA) using the Laemmli
system (Laemmli. 1970) with an acrylamide concentration of
15% (w/v). Samples of D. far. extract for electrophoresis
contained 105 biological units (BU) of protein per lane. Proteins
were transferred from gels to nitrocellulose by electroblotung as
described by Towbin, Staehelin & Gordon (1979). Blots were
reversiblv stained by dipping for a few seconds in Amido biack
(0-1% in 0-5% acetic acid) and washed with distilled water to
permit accurate localization of protein lanes (Fig. 1). Blots were
further washed with 0-1% Triton X-100 in phosphate-buffered
saline (PBS) and then with PBS alone prior to use. Each
nitrocellulose blot (0-5x4 cm) was divided into 20 equal
sections. These sections were then solubilized using the modifi¬
cation of Abou-Zeid et al. (1987). Dimethvlsulpnoxide (1 ml)
was added to each section for 1 hr at room temperature followed
by an equal volume of bicarbonate/carbonate buffer. pH 9-6. to
allow reprecipitation. The preparations were then precipitated
in a microfuge at 10.000 r.p.m. and washed four limes with
RPMI-1640 medium (Flow. Irvine. Ayrshire) and resuspended
to a final volume of 0-5 ml. of which 20 p\ were added to each
well in proliferation assays. Molecular weights were determined
from a standard curve obtained using molecular weight markers
(Sigma. Poole. Dorset).
Preparation of lymphocytes
Peripheral blood mononuclear leucocytes (PBMC) obtained
from a healthy adult with perennial rhinitis and a positive skin
prick test to the house dust mite D. far. were isolated by
centrifugation on a discontinuous gradient of Ficoll-Paque
(Pharmacia).
Isolation of antigen-reactive T-lymphocyte lines and clones
Antigen-reactive T-cell line and clones were isolated as de¬
scribed previously (Lamb et al.. 1982). Briefly. PBMC (2-5 x 105
ml) were cultured with D. far. antigen (10* BU/ml) for 7 days in
RPMI-1640 supplemented with 2 m\i L-glutamine. 100 IU/ml
penicillin/streptomycin and 5% screened AB~ serum. Lvm-
pnoblasts enriched on Ficoll-Paque were established as a long-
term line in the presence of irradiated (2500 raas) autologous
PBMC, D. far. and interleukin-2 (IL-2: Lvmphocult T. Biotest
Folex. Frankfurt. FRG) or cloned by limiting dilution from the
line. For cloning, lvmphoblasts (33-y cells/ml) were plated in
Microtest II trays together with irradiated autologous PBMC
(5 x 105/ml). D.far. (103 BU/ml) and IL-2 (Lvmphocult T 5% v/
v supplemented with recombinant IL-2. 5 U/ml. the generous
gift of Boenringer. Mannheim. FRG). After 7 days, growing
clones were transferred to flat-bottomed 96-well microtitre trays
and subsequently to 24-well iravs. At each transfer the clones
received fresh IL-2 and irradiated autologous PBMC together
with specific antigen (D. far.: 10* BU/ml). The clones were
maintained with further IL-2 every 3-4 days, and irradiated
autologous PBMC and D. far. were added even.- 7 days. Before
use in proliferation assays, the clones were rested for 6-8 days
after the last addition of filler cells and antigen.
Proliferation assays
T cells of the long-term line (DX2) and clone (DD11: 5 x 1 (F/ml)
were cultured with soluble or insoluble antigen in the presence of
autologous irradiated PBMC (5 x 105/ml) in 96-well flat-bot¬
tomed microtitre plates, as described previously (Young &
Lamb. 1986). After a 72 hr incubation, the cultures were pulsed
with 0-66 pCi of triuated methyl thymidine ([3H]TdR: Radio¬
chemicals Inc.. Amersham. Bucks. U.K.) for 8-16 hr. then
harvested onto glass-fibre filters.
Proliferation as correlated with [3H]TdR incorporation was
measured by liquid scintillation spectroscopy. The results are
expressed as the mean counts per minute (c.p.m. ± SEM). The
duration of unfractionated PBMC cultures (10s/well) was 7
days.
Autoradiography from immunoblots of D. far. and D. pter.
Nitrocellulose-transferred SDS-PAGE immunoblots of D. far.
and D. pter. were prepared as described. Western blotting and
autoradiography were performed using the modification of Tee
et al. (1987). Briefly, non-specific binding was blocked by
immersing the nitrocellulose sheets in 2% human serum albu¬
min in Tris buffer (pH 7-5) for 1 hr at 39c. After washing, a range
ofconcentrations of autologous serum (undiluted. 1:2. 1:5) was
allowed to react over the nitrocellulose sheets for 16 hr. After


































Figure 2. T-cell proliferative responses to a panel of soluble aeroaller-
gens. (a) PBMC (ICP.'weil) were cultured with soluble D. far.. D. pter.,
Timothy grass. Parietaria and five-grass mix. Proliferation was deter¬
mined by [JH]TdR incorporation in a 7-dav assay. The results are
expressed as counts per minute (c.p.m.) ±SEM of triplicate cultures.
Background response of PBMC in the absence of antigen was 349 ±48
c.p.m. (b) T ceils of line (DX2) and (c) clone (DDI I) (104 well) were
stimulated with the same aeroailergens together with autologous
irradiated PBMC (5 x l04/well). [JH]TdR incorporation was determined
at 72 hr. Background responses of the DX2 ana DDI 1 to APC in the
absence of antigen were 87 ± 19 and 95 — 30 c.p.m., respectively.
washing, this was followed by a further 16-hour incubation with
the tracer 125I anti-IgE (Pharmacia) (100 ^I/approximately 104
c.p.m.). The washed, dried sheets were exposed to X-OMAT L
Kodak film with Du Pont Quanta III intensifying screens at
— 70° for 48 hr, and then developed. Negative controls using
serum (1:2 and 1:5) from a non-atopic individual were pro¬
cessed in parallel.
Cytojiuorimetric analysis
T cells were incubated with monoclonal antibodies Leu 2a. Leu
3a, Leu 4, HLA-DR and anti-IL-2R followed by FITC-
conjugated rabbit anti-mouse immunoglobulin (Ft'ab):; Dako-
patts. High Wycombe. Bucks. U.K.). The ceils were analysed for
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Figure 3. Differential pattern of reactivity of the T-ceil line (a) and done
(b) to SDS-PAGE antigens soiubiiized from immunoblots of D.far. T
ceils of the D. far.-specific line (DX2) and the clone (DDI I) (KP/mi)
were cultured with SDS-PAGE-separated immunoblots (20 fractions)
after solubilization with DMSO. together with irradiated PBMC
(5 x 105/ml) and assayed as described in the legend to Fig. 2b and c.
Background response of DX2 and DD11 to APC in the absence of
antigen was 973 ±20 and 66 ± 16 c.p.m.. respectively.
RESULTS
T-cell proliferation in response to soluble D.far. antigen
PBMC from a patient with perennial rhinitis proliferated in a
dose-dependent manner when stimulated with soluble D. far.
extract (Fig. 2a). In addition, proliferative responses were also
observed to the other aeroailergens as compared to the medium
control. Although no response was observed to Timothy, the
biological activity of the allergen was confirmed in sensitized
patients. Both the long-term T-cell line (DX2) and cloned T cells
(DDI 1) proliferated in response to the inducing antigen D.far..
but failed to recognize the allergens Timothy, Parietaria and
five-grass mix over a range of concentrations. DX2 gave a
limited proliferative response to D. pter.. but DDI 1 showed no
recognition of this allergen (Fig. 2b and c). This confirms the
specificity of the T-cell line and clone for D.far.
Reactivity pattern of T-cell line and clone to SDS-PAGE
immunoblots of D. far.
T lymphocytes from the line and clone in the presence of
accessory cells were observed to proliferate in response to D. far.
supplied in particulate form bound to nitrocellulose alter
fractionation on SDS-PAGE (Fig. 3). The long-term T-ceil line
(DX2) predominantly recognized antigenic determinants within
the molecular weight range 9000-13,000 (Fig. 3a) which
contained the only determinant.recognized by the clone DDI 1
(Fig. 3b). In addition, the line showed minimal recognition ot
the protein band (24.000-29,000) that would correspond to the












Figure 4. Auioraaiographs ofWestern blots showing the lgE response of
autologous and non-atopic allogeneic sera to D. far. and D. pier.
antigens. D.far. (a i and D.pier. Cb) mite body extracts were separated by
SDS-PAGE and transferred to nitrocellulose. The strips were probed
with sera from the mite-allergic PBMC donor (undiluted. Lane 1: 1:2.
Lane 2: and 1:5. Lane 3) and from a non-allergic control (1:2. Lane 4:
and 1:5. Lane 5) and autoradiographed to detect binding of IgE as
described in the Materials and Methods.
DerfI and DerfIII allergens. To control for the possibility that
proliferation was a non-specific mitogenic effect, all 20 fractions
were added in the presence of accessory cells to cloned T cells
reactive with influenza haemagglutinin (Lamb &. Green. 1983).
with the result that no proliferation was observed. Neither were
any of the fractions able to inhibit the response of this clone to
influenza, thus eliminating the presence of non-specific inhibi¬
tors (data not shown). These results would suggest that the
proteins in the molecular weight range 9000-13.000 constitute
the major component of T-cell recognition for this individual.
Reactivity pattern of specific IgE to immunobiots of D. far.
The autoradiographs using autologous serum showed strong
IgE binding at the 13.000 fraction corresponding to the major
site of T-cell recognition (Fig. 4a). Fainter bands were demon¬
strable at 26.000. 29.000 and 42.000 MW. These first two bands
correspond to the molecular weights ofDerf I and Der/III. and
reflect the minor recognition site of the T-cell line DX2.
Similarly, the pattern of binding to D. pier, was predominantly
against the 13.500 MW band, with additional bands at 41.000
and 31.500 (Fig. 4b).
Interestingly, the major protein band on this gel was
consistent with Der p I (Fig. 1). None of these antigens was
recognized by the control sera.
Phenotvpic analysis of cloned T lymphocytes
Since the T cells showed identical specificity to the anti-D.far.
IgE response (Fig. 4a). it was of interest to determine if those T
cells were of the helper phenotype. Both the long-term T-cell line
DX2 and clone DD11 expressed CD3 and MHC class II
determinants characteristic of activated mature peripheral T
cells. The clone DDI 1 was CD4-posuive and therefore of the
helper/inducer population. The line was also predominantly
CD4-positive. although there was a minor component of CDS
(suppressor/cvtotoxic T subsets/positive T cells. The reduced
expression of IL-2R in clone DD11 as compared to the line may
reflect the state of activation (IL-2R down-regulation) since the
cells were rested for 6-8 days after the last addition of filler cells
and antigen before phenotypic analysis (Fig. 5).
DISCUSSION
The T-cell dependency of antibody production in allergic
disease is well established flshizaka. 1984). However, the
specificity and regulatory role ofT cells in the immune response
to house dust mite remain to be explored.
In this study the antigen specificity of both the polyclonal
and clonal response of a patient with perennial rhinitis attribu¬
table to house dust mite allergy has been analysed. At the
polyclonal level, both D.far. and the closely related house dust
mite D. pier, were able to induce marked T-cell proliferation.
Therefore, in order to determine whether or not T-cell recogni¬
tion of D. far. was limited to cross-reactive determinants also
present on D. pier., an IL-2-dependent T-cell line and done
induced with D. far. were isolated. Similar to the polyclonal
response, the T-cell line responded to both D. far. and D. pier..
although the magnitude of the response to the latter was
considerably less, suggesting that T-cell recognition was dir¬
ected mainly to species-specific determinant(s). Indeed, the
cloned T cells also appeared to recognize a species-specific
antigen of D.far.
The information available on T-cell recognition of the genus
Dermaiophagoides is limited. Rawle et al. (1984) described
polyclonal T-cell proliferation to the pi antigen of D. pier.;
however, whether or not the responses were cross-reactive with
D. far. was not investigated. Certainly it would appear that
human IgE antibody response to Der p 'I and Der f I is
predominantly cross-reactive (80-95%: Chapman. Hevmann &.
Platts-Mills. 1987). and although T and B cells may recognize
different determinants within a protein antigen (Berzofskv,
Richman & ICillon. 1979: Lamb & Green . 1983). the specificity
of the T-cell response may parallel that observed for B ceils. In
order to determine whether the T-cell response was directed
towards Der f I. the reputed major allergen of D. far.,
nitrocellulose immunobiots of SDS-PAGE-separated antigen
were prepared and added to T-cell proliferation assays. Using
this approach the determinant(s) recognized by both the T-cell
line and clone could be mapped in the molecular range of 9000-
13.000. This co-migrates with Der /II (MW 12,500). recently
proposed by Hevmann et al. (1987) to be a major allergen of D.
far. in addition to the 24.000 MW protein Derf I (Hevmann et
al.. 1986). Interestingly, the results reported would suggest that
the T-cell response of this individual is directed predominantly
against a species-specific determinant(s) in Derf II. Whether or
not Der f II. as opposed to Der f I for example, is an
immunodominant T-cell allergen for the haplotype of this
individual, such as has been described for the cytotoxic T-cell
response to the internal components of influenza (Gotch ei al..
1987) warrants investigation. Alternatively, as suggested by the
polyclonal response. T-cell recognition is neither limited to
species-specific determinants, or indeed to Der f II. and
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Figure 5. Indirect immunofluorescent cytofluorimetric analysis of cione DDI I. Sampies were analysed with monoclonal antibodies as
indicated above the histograms. Percentage positivity is shown.
therefore the clonal response merely reflects the restriction
element usage for a specific epitope.
In analysing the specificity of the D. far. IgE antibody
response, similar to the T cells, recognition was predominantly
of a protein that migrates with the samemolecular weight as the
Der f II allergen (12.500), although antibodies reactive with
determinants that migrate with identical molecular weights to
the f I and f III allergens (26.000 and 29.000) respectively
(Heymann et ai.. 1987) were also observed. These results are
interesting for they suggest that while the T-cell recognition is
mainly of the Der f II. allergen, the IgE antibody response is
directed towards both the major and minor allergens. The
human IgE antibody to Der p I and Derfl appears to be 80-95%
cross-reactive (Chapman et al., 1987), therefore it is possible
that T cells primed to D. pier, are providing the helper activity
for the cross-reactive B-cell response. Indeed, the PBMC of this
individual were able to respond to D. pier. Whether or not the
antibody response to DerfII and Der/III operates through the
samemechanism is unclear. Alternatively, the Der/II-reactive T
cells may provide not only specific helper activity for the anti-/II
antibody response, but also 'intermolecular' help (Lake &
Mitchison, 1977) for the anti-/I and/III B-cell response. These
same arguments may apply to the immune response to D. pier.
Furthermore, the fact that the cloned T cells and the line
described here express membrane CD4 raises the possibility that
they are able to regulate IgE synthesis, and therefore may be
important in the pathogenesis of the allergic response to the
house dust mite.
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SUMMARY
An allergen-dependent in vitro model of immunoglobulin E (IgE) synthesis by human B ceils is
reported. Using this model, it is demonstrated that polyclonal T cells and CD4* Dermatophagoides
spp. (house dust mite)-specific T-cell clones derived from an atopic, house dust mite (HDM)-allergic
individual are able to support IgE synthesis by autologous B cells. The helper activity was interleukin-
4 (IL-4) dependent as only cloned T cells expressing detectable mRNA for IL-4 were able to induce
IgE synthesis without the addition of exogenous IL-4. Peripheral and cloned T cells reactive with
HDM could also be identified from a non-atopic individual but neither population was able to
support IgE production even in the presence of exogenous IL-4.
INTRODUCTION
Immunoglobulin E (IgE) is responsible for allergic sensitivity in
atopic individuals (Ishizaka, 1984). Although it is evident that
IgE synthesis is regulated in part by interieukin-4 (IL-4), which
in the mouse is secreted by a particular subset of helper T cells
(Howard & Paul, 1983; Coffman et al., 1986; Mosmann &
Coffman. 1987), basic differences between atopic and non-
atopic individuals in the regulation of IgE synthesis have not
been resolved. This has been hindered by the absence of suitable
allergen-dependent systems for in vitro IgE production by
autologous B cells (Leung & Geha, 1987). Much of the available
information has been derived from the analysis of pathological
variants associated with hyper-Ig£ production (Geha et al..
1981; Buckley & Fiscus. 1975) or from the use of alloreactive
(Lanzavecchia & Parodi. 1984: Umetsu et al.. 1985) and
autoreactive (Leung, Young & Geha. 1986) T-cell clones.
Furthermore, polyclonal B-cell activators have failed to induce
IgE synthesis in peripheral blood B cells of both non-atopic and
allergic donors, thereby failing to provide suitable models for
the analysis of IgE regulation (Saryan, Leung & Geha. 1983;
Fiser & Buckley, 1979).
Abbreviations: Bu. biological unit; D. farinae. Dermatophagoides
farinae. IgE. immunoglobulin E; IL-4, interieukin-4: PBMC. Peripheral
blood mononuclear ceils: SDS-PAGE. sodium dodecylsuiphate polyac-
rylamide gel electrophoresis.
Correspondence: Dr R. E. O'Hehir. Dept. of Allergy & Clinical
Immunology, National Heart & Lung Institute. Dovehouse Street.
London SW3 6LY. U.K.
In this report, an in vitro modei of IgE synthesis using
autologous B cells is described for the most common mite
species inducing allergy (Dermatophagoides spp.; house dust
mite. HDM) and. using allergen-specific polyclonal T cells and
clones from an atopic and a non-atopic individual, the differ¬
ences in IgE regulation are investigated.
MATERIALS AND METHODS
Antigen preparations
Lyophilized extracts of Dermatophagoides farinae (D. farinae).
Dermatophagoides pteronyssinus (D. pteronyssinus), Parietaria
judaica. Timothy grass and mixed grass pollen were kindly
provided by Pharmacia (Uppsala, Sweden).
Isolation ofhuman T cell clones
A panel of house dust mite-specific CD4-*- T-ceil clones was
isolated from the peripheral blood of an atopic individual with
perennial rhinitis and a non-atopic healthy subject, using the
limiting dilution cloning method described previously (O'Hehir
et al.. 1987). For cloning, viable cells (0-3 cells/well) were
resuspended in complete medium (RPMI-1640 supplemented
with 2 mM L-glutamine, 100 IU/ml penicillin/streptomycin)
containing 5% screened human AT serum and plated in
Microtest II trays together with irradiated (2500 rads) auto¬
logous peripheral blood mononuclear cells (PBMC; 1 x 106/ml),
D. farinae (I03 BU/mi) and interleukin-2 (IL-2; Lymphocult T,
10% v/v, Biotest Folex. Frankfurt. FRG). Before use in assay
systems the clones were rested for 6-8 days after the last addition
of filler cells and antigen.
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Proliferation assays
Cloned T cells (5 x \0*fm\) were stimulated with D.farinae and
mixed grass pollen at different concentrations in the presence of
autologous irradiated PBMC (l-25x 105/ml). After 60 hr in¬
cubation, tritiated methyl thymidine (pH]TdR: 1 /xCi/well.
Amersham International, Amersham, Bucks) was added and
the culture harvested onto glass-fibre filters 8-16 hr later.
Proliferation, as correlated with pH]TdR incorporation, was
measured by liquid scintillation spectroscopy. For polyclonal
T-cell responses, PBMC (2-5xl05/ml) were stimulated with
antigen for 6 days. The results are expressed as mean counts per
minute (c.p.m.) for triplicate cultures.
Culture conditions for in vitro antibody production
Erythrocyte rosette negative cells (E") containing B cells and
monocytes (<2% contaminating E+ cells)-were isolated using
aminoethylisothiouronium bromide hvdrobromide (AET)-
treated sheep erythrocytes and centrifugation on Percoll (Phar¬
macia) gradients (Lamb et al1983). Cloned T cells (2-5 x 105/
ml) or E+ cells (1 - 5 x 106/ml) were cultured with D. farinae or
mixed grass pollen (5 x 103 BU/ml) and autologous E~ cells
(2-5 x 105/ml) in complete medium containing 10% fetal calf
serum (FCS), with or without the addition of recombinant IL-4
(100 U/ml; Genzyme, Boston, MA). The supernatants were
harvested at 10-12 days and the total levels of IgE and IgG
determined by enzyme-linked immunosorbent assays (ELISA).
Determination of immunoglobulin synthesis
Total IgE and IgG were measured using solid-phase ELISA as
described in detail elsewhere (Larche et al.. 1988). Briefly, for
IgG, plates were coated with goat anti-human IgG (1 :500:
Miles Scientific. Slough, Bucks), blocked with 1% bovine serum
albumin (BSA) and then incubated with the test samples. For
detection of IgG, alkaline phosphatase-iabelled goat anti-
human IgG (1:500 dilution: Sigma, Poole. Dorset) conjugate
was used and absorbance measured at 405 nm. For IgE, mouse
anti-human IgE monoclonal antibody (1:500: Serotec. Kidl-
ington, Oxon) was used to coat plates and biotinvlated goat
anti-human IgE (1:250; Vector. Peterborough. Cambs) was
used as a second antibody followed by streptavidin biotinv-
lated-horseradish peroxidase conjugate. Absorbance was mea¬
sured at 450 nm. For both IgG and IgE assays standard curves
were performed. The limits of detection were 8-1000 ng/ml and
50-12.000 pg/ml for IgG and IgE, respectively. IgG or IgM at
concentrations of 50 /zg/well were not detected in the IgE assay.
Dot blot analysis of T-cell clones
T-cell clones were activated on solid-phase anti-CD3 antibody
(OK.T3; Ortho Pharmaceutical Corp.. Raritan. NJ) for 6 hr in
the presence of 5% IL-2. collected, washed and resuspended
in phosphate-buffered saline (PBS) containing cvcloheximide
(50 /xg/ml) and vanadyl ribonucleoside complex (10mM). Selec¬
tive mRNA immobilization on the nylon membrane (Hybond-
N. Amersham) was as described elsewhere (Bresser. Doering &
Gillespie, 1983). Briefly, cells were lysed using pronase digestion
followed by detergent treatment; the lysate was saturated with
sodium iodide and put onto the membrane. After washing, the
membrane was exposed to UV light before storage. Prehvbridi-
zation and hybridization were earned out at 42° in 50%
formamiae ana 6xSSC (20xSSC = 3 m NaCl 4-0-3 m Na
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Figure 1. Antigen specificity of PBMC from an atopic and a non-atopic
individual. PBMC (2-5 x 10s/ml) were cultured with a panel of soluble
aeroallergens at different concentrations. Proliferation was determined
by [3H]TdR incorporation after 6 days. Background responses of
PBMC to medium in the absence of antigen were less than 115 c.p.m.
labelled by random pnming using a DNA-labelling kit (Boeh-
ringer Mannheim, FRG), and for IL-4 two partially overlap¬




were annealed and filled in using 3:PdCTP (Amersham) and
three unlabellea dNTPs in the presence of Klenow enzyme.
Autoradiography from immunoblots ofD. farinae
Mite body extract of D. farinae was separated by SDS-PAGE
and transferred to nitrocellulose. The strips were probed with
sera from the mite-allergic clone donor and from the non-
allergic clone donor and autoraaiographed to detect binding of
IgE as described previously (O'Hehir et al., 1987). Briefly, after
blocking non-specific binding with 2% human serum albumin in
Tns buffer (pH 7-5), dilutions of the sera (1:2 and 1:5) were
allowed to react over the nitrocellulose sheets for 16 hr. After
washing, they were incubated for a further 16 hr with 125I anti-
IgE (Pharmacia: 100 ^I/approximately 104 c.p.m.). The washed,
dried sheets were exposed to X-OMAT L Kodak fiim with Du
Pont Quanta III intensifying screens at — 70' for 48 hr and then
developed.
RESULTS
Antigen specificity of polyclonal and monoclonal T cells isolated
from an atopic and a non-atopic individual
At the polyclonal level, the response of peripheral T cells from
an atopic individual with perennial rhinitis and a non-atopic
donor to D. farinae extract was comparable (Fig. 1). T cells from
both individuals proliferated in a dose-dependent manner when
stimulated with soluble D.farinae extract. Furthermore, proli¬
ferative responses were observed to the closely related member
of the same genus. D. pteronyssinus. and to Parietaria judaica
compared with the medium control.
Cloned T cells derived from the same individuals (clones
DE26 and DE9 from the atopic subject and clone DF1 from the
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Figure 2. Cloned T cells (5 x lO^mi) were cultured with D.farinae and
mixed grass pollen over a concentration range in the presence of
autologous, irradiated PBMC (1-25 x l05/ml). Proliferation was deter¬
mined by [3H]TdR incoporation at 72 hr. Dose-response curves for
D.farinae are shown; DE26 (open circles), DE9 (closed circles) and DF1
(closed squares). Only the maximum proliferative response to mixed
grass poilen is plotted. Background responses to accessory cells in the
absence of antigen were less than 275 c.p.m. and in ail cases the
percentage SEM was less than 25%.
50 20 10 5 x I04




Figure 3. Dot blot analysis ofmRNA for IL-2 and IL-4 in T-cell clones.
Cloned T lymphocytes, activated for 6 hr with solid-phase anti-CD3.
were probed using human IL-2 as cDNA and IL-4 oligonuclotides.
Comparable mRNA for actin was present in all clones.
non-atopic subject) proliferated strongly in a dose-dependent
fashion in response to the inducing allergen, D. farinae, but
failed to recognize the unrelated allergen, mixed grass pollen
(Fig. 2).
Dot blot analysis of mRNA for IL-2 and IL-4 in T-cell clones
The levels of IL-2- and IL-4-specific mRNA were compared for
the T-ceil clones DE9 and DE26 from the atopic and DF1 from
the non-atopic individual 6 hr after activation with insolubilized
anti-CD3 antibody (OK.T3). Dot blot analysis of clones DE9
and DE26 revealed the presence of comparable levels of IL-2
transcripts (positive at 10 x 104 ceil equivalents/spot: Fig. 3)
whereas clone DF1 was positive at 50 x 104 cell equivalents/
spot. DE26 also gave positive hybridization for IL-4 mRNA
(10 x 104 cell equivalents/spot) as opposed to DE9, which was
only weakly positive when mRNA from five-fold the number of
cell-equivalents/spot was probed, and DFl, which had no
detectable IL-4-specific mRNA.
Table 1. D.farinae-induced immunoglobulin synthesis
by polyclonal and cloned T cells from an allergic
individual





(a) DE26 4. _ _ 0 48
DE26 4- D. farinae - 252 565
DE26 — Grass poilen - 0 30
DE26 4- D. farinae 4- 682 452
(b) DE9 4- - - 0 0
DE9 4- D. farinae - 0 73
DE9 4- Grass pollen - 0 0
DE9 4- D. farinae 4- 595 2843
(c) E* D. farinae - 90 12
- 4- D. farinae - 0 0
- -r Grass pollen - 0 0
- 4" D. farinae' 4- 41 11
E"" 4- D. farinae 4- 245 1335
E* 4" — 4" 40 0
T-ceil clones DE26 (a) and DE9 (b) were isolated
from the same atopic individual. IgE and IgG synthesis
by E~ cells (c) cultured with IL-4 and antigen without
added T ceils are shown. Polyclonal T-cell help pro¬
vided by E* ceils (c) was also determined. Background
IgG and IgE synthesis by E" cells cultured with antigen
have been subtracted from the test groups. These were
as follows: For (a), IgG^15 ng/ml. IgE^98 pg/ml:
(b), IgG^ 15 ng/ml. IgE^90 pg/ml: (c), IgG ^ 14 ng/
mi. IgE ^47 pg/mi.
Ability of Dermatophagoides spp.-specific T-ceil clones to support
IgE and IgG synthesis in vitro
Clone DE26 isolated from the atopic subject with detectable
mRNA levels for IL-4 was able to collaborate with autologous
E" cells in the presence of the specific D. farinae allergen to
support IgE synthesis. This was enhanced three-fold by the
addition of exogenous IL-4 at the initiation of cultures
(Table la). Clone DE9 with barely detectable IL-4 transcripts
helped IgE synthesis only when exogenous IL-4 was added to
the cultures (Table lb). Similarly, allergen-dependent IgG
synthesis mediated by T-cell clones DE26 and DE9 was also
enhanced in the presence of exogenous IL-4. The failure of the
autologous E~ cells cultured with antigen and IL-4 to stimulate
marked IgE synthesis demonstrated the requirement for T cells
in the system (Table 1c). The presence of antigen was required
since E*" and E~ cells co-cultured with IL-4 were unable to
induce IgE synthesis. Peripheral T cells (Ef) from the atopic
donor when cultured with autologous E ~ ceils and D. farinae
induced the synthesis of IgE that was enhanced by the addition
of IL-4 (Table lc).
Cloned CD4+ T cells (DFl) from the non-atopic donor,
which had no detectable mRNA for IL-4 (Fig. 3), were unable to
induce IgE synthesis even in the presence of exogenous IL-4
(Table 2a), although able to support IgG secretion. Total IgG
synthesis was also enhanced by the additional IL-4 added to the
cultures. Similarly, stimulation of E" cells from the non-atopic
individual with allergen and peripheral T cells failed to induce
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Table 2. D.farinae-induccd immunoglobulin synthesis by
polyclonal and cloned T cells from a non-atopic indi¬
vidual
IgE IgG
T cells E" Antigen IL-4 pg/ml ng/ml
(a) DF1 + _ _ 0 0
DF1 + D. farinae - 0 290
DF1 + Grass pollen - 0 0
DF1 + D. farinae + 0 420
(b) E- + - - 0 0
E* -r D. farinae — 0 122
- + D. farinae + 20 190
E+ 4- - 4- 40 200
E+ + D. farinae + 55 360
(c) E+ alio 4- - - 93 26
E+ alio 4- - 4- 575 2385
T-cell done DF1 (A) was isolated from a healthy,
non-atopic individual. IgE and IgG synthesis by E~ cells
cultured with IL-4 and antigen without added T cells is
shown (b). Polyclonal T cell heip provided by E+ cells (b)
ana cloned allogeneic E* cells (c) are shown. Background
immunoglobulin synthesis by E~ ceils cultured with
antigen have been subtracted from the test groups. These
were as follows: For (a), IgG <70 ng/ml, IgE ^ 190 pg/
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Figure 4. Autoradiographs ofWestern blots showing the IgE response of
sera to D. farinae. Mite body extract of D. farinae was separated by
SDS-PAGE and transferred to nitrocellulose. The strips were probed
with sera from the mite allergic done donor (1:2) dilution, lane I;
1: 5 dilution, lane 2) and from the non-atopic clone donor (1:2 dilution,
lane 3:1:5 dilution, lane 4) and autoradiogranhed to detect binding of
IgE.
IgE secretion, although IgG was produced, albeit at low
amounts (Table 2b). The addition of exogenous IL-4 to these
cultures did not markedly enhance IgE synthesis above that
observed in the controls (Table 2b).
The stimulation of B-cell enriched populations from the
non-atopic subject with cloned allogeneic T cells confirmed their
capacity for the synthesis of IgE (Table 2c). This response was
strongly enhanced in the presence of exogenous IL-4 for both
IgE and IgG synthesis.
Reactivity pattern of specific IgE to immunoblots of D. farinae
Autoradiographs using serum from the allergic donor of clones
DE9 and DE26 showed strong IgE binding to the D. farinae
immunoblots (Fig. 4). A distinct band was evident at 13,000
MW, which corresponds to the Derf II allergen of D. farinae
that has recently been recognized as a major allergen. Fainter
bands were also evident at 26.000 and 29,000 MW, correspond¬
ing to the Derf I and Derf III allergens.
The autoradiographs using serum from the non-atopic clone
donor showed no evidence of specific IgE directed at any of the
determinants of D. farinae, consistent with the lack of allergic
symptoms, negative prick skin tests and negative radioallergo-
sorbent testing (RAST; data not shown).
DISCUSSION
The inability to isolate antigen-specific T cells combined with
the absence of an allergen-dependent in vitro model of antibody
synthesis has restricted the investigation of differences in T-cell
regulation of IgE induction in atopic and non-atopic indi¬
viduals. In this report it is demonstrated that the T-cell
repertoires of an atopic and a normal subject both include cells
capable of recognizing house dust mite allergen, and that
HDM-specific T-cell clones can be isolated from each donor.
Furthermore, differences in the functional activity of these
T-cell clones and polyclonal E+ cells were examined in an in vitro
model of allergen-dependent IgE synthesis.
Analysis of murine T-cell clones suggests that there are two
non-overlapping subsets of CD4+ T cells (Thl and Th2) that
differ in their lymphokine production and functional activities
(Mosmann & Coffman, 1987). The Th2 cells, which produce IL-
4 but not IL-2 or IFN^y, are potent helpers for B cell IgE
synthesis (Howard & Paul, 1983; Coffman et al., 1986).
Therefore, the HDM-specific T-cell clones described here were
analysed for their ability both to produce IL-4. as determined by
dot blot analysis for mRNA. and to support IgE synthesis. The
T-cell clones from the atopic individual differed markedly in
their levels of IL-4 transcripts, whereas no mRNA for IL-4
could be detected in the cloned T cells (DF1) derived from the
non-atopic subject. In contrast, all the clones had detectable
levels of IL-2 transcripts. Thus, the dichotomy of lymphokine
production observed for murine T-cell clones appears not to
apply so broadly to human T-cell clones. From the hetero¬
geneity of T cells as regards their ability to secrete lymphokines
(Del Prete et al.. 1988), caution must be exercised in extrapo¬
lating from the analysis of these clones to the intact T-cell
repertoire of the individuals tested in this study. However, the
functional characteristics observed at the polyclonal T-cell level
would support these observations.
Investigation of the functional activity of the HDM-specific
T-cell clones revealed that clone DE26, with marked IL-4
mRNA levels when co-cultured with autologous E~ cells, and
D. farinae induced IgE synthesis that was enhanced by the
addition of exogenous IL-4. In contrast, clone DE9, also
isolated from the atopic individual but with minimal levels of
IL-4 transcripts, supported IgE synthesis only in the presence of
exogenous IL-4. The T-cell dependence of IgE induction was
demonstrated by the failure of E" cells to synthesize IgE when
cultured with only IL-4 and D. farinae. Similarly, the necessity
for antigen is demonstrated as E* and E" cells co-cultured with
IL-4 alone failed to induce IgE synthesis, and this suggests that
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antigen rather than IL-4 activates the T ceils to provide B-ceil
help. Further support for this is that the T-cell clones are
unresponsive to IL-4 stimulation (data not shown). The obser¬
vation that peripheral E* cells from the atopic individual were
capable of supporting allergen-dependent IgE synthesis implies
that the T-cell clones were not unique cells but representative of
those in the polyclonal population. The relatively low levels of
IgE induced by polyclonal T cells reflects the low numbers of
HDM-immune T cells circulating in peripheral blood (Haivor-
sen, Bosnes & Thorsby, 1986). These findings are consistent with
the concept that B cells from atopic individuals are able to
synthesize IgE when the appropriate T-cell help is provided.
In contrast, both polyclonal and cloned CD4+ T cells
reactive withHDM from the non-allergic subject were unable to
induce allergen-dependent IgE synthesis even following the
addition of exogenous IL-4. The presence and absence of
D.farinae-specific IgE in the sera of the atopic and non-atopic
individuals, respectively, was confirmed by immunoblotting and
autoradiography and suggests that the in vitro findings reflect
the in vivo status of these subjects. The stimulation of B cells
from the non-atopic donor with cloned allogeneic T cells
confirmed their capacity to synthesize IgE. It is well documented
that non-atopic individuals are capable of generating an IgE
response following parasitic infection (Nutman et al., 1985) and
allostimulation (Umetsu et ai., 1985). The failure of done DF1.
or of the peripheral E* ceils from the non-atopic subject, to
induce IgE synthesis cannot be explained solely by its inability
to secrete IL-4 for the addition of exogenous IL-4 did not
overcome the defect. Additional regulatory mechanisms may be
required (Maggi et al., 1988) or there may be a defect in the IL-4
receptor. It has been suggested that the inability of T cells
lacking IL-4 to support IgE synthesis is partly due to the
production of IFN-y (Mosmann & Coffman. 1987; Coffman 8c
Carty, 1986; Snapper 8c Paul, 1987). Nevertheless, in the
presence of anti-IFN-y antibody and IL-4, clone DF1 was
unable to provide appropriate help although marked enhance¬
ment of IgE synthesis was observed under similar culture
conditions with the clone DE9 (data not shown). Furthermore,
the observation that cloned CD4+ HDM-specific T ceils from
the non-atopic individual fail to support IgE synthesis con¬
tradicts the hypothesis that failure of IgE production in non-
allergic subjects results solely from inhibition by regulatory
(CDS'*" suppressor) T cells. Nevertheless, it must be emphasized
that population studies are required to resolve differences
uneqivocally in the regulatory mechanisms of both atopic and
non-atopic individuals in their responses to allergen.
The absence of allergen-triggered IgE in the non-atopic
system may result from the absence of specific B cells which can
act as highly efficient antigen-presenting cells concentrating
antigen via Ig receptors (Lanzavecchia. 1985) which are already
cionally expanded in the atopic individual. Alternatively, the
failure to synthesize IgE could be due to a defect in isotype
switching (Cebra, Komisar 8c Schweitzer. 1984; Radbruch et al..
1986; Gearhart. Sigai 8c Klinman. 1975) in the non-atopic
subject. However, the induction of IgE synthesis by allostimuia-
tion makes this explanation unlikely. Interestingly, both sub¬
jects were able to synthesize IgG in response to D. farinae
stimulation.
If the T-cell clones studied here recognize different deter¬
minants within the allergen and the T-cell recognition of a
particular epitope within a protein can influence immune
function (Adorini et al., 1977) then this could also offer an
explanation for the inability of DF1 to induce IgE synthesis.
This is supported by the observation that only the peripheral
T cells ofHDM allergic subjects respond to affinity-purified Der
p I allergen (Rawle et al.. 1984). Furthermore, as T-cell antigen
recognition depends upon the binding of peptide antigen to
MHC proteins, the hapiotvpe of the individuals will influence
the epitopes recognized and the immune response induced
(Rothbard et al., 1988). Indeed, this is supported by the
observation that immune responsiveness to Amb a VI in allergic
individuals, as assessed by the presence of specific IgE in the
serum, is HLA-DR5 associated (Marsh et al., 1987).
The experimental model described here has allowed analysis
of qualitative differences in helper activity for allergen-depen¬
dent in vitro IgE synthesis mediated by Dermatophagoides
spp.-specific polyclonal and monoclonal T cells derived from an
atopic and a non-atopic individual. Knowledge ofmechanisms
involved in such IgE regulation is required to facilitate the
development of effective therapeutic regimens for allergic
diseases.
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ABSTRACT Sensitivity to house dust mite antigens in
atopic individuals is a.major cause of allergic diseases, ranging
from asthma to rhinitis and dermatitis. We have studied the
T-cell receptor (TCR) usage of house-dust-mite-specific CD4-
T-cell clones isolated from an atopic individual, by using the
anchored polymerase chain reaction, and have analyzed the
peripheral TCR repertoire of the same individual. Several
T-cell clones had identical TCRs at the sequence level, despite
the fact that they had been independently isolated, in some
cases, in different years. These data suggest the presence in vivo
of long-lived T-cell clones. We have also shown that junctional
sequences identical to these clones are present in peripheral
blood T cells taken 6 years after the isolation of the T-cell
clones. The analysis of TCR genes used by the panel of clones
reveals oiigoclonality, with the variable (V) region gene seg¬
ments Va8 and V/33 being dominant, although there is minimal
conservation of junctional sequences. The results have impli¬
cations for understanding the TCR recognition of an environ¬
mental aeroallergen and the life span of T-cell clones in vivo
during a chronic immune response.
The production of specific IgE by atopic individuals after
exposure to common environmental aeroallergens represents
an aberrant and potentially pathogenic immune response.
One-third of the population is atopic, whereas allergic dis¬
eases affect =10% of the population. CD4^ T lymphocytes
play a central role in the regulation of IgE production (1, 2).
Human house-dust-mite (HDM)-specific CD4* T-cell clones
isolated from atopic individuals show an "interieukin (IL)
4-dominant" (Th2) functional phenotype (3, 4) and promote
specific IgE synthesis in vitro from autologous B cells (3). In
contrast. HDM-specific T-cell clones from nonatopic indi¬
viduals express an "interferon y-dominant" (Thl) phenotype
and fail to support IgE production in vitro. The two major
species of HDM, Dermatophagoides pteronyssinus and Der-
matophagoides farinae. produce ubiquitous allergens that
are derived from the fecal pellets and bodies of the mites.
There are at least fourmajor groups ofHDM antigens (groups
I—IV). The cloning and sequencing of some of these allergens
(5) have facilitated the study of their major T-ceil epitopes:
however, to our knowledge, the T-cell receptor (TCR) gene
segments that recognize these antigens have not been previ¬
ously investigated.
The TCR a/3 heterodimer confers antigen specificity
through the use of different variable [a chain V region (Va)
and /3 chain V region (V/3)J, diversity (D/3), and joining (Ja
and J/3) gene segments that undergo somatic rearrangement
during thymocyte development (6). The insertion or deletion
ofjunctional nucleotides creates further diversity (forreviexv,
see ref. 7). Studies of TCRs recognizing defined peptide-
major histocompatibility complex (MHC) complexes have
The pubiicauon costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
shown restriction of V gene usage and/or conservation of
junctional sequences (8-10). Other groups have demon¬
strated oligocionality of V gene usage by T cells isolated
directly from a disease site, where the antigen specificity is
unknown (11. 12). There have been few detailed studies of
TCR sequences from human -T cells whose central role in a
chronic immune response is well documented and, to our
knowledge, no such previous studies in the field of allergy.
We have analyzed the TCR sequences of a panel of
HDM-specific T-cell clones from an individual with perennial
rhinitis, using the anchored PCR. ! These clones are hetero¬
geneous in both antigen and HLA class II restriction speci¬
ficities. yet analysis of TCR gene usage indicates limited
diversity. The unexpected finding of identical TCR se¬
quences in clones isolated in different years led us to screen
peripheral blood lymphocytes (PBLs) isolated 6 years later
for the same junctional sequences.
MATERIALS AND METHODS
.Antigens. Lyophilized unfractionated extracts of D. pter¬
onyssinus and D. farinae HDM were generously provided by
Bencard (Brentford, Middlesex, U.K.) and H. Lowenstein.
(ALK Laboratories, Copenhagen).
PBL and T-Cell Clones. PBLs were isolated by Ficoll
density gradient centrifugation. HDM-specific T-cell clones
were isolated from an atopic donor with perennial rhinitis as
described (13). Serological typing showed the haplotvpe of
this donor to be A2. 24(9); B50(21), 27; DR11(5), 7; DR52. 53;
and DQ2, 7. Briefly, PBLs were stimulated for 7 days with
unfractionated D. farinae extract, and activated T cells were
then cloned by limiting dilution (0.3 cells per well) in the
presence of specific antigen, irradiated autologous PBLs as
accessory cells, and 1L-2. To determine MHC restriction
specificity, T-cell clones (1 X 10s ceils per ml) were stimu¬
lated with HDM (1-30 ,u.g/ml) in the presence of an equal
number of irradiated (2500 rads: 1 rad = 0.01 Gy) autologous
PBLs or mitomycin C-treated murine fibroblasts expressing
HLA-D region gene products as antigen-presenting cells.
Murine fibroblasts (DAP3), transfected with the following
HLA-D region genes, were used; DRBl'0101 (from J. Trows-
dale. ICRF). DRBI'1201 and DRB4*0101 (from S. Rosen-
Bronson. Georgetown University, Washington, DC), and
DRB3*0101 and DRB3*020I (from B. Mach. University of
Geneva. Geneva). .After a 60-hr incubation, the cultures were
pulse-labeied with [3H]thymidine (1 pX2i per well: 1 Ci = 37
GBq; Amersham) and harvested 8-16 hr later. Proliferation
Abbreviations: TCR. T-cell receptor: V, variable: D, diversity: C.
constant: J. joining; IL. interieukin: MHC. major histocompaubiiitv
complex: PBL. peripheral blood lymphocyte: V/3. Ca, etc.. 0 chain
V region, a chain C region, etc.; HDM. house dust mite.
To whom reprint requests should be addressed.
liThe sequences reported in this paper have been deposited in the
GenBank data base (accession nos. Z22965-7 and Z23039-47).
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as correlated with [3H]thymidine incorporation was deter¬
mined by liquid scintillation spectroscopy.
Isolation of RNA, cDNA Synthesis, and PCR. Total RNA
was isolated from T-cell clones and PBLs by the acid
guanidinium thiocyanate/phenol method (14). Total RNA (5
qg) was used in first-strand cDNA synthesis, using a dT(i2_i8)
primer and avian myeloblastosis virus reverse transcriptase.
The products were precipitated three times using 2 M am¬
monium acetate and 3 vol of ethanol and then tailed with
dGTP by using terminal deoxynucleotidyltransferase. Five
percent of the cDNA product was used as template in the
PCR with a 5' polydeoxycytosine primer (5'-CTATCTA-
GAGAGCTCGCGGCCGCCCCCCCCCCCCC) and a 3'
primer for the /3 chain constant region (C/3) (5'-CGCGAAT-
TCAGATCTCTGCTTCTGATG), or the a chain constant
region (Co) (5'-TGACCGCAGTCGACAGACTTGTCAC-
TGGATT). Reaction conditions were as follows: one cycle of
94°C for 5 min. 55°C for 1 min, and 72°C for 5 min, followed
by 29 cycles of 94°C for 1 min, 55°C for 1 min. and 72°C for
2 min, with a final extension period of 10 min. These reactions
produced specific products of 600-650 bp.
Cloning and Sequencing of Amplified TCR Gene Products.
After treatment with proteinase K. the amplified products
were digested with Not I and Bgl II (TCR/3 chain products)
or Not I and Sal I (TCRa chain products) and cloned into a
modified form of the M13mpl8 bacteriophage vector (kindly
supplied-by P. Moss and J. Bell, Oxford). DNA sequencing
was by the dideoxynucleotide chain-termination method (15).
usingT7 DNA polymerase. ForT-cell clones, between lOand
20 M13 clones from each amplification were sequenced.
From the products ofPBL cDNA amplification. 50 TCRa and
50 TCR/3 in-frame sequences were determined and assigned
to previously published V gene families (7, 16-23). Out-of-
frame or aberrant rearrangements were not included in the 50
sequences but were noted.
Oligonucleotide Probing of PBL Transcripts. For the
screening of PBLs for TCR sequences that were identical to
those of the T-cell clones, venous blood was taken 6 years
after the original cloning work, and cDNA was prepared.
PCR was performed using the 3' C/3 primer as above and a 5'
V/3 primer for V/321 (5'-TGCTGGGCGGCCGCCTGTC-
TCCTGGGAG1 or V/36 (5'-GGATGTAGAGCTCAGGTGT-
GATCCAATTTCAG) families with conditions as follows:
94°C for 5 min, followed by 29 cycles of 94°C for 1 min, 63°C
for 1 min. and 72°C for 2 min. PCR products were digested,
cloned into modified M13mpl8. and transferred to Hy-
bond-N- nylon filters. Oligonucleotides were labeled using
T4 polynucleotide kinase and [y-32P]ATP (5000 Ci/'mmol.
Amersham). Filters were probed with oligonucleotides com¬
plementary to the N region of the clones of interest. (DH15N.
5'-CTCTCCTCGACTGCTCCCGCTAG; DD11N, 5'-GGC-
TGGTTTCCCCCCCTATCTAA). and internal V/3-specific
oligonucleotides (V/36.7a, 5'tGAGCTCAGGTGTGATC-
CAATTTCA; V/3 21.5. 5'-TGTGGCTTTTTGGTG-
CAATCCTAT). Membranes were prehybridized in 6x stan¬
dard saline citrate (SSC)/5x Denhardt's solution/0.1% SDS
and hybridized at 58°C for 16 hr. They were then washed at
45°C in 3x SSC/0.1% SDS for 10 min before exposure to
x-ray film for 4 hr at —70°C. Positive plaques were picked and
the DNA sequences of their inserts were determined.
RESULTS
Recognition Patterns of T-Cell Clones. The antigen speci¬
ficity of the panel of 10 T-ceil clones was examined using D.
farinae, the inducing antigen, and a closely related HDM
species. D. pteronyssinus. Six of the clones were species
specific to D. farinae, and the remaining T-cell clones were
cross-reactive on D. farinae and D. pteronyssinus (Table 1).
Further analysis of these cross-reactive clones showed that
Table 1. Antigen specificity and MHC restriction of
HDM-induced T-cell clones
Proliferauon to
Clone D. farinae D. pteronyssinus MHC restriction
DE41 DR52
DE47 DR52




DE5 + DR53 •




they were specific for the group I allergen (data not shown).
The MHC class II restriction specificities of the T-cell clones,
as determined using transfected murine fibroblasts express¬
ing HLA-D region gene products, are shown in Table 1.
TCRa and TCR/3 Gene Rearrangements in T-Cell Clones.
The Va and V/3 regions used by the 10 T-cell clones analyzed
are summarized in Table 2. The nucleotide and predicted
protein sequences spanning the junctional V(D)J regions of
the TCRa and TCR/3 chains are shown in Fig. 1. Only one
in-frame TCR/3 rearrangement was detected in each of the
T-cell clones. However, in several T-cell clones, two distinct
in-frame TCRa sequences were detected. In each case, one
TCRa transcript was always found at a much higher fre¬
quency than the other in the PCR amplification products.
Therefore, it is most probable that the products of the major
TCRa transcript are expressed in association with the TCR/3
chain, at the cell surfaee. Six T-cell clones utilized unique
TCR sequences, whereas four clones were found to be
identical at the sequence level (including the sequence across
the VDJ or VJ junctions) to others within the panel. Thus,
DE12, DE41, and DE47 were identical to DD11, and DE9 was
identical to DH15, although all clones had been isolated
separately, and clones with different letters (DD, DE, or DH)
originated from different blood samples. Specifically, clone
DD11 was established in the year prior to the DE clones,
whereas DE9 and DH15 were isolated 10 months apart.
Oligoclonalitv of V Gene Usage. A restricted number of
TCR V genes were used by the panel ofT-cell clones. Three
clones. DH12, DE26, and DE49, used V/33.1. whereas mem¬
bers of the Va8 family were used by three clones. DD11 (itself
identical to three other clones), DH12. and DH15 (itself
identical to one other clone) (Table 2). The V/3 sequence of
DD11 (and DE12. DE41. and DE47) is identical at the protein
level to the cDNA clone VblWlO (22), where it is named
V/321.5. and differs by only 1 nt. which is silent at the protein
level, from a sequence (cDNA clone IGRbOl) classified
Table 2. Summary of TCR V gene segments used by the panel
of T-cell clones
TCR/3 TCRa
Clone(s) V D J C V J
DE49 3.1 1 1.2 1 15.1 AB19
DE26 3.1 2 2.5 2 1.2 JaG
DH12 3.1 1 1.1 1 8.2 IGRJa04
DD11. DE12 21.5 1 1.5 1 8.1 AB22
DE41. DE47
DH15. DE9 6.7a t 2 7 2 8.1 JaC
DE5 9.1 1 1.4 1 V55 JaN
TCR a and /3 sequences were assigned according to previously
described families, by using refs. 7. 16. 18. 21. and 22 for TCR/3
chains and refs. 7. 17. 20. 24, and 25 for TCRa chains.




Y F C A
DE26 TAC7TCTGT GTTGTGAGTCACCTTCATGGCTCTJ
Y F C VVSDLHGSS!
GTTGCGGC7CGAGGCTTC
V G A a G F
TACAAGAACACAGGC7TTCAG
Y K W T G F Q
TCGCCCAGGGGTTCTGCAAGG















N I Q N
b












L Y G A t
TTATTCAAliCCGfiffTAC
L P N S G Y
TTAGTTGAACGCGTC
X. V K R V
TTAGATAGGGGGGGA















E D X, N
GAGGACCTGAAC
GAGGACCTGAAA
Fig. 1. Sequence analysis of HDM-reactive T-cell clones. DNA sequences encoding TCRa: (a) and TCR/3 (b) chains spanning the junctional
regions are shown. Predicted amino acid sequences are also given. Spaces have been introduced to allow alignment of conserved sequences.
The nucleotides contributed by germ-line D/3 sequences are underlined. Those T-cell clones with identical junctional sequences (i.e.. DE9.
identical to DH15; DE12, DE41, and DE47. all identical to DD11) are not shown.
within the V/321 family (19). The Va segment of DE5 is
classified as a V<5 gene (17) but has rearranged to a Ja and the
Ca segment. This phenomenon is now weil recognized (26.
27) and has been estimated to occur in =»1% of ail productive
TCRa rearrangements (23). Howevef, we believe this to be
the first demonstration of the use of V55 in a TCRa chain of
a well-characterized human T-cell clone. There was no
detectable conserved motif in the V(D)J junctional region of
either the TCRa: or TCR/3 chains, although four of the six
TCR/3 chains have a leucine residue at position 96 (28). the
first coded for by N region nucleotides.
Screening of PBLs for Persistent Clones. To study the
possible in vivo life span ofT-cell clones that appear to persist
in this chronic response, venous blood was taken 6 years after
the original isolation of these clones. cDNA was prepared
and screened for the TCR/3 sequences of interest by using a
V/3-specific family PCR and oligonucleotide probing. In both
cases, sequences identical to the VDJ region of the clones
were demonstrated in full-length in-frame transcripts from
unstimulated PBLs (Fig. 2).
Peripheral Repertoire Studies. The peripheral blood TCR
Va: and V/3 gene usage of the individual from whom .the T-ceil
clones were established was analyzed by anchored PCR. The
repertoire of this individual is shown in Fig. 3. Each of the 50
VaJ or V/3DJ in-frame productive sequences was unique. The
frequency of Va: and V/3 usage was in broad agreement with
previously published repertoire studies, although there is
considerable intenndividual variation (29). Three TCRa:
chains used a V5 gene segment. In addition to the productive
TCR sequences, several sequences could not code for a
functional TCR chain. Thus, 10% of Va and 5% of V/3
rearrangements had no open reading frame for VDJ transla¬
tion. The changes in transiationai reading frame were always
found within the junctional regions, consistent with out-of-
frame rearrangements, rather than errors in the PCR ampli¬
fication. In addition. 5% of both TCRa and TCR/3 transcripts
contained oniy D and/or J sequences 5' of Ca or C/3 or
contained germ-line sequence 5' to the C gene segments.
PBLs from this individual were also stained with a panel of
antibodies specific for V/3 gene products, within the CD3-,
CD4-, and CD8-positive populations and analyzed by immu¬
nofluorescence. These data were in broad agreement with
those obtained by PCR analysis (data not shown).
DISCUSSION
In this study, designed to investigate the diversity of TCR
usage by CD4"" T ceils in atopic individuals sensitized with
allergens of Dermatophagoides spp. (HDM), we have ob¬
served dominant expression of TCR V/33 and Va8 genes.
Furthermore, the TCR sequence data suggest the presence of
dominant T-cell clones that are long lived in vivo, presumably
maintained by chronic allergen exposure. The analysis of the
HDM-specific CD4^ T-cell response in atopic individuals has
attracted considerable attention (13, 30). The results of such
studies have established that T cells expressing an IL-4-
dominant phenotype are predominantly activated. From our
investigation of the antigen and HLA class II restriction
specificity, it appears that even within one individual the
HDM T-cell response is heterogeneous. Several epitopes
derived from both the group I and II major allergens are
known to be recognized by "'disease-associated" T cells,
namely, those that produce high levels of IL-4 and support
the production of HDM-specific IgE. It has also been dem¬
onstrated that HLA-DRB1, -3, -4, and -5 gene products and
DP class II molecules may restrict recognition of HDM-
derived T-ceil determinants (31).
It is remarkable, therefore, that a considerable degree of
oiigocionaiity was observed in this panel of HDM-reactive
clones. A further unexpected observation was that two













Fig. 2. Autoradiographs from sequencing gels of PBL TCR/3
transcripts showing sequences corresponding to the N-region nucle¬
otides of the DD11 (Left) and DH15 (Right) T-ceil clones (for
comparison of these sequences with those in the-T-cell clones, see
Fig. 1).
groups of T-cell clones used identical TCRs. Each of these
groups must represent cells that originated from one precur¬
sor because the TCR sequences were identical even across
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V/3 and Va repertoire analysis. The percent usage of
V/31-24 (a), Va1-20 (b), and Va21-33 and V51-6 (where a VS has
rearranged to the Ca gene) (c) in 50 PBL TCR or and 50 TCR/3
sequences analyzed is shown.
tical to the TCR/3 N regions in unstimulated PBLs from 6
years later. It is possible that different peripheral blood T
cells possess TCR/3 sequences identical at the nucleotide
level even across the CDR3 junctional region but use differ¬
ent TCRa chains. However, we believe that these data
provide strong evidence for the existence of the same long-
lived clone over 6 years. This is to our knowledge the first
report of such long-lived T-cell clones in vivo. One explana¬
tion for the existence of long-lived clones in this individual is
that disease-specific T cells are constantly stimulated to
divide by chronic exposure to HDM antigens. In this-context,
it is interesting that the CD45RO "memory" T-cell popula¬
tion has been shown to have a short intermitotic time in vivo
(32).
The anchored PCR has now been used by several groups
to study TCR use by T-cell clones and lines and PBLs. It has
the theoretical advantage of being able to amplify all possible
TCR sequences equally, since the two primers are the same
for any transcript. The results of our repertoire study are in
many ways comparable to other studies, although the high
representation of V/33 in PBL transcripts from this individual
was unusual. In other reports, V/33 usage is generally be¬
tween 1 and 6% of TCR/3 in PBLs (ref. 29 and L.R.W.,
unpublished observations). Many factors could account for
this, such as MHC or other genetic differences and environ¬
mental influences, all of which will have affected thymic
selection.
The potential to inhibit allergic inflammation using com¬
ponents of specific antigen is the underlying goal of allergen-
based desensitization. There is evidence to suggest the pres¬
ence of dominant antigenic regions in the major allergens of
HDM, but overall both the array of epitopes recognized and
the number of restriction elements used in the T-cell response
of atopic individuals are diverse. Therefore, while it has been
reported that the administration of immunodominant T-cell
epitopes, as peptides, in vivo can induce antigen-specific
nonresponsiveness (33), peptide-based hyposensitization
may be difficult to achieve for allergic responses to HDM.
Furthermore, in some of the autoimmune diseases, the spec¬
ificity of the "disease-associated" T-cell repertoire may shift
as illustrated in murine experimental allergic encephalomy¬
elitis (34). During the induction phase of disease, the T-cell
response is directed toward an immunodominant NH,-
terminal region of myelin basic protein, but as the disease
becomes chronic, additional determinants that are cryptic
after the initial immunization then become immunogenic (34).
From TCR sequence analysis of cloned T cells and PBLs.
we suggest that the in vivo T-cell response to HDM is
dominated by, and limited to. a small number of long-lived
T-cell clones, which use a restricted number of TCR gene
segments. Therefore, even if responses to minor T-cell de¬
terminants are retained, inactivation of the dominant HDM-
reactive T cells might allow a decrease in clinical symptoms.
In the experimental allergic encephalomyelitis model, it has
been reported that the "pathogenic" T cells predominantly
express the V/38* TCR and immunization with CDR2 pep¬
tides derived from V/38 prevents disease (35). This would
support the potential application of TCR-based therapy as an
alternative approach for regulating HDM allergic immune
responses.
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Analysis of human T call responses to the
group II allergen of Dermatophagofdes
species: Localization of major antigenic sites
Robyn EL.O'Hehir, MD, PhD,* Adrierine Varhoef, MSc,*
Elisabeth Panagiotopoulou, MD," Sanjay Keswani, BSc,"
John D. Haybail, BSc,* Wayne R. Thomas, PhD," and
Jonathan R. Lamb, PhD*
London,- England, and Perth, Western Australia
Background: IgE antibodies reactive with the group IT allergens of Dermatophagoides species
(house dust mite [HDM]) are amajor component of the allergic immune response in
HDM-allergic atopic individuals.
Methods: Here we demonstrate, with the use of overlapping synthetic peptides of the group II
allergen ofDermatophagoides pteronyssinus fDer p IT), that polyclonal T ceils isolated from
the majority of atopic HDM-allergic individuals and healthy nonatopic control subjects respond
to Der p II and that T-cell epitopes are present in ail regions of the protein.
Results: From comparison ofpeptidc-specific T-cell proliferation in both groups of individuals,
it appears that together peptides 61-36 and 78-104 are the most frequently recognized (16 of
18 individuals). We also observed that nine of the 18 individuals responded to T-cell epitopes
in the region 11-50, and with Der p ll-reactive T-ceil clones, three distinct T-ceil epitopes were
mapped within the sequence 11-35. Also, with the use of T-ceil clones, two additional epitopes
were'identified at residues 81-96 and 91-101.
Conclusions: These results suggest that T-cell epitopes located in these regions (11-50 and
61-104) are immunodominant. The value of this information in the potential application of
Der p II peptides to desensitize HDM allergic responses is discussed. (JAllergy Cun Immunol
1993;92:105-13.)
^ Key words: Peptides, T cells, Dermatophagoides species, house dust mite, Derp IT, densensithntion
In approximately 15% of the population,1 T-ceil
recognition of proteins derived from common
environmental aeroallergens may result in both
the induction of specific IgE synthesis and the
activation of polymorphonuclear granulocytes.
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Together these two effector pathways contribute
to the allergic immune response.2"3 The clinical
symptoms that result from the activation of these
effector pathways range from extrinsic asthma
and allergic rhinitis to atopic dermatitis. Evidence
accumulated from clinical studies has impli¬
cated proteins from the house dust mite (HDM)
Dermatophagoides species (D. pteronyssinus and
D. farinae) as a primary cause of respiratory
allergy.^ 7
Multiple antigens have been identified in ex¬
tracts ofHDM that bind IgE antibodies present in
the sera of HDM-allergic patients3; nevertheless,
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p II 1-15 DQVDVKDCANHE I KK
p II 1-20 DQ VD VKD C ANH E I K K V L V P G
p II 11-23 H E I KK VL V PGCHG S E
p H 11-35 HE I KKVLVPGCHGS EPC I IHRGKPF
p n 21-35 CHGSEPCIIHRGKPF
p 11 22-35 HGSEPCI IHRGKPF
p II 22-50 HGSEPCI I HRGKPFQLEAVFEAVQNTKT A
p II 31-47 R G KP F OL E A VF E A VQNT
p II 36-60 RGKP F QLEAVFE AVQNTKT AKI El KASI DG
p II 41-55 F E A VQNTKT AKI E I K
p n 51-65 KI EI KASI DGLEVDV
p H 51-77 KI E I KAS 1 DGL E VD V
p II 61-75 L E VD V
p 11 61-86 L E V D V
(p E 51-77) PGIDPNACHYMK
(p E 61-75) PGIDPNaCHY
(p n 61-86) PGIDPNACHYMKCPLVKGQQY
p 11 71-86 N ACH YMKC P L VKGQQ Y
p II 81-96 VKGQQ YD I K YTWN V P K
p H 78-104 CPLVKGQQYDI K YTWN VPKIAPKSENV
p II 91-105 TWN V P K I AP KS E N V V
p II 87-112 D I K YTWN VPKIAPKSENVVVTVKVMG
p D 101-115 S E N V V VT VK VMGD DG
p E 105-129 VVVTVKVMGDDGVLACAI ATHAKI RD
p E 111-129 MGDDGVLACAI ATHAKI RD
FIG. 1. Amino acid sequences of overlapping synrnetic peptides derived from Der p II. Residues
are indicated with the single letter code.
the major component of the humoral response
appears to be directed against four major allergic
proteins (groups I to IV).8"12 Initially, although
interest focused on the analysis of group I aller¬
gen-specific IgE. the importance of the group II
allergens has now been substantiated by several
independent studies, and it appears that the anti-
group II (Der p II) reactive antibodies may ac¬
count for between 40% and 88% of the HDM-
specific IgE antibody response in HDM-allergic
individuals.8' 11 Indeed in one report it was dem¬
onstrated that in the serum of 92% of the HDM-
allergic patients investigated, IgE antibodies reac¬
tive with Der f II could be detected, whereas
anti-Der/I and Der fill antibodies were present
in the sera of only 78% and 16% of the patients,
respectively.10
It is well established that CD4- T-cell recog¬
nition of allergen is central to the induction of
specific allergic immune responses.2'3 However,
for many aeroallergens, including HDM, detailed
information on the localization and frequency of
T-cell epitopes within these proteins is limited.
The identification of dominant T-cell determi¬
nants in specific allergens is relevant to under¬
standing the functional role of antigen-specific T
cells in the development of allergic inflammation
and a critical initial step in the deveiopment of
allergen-based immunotherapy.13, 14 There is evi¬
dence indicating that all of the individual group-
specific proteins of HDM are antigenic for T cells
at the polyclonal level.4 However, on the basis of
the initial serologic data, analysis of the antigen
specificity of the HDM-reactive T cells has fo¬
cused primarily on the response of atopic individ¬
uals to group I allergen prepared By electrophore¬
sis and gel filtration.13 Similar to antibody re¬
sponses. it is now apparent from specificity studies
with T-cell clones,16 and more recently polyclonal
populations.17 that a major component of the
peripheral T-cell repertoire is reactive with the
group II allergens. The complementary DNA se¬
quences that encode both the group I and II
genes have been cloned, and from the nucleotide
sequence, the primary amino acid sequence has
been derived.18, 19 Therefore it is now possible to
investigate the T-cell epitopes in these proteins
with the use of truncated recombinant proteins
and synthetic peptides.
In this report to identify the T-cell epitopes
present in Der p II. we synthesized overlapping
peptides that cover the entire length of the mol¬
ecule and screened them for their ability to in¬
duce proliferation of polyclonal T cells isolated
from both HDM-allergic atopic individuals and
normal healthy nonatopic control subjects. Using
this anproach, we demonstrate that both atopic
and nonatopic individuals respond to Der p II.
The proliferative responses of polyclonal T-cell
populations indicate that, although T-cell
epitopes are present throughout the protein, the
sequences 11-50 and 61-104 contain the dominant
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TABLE I. The polyclonal proliferative response of peripheral blood T ceils to Der p II peptides
Subject Medium 1-20 11-35 22-50 36-SO 51-77 61-88 78-104 87-112 105-129 HDM
A1
■
1.6 5.6 13.9 12.7 7.0 3.8 54.6 35.7 173 7.0 613
AZ 122 2.7 2.5 8.6 1.8 13 8.7 5.7 Z7 23 37.7
A3 1.0 222 3.2 3S 13.4 2.0 10.0 5.9 53 22.9 253
A4 . 0.4 0.6 L2 L3 0.6 0.7 L0 73 83 LZ 11.6
A5
'
3.0 5.0 6.8 43 43 4.2 8.1 3.8 4.1 4.7 333
A6 ID. 3.7 6.0 2.7 ZS 2.8 zs 15.3 Z4 3.0 19.1
A7 0.9 0.9
. 1.5 1.6 0.9 13 5.9 1.7 13 Z2 72.7
A8 0.4 0.5 LI L0 03 0.6 0.7 0.8 0.4 1.4 60.4
A9 1_3 2.0 2.7 3.0 23 3.4-
'
ZS 3.7 Z4 13 362)
NA1 2.1 4.4 4.8 93 23 2.4 2Z0 14.6 ZS 53 713
NA2 023 0.6 0.6 03 0.3 43 4.0 3.1 03 03 6.1
NA3 1.0 4.0 3.5 8.0 103 10.9 93 133 321 3.8 13.9
NA4 0.3 0.3 0.4 0.6 03 2.6 33 LI 0.4
.
43 83
NA5 1.2 1.6 33 2.1 4.0 2.0 ZS 5.6 Z6 1.7 563
NA6 0.4 0.5 0.6 03 03 1.0 1'3 1.0 1.1 0.8 18.4
NA7 0.7 0.7' 1.0 0.7 0.7 0.7 0.7 0.7 0.8 1.0 11.1
NA8 0.6 0.7 0.7 0.7 0.8 0.7 0.8 13 0.6 0.7 31.0
NA9 1.4 1.4 3.1 1.4 1.4 1.4 33
'
2.1 1.4 1.7 113
PBMCs from atopic (A1 to A9) and nonatooic (NA1 to NA9) individuals were stimuiated with the Der p II peptides over a
concentration range of 0.1 to 50 y.g/ml in 7-day cultures. The maximal response for each peptide is given as counts per minute
x 10~3 and compared with the control response of PBMGs in medium alone. SEM was less than 25% in ail experiments.
Responses of greater than or equal to 2_5 times background are in boldface type.
T-cell epitopes. From the analysis of HDM-reac-
tive T-cell clones a cluster of three distinct T-cell
epitopes was identified within residues 11-35, and




Lyophilized unfractionated extracts of D. pteronyssi-
nus were generously provided by Bencard (Brentford.
Middlesex. England). Recombinant Derp H was cloned
and expressed as previously described." Peptides that
covered the entire Der p II molecule (Fig. 1) were
synthesized with solid-phase techniques on an Applied
Biosystems (Foster City, Calif.) peptide synthesizer as
described previously.20 The purity of the peptides as
determined by high-performance liquid chromatogra¬
phy was greater than 90%.
Characterization of patients
Atopic status with HDM allergy was defined by the
presence of positive prick skin test results"1 (>3 mm
diameter wheal) to D. pteronyssinus and D. farinae
extracts in the presence of a negative saline controL
Nine HDM-ailergic atopic subjects, aged 25 to 40 years,
were included in the study. All of these individuals had
clinical symptoms of HDM allergy (perennial rhinitis
and/or asthma) and had grade IH or IV serum-specific
IgE for HDM as measured by RAST.
Nonatopic status was defined in a subject who was
free of symptoms by the absence of positive skin prick
test results to a panel of common environmental aller¬
gens (D. pceronyssinus, D. farinae, mixed grass pollen,
birch pollen. Aspergillus fumigams. Cladosporium her-
barum, plane tree, nettle) in the presence of a positive
wheal response to histamine hydrochloride (lmg/ml) of
a 3 mm and a negative response to a saline control.
Nine aonatopic individuals participated in the study.
All had normal total IgE and negative specific IgE to
the skin test panel of allergens as-measured by RAST.
No patients were receiving oral corticosteroid therapy
or had previously undergone allergen-specific desensi-
tization.
Isolation of human HDM-raactive clones
Cloned T cells reactive with Der p II peptides were
isolated from HDM-allergic subjects by limiting dilu¬
tion cloning from established T-cell lines as published
elsewhere. "■ 12 Briefly, peripheral blood mononuclear
cells (PBMCs: lO'/ml) were stimulated with an optimal
concentration of recombinant Derp II (10 p.g/ml) for 7
days in RPMI-1640 medium supplemented with 2
mmol/L L-glutamine, 100 IU/mi penicillin/streptomycin
(Gibco, Life Technologies. Paisley, Scotland) and 5%
screened, inactivated human A-t- serum (Blood Trans¬
fusion Service, Edgeware. England). Lymphobiasts en¬
riched on Ficoll-Paque (Pharmacia Biotech Ltd., Mil¬
ton Keynes, England) were established as a long-term
line in the presence of irradiated autologous PBMCs
(5 x lCP/ml: 2500 rad), recombinant Derp II (20 tag/ml)
and interieukin-2 (IL-2), (10% vol/vol; Lympnocuit T,
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FIG. 2. The effect of peptide concentration on polyclonal
T-cell proliferation to Der p ll-derived peptides. Polyclonal
T cells from an atopic individual were stimulated with
different concentrations of the Der p II peptides 1-20 (o),
11-35 (•), 36-60 (□) and 61-86 (■) and proliferation (in
counts per minute) was measured (A). In B the dose-
deoendent proliferation of T cells from a nonatopic indi¬
vidual to peptides 22-50 (o), 61-86 (•), 78-104 (□), ana
87-112 (■) was measured.
Biotest Folex. Frankfurt, Germany) and subsequently
cloned by limiting dilution. For cloning, viabie cells (0.3
cells/well) were resuspended in supplemented medium
and plated together with irradiated autologous PBMCs,
Der p II, and IL-2. After 7 days, growing clones were
expanded and maintained with IL-2 every 3 to 4 days,
and irradiated autologous PBMCs and antigen were
given every 7 days. Before use in proliferation assays,
the clones were rested for 7 to 8 days after the last
addition of antigen-presenting ceils (APCs) and an¬
tigen.
Proliferation assays
Polyclonal T-cell responses. Uniractionateri
PBMCs (2.5 x 10!/ml i were cultured with unfraction-
ated D. pteronyssinus extract (20 u-g/mi), recombinant
Der p II (10 (xg/ml). and Der p II peptides (0.1 to 50
Ug/ml). After 6 days' incubation, the cultures were
pulsed with tritiated methyl thymidine (1 pCi/well.
Amersham International Inc.. Amersham, England)
and harvested 8 to 16 hours later. Proliferation as
correlated with tritiated methyl thymidine incorpora¬
tion was determined by liquid scintillation spectros¬
copy. The results were expressed as mean counts per
mmute for triplicate cultures with SEM less than 25%
for all experiments with PBMCs.
Clonal T-cell responses. Cloned T cells (105
cells/ml) were stimulated with recombinant Derp II (10
Ug/ml) or Der p II peptides (0.01 to 30 uiVml) in the
presence of an equal number of irradiated (2500 rad)
autologous PBMCs as APCs. After 60 hours of incuba¬
tion, tritiated methyl thymidine was added to the cul¬
tures for 8 to 16 hours, and they were then harvested as
described for the polyclonal T-cell proliferation assays.
The results are expressed as mean counts per minute
for triplicate cultures with SEM less than 15% for all
experiments with cloned T cells. All experiments were
repeated with similar results on at least ihree separate
occasions.
RESULTS
Response of polyclonal T cells to
Der p II peptides
To identify those regions of Der p'll in which
the major epitopes recognized by T ceils are
located, proliferative responses of PBMCs to un-
fractionated HDM extract and overlapping pep¬
tides derived from Der p II were compared for
nine HDM-allergic atopic (donors Al to A9.
Table I) and nine nonatopic (donors NA1 to
NA9, Table I) individuals. T cells from both
groups of subjects proliferated to HDM extract,
with responses ranging from 6.1 to 72.7 x 103
cpm, and in general, the magnitude of the re¬
sponse of atopic subjects exceeded that of the
nonatopic subjects. The background proliferation
of unstimulated T cells cultured m medium alone
was in the range of 0.3 to 3 x 103 cpm (Tabie I).
Comparison of the maximal T-cell response to
each Der p II peptide with the medium control,
for the panel of individuals investigated here,
revealed that each peptide induced proliferation
in at least one donor. Furthermore, when we used
the criterion that proliferation equal to or greater
than 2.5 times the background response of cells
cultured in medium alone constitutes a positive
response (highlighted in boldface type in Table I),
the majority of subjects responded to one or more
of the peptides. An exception was donor NA7
who failed to show a proliferative response to any
of the peptides, despite a proliferative response of
10.3 x 103 cpm to the intact recombinant Derp II
J ALLERGY CLIN IMMUNOL
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FIG. 3. Antigen specificity of Der p ll-reactive T-ceil clones. Cloned T cells from an HQM-atopic
individual were stimulated with Der p II peptides in the presence of APCs. and proliferation was
measured.
protein. The sequence 1-20 was the least antigenic
of the peptides tested, in that for each of the
subjects there were at least two peptides that
stimulated greater proliferation; nevertheless, in
donors Al, A6, and NA3 Der p II residues 1-20
induced stimulation indices of 3.5, 3.1, and 4,
respectively (Table I). T-ceil recognition of the
Der p II peptides varied among individuals, and
no pattern of proliferation that was unique to
either the atopic or the nonatopic groups was
observed (Table I). However, it appeared that
both the atopic and nonatopic groups recognize
predominantly T-ceil determinants located within
the region of 61-104 of Der p II, in that 16 of the
18 individuals had strong responses to peptides
61-86 and/or 78-104. Nine of the 18 subjects also
responded to peptides spanning the region 11-50
(peptides 11-35 and 22-50). The sensitivity of the
polyclonal T ceils to different concentrations of
peptide as illustrated in the dose-response curves
of two individuals, one atopic subject (donor Al;
Fig. 2, A) and one nonatopic subject (donor NA1;
Fig. 2, B) may result from a number of different
effects such as variation in T-cell receptor affini¬
ties (Fig. 2). The induction of T-cell nonrespon-
siveness may account for the reduction in prolif¬
eration observed at higher concentrations of pep¬
tide as observed in the response of donor Al to-
peptide 61-86, for example (Fig. 2, A). The influ¬
ence of peptide concentration on proliferation, as
illustrated in Fig. 2, reinforces the need to assay
peptides over a wide range of concentrations to
determine whether or not the T ceils of a given
individual are reactive. The failure of any one of
the Der p II peptides to induce proliferation in
all individuals indicates that these peptides do
not have the properties of antigen-nonspecific
mitogens.
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FIG. 4. Polyclonal T-cell response to Der p II peptides by
HDM-aliergic atopic individual from whom the T-cell
clones shown in Fig. 3 were derived.
Isolation and characterization of Der p II
reactive T-cell clones
In order to identify those regions of Der p II
that constitute the major sites of T-cell recogni¬
tion, PBMCs from an HDM-allergic atopic indi¬
vidual were stimulated with recombinant Der p II
under optimal conditions and cloned by limiting
dilution. Four of the Der p II-induced T-cell
clones responded to epitopes at the amino termi¬
nal end of the molecule located between residues
11 and 35 (Fig. 3, A to C). Two of the T-cell
clones proliferated to peptides 21-35 and 22-35
(Fig. 3, A and B), whereas one T-cell clone
responded to only peptide 21-35 and not the
sequence 22-35 (Fig. 3, C). The fourth T-cell
clone was reactive with the N-tenninus ofDerp II,
recognizing residues 11-35 but with considerably
reduced proliferation to the peptide 21-35 (Fig.
3, D). An additional T-cell clone that responded
strongly to the peptide containing residues 81-96
but less well to 71-86 was isolated. However, the
ability of both peptides to induce proliferation of
the T-cell clone suggests that the core residues of
the epitope are associated with amino acids 81-86
(Fig. 3, E). In accordance with these results, the
polyclonal T cells of this donor responded to
recombinant Der p II and to the Derp II peptides
11-25 and 21-35, with the dominant response
directed to residues 71-86 (Fig. 4). In contrast,
proliferation to residues 81-96 was more limited
(Fig. 4).
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From the peripheral blood of a second HDM-
aliergic atopic individual, T-cell clones were In¬
duced with recombinant Derp II. Analysis of the
antigen specificity of the cloned T cells isolated
from this atopic subject revealed that they re¬
spond to peptide 91-105 but not to residues 81-96
or 101-115, suggesting that the epitope maps to
residues 91-101 (Fig. 5). At the polyclonal level
the T cells from this donor proliferated strongly to
peptides containing residues 51-77, 61-86, and
78-104 (Fig. 6). Thus the presence of major T-cell
determinants suggested by analysis of the polyclo¬
nal response are reflected at the clonal level.
DISCUSSION
Although initially the major allergenic determi¬
nants were thought to reside in the group I
allergens of HDM, recent analyses of specific
antibody8"12 and T-cell responses16'17 indicate that
immune recognition of the group II allergens is an
equally important component of the allergic re¬
sponse to HDM. In this smdy, designed to inves¬
tigate the specificity of human T-cell responses to
the group II allergen of D. pteronyssinus at the
epitope level, we demonstrate, using overlapping
peptides, the presence of multiple T-cell epitopes
located in all regions of the protein capable of
stimulating T cells from both atopic and non-
atopic individuals. Furthermore, we observed that
the majority of both atopic and nonatopic individ¬
uals examined here respond to T-cell epitopes
located within regions 11-50 and 61-104.
The analysis of the proliferative response of
polyclonal T-cell populations to intact Der p II
expressed as a recombinant protein and synthetic
peptides indicated that components of the T-cell
repertoire of both atopic and nonatopic individ¬
uals are reactive with Der p II, although quanti¬
tatively the responses may differ. One nonatopic
donor, however, although able to recognize the
full-length Der p II molecule, failed to respond to
any of the peptides tested. Differences in the
amino acid sequences of "naturally processed"
T-cell epitopes as compared with the peptides
that were synthesized may account for this obser¬
vation. The findings • reported here support our
previous observations that HDM-reactive T cells
are present in the peripheral T-cell pool of both
atopic and nonatopic individuals.16 In contrast, it
has been reported that peripheral T cells from
nonatopic individuals fail to proliferate to Der p
II,17 as well as Der p I.25' 17 Furthermore, in. the
studies described'here, it appears that the poly¬
clonal T cells from both groups of subjects prolif¬
erate more vigorously to sites located between 61
J ALLERGY CLIN IMMUNOL
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FIG. S. Antigen specificity of Oer p ll-tesctive T-ceil
clones. Cloned T cells from a HDM-atopic individual were
stimulated with Oar p ii peptides in tne presence of APCa.
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FIG. 6. Polyclonal T-cell response to Oar p II peptides by
HDM-allergic atopic individual from whom the T-ceil
clones shown in Rg. 5 were derived.
and 104 than to other sequences in Derp II. The
reason that this region of the protein is immuno¬
dominant has not been denned but may reflect
the presence of peptides capable of binding with
high- affinity to a 'wide range of major histocom¬
patibility complex class II molecules. The majority
of individuals responded to two or more peptides,
and multiple T-cell epitopes appear to be distrib¬
uted throughout the protein, as has been observed
for Der p lp3 with no apparent immunologically
silent regions. Furthermore, no characteristic pat¬
terns of proliferation that ailowed atopic and
nonatopic subjects to be differentiated were ob¬
served, which may reflect differences in the HLA
haplotype of the different individuals studied.
The presence of T-cell epitopes in Derp II was
examined further by analyzing the antigen speci¬
ficity of Der p H-induced T-cell clones isolated
from the peripheral blood of atopic individuals. In
the first of the atopic individuals (whose polyclo¬
nal T ceils responded to residues 11-25, 21-35,
and 71-86), four T-ceil clones that recognize de¬
terminants at the amino terminus of the molecule
were isolated. From the analysis of the fine anti¬
gen specificity of these T-ceil clones, three closely
related epitopes within residues 11-35 were iden¬
tified. Another T-cell clone that was isolated from
the same individual responded to stimulation with
residues 81-96, even though the polyclonal T-ceil
response to this peptide was weak. With overlap¬
ping peptides from this region of Derp II, it was
observed that peptide 71-86, which was immuno¬
dominant at the polyclonal level, did not contain
the optimal T-cell epitope recognized by the
cloned T ceils. For another atopic donor, from
whom Der p El-specific T cells were cloned, their
specificity for residues 97-105 overlapped with
one of the regions identified at the polyclonal
level. However, the most marked proliferative
response of the unfractionated' T cells was to
residues 51-77. In both donors the antigen speci¬
ficity of the T-ceil clones and-the polyclonal re¬
sponse overlapped, indicating that T-cell clones
may provide a valid reflection of the T-ceil rep¬
ertoire as a whole. When synthetic peptides were
used to probe the specificity of Der p II-reactive
IgE. a B-cell epitope in the same region (residues
65-78) of the molecule was mapped.1" Although T
cells and B cells tend to recognize distinct
epitopes within a protein.25 there are instances in
which it has been demonstrated that they over¬
lap.26 However, the majority of the Der p II
peptides failed to bind IgE, which may reflect an
alteration in the conformation of B-ceil sites as
compared with the intact protein.27
The identification of the major T-cell determi¬
nants in allergens has practical applications in the
design of immunotherapeutic agents for clinical
desensitization, and considerable interest has
been directed to the use of peptides for redirect¬
ing23 or downregulating allergic immune re¬
sponses.23 Although we observed that the region
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encompassed by residues 61-104 (peptides 61-86
and 78-104) is recognized by 89% of the individ¬
uals tested in this study, the overall heterogeneity
of the antigen specificity of the Der p II-reactive
T-cell repertoire suggests that peptide-based hy¬
posensitization may be difficult to achieve. This
will be further complicated by the differential
sensitivity of polyclonal T cells to different con¬
centrations of particular peptides. Furthermore,
the region of the protein encompassing residues
61-104 contains an epitope that binds Der p II-
specific IgE.2* and therefore therapy based on
peptides that contain the dominant T-cell
epitopes in this instance may induce adverse re¬
actions in patients with serum antibodies of this
specificity. Even if nonresponsiveness were in¬
duced to dominant epitopes, it is possible that
other minor regions may trigger allergic immune
responses.30 In the murine model of experimental
allergic encephalomyelitis, during the induction
phase of the disease, the T-cell response is di¬
rected toward an immunodominant site at the
amino terminus of myelin basic protein.31 How¬
ever. as the disease becomes chronic, or if enceph¬
alomyelitis is induced with the amino terminal
peptide alone, additional determinants that are
cryptic after the initial immunization then become
immunogenic.32 This suggests that desensitization
with polypeptide fragments of Der p II, in which
the B-cell sites have been silenced, may offer an
alternative approach to inducing nonresponsive¬
ness to Der p II.
We thank Dr. M-C. Kuo of the ImmuLogic Pharma¬
ceutical Corporation in Waltham, Mass., for providing
some of the peptides used in this study.
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Induction of T cell responses to the
invariant chain derived peptide CLIP in mice
immunized with the group 1 allergen of
house dust mite
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Abstract
In this study we demonstrate that immunization of H-2b mice with the allergen Oer p 1 induces
MHC class II restricted T cells that proliferate to residues 15-29 of Der p 1 (p15-29) and to the
murine MHC class ll-associated invariant chain derived peptide (CLIP). T cells from naive H-2° mice
and those immunized with murine CLIP fail to respond to either CLIP or p15-29. T cell lines and
clones reactive with p15-29 strongly proliferate in response to splenic antigen-presenting cells
(APC) from normal H-2b mice but show reduced proliferation to APC from invariant chain deficient
mice. Furthermore, T cells isolated from Der p 1 primed mice and expanded on H-2b spleen cells in
the absence of the p15-29 epitope retained specificity for both p15-29 and CLIP, suggesting that
naturally presented self components can act as mimetic peptides and may maintain T cell memory
to foreign antigens.
Introduction
The group 1 allergen of house dust mite (Dermatophagoides
pteronyssinus. HDM) is a major target of the IgE response in
HDM atopic individuals (1) and allergen-specific CD4' T cells
play a central role in the regulation of allergic inflammatory
responses (e.g. 2,3). From several experimental models there
is evidence to suggest that it is possible, using allergens or
their derivatives, to modulate the function of specific CD4" T
cells (e.g. 4-6). Although a significant proportion of naturally
processed peptides bound to MHC class II molecules are
derived from self antigens (7-10), the peripheral T cell reper¬
toire remains unresponsive to self. Such observations have
generated interest in the potential of certain peptides derived
from self molecules, such as MHC class II, to inhibit T" cell
recognition of foreign antigens (e.g. 11). This prompted us to
investigate the efficacy of a non-immunogenic l-Ab binding
peptide, i.e. the invariant (li) chain derived CLIP peptide, in
down-regulating murine immune responses to HDM allergens,
as an alternative approach to using derivatives of HDM.
Newly synthesized MHC class II a and (5 chains associate
in the endoplasmic reticulum (ER) and form complexes with
the li chain. The li chain molecule contains signal sequences
that guide nascent MHC ciass 11 to the appropriate endosomal
compartment (12.13) and prevents the binding of endogenous
peptides in the ER (14-16). The li chain is removed from the
MHC class II molecule by stepwise proteolysis to allow the
acquisition of peptides. This results in the generation of a
series of nestea CLIP peptides, which are encoded by the
third exon of the li chain gene (17). CLIP peptides have been
eluted from a subset of murine and human class II MHC
molecules, and appear to bind to a marked proportion of the
intracellular pool of MHC class II molecules (7-10,18). CLIP
can bind to MHC class II moiecules in w'frowith similar binding
kinetics to traditional antigenic peptides (19). Furthermore,
the recent resolution of the crystal structure of CLIP-HLA-
DR3 complexes (20) shows that CLIP occupies the antigen
binding groove in a manner almost identical to that of a
peptide antigen. Relatively high levels of CLIP-MHC class II
complexes can be detected on the surface of human B
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lymphoblastoid cell lines (21). However, it remains to be
established whether such complexes reach the cell surface
of normal cells. If they do. it appears that they fail to induce
T cell responses in the periphery either because they are not
present in sufficient density or the peripheral T cell repertoire
is tolerant to them. Consequently; immunizing mice with
murine CLIP has failed to induce T cell responses (22),
whereas specific T cells can be primed in mice with human
CLIP (23).
Mimicry between self and foreign antigens has been mooted
as a potential mechanism for breaking self tolerance leading to
the development of autoimmunity (e.g. 24,25). The observation
that peptide analogues, derived from common human patho¬
gens. can act as molecular mimics for autoreactive human
CD4~ T cell clones specific for myelin basic protein (MBP)
suoports this hypothesis (26). However, the converse may
also hold true, i.e. that peptides derived from self antigens
may have the capacity to activate memory T cells already
primed to foreign antigens. By the variation in.sequence these
self derived peptides may function as partial agonists or
altered T cell ligands. It appears that variants of self peptides
may arise naturally in vivo and thus have the potential to
influence the selection of the repertoire (e.g. 27,28). Changes
in the affinity of TCR-ligand interactions can modify the
effector function of mature T cells, and the state of T cell
differentiation may also influence both quantitative and qualit¬
ative aspects of signals delivered by altered T cell ligands
(29-34).
Here we report that a peptide located in the N-terminus of
Der p 1, p 15-29, shares a high degree of sequence homology
to the CLIP peptide. CD4~ T cells primed in vivo with Der p
1 respond to tne HDM peptide but also to murine CLIP. T cell
responses to CLIP or p15-29 could not be induced by
immunizing with the murine CLIP peptide or with an irrelevant
foreign antigen. The cross-reactivity was further investigated
using oligoclonal T cell lines, T cell clones and hybridomas.
isolated from Der p 1 primed mice, and we demonstrate that
p 15-29-reactive CD4~ T cells can be induced to proliferate,
in the absence of exogenous peptide, by the addition of
increasing numbers of spleen cells from normal H-2" mice.
We propose that CLIP acts as a weak agonist for the Der p
1 -specific T cells through molecular mimicry rather than acting
as an altered T cell ligand. The ability of self peptides to
perpetuate responses to allergen-derived peptides is relevant,
not only in the pathogenesis of allergic inflammation, but also
in the development of immunotherapy.
Methods
Mice and cell lines
C57BL/6J female mice were purchased from Harlan (Chester)
UK at 6-8 weeks of age and maintained under conventional
conditions. C57BL76J mice homozygous or heterozygous for
a disruption of the Invariant chain gene were a kind gift from
Drs D. Mathis and C. Benoist (IGBMC, Strasbourg, France),
and have been described elsewhere (35). The 8W 5147
(TCRaP"'") fusion partner was a kind gift from Dr H. Boomer
(Nuffield Department of Clinical Medicine, Oxford. UK). The
ovalbumin (OVA) 323-339 specific T cell hybridoma BO 17.10
was a kind gift from Dr C. Hauser (Department of Dermatology,
Hospital Cantonal Universitaire, Switzerland).
Immunization
Mice were primed s.c. at the base of the tail with 50 )tg of
antigen in complete Freund's adjuvant (CFA; Sigma, St Louis,
MO). Periaortic and inguinal lymph nodes were collected 8-
10 days post immunization, teased with frosted glass slides
and washed. The single cell suspension was used in prolifera¬
tion assays or for long-term culture.
Antigens and antibodies
Der p 1 protein was affinity purified from spent mite medium
as described previously (36). Peptides were synthesized
by standard solid phase methods, on an ABI 431 peptide
synthesizer (Foster City, CA), using F-moc chemistry. Peptides
were based on the sequences of: Der p 1 (p15-29.
p113-127 and p 111—139), the murine li (murine CLIP residues
82-104), the human li (human CLIP residues 99-122 ) and
the l-AD-restricted OVA peptide 323-339 (37-40).
Culture medium
Cells were cultured in RPMI 1640 supplemented with 5%
FCS, 2 mM L-glutamme, 100 lU/ml penicillin. 100 ng/ml
streptomycin (Gibco, Grand Island, NY) and 50 mM 2-
mercaptoethanol (Sigma, St Louis, MO).
Isolation of long-term Tcell lines, Tcell clones and hybridomas
Lymph node cells from Der p 1 primed mice were cultured
at 3x10s cells/ml with 10 (ig/ml Der p 1 (line F2.2) or p 111—
139 (line F1) in 1.5 ml final volume in 24-well plates (Nunc.
Roskilde, Denmark). T qplls were then re-stimulated several
times in 25 cm2 vented culture flasks (Costar, Cambridge,
MA) every 10-14 days with 5 ng/'ml p 111—139 (F1) or 10 ng/
ml Der p 1 (F2.2) at a 1:30 ratio of T cells to antigen-presenting
cells (APC; C57BU6J spleen cells irradiated with a dose of
2500 rad).
Resting T cells from a Der p 1-specific long-term T cell line
were cloned by limiting dilution with the peptide p 15-29.
5x10s APC/well and 20 ng/ml human recombinant IL-2
(Biogen, Boston, MA). Selected clones were subclonea by
limiting dilution on either p 15-29 or "murine CLIP as above.
Der p 1-specific T cell hybridomas were generated by poly¬
ethylene glycol (Sigma)-induced fusion of Der p 1-specific T
cell clones and lines with the BW 5147 (TCRa/p-i~) fusion
partner and selecting with HAT medium (Sigma).
Proliferation and cytokine assays
Lymph node cells from primed mice were cultured at 2.5X103
cells/well for 72 h. T cell lines or clones were cultured at
2-3X104 cells/well in the presence of 8-10X104 APC [irradi¬
ated 2500 rad or mitomycin C (Sigma)-treated C57BL76J
spleen cells] for 48 h. Cells were cultured in triplicates in
200 qJ meaium/well in round-bottom piates (Nunc. Roskilae,
Denmark), either alone or in the presence of varying doses
of antigen and were pulsed for the last 6 h with 0.5 jj.Ci
[3H]thymidine/well (Amersham Life Sciences). Cells were
harvested onto glass fibre filters and proliferation was deter¬
mined as the incorporation of [3H]thymidine, measured
by a liquid scintillation counter 1205 Betaplate (Wailac).
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Fig. 1. T cells from mice immunized with Der p 1. but not with OVA. resDond to murine CLIP peptide in vitro. Lymph node cells from mice
primed with either (A) Der p 1 or (B) OVA were tested for IL-2 production ano proliferation in response to the indicated antigens. Similar
response profiles are seen with IL-2 production and proliferation. The responses shown are geometric means of IL-2 responses to 5 uM









To measure IL-2 production T cells were cultured as above
and after 24 h incubation 50 )il culture supernatant was
collected. Activation of T cell hybridomas was measured by
culturing 5x104 hybridoma cells in 200 ill of media with APC
and peptide for 20 h and assaying the IL-2 contents of the
supernatants.
IL-2 was measured in culture supernatants using the IL-2-
depenaent cell line CTLL-2. Sriefly, 5000 cells in 50 txl medium
were cultured in the presence of 50,1x1 supernatant for 24 h.
Cells were pulsed for 6 h with 0.5 |xCi [3H]thymidine/well and
proliferation was determined as above.
Results
Immunization with Derp 1 induces polyclonal T cell responses
to an ammo terminal Der p 1 epitope (residues 15-29) ana
to murine CUP
Prior to investigating the efficacy of CLIP in the modulation of
HDM-specific T cell responses, we assessed the ability of
this peptide to induce polyclonal T cell responses in H-2°
mice primed with Der p 1. Regional lymph node cells from
mice immunized with Der p 1 were tested in vitro with
increasing concentrations of HDM-derived antigens or murine
CLIP. T cells respond in a dose-dependent manner to intact
Der p 1. a peptide containing the immunodominant CD4-
restricted Der p 1 epitope (p 110—131) and to murine CLIP
(Fig. 1A). The CLIP peptide is not mitogenic since it fails to
stimulate proliferative responses or IL-2 production in T cells
from naive H-2° mice (data not shown) or mice immunized
with OVA, an unrelated antigen (Fig. 1B). Although Der p 1-
induceo T cell responses can be recalled by stimulation with
the CLIP peptide in- vitro, immunization with either murine or
human CLIP itself in CFA has failed to prime T ceil responses
to either CLIP, Der p 1 or Der p 1-derived peptides (data
not shown).
Comparison of the primary amino acid sequences revealed
a high degree of homology between CLIP and the N-terminal
region of Der p 1 (Table 1). MHC class II binding motifs have
been predicted based on analysis of the sequences of known
l-A°-restncted peptides (Table 1). The homologous regions
of CLIP and Der p 1 complies with one predicted motif (41),
where a bulky amino acid (Phe, Tyr or Met) constitutes one
anchor residue, separated by two to four variable residues
from the second anchor residue, which is a-non-polar amino
acid residue (either Pro or Ala). Furthermore, it has been
proposed that methionine residues in human CLIP may pro¬
vide important MHC contact residues, facilitating binding to
many different MHC class II molecules (42). This suggests
that murine CLIP and the homologous Der p 1 peptide can
be presented to T cells in an l-A°-restricted manner. In order
to assess whether or not this region of Der p 1 can be
recognized by T cells from Der p 1-primed mice, a 15 amino
acid peptide representing residues 15-29 of Der p 1 (p 15—
29) was synthesized. The p 15-29 peptide has been tested
over a wide concentration range and elicits strong in vitro
proliferative responses as well as IL-2 production in lymph
node cells from Der p 1-primed H-2° mice (Fig. 1A), but not
from mice primed with OVA (Fig. 1B).
T cell reactivity to p 15-29 and murine CUP is retained during
long-term in vitro culture
In order to investigate whether or not specificity for p15-29
and CLIP was retained during long-term in vitro culture, the
reactivity of Der p 1-specific T cell lines and clones was
examined. T cell lines derived from Der p 1-primed mice
proliferated in response to p 15-29 and CLIP peptide, but
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Fig. 2. Long-term T cell lines specific for HDM-aerived peptides cross-react with murine, but not human. CLIP peptide. T cell lines were
derived by cultunng iympn node cells from mice primed with (A) Der p 1 (line F2.2) or (B) the peptide p111-139 (iine F1) and re-stimulating
several times with irradiated spleen cells and tne relevant antigen. The data snown is Droliferative responses of resting T cells in the apsence
(can-, oars) or presence of 1 jig/ml (open pars) ana 10 ug/ml (cross-hatched bars) of tne indicated antigen.
Table 1. Comparison of primary amino acid sequences of HDM derived peotides and murine and human CLIP
I-Ab binding motif N X X X X X P
D I
Q s
F X X X X P
Y A
M
Rudensky ct al. (18)
Hobohm and Meycrhans (411
Der p 1 (113-127)
Der p 1 (15-29)
Murine Invariant chain (82-104)
Human Invariant chain (98-122)
1 S N YcqiyPpnanki
DLRQ MRTVT P IRMQG
PKSAKPVS Q M RMAT PLLMRPMSM
PKPPKPVS K MRMATPLLMQALPMGA
The pi 13—127 peotiae is the minimal CD4-restnctea Der p 1 epitope (N. M. Kristensen. unpublishea aata). The peptides p 110—131 and
p 111-139, which also contain this epitope and induce similar responses, have also been used in this study. Bold letters indicate potential
MHC class II anchor residues according to the l-A° binding motif suggested by Hobonm and Meyernans (41). The l-A° binding motif suggested
by Ruoensky et ai. (18) is also shown.
more strongly to p15-29 than to murine CLIP, as illustrated
by the pattern of responses of the T cell lines F2.2 and F1
(Fig. 2A and B). We furthermore isolated a panel of T cell
clones from a long-term Der p 1-specific T cell line and
selected T cell clones were subsequently subclened on p15-
29 or murine CLIP. All T cell subclones, regardless of the
selecting peptide, responded more strongly to p15-29 than
to murine CLIP, as illustrated by two representative subclones
(Fig. 3A and B). The examined clones all produced IFN-y as
well as IL-2 upon antigen stimulation and the cytokine
response profiles of each clone were qualitatively similar after
stimulation with either p15-29 or murine CLIP (data not
shown). In order to rule out the possibility that the p15-29-
soecific cells can be stimulated by any stable l-AD-peptide
complex, the responses of the clones to human CLIP were
tested. This peptide shares a large degree of homology with
murine CLIP and it has recently been shown to induce l-A°-
restricted responses (23). However, it failed to induce cytokine
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Fig. 3. T cell clones proliferate doth to p 15-29 and murine CUP. but not to the l-A° binding human CLIP. The responses snown are those of
two reoresentanve clones to 0.5 |iM (open bars) or 5 nM (cross-hatched bars) of the indicated peptides. Background proliferation (r SD) in
the presence of APC was (A) 1135 = 589 c.o.m. and (B) 1857 = 1357 c.p.m.
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Fig. 4. T cell hybridomas specific for pf5-29 cannot be activated by l-Ab complexed with the unrelated l-A°-restricted OVA peonde. whereas
an OVA-spec:fic T cell hybrldoma can. T ceil hybridomas were assayed for IL-2 production after culture with increasing doses of 015-29 (filled
sauares) or OVA323-339 (open squares) and APC. The results presented are for a representative p 15-29-specific hybridoma (A) and the
OVA323-339-specific hybridoma BO 17.10 (B). Background proliferation (I.e. T cell hybridomas cultured with APC only) was (A) 6189 r 557
c.p.m. and (B) 8447 o 515 c.p.m.
production or proliferation (Fig. 3 and data not shown).
Furthermore, a set of T cell hybridomas was generated
and tested against a wide concentration range of the l-A°-
restrioted epitope OVA323-339. None of the p15-29/CLIP-
specific hybridomas responded to the OVA epitope, as illus¬
trated by a representative hybridoma (Fig. 4A).
The line F1 was isolated from H-2° mice immunized with
Der o 1. but selected in vitro with splenic APC ano the peptide
p111-139. which contains the dominant l-A°-restricted Der
p 1 epitope p 113—127 (N. Kristensen, unpublished data).
Although F1 thus was selected in the absence of the p15-29
epitope it proliferated strongly to pi5-29 and murine CLIP as
well as to Der p 1 (Fig. 2B). The outgrowth of p15-29/murine
CLIP-specific T cells in this line may be attributed to the
combination of bystander help provided by T cells stimulated
to release cytokines by the immunodominant epitope and the
high number of APC, supplying a sufficient density of CLIP-
MHC class II complexes. We observed markedly higher levels
of proliferation for T cell lines and clones cultured in the
presence of APC than in medium alone (e.g. Fig. 2A and B).
These findings suggest that the T cell reactivity to CLIP and
p 15-29 may be maintained by splenic APC in the absence
of exogenous antigen. Therefore, we investigated the proli¬
ferative responses to increasing doses of splenic APC
1096 T cell cross-reactivity to CUP and mite allergen
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Fig. 5. Antigen-presenting capacity of spleen cells from li chain deficient mice ana control neterozygous littermates. (A) T cells from tne line
F2.2 were cultured with 0.5 fiM (open bars) or 5 llM (cross hatcned bars) of the indicated peptides and mitomycin-treated spleen cells from
C57BL/6J mice either heterozygous (li*'" APC) or homozygous (li"'" APC) for a mutation in the li chain gene. Proliferation to medium aione or
SDieen cells in the absence of-peptide antigen (shaded bars as indicated) is also shown. (B) T cells were cultured with increasing numoers
APC irom of li"'" mice (cross hatched bars) or APC from Ir'" (shaded bars).
from mice expressing li chain or deficient in li chain
expression.
Proliferative responses ofp 15-29/murine CUP-reactive T cells
induced by splenic APC from normal and li deficient mice in
the presence and absence of exogenous antigen
The capacity of APC from li chain deficient mice (li"'") and
controi heterozygous littermates (li*'") to present peptides
in vivo was examined. Consistent with previous reports we
found that APC from the li"*'" mice, though expressing consid¬
erably reduced levels of membrane bound MHC class II
molecules (35). couid present the peptides p15-29 and
murine CLIP as efficiently as APC from li*'" mice. No
responses to human CLIP were observed (Fig. 5A). T cells
from long-term T cell lines and clones were cultured with
increasing numbers of APC from either li*'" or li"'" H-2° mice
in the absence of exogenous antigen. A dose-dependent
increase in T cell proliferation was observed with APC from
li*'" mice. However, the response of the T cells to li
APC was greatly reduced compared to that obtained with
equivalent numoers of APC from li"'" mice (Fig. 5B).
Discussion
In this report, we demonstrate that CD4* T cells specific for
a peptide (residues 15-29) derived from a major allergen of
HDM, Der p 1, are cross-reactive with an li chain processing
intermediate (CLIP, residues 82-104). The observation that
immunization with an allergenic protein can stimulate T cell
responses to murine CLIP raises the possibility that self
peptides may play a role in the maintenance of immunological
memory of T cells specific for foreign antigens by generating
cross-reactive responses in vivo.
From comparison of the primary amino acid sequences a
region located within the N-terminus of Der p 1 was identified
with marned simiiarity to murine CLIP (Table 1) and it is likely
that the homology between the two sequences accounts for
the T cell cross-reactivity. The resolution of the crystal structure
of the CLIP-HLA-DR3 complex (20) and the reports that CLIP
binding to MHC class II molecules has similar kinetics to
conventional antigenic peptides, and is influenced by ailelic
polymorphism (19,42.43), suggest that CLIP has the binding
properties of a conventional peptide. Furthermore. I-A°-
restricted responses tokhe highly homologous human CLIP
have recently been reported (23). The responses seen with
murine CLIP did not occur as the result of mitogenic or
superantigen effects, since we failed to detect CLIP-reactive
T cells in mice immunized with an irrelevant antigen (OVA)
and CLIP-reactive T cells could not be isolated from OVA-
reactive T cell lines.
It could be argued that the Der p 1-specific T cells are
cross-reactive with an epitope on l-Ab which is exposed upon
stable peptide binding, and that the T cells therefore can be
stimulated by any l-AD-peptide complex. However, neither
human CLIP nor an l-Ac-restricted OVA peptide could induce
responses in p 15-29-specific T cell lines, clones and
hybridomas. Thus, it appears that p15-29-specific T cells
induced by immunization with Der p 1 can specifically recog¬
nize murine CLIP when presented as exogenous peDtiae
in vitro.
It still remains to be resolved if CLIP-MHC ciass II is
constitutiveiy expressed on the surface of normal APC. Never¬
theless, p 15-29-specific T cells could be induced to proliferate
in vitro, in the absence of exogenous peptide by the addition
of splenic APC from normal H-2b mice. If CLIP is the ligand
in normal H-2° APC inducing proliferation it might be expected
that splenic APC from li"'" mice would be unable to elicit a
response. The proliferation was greatly reduced with APC
from ii"'" mice; however, it was not completely abrogateo.
Adding murine CLIP to the li"'" APC restored strong T cell
responses. There are several explanations to account for the
residual proliferation in the presence of li"'" APC, including
bystander help mediated by the release of cytokines from
APC, when added at high density. Additionally, it cannot be
excluded that the T cells we describe here can respond to
more than one self peptide and it is recognition of unidentified
peptides that induces proliferation seen with H-2° APC in the
absence of exogenous peptide. Nevertheless, the finding that
CLIP can induce proiiferation of T cell clones and lines
specific for p 15-29, suggests that CLIP is a cross-reactive
ligand recognized by these T cells. Moreover, we have
subcloneo the cross-reactive T cells using murine CLIP and
the T cells isolated maintain stronger responses to the HDM
peptide than to CLIP. These results would support CLIP as a
ligand for the HDM-reactive T cells.
Cross-reactivity between self and foreign antigens occur¬
ring in vivo may have the potential to break peripheral
tolerance and lead to the induction of autoimmune disease
(e.g. 24.25). In order to activate self reactive CD4^ T cells
foreign peptides must be able both to bind to MHC class II
molecules and form productive interactions with the TCR.
Recently, it has been described that autoreactive human
CD4" T cell clones specific for MBP could be stimulated
in vitro by peptides derived from common human pathogens
(26). The mimetic peptides displayed only limited seguence
homoiogy to the MBP peptide, nevertheless, they all stimulated
strong proliferative responses in the appropriate T cell clones.
If foreign antigenic peptides can activate self reactive T cells
througn molecular mimicry, then the converse may also be
true in that T cells specific for a foreign antigen may be
stimulated by mimetic self peptides. Thus T ceils primed to
selected foreign antigens, such as Der p 1, may be maintained
in vivo by recognition of naturally occurring self peptides,
which act as weak agonists or altered T cell ligands, when
presented on the surface of professional APC. While CLIP
may be unable to activate naive p15-29/CLIP-spec:fic T cells,
memory T cells which have previously encountered p 15-29
may have a lower activation threshold, which enables CLIP
to act as an agonist. Signalling through ligation of the TCR
by peotide-MHC class II complexes with altered affinities can
dissociate selective T cell effector functions (44,45). Our
results indicate that recall responses to murine CLIP are
consistently lower than those to the original antigen p 15-29,
however, both ligands induce proliferation and similar profiles
of cytokine production. Thus, murine CLIP acts as a weak
agonist rather than an altered T cell ligand.
The failure of the human CLIP peptide to stimulate the p1 S—
29-reactive T cells is interesting since murine and human
CLIP are more homologous to each other than to the HDM
peptide. A recent report has proposed that the minimal epitope
necessary for binding of human CLIP to l-Ab comprises
amino acid residues 117-125, which are identical to the
corresponding region in murine CLIP (residues 91-99) (23).
Assuming that p 15-29 binds to l-A° in a manner similar to
human CLIP, comparison of the amino acid sequences of
p 15-29. murine and the non-stimulatory human CLIP suggests
that the onmary TCR contact residue could be Gin at position
18 in p 15-29. corresponding to position 90 in murine CLIP.
At the corresponding position in human CLIP there is a non-
conservative substitution of Gin to Lys at position 106 and
this change would be sufficient to abrogate T cell recognition
if the residue at this position is a primary TCR contact (30).
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It is unlikely that all potential self antigens can be presented
in the thymus and evidence suggests that autoreactive T cells
are present as a component of the normal peripheral T ceil
repertoire (46). It is possible that CLIP-specific CD4~ T
ceils may escape negative selection and be present in the
periphery. However, our own and previous findings have
shown that mice immunized with murine CLIP fail to elicit T
cell responses (22). This together with the observation that
all of the T cell clones that we studied responded to both
CLIP and p 15-29 would argue against the existence of a
population of peripheral T cells uniquely specific for CLIP.
The central implication of this paper is that T cell cross-
reactivity between self and foreign antigens exists and that it
may be possible to maintain immunological memory to foreign
antigens by stimulation of specific memory T ceils by self
peptides displaying a degree of molecular mimicry. Whether
this mechanism may contribute to the chronic nature of some
diseases, including.allergy requires further study. Our findings
may also have an important consideration for the design of
peptide vaccines for the therapy of immune disorders as well
as for protection against infectious microorganisms.
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CPA complete Freund's adjuvant
CLIP class II associated invariant chain derived peptide
Der p 1 Dermatopnagoiaes pteronyssinus group 1 allergen
ER endoplasmic reticulum
HDM house dust mite
li invariant chain
MBP myelin basic protein
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T-cell responses to allergens: epitope-
specificity and clinical relevance
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Jonathan R. Lamb
Allergen-specific T cells play
an important role in the
pathophysiology ofatopic allergies.
Recently, cDNAs that encode many
important allergens have been
cloned and their amino acid
sequences deduced, thus alloiuing
the elucidation of the epitope-
specificity ofallergen-specific
T cells. Here, foost van Neerven
and colleagues discuss the results
of these studies, and the
implications for the development
of efficient strategies for specific
immunotherapy.
n type I allergy there appears to be a
breakdown of tolerance to innocu¬
ous proteins that is manifest by an
immune response that causes a di¬
rect hypersensitivity reaction, local tissue
! damage and even systemic responses. In
| atopic patients, these symptoms are associ-
| atod with high serum levels of allergen-
! specific IgE and eosinophils, and are in-
! duced by a spectrum of type 2 cytokines
: produced by allergen-specific CD4" T cells,
j Specific inactivation of these cells, or the in-
j duction of T helper I (Till) type cytokines,
j might directly interfere with the disease pn>-
cess. Therefore, allergen-specific T cells are
j obvious targets for intervention in atopic
! disease and a detailed characterization of the
| epitopes present on major allergens might lead to improved forms
'
of therapy, using either synthetic peptides or recombinant allergens.
T-cell responses to allergens
Many allergen-specific human CD4* T-cell clones have been shown
to resemble murine Th2 cells, producing large amounts of inter-
leukin 4 (lL-4)and IL-5, but little or no IL-2and interferon 7 (IFN-7)
upon activation1-. Th2-like cells have been identified in peripheral
blood and lesions ofatopic-dermatitis patients, in the nasal mucosa of
rhinitis patients, and in the bronchial alveolar lavage (BAL) fluid of
asthma patients: observations that highlight the involvement of Th2
cells in atopic diseases,-u\ Figure I gives a schematic representation
of the role of T cells in the allergic immune response.
Because activation of allergen-specific Th2-like cells seems to
be causally related to the pathophysiology of allergic disease, infor¬
mation about the precise proteins they recognize and their T-cell
epitopes is needed before allergen-derived synthetic peptides or
recombinant allergens can be considered for immunotherapy.
Major allergens contain multiple T<ell epitopes
A large proportion of allergen-specific T cells are specific for major
allergens"-1", i.e. proteins that are recognized by serum IgE of more
than 5W> of allergic patients, and T-cell epitope mapping studies
have focused on these molecules. The recent cloning and sequenc-
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ing of several cDNAs that encode major al¬
lergens has allowed the identification of T-
cell epitopes, as well as an estimation of
their relative importance in inducing T-cell
activation. Epitope mapping studies using
long-term T-ccll clones and lines, have
found that all allergens studied to date, i.e.
mite-, grass pollen-, tree pollen-, cat-, bee
venom-, and chicken-derived allergens (see
Table 1) contain multiple T-cell-activation-
inducing epitopes dispersed throughout the
molecule"-12-14-17-1"-15. These epitopes are rec¬
ognized by allergen-specific T cells isolated
both from atopic patients and from healthy,
nonatopic individuals1-15-25. In addition, T-
cell clones with distinct epitope specificities
for a given allergen can be isolated from a
single atopic donor"1"-1". This suggests that certain epitopes are rec¬
ognized in the context of different major histocompatibility (MHC)
class II molecules"-1", and that certain HLA molecules present mul¬
tiple allergen-derived epitopes to the immune system. Furthermore,
epitopes might exist that can only be presented by a single HLA-
DR, DQ or DP molecule.
Polyclonal T-cell responses might give a better representation of
the diversity of T-cell responses to allergens than responses meas¬
ured with T-cell clones because a bias towards certain T-cell clones
might be selected during the in vitro cloning procedure. As expected,
polyclonal allergen-specific T-cell lines have been shown to rec¬
ognize a broader range of T-cell epitopes, with T-cell lines of some
atopic individuals recognizing up to six different epitopes within
the same allergen'"-,2. Interestingly, when peripheral T cells
from large panels of patients are tested for reactivity with pep¬
tides of major allergens, immunodominant regions can be
iden ti fied1 5-22 ~2J-2*-2"-11.
MHC class II restriction and Tcell receptor usage of
allergen-specific CD4+ T cells
MHC restriction patterns of allergen-specific human T cells appear
to be very diverse, as is T-cell epitope recognition. HLA-DRB1, HLA-
DRB3, HLA-DP and HLA-DQ restriction has been demonstrated
for several allergens"vM2-,';|"—-u-w\ Such diverse restriction patterns
suggest that there is only a weak or no correlation between HLA
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Table I. Human Tcell epitopes of allergens








































24 kDa, 222 aa
15 kDa, 129 aa
17 kDa.
70 i 92 aa
(dimer)
17 kDa. 159 aa
41—45 kDa.
353 aa
34 kDa. 240 aa
34 kDa. 240 aa
28 kDa. 268 aa
Venom allergens:
Insects
Apis mellifera Api m I (PLA2) 19 kDa, 134 aa








1-15, 11-24, 20-33, 29-42, 38-51,
47-60, 56-69, 92-105. 101-114. 116-129
I-20, 11-35. 22-50. 36-60, 51-77. 61-86.
78-104, 81-96, 91-105, 87-112. 105-129
II-25. 16-31, 21-35, 22-40. 71-86.
81-96. 82-100. 111-129
20-33
1-15, 11-25. 21-35, 31-47. 41-55, 51-65.
61-75, 71-86, 81-96. 91-105. 101-115.
111-129
39-52. 53-66 (chain I),
9-21. 22-35. 57-70 (chain 2)
1-17, 9-25. 18-32, 29-42. 37-55. 44-60.
56-70 (chain I)
1-22, 12-33, 23-48, 34-59, 49-68, 60-82,
74-92 (chain 2)
2-16. 11-22, 61-72, 77-88. 85-96,
113-124, 145-156, 147-158
1-16, 27-40, 35-48, 75-92, 77-92,
93-110, 141-156
1-16, 11-26, 61-76, 63-78, 65-80, 75-90,
77-92, 95-110. 97-112, 111-126,
113-128, 127-140, 141-156
1-15. 8-23, 19-33. 29-43. 46-63. 58-73,





1-20, 11-30, 21—40, 31-50, 41-60. 50-70.
71-90.91-110. 101-120, 111-130.
121-140, 131-150. 141-160. 151-170.
171-190. 181-200. 191-210.221-240
Several
22-36, 25-39, 34-45, 70-84. 73-84.
91-102, 97-111. 91-102. 100-114.
109-123. 121-134, 127-138. 130-141,
142-155, 157-168. 169-183, 211-225,
226-240




45-62, 74-91, 76-93, 81-92, 81-98,
107-124, 111-128. 113-124, 114-131


















































PBMC and TCC 15
TCC 33
Abbreviations: aa, amino acids; PBMC, peripheral blood mononuclear cells; PLA,, phospholipase A2; TCC, T-cell clone; TCL, T-cell line.
* Even though the presence of several T-cell epitopes was described, T-cell epitopes that were recognized by >50% of all individuals tested have been identified in
these studies.
bSizes are shown as SDS-PAGE mobility of the native protein (in kDa) and as number of amino acids (based on the recombinant sequence).
1 These papers describe reactivity with several peptide pools. Exact amino acid sequences are not clear
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alleles and IgE responsiveness. Correlations between HLA and IgE
responsiveness have been described (see Table 2) but p-values and
relative risks appear to be high only for the smallest allergens,
which presumably contain limited sets of T-cell epitopes owing to
their size37-43. In addition, because allergenic extracts are generally
complex mixtures of many allergens, a correlation between HLA
and one of these allergens does not strongly affect lgE responsive¬
ness to an allergen extract.
In some immunological diseases there is an oligoclonal expan¬
sion of T cells that express a limited number of T-cell receptor (TCR)
variable (V)p-gene products44,4*. If allergen-specific T cells with a
limited use of TCR V-gene products play a role in allergic responses,
the possibility exists for immunotherapy specifically targeted at the
TCR expressed on these cells. However, as expected from the HLA
restriction and epitope diversity, human allergen-specific T-cell
clones use a diverse set of T-cell receptor V(i- and Va-gene seg-
ments9'10*30'46""48. Although only a small number of T-cell clones have
been tested in these studies, no biased TCR V-gene product usage
could be demonstrated, thus complicating the issue of TCR-directed
intervention.
Conversely, the results of Mohapatra et al. suggest that the diver¬
sity of the TCR V«- and joining (J)a-gene segment usage of Lol p 1-
specific T-cell clones appears to be limited49, whereas it was shown
in another study that T-cell responses to Der p could be inhibited by
TCR VfJ-derived synthetic peptides: indicating that TCR usage by
allergen-specific T cells is restricted in some individuals50.
A recent study showed that polyclonal populations of T cells,
expressing almost the full range of TCR V«- and TCR V0-gene
segments, are present in BAL fluid and peripheral blood of allergic-
asthma patients51. However, after exposure to allergens, an olig¬
oclonal T-ccll expansion could be observed in BAL fluid, but not in
the peripheral blood, suggesting that allergen-specific T cells are
expanded or recruited in lung tissue after allergen exposure51.
TCR usage has also been employed to estimate the longevity of
allergen-specific T cells. Weddcrburn et al. have reported that T-cell
clones with identical TCR V and J regions can be isolated from the
same patients after an interval of six years52. These findings are
consistent with data from Ebner el al., who reported that epitope-
specificity of Bet v 1-specific T cells from a birch-pollen-allergic
patient was unchanged when T cells were isolated from the same
patient after a two-year interval16.
Importance of isoallergenic variation for the design of
immunotherapy
ll is becoming increasingly clear that many isoallergenic forms of
major allergens exist in nature53. These isoallergens differ from one
another in one to several amino acids18-27'54'55. Some isoallergens
have a very high degree of identity with homologous allergens in
related species, which might explain the high degree of crossreac-
tivity at the IgE level, as well as at the T-cell level.
As a result of structural homology, major-allergen-specific T cells
might crossreact with allergens from different species within the










Fig. I. The role ofCDV T cells in the allergic immune response. Upon
entry into the human body, the allergen is taken up and processed by an
APC. The presented allergen-derived peptide is recognized by an allergen-
specific Tli2-like cell that produces IL-4, IL-5 and IL-13. IL-4 and IL-13
induce the isotype switch to IgE in B cells. IgE binds to the high affinity
Fee receptor on mast cells, which degranulate upon Fee-receptor
crosslinking, resulting in the immediate Till-type response. IL-5 produced
by the Th2-like cells plays a role in the differentiation and survival of
eosinophilic granulocytes, which are responsible for the late-pliase
response (especially in allergic asthma). Abbreviations: APC, antigen-
presenting cell; EO, eosinophilic granulocytes; IL-4, interleukin 4; TCR,
T-cell receptor; Th2, T helper 2 cell.
clones and lines that crossreact with house dust mite Der p (Refs 7,
35). A similar phenomenon can be observed among grass pollen
group 1 allergen-specific T cells30 and tree pollen group 1 allergen-
specific T cells (S.H. Sparholt et al., unpublished) that crossreact
with group 1 allergens from different genera of grasses and trees.
At least a part of the latter crossreactivities must result from iso¬
allergenic variation since some natural Bet v 1 or Phi p 1-specific
T-cell clones were shown to crossreact with group 1 allergens from
other families, but did not react with recombinant Bet v 1 or Phi p 1,
representing single isoforms.
The existence of many isoallergens has several implications for
possible use of peptides in immunotherapy: T-cell epitopes identi¬
fied by using T cells that react with recombinant allergens (and their
peptides) might represent only a proportion of the repertoire of
allergen-specific T cells present in the human body. Studies by
Ferreira et al.5h and by S.H. Sparholt et al. (unpublished) clearly
show that multiple isoallergens are involved in the sensitization to
Bet v 1, the major birch-pollen allergen. Some of the isoforms stud¬
ied have complete T-cell-activation capacity, but fail to bind IgE in
vitro, and induce very weak skin prick tests56. Such isoforms can be
considered for immunotherapy, since they might be safer than natu¬
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DR3 57 7 0.00001 18
DR5 85 14 0.0000007 35
DR5 40 6 0.001 23
DR4 26 16 0.006 1.9
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DRI 16 9 0.02 2.0
DR3 16 17 0.078 < 1
DR3 36 7 0.01 7.3
DR3 33 14 0.01 3.1
for induction of anaphylactic reactions.
However, their potential use might be lim¬
ited since not all T-cell specificities will he
present on these isotorms.
Modulation of allergic responses
using synthetic peptides
In order to evaluate the potential of syn¬
thetic peptides for immunotherapy, both in
vitro and in vhtn experimental systems have
been used. Using these models, the ability of
allergen-derived synthetic peptides to in-
hihil (rlhilai responses and humoral re
spouses Im allergens has been studied, pro¬
viding evidence that allergen-specific
immune responses can be inhibited.
It has been demonstrated that the incuba¬
tion of human influenza-specific T-cell clones with supraoptimal
concentrations of influenza peptide in the absence of antigen-pre¬
senting cells (APCs) resulted in a state of nonresponsiveness (or an-
ergy), during which no proliferative responses were observed - even
after subsequent stimulation of the cells with the same peptide in
the presence of APCs (Ref. 57).
More recently, using the same experimental conditions, it has
been shown that anergy can also be induced in allergen-specific Th2
clones following stimulation with allergen-derived peptides58""60.
After initial activation, accompanied by the production of large
amounts of cytokines, including IL-4, 1L-5, IL-13, granulocyte-
macrophage colony-stimulating factor (GM-CSF), and tumor nec¬
rosis factor a (TNF-a) (S. Fasler and H. Yssel, unpublished), Der p 1-
specific Th2 clones become unresponsive to further stimulation
wilh Der p l-pulsed APCs (Rcfs 58, 59). Interestingly, stimulation of
the anergic T-cell clones with a combination of phorbol ester and cal¬
cium ionophore resulted in the production of normal levels of these
cytokines58'59, suggesting that peptide-mediated nonresponsiveness
might result, in part, from impaired signalling through the TCR/CD3
complex, independent from the expression of this complex on the
surface of the cells59.
However, information about signalling pathways in human an¬
ergic T cells is still limited. It has been reported that the anergic state
induced in mouse T-cell clones following stimulation with altered
peptides is characterized by a unique pattern of phosphorylation of
the TCR£ chain, as well as a failure of the protein kinase Zap-70 to
associate with this chain61. It has yet to be established whether simi¬
lar observations can be made in peptide-mediated anergy induced
in human T-cell clones. Importantly, in contrast to Der p 1-specific
T-cell clones optimally stimulated with antigen-pulsed APCs, aner¬
gic Th2 clones failed to give help to B cells for the synthesis of lgE,
even in the presence of exogenous IL-4 or IL-13, despite comparable
levels of expression of the costimulatory CD40 ligand on both active
and anergic T-cell populations59.
The activation of allergen-specific T cells and immunoglobulin
synthesis in mice can also be inhibited in vivo by intra-nasal, oral or
subcutaneous administration of peptides60,62-64. Naive mice that
were pretreated with the dominant peptide of Fel d 1 or Der p 1 did
not develop an immune response when challenged with native
Der p 1 or Fel d 1. In addition, ongoing immune responses to native
Der p 1 and Fel d 1 could be substantially downregulated by pep¬
tide treatment. This could also be achieved using minor epitopes of
Der p 1 that are recognized when mice are immunized with these
peptides but not when they are immunized with whole protein*'4.
It should be noted that administration of peptides results in inhi¬
bition of responses to the entire allergen, indicating that not all
allergen-derived T-cell epitopes have to be present to obtain in vivo
tolerance to allergens.
Can synthetic peptides of allergens be used for
immunotherapy?
Allergen extracts have been extensively characterized and standard¬
ized over the past decades, however, allergen immunotherapy has
hardly changed since its introduction by Noon in 1911 (Ref. 65).
During immunotherapy, gradually increasing doses of complete
allergen extract are injected, resulting in a reduction of clinical
symptoms of allergy. T cells are believed to be the target cells that
are affected by successful immunotherapy but there is no obvious
evidence concerning the mechanism (see Fig. 2).
As a result of the abundance of human T-cell-activation epitopes
on allergens (see Table 1), and the problems posed by the occurrence
of isoallergenic variation, it is clear that immunotherapy might
have an optimal efficacy when natural allergen extracts, and not
peptides or recombinant allergens, are used. Cross-epitope inhibi¬
tion can be demonstrated in experimental models62,63, although as
yet, there is no evidence in humans to support the contention that
vaccination with a single peptidewill downregulate the response to
an intact protein.
However, adverse reactions occur occasionally during specific
immunotherapy with native allergens as a result of binding of in¬
jected allergens to allergen-specific IgE bound to mast cells. This













Fig. 2. Factors and cells involved in the generation of Th2, TliO and Till responses. APC-derived
factors, T-cell derived cytokines, APC type, and the dose and administration route ofallergens can
strongly influence the outcome ofan allergen-specific T-cell response. During natural sensitization,
low doses of allergens are absorbed in the airway mucosa, leading to Th2-type responses in atopic
individuals. During specific immunotherapy, high doses of allergens are injected subcutaneously
over 3-5 years, resulting in a bias for the production ofThl-type cytokines71 71. Several novel im¬
munotherapy strategies are under development that might specifically interfere with the outcome of
allergen-specific T-cell responses. The use of particulate antigens (to select for IL-12-producing
professional APCs), naked DNA vaccination (to induce IFN-y-producing HLA class l-restricted
T cells), Till-biasing adjuvantia, and high doses of peptides (high dose without IgE related side-
effects) or recombinant allergens (easier to standardize than complex allergen extracts) might result
in a bias for the production of Thl-type cytokines. However, oral, nasal, or sublingual delivery of
allergens, and high doses of peptides might directly induce tolerance in allergen-specific Th2-like
cells. Abbreviations: APC, antigen-presenting cell; IFN-y, interferon y; IL-10, interleukin 10;
PGE2, prostaglandin E2; Till, T helper 1 cell.
kines takes place in successful immunother¬
apy71-73; this might result from the activation
of IFN-y-producing, allergen-specific CD8'
or TCRySf cells that inhibit IgE synthesis, as
described in animal models74'75. If this turns
out to be the mechanism underlying suc¬
cessful immunotherapy, careful selection and
combination of peptides of several major al¬
lergens might be the most crucial step in de¬
signing peptide therapies. However, the
high degree of isoallergenic variation of
some allergens, such as tree pollen and grass
allergens might favour approaches that are
based on the use of natural allergenic extracts
that are degraded to peptides76, or on the
use of recombinant T-cell epitopes that do
not bind lgE, as described by Rogers et a/.18.
Another strategy for optimizing allergy
immunotherapy is directed at finding ways
to change the cytokine profiles of allergen-
specific CD4f T cells. The crudest method
would be to co-inject a protein extract (e.g.
purified protein derivative), cytokine (1L-12,
IFN-y), or an IL-12-inducing factor, in com¬
bination with allergen extracts in order to
shift the T-cell response towards a Thl spec¬
trum. T cells that maturate in this artificially
created microenvironment will preferen¬
tially become T cells with a ThO- or Thl-type
cytokine profile. Alternatively, other ap¬
proaches might be aimed at inserting aller¬
gens in attenuated live, bacterial or viral
vectors, that themselves evoke strong Thl-
type responses. In addition, studies on the
can be avoided if allergen-derived synthetic peptides are used in¬
stead of whole allergen extracts. Binding of allergen-specific IgE to
allergen-derived peptides is strongly reduced66, whereas the desired
effects on T cells are unaltered. Therefore, the safety of immunother¬
apy can increase when peptides or low IgE-binding recombinant al¬
lergens are used. The answers to these problems will have to await
results of clinical trials with peptides or recombinant allergens. So
far, a trial with bee venom phospholipase A2-derived peptides has
shown good clinical efficacy with no adverse reactions67, and an¬
other trial using Fel d 1-derived peptides is currently under way68.
An important question that these clinical studies will have to an¬
swer is whether the inhibition of immune responses to major aller¬
gens will be sufficient to silence allergic responses to other proteins
present in the allergen extract, or whether the specificity of the al¬
lergic response will shift to minor allergens that can also be recog¬
nized by T cells7''9'60. This might be expected from the work of
Gammon et al. who showed that T cells with specificities for minor
epitopes of antigens can escape tolerance induction70. Several stud¬
ies have indicated that a shift in the production of Th2 to Thl cyto-
role of APCs in the generation of Th2 vs.
Thl-type responses by the production of soluble mediators such as
prostaglandin E2 or IL-12, respectively, might yield information on
the underlying mechanism of the in vivo outgrowth of T cells with
biased cytokine production profiles77.
Concluding remarks
The increasing knowledge of the role of the immune system in the
pathophysiology of atopic disease has revealed new possibilities
for designing immunotherapeutic approaches. The future course of
specific immunotherapy as treatment for allergic diseases will to a
large extent be dependent on the results of clinical trials that use
synthetic peptides, recombinant allergens, degraded allergenic ex¬
tracts, or modified allergens that selectively tolerize Th2-type or
activate ThO-type or Thl-type responses to allergens.
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Human Helper T-Cell Clones That Recognize Different
Influenza Hemagglutinin Determinants Are Restricted by
Different HLA-D Region Epitopes
David D. Eckels1*, Thomas W. Sell1, Sandra Rosen Brcmson1,
Armead H. Johnson1, Robert J. Harrzman2, and Jonathan R. Lamb2
Abstract. Human T-lymphocyte clones (TLCs) were generated against the
hemagglutinin (HA) of A/Texas/1/77 iniluenza virus by limitmg dilution. TLCs
were then screened for antigen specificity on chemically synthesized peptides
representing the HA1 molecule. It has been hypothesized that different T ceils
that recognize the identical antigenic determinant are controlled by (restricted
by) the same class II epitope. Two TLCs, HA1.4 and HA1.7, both recognized the
same HA peptide and in proliferation studies exhibited identical restriction
patterns. Two other clones. HA 1.9 and HA 2.43, recognized different HA
determinants and also had distinct restriction patterns. Proliferation inhibition
studies with monoclonal antibodies against human class II molecules dem¬
onstrated three unique patterns of blocking with the clones, suggesting that
clones may be restricted to a unique class II epitope depending on the HA
determinant recognized. These data can be interpreted as supporting the
argument that human immune responses to influenza hemagglutinin are under
Ir gene control exerted at the level of the viral antigenic determinant recognized
in association with particular D-region restricting elements. The determinant
selection and clonal deletion theories are compared for their capacity to best
explain these findings.
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Introduction- .
Class IImolecules are thought to be immune response (Ir) gene products (Betzofsky
1980). Mouse studies have shown that both the I-A and I-E subregions (Klein er aL
1981) control the ability to respond to particular antigens including, such diverse
materials as random synthetic peptides (McDevitt. and Benacerraf 1969), sperm
whale myoglobin (Berzofsky et aL 1982), cytochrome C (Heber-Katz et aL 1982),
and DNP-ovalbumin (Sredni and Schwartz 1980). The concept emerging from these
investigations is that a particular Ir gene controls immune responses to a single
antigenic determinant, pro'oabiy by influencing the way in which the T ceil
recognizes antigenic structures. One interpretation of such experiments depends on
the abiiity ofantigen-presenting ceils (APCs) to display antigen on their surfaces in a
form immunogenic to T ceils (Rosenthal et aL 1981, Benacerraf 1978). APCs lacking
appropriate Ir genes (and presumably the appropriate class II molecules, therefore)
are unable to present antigen to specifically primed T-lymphocytes. An alternative
hypothesis suggests that Ir gene phenomena reflect deletion from the T-cell
repertoire of those clones which are capable of recognizing a given antigen in the
context of a particular restricting element; where this deletion occurs' is not entirely
clear (Schwartz 1978. Ishii et aL 1983). Typically, experiments examining the above
questions require that antigen be presented to primed T ceils by allogeneic or
semiallogeneic APCs. A problem with this approach, in the mouse and especially in
man. is that even primed T-lymphocyte populations contain ceils which recognize
allogeneic (nonseif) class II antigens and thereby obscure responsiveness to specific
antigen (seif-r-X). Another aspect of this same problem is that the human major
histocompatibility complex (MHQ is incompletely understood so that while two
individuals may share some identical D-vsgion antigens, there may exist other
regions or loci contributing to class II antigen disparity and thus, high background
alloreactivity (Bergholtz et aL 1980, Kurnick et aL 1981). This consideration further
muddles an already complex interpretation of the experimental data.
We have used T-ceil ciones to investigate the nature of Ir gene control of cellular
immune responses to influenza virus antigens. The ciones are antigen-specific
(Lamb et aL 1982a. b, c) and restricted by antigens encoded in the HLA-D region
(Eckeis et aL 1982, L£83a. b; Lamb et aL 1982a) in that they recognize only
components of influenza A/Texas, not B/Singapore, and respond only when antigen
is presented by APCs bearing class II molecules common to both the T-lymphocyte
ciones (TLQ and APC. We have posed the question of whether ciones which
recognized the same antigenic determinant were also restricted by identical human
class II molecules (HLA-D region antigens) or Ir gene products. We report here on
four hemagglutinin specific ciones that recognize three distinct HA determinants
and which are restricted by at least three different epitopes associated with the
HLA-D region. When monoclonal antibodies (MoAbs) specific for human class II
molecules were used to block TLC-APC interactions, three different blocking
patterns were obtained, that is, two ciones which apparently recognize the same HA
determinant had identical patterns of blocking with the MoAbs on two different,
allogeneic APCs, suggesting that these ciones may be restricted by the same epitope.
These results are compatible with the concepts that TLCs. recognizing different
antigenic determinants can be controlled by distinct Ir genes ana that T-ceil
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recognition, as reflected, in Ir gene phenomena is exquisitely sensitive to subtle
differences- in the combination or interaction of antigenic determinants with their
corresponding restricting epitope
Materials and Methods
Clones. Peripheral blood lymphocytes (PBLs) (2.5 x LO3 mil were primed nnrii-r optimal conditions with
the isolated hamagglurimn (HA) of A/Texas/ 1/77/X-49 influenza virus (0.1 pg/mi) or whole virus
(5 HAU/mi). After 6 days, responding ceils were cloned by limiting dilution (0G cells/well) in the wells of
Falcon Microtest II trays, each containing 10* autologous PBLs (30 Gyj and antigen in 20-ai tissue
culturemedium with 20%TCGF. TLCs were successively expanded,maintaining the same proportion of
T-scil growth factor (TCGF), feeders and antigen rcione split to 2 x 105/ml)and haveexceeded 10® viable,
functional ceils. TLCs could be frozen in standard protocols and recovered for later use. These methods
have been extensively described elsewhere (Lamb et ai 1982a. 1983a. b. et aL 1982).
Assay conditions. TLCs wereassayed for proliferation as indicated by incorporation ofJHTdR after 72 h.
Clones at 5-10 x 10J/well were culturedwith 25-50 x 10J irradiated histocompatibleandhistomcompat-
ible PBLs or with 5 x 103 irradiated E" (T-ceil depleted) APCs: optimized antigen concentrations were
used as indicated (A/Texas. B/Singapore/222/79. A/Japan/170/62 and A/Japan/305/57 at 2G-20
HAU/mi: HA from A/Bangkok/1/79 and synthetic peptide at 0.25-2.0 pg/mii EBV-transformed
lymphoblastoid ceil lines were used at 2_5 x 10*/weil (60 Gy) with optimal antigen concentrations.
Further details can be obtained from Lamb and co-workers (1982b. c). Synthetic peptides of the HA1
moiecule were kindly provided by Drs. N. Green and R. Lerner. Scripps Institute. San Diego. California.
HLA phenotyping was periormed as previously described (Eckeis and Hartzman 1982. Amos ana
rCostvu 1980).
Monoclonal antibodies against human class II: molecules were analyzed for their capability of
blocking TLC proliferation. MoAb (approximately 0.2-50 ug/ml) was adoed to optimized cultures and
was present throughout the 72-h culture period. The MoAbs used in this study included the DR-specinc
SG157 (Goyert et aL 1982a), DS-speciflc SG171 (Goyert et aL 1982b). DC-speciflc SG465 and SG52Q.
(Goyen and Silver 1983), kindly provided by Drs. S. Govern and J. Silver, the DR-speciflc monoclonal
antibodies IIIE3 and IVGI (Hurley and Nunez 1982) which were generously provided by Drs. C. Hurley
and D. Capra as well as Q2/70 and Q5/6 (Quaranta et aL 1981) which react with isolated class II beta
chains and were kindly provided by Dr. V. Quaranta.
Results
TLC specificity and function. The TLCs used in this study have been extensively
characterized. In summary, the TLCs HA1.4, HA1.7, HA1.9, HAL43, FL2.8, and
FLL20 have been shown by fluorescence-activated cell sorter analysis to have the
following phenotype: Leu-1", T3", T4", Leu-7~, T8~, TICF, Til", class I", class
II", slg" (data not shown). Furthermore, HA1.4, HA1.7, HA1.9, and FLL20 have
been observed to induce the release of influenza virus-specific, antibodies from
autologous B-lymphocytes (Lamb et al. 1982cL 1983a. b; J. R. Lamb, personal
communication). All except HA1.9 and FL2.8 secrete gamma interferon when
induced by specific antigen or T-ceil mitogens (S. Jacobson et aL. manuscript in
preparation). The antigen specificities of the HA-speciiic clones are shown in Table
1. Note that (1) TLCs HA1.4, HA1.7 and HAL43 recognized peptide 20 of the HAi
moiecule as well as purified HA from A/Bangkok. (2) HAL43 recognized
A/Japan/305, and (3) HAI.9 failed to respond to peptide 20 although it recognized
and responded to A/Japan/170 and .A/Texas. Similar results have been reported by
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Tabi« L Antigen specificities. ofHA-specfic TLCs
D. D. Fcln-is et ai.
Antigen * Range of TLC responses (cpm)m
HA1.4 HA 1.7 HA1.9 HA2.43
A/Texas/l/77/x-49 (intact virus) 926-8 062 219-8 234 257—1 325 152-1094
Purified HA (A/Texas; H3)f +• -r +■ •+.
Purified HA (A/Bangkok; H3) 8938-23999 4 669-25 191 129-852 1 132-5 255
A/Japan/170/62 (intact virus) 1419-2725 501-739 31052-19 842 367-820
A/Japan/305/57 (intact virus|r — — nt +.
Peptide 20 (aa 306-330) 26 325-37844 22 723-32 047 76-136 4024—6 879
B/Singapore/222/79 (intact virus) 70-112. 56-74 42-209 46-87
*TLC was used at ICT/weU. autologous PBLs as a source ofAPCs ac 5 x 107'weilwith anngen as follows:
A/Texas 5-40 HAU/ml: purified HA from A/Bangkok 0.25-2.0 pg/ml; A/Japan/170 1:500 to 1:4000
dilution; p20 p-25-2.0 ug/mi; B/Singapore 5-40 HAU/mi Note significantly high backgrounds in the
presenceofA/Japan/170 due to backsdmuiauon from T-ceils in PBL population (<£ Lamb etai 1982b).
Antigen previously testedon these TLCs and is no longer available. Therefore, results are summarized
from Lamb et ai 1982c.
Lamb and co-workers (1982c) and suggest thatHA1.4 and HA1.7 may recognize the
same antigenic determinant which may be distinct from that recognized by HA2.43
which is in rum distinct from that recognized by HA 1.9. Thus, the four
hemagglutinin specific TLCs were capable of recognizing three different HA
determinants- Based on the above data, the following postulate was suggested:
Clones recognizing three distinct determinants should have three distinct restriction
patterns if distinct Ir gene products control such responses.
Restriction patterns ofHA-specific TLCs. Eleven different TLCs were analyzed for
responsiveness on a panei of 'aistocompatible and hisioincompazible PBLs. Tne panel
included irradiated ceils from 84 individuals representing 158 unrelated hapiotypes.
as well as 16 EBV-transfonned lympnoblastoid B-ceil lines (LCLs). Representative
data are provided from 31 panel members due to space considerations. However,
the statistics included are based on the full panel The current HLA phenotypes of
panel members used herein are shown in Tabie 2. The response patterns of
ailoreactive (AL14.12. AL14.65, AL14.71, S3.il and S3C33) ana antigen reactive
(FL3L20, FL2.38, HA1.4, HA1.9, and HA2.43) clones are shown in Tabie 3. Tne
Dwl/DRl ailoantigenic complex is defined by TLCs AL14.12. AL14.65 ana
AL14.71. DR3-associated alloantigens are detected by the TLCs S3.11 and S3.233.
Note that not ail DR1 ~ or DR3- stimulating ceils were capable of eliciting a
response from all of these ailoreactive clones. Tne response patterns of two virus-
specific ciones (FL2.38 and FL2.20) with restriction associated with DRi and DR3
antigens, respectively, are also presented for comparison. It is not known which viral
subcomponents FL2.20 and FL2.38 recognize.
Of the four HA-specific TLCs, HA1.4 ana HA1.7 recognized the same peptide
fragment and were also restimuiated by virus presented on the same APCs: Both
TLCs were positive with 13/17 DR1""/Dwl'4" APCs. 9/25 DR4+ APCs and 1/46
DRT/DwT, DR4~ APCs. No ciear statistical association was evident between
Ganeac Rotncnoo.ofUnman.TI.Cs- _ 4tX
' positive responses, fay HALik and: EEA-LT and any other known; SLA allele In
contrast- theTLC HA1Z9- recognized a different determinanr on theHA.molecale
andTalso had a different restriction pattern, recognizing: virus presented fay TftS
DR1"VDwLh- APCs- Finally, HA2.4-3 recognized a hemagglutinin determinant
present in peptide 20 and A/Japan/305 as well as A/Bangkok EEA unirior the other
three TLCs and HA2.43 also exhibited a third restriction pattern in that it was
cieariy resrimuiated oniy fay autologous APCs and marginally fay 2/15 unrelated
DR17DWL*- APCs.
Lymphoblastoid cell lines from, homozygous typing ceil'donors were used to
present viral antigens to HA1.4- and HA.1.7 (Table 4). The LCLs were kindly
provided by Dr. N. Suciu-Foca of Columbia University, New York. As might be
expected, TLCs HA1.4- and HA1.7 responded to virus presented by AR, a Dwl*"
Tabic — f€LA pheno typing of ceil panel
Ceil HLA loci
A C B wA/wo 0- DR MB AIT SB
0006 1.- 7. 8. 6. 3,0- 3.0 20 20 1.4
0022 2.2 5.5 44,44. 4,4 4,4 4,4 3.3 3.3 4,4
0127 L32 , 14,3 ,6 3.7 3," 20 23 1.2
0144. 1, 7. 8, 6. 1.3 1.3 1.2 1.2 24
0500 2.3 4,4 3535 6.6 5,1 5.1 3.1 21 4,4
0633 3,3 8.0 14,41 6,6 0,0 1.4 1.0 1.0 4.4
0634. 3.11 0,0 4132 6.4 4,6 4,61 0.1 0.1 . 4, Z
0640 25JZ 39,8 4,6 DB3.DB3 4,4 3. , 3.3
9030 1,3 3.7 6.6 7,2 7,2 0.1 0.1 4,4
0938 24.2 25 27144 4.6 4,5 4,5 0.3 3.2 6.2
0954 30,29 6.3 13.60 4,6 1J-O40 1.4 1.0 1.0 0.3
0957 2.2 23 4135 6.6 3,8 3.3 23 t i 1.4
1010 2.24 3.6 6245 6. 4J3SK 4.9 3.0 3.0 1.4
1011 2823 7,0 18.49 4,6 1.0 1.4 1.3 1.3 4,6
1014 1.23 4, 53.45 4,6 20 23 1.0 1.2 1.3
1023 231 4.3 51.60 4,6 1,10 1.4 1.0 1.3 3.4
1042 13^ 6.7 57,18 4, 6 7,0 7,4 0.0 3.0 4.6
1053 28,3 6.3 5831 4,6 0.0 3.7 20 23 1.0
1060 2314 5, 44.3 4.6 4,3 4,3 3.4 3.2 4.4
1061 1121 ,1 727 6.4 23 23 1.2 1.2- 4,4
1078 1.3 7,7 8,7 6.6 3,5 3,5 23 2.2 4,2
1279 US 1.5 27,44 4,4 1.0 , , 24




, , 1. , 4,0
1291
, , 1. , 4,7
1298 33.2 8. 14,55 f 1.T324 1.2 1.1 I. 4.7
1528 1.3 3,7 55.7 6.6 4.2 4,2 21 ,1 20
1531 224 0,3 5262 4,6 0.1 21 1.1 1.1 20
1651 231 ,8 3.14 6.6 6,7 61.7 1.2 23 4.2
2000
• • '• • • ' 23 • 1.
* Zero indicates that the specificity was typed for but no assignment couid bemade Blank indicates that
the specificity was not typed for.
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Taite 3. Rctricnon partcrm ofhumiur TOymphocyte clones
Cdls HLA-DK HLA-D AL14.71 -AL14.12 AL14.65 S3.11 S3.233 FL2J8
1298 ''U 1.TB24 46 21 1925 21 25 1275
1291 1.- . 23 12 9271 27 19 1 794
633 -r.4 183 43 4055 • 37 34 2429
500 1.5 U -+■ ■+• 4 NT NT 38 103
1290 —• L- 5059 8 507 4709 28 15 2183
954 1.4 1XD40 6986 2997' 2404 24 17 995
1023 1.4 1.10 4050 3 263 2655 37 19 1 877
1011 1.4 1.- 9049 1 875 3440 674 230 8 764
1279 1.— 10 863 1 774 5 549 133 155 7 856
1531 u L- 3515 8457 2613 27 15 2 658
144- 1J U 13833 3 392 9469 2465 2929 13 864
6 31- 3. — 30 45 28 7 304 3 289 237
1053 3.7 18 20 35 1 123 2483 0
127 3.7 3.7 25 27 19 527 1436 5
957 3.8 3.8 25 35 34 3 852 862 21
2000 2_; 27 35 23 1 652 1 282 20
1286 4,- 23 79 41 133 2093 - 39
1078 3.5 34 17 24 21 242 281 109
1014 •? i 2.— 27 24 36 16 23 58
22 4.4 4,4 37 2< 31 26 19 37
1010 4.9 43SK 201 218 50 799 29 0
1528 2.4 2.4 18 23 28 39 20 31
634 4.6.1 4.6 — — - NT NT 352
640 4.4 DB3.DB3 NT NT NT NT NT 48
938 4.5 44 51 39 37 . 15 19 19
1042 4,7 -.7 NT NT NT NT NT 892
1060 4J 4.3 NT NT NT NT NT 2 171
1285 4,- LD40.- 35 25 218 17 23 34
930 ") 'J 2.7 62 49 44 9 24 15
1061 23 24 NT NT NT NT NT 92
1651 6.1.7 6.7 NT NT NT NT NT 53
* Autologous cionc donor.
-4/— , positive or negative in previous testing.
NT, not tested.
Underline indicates positive response.
LCL. Additionally, the 7618 LCL (Dw4T) was able to present antigen to HA1.4 and
HA1.7 while the 7337 LCL (DR4~/DwlO"; failed to present. Thus, these results
confirm the conclusion and that the restriction element recognized by HA1.4 and
HA1.7, though common to some Dwl"" or Dw4~ cells, is separate from the
molecule or epitope expressing the DR. determinant.
To summarize, three distinct patterns of restriction were observed for the HA.-
specific clones: HA1.4 and HA1.7 both recognized the same antigenic fragment
(peptide 20) and showed concordant restricted patterns of responsiveness: the
restriction patterns for HA1.9 and HA2.43 were different from HA.1.4 and HA1.7
and were also quite different from one another which again may correspond to the
fact that they recognized distinct HA determinants. The statistics of association
between restriction responses and known HLA-D region alleles were inconclusive
. Genetic Kcstrictioa o£Human TX.Cs. --
FL220 HA1.4 HA1.7" HA1-91 HA2.43
25 16 12. 3060
45 24 IT 5561 26
37 27 2k 2335 24
243 47198 33 253 NT NT
22
. 4776 3 008 49 170
24 4661 3 426 381 272
22 3 705 2121 66 49
106 11286 9032 2434 905
31 8 867 9 556 2368 731
38 3 736 3 151 115 135
4463 15519 13 100 10141 Z120
8430 45 25 23* 65
1424 122 37 47 32
563 20 26 70 38
75 15 6 23 19
2317 29 24 17 -18
403 183 215 21 26
1 111 15 16 28 16
35 14 22 54 42
22 1336 1209 17 24
281 7231 6 854 153 300
29 2328 478 29 38
13 7 14 NT NT
0 41 0 NT NT
32 99 43 27 55
237 140 78 NT NT
3 503 5004 2770 NT NT
41 24 22 27 26
15 23 21 - 12 26
4576 30 42 NT NT
192 8 100 3 038 NT NT
aithougii the response patterns of HA1.9 and HA2.43 appeared to "split" the
DRl/Dwl antigenic complex since no DR1~/DwL~ APC was able to present
antigen to them. From these data we conclude that four TLCs, each recognizing one-
of three discrete HA determinants, were also restricted by at least three distinct
interaction elements.
MoAb inhibition ofTLCproliferation. To further define the class II molecules acting
as restriction elements, monoclonal antibodies against specific human class II
epitopes were used to blockTLC proliferation (Fig. L).ThecionesHA1.4andHA1.7
that presumably recognized the sameHA determinant were also blocked identically
by different MoAbs.While the anti-DR SG157 (Goyert et aL 1982a) produced little
relative attenuation of the response by HA1.4 and HA1.7, the response of both
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Table 4^ Presentation of influenz ■' virus by HTC lymphoblastoid B-cell lines (cpm)
_
LCL HLA-D specificity HA1.4—Ag HA1.4—Ag HA1.7 -t-Ag HA1.7—Ag
AR Dwl 6 116 1 172 5700 828
AP Dw2 680 696 684 502
AQ Dw3 248 206 350 330
7618 Dw4 6 727 918 5 559 1030
7336 Dw5 369 328- 321 294
7617 Dw6 723 668 747 640
7380 Dw7 759 846 703 778
AM Dw8 1089 994 1051 950
7339 Dw9 521 474 562 592
7337 DwlO 894 988 937 986
Med — 9 18 —
TCGF - 1059 - 2205 —
TLCs at lO^/well were added to cultures containing 2_S x 104, LCL cells (irradiated with 60 Gy) and
A/Texas at 10 HAU/mi or medium. Note that LCL 7337 is DR4-positive.
- 2 in 3 6 7
Dilution —
12 2 4 5 6 1 2 2 4 5 6 1 2 2 4 5 6 7
Fig. 1. The biocidng effects of monoclonal antibodies SG157. SG171. SG465. and SG520 on clones
HA1.4. HA 1.7, HA1.9. and HA2.43. Ten'thousand TLC cells were incubated with 5 x 104, irradiated
(30Gy) autologous PBLs (donor 144) in the presence ofMoAb for 72 h. The dilutions l-o correspond to
serial 1:3 dilutions: dilution 7 corresponds to the untreatedmedium controL The starting concentrations
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Fig.2-The blocking effects ofMoAbs TTIK3 and IVG1 on HA1.4, HA1.7; and HA2.43. IHEj and IVGl
recognize different determinants of the same DR-relaxed class II molecules on some ceil lines. See legend
to Figure L for methodology. The presenting ceil in this figure is derived from donor 144. (autologous);
note different effect of these MoAbs on different -presenting ceil (donor 22; cL Fig. 3).
clones was markedly inJiibited by the MoAbs SG17L (Goyert et aL 1982b), SG465
and SG520 (Goyert et aL 1983) which recognize a. second subset of human class II
molecules (DS/DQ. This, result was in contrast to the restriction patterns for these
clones which could not be correlated with any known MB/MT/DC allele. All of the
MoAbs, SG157,. SG171, SG465, and SG520, markedly inhibited responses to
A/Texas by the TLCs HA1.9 and HA2.43 in the presence of autologous APCs.
The MoAbs IIIE3 and IVGI may recognize different epitopes on the same set of
HLA-DR molecules (Hurley and Nunez 1982). While IHE3 had virtually no effect
on HA1.4 and HA1.7 (Fig. 2), the responses of ciones HA1.9 and HA2.43 were
partially abrogated by this MoAb at the highest concentration (81% and 85%
inhibition, respectively). IVGl profoundly reduced proliferation by HA1.4, HA1.7,
HA1.9, and HA2.43 to background levels. Interestingly, comparison of these
MoAbs ability to block KA1.4 and HA1.7 on APCs from donor 22 revealed that
while IHE3 behaved as before, IVG1 was no longer capable of completely blocking
responses by the TLCs (Fig. 3).
The Q2/70 MoAb (Quaranta er aL 1981) completely ablated responsiveness by
theHA1.9TLC whilenot significantly inhibiting the responses ofHA1.4,HA1.7 and
HA243 on autologous APCs (Fig. 4). TheMoAb Q5/6, on the other hand, inhibited
ail the HA-speciiic TLCs with equal effectiveness.
The results from these experiments support the argument that the four TLCs
may be restricted by three distinct restriction elements. Significantly, these daxa
further indicate that HA1.4 and. HA1.7 couid recognize restriction elements that
may correspond to epitopes of a DS/DC/MB/MT-associated class II molecule
Discussion
Since the initial description of genetic restriction (Shevach and Rosenthal 1973,
Rosenthal and Shevach 1973),much effort has been expended towards determining
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" HAL.T
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Fig. 3. Loss of blocking effect by IVG1 on
HA1.4 and HA1.7 when allogeneic
(DR4"; Dw4.~) presenting cells from do¬
nor 22 were used. See legend to Figure 1
for methodology. Compare with appro¬
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Fig. 4. Differential blocking o*HA1.9 proliferation by Q2/70. See legend to Figure I for methodology.
Note that HA1.9 is restricted by a different D-region epitope as compared wuh HA1.4, HAi.7 and
HA2.43 in panel studies.
the mechanism of Ir gene phenomena. The early studies tended to indicate that
nonresponder presenting ceils were incapable of presenting reievant antigenic
determinants to primed syngeneic T ceils. However, it was later shown that bone
marrow ceils from responder animals, when allowed to differentiate in the presence
of nonresponder thymuses, acquired the nonresponder phenotvpe (Zinkemagei et
aL 1978 Miller et aL L979). Furthermore, relatively recent studies indicate that Ir
gene phenomena may be due to missing clones or "T-ceil hoies" (Schwartz 1978,
Ishii et aL 1983). By eliminating ailoreactive T ceils using BUdR and light, Ishii and
co-workers (1981) were abie to show that nonresponder APCs were abie to present
antigen to responder primed T cells. These results have been confirmed by several
Genetic Restriction ot Human TL.Cs
' lahninrni-t^irTarinnri ghwyaclr 1982.Thomas andHoffman 1982) inciiidingtharoff
Ford and co-workers (1982) who demonstrated that the generic restriction: of
human.Testis is imposedby tb.eEELA.-DR. typeoftheA_PCs usedinprimarycuitore.
Therefore, it rhnr la.antigens play an important roie in selecting: theT-ceil
repertoire during ontogeny as weil as during postthymic maturation. a concept
which is further extended by the results of Sredni and Schwartz (1980) demonstrat¬
ing T-ceil clones specific for DNT?-ovalbumin that "cross-react""with. allogeneic la
antigens.Although these results are consistentwith a"T-ceilhole" theory, it remains
possible that within the constraints, imposed by the available T-ceil repertoire,
determinant selection still occurs and may be controlled by the la. antigens of the
APC.. a concession made also by Ishii and co-workers (1983). Further evidence for
determinant selection has. been provided by Werdeiin (1982VHeber-Katz and co¬
workers (1982).RocicandBenacerra£( 1983), and Maris and co-workers (1983). The
common denominator in all of these latter experiments is that there is a
demonstrable, albeit subtle, interaction directly between class II molecules and
antigen. Therefore; determinant selection may play a viable roie in the selection of
responsive T-ceil clones, subsequent to thymic differentiation.
In this context we have demonstrated that monoclonal human T cells which
recognize distinct antigenic determinants on the same HA molecule are controlled
(restricted) by different HLA-D region epitopes. The details regarding the fine
specificity of these clones have been presented elsewhere (Lamb et aL 1982c) and are
only summarized herein. Clearly, HA1.9 and HA2.43 recognize different antigenic
determinants from each other as weil as HA1.4 and HA1.7, although it has not been
possible to determine whether HA1.4 and HA1.7 do in fact recognize the same
determinant on the HA molecule. In any event, the determinant!s) recognized by
HA1.4 and HA1.7 is quite different from that recognized by the other two HA-
specific TLCs and the restriction patterns for the four clones suggested that different
genes may be controlling responses depending on the antigenic determinant
recognized. If HA1.4 and KA1.7 recognize the same determinant then identical
restriction patterns for these clones would be expected and are in fact what was
observed. Such, an expectation wouid also hold if HA1.4 and HA1.7 were derived
from the same parental ceil in the original priming culture.
It was somewhat surprising that no dear correlation was found between the
restriction patterns of the clones and any one D-region specificity such as DR, D, SB,
DC, etc. To investigate this further, we attempted to block TLC activation with
MoAbs against various ciass II molecules. We thought that ifa MoAb recognized a
DC-framework epitope, for example, and preferentially interfered with clonal
recognition, we couid then infer something about the subclasses of la-like antigens
controlling human immune responses. This is in fact what occurred although the
conclusions must be qualified by the reservation that anti-ciass II MoAbs are of
heterogeneous avidities, "cross-reactive" in the extreme and capable of exerting
effects at the level of other interaction structures (e. T4) or the TLC itself.
Resolution of these problems awaits a more suitable experimental system in which
monoclonal antibodies against human ailotopic sites are available Also becoming
increasingly clear is the fact that the framework epitopes recognized by most
currently available MoAbs are represented on multiple class II molecules (S. M.
Goyert and J. Silver, personal communication). Nevertheless, if the clones, HA1.4
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andHALT, recognize-the sameanrigenic determinant andare restricted by thesame
class U epitope, the patterns of inhibition with, anti-class II MoAbs should be
identical. Since identical! blocking patterns were observed our results would
thereforesupport this interpretation with the caveat thar the determinant structure
of peptide 20 needs further clarification to ascertain whether HA1.4- and HA1.7
recognize different determinantswithin the p20 fragment. Thatmultiple recognition
sites can be found in the p20 region of the HA1 molecule is borne out by the
observation that HA2.4-3 recognizes both p20 and A/Japan/305 (Lamb et aL 1982c)
whileHA1.4 and HA1.7 recognized only p20. Ofinterest is the fact that responses to
p20 presented by APCs from donor 22 were not blocked by the MoAb IVG1 while
responses in the presence,of autologous APCs were blocked. These results suggest
that either the MoAb binds to different sites on different class EL molecules or that
different sites are recognized as restriction elements depending on the APC/TLC
interaction. In this regard Heber-Katz and her colleagues have shown that single
amino acid differences in the antigen can be crucial for T-cell recognition of antigen
(Heber-BCatz et aL 1982, Matis et aL 1983). Our results would be consistent with
subtle interactions taking place at the level of the T-ceil receptor and the APC class
II molecule. However, whether the same class II epitope acts to restrict responses to
a given antigenic determinant still remains to be resolved. This question awaits
resolution within a single individual as well as the whole population.
Therefore our data would be consistent with a determinant selection typemodel
if it is first recognized that the clones derived have already undergone thymic
maturation, obviously in the presence of self class II antigens. Thus, an antigen or
peptide fragment in association with different class II molecules would be expected
to be recognized by different clones of T cells, each recognizing that antigen in a
slightly altered context. Unlike other experiments with polyclonal T ceils, these
speculations need not be tempered by such concerns as those raised by Sercarz ana
his colleagues (reviewed by Goodman and Sercarz 1983) demonstrating that
different antigenic determinants eiicit specific and potentially antagonistic effects on
T-ceil populations. Indeed, T-ceil clones should provide an ideal approach to such
questions as they would facilitate studies of the isolated TLCs induced by different
determinants which could then be further studied for interactive effects in cocuiture
assays.
Although great strides have been made recently in the murine system, the
fundamental mechanisms operating in human genetic restriction and Ir gene
phenomena remain largely unknown. Accumulating data strongiy suggests that the
human genome contains many class II sequences (Mawas 1983). Since it is
impossible to develop congenic human lines for the purpose of isolating and
studying human class II antigenic function, TLCs should prove on ideal link
between structural and functional investigations. The subtleties of T-ceil re¬
cognition may seem esoteric at first glance; however, in view of evidence that so-
called I-J determinants may exist as covert determinants on the I-A and/or the I-E
beta-chains (Baxevanis et ai. 1983, Ikezawa et aL 1983) and can act as restriction
elements for suppressor T-ceils, we can only assume similar mechanisms will be
found to operate in man. Shouid this prove out in the laboratory, the ciinicai
ramifications for MHC-linked diseases are obvious and thus human TLCs may be
the oniv tool for dissecting such complex structural and functional relationships.
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Fig. 1 Proposed scheme for HOC! production by human PMNs
and its reaction with TMB.
20 •AO 60
Fig. 2 Oxygen uptake and chiorination by normal human PMNs
(2.5x10° ceiis per rai: prepared as previously described"', in
HH?5S-butTered saline {pH 7.4. 37 eC> containing '^C-TMB
(l.Ox The ceils were stimulated with polystyrene beads
I.0.S2 pun diameter: concentration = l.i x 109 beads con¬
taining adsoroed pnorooi myristate acetate 150 ng per 1010 beads).
Oxygen concentration was monitored wTth a Gark oxygen eiec-
troae. Chionnation was mor.itorea by removing aiiquots" ana
measunng the concentration of TMB and TMBCI in each. Each
aliquot was brieriv sonicated tc disrupt ail ceils, allowed to stand
for 10 nun (optional), treated with excess sodium thiosuipnate ana
cenrriiuged at 13,000g for 2 mm to peilet the polystyrene beads.
The supernatant was passed through a Waters Cis Sep Pac pre-
coiurnn followed by 6 mi of water and 6 mi of methanoi. A mixture
of unlabeilea standards iTMB and TMBG) was added to the
methanol fraction, which was evaporated under a stream of
nitrogen at 35 °C to a final volume of 200 ui. 20 id of this solution
was analysed by HPLC (Altex Ultrasphere ODS column. 4.6 x
250 rami using isocratic eiution with acetomtnie/water (45:55):
LTV absorption was monitored at 216 nm. The column effluent
was divided using UV detection of the uniabeiled standards as a
guide ana the C-activity of each fracnon was measured by liquid
scintillation counting.
molecuies (such as proteins) for the available chlorinating
agents3'13. Indeed, chiorination of TMB (10"^M) with HOG
(10~*M) was 95% suppressed in the presence of 5x10"'M
bovine serum aibumin (BSA). As this concentration of 3SA is
also present in the PMN buffer medium. 3SA aimost cenainiy
competes with TMB for some of the PMN-generated chion-
nating agents. The fact that chiorination by PMNs is not more
fully suppressed by BSA suggests that much of the observed
chlonnanon may be occurring intracelluiarly.
Gilonnation by PMNs from a patient with chronic
granulomatous disease was aiso measured. 3ecause of a genetic
defect, such PMNs fail to exhibit a respiratory burst1. Consistent
wnh the scheme shown in Fig. I, we could detect no (that is,
=sS nraol per 107 ceils) TMBG production by these ceils.
Mveioneroxidase-dencent PMNs or aziae-treatea normai
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PMNs are also dericient in their ability to chlorinate TMB (data
not published).
These results demonstrate the formation of strong chlori¬
nating agents by stimulated PMNs on a similar time scaie to
that of expression of microbicidal activity. As the precursors
of the chlorinating agents (for example, MPO/H20-/G~)
appear to be localized in the phagocytic vacuole1"5, our resuits
support the argument'"1,4 that chlorinating agents provide at
least one strong microbicidal agent in the intact PMN. This
new assay shouid prove generally useful for studying the meta¬
bolism ana microbicidal function of normal and defective
phagocytes.
We thank Richard Root and Julie Metcalf of Yale Universirv
for help with some of the chiorination assays. This work was
suDoorted by USPHS grants GM-20080, CA-30526 ana AI-
16252.
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SB-restricted presentation of
influenza and herpes simplex
virus antigens to
human T-Jymphocvte clones
David D. Eckels*, Phil Lake"", Jonathan R. Lamb'",
Armead H. Johnson*, Stephen Shawi,
James N. Woody? & Robert J. Hartzman?
"Vincent T. Lomoardi Cancer Research Center and the
Departments of Pediatrics and Microbiology, School of Medicine,
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The HLA-D region of the human raaior histocompatibility
complex (MHC) has been shown to be homologous to the
murine / region in terms of both structure and function. Both
regions encode class II MHC molecules which restrict T-
lymphocyte interactions with antigen-presenting ceils. We have
recently described the MHC restriction and antigen specificities
of human T-lympnocyte clones directed at strain A influenza
virus1"3. The majority of T-iyraphocvte clones recognized anti¬
gen in (he context of ceil surface interaction products encoded
by HLA-DtDR genes. However, a few clones recognized anti¬
gen presented by ceils histoincompatibie for D/DR antigens.
We report here that some of these clones recognize rind anti¬
gens in association with antigens encoded by genes identical
with or closely iinked to the recently described secondary B-ceil
{SB) locus of the MHC*'5. This is the first report that SB-
restricted antigen recognition may form an integral part of
normai. human immune responses.
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Peripheral blood lymphocytes (PBLs) from donor 144 (HLA-
Al; B8; DR1, 3; Dwl, 3; SB2, 4) were primed in vitro with
the strain A influenza virus A/Texas/l-77/x-49. Lymphoblasts
were enriched on a Percoll gradient and cloned by limiting
dilution in the presence of T-ceil growth factor, antigen and
irradiated autologous PBLs. Details of the cloning protocol,
growth, pnenotyping, antigen specificities and the behaviour of
subclones have been described elsewhere1*2. Assays for antigen
presentation using histocompadble and histoincompatibie PBLs
required fractionation of the presenting cells into T (E~) and
non-T (E~) fractions by resetting with sheep erythrocytes
treated with S-2-aminoethyiisothiouronium bromide hydro-
bromide as described previously1. Proliferation, as correlated
with incorporation of tritiated methyl thymidine, was assessed
by liquid scintillation spectroscopy. Responses were categorized
as positive or negative based on the kurtosis test for response
outliers as described previously2. In our system, T-lymphocyte
clones do not respond to presenting ceils in the absence of
specific antigen1"2.
The A/Texas neuraminidase-spetific T-lymphocyte clone,
FL1-71, was assayed for.proliferation to influenza A virus




cell ' D-region phenotype Responder cell (c.p.m.)
DR D SB FL1-71 CTLL A CTLL B
1077* 3,5 3,5 4,4 124 21.911 6,291
10727 5,4 ■ 5, DB3 2,3 6.288 • 5.293 10,095
1003 3,5 3,5 4,2 3.379 16,783 6.680
1074 5,5 5,5 4,2 4.056 9,846 9,535
1078 3,5 3,5 4,2 3,795 19,675 8.561
1073 3,4 3, DB3 4,3 48 18,566 5.526
144i 1,3 1.3 2,4 1.452 27,634 805
101 5. 63 5,6 2.3 8,234 8.954. 6,637
1023 1,4 1,10 3,4 93 25.697 4.911
1022 2,4 12.4 6.7 298 6,026 10,554-
PBLs from donor 144 (HLA-A1; B8; DR1,3; Dwl, 3; SB2.4) were
suspended at 5 x 103 per ml in RPMI 1640 medium containing 10%
screened, pooled human A"" plasma, 2 mM L-giutamine, 25 mM
HEPES buffer. 50 u.g ml-1 gentamicin, 25 IU ml"1 Na-neparin. 1 mM
Na-pyruvate and 5 haemaggiutinating units (HAU) per ml of influenza
A/Texas/l-77/x-49 (Lot no. 53142; Merck. Sharpe andDohme). After
6 days at 37 *C in 5% C02, responding lymphobiasts-were doned by
,;miting dilution at 023 ceils per well in 60-wpll Terasaki microntre
ates; each well contained 20 id of medium as above and 20% T-ceil
growth factor (TCGF). TCGF was obtained from screened donors by
sumuiating irradiated PBLs with 0.1% v/v purified pnytohaemag-
glutinin (PHA) for 48 h and collecting the supernatant. Generally, 107
to 10 cells can be obtained from each T-lymphocyte done using
described protocols1. For assessment of antigen-spedfie stimulation,
5-10 x 103 cloned ceils and 5-10 x 103 E~ antigen-presenhng cells were
added together in triplicate to 200 pi of supplementedmedium contain¬
ing 5 HAU of virus perml in 96-well; U-bottom plates. After incubation
for 3 days each well was pulsed with 1 p.Ci of tritiated methyl thymidine
and incubated overnight. Cultures were collected onto glass fibre filters
and the radioiabel incorporation was measured by liquid sdntillation
spectroscopy. The data are expressed as the mean of triplicate cultures.
The standard error of each triplicate averaged less than 20% of the
mean and is therefore not presented. Additionally, as no ailoreactivity
has ever been observed with this system, controls of the responding
T-cell plus presenting ceils without antigen have been omitted. The
ceil line CTLL A was derived from donor 144 primed in vitro to
influenza as above and expanded in TCGF to providea positive control.
The cell line CTLL B was also derived using PBLs from donor 144
except that the ceils were primed against a pool of irradiated allogeneic
PBLs from five different donors before expansion in TCGF. Detailed
descriptions of the cellular typing protocols used to detect HLA-D and
SB antigens are found in refs 3 and 4.
* Father.
t Mother.
i Autologous control (TLC donor) and positive control tor CTLL A
and negative control for CTLL B.
presented by E" cells from a family in which the SB2 locus
was segregating (Table 1). Within this family, FL1-71 gave
significant proliferation only in the presence of SB2" presenting
ceils. The responses to antigen presented by SB2" ceils (1077
and 1073) were 12= 21 and 48= 14 c.p.m-, respectively. In
contrast, cells from donor 1077 and 1073 were able to present
antigen to a non-cional cell line reactive to influenza A (CTLL
A) and stimulate an alloreactive cell line (CTLL B) sensitized
to a pool of allogeneic donors. (Both these primed responrier
cell lines were derived from donor 144.) Thus the presenting
cells from donors 1077 and 1073 failed to collaborate with the
T-lymphocyte clone FL1-71 although they were functionally
intact. Responses to autologous (144) presenting ceils and an
unrelated SB2~ individual are also shown in Table 1 as well as
the lack of response to rwo SB2" individual*. 1023 and 1022.
Somewhat surprisingly, CTLLA appeared to recognize'antigen
in conjunction with presenting ceils from donor 1022 even
though there exists no apparent D-region compatibility (Tabie
1). However, one of the T-iymphocyte ciones which has been
previously described1*2 as DRl-restricted (FL1-6) aiso recog¬
nizes antigen presented by E~ cells from donor 1022; this result
has been published elsewhere6. We postulate that 1022 shares
an epitope with DR1" individuals that is undetectable by con¬
ventional means or, more likely, that recombination within the
D region in donor 1022 has occurred. Both alternatives are
under investigation. Tnese data suggest that donors-144 and
1022 share some common presenting element, but such a
finding-does not alter the results suggesting that FL1-71 may
be restricted by an antigen associated with SB2.
Although no recombinant families with cross-overs isolating
SB2 from D/DR are available, the statistical data from unre¬
lated cell panels indicate an extremely tight association between
SB2 and positive responses by FL1-71 (P < 3 x 10-4 by Fisher's
Table 2 Contingency analysis of associations between FL1-71
responses and various D-region antigens
Sperifici ry
of Fisher's Corrected
presenting FLl-71/antigen exact probability
cells +/+ -r/- -/+ ■-/- probability (n -19)
DR1 2 3 5 6 0.635 NS
DR2 0 5 1 10 0.688 NS
DR3 0 5 5 6 0.106 NS
DR4 2 3 3 S 0.861 NS
DR5 2 3 2 9 0.937 NS
Dw6 1 4 2 9 0.786 NS
DR7 0 5 0 11 1.0 NS
DRw8 0 5 1 10 0.688 NS
Dw9 0 5 1 10 0.688 NS
DwlO 0 5 1 10 0.6SS NS
Dwll 0 5 0 11 1.0 NS
Dwl2 0 5 1 10 0.688 NS
SB1 0 5 4 7 0.181 NS
SB2 5 0 0 11 2.289 x 10~* 4349 x 10"3
SB3 2 3 2 9 0.937 NS
SB4 3 2 10 1 0.214 NS
SB5 0 5 0 11 1.0 NS
SB6 0 5 1 10 0.688 NS
SB7 0 5 1 10 0.688 NS
In panel experiments. E~ antigen-presenting ceils from 16 unrelated
donors and the autologous control (144; HLA-A1; B8; DR1, 3: Dwl,
3; SB2,4) were tested for their capacity to present influenza A/Texas/1 -
77/x-49 to the T-lymphocyte clone FL1-71. Proliferation assays were
performed as described in the legend to Table 1. Representative data
can also be seen in Tabie 1. Responses were classified as positive or
negative based on a test for outliers using the kurtosis statistic as
described previously2. The data were divided into positive and negative
responses and the results were analysed in a 2x2 contingency tabie
and the probability of association (P) between D-region alleles and
positive responses by FL1-71 was computed using Fisher's exact test.
Although only a small panel has been tested, the results with SB2 are
highly significant but they do not prove identity between SB2 and the
interaction product recognized by the done. NS, not significant.
Lhi i EHSTu NATLRE-
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Table 3 Responses of an HSV-speanc. S3-restnc:ed T-iyrnpnocyte
clone
Phenocype Proliferative response ic.p.ra.)
Donor DR D SB A53—media A53 — HSV
1053 3,7 3, 7 1. ? 49 55
101 5, 6.3 5, ? . ■ 2.3 7S 36
1022 4. 12 4. 2 6.7 1.460 1.057
1199 3.? 3, 5 1.4 468 21.287
1003 3,5 3, 5 2,4 90 19.837
144* 1,3 1.3 2.4 47 4.616
1011 1,? 1. 4 2,4 24 12.915
1023 1.4 1.10 3.4 51 3,663
1005 2,7 2,7 4, ? 21 14.204
506
. 4,6.1 4.? 4, ? 159 18.531
694 1.5 ND 4, ? 151 19.385
1009 2,7 2. 7 4 47 19.120
9999 ND ND 4, ? 191 15.041
PBLs from donor 144. (HLA-A1; B8: DR1, 3;Dwl. 3: SB2, 4) were
pruned to- UV-inacuvated iysates of HSV-inxected VERO ceils and
cloned in a protocol as described in Table 1 legend. For assay, 10* of
the cloned ceils, were added to 10* irradiated E~ antigen-presenting
ceils from 13 unrelated donors (including the autologous controi, 14-4)
who were previously typed for HLA and SB antigens. Culture con¬
ditions and assay procedures were identical to those described for the
influenza system. Clone A53 gave positive responses oniy in the pres¬
ence of antigen and S~ ceils bearing S34. The presenting cell. 1022.
appeared to be stimulatory even in the absence of antigen and was
therefore considered negative reiative to other ceils giving specific
responses.
ND, not done.
" Autologous control (TLC donor;.
exact test: Table 2). Even if this value is corrected by the
number of antigenic specificities typed for (n = 19), the result
remains highly significant.
In another system. T-lymphocyte clones were generated from
the same donor (144.) against herpes^simpiex vims (HSV) ana
one clone was identified (A53) which appeared restricted by
S34 (Table 3); ess&ntiaily background level responses were
obtained when. S34^ antigen-presenting ceils were used to
present HSV to A53. Such data from two different antigen
systems confirm the generalization that the SB region may
indeed encode functional interaction products. However, even
though such data reveal a high degree of association they-do
not. at this stage, prove identity between SB2 and the interac¬
tion product recognized by the clone.
At present, there is no apparent correlation between restric¬
tion specificities and the antigen specificity or function of the
T-lymphocyte clones. However, further experiments are
required to define the compiete functional capabilities of S3-
region products. Although a clear functional dichotomy exists
for molecules encoded by /-A and l-E in the mouse, this is
not the case for SB and DR which both appear to code for
/-c-like a and (3 chains7. Other data from our laboratory
suggest that both D/DR and S3 may comprise gene clusters
encoding multiple ceil-surface, class II molecules3'8. Further¬
more, it is not yet known whether such products can associate
on the ceil surface to form functional interaction products or
complex ailoantigens as has been described for the {-A* ana
1-3" chains9. We are now using T- lymphocyte clones to dissect
the human MHC to investigate the role of different ciass II
ailoantigens in controlling immune responses to denned anti¬
genic determinants. This approach is based on the hypothesis
that multiple D-region products, probably encoded by immune
response' genes, interact to control the response of any given
T ceil to particular antigenic epitopes.
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An inherited polymorphism in
the human apolipoprotein A-I
gene locus related to the
development of atherosclerosis
Sotirios K. Karathanasis, Robert A. Norum1",
Vassilis I. Zanni.s Sl Jan L. Breslow
Metabolism Division. Children's Hospital Medical Center, 3oston.
Massachusetts 02115. USA and "Cinicai Genetics Division.
Henry- Ford Hospital. Detroit, Michigan 48202, USA
Epidemiological studies have identified elevated low density
Lipoprotein (LDL)1"3 and diminished high density lipoprotein
(HDL) cholesterol levels"5"* as risk factors for coronary artery
,disease. The major protein component of HDL is apoprotein
A-I iapo A-D. a polypeptide of 243 amino acids of known
primary amino acid sequence5. This apoprotein serves as a
cofactor for the plasma lecithin—cholesterol acyltransferase
(LCAT) enzyme responsible for the formation of most
choiesteryi esters in plasma, and also promotes cholesterol
efflux from ceils3,7. The primary translation product of apo A-I
contains both a pre and a pro segment3, and post-translarionai
processing of apo A-I may be involved in the formation of the
functional plasma apo A-I isoproteins9"10. Defective apo A-I
processing may be the underlying problem in Tangier disease"1,
in which patients have low plasma HDL and apo A-I leveis
despite normal apo A-I synthesisLZ"13. Patients have been repor¬
ted with conditions distinct from Tangier disease in whom
severe deficiency or absence of. apo A-I has been associated
with very low HDL leveis and severe coronary artery dis¬
ease1*"". We have now examined the apo A-I gene in two such
patients and their first degree relatives. These patients have
been reported to have skin and tendon xanthomas, corneal
clouding and severe premature coronary atherosclerosis associ¬
ated with very low HDL leveis and deficiencies of two
apoproteins, apo A-I and apo C-ITI13. We show that both
probands are homozygous for a defect in the apo A-I gene locus.
We have previously reported the isolation of apo A-I doubie-
stranded ids) cDNA clones from an aauit human liver cDNA
library"6. One of these clones (pAI-113) carnes an insert having
a DNA sequence corresponding to the 3'-untranslated region
and extending in the 5' direction to the codon representing the
94th ammo acid of apo A-I. This done was used to prepare
the apo A-I probe for the experiments described here. Figure
I shows the hybridization patterns obtained by restriction diges¬
tions of chromosomal DNA prepared from a normal individual
and from one of the apo A-I-dencient patients after biocting"
and hybridization with the apo A-I probe. In the normal
individual the probe hybridized to a unique 12-kiiobase (kb;
EcoRI fragment, whereas EcoRI-digested DNA from the
patient hybridized to a unique 6.5-kb band. To examine further
the molecular basis of this difference, we performed genomic
blot analysis of normai individuals and both probands snowing
apo A-I deficiency using various combinations of restriction
enzymes (Fig. I). The sizes of the DNA fragments hybridizing
to the aoo A-I probe are shown in Fig. 1 and have been compiiec
in Table 1. .As can be seen. EcoRl and Psrl either singly or ;n
combination with other enzymes produce fragments of different
size when DNA from normal individuals and apo A-I-defic:enc
0023-0836/83/080718—33 501.00 3 19S3 Macnilan Journals L:3
NATURE VOL. 31? JANUARY :98S
LETTERSTONATURE- 61
Funcrional expression of HLA-DP
genes transfecred into mouse fibroblasts
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The HLA class II antigens are a highly polymorphic family of
dimeric ceil-surface glycoproteins, expressed predominantly on
the surface of immunocompetent ceils. They are intimately involved
with the induction of the T-ceil response to extrinsic antigenI—t
ana are important predisposing factors for a wide specrrum of
autoimmune diseases5. We describe here the expression of a class
II product from the HLA-DP (new WHO nomenclature, formerly
53) subregion after transfer of cloned genes into mouse fibro¬
blasts. The transfected DP antigen is recognized by several HLA
class II monoclonal antibodies and. though present in a mouse
ceil background, is able to function in the presentation of influenza
antigen to cloned DP-restricted human T lymphocytes.
Molecular cioning studies show that the HLA class II region
contains a minimum of six a-chain3 and seven $-chain genes,
which on sequence analysis can be resolved into the three
subgroups—DP (formerly SB), DQ (formeriy DC) and DR—
denned by serological and celluiar typing (for a review, see
ref. -i). The DP region, originally defined by primed lymphocyte
typing', contains rwo a and two j3 genes arranged in the order
DPQ2, DPccl. DP$ I, DPcrl (ref. 8). The products of this com¬
plex, cioseiy linked ana higniy related gene family are normally
expressed coordinateiy, posing problems in attributing structural
features, such as antigenic epitopes, and functional properties,
such as T-cell recognition, so any one antigen. The transfcction
and expression of cloned genes is thus a useful approach to
characterizing the structure and function of each product in
isolation.
Expression after gene transfer of . both human and mouse
major histocompatibility complex (MHO class II genes has
been reported*'tZ. In the mouse, the functional activity of the
transfected molecules was also investigated and the caoacity of
B-ceil lymphomas10, interieron-induced macrophages11 and L-
ceil fibroblasts1* to present antigen aftertransfection was demon¬
strated. The B-ceil transfcctants were also shown to enect ailo-
stimuiation10 and the L-cell transfectants to act as targets for
allogeneic killing12. The present experiments aimed to demon¬
strate the expression of human HL.A-DP genes in mouse L ceils
ana to determine their abiiitv to activate DP-restricted infiuenza
virus-specific T ceils.
The cosmid clone JGSa, isolated from a library of placental
DNA. contains two DPa-related genes and one DP$-relatea
gene3 (Fig. 1). The genes were introduced into mouse L ceils by
co-precipitation with calcium phosphate followed by selection
for thymidine kinase (TK). .An initial analysis of TK" transfec¬
tants for expression at the messenger RNA level showed that
transcription was occurring from ail three genes (data not
shown). On testing mass cultures of JG3a transfectants with a
variety of HLA class II monoclonal antibodies, DA6.231 (anti-
DR, -DQ and -DP) gave consistent, above-background staining
on flow microfluorimetry analyses using the fluorescence-acti¬
vated cell sorter (FACS). This antibody was then used to seiect
for cransfectants with comparatively high leveis of DP
expression, either by FACS sorting or screening of primary TK"
transfectants. The experiments described here analyse the anti¬
body-binding patterns and functional activity of one such selec¬
ted line.
The pattern of antibody binding to the DP transfectants is
illustrated by the data from FACS anaivsis and from an enzyme-
linked immunosorbent assay (ELISA) (Fig. 2a, b). The results
show positive binding of four HLA class il monocionai anti¬
bodies, DA6.231 (anu-DR. -DQ ana -DP), TU39 (anti-DR, -DQ
and -DP), SG171 (anti-DR. -DQ and -DP) and 37/21 (anti-DP.
onginaily ami-FA. see below and ref. 13), but oniv background
binding with DA6.164 (anti-DR), L203 (anti-DR), TU22 (anti-
DQ, possibly aiso anti-DR) and MHM4 (classified as anti-DP).
The locus specificity attributed to these antibodies is based on
binding studies of y-irnidiation-induced B-ceil deletion mutants
selected for loss of class II expression105 and immunochemical
analysis on two-dimensionai geis'3''6. In the case of DA6.231,
Fig. 1 Schematic maps and transfec¬
tion of cosmids JG3a and LCI A Cos-
mid JG3a contains two DP-region a-
chain genes and one B-chain gene. The
restriction sites for EcoRl and Nrul
are shown. Further details have been
published elsewhere3. Cosmid LCI*'6
contains an incomplete DQa gene and
a DQ8-reiatea gene found on EcoRl
fragments of 5.5 and 18 kb as shown.
Methods: DNA was introduced into a
subline of LTK~ ceils previously
shown to give good surface expression
of transfected HLA-DR genes'. The
technique adopted was that of co-preapitation with calcium phosonate"7 using purified cosmid DNA and LTK" carrier DNA at a tinai
concentration of 15 ngmi"' transfection cocktaii. The precipitate was added to LTK" ceils, seeded at a density of 0.5 x 106 ceils per 9-cm
dish, and given a fresh cnange of Duibecco's modified Eagie's medium (DMEM) with 10% fetai caif serum : FCS) a h before transfection.
0.b6 ml of transfection cocktail was added to 5.5 mi medium in each dish and after -t-iOh incubation at 37 °C. 10% CO-, a giyceroi shoe*
was given. The ceils were overlaid with 25% giyceroi in DMEM for 1 mm before washing and adding !0mi DMEM with 10% FCS and
5 mM sodium butyrate"8. .After a further 12 h incubation, the medium was changed to selective medium containing 15 |igmi~' hypoxanthine.
0.2 ug mi"1 methotrexate and 5 p,g rai"' thymidine. The cells were subsequently maintained in this medium with changes every 3—- days. TK
colonies were visible after —12 days and were either removed by trypsinization to form a mass culture or trypsimzed individually using cioning
rings. DNA used in the transfection experiments to produce the lines described was as follows. LSa.5: 5 u.g JGSa cut with Nrui, i ag pOPF
.cut with EcoRl. 5 ag LTK" DNA: LpOPFm: I u.g pOPF cut with EcoRI. 9ug LTK" DNA: LJ4m: 2 ag LCIA 3 u.g LTK" DNA. The
co-transfecnon procedure used to produce LSa.5 reduced the efficiency of TK" coiony formation at least 10-foid wniist improvtng the leveis
oi DP expression observed in the resulting transfectants. The .Yrui digestion linearizes the cosmid and destroys thymidine kinase activity,
while cutting at the EcoRl site at the 5' end of the tk gene truncates important reguiatory sequences and reduces transcription ieveis. Use oi
this EcoRl fragment has been described in constructs to promote high copy number integration"'. The line LSa.5 was derived from a single
TK colony and selected for further study on the basis of comparatively high ieveis of DP expression. Southern blot analyses demonstrated
the high copy number of integrated sequences found (data not shown/. The lines LpOPFm and LI4m are mass cultures derived irom —100
colonies and are used as controls in subsequent experiments. Before experimental analysis, the L ceils were incubated for 16-24 h in medium
containing 5 mM sodium butyrate, a procedure found to enhance levels of DP expression.
MSV-TK DP s.2
3" 5' 5" :
Vector pOPF
HSV-7K DQ a
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Fig. 2 Surface expression of DP antigen by transrected mouse L
ceils, a. Flow microfluorunetry analyses of the transfectants LSa.5
(thin lines; and LI4m (thick lines; using a panel of monocionai
antibodies to HLA class II determinants and an ann-H-2* class I
antibody. Fluorescence intensity is plotted as a linear function of
cell numoer and 10,000 cells were analysed for each histogram, b,
ELISA assay for binding of HLA class II monoclonal antibodies
to the EBV-transformed lymphoblastoid ceil line LNAT (C) and
L-ceil transfectants LpOPFm (•) and LSa-5 (▲).
Methods: a. 1 x 10® cells were washed with cold phosphate-buffered
saiine (PBS) containing 5% fetal calf serum (FCS) and incubated
with 100 pi of antibody diluted in PBS-r5% FCS for 30 nun on
ice. All HLA class II antibodies were used in the form of ascites
fluid diluted I in 200: 11 4.1 was used as a hybridoma supernatant
diluted 1 in 2. Ceils were washed three times in cold PBS—5%
FCS and incubated for a further 30 nun on ice with a I in 10
dilution of fluorescinated IgG fraction rabbit ann-mouse IgG (Cap-
pel Laboratories). .Aftertwo anal washes the cells were resuspended
in cold PBS and analysed on a FACS-1 (Becton <3c Dickinson), b,
Ceils were washed three times in PBS and added to 96-well plates
pretreated for I h with 0.1 mgml"' poiv-l-lysine in PBS (l(r cells
in 50 M-i PBS per well). The ceils were spun onto the base of the
wells and then axed by gently adding 200 pi per weil 0.025%
giutaraidefayae in PBS and standing at room temperature for
20 min. After washing, the plates were stored at 4 °C in a solution
of 200 q.gmi~' gciatin. 0.02% NaN3 in PBS. 3efore adding anu-
body, the ceils were treated with 0.1% pheny[hydrazine in PBS
for I h and then washed in PBS (3x) and once in PBS->-0.2%
Tween 20. Antibody ascites, diluted at I in 500 in PBS —5% FCS
and at subsequent five-fold serial dilutions, were added to the ceils
at 50 pi per weil in triplicate and the piates were incubated at room
temperature for 2 h. The ceils were washed (as above) and then
incubated for 30 min with 25 ixl per well 5% goat ami-mouse
immunoglobulin (Central Laboratory of the Netherlands Red
Cross Blood Transfusion Service) in 200 mM Tris-HCl pH 7.6 with
10% normal goat serum (NGS). After further washes the piates
were incubated for 30 min with peroxidase-anuperoxida.se immune
complexes (PAP) in Tris-HCl 7.6-e 10% NGS. After final washing,
substrate (1 mgmi"1 o-phenyienediamine, 0.05% H;0- in suo-
strate buffer, 156 mM Na3HP04, 27 mM citric acid pH 6.0) was
added (100 p.1 per well) and the piates were incubated in darkness
for 30 mm. Absorbance at 450 am was read on the Titer Muitiscan.
Results are expressed as the mean of triplicate weils.
TU39, SG171, TU22, L203 and DA6.164, the binding results for
the DP transfectants strengthen the argument for these iocus
assignments. Positive binding of B7/21 supports the view that
this antibody detects DP-region rnoiecuies17, previously termed
FA12. Conversely, the lack of binding by the MHM4 antibody
questions its specificity for DP, although it may weil recognize
the DPQ2 product or a polymorphic DP$[ produce not
expressed by the transfeoants. These results emphasize the vaiue
of such transfectant lines in elucidating the compiex cross-
reactions of HLA class II antibodies. Accurate quantitation of
the level of surface antigen expression relative to tnat seen on
B-ceil lines is difficult because of these cross-reactions. However,
comparison of mean fluorescence leveis observed on binding
B7/21 to the B-ceil line LNAT suggests that surface expression
is approximately fivefold lower on the DP transfectants.
The presence of the DP antigen was confirmed biochemically
by immunoprecipitation using the monocionai antibodies SG171
and B7./2I coupiea with rwo-dimensionai non-equilibrium pH
gradient electrophoresis/sodium dodecyi sulphate poiyacryi-
amiae gei electrophoresis (NEPHGE/SDS-PAGE) analysis.
Figure 3 shows the two-dimensional partem of l25I-labeiled
polypeptides derived from microsomes of the mouse L cells
(Fig. 3a) and the L cells transfected with cosmid done JG8a
(Fig.3b). In addition to the nonspecific polypeptides found in
both cells, the monocionai antibodies predpttated a singie puta¬
tive a-chain of relative molecular mass (Mr) 30,000-32,000 and
at least two possible /9 subunits of. 29,000-32,000 from the
DP-transfected cells. The identification of these spots is based
on the isoelectric points and M. positions previously found for
HLA-D region antigens17,18. The labelled a-chain spot suggests










Fig. 3 Two-dimensional NEPHGE/SDS-PAGE analysis of
immunoprecipitates using a combination ofmonocionai antibodies
SG271 and B7/21 against mouse L ceils (a) and mouse L ceils
transfeaed with cosmid clone JG8a ( b). Numbers on che left-hand
side represent size markers (Mrx 10~J).
Methods: Microsomes were prepared by shearing the ceils in a
Stansted ceil disrupter, centnfugmg at 1.500 r.p.m. for 5 mm to
remove nuclear deons and finally at 18,000 r.p.m. for 30 min to
pellet the membrane vesicles. The resuspended peilet was labelled
with I2JI by lactoperoxidase-cataivsed iodination32, washed and
then soiubiiized in lysis butfer 11% (w/vl Nonidet P-40 in 10 mM
Tris-HCI buifer pH 8.2 containing !50mM NaCI. 1 mM EDTA
and 1 mM phenyimethyisuiphonyi fiuondej. A glycoprotein frac¬
tion was prepared by binding to Ltns cuiinans lectin ana eiuting
with 10% cr-methyi-D-mannosiae. The lysate (5 x 10' ceil
equivalents) was incubated overnight at 4°C with 5 pJ of ascitic
fiuid of SG171 ana B7/21 before precipitating the immune com¬
plexes with 20 pj of 10% Staphylococcus aureus Cowan 1 strain
(SaCD. Immunoprecipitates were washed twice in lysis butfer
containing 500 mM NaSl and once in lysis buifcr alone. Immune
complexes were eiuted from SaCI peilets by incubating in isoelec¬
tric focusing sampie butfer (9.2 M urea. 2% Nonidet P-iO. 5%
amonoiines pH range 3.5-i0 (LK3) at*50°C for 30 min. Two-
dimensional NEPHGE/SDS-PAGE analysis was done as
described previously30"31.
that, contrarv to the case of the DP a-chain on the surface of
intact 3 cells'" the a-chain in microsomes from the L-ceil
transfectants is accessible to lactoperoxidase-cataivsed iodina-
tion. It is likely to correspond to the DPa 1 gene product, as
the sequence from this gene matches the sequence available for
DPa cDNA clones and protein sequence data3. However, the
data do not exclude concomitant expression of the DPaZ gene.
The presence of multiple /3-ohams probabiy redects stages of
givcosylation;8.
Having established that the JG3a transfectants were express¬
ing a DP antigen at the ceil surface, the L-ceil transfectants were
assayed for their ability to induce proliferation of the ~T-
lymohocyte clone TLC7I in the presence of antigen. TLC71 has
been shown to proliferate in response to DPw2 class II deter¬
minants'^ and the neuraminidase < NA) glycoprotein of induenza
A virus"0. In the presence of intact induenza virus
(A/Texas/ 1/77) or NA CN-, of Papua New Guinea/1/75), the
DP L-ceil transfectant was abie to induce TLC71 to proliferate
(Fig. 4-a;. However, in the presence of an irrelevant antigen,
peptide 20 (p20: residues 306-329 of the HA1 molecule of
induenza haemaggiutimn":) or with DQ tnmsfectants, there was
no response. Neither HA1.7 (DQ restricted and specific for p20)
nor TLC 37 (DR restricted and specific for matrix protein)
T-ceil clones were activated by the L-ceil transfectants. However,
both HA1.7 and TLC 37 ciones proliferated in response to
specific antigen presented by autologous peripheral blood lym¬







Fig. 4 .Antigen presentation assay. The proliferation response of
T-iymphocyte ciones TLC71 (neuraminidase specific, DP-
restneted). TLC37 (matnx protein specific, DR-restncted) and
HA1.7 (peptide 20 specific, DQ-restncted) in the absence of antigen
(coiumn 1), or with intact virus (A/Texas/ 1/77*49 at 5 haemag-
gluunating units mi"'. column 2). or neuraminidase (N- of Paoua
New Guinea/1/75 at 10~3 v/v. column 3). or p20 (l.Oagmi"',
coiumn a). Presenting ceils: a. DP L-ceil transfectants L3a.5 (
(1.25 x 10* mi"'): DQ L-ccil transfectants LUm ( ) (1.25 x
10* mi"1), b, Autologous PBL (— ; (1.25 x I03 mi~!); E3V-
transformed autoiogous B-cell line LNAT ( ) (0.5 x I03 mi }
c, Inhibition of the proliferation resDonse by TLC71 with ami-H LA
Class II antibodies. The assay for the proiiferauve response to
intact virus was performed as before using DP transfectants LSa.c
(▲) and autologous PBL (C) as presenting ceils. .Antibody ascites
was added at the initiation of the cultures in the diiuuons shown,
and left in for the duration of the experiment.
Methods: The isolation ana characterization of T-ivmphocyte
clones TLC71. HA1.7 and TLC37 have been desenbea in detaii
elsewhere :9-20J3"37 Bnefiv, PBL from the donor LNAT were cul¬
tured for 5 days with specific antigen. The lymphooiasts were
enriched on a discontinuous Percoil (Pharmacia) gradient and
resuspended in RPMI-1640 iGibco) containing 10% A" scrum
and 20% interieukin-2 (1L-2) and piated at one ceil every thira
weil in Microtest II travs (Faicon) with iO* irradiatea 2.500 raa)
autoiogous PBL and antigen. .After " days, growing clones were
transferred to 96-weil microtitre trays ana subsequently to 24-wet!
travs. At each transfer the ciones received fresh 1L-2 ana irradiated
PBL together with antigen. The ciones were expanded in 25-cm"
tissue culture fiasks receiving I L-2 every 3 days ana irradiatea
histocompatible PBL and intact virus (A/Texas/1/77) every 7 days.
1 L-2 was prepared from 4g-h supernatants of PBL (1 x 10° mi~'^
cultured with 0.1% punned phytonaemaggiunnin (PHA-P. Ditcoi
in complete meaium containing 2.5% A" serum. The ciones were
used in proliferation assays 6-7 days after the addition of feeder
cells (irraaiated PBL). Coned T ceils (5 x 10* mi"') were cuitured
together with the antigens and presenting ceils described above.
The L-oeil transfectants and E3V-Iine received 5.000 raa and PBL
3,000 rad before use. Following 60 h incubation, the cultures were
puised for 8-16 h with 1.0 p.Cl JH thymidine f3H-TdR. Amersham)
and collected onto glass fibre filters. Proliferation as correiatea
with 3H-TdR incorporation was measured by liquid scintillation
spectroscopy. Results are expressed as the mean counts per mm
of triplicate cultures =s.e.m.
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cells (Fig. 4b). These results show that T-cell activation by the
DP transfectants is both HLA dependent and antigen specific.
To confirm the specificity of the transfected DP molecule in
antigen-induced activation of TLC71, the inhibitory effect of
antibodies to various class II HLA molecuies was tested. Figure
4c shows that the anti-DP antibodies TU39 and B7/21 inhibit
the proliferation of TLC71 whereas TU22 and L203 have no
effect. In a parallel experiment, TU22 (anti-DQ) and L2Q3
(anti-DR) effectively inhibited the response of HA1.7 (De¬
restricted ) and TLC37 (DR-restricted), respectively, to intact
A/Texas in the presence of autologous PBL (data not shown).
Further analysis of the polymorphic specificity ofT-cell recogni¬
tion can now be pursued using both transfectants and T-cell
clones of different specificities.
The capacity of the DP-expressing mouse fibroblasts to
activate human T cells in the presence of antigen indicates
that antigen presentation is not restricted to the
macrophage/monocyte or B-cell lineages. Tnis agrees with our
recent observation that thymocytes expressing ciass II antigens
can activate human T-cell clones12 and also with the results for
the mouse ciass II L-cell transfectantsThe implication is that
either secondary signals such as the secretion of interieukin-I
(1L-I) are not aiways essential or that cells other than classical
antigen-presenting cells such as mouse fibroblasts are aole to
provide them. Similarly, the postulated interactions between the
T-cell surface antigens such as T4 (refs 23,24) and LFA-i (ref.
25) and the antigen-presenting cell are cither not obligatory or
arc directed against targets present on the surface of the L-cell
transfectants. Requirements for T-cell activation may well be
more stringent for primary rather than secondary stimulation
and may also vary with the particular antigen and T-cell clone
involved. However, in the system described, it is dear that
antigen-dependent activation can occur in the absence of any
human cell-surface molecule on the presenting cell, other than
the HLA restriction element recognized by the T-cell receptor.
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Six unrelated HLA-DR-matched adults
recognize identical CD4+ T cell epitopes
from influenza A haemagglutinin that are not
simply peptides with high HLA-DR binding
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Abstract
Influenza A/Beijing/32/92 (H3N2) haemagglutinin (HA)-speciflc short-term CD4+ T cell lines were
generated from six unrelated HLA-OR0701, 1501 positive adults (aged 27-60 years) 3 months
following administration of an influenza subunit vaccine containing HA A/Beijlng/32/92. Epitope
recognition was examined using 118 HA A/Beijing/32/92-specific 16mer peptides which overlapped
by 11 residues and which spanned the entire molecule. Following influenza vaccination the donors
recognized identical HA peptides. The selected peptides represented HA regions which have been
free from extensive drift mutation since the emergence of human H3N2 influenza A strains. Using
DAP OR7.0701 ceils (a murine ceil line expressing HLA-OR0701) as antigen-presenting cells the
majority of CD4"1" T cell response^were shown to be HLA-QR0701 restricted. The relationship
between HA peptide recognition and relative strength of HA peptlde-HLA-DR07Q1 binding was then
explored in a competition assay with biotinylated CLIP peptide. Although peptides representing
dominant HA epitopes bound to QR0701, the relationship between relative strength of binding and
immunodominance was complex, and many strongly binding peptides, particularly those with
giycosylatlon sites and showing inter-strain variation, were not recognized. These results illustrate
the control HLA class II exerts over CD4+ T cell HA epitope selection in unrelated adult humans.
Immunodominancs appears not to be directly related to the relative strength of HA peptide-HLA
class II binding, and thus reflects complex interactions between antigen processing, intracellular
competition for HLA binding, TCR repertoires and repeated exposure to different strains of
influenza A viruses.
Introduction
CD4+ T cells are important in defence against influenza A
virus infection: as well as controlling neutralizing antibody
production (1), they amplify cytotoxic T lymphocyte responses
(2), and may participate more directly in viral clearance by
the secretion of IFN-y and other cytokines (3). Previously we
have examined human CD4+ T cell recognition of influenza
A/Beijing/32/92 (H3N2) haemagglutinin (HA) following natural
infection with A/Beijing/32/92-like strains and demonstrated
that in adults CD4+ T cells principally focus on HA regions
which have not been subject to frequent drift mutation (con¬
served regions) (4). We also found a similar pattern of CD4^
T cell recognition of HA following influenza subunit vaccination
(5). These studies included pairs of unrelated donors who
expressed identical HLA-DR alleles and each pair responded
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to identical HA regions, with only minor variations in the
magnitude of their responses in spite of differences in their
age and exposure to influenza A viruses.
In order to extend our initial oDservations and to explore in
detail epitope selection by HLA class II. we have now exam¬
ined the HA-specific repertoires of six unrelated adults, aged
27-60 years, selected because they expressed identical HLA-
DR alleles (HLA DRB1"0701, "1501). Five of the six donors
also expressea the same HLA-DRW (DRB4*01, *501) and
HL4-DQ alleles (DQA"0101/4, *0501 and DQB1*02, *0601/
2). Short-term CD4~ T cell lines were selected with full length
HA A/Beijing/32/92 (H3N2), prior to and 3 months following
vaccination with a trivalent subunit influenza vaccine con¬
taining HA A/Beijing/32/92. Epitope recognition was examined
using a panel of 118 synthetic peptides 16 amino acids in
length and overlapping by 11 residues, that spanned the
entire HA A'Beijing/32/92 molecule.
Because murine studies using panels of overlapping syn¬
thetic peptides spanning the sequence of staphylococcal
nuclease have reported a strong association between the
strength of CD4+ T cell peptide recognition and peptide
binding affinity for MHC class II (6-8), we then employed a
competition assay, using biotinyiated CLIP peptide, to estim¬
ate the relative binding affinities of the HA peptides for purified
HLA-DR.-This allowed a preliminary analysis of the importance
of peptide-HLA class II relative binding affinity in the develop¬
ment of a hierarchy of immunodominance for human CD4+ T
cell responses to HA.
Methods
Subjects and vaccination
CD4T T cell responses by six unrelated healthy Caucasian
adult volunteers, aged between 27 and 60 years, to HA from
influenza A/Beijing/32/92 (H3N2) were investigated prior to
and 3-4 months following influenza subunit vaccination,
although the pre-vaccination line from donor C was lost in
culture. Subjects D, E and F were originally found by chance
to share HLA class II types. Donors A-C were specifically
cnosen because they were known to have a very closely
matched HLA class II type to donors D, E and F (see below).
HLA-DR and DQ typing was performed using the 'phototyping'
method (employing sequence specific primer PCR) (9).
Donors A-C. E and F expressed identical HLA-DRB1"1501.
*0701, DRB4-01. DRB5*01, DQA1*0101/4, "0501 and
DQB1"02, *0601/2 alleles. Donor D differed only in that he
expressed DQB1*0303 rather than DQB1"02. this is associ¬
ated with the non-expression of the donor's DRB4"01 allele
(10). The following HLA-DP types were obtained by sequen¬
cing: donor B, HLA-DP*0301, *0402: donor C HLA-DP"0201,
*0401: and donor F, HLA-DP*0401, "0402. Donors HLA class
I types, as determined by phototyping, were as follows:
donor A, HLA-A3, B7.13 Cw4,6: donor B, HLA-A1.2. B62.64,
Cw8.304: oonor C, HLA-A30.31. B7.13, Cw6,7; donor D, HLA-
A2. 28, B7.17, Cw6.7: donor E. HLA-A3.23, B7.44, Cw4.702;
donor F, HLA-A2.30, 844.51.
Subjects received 0.5 ml of Influvac s.c., containing 15 pg
of HA from the following influenza viruses: A/Beijing/32/92
(H3N2), A/Singapore/6/86 (H1N1) and B/Panama/45/90
(influenza B) according to the manufacturer's instructions.
The vaccine was kindly donated by Dr R. Branas (Solvay
Duphar, Weesp, The Netherlands).
Peptides and antigens
Highly purified full-length HA derived from influenza A/Beijing/
32/92 (H3N2) was a gift from Dr R Brands. HA from influenza
A/Aichi/68 (the original H3N2 human influenza strain) was the
gift of Dr J. Skehel (National Institute for Medical Research,
Mill Hill, London, UK) and was obtained by bromelain cleavage
of the recombinant influenza A virus X-31. It contained trace
contaminants of other influenza proteins (11).
A series of 16 amino acid peptides overlapping by 11
residues was derived from the nucleotide sequence of the
HA1 subunit of HA A/Beijing/32/92 and the HA2 subunit of
the closely related A/Hong Kong/90 virus, as no sequence
information was available on the HA2 subunit of A/Beijing/32/
92. Unpublished sequence information from both viruses was
kindly supplied by Dr N. Cox (CDC, Atlanta, GA). The amino
acid sequence and method of synthesis of the peptides has
been previously described, and they showed no significant
mitogenic activity on a CD4^ T ceil line specific for Mycobac¬
terium tuberculosis soluble extract (4). In the text peptides
are numoered according to their N- and C-terminal residues,
and peptide pools are numbered by the N-terminal residue
of their N-terminal peptide and the C-terminal residue of their
C-terminal peptide.
CD4+ T cell lines
Short-term CD4+ T cell lines were selected using purified full-
length HA A/Beijing/32792 as previously described (4). In
brief, short-term CD4T T ceil lines were obtained by stimulating
fresh peripheral blood mononuclear cells (PBMC) (5X106/
well) with purified HA A/Beijing/32/92 0.05 ng/ml, in RPMI
1640 supplemented with 5% heat inactivated human AB*
serum (Sigma, Poole. UK), 2 mM glutamine, 100 IU/I of
penicillin-streptomycin at 37° C. 5% CO2. At 7 and 14 days
T cells were re-stimulated with equal numbers of autologous
irradiated (3000 rad) PBMC (freshly thawed, from liquid
nitrogen storage) pre-pulsed with 0.01-0.05 ng/ml of HA A/
Beijing/32/92, and cultured in complete medium at a density
of 1X105T cells/well. Then 10% Lymphocult (Biotest Folex,
Frankfurt. Germany) as a source of IL-2 was added on days
8. 11, 15 and 18. By 21 days of culture, short-term CD4" T
cell lines selected as above are >90% CD3+, 78-88% CD4T
and 2-10% CD8" (4).
Analysis of T cell specificities using overlapping HA peptides
At 14 and 21 days of culture autologous, irradiated (3000
rad) PBMC (4X104 cells/0.2 ml well) were incubated with
whole HA (HA A/Beijing/32/92, 0.01-0.1 ng/ml) or HA peptide
pools (five peptides at an individual concentration of 10 tig/
ml) and cultured with 4X104 responder T cells/well. At 48 h
the cells were pulsed with 1 jiCi/well methyl-[3H]thymidine
(Amersham International, Amersham, UK) and harvested 16 h
later. Proliferation was measured by liquid scintillation spectro¬
scopy. Fine specificity of the T cells was mapped in more
detail with individual HA peptides (5 ug/ml) at 14 and 21 days
of culture as above.
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HLA ciass II restriction studies
At 21 aays irradiated (3000 rac) PBMC from a donor with a
DRB1*0101,0701 DRB4*01 OGB1*02.05 haoiotype (OR0701
donor), and a donor with a DRB1"0408,1501 DRB4-Q1
DRB5*01 DQB1"0301.0601/2 haoiotype (DR1501 donor) were
used to present HA A/Beiiing/32/92 and HA peptides to
developing short-term T cell lines as aDove.
Further HLA restriction studies were conducted on a 2
week HA/Beiiing/32/92-soeciric CD4^ snort-term T ceil !ine
derived from donor 0 as described aDove. HA peptide
proliferation was examined as described above with one
modification: 4X104 irradiatec DAP.DR7.0701 ceils (a murine
fibroblast line which expresses DRB1"0701) were used in
place of autologous PBMC as antigen-presenting cells (APC).
The DAPDR7 line was the gift of Professor R. Lechler (Royal
Postgraduate Medical School. London, UK).
Purification of HLA-DR0701, 0101, 0401, 1302
HLA-DR protein was preoared from the following Epstein-
Barr virus-transformed 8 ceil lines: DR0101, LG-2 (12),
QR0401, 8m 14. DR0701, L3F (13), OR 1302 and WT-47 (14)
as previously described (15). In brief a 10 g cell pellet was
lysec in PBS containing 2% CHAPS (v/v), leuoeotin (2 ixgl
mi), peostatin (2 ng/ml) and 5 mM EDTA. Cell lysates were
centrifuged at 100.000 g for 90 min at 4°C then loaded onto
an L-243 affinity column. The column was washed extensively
and then material eiuted with 0.05 % diethylamine/150 mM
NaCI/0.1% CHAPS. pH 11.5. Eiuate was concentratec on a
Centricon-10 column (Amicon).
Psotide binding studies
An invariant chain fragment containing the CLIP peptide
(LPKPPKPVSKMRMATPLLMQ) (li-(97-120)] was biotinyiated
using biotinamidocaproate W-hydroxysuccinamide ester
(Sigma). Binaing of peotioes to DR molecules was measured
by their ability to inhibit the binding af the biotinyiated CLIP
peotide as previously described (14). Briefly, 0.1 ug of HLA-
DR was incubated with biotinyiated CLIP peotide (0.02 ,ug)
with or without inhibitor peotide (10. 1 and 0.1 ug) at 37°C
for 24 h at pH 5. Solutions were neutralized with Tris-HCI (pH
7.5) before transfer to wells pre-coated with L-243 antibody.
Binding of biotinyiated peptide was detected with ExtrAvidin-
horseradish peroxidase conjugate (Sigma) ano developed
with o-phenylenediamine. The OD at 492 nm was measured
using an ELISA plate reader and the concentration of each
HA peotide which caused a 50% inhibition in biotinylatec CLIP
peptide binding calculated (IC50) using standard methods.
Results
HA and HA peotide recognition
Recognition of HA and the HA peotide pools by snort-term
CD4- T cell lines selected prior to HANA influenza subunit
vaccination was variaDle in magnitude (Conors A. 3 and D.
Fig. 1, and two donors reported in ref. 5. the line from donor
C was lost in culture), which prooaoly reflects differences in
their previous exposure to influenza A strains. After suounit
vaccination short-term CD4~ T cell lines derived from every
donor mounted strong proliferative responses to HA A/Beijing/
32/92. HA A/Aichi/68. and HA peotide pools 72-107. 232-
262. 407—142 and 456-488 (Fig. 1). Their minor HA responses
were also simiiar, with five of six donors recognizing peptide
pools 1-35. 49-^2. 208-243. 295-328 and 503-536.
When CD4~ T ceil responses to individual HA peotioes
within the dominant peDtioe pools were examined (Fig. 2).
every CD4~ T cell line was found to recognize identical HA
peptides cr pairs of overlapping peptices. with the exception
of donor E. whose responses to pools 407—142 and 4=6-
488 could not be localized. Furthermore, where responses
localized to pairs of overlapping peptides, the relative strength
of responses to eaon individual peptide was the same.
Thus the response to peptide 87-102 was stronger than the
response to peptide 92-107. the response to peotide 232-
247 was stronger than the response to peptide 228-243. and
the responses to peptides 463^-78 and 468—183 were simiiar
to each other in magnitude (with the exception of donor E).
These peptides represent regions of HA wntcn have been
free of extensive drift mutation since the emergence of the
H3N2 subtype. Thougn the CD4~ T ceil response of these
donors is principally focused on conserved regions of HA,
we cannot exclude the possibility that donors A, C and G
have mounted minor but significant (>5 times the geometric
mean background) resoonses to neutralizing antibooy sites
A. B, ano/or D which are represented by peptides in pool
137-171.
HLA class II restriction of T call responses to intact HA ana
HA peptides
In order to examine HLA restriction of CD4"" T ceil resoonses
to HA. PBMC from two donors with partiai HLA class II
matcnes were used as APC (Fig. 3). The QR070V donor
expressed HLA-ORB 1 *0101, DRBl *0701. DRB4*01, DC81 '05
and DQB1*02. The 'DR15' donor expressed HLA-ORB 1*0408.
DRB1 "1501. DRB4-01, DRB5*01, DQB1*0301 ano
DGB1"0601/0602. When PBMC from the DR0701' oonorwere
used as APC. strong T cell proliferative responses were
seen to peptides 87-102, 232-247, 463-478 and 468-493.
indicating that these responses were primarily restricted to
either HLA-ORB 1*0701. DRB4*01. DGB1 "02 or HLA DP (see
beiow). When PBMC from the 'DR1501 donor' were used as
APC, T ceil responses were seen to peptides 232-247 and
417-432.
CD44 T ceil recognition of peptides 37-102, 232-247. 463-
478 and 468-493 is uniikely to be primarily 0GB1 *02 restricted
because donor D. who does not express DCS 1*02. had a
very similar peptide recognition pattern to the other donors.
These resoonses are aiso unlikely to oe ORB4*01 restricted.
First, both the 'DR0701' donor and the DR15011 donor
expressed DRB4*01, yet strong resoonses to peptides 87-
102. 232-247, 463-478 and 468—193 were only seen wnen
PBMC from the 'DR0701' donor were used as APC. seconcly,
donor D. wno does not express DRB4*01 (10) has a very
simiiar HA peptide recognition pattern to the other donors:
ano, finally, we have previously examined five other ORB4"01
positive donors, none of whom recognized peptides 37"—102
and 232-247 (4,5). CD4"' T ceil recognition of oeotides 37-
102, 232-247, 463-478 and 468—193 is also uniikeiy to 06
primarily HLA-DP restricted because donors 3. C anc :
express different HLA-OP aileles (HL4-DP*0301.*0402. HLA-
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DP*0201,"0401, and HLA-DP*0401."0402 respectively). This
indicated that the majority of CD4- T cell responses to HA in
these donors were HLA-DR0701 restricted.
In order to test this hypothesis we repeated the HA peptide
proliferation studies using a murine fibroblast line expressing
HLA-DRB1-0701 (DAP.DR7.0701) as APC (Fig. 4). CD4T T
cell responses were seen to peptides 232-247. 417-A32,
463-478. 468-483 and 508-523 indicating that these
responses were DR0701 restricted. No T cell proliferative
response was seen to peptide 87-102, the reason for the loss
of recognition of this peptide is not clear but might reflect
differences in antigen processing between murine fibroblasts
and human PBMC (see Discussion).
HLA-OR0701 peptide binding studies
We were interested to examine whether the observed CD4*
T cell HA epitope recognition pattern was simply a con-
sepuence of dominant HA peptides having high binding
affinities for HLA-DR0701, leading to their preferential recogni¬
tion to the exclusion of other potential epitopes. The relative
binding strength of the 118 HA peptides for purified DR0701
was estimated in a competition assay using biotinyiated
invariant chain peptide (li) (Fig. 4). Fifty seven of the peptides
inhibited li binding with an IC5o < 100 p.M. Of these nine had
an IC5o = 1.0 pM and 31 had IC50 = 10uM (Table 1). The
HA peptides recognized by CD4T T cells in the context of
DR0701 either had detectable binding to this molecule or in
the case of peptide 468-483 overlapped (by 11 residues) a
peptide which was recognized in the context of DR0701 and
had a relative binding strength of <10 uM for this molecule.
The strongest proliferative response was associated with a
peptide with ICS0 = 1 pM (peptide 232-247). However, there
was no direct relationship between relative binding strength
and magnitude of response; the second strongest response
was associated with two overlapping peptides, one with
IC50 = 8.1 pM (peptide 463-478) and the other with IC50
> 100 plvl (peptide 468^183), and the third strongest was
associated with two peptides with IC50 = 20 pM. Only five
peptides representing the HA2 subunit (residues 329-550)
had IC50 < 100 pgM, with the highest relative strength
belonging to peptide 508-523 (2.1 pM). In addition the peptide
with the highest relative strength for DR0701 (peptide 192-
207) was not recognized by CD4^ T cells, despite its ability
to induce proliferation in the context of DR0101 [(4.5), and
C. Gelder and 8. Askonas. unpublished observations].
Relative binding strength of a panel of frequently recognized
HA peptides for common OR alleles
In order to extend our ODservations on the relationsnio
between HA peptide relative binding strength and CD4" T
cell recognition we investigated the binding strength of 13
HA peptides which we had previously found to be recognized
in association with other HLA class II alleles (4.5). The results
of this study are shown in Fig. 5. Because of the varying
strength of CLIP for individual HLA-DR molecules (16), results
for different HLA class II molecules cannot be directly com¬
pared. HA peptide binding was a prerequisite for CD4~ T
cell recognition. However, peptide binding to HLA-DR did not
automatically result in CD4~ T cell recognition, in particular,
peptide 232-247, which elicits strong responses in the context
of DR0701. also had measurable binding to DR0101 and to
DR1302, and we have not observed CD4T T cell recognition
of peptide 232-247 in the context of these HLA molecules
[(4,5), and C. G'eider and 8. Askonas. unpublished obser¬
vations].
Comparison of observed pattern of HLA-DR0701 HA peptide
binding to a previously described DR0701 peptide binding
motif
The observed pattern of HA peptide binding matched was
compared with a reported HLA-DR0701 peptide binding motif
(PI = FILVY, P4= NST) derived from pool sequencing of
peptides eluted from DR0701 (17). Though some of the HA
peptides can be aligned with this motif, a new motif P1 I, L.
V, (W or Y) and P9 V, I, L. (Y or F) fitted the observed pattern
of HA peptide binding more exactly, and there appears to
be a preference (though not an absolute requirement) for
hydrophobic residues at P2 and P7, polar residues at P4 and
P6, and small residues at P5 (Table 1). This putative motif
suggests that though the P1 and P9 pockets are important
for peptide selection, other residues in the peptide binding
groove interact with DR0701 and that the final peptide affinity
for DR0701 is the combination of several pocket specificities.
Interestingly the few peptides which did not fit the P9 require¬
ments have suitable residues located at P10 or PS. which
might reflect some flexibility in peptide binding.
Discussion
In this report we have shown that HA-soecific short-term
CD4"'" T cell lines generated from six unrelated DR0701, 1501
Fig. 1. CD4'r T cell recognition of HA by donors A-O. Short-term C04'" T cell lines were derived before (snadeo columns) and 3 months
following vaccination with Influvac (dark columns). Tne line derived from donor C prior to vaccination was lost in culture, and the CD4'r T ceil
responses of donors E and F have previously been reported (5). Short-term lines were selected with HA A/8eijing/32/92. and T cell proliferation
to HA A/Aichi/68, HA A/Beijing/32/92 and HA peptide pools tested at 14 and 21 days of culture. At 48 h T cells were puiseo with (3H]thymiaine
and harvested 16 h later. The x-axis represents geometric mean of triplicate wells: control. Cont' = proliferative response to complete medium
and autologous APC. 'Aichi' = response to A/Aichi/68 HA, 1.0 ug/ml. Beij" = response to HA A/Beijing/32/92. 0.1 ng/ml. Peptide pools labelled
according to N-termina! residue of the first peptide in pool (five peptides per pool, 10 ug/mi each peptide). 1 = peptide pool (pp) 1-35. 25 =
PP25-59. 49 = pp49-82. 72 = ,op72-107, 97 = 0097-128. 118 = op118-147, 137 = pp137-171. 161 = pp161-193, 183 = pp183-217.
208 = pp208-243. 232 = pp232-262. 252 = pp252-283. 273 = pp273-305, 295 = pp295-328. 317 = pp317-348. 333 = pp336-369. 357 =
PP357-393, 384 = pp384-418. 407 = pp407^M2. 432 = pp432-467, 456 = pp456-488. 478 = pp478-513, 503 = pp503-536. 526 =
pp526-550. The y-axis represents c.p.m. Donor D differs in HIA-DQ type from the other five donors and this is associated with the non-
expression of his HLA-DRB4-Q1 allele (see Methods).
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Fig. 2. CD4" T cell HA responses to individual peptides within dominant HA peptide pools. T cell proliferation by donors A-F to individual
I6mer peptides (5 ug/m!) within dominant peptide pools was tested at 14 and 21 days of culture using irradiated autologous PBMC as ARC.
72 - peptide (p) 72-87. 77 = p77-92. 82 - p82-97, 87 = p87-102. 92 = p92-107. 208 = p208-233. 213 = p213-228. 218 = p218-233.
223 = p223-238. 228 = P228-243, 232 = p232-247, 236 = P236-251, 238 = p238-253. 243 = p243-258, 247 = P247-262, 407 = p407-
422. 412 = p412-427. 417 = p417-432. 422 = p422-437. 427 = p427-442. 456 = p456-471. 459 = P459-474, 463 = 0463-478. 468 =
p468-483, 473 = p473-488. Data shown represents individual results from triplicate wells. Details otherwise as Fig. 1.
adults following influenza subunit vaccination principally focus
on five HA peptides (peptides 87-102. 232-247, 417-432.
463—478 ana 468-493) representing regions of the molecule
which have been free from extensive drift mutation since the
emergence of the H3N2 subtype. The observed pattern of
epitope selection was HLA-DR0701, 1501 specific, as different
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patterns of HA epitope recognition have been reported in the
context of other HLA-OR molecules (4,5). Using DAP.DR7
cells as APC (a murine cell line which expresses HL4-
DR0701) CD4~ T cell recognition of four of the selected
peptides (peptides 232-247, 417-432, 463-478 and 468-
493) was shown to be -HLA-DR0701 restricted and other
evidence was provided that recognition of the fifth peptide
(peptide 87-102) might also be DR0701 restricted.
Using biotinylated CLIP peptide, purified DR0701 and a
competition assay, the relationship between CD4+ T cell
recognition and relative binding affinity of the HA peptides
for purified HLA-DR0701 was explored and found to be
complex. The relative binding affinity of the five principally
recognized HA peptides varied from 0.2 (peptide 232-247)
to >100 pM (peptide 468-483). Furthermore, the majority of
peptides which bound to OR0701, including the peptide with
the highest relative affinity for DR0701 (peptide 192-207,
0.09 pM), were not recognized by CD4+ T cells. The finding
of peptide binding in the absence of a CD4T T cell response
was not unique to DR0701. as peptide 232-247 bound to
both HLA-DR0101 and 1302 but was not recognized in the
context of either HLA molecule.
3 DR0701
■ ORB 1501
Fig. 3. CD4T T cell responses to HA and HA peptides using single
haplotype-matched PBMC as APC. Donor D's CDa- T cell proliferation
to HA A/Aichi/68. HA A/Beijing/32/92 and HA peptides was assayed
at 21 days using PBMC from two partially MHC class Il-matcned
donors as APC. 'DR0701' donor = DRB1*0101,"0701 DRB4'01,
DQB1*02."05. DR1501' donor = DB1-0408, "1501, DRB4*01.
ORB5*01. DQB1 "0301,-0601/2. Details as Fig 1.
Our finding that in adults CD4^ T cells principally focus on
conserved HA regions contrasts the murine CD4- T cell
responses to HA following nasal H3 influenza A infection where
both CBA (18.19) and BALB/c (18.20,21) mice principally
recognize HA epitopes closely associated with the highly
variable antibody neutralizing sites rather than conserved
regions of the molecule (22). The murine response has aiso
been reported to be diverse with T cell clones from individual
syngeneic mice recognizing different HA epitopes and clear
MHC-restricted patterns of response only emerginge once
the responses of several mice are combined (23). These
apparent species differences may reflect differences in pre¬
vious exposure to influenza. The mice were examined after a
single in vivo Infection, whereas our adult human donors will
have been repeatedly exposed to different strains influenza
A virus (see below).
CD4+ T cell epitope selection is dependent on many
factors, which include antigen processing (24.25), the ability
of processed peptide to bind to MNC class II molecules (26),
competition amongst peptides for MHC binding (27,28) and
the presence of an appropriate repertoire of TCR (29). There
are therefore several possible explanations for our finding
that the relative strength of HA peptide DR0701 binding does
not directly relate to the observed CD4^" T cell repertoire.
Some HA peptides may not elicit T cell responses because
their natural equivalents do not emerge from antigen pro¬
cessing in vivo. As the purity of the majority of HA peptides
is not quantitated. it is possible that truncated peptides may
have interfered with peptide-MHC binding. However, several
of the HA peptides with high relative binding affinities for
DR0701 whicn were not recognized, elicited strong responses
in the context of other HLA class II alleles (e.g. peptides 20-
35. 100-115. 105-120 and 192-207) [(4.5). and C. Gelder
and B. Askonas. unpublished observations].
It is also possible that failure of some of the HA peptides
to be recognized might be due to the absence of CD4* T
ceil expressing appropriate TCR, due to regions of sequence
identity between the HA peptides and self proteins. Such
cross-reactivity has been demonstrated in a murine CTL clone
specific for HA residues 210-219 of influenza A/Jaoan/57
(H2N2), which also recognized the variable region of a
c.p.m.
Fig. 4. HLA class II restriction studies using DAP DR7 cells as APC. HA peptide-specific CD4"" T cell proliferation assays were performed on
a 2 week CDA"1" T cell line selected from donor D. as described in Fig. 1. except that irradiated DAP DR7 ceils (murine fibroblasts exoressing
HLA-DRB 1*0701) were used as APC in the proliferation assays. Data snown represents individual results from triplicate weils.
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Table 1. Rank order of relative HA peptide binding affinity for DR0701




192 0.09 T S L Y V R A S G R V T V s T K
232 0.2 30900 I Y W 7 I V K P G D I L L I N s
236 0.3 I V K P G D I L L I N S T G N L
247 0.3 S T G N L I A P R G Y F K I R N
188 0.3 D R D Q T S L Y V R A S G R V T
243 0.4 L L I N S T G N L I A p R G Y F
228 0.5 6680* S R i S I Y W T I V K P G D I L
238 0.9 K P G D I L L I N S T G N L I A
218 0.9 G S R P W V R G L S S R I S I Y
252 1.4 I A P R G Y F K I R N G K S S I
30 1.7 T N D Q I E V T N A T E L V Q S
303 1.8 G A C P R Y V K Q N T L K L A T
508 2.1 3260 K S G Y K D W I L W I S F A I S
146 2.5 S F F S R L N W L H K S E Y K Y
39 2.9 A T E L V Q S S S T G R T C D S
213 3.2 V 7 P N I G s R P W V R G L S S
513 4.0 D w I L W I S F A I S C F L L C
20 4.2 V P N G T L V K T I T N D Q I E
105 4.3 Y A S L R S L V A s S G T L E F
208 4.8 R S Q Q T V T p N I G S R P W V
282 5.1 I T P N G S I D N D K P p Q N V
100 6.9 V D V P D Y A S L R S L V A S S
300 7.1 I T Y G A C P R Y V K Q N T L K
198 7.7 A S G R V T V S T K R s Q Q T V
168 7.9 M P N N G K F D K L Y I W G V H
354 8.0 R H Q N S E G T G Q A A D L K S
463 8.1 20100 G N G C F K I Y H K C D N A C I
156 9.4 K S E Y K Y P A 1 N V T M P N N
273 9.7 P I G T C S S E c I T P N G S I
257 9.8 Y F K I R N G K s S I M R s D A
363 9.7 Q A A D L K S T Q A A I -O Q i N
417 12.4 13500 K I D L W S Y N A E L L V A L E
92 20.5 7000* K A y S N C Y p Y D V P D Y A
87 21.2 17000* F V R S K A Y S N C Y P Y D V
468 >100 20900 K I Y H K C D N A C I G S I R N
H H V
Possible L P P S P P L
DR0701 I h 0 m 0 h I
oeotiae V 0 I a I 0 F
binaing W b a I a b M
motif Y i r I r i W
c c
HA peptides with a relative affinity of <10 am for purified DR0701 are shown, plus four peptides with a lower affinity which were associated
with HIA DR0701 restricted CD4~ T cell proliferation. Peptides with the highest affinity for DR0701 have lowest IC50 Mean proliferation is
geometric mean of CD4* T cell responses by six donors to individual peptides, an asterisk indicates DR0701 restriction proposed on the
basis of experiments with partially HLA matched APC. Sequence of HA A/Beijing/32/92 shown with sequence variation between A/Beiiing/32/
92 and original human H3N2 influenza A virus A/Aichi/68 underlined. Hpnobic - hydrophobic.
myeloma VH chain (30). We therefore searched the Swiss
Protein Database for regions of sequence identity between
the HA peptides which bound to DR0701 but were not
recognized and self proteins. Interestingly we found 79%
homology between the nine core residues of peptide 192-
207, as predicted by our putative HLA-DR0701 peptide
binding motif, and human galactosidase 2 (data not shown).
Antibody binding to an antigen has also been reported to
modulate CD4~ T cell responses (31,32). Several HA peptides
wnicn were not recognized by CD4" T cells, including peptide
192-208 which displayed the highest relative binding strength
for DR0701, were located in or close to antibody neutraiizing
sites. The neutralizing antibody response to HA is variable
between individuals and is largely influenced by exposure
history (33). As the pre-vaccination exposure of these six
donors varied, a more diverse pattern of CD4~ T cell HA
recognition might be expected, if significant antibody modula¬
tion of CD4~ T cell recognition had occurred in this system.
Viral drift mutation may also have influenced CD4~ T cell
HA epitope recognition. The maiority of peptides with an IC50
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Rg. 5. Relative HA peptide binding strength for HLA-DR0701. HLA-DR0701 was incubated with biotinylated CLIP peptide with or without
individual HA peptides at 37°C for 24 h at pH 5. Solutions were neutralized with Tris-HCI (pH 7.5) before transfer to wells pre-coated with L-
243 antibody. Binding of biotinylated peptide was detected with avidin-horseradish peroxidase conjugate and developed with o
phenyienediamine. Results are presented as IC50 (in p.M) of peptide causing 50% inhibition of invariant chain binding. The x-axis represents
individual HA peptides, labelled by their N-terminal residue. The y-axis represents IC50 and is logarithmic, and in reverse order. Thus peptides
with the highest strength (and therefore lowest IC50) for DR0701 are represented by the highest columns. Riled columns indicates CD4"*" T
cell recognition of HA peptide. An asterisk indicates CD4'r T cell recognition of HA peptide with a relative binding strength for DR0701 of > 100 nM.
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Fig. 6. Relative binding strength of 13 HA peotides for HLA-DR0101. 0401. 0701 and 1302. Binding strength of 13 freouently recognized HA
peotides to three commonly expressed DR moiecules was investigated using a competition assay and biotinylated CLIP peptide, results for
DR0701 given for comparison. Affinities expressed as IC50 On uM) A polyalanine peptide was used as a negative control, otherwise
experimental details as Fig. 5. Results are not directly comparable between individual DR molecules because of differences in binding strength
of CLIP for individual alleles (see text). Solid columns indicates CD4"*" T cell proliferation in the context of a given DR moiecuie. clear columns
indicates no response seen in the context of this DR molecule. Shaded columns-indicates responses seen to the peptide pooi containing this
peptide, but response either not localized within the peptide oooi or HLA class II restriction of CD4^ I cell response unxnown.
for DR0701 of < 10fiM which were not recognized by the
short-term CD4~ T cell lines represent regions of HA that
have undergone drift mutations since the emergence of the
H3N2 subtype in 1968 (see Table 1; N. Cox, CDC, Atlanta.
GA, pers. commun.). These mutations were frequently non-
conservative in nature. Six peptides representing conserved
regions of HA (peptides 100-115, 105-120, 282-297, 354-
369,363-378 and 513-528)were not recognized in the context
of DR0701 despite relative binding affinities for DR0701 of
<10 uM. We have previously observed responses to two of
these peptides (100-115 and 105-120) in the context of
DR0101 [(4,5), and C. Gelder and B. Askonas, unpubiisned
observations). In contrast, the HA peptides which induced
CD4" T cell responses in the context of DR0701 contained a
maximum of two highly conservative drift mutations and did
not represent glycosyiated regions of the molecule (see
below). Thus the observed DR0701-associated HA epitope
recognition pattern seen in these adult donors may have
emerged as a consequence of repeated exposure to influenza
A strains, differing in HA, boosting recognition of conserved
regions of the molecule. Such selection of T cells specific for
conserved HA epitopes would explain the apparent species
differences in HA recognition described above, in order to
test this hypothesis it will be important to examine CD4" T
cell recognition of HA by infants and children following their
first exposure to influenza.
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Several of the peptides which Pound to DR0701 but which
were not recognized, represent HA regions with potential
glycosylation sites (glycosyiation motif is Asn-X-Ser/Thr, pep¬
tides 20-35. 30-45. 156-171. 236-251. 238-253. 243-258.
273-288 and 282-297) (N. Cox. CDC. Atlanta. GA. pers.
commun.). Glycosylation. of HA has been shown in murine
systems to abrogate CD4^ T cell recognition of HA (34) and
therefore may account for the absence of CD4+ T cell
recognition of our synthetic peptides despite their high relative
binding affinities for DR0701. We have only rarely seen
significant T cell recognition (5 times the geometric mean of
background response to medium and APC) of peptides
representing glycosylated regions of HA in the context of any
HLA-DR molecule examined to date (DR0101, 0102, 0103,
0301. 0401. 0402. 0408. 0701, 0801,1001, 1101, 1201. 1301.
1302, 0101, 0102. 0103. 0301, 0401. 0402. 0408. 0701.0801.
1001. 1101. 1201, 1301, 1302, 1501) [(4.5). and C. Gelder and
B. Askcnas. unpublished observaticns]. It will be important to
examine whether human CD4"1" T cells are able to recognize
glycosylated synthetic peptides representing these regions.
Finally these results illustrate the difficulty in accurately
predicting CD4^ T cell epitopes in virai antigens on the basis
of peptide binding studies alone.
In conclusion we have demonstrated the precise control
HLA class II exerts over CD4~ T cell HA epitope selection in
unrelated adults. Immunodominance appears not to be dir¬
ectly related to the relative strength of HA peptide-HLA class
II binding, and thus reflects complex interactions between
antigen processing, intracellular competition for HLA binding,
TCR repertoires and repeated exposure to different strains of
influenza A viruses.
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Prediction and identification of an HLA-DR-restricted
T cell determinant in the 19-kDa protein of
Mycobacterium tuberculosis
An allele-specific motif has been identified in the sequence of several peptides which
are recognized by T cells in association with HLA-DR1. In order to test the predictive
values of such a motif we analyzed the 19-kDa antigene from Mycobacterium tuber¬
culosis and identified a sequence containing a pattern characteristic of DR1 restric¬
tion. Peripheral blood mononuclear leukocytes from every DR1 and 4 individual
tested responded to the corresponding synthetic peptide. Nine other donors, con¬
stituting seven different DR alleles, failed to recognize this sequence. Recognition of
the peptide in association with DR1 and DR4 was confirmed using T ceil clones and
transfected murine L cell lines expressing DR molecules.
1 Introduction
The induction of the cellular immune response is inititated
when an appropriate T ceil receptor recognizes the complex
formed between fragments of protein antigens and molecules
encoded by the major histocompatibility genes [1]. Recent
experiments have demonstrated that the genetic basis of anti-
gen-specific immune responsiveness can be explained by the
ability of a particular major histocompatibility complex
(MHC) allele to bind a fragment of the immunizing protein or
pathogen [2]. Understanding the structural basis of this genetic
restriction is important in selecting antigens for use both as
diagnostic reagents and/or components of potential vaccines.
The identification of peptide antigens with similar structural
features restricted by the same MHC class II molecule has
suggested the presence of alleie-specific subpatterns in T ceil
epitopes [3]. In the case of the HLA class II allele DR1, a
cluster of a positively charged amino acid and three
hydrophobic residues in relative positions 1, 4, 5 and 8 is com¬
mon in two defined determinants and appears to be necessary
for this peptide to interact with the restriction element [4], If
the peptides adopt a helical conformation then these discon¬
tinuous residues would be juxtaposed to form a common
facade of the helix allowing the peptides to selectively bind
DR1.
To test the predictive value of this template, we scanned the
sequence of the 19-kDa protein of mycobacteria for the pres¬
ence of the motif. The protein was chosen because T ceils
[I 6780]
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specific for it are well represented in both the human [5. 6] and
murine [7] repertoires reactive with mycobacteria. The pep¬
tide corresponding to the only area containing the motif in the
protein sequence was shown to be recognized by DR1 and
DR4-restricted T cells.
2 Materials and methods
2.1 Antigen preparations
Mycobacterium tuberculosis soluble extract (MTSE) was pre¬
pared by mechanical distruption of M. tuberculosis H37Rv
grown as a surface pellicle on Sauton's medium. The recom¬
binant 19-kDa (clone Y4147) and Xgtll antigen preparations
were prepared as described previously [5]. Purification of the
19-kDa protein by affinity chromatography using antibody
TB23, and sequencing of the DNA insert from a kgtll clone
(Y3239) which expresses the 19-kDa antigen are described
elsewhere (Lathigra et al., manuscript in preparation). The 19-
kDa peptide (see Table 1, Sect. 3) was synthesized by using
solid-phase techniques [4].
2.2 Isolation of human T cell clones
Peripheral blood mononuclear leukocytes (PBMC; 2.3 x IIP/
ml) were stimulated in RPMI 1640 medium supplemented
with 10% screened human A' serum, 2 mM L-glutnmine and
100 IU/ml penicillin/streptomycin with 1.0 ug/mi of affinity-
purified 19-kDa protein. Activated lymphocytes were isolated
on Ficoil-Paque (Pharmacia, Uppsala, Sweden) and cloned by
limiting dilution (0.3 blasts/well) in the presence of autologous
irradiated PBMC mixed (4:1) with Epstein-Barr virus (EBV)-
transformed B ceils (total ceil number 5 x 105/ml), inter¬
ieukin 2 (IL2; Lymphocuit-T, Biotest Serum Institut GmbH,
Frankfurt, FRG) and affinity-purified 19-kDa protein (1.0 ugi
mi) in Terasaki plates (Nunc, Roskilde. Denmark) as
described previously [5, 8], Growing clones were transferred
at day 7 to 96-weil flat-bottom microtiter plates and subse¬
quently to 24-well plates. At each transfer the clones received
filler cells, antigen (MTSE;, 1 pg/ml) and IL2. The clones
were expanded by the addition of fresh IL2 every 3—4 days
and filler cells together with antigen every 7 days. Prior to use
© VCH VerlagsgeseilschaftmbH, D-6940 Weinheim. 1988 0014-2980/88/0606-0973S02.50/0
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in proliferation assays the T ceil clones were rested 6-8 days
after the last addition of filler cells.
2.3 Proliferation assays
Goned T cells (5 x 10"/ml) were stimulated with antigen in the
presence of irradiated autologous EBV-transformed B ceils
(lCP/ml) or mitomycin C-treated transfected murine L cells [4],
After 60 h incubation tritiated methyl thymidine ([3H]dThd;
1 uCi/well: Amersham International. Amersham. Bucks.,
GB) was added and the cultures were harvested onto glass-
fiber filters 8—16 h later. The duration of unfractionated
PBMC cultures (1 X 105) was 7 days. Proliferation as corre¬
lated with [3H]dThd incorporation was measured by liquid
scintillation spectroscopy. The results are expressed as mean
counts per minute (cpm) ± % standard error of the mean for
triplicate cultures.
2.4 Transfected murine L cells
Full length cDNA clones encoding HLA-DRip and
DR4(Dwl5)(3 were subcloned together with a DRa cDNA
clone into an SV40-based cDNA vector (Ikeda, H., manu¬
script in preparation). These constructs were transfected into
mouse Ltk" cells using the calcium phosphate technique [9]
and transfectants selected with hvgromycin B (Calbiochem/
Behring Diagnotics. La Jolla. CA) at a concentration of 1 mg/
mi. Transfectant cell lines expressing high levels of the surface
expression of DR1 and DR4 products were isolated by flow
microfluorimetric sorting. The HLA-DR7 expressing transfec¬
tants have been described previously [10].
2.5 HLA typing
HLA-DR and DQ typing was performed on PBMC using 80
sera and the two-color fluorescence test [11],
3 Results and discussion
A peptide corresponding to the first 15 amino acids of the
predicted sequence of the 19-kDa protein of M. tuberculosis
was synthesized and tested for its ability to be recognized by
Table 1. Structural similarity of the amino terminal peptide of the
19-kDa protein of mycobacteria to known HLA-DRl-restricted pep¬
tides"
• TntTiiertra herrrayytiTTrmn ' ; - — v.""".- r. ■ - - -
-1niluenza,matrix: 17129- . S-G-P-L-K-A-E-I-A-C2-R-L-E:
J9-kDa..l-15f • E-TT-R-VtK-R-G'-L-T-V-A-V^A-G^A.
a) Ammo acids represented by the single letter code. The underlined
residues identify the presence of the motif associated with HLA-
DR1 restricted T cell epitopes [3.4]. The 19-kDa peptide
sequence is derived from the open reading frame identified in the
DNA insert from a /.gtll recombinant clone Y3293 that codes for
19-kDa protein of mycobacteria (Lathigra et al., manuscript in
preparation).
human helper T cells (Table 1). This particular region was
chosen because it contained a similar pattern of amino acids
previously identified in DRl-restricted T cell epitopes from
influenza virus [4], PBMC. isolated from either Bacillus Cal-
mene Guerin (BCG)-vaccinated individuals or tuberculosis
patients, were screened for their ability to proliferate in
response to whole bacterial extract or the peptide. As pre¬
dicted, lymphocytes from each DR1 individual tested
responded to the peptide (Table 2). Individuals expressing
DR4 gene products also recognized this sequence (Table 2).
The ability of DR1 and DR4 class II molecules to present the
identical peptide has been observed previously for influenza
virus-reactive T cell clones [12], and can be accounted for by
sequence and structural similarity in their antigen-combining
sites ([13], Rothbard et al., manuscript in preparation). Only
two out of the 11 donors lacking DR1 and/or DR4 (LB14)
responded to this peptide, of which one was DR13,14 while
the other was a DR3 homozvgote. However, other individuals
expressing each of these alleles failed to respond to the pep¬
tide.
The results of the panel study were confirmed by examining
the specificity and restriction of T cell clones isolated from one
of the donors (PTER) by growing the lymphocytes in the pres¬
ence of affinity-purified 19-kDa protein. Of the two clones
specific for the recombinant antigen isolated, one (API. 17)
was specific for the 15 amino acid peptide (Table 3), demon¬
strating that this peptide is naturally immunogenic.
The restriction specificity of clone API. 17 was analyzed using
murine L cells expressing products of transfected HLA-DR
genes to present the peptide antigen (Table 4). Transfectants
were selected as the source of antigen-presenting cells because
they express only the products of the transfected genes in iso¬
lation from other MHC class II species. Murine L cells expres¬
sing DR1. compatible with the HLA-DR serotype of the
donor (Table 2), were able to induce antigen-dependent pro¬
liferation of clone API.17 unlike the control DR7" L cell. This
confirmed the results of the population study that recognition
of the 19-kDa peptide was DR restricted. Furthermore, L cells
expressing DR4(Dwl5) also were able to repesent the peptide.
The analysis of peptides capable of stimulating DRl-restricted
influenza virus-immune T cell clones has identified a sequence
motif involved in the binding of peptide in combining site of
DRI molecules [4j. The experiments described in this study
demonstrate that this motif can be used predictiveiy to identify
regions of proteins capable of interacting with DRI and
DR4dwl5. The results also imply that the three peptides, the
two from influenza and the peptide from the 19-kDa protein,
interact with similar residues in both DRI and DR4. In addi¬
tion. the T cell receptors on each of the antigen-specific clones
must be capable of binding each peptide in the context of the
two MHC alleles. Modelling the class II sequences based on
the HLA-A2 structure reveals that the proposed antigen-com¬
bining site is composed of residues of both the conserved a
chain and the polymorphic (3 chain [14. 15]. In addition, the
upper facade of the helix of the 8 chain is identical between
DRI and DR4dwl5 [4], There are nonconservative changes in
the residues that form the bottom of the binding site in the two
alleles, but whether they are sufficiently similar to allow iden¬
tical peptides to bind both sites or whether the peptide does
not directly interact with them remains to be determined. We
are currently analyzing the ability of mutants of these three
peptides to be recognized by T cell clones in the context of
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Table 2. Polyclonal T cell responses to the peptide to the 19-kDa peptide-"





a) The results are expressed as Acpm where the medium backgrounds (mean < 250 cpm) are subtracted from the response to antigen. Standard
errors were less than 25%. LB14 is a newly defined DR specificity which is associated with DR1. 4 and DRwlO and is closely related with, if
not identical to, MCI [14].
Table 3. Antigen specificity of T cell clone induced with the 19-kDa
protein-1'
Table 4. Proliferative response of cloned T cells to the 19-kDa pep¬
tide presented by murine L ceils expressing HLA-DR1 or DR4"
a) T cell clones (5 x 104/ml) were stimulated with autologous irradi¬
ated EBV-transformed B cells (5 x 107ml) in the presence of
MTSE (1 |Ag/ral), affinity-purified 19-kDa (1 ug/mi), 19-kDa pep¬
tide (10 lig/ml), 19-kDa recombinant antigen (Y4147; 10 ug/mi)
and Xgtll (10 ug/mi). Proliferation was determined by [3H]dThd
incorporation at 72 h. The results are expressed as mean cpm ± %
SEM for triplicate cultures.
DR1 and different DR4 alleles to determine the precise orien¬
tation of the peptides in the binding site.
We should stress that not ail peptides with this 4 amino acid
motif will bind DR1 because these are not the sole contacts
between the MHC protein and the peptide [4]. Further experi¬
ments are required to refine and expand the motif to include
ail the residues needed for DR1 binding. Also, we do not
beiieve that all DRl-restricted peptides will be recognized by
DR4. Even though these three examples appear to bind in a
similar fashion, other peptides could have different orienta¬
a) T ceils of clone API. 17 (5 x 107ml) were stimulated with and with¬
out 19-kDa peptide (1 ug/mi) in the presence of irradiated autolo¬
gous EBV-transformed B cells (lCP/ml) or mitomycin C-treatea
transfected murine L cells. Proliferation was determined as
described in the legend to Table 3.
tions in the binding site. Nevertheless, the ability of a given
short peptide to bind to more than a single MHC class II pro¬
tein has practical applications in the development of vaccine
components, as will the identification of similar predictive
motifs for other HLA-DR alleles.
The authors thank Drs. R. Lathigra and R. Young for communicating
the sequence of the 19-kDa protein. Dr. /. Schreuder and colleagues for
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Announcements
International Meeting on Opportunistic Infections
Paris
November 24-26. 1988
Review lectures, round tables and poster presentations on
interactions between specific pathogens and the immunocom-
promized host and on some clinical and therapeutical aspects
of opportunistic infections.
Registration and abstract submission to Dr. N. Wierzbicki.
Fondation Franco-Allemande, LTM/Sarbach - BP 22, F-92151
Suresnes Cedex. France.
Third Banff Conference on Reproductive Immunology





The conference organizers will be Thomas G. Wegmann and
Thomas J. Gill III. Those interested in attending, and present¬
ing a poster if desired, should contact Dr. Thomas J. Gill III.
Department of Pathology .University of Pittsburgh School of
Medicine. Pittsburgh. PA 15261. The registration fee will be
US$150.
Micronutrient Effects on Immune Functions
Omni Park Central. New York
June 1-2. 1989
The conference will bring together the leading investigators in
the fields of micronutrients (vitamins and minerals) and
immune functions, providing a synthesis of current views on
these topics. Recent experimental as well as clinical findings
will be emphasized. The potential impact of micronutrient
status on the immune system of individuals suffering from
burns, trauma, sepsis. AIDS, autoimmune and hemolytic dis¬
eases as well as functions of the immune system during the
early and late stages of life will be examined in depth. The
meeting should be of interest to immunologists. nutritionists,
registered dieticians, clinicians, biochemists and public health
officials.
Conference chair persons:
Ranjit. K. Chandra, M.D., F.R.C.P.(C), Department of
Pediatrics, Memorial University of Newfoundland, St. Johns,
Newfoundland. Canada.
Adrianne Bendich, Ph.D., Clinical Nutrition. Hoffmann-
LaRoche Inc., Nutley, NJ, USA.
There will be a contributed poster session. The deadline for
submission of abstracts (200 words or less) is February 1,
1989. Send abstracts to: Dr. Adrianne Bendich, Clinical Nutri¬
tion, Hoffmann-LaRoche Inc., 340 Kingsiand Avenue, Nut-
ley, NJ 07110-1199, USA (Abstract form is not necessary).
For further information, please contact: Conference Depart¬
ment. The New York Academv of Sciences. 2 East 63rd
Street. New York. NY 10021, USA (212) 838-0230.
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Overlapping T-cell epitopes in the group I
allergen of Dermatophagoides species
restricted by HLA-DP and HLA-DR
class II molecules
Julie A. Higgins, PhD," Christopher J. Thorpe, BSc," John D. Haybail, BSc,"
Robyn E. Q'Hehir, MD, PhD," and Jonathan R. Lamb, PhD" London, England
The induction of IgE antibodies reactive with the group I allergen of Dermatophagoides
species (house dust mite [HDM]), which comprise a major component of the allergic immune
response in HDM-atopic individuals, is dependent on the functional activity of specific CD4 —
T cells. In this report we demonstrate that for a particular HDM-atopic individual the T-cell
response to the group I allergen of Dermatophagoides pteronyssinus (Der p I) is limited to a
single region (residues 101-143) of the protein. By mapping the fine antigen specificity with
T-cell clones, we observed that the sequence 101-131 of Der p I contains a duster of at least
three overlapping T-cell epitopes. Analysis of the HLA class II restriction specificity of the T-ceil
clones revealed that the T-cell epitope, residues 110-131. was restricted by HLA-DRB1*0101.
In contrast, peptide Der p I, 110-119 was recognized in association with HL.4.-DPB1*0402.
However, the ability of cloned T cells to proliferate to the peptide Der p I. 107-119 presented by
HL.4-DPB1*0401, HL.4-DPB1 *0402. and HLA-DPB1*0501 expressing accessory cells
illustrates the heterogeneity of the restriction specificity of this region of Der p I. The
application of this information in the design ofpepnde-based immunotherapy in the
management of allergic responses to HDM is discussed. (Jallergy Clin immunol
1994:93:891-9.)
Key words: Peptides, house dust mite. Der p /, HL.4-DR, HLA-DP, T-cell epitopes
In genetically susceptible individuals, exposure
to proteins derived from mites of the genus Der¬
matophagoides (D. pteronyssinus and D. farinae)
results in clinical symptoms ranging from extrinsic
asthma and allergic rhinitis to atopic dermatitis.
Serologic analysis with IgE antibodies from pa¬
tients with house dust mite (HDM) allergy sug¬
gests that multiple antigens are present in HDM
extracts.1 Nevertheless, it appears that a major
component of the humoral immune response
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and Medicine: and 'Laboratory of Molecular Bioiogy, De¬
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HDM: House dust mite
PBMCs: Peripheral blood mononuclear cells
comprises antibodies reactive with the group I
allergens of HDM (Der p I and Der f I).2- 3 The
results of several studies suggest that in excess of
50% of anti-HDM IgE antibodies are specific for
Der p I and are found in approximately 70% of
sera from allergic individuals.4' 5
The induction of specific IgE antibodies and
the activation of polymorphonuclear granulocytes,
both of which contribute to inflammatory re¬
sponses to HDM allergens, are dependent on
CD4+ T cells.4"8 Therefore in the development of
specific immunotherapy, targeted at the CD4 —
T-cell population, it is essential to define in detail
the antigen and HLA class II restriction specific¬
ity of the HDM-reactive T-ceil repertoire in
HDM-atopic individuals. In the peripheral blood
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HLA-DR specificities DRB1 DRB3 DRB4 DRB5 DQA1 DQB1 DPA1 DPB1
HOM2 DR1 Dwl 0101 — — — 0101 0501 ND 0401
PGF DR15 Dw2 1501 — — 0101 0102 0602 01 0401
PMG075 DR1 Dw20 0102 — — — 0101 0501 01.02 0301.041
TTSI DR11 DR52 Dw25 1103 0202 — — 0501 0301 01 0402
WT24 DR16(2) Dw21 1601 — — 0201 0102 0502 01 0301
YAR DR4 DwlO 0402 — 0101 — 0301 0302 01 0401
of HDM-allergic individuals T cells that prolifer¬
ate in response to stimulation with extracts of
HDM have been identified.'"11 Furthermore, with
electrophoretically separated and affinity-purified
allergen preparations. T-cell responses to Der p I
have been demonstrated.13 However, now that the
complementary DNA encoding Der p I has been
cloned, allowing the primary amino acid sequence
to be derived from the nucleotide sequence,14 it is
possible to analyze the specificity of the T-cell
repertoire reactive with Der p I with the use of
truncated recombinant proteins and synthetic
peptides. When this approach to analyze the an¬
tigen specificity of Der p I-induced T-cell clones
was used, four regions of the protein (residues
45-67, 94-104, 101-119, and 117-143) that contain
T-cell epitopes were identified.15, 16 Furthermore,
the HLA class II restriction specificity of these
T-cell clones was determined and revealed that
both HLA-DR- and HLA-DP-encoaed gene
products are functional in the presentation of
Der p I.
It is important to identify the immunodominant
sites in Derp I that are recognized by T cells from
atopic individuals. The information derived from
these studies will be of value both in enhancing
our understanding of the role of T cells in allergic
inflammation and in the development of allergen-
based immunotherapy. This prompted us to inves¬
tigate in detail, with the use of a T cell line and
clonal analysis, the diversity of the antigen and
HLA class II restriction specificity of the T-cell
repertoire reactive with Der p I, a major allergen
of HDM. We observed that for a particular atopic
HDM-allergic individual the anti-Der p I T-cell
response was directed exclusively toward the re¬
gion of the protein spanning ammo acids 101-143.
When the fine specificity of T-cell clones from this
donor was mapped, it appeared that within a
region of Der p I encompassing amino acids 101-
131 there is a cluster of overlapping T-cell
epitopes. Furthermore, from the patterns of pro¬
liferation when allergen was presented by differ¬
ent HLA class II molecules, it appeared that the
T-cell epitope spanning residues 110-131 was re¬
stricted by HLA-DRB1*0101, whereas residues
107-119 and 110-119 were recognized in associa¬
tion with HLA-DPB1*0402. T cells specific for
the peptide Der p I, 107-119 and able to respond
to peptide in association with HLA-DPB1*0401,
HLA-DPB1*0402 and HLA-DPB1*0501 were




Lvophilized extracts of D. pteronvssinus and D. fari-
nae were supplied by SmithKiine Beecham (Epsom,
Surrey, England). Peptides derived from nucleotide
sequences of Der p I and Der p II were synthesized in
our department as previously described.15 The peptides
were the generous gift of Dr. M-C. Kuo. ImmuLogic
Pharmaceutical Corporation, (Waltham. Mass.) or were
purchased from Chiron Mimotopes Ltd. (Clayton. Vic¬
toria, Australia).
Antibodies
The monoclonal antibodies L243 (anti-HLA-DR)17
and B7/21 (anu-HLA-DP)18 were isolated from the
culture supernatants of the respective hvbridoma ceil
lines and purified with protein A Sepharose (Pharma¬
cia, Uppsala, Sweden).
isolation of human HDM-reactive clones
Derp I-reactive T-cell clones were isolated from an
HDM-allergic individual by limiting dilution cloning as
described previously.10 Penpheral blood mononuclear
ceils (PBMCs) (107ml) from an HDM-atopic individual
with perennial rhinitis were stimulated with an optimal
concentration ofD. pieronyssmus (20 q.g/ml) for 7 days in
RPMI-1640 medium supplemented with 2 mol/L
L-glutamine, 100 ru/mi penicillin/streptomycin (Gibco
Life Technologies, Paisley, Scotland) and 5% screened,
inactivated humanA- serum (National Blood Transfu-
J ALLERGY CLIN IMMUNOL
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FIG. 1. Antigen specificity of 0. pteronyssmus-induced T cell line. T cells from an HOM-atooic
individual were stimulated with extracts of 0. pteronyssinus and D. farinae. peptide pools were
-derived from Der p I and Der p II (5 jig/ml) in the presence of APCs, and proliferation was
measured.
sion Service. Edgeware. England). A long-term line of
one of the donors was established by enriching Ivmpho-
biasts on Ficoll-Paque (Pharmacia) in the presence of
irradiated autologous PBMCs (5 x l03/mi; 2500 rad),D.
pteronyssinus (20 p.g/ml) and interleukin-2 (10% voi/vol:
Lymphocutt T. Biotest Folex. Frankfurt. Germany). Vi¬
able ceils from the various lines (0.3 cells/well) were
cloned by limiting dilution in supplemented medium and
plated in Microtest II plates (Nunc. Gibco Life Tech¬
nologies) together with irradiated autologous PBMCs.
D. pteronyssinus, and interieukin-2. After 7 days, growing
clones were transferred to flat-bottom 96-well mtcrotiter
plates and subsequently to 24-weil plates. The clones
were maintained with interleukin-2 every 3 to 4 days ana
irradiated autologous PBMCs and D. pteronyssinus every
7 days. In ail experiments clones were tested 7 to 8 days
after the last addition of antigen and antigen-presentmg
ceils (APCs).
Proliferation assays
Cloned T cells (103 cells/ml) were stimulated with
peptides (0.1 to 10.0 p.g/ml) in the presence of APCs.
The .APCs used in the experiments were irradiated
(2500 rad) autologous PBMCs (103 cells/ml), irradiated
(5000 rad) Epstein-Barr virus (EBV)-transformed 3
ceils (103 cells/mi) (Tabie I), or mitomycin C-treated
murine fibroblasts expressing HLA-D region gene
products (105 cells/mi). The murine fibroblasts (DAP3),
transfected with DRB1"0101, DPB1"0401. DPB1*0501.
and DPB1*0402 genes were kmdlv provided by Dr.
John Trowsdale. ICRF, London: Dr. Sandra Rosen-
Bronson. Georgetown University Medical School.
Washington D.C.; and Dr. Hidetashi Inoko. Tokai Uni¬
versity School of Medicine. Bosheida. Japan, respec¬
tively. In serologic inhibition assays antibodies were
added over a concentration range at the initiation of
cultures. After 60 hours of incubation the cultures were
pulsed with tritiated methvi thymidine (1 p.Ci/well:
Amersham International Inc.. Amersham. England),
and the cultures were harvested 8 to 16 hours later.
Proliferation as correlated with tritiated methyl thy¬
midine incorporation was measured by liquid scintilla¬
tion spectroscopy. The results are expressed as mean
counts per minute for triplicate cultures. The stan¬
dard error of the mean for ail experiments was less
than 20%.
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FIG. 2. Anti-HLA-DP ciass II antibody inhibits antigen-
aepenrient proliferative resoonse of Der p I—reactive T cell
line. The inhibitory effects of anti-HLA-DP (B7/21) (•! and
HLA-DR (L243) antibodies (o) were determined in prolif¬
eration assays with the T cell line, APCs, and D. pxeronys-
sinus (20 n.g/ml).
RESULTS
Antigen and major histocompatibility
complex class II restriction specificity of
D. pteronyssinus—induced T cell line
The antigen specificity of a long-term T cell line
expanded from PBMCs isolated from an HDM-
atopic individual was analyzed with pooled pep¬
tides derived from the sequences of Der p I and
Der p II. Although proliferation to each of the
peptide pools was determined over a range of
concentrations (0.1 to 50 p.g/ml) the T cell line
responded to only Der p I 101-143 (peptides
101-119, 110-131, 111-134, and 120-143) (Fig. 1).
Furthermore, the T cell line responded to both
D. pteronyssmus and D. farinae extracts, suggesting
the presence of T cells reactive with conserved
sequences located between residues 101-143 of
Der p I and Der f I. The ability of the murine
monoclonal anti-HLA-DP (B7/21) antibody but
not the anti-HLA-DR (L243) antibody to inhibit
antigen-induced proliferation in a dose-depen¬
dent manner (Fig. 2) suggests that the major
component of the T cell line responds to allergen
presented in association with HLA-DP ciass II
molecules.
Antigen specificity of Der p 1—reactive
T-ceil clones
The T cell line was cloned by limiting dilution,
and three T-cell clones were screened for their
antigen specificity with overlapping peptides of
Derp I (Fig. 3, A-C). T cells of clone KS7.4 were
screened with a nested set of overlapping peptides
covering residues 103-125. Peptides 105-119 and
110-124 stimulated the T cells, whereas peptides
105-118 and 111-125 both failed to induce prolif¬
eration (Fig. 3, A), suggesting that the minimal
T-cell epitope recognized by KS7.4 is residues
110-119. In a previous report we demonstrated
that T cells of clone KS2.12 respond to residues
101-119, defining the importance of lie at position
119." Now with peptides truncated from the
amino terminus (residue 106) it is apparent that
residues 107-119 contained the optimal T-cell
epitope recognized by the T-cell clone KS2.12
(Fig. 3, B). The T-cell clone KS2.15 responded to
peptides 101-143 and 110-131 but not to peptides
107-118, 123-136, or 126-139 (Fig. 3, C) when
tested over a concentration range. Thus KS2.15
recognizes a region of Der p I between residues
110 and 131. Unlike the T cell line from which
they were isolated.'none of the T-cell clones were
cross-reactive" with D. farinae (data not shown).
HLA-D region restriction specificity of Der p I
T-cell clones
In order to determine the HLA-D region re¬
striction specificity, the T-cell clones were stimu¬
lated with antigen in the presence of either HLA-
typed EBV-transformed B cell lines (Table I) or
murine fibroblasts expressing HLA-D region mol¬
ecules. A dose-dependent proliferative response
of T-cell clone KS7.4 was induced to antigen
presented by fibroblasts expressing HLA-DPB1*
0402 but not HLA-DPB 1*0401 (Fig. 4,A). Simi¬
larly, the untransfected fibroblast line (DAP 3)
and fibroblast lines expressing HLA-DRBI *0101
failed to present antigen. The EBV-transformed
B-cell line (WT24) induced proliferation in the
presence of high concentrations of antigen but
was markedly lower than that mediated by autolo¬
gous EBV-transformed B cells (KSE; Fig. 4. A).
Previous investigation of the HLA class II restric¬
tion pattern of KS2.12 demonstrated that T cells
derived from this clone recognized antigen in
association with HLA-DPB1*0401.IS Extension
of this analysis with murine fibroblasts express¬
ing different alleles of HLA-DP revealed that
HLA-DPB1*0401, DPB1"0402. and DPB1*0501-
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expressing fibroblasts all presented peptide to
KS2.12, although DPBl*0501-positive ceils were
less efficient (Fig. 4, B). No response to antigen
was observed in the presence of DRB1*0101-
positive fibroblast transfectants. Comparison of
the primary amino acid sequences indicates that
HLA-DPB1*0401, HLA-DPB1 *0402, and HLA-
DPB1*0501 differ at positions 31, 38. 57, 58, 86.
87, 88, and 89 (Fig. 5).
The T-cell clone KS2.15 proliferated to HDM
allergen presented by the EBV-transformed B
cells. KSE and HOM2 (Fig. 4, C). In contrast, the
B cell lines TTSI. PGF, PMG075, and YAR ail
failed to induce antigen-dependent proliferation.
The B cell line WT24 was able to stimulate
KS2.15 but only in the presence of high concen¬
trations of antigen and was suboptimai compared
with KSE or HOM2 (Fig. 4, C). Comparison of
the pattern of proliferation with the HLA class
II haplotypes of the EBV-transformed B ceils
(Table I) suggests that KS2.15 is restricted to
HLA-DRB1*0101.
Molecular models of T-cell epitopes mapped
on a computer model structure for the
Der p I molecule
The T-cell epitopes for HLA-DPB1*
0401/HLA-DPB1*0402 (107-119) (Fig. 6. A), and
HLA-DR1 (110-131) (Fig. 6. B) were mapped on
a computer model of the structure for the Der p I
molecule. The epitopes are shown by displaying
the side chains of component residues in a dark
gray. It may be observed that the T-cell epitopes
defined here are located on the exposed surface
of this model of Der p I.
DISCUSSION
In this study we have investigated in an HDM-
allergic individual the antigen and restriction
specificity of the peripheral T-cell repertoire re¬
active with the group I allergen of D. pteronyssirtus
(Der p I). With peptide pools covering the entire
sequence of Derp I and the group II allergen (Der
p II) the antigen specificity of a T cell line reactive
with D. pteronyssinus was examined. We observed
that the major component of the HDM-reactive
T-cell repertoire was directed toward residues
101-143 of Der p I and was cross-reactive with the
closely related species of HDM, D. fannae. Anal¬
ysis of fine antigen specificity of the T-ceil re¬
sponse to this region was explored with T-ceil
clones isolated from the line and allowed three
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FIG. 4. HLA class II restriction specificity of Der p I—
reactive T-cell clones. A, T cells of clone KS7.4 were
stimulated with antigen in the presence of autologous
EBV-transformed B cell line KSE (o) and WT24 (•) or with
the mouse fibroblast lines: control DAP3 (□) and DAP3
transfected with DRB1*0101 («|, DPB1*0401 (A), and
DPB1*0402 (a). B, T cells of clone KS2.12 were stimulated
with antigen in the presence of mouse fibroblasts trans¬
ferred with DRBI'0101 (■), DPB1*0401 (A|, DPB1*0402
The T-cell clones KS2.12 and KS7.4 recognized
two closely overlapping epitopes, 107-119 and
110-119, respectively; whereas the T-cell clone
KS2.15 responded to residues 110-131. From se¬
quence analysis it appears that there is 74%
identity between Derp I and Derf I in the region
101-13.1 as opposed to an overall 81% identity for
the two proteins; nevertheless, none of the T-cell
clones analyzed were cross-reactive.19 Amino acid
substitutions at positions 108 (Ser to Ala), 110
(Arg to His), and 111 (Phe to Tyr), although
conservative, appear to be important for T-cell
recognition by the clones KS2.12 and KS7.4. Simi¬
larly, the unique specificity of KS2.15 for Der p I
suggests that these residues and/or additionally
those at residues 123-126 are critical. With the
use of truncated recombinant proteins of Der p I,
an independent study identified T-cell epitopes at
residues 45-67, 94-104, and 117-143.16
Although in many instances T cells and B cells
respond to distinct regions within a protein,20
overlapping epitopes have been identified.21 With
regard to B-cell recognition of Derp I, analysis of
specificity of serum IgE antibodies demonstrated
that residues 60-80, 81-94, and 101-111 all contain
B cell sites22 and thus have only limited overlap
with the T-ctll epitopes. Mapping the T-ceil
epitopes defined here on a structural computer
model of Der p I positions them on exposed
surfaces of the molecule. Sequence analysis of
Der p I protein (residues 94-143), which contain
multiple T-cell epitopes restricted by different
major histocompatibility complex molecules sug¬
gests that this region has low identity to homolo¬
gous nonhuman cysteine proteases, such as cathe-
psin B, from which the model has been built.
Differences in the sequence of Der p I and the
corresponding self-proteins may account for the
immunodominance of this region.
The ability of anti-HLA-DP, but not anti-
HLA-DR framework antibodies, to inhibit
antigen-dependent proliferation of the Der p L
101-131-reactive T cell line indicated that HLA-
DP class II molecules restrict T-cell recognition.
Previous analysis of the restriction specificity of
long-term HDM-reactive T cells has established
that HLA-DRB1, HLA-DRB3, and HLA-DRB5
encoded gene products may present anti¬
gen.
15. 16. 23. 24 Using EBV-transformed B-cell lines
and murine fibroblasts expressing alleles of HLA-
(a), and DPB1*0501 ( + ). C, T cells of clone KS2.15 were
stimulated with antigen in the presence of EBV-trans¬
formed B cell lines KSE (o), WT24 (•), HOM2 <-r), T1SI (□),
PGF (A), PMG075 (XI, and YAR (■).
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FIG. S. The T-cell epitopes for (A) HLA-OPB1*0401/HLA-DPB1*0402/HLA-QPB1'0501 (107-119)
and (B) HLA-DR1 (110-131) mapped on a computer model structure for the Oer p I molecule. The
epitopes are shown by displaying the side chains of component residues in dark gray.
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DP, we observed that both the T-cell clones KS7.4
and KS2.12 responded to antigen in association
with DPB1*0402. Although HLA-DP-restricted
T-cell clones that are reactive with mycobacterial
heat shock protein 65 or viral antigens have been
reported,15- 26 these HLA class II molecules ap¬
pear to be less frequently used than HLA-DR.
Antigen recognition by the T-cell clone KS7.4 was
restricted by DPB1*0402 but not DPB1*0401
class II molecules, which differ at residues 38 (Ala
to Val), 57 (Ala to Asp), 58 (Ala to Glu) (Fig. 5).
On the basis of the crystalline structure of HLA-
DRBl,'7 the residue at position 38 in HLA-DP
wouid be located on the 3-pleated sheets forming
the floor of the cleft, whereas those at positions 57
and 58 wouid reside at one end of the a-helicai
wall of the antigen-combining site. Substitutions
at any of these positions may affect peptide bind¬
ing and T-cell recognition. The T-cell clone
KS2.12 recognizes peptide in association with
DPB1-0401, DPB1*0402. and DPB1*0501, de¬
spite amino acid differences at a number of posi¬
tions (residues 37, 58, 86, 87, 88, and 89) in the 31
domain. Substitutions at positions 85 and 86 in
DR class II molecules influence T-cell recognition
for selected T-cell clones.23 However, for the T-
ceil clone KS2.12, it appears that residue 86 is not
critical for antigen recognition. The presence of a
proline residue at position 88 is unique to certain
HLA-DPB molecules and may cause a shortening
of the 3-chain helix, resulting in a conformational
change at this end of the antigen-binding site. The
substitution of this Pro by an Ala residue in
HLA-DPB1*0501 would not have the same effect,
which may account for the differential pattern of
presentation by HLA-DPB *0501 class II mol¬
ecules. The presence of polymorphisms at either
end of the cleft and the ability of the peptide to be
presented by the three HLA-DPB alleles suggest
that the majority of binding interactions are
formed in the center of the peptide. These results
extend our earlier findings,15 and together with
recent generic epidemiologic studies, which dem¬
onstrate a positive correlation between allergen-
specific IgE and expression of certain HLA-DP
alleles, highlight the potential importance of these
class II molecules in atopic disease.29, 30
The third of the T-cell clones analyzed in this
study, KS2.15, which is specific for the peptide
residues 110-131, recognizes antigen presented by
HLA-DRB1*0101 expressing APCs. HLA-DR re¬
striction of Der p I peptides has been previously
described, and in that study T-cell recognition of
residues 45-67 and 117-143 of Der p I was re¬
stricted by HLA-DR7, and T-cell recognition of
residues 94-104 was restricted by HLA-DR2.
HLA-DR11 (DR5), and HLA-DR8.16
The development of subunit vaccines, targeted
at allergen-specific CD4+ T cells, as potential
immunotherapeutics for clinical desensitization
requires the identification of immunodominant
T-cell epitopes and the definition of their major
histocompatibility complex class II restriction
specificity. Our results together with other iden¬
tified T-cell epitopes of Der p I8, " suggest that
residues 82-143 are an immunodominant region
of Der p I, containing multiple T-cell epitopes
restricted by different HLA class II molecules.
Therefore any potential use of this region of
Der p I as an immunotherapeutic for desensitiza¬
tion would not be limited to a restricted number
of HLA class II specificities.
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Abstract
The contribution of the HLA-DRB1, -B3, and -B5 gene products in the recognition of
Dermatophagoides spp. (house dust mite) by helper T cells isolated from an atopic individual
(HLA-0Rw12, DR7; DRwS2b) with perennial rhinitis was investigated. Using a panel of
histocompatible and histoincompatible accessory ceils, the restriction specificity obtained for a
long term T cell suggested that a component of the dust mite reactive repertoire recognized
antigen in association with DRB3 gene products. Oligonucleotide DNA typing of the presenting
cell panel demonstrated a correlation between the DRw52b allele and T cell responsiveness.
Murine fibroblasts expressing DRwS2b, but not DRw52a or -c molecules, presented antigen to
both the T cell line and cloned T cells (DE26) derived from the line, indicating that the supertypic
specificity DRw52b was able to restrict recognition of dust mite antigens. Additional T cell clones
(DE9 and 0E41) also isolated from the line were restricted by the products of the B1 gene locus
(DRw12B1) as determined by murine fibroblasts transfected with the appropriate HLA-QR genes.
Clone DE9 was degenerate in its restriction specificity, also recognizing dust mite presented by
accessory cells expressing the DR2 subtypes. Presentation by fibroblasts transfected with
DRW12B1, DR2Dw2B5 genes and EBV-transformed B cell lines expressing DR2Dw21B1 and -B5
indicated that the functional site restricting recognition may be associated with residues 70 and
71 of the DRfl chain helical wall of the antigen combining site. Furthermore, we have recently
demonstrated that both T cell clones 0E9 and 0E26 induce allergen dependent IgE synthesis
in vitro. Thus these results demonstrate directly that the DRB1, -B3, and -85 gene products are
functional in the restriction of T cell recognition of dust mite antigens.
Introduction
Immune responses are initiated following the interaction of the
antigen specific receptor of CD4- T lympnocytes with molecular
complexes formed between peptide fragments of antigen and
MHC class II proteins (1-4). In man. MHC class II genes
encode three major families of molecules, HLA-DR, -DQ, and
-DP, all of which appear to function in the regulation of immune
responsiveness (5-7). Furthermore, the OR locus on most
haplotypes contains two expressed B genes, the products of
which pair with the same DRa chain to give rise to two DR
molecules, DRaJI and DRadlll (or DRaJIV or DRaiSV), the maior
DR and the suoertypic specificities respectively, both of which
are polymorphic and able to restrict T cell antigen recognition
(8-10).
Immune recognition of the aeroallergen Dermatophagoides
spp. (house oust mite) induces immunoglobulin E (IgE) synthesis
and symptomatic allergic disease in 10-15% of the population.
Detailed analysis of the specificity and effector function of IgE
in mite allergy is well documented (11-13). Although IgE
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synthesis is T cell dependent, only limited information is available
on the antigen and MHC class II restriction specificity of the T
cell repertoire activated in atopic individuals after exposure to
house dust mite. Investigation of polyclonal responses to only
the group I allergen of Dermatophagoides pteronyssinus, Der
p I, indicated that T ceils from atopic but not control non-atopic
subjects proliferated to allergen (14). In addition, the results of
experiments using anti-HLA class II antibodies to inhibit the
antigen-dependent response of D. pteronyssinus reactive T cell
clones and lines indicated that HLA-DR molecules restricted
recognition of house dust mite but failed to identify the HLA-D
region locus encoding the restriction elements used (15).
In previous studies we examined the HLA class II restriction
of D. farinae reactive T cell clones isolated from the peripheral
blood of an atopic individual using serological inhibition and
allogeneic presenting cell panels (16,17). Complex patterns of
restriction specificities were obtained suggesting that the product
of locus DRAB3. in addition to the DRAB1 gene products, may
function as restriction elements in T cell recognition. This
prompted us to investigate the functional role of DRw52 class
II molecules in the allergic response by correlating the patterns
of reactivity of dust mite specific T cells with the results of DRB3
allele-specific hybridization with oligonucleotide probes in panel
studies. Additionally, T cell clones capable of supporting allergen
deoendent IgE synthesis in vitro (18) were Isolated from the
T cell line and their restriction specificities examined using
homozygous Epstein - Barr virus (EBV) transformed B cells and
murine fibroblast transfectants expressing specific HLA-DR
genes as antigen presenting cells (APC), The results of these
experiments indicate that HLA-DRB1, -B3, and -B5 gene
products are able to restrict the recognition-of house dust mite




Lyophilized extracts of D. farinae were obtained from Pharmacia
Ltd. Uppsala, Sweden.
Isolation of antigen reactive T cell line and clones
The isolation of the T cell line and clones used in these
experiments has been described in detail elsewhere (16.17),
Briefly, peripheral blood mononuclear leukocytes (PBMC;
2.5 x 105/ml) were stimulated with an optimal concentration of
D. farinae [103 Biological Units (BU)/ml] for 7 days in RPMI
1640 (Flow Laboratories, Irvine, Ayrshire. UK) medium
supplemented with 2 mM L-glutam'ine, 100 U/ml penicillin/strepto¬
mycin, and 5°/o v/v screened, heat-inactivated human A- serum
(National Blood Transfusion Centre, Edinburgh. UK). Lympho-
blasts enriched on Ficoll-Pague (Pharmacia) were maintained as
a long term line in the presence of irradiated (2500 rad)
autologous PBMC, D. fannae, and interleukin 2 (IL-2, 10°/o v/v;
LymphocuItT, Biotest Folex, Frankfurt. FRG), or cloned by limiting
dilution from the line. For cloning, viable cells (0.3 cells/well) were
plated in Microtest II trays together with irradiated autologous
PBMC (5 x 105/ml). D. fannae, and IL-2. After 7 days, growing
clones were transferred to 96-well flat-bottom microtitre trays and
subsequently to 24-well trays. At each transfer the clones received
filler cells, antigen, and IL-2. The clones and the line were main¬
tained and expanded by the addition of IL-2 every 3-4 days
and antigen together with filler cells every 7 days. Prior to their
use in proliferation assays, the T cell clones and the line were
rested for 6-8 days after the last addition of filler cells and
antigen.
Antigen specificity of the T cell line and clones
The T cell line (DX) recognizes both major species of house dust
mite (D. farinae and D. pteronyssinus) but the predominant
specificity was for the group II allergen (Der f II; 12.5 kd) of
D. farinae as determined using nitrocellulose immunoblots of
fractionated antigen (16). T cell clones DE9 and DE26 responded
to both dust mite species, with the determinant recognized by
DE9 being further mapped to the group I allergens (26 kd). The
T cell clone DE41 was only stimulated by D. farinae preparations.
Cell populations used as antigen presenting cells
Autologous and allogeneic PBMC, homozygous EBV trans¬
formed B cells, and murine fibroblasts transfected with HLA-D
region genes were used as antigen presenting cells. The
HLA-typed antigen presenting cell panel was generously
provided by Dr D. Eckels, Blood Center of Southeastern
Wisconsin, Milwaukee, Wl. The cloning of the DR1Dw1,
DRw2Dw2B1 (DRBT1501), DR2Dw2B5, DRw12B1, DR7Dw17,
and DRw52a. -b, and -c genes and their co-transfection with the
DRA gene into the Ltk- fibroblast cell line (DAP3) has been
described elsewhere (19-25).
T lymphocyte proliferation assays
T cells of the long term line (DX) and clones (DE9, DE26, and
DE41; 5 x 104/ml) were'cultured with antigen in the presence
of irradiated HLA typed histocompatible and histoincompatible
PBMC (1.25 X 105/ml), EBV transfo.med B cells (105/ml), or
mitomycin C treated transfected murine fibroblasts (105/ml) in a
total volume of 200 /il of complete medium in 96-well U-bottom
plates. Assays in which fibroblasts were used as presenting cells
were performed in 96-well flat-bottom plates. After 72 h of
incubation, tritiated methyl thymidine (1 ^Ci/well, [3H]TdR;
Amersham International Inc., Amersham. UK) was added to
cultures which were harvested onto glass fibre filters, 8-16 h
later. Proliferation as correlated with [3H]TdR incorporation was
measured by liquid scintillation spectroscopy. The results are
expressed as mean counts per minute (c.p.m.) + % error of the
mean for triplicate cultures and were <20% in all experiments.
Mitomycin C treatment or murine fibroblasts
After trypsinization, cells were washed in serum free medium.
Cells, up to 107/ml, were suspended in serum free medium
and mitomycin C (Sigma) was added to a final concentration
of 50 ng/ml. Cells were incubated at 37°C for 45 min,
washed extensively in A* supplemented medium, and used in
proliferation assays (20).
Oligonucleotide DNA typing
DNA was prepared from the presenting cell panei and
probed with oligonucleotides labelled with [7-32P]dATP as
described previously (21). The oligonucleotide 52a (GGAGCT-
GCGTAAGTCTGAG) probe is complementary to the nucleotide
sequence residues 11 - 29 of DRw52a which encode for
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ammo acid residues 8-14 of the 01 domain of the DRw52a
allele. Oligonucleotide 52b (GTTCCTGGAGAGACACTTCC) is
complementary to the nucleotide sequence residues 62-81
of the DRw52b allele and oligonucleotide 52c (GTTCCTGGA-
GAGATACTTCC) is complementary to the nucleotide sequence
62-81 of the QRw52c allele (9). Nucleotide sequence residues
62-81 encode for amino'acid residues 25-31 of the (31 domain
of DRw52b and DRw52c.
Results
identification of Oermatophagoides reactive T cell restricted by
DRw52 associated determinants by oligonucleotide hyoridization
The restriction specificity of a long term T cell line (DX) reactive
with D. farmae was examined using a panel of histocompatible
and histoincompatible PBMC, including RM (DRw12, DR7:
DRw52), the autologous control, as accessory cells (Table 1):
In each of the experiments examining the restriction specificity
of the T cell line the complete panel of accessory cells was used
and identical protocols were followed. The pattern of restriction
was complex and revealed no clear correlation with the
serologically defined B1 gene products. All of the accessory cells
expressing DR7 were able to present D. fannae with the exception
of 005G, which may reflect polymorphism in the DR7 allele. No
proliferation was observed in the control cultures containing the
T cell line and accessory cells in the absence of antigen. Althougn
certain panel members had apparently identical specificity as
determined serologically (150G and 814G: 857D and 826E), they
differed in their efficiency as presenting cells. This may reflect
microheterogeneity in the class II alleles that may not be detecteo
unless the individual alleles are sequenced. Furthermore, a
component of the long term T cell line recognized antigen
presented by all the DRw11- ana DRw12~ accessory cells
tested. Based on the sequence variation in the DR5 subtypes
(DRw11 and DRw12), the pattern of proliferation suggests that
the DRB3 gene product DRw52. as well as the DRB1 gene
product, may also be restricting T cell recognition.
The supertypic specificity DRw52 is associated serologically
with HLA-DR3, -5. -w13, and -w14. It was found by transfection
studies to be encoded by the DRB3 locus (22) and sequence
analysis has revealed at least three alleles at that locus (8). The
restriction specificity of tetanus toxoid T ceil clones has suggested
a functional role for products of the DRB3 locus (10). To investi¬
gate further the possibility that DRB3 gene products were restrict¬
ing T ceil recognition of house dust mite antigens, the panel of
presenting cells was typed using oligonucleotide probes specific
for the QRw52a. -b, and -c alleles. The results demonstrated
a complete correlation between the DRw52b oligonucleotide
hybriaization pattern in those cells expressing DRw52 (not donors
305G and 239G) and the induction of antigen dependent
proliferation (Table 1). In contrast, the T cells failed to recognize
D. fannae presented by accessory cells expressing DRw52a
and -c.
Antigen presentation bymurine fibroblasts expressing DRw52b
class II molecules
To confirm the functional role of DRw52 in the recognition of
O. fannae. murine fibroblasts transfected with DRw52a. -b,
or -c genes were used as antigen presenting cells. Only those
fibroblasts expressing DRw52b. but not DRw52a and -c. were
able to present antigen in a dose dependent manner to T cells
of the long term line DX (Fig. 1). Comparison of the primary
sequence reveals that amino acid substitutions at positions
30. 37, 38, 51, 57, and 60 of the 0 chain distinguish between
DRw52b and the other two subtypes. DRw52a and -c (Table 2).






RM 7.w12 b _ 28.501
088G 1.5 b - 2484
150G 4 w12 b +. 11.855
814G 4.w12 b a. 2694
056G 5.- b/b - 6802
857D 5.6 b - 18.074
826E 5,6 b - 6424
005G 1.7 - 4- 271
305G 2.7 - + 15.320
239G 7.9 - 4499
161E 2.9 - +■ 202
855E 2.4 - -h 173
001C 2.- - - 798
1009 3.8 a - 285
004C 3.- a - 877
804E 3.6 aJc 482
The long term T cell tine was stimulated with O. fannae in the oresence
of a oane! of histocompatible and histoincompatible irradiated PBMC as
a source of APCs. Background responses to APCs in the absence of
antigen have been subtracted in eacn case (<1000 c.o.m.). Culture
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Fig. 1. Proliferative response of the T cell line DX to D. iarmae presented
by murine fibroblasts expressing the QRw52 alleles. T ceils (10s.'ml) were
cultured with O. farmae (5 - 20 x 103 BU/ml) in the presence of
autologous PBMC (1.25 x 105/ml: •) or mitomycin C-treated murine
fibroblasts (105/ml) expressing DRw52a (G), DRw52b (A), DRw52c ill).
DRIDwl (■), and Ltk- cells (C). Background responses of Tcells to
accessory ceils in the absence of antigen were <500 c.p.m. Culture
conditions and proliferation were determined as described in Methods.
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No proliferation was obtained when antigen was presented
by control fibroblasts expressing DR1. The failure of L cell
transfectants to present house dust mite components in the
experiments described in this paper could not be attributed to
their lack of functional activity as they supported antigen
presentation in other moaeis of T cell antigen recognition (20.24,
m-
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Fig. 2. Recognition of D. farinae by T cell cione DE26 is restricted by
the DRw52b specificity. Cloned T cells (105/ml) were cultured with O.
farinae (5-20 x 103 BU/ml) in the presence of autologous PBtvIC
(1.25 x 105/ml; •) or mitomycin C-treated murine fibroblasts (105/ml)
expressing DRw52a (□). DRw52b (▲), DRw52c (A). DRIDwl (■)
DR7Dw17 (▼), and Uk" cells (O). Background responses of T cells to
accessory cells in the absence of antigen were <350 c.p.m. Culture
conditions and proliferation were determined as described in Methods.
personal communications). Stimulation of T cells by the house
dust mite was markedly greater in the presence of autologous
PBMC. The absence of accessory molecule interactions and the
potential for differential processing by murine fibroblasts may
account for the less efficient antigen presentation.
In order to examine the relative contribution of the DRB1 and
B3 gene products in the recognition of house dust mite antigens
the T cell line was cloned by limiting dilution. The patterns of
proliferation obtained-with T cell clones DD11. DE12, and DE26
isolated in this way were similar to that observed for the T cell
line as regards their response to antigen presented By DR5*
(DRw11 - and DRw12*) cells (17). Consequently, the restriction
specificity of T cells of clone DE26 was examined using DRw52
transfected murine fibroblasts. Antigen dependent proliferation
was obtained only in the presence of fibroblasts expressing
DRw52b (Fig. 2). Neither the DRw52a nor the DRw52c
transfectants were able to present antigen to DE26. Similarly, in
control cultures containing DR1*. DR7*. and Ltk- fibroblasts
no proliferation was observed. Thus allergen reactive T cells
restricted by the DRAB3 gene product (DRw52b) could be
identified at both the oligoclonal and monoclonal levels.
DRAB1- and DRAB5-restricted T cell recognition of Dermato-
phagoides
From the pattern of T cell proliferation of the long term line
observed using the allogeneic presenting cell panel (Table 1) and
from the results of previous experiments (17). it appeared that
DRAB1 gene products also contributed to the recognition of
house dust mite allergen by T cells of this individual (Table 1).
The restriction specificities of the T cell clones DE9 and DE41.
derived from the T cell line, were examined in detail.
T cells of clone DE9 wq;e stimulated by antigen in association





Fig. 3. EBV transformed B cells expressing 0R2 or DR5 class II proteins
restrict the recognition of D. larmae by the T cell clone DE9. Cloned T
cells of DE9 (105/ml) were cultured with D. farinae (5-20 x 103 BU/ml)
in the presence of autologous PBMC (1.25 x 105/ml; •), or EBV-
translormed B cells (105/ml) expressing DRw2Dw2 (□), DR2Dw21 (■).
DRw12 (O). or DR7Dw17(A). Background responses of T cells to
accessory cells in the aDsence of antigen were <1400 c.p.m. Culture
conditions and proliferation were determined as described in Methods.
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Fig. 4. Mapping the fine restriction specificity of T cell clone DE9 with
murine fibroblasts expressing the DRw12 and DR2Dw2 specificities as
presenting cells. Cloned T cells of DE9 (105/ml) were cultured with D.
tarinae (5-20 x 103 BU/ml) in the presence of autologous PBMC
(1.25 x 105/ml: •) or mitomycin C-ireateo murine fibroblasts (10=/ml)
expressing DRw12B1 (□). DR2Dw2B5 (O). DR2Dw2B1 (■). and
DRIDwl (A) gene products. Background responses of .T cells to
accessory cells in the absence of antigen were <940 c.p.m. Culture
conditions and proliferation were determined as described in Methods.
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Homozygous EBV-transformed B cells expressing DR2Dw2 or
DR2Dw21 molecules were able to present mite antigens to the
T cell clone (Fig. 3). However, their capacity to present antigen
was quantitatively different, with DR2Dw2 EBV B cells being
markedly more effective. Nevertheless, presentation of the
DR2Dw21 * B cells was always >4-fold that of the background
accessory cells alone and antigen presented by class II molecules
of unrelated specificity. Similarly, the-parental allele DRw12*- but
not the control 0R7* EBV B cells induced antigen dependent
proliferation of T cell clone DE9 (Fig. 3).
To determine the contributions of DRB1 and DRB3 gene
products to the presentation of antigen by DRwl2, DR2Dw2,
and DR2Dw21 expressing EBV B cell lines, murine fibroblasts
transfected with the appropriate HLA class II genes were used
as presenting cells. Fibroblasts expressing the DRw12B1 or
DR2Dw2B5 gene products were able to present antigen to clone
DE9 in a dose dependent manner (Fig. 4). In contrast, the
DR2Dw2B1 gene expressed in fibroblasts failed to induce T cell
proliferation. In the absence of antigen or with control DR1 Dw1 +
transfectants no activation of the T cells was observed. From the
results of previous experiments T cell clone DE41 appeared to
be restricted by DRw12* (DR5) accessory cells (17). Indeed,
murine fibroblasts transfected with the DRw12B1 gene were able
to present Dermatophagoides to the T cell clone DE41 (Fig. 5).
However, the efficiency of presentation by these cells was
reduced as compared with autologous PBMC.
Discussion
In this paper the HLA class II restricticn specificity of T ceil
recognition of the house dust mite. Dermatophagoides spp., is
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Fig. 5. Recognition of D. larinae by T cell clone 0E41 is restricted by
the DRw12 class II specificity. T cells of clone DE41 (i0s/ml) were
cultured wilh D. farinae (5-20 x 103 BU/ml) in the presence of
autologous PBMC (1.25 x 105/mi: •) or mitomycin C-treated murine
fibroblasts (105/ml) expressing DRw12B1 (C), DRIDwl (■), and Ltk-
cells (C). Background responses of T cells to accessory cells in the
absence of antigen were <410 c.p.m. Culture conditions and proliferation
were determined as described in Methods.
of an atopic individual with perennial rhinitis (16,17). To investigate
the heterogeneity of the HLA class II alleles regulating the
responsivenss to house dust mite allergens a panel of HLA-DR
histocpmpatible and histoincompatible PBMC was used to
present antigen to an oligoclonal T cell population. The T ceil
line responded to both major species of the house dust mite,
although the dominant specificity was for component(s) of the
group II allergen of D. farinae. Although T cell recognition was
HLA class II restricted, the pattern of the proliferative responses
did not correspond to serologically defined DRB1 gene products.
However, correlation between the functional studies and
oligonucleotide typing of the presenting cell panel strongiy
suggest that the B3 gene products were able to restrict recogni¬
tion of components of house dust mite. Although QRw52a
restricted T cell recognition of tetanus toxoid has been reported,
unlike the response to dust mite (17), the major component of
the tetanus toxoid reactive repertoire is not restricted by B3 gene
products (10). Furthermore, using murine fibroblasts expressing
each of the three alleles of DRw52 (10) as presenting cells, the
restriction determinants were assigned to the DRw52b molecule.
Similarly, cloned T cells reactive with a shared determinant in
both species of dust mite (DE26) were isolated from the T cell
line and showed identical restriction specificity for DRw52b
expressed on murine fibroblasts. These findings demonstrate
directly that the product of locus DRB3 is functional in antigen
presentation and that it contributes to the recognition of house
dust mite allergens. The magnitude of the proliferative response
induced in the T cell line when D. farinae was presented by
DRw52b- fibroblasts indicated that this was a major restriction
element. This resuit is somewhat surprising for, although DR
proteins, as opposed to DQ and DP (26), are the main restric¬
tion elements used in T cell recognition, this can be mapped to
the B1 gene products in most cases. Quantitation of mRNA for
class II proteins suggests that the B3 gene products are
expressed at 2- to 5-fold lower levels than the 81 gene products
(27). Thus, the dominance of the DRw52 allele as a restriction
element in the recognition of the house dust mite by this individual
is independent of the differential expression ofthe B1 and B3
gene products and may reflect differences in the binding of house
dust mite peptides or in the T cell repertoire activated in the
allergic immune response, with a very different pattern of allelic
diversity observed among the DRB3 alleles than among the
DRB1 alleles (10). As the specific T cell response of other house
dust mite allergic individuals is inhibitable by an antibody reactive
with DRw52b, this indicates that the contribution of the 83 gene
products in the recognition of Dermatophagoides is not limited.
The immunodominance of allele 52b in the case of the house
oust mite is also of interest in view of the wide distribution of that
allele.
From comparison of the primary amino acid sequence of
the first domain of the i3 chain of the DRw52 alleles, differences
in positions 30. 37, 38, 50. 57, and 60 distinguish DRw52b
from the other two DRw52 alleles (Table 2). Based on the
three dimensional structure of HLA-A2 (28) and the sequence
homologies between class I and class II histocompatibility
proteins, a hypothetical model of the antigen combining site of
MHO class II molecules has been generated (29). From their
proposed location in the combining site, the amino acios at
positions 30. 37, 57, and 60 may influence T cell recognition.
Residues at positions 30 and 37 are located on the central strands
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Table 2. The primary amino acid sequence of the B1 domains of suoertypic specificities DRw52a. -b. and -c
1 0 .2 0 3 0 4 0
DR cons PRFL E Q x KSECHFFNGTERVRx L 1 Rx FHNQEEx VRFDSDVGEYRA
DRw52a LR :-Y-D-Y Ft
DRw52b LI F-E-H YA
DRw52c LL F-E-Y FV
SO 60 70 80 ,9 0
DR cons VxELGRPxAExWNSQKDLLEQKRGAVDNYCRHNYGVxESFTVQRR
DRw52a -T V--S R G
DRw52b -R D--Y Q V
DRw52c -T V--S - - - Q V
Table 3. The primary amino acid sequence, of the B1 domains of DFiw12B1, DR2Dw2B1, -Dw2B5, -Dw21 B1, and -Dw2185 MHC
class II proteins









DRw 1281 — - — — - -_V — — 5 — — — - — — I - -DR-------------AV--------
DR2Dw2B5 -F--DR
DR2DW2BI - ......| _._A...........---V---
DR2DW2IB5 - ---..|...A-.....-------AV..
DR2DW2IBI -- -----F--0R----- ------------------
•
DR cons P R F [_ p Q x K x
DRw 12B1 Y 5 T G
DR2Dw2B5 - - - - Q - D - Y
DR2Dw2B1 - - - - W - P - R
DR2Dw21B5 - C - - Q - D - Y
DR2Dw21B1 - - - - W - P - R
of the 0 pleated sheets forming the floor of the combining site,
whereas positions 57 and 60 would be located at one end of
the a helical wall of the cleft. All four residues are remarkably
clustered on the DR molecule. Substitutions at any of these
positions may affect antigen binding and T cell recognition.
Similarly, the residue at position 38 may influence the conforma¬
tion of the a heiical wall and thus restrict the ability of certain
peptides to occupy the antigen combining site. By site directed
mutagenesis it has been demonstrated that a single amino acid
substitution at position 29 in the floor of the antigen combining
site could determine T cell recognition of pigeon cytochrome c
(30). This would imply that amino acid variation at position 30
may be critical for T cell recognition of house dust mite peptides
restricted by the DRw52 molecule. Likewise, residue differences
at position 57 alone in the DQB chain have been reported to
influence the susceptibility to insulin dependent diabetes (31).
To extend this analysis on the contribution of the polymorphic
residues in DRw52 on T cell recognition of dust mite, defined
T cell epitopes are required. However, this is hampered by a
lack of structural information on the components of mites, with
only the group I allergens of D. pteronyssinus naving oeen cloned
and sequenced. Nevertheless, the ability of unfractionated house
dust mite allergen to competitively inhibit the binding of peptioes
to fibroblasts expressing DRw52 supports the role of the B3 gene
products as the major restriction elements in the recognition of
Dermatophagoides (R. E. O'Hehir and J. R. Lamb, unpublisned
results).
Population analysis of the immunogenetic basis of atopy has
indicated associations between the HLA-DR phenotype and the
induction of specific IgE for several purified allergens (32-34).
The isolation of T cell clones from the long term line also allowed
the functional sites on the B1 gene products capable of restricting
recognition of house dust mite determinants to be mappea. The
restriction specificity of the T ceil clone DE9, which recognizes
an invariant sequence in the group I allergens of the house
dust mite, was degenerate in that antigen was recognized in
association with the parental allele DRw 12 as well as DR2Dw2
and DR2Dw21. This is in contrast to the D. farinae reactive T
.mLA ciass :i restricted T ceil recognition of house oust mite 891
ceil clone DE41. whic.n <s restricted by DRw12 but snows no
degeneracy on the DR2Dw2 or DR2Dw21 proteins. Interestingly,
the presence or serum IgE specific for the pollen antigens. Amo
a V and Amo a VI, are DR2Dw2 and DR5 (DRwi 1) associated.
resDectively (32.33). Amino acio seouence comoanson of the
.31 domains of DRw12B1 (DRB1 *1201) and DR2Dw2B5 reveals
extensive differences in the N-terminai half of the comains (Taoie
3). the region predicted to compose the floor of the antigen
combining site (29). In contrast, the C-terminai naif of these
domains, predicted to form the a henx running across the floor
of anti-parailel strands, is similar for these two OR molecules, with
identity at positions 70 and 71. The DR2Dw2B1 and DR2Dw21 B5
a helical seguences differ from DRwi2B1 and DR2Dw2B1 at
these positions; however, the seouence of the OR2Dw21 B1 gene
product is identical. These observations imply that the HLA class
II restriction of this T ceil clone is determined by alleiically poiy-
morpnic residues in the a helix of the £1 domain, irrescective
of seouence differences in the floor (35). Simiiar patterns of MHC
restriction nave been described for the influenza haemaggiutimn-
specific. DRlDw-1-restricted T eel! clone. HA1.7 (36), and for
multiple murine T cell clones (1.35). Another imolication of the
results of these experiments is that, although the B1 gene oroduct
is the restriction element on the DRwi2 and DR2Dw21
haolotvpes. :t is probaoie that the 35 gene product is used n
the case of the DR2Dw2-exoressing ceils. This can be inferred
from the seouence identity of these molecules at positions 70
and 71. Simiiar flexibility of MHC restriction may account for the
DR2/DR5 association of the allergic immune resconse to the rye
allergen. Lol p III (34). since these alleles have different seouences
but share the same 33 gene seguence. This may be the
molecular basis for DR3/DR5 restricted recognition of Lot p ill
as ODposed to conserved residues (amino acios 9- 13) m the
3 strands of the floor of the antigen combining site (34).
The findings reported here demonstrate the Heterogeneity of
MHC class II restriction or T cei! recognition of house dust mite
antigens within an individual in terms of the use of the 31 ano
83 gene products. Furthermore, both clones DE9 ano DE26.
althougn restricted by 31 ano 33 gene products rescectiveiy.
are able to provide heip for IgE synthesis n an allergen
dependent in vitro B cell assay (17,18). It is surprising that the
major component of the T ceil repertoire is restricted by the 33
gene products in view of their reduced expression relative to the
31 locus products (27). Contrary to the B1 gene orooucts. wnere
the polymorphism is restricted to three variapie domains, n the
DRw52 aileies sequence differences are scattered througnout
the 31 domain (Table 2). This may reguiate T cell recognition
auaiitativeiy by restricting the diversity of peptides capacie of
occupying the antigen combining site (37), in this case DRw52b.
ano the suosequent activation of T cells wheh requires de¬
recognition of MHC class II ano peptide. The immunological
advantage of 31. 83. ano B5 gene products functioning as
restriction elements may be to increase the diversity of the 7 ceil
repertoire activated in response to the house oustmite, aithougn
in some individuals sensitized with allergen the population of T
ceils activated may Induce an aberrant immune response.
The Heterogeneity of the antigen and restriction specificity of
T ceil recognition ot the house oustmite is of practical importance
for ;ne development of therapy oased on immunological inter¬
vention. sucn as the induction of T ceil tolerance or competitive
inhibition of MHC class II proteins (38).
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Abstract
The group 2 allergens of Dermatophagoides spp. (house dust mite, HDM) are a major
immunological target for IgE antibodies in the allergic immune response of HDM atopic
individuals. In this report the heterogeneity of the T cell repertoire reactive with the group 2
allergen of Dermatophagoides pteronyssinus (Der p 2) of a HDM allergic individual was
investigated using overlapping synthetic peptides. By clonal analysis four distinct T cell epitopes
were identified, located within residues 16-31, 22-40, 82-100, and 111-129. The importance
of these epitopes was confirmed by investigation of the peripheral T cell repertoire, with the
polyclonal T cell response to Der p 2 failing to show marked variations in epitope specificity over
time. Serological inhibition studies and the use of Epstein-Barr virus transformed B cell lines
characterized for their expression of HLA-D region gene products demonstrated that recognition
of peptides 16-31 and 111-129 was restricted by HLA-OQ (DQB1 "0301), whereas peptide
82-100 is recognized in association with HLA-DR (DRB1 *1101). Peptide 22-40 was presented
by both HLA-DRB1 *1101 and -DQB1*0301 class II molecules. The potential application of these
findings lies in the design of peptide-based immunotherapeutlcs for the management of HDM
allergic disease.
Introduction
The exposure of geneticaiiy susceptible individuals. -10 -15%
of the population, to environmental allergens including the
proteins of house dust mite (HDM) results in clinical symptoms
that range from extrinsic asthma and allergic rhinitis to atopic
aermatitis (1). The inflammatory responses that cause these
clinicai symptoms are due to the synthesis of allergen specific
IgE antibodies and the activation of polymorphonuclear granulo¬
cytes (2.3). Initially, interest focused on the specificity of IgE
antibody responses and, although multiple proteins have been
identified in HDM that bind IgE from the sera of HDM allergic
individuals (4), the major component of the HDM reactive 8 cell
repertoire is directed towards the group 1 and 2 proteins and
is cross-reactive to both species of HDM, Dermatophagoides
pteronyssinus and D. fannae (5,6). Furthermore, it appears from
several studies that between 40 and 38% of the IgE antibody
response is specific for the group 2 allergens (Der p 2 and
Der f 2), and illustrates their importance as target antigens in the
allergic immune response to HDM (7).
It is well established that the induction of the allergic
inflammatory response, including allergen specific IgE synthesis
and the growth, differentiation and activation of non-specific
granulocytes depends on the activity of CD4* T cells (2.3.8).
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CD4* T cell activation requires the combined effects of
co-stimulatory signals and occupancy of specific TCR by peptide
fragments of antigen complexec with class II MHC molecules
(9-11). In order to understand the pathogenesis of allergic
infiammatory responses and to develop new approaches to
immunotherapy, information on both the antigen and MHC class
II restriction specificity of T cell recognition of the mapr proteins
of HDM is required. With the primary amino acid sequences of
the group 2 allergen availaoie from the nucleotide sequence of
cloned cDNA (12.13), it is possible to identify the immuno¬
dominant epitopes in this protein that are recognized by the T
cell repertoire of HDM allergic individuals (14).
Genetic epidemiological studies have failed to establish a clear
association between the expression of a particular HLA
phenotype and allergic responsiveness to HDM (15,16), and
therefore much of the information available on those HLA class
II molecules that contribute to HDM responsiveness is based on
characterization of the restriction specificity of T cell clones
(17,18). These studies have demonstrated that HLA-DRB1,
-DRB3, -DRB5, and -DP encoded gene products all may function
as restriction elements in T cell recognition of HDM allergens
(19-21). However, at present detailed analysis of the restriction
specificity of T cell recognition of Der p 2 at the epitope level
is incomplete. This prompted us to investigate by clonal analysis
the heterogeneity of T cell responses to Der p 2. With overlapping
peptides we have identified four distinct T cell epitopes at residues
16-31. 22-40, 82-100, and 111-129. Furthermore, from
seroiogical inhibition studies and the patterns of proliferation
observed when specific peptide was presented by antigen
presenting ceils (APC) expressing different HLA class II
moiecules, it appeared that recognition of peptides 16-31 and
III -129 was restricted by HLA-DQ (DQB1"0301), whereas
peptide 82-100 was recognized in association with HLA-DR
(DRB1M101). Peptide 22 - 40 was presented by both HLA-
DRB1 "1101 and -DQB1 *0301 class II molecuies. The analysis
of the peptide sequences suggests that allele specific anchor
residues are present determining binding to DQB1 "0301.
Methods
Antigens
Overlapping peptides derived from the nucleotide sequence of
Der p 2 were synthesized in our department as previously
described (22), or purchased from Chiron Mimotopes
(Melbourne. Australia). The primary amino acid sequence of
Der p 2 is snown in Fig. 1.
Antibodies
The monoclonal anti-HLA-DR (L243) (23), anti-HLA-DP (B7/21)
(24), and anti-HLA-DQ (SPV-L3) (25) antibodies were isolated
from the culture supernatants of the respective hybridoma cell
lines and purified using Protein A-Sepharose.
Isolation of Der p 2 reactive T cell clones
T cell clones reactive with Der p 2 were isolated from a HDM
allergic individual (AC; haplotype DR7, DR11 (5), DQ2, DQ7(3),
DPB1 *0101/"0402] by limiting dilution cloning as described
previously (14,17). Briefly, peripheral blood mononuclear cells
(PBMC; 106/ml) were stimulated with an optimal concentration
of Der p 2 (20 ^g/ml) for 7 days in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 100 lU/ml penicillin/strep¬
tomycin (Gibco, Life Technologies. Paisiey, UK) and 5%
screened, inactivated human A* serum (National Blood
Transfusion Service. Eogware, UK). A long-term line of the oonor
was estapiisneo with lymohobiasts enriched on Ficoll-Paque
(Pharmacia. Milton Keynes, UK), in the presence of irradiated
autologous PBMC (5x105/ml; 2500 rad), Der p 2 (20 jig/ml)
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Fig. 1. Primary amino acid sequence of tne Der p 2 moiecuie (boxed residues refer to tne defined eDitooes).
and IL-2 (IL-2. 10% v/v; Lymphocult T, Biotest Fclex, Frankfurt.
Germany). Viable cells (0.3 cells/well) were cloned by limiting
dilution in supplemented medium and plated in 96-well flat bottom
plates (Nunc. Gibco. Life Sciences, Paisley, UK) together with an
irradiated autologous Epstein - Sarr virus-transformed B cell line
(EBV-B cell line) (1 x 10s/rnl; 5000 rad), allogeneic PBMC from
two donors (1 x 106/ml total; 2500 rad), Der p 2 (20 ng/ml), and
Leuco A (1 /ig/ml) (Pharmacia. Milton Keynes. UK). After 7 days,
growing clones were transferred to 24-well plates. The clones
were maintained with IL-2 every 3-4 days and irradiated
T cell epitopes of house dust mite 1591
autologous PBMC and Der p 2 every-7 days. Clones were rested
for 7-8 days after the last addition of antigen and antigen
presenting cells before experimental procedures.
Proliferation assays
Polyclonal T cell assays. Unfractionated PBMC (1 x 106/ml) were
cultured with Der p 2 peptides (10 and 30 ng/ml). On day 7, T
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Fig. 2. EpitODe specificity of Der p 2 specific T cell clones. A, AC1; B, AC2; C. AC3; D. AC5; E. AC28; and F, AC29. T ceil clones were stimulated
with overlapping peptides of Der p 2 at 1 and 10 ^g/ml in the presence of APCs (irradiated autologous EBV-8 ceils). The maximal proliferative response
ootaineo for eacn peptide is shown. Control responses to IL-2 or medium alone were also determined.
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tritiated methyl thymidine (1 /iCi/well, [3H)TdR; Amersham
International, Amersham, UK) and the cultures harvested 8 -16 h
later. Proliferation as correlated with [3H]TdR incorporation was
measured by liquid scintillation spectroscopy. The results are
expressed as mean c.p.m, for triplicate cultures. The standard
error of the mean for all experiments was <20%.
Clonal T cell responses. Peptides (0.1-50.0 fig/ml) were
presented to cloned T cells (10s cells/ml) with irradiated
autologous PBMC (2500 rad), autologous EBV-B cells or HLA
typed EBV-B cells, histocompatible or histoincompatible at the
D region loci (5000 rad), as a source of APCs. In serological
inhibition assays, antibodies were added over a concentration
range at the initiation of cultures. After 60 h incubation the cultures
were pulsed with [3H]TdR (1 ^Ci/well) and harvested as
described for the polyclonal proliferation assays. The results are
expressed as mean c.p.m. for triplicate cultures. The standard
error of the mean for all experiments was <20%.
Results
recognized by the peripheral T cell repertoire of this HDM atopic
individual (Fig. 1).
Polyclonal T cell responses to Der p 2 peptides
Polyclonal T cells from the same individual were stimulated with
overlapping peptides covering the complete sequence of
Der p 2, at 10 and 30 *ig/ml on two separate occasions 8 weeks
apart (Fig. 3A and B). Only the maximal proliferation induced
by either of the peptide concentrations is presented. Although
quantitatively different at these time points, the polyclonal T cell
response was directed towards similar regions of the protein and
the immunodominant peptides were located at amino acids
21 -35 and 71 -86 (Fig. 3A and B). When the overall magnitude
of the proliferation was higher, T cell responses were also
observed to the peptides spanning the flanking sequences
11 - 25 and 81 - 96. Nevertheless, relative to the background
response of T cells cultured in medium alone, no other regions
of the protein induced marked proliferation. The difference in the
magnitude of proliferation observed on the two occasions may
reflect frequency of environmental exposure to allergen.
Epitope specificity of T cell clones induced with Der p 2
In order to investigate the heterogeneity of the peripheral T cell
repertoire' reactive with Der p 2, a panel of T cell clones was
isolated and their epitope specificity mapped using a set of
overlapping peptides derived from the primary amino acid
sequence of Der p 2 (Fig, 1). Each peptide was tested at 1 and
10 uglml but only the maximal proiiferation observed at either
concentration is presented (Fig. 2). The T cell clones AC1, AC2,
and AC3 all responded to three overlapping peptides (residues
22-34, 25-37, and 28-40) spanning the sequence 22-40
(Fig. 2A-C). The optimal responses for AC1 and AC2 were
obtained using 1 /ig/ml of peptide (residues 25-37 and 28 - 40)
and 10 jig/ml (residues 22 - 34). For AC3, 10 ^g/ml was optimal
for all three stimulatory peptides. The remaining clones, AC5,
AC28. and AC29, were all maximally stimulated using 10 /ig/ml.
However, the pattern and magnitude of the responses to the
nested set of peptides were variable with peptide 22 - 34 being
the least potent at inducing proliferation of the T cell clones. T cell
clones AC1 (Fig. 2A) and AC3 (Fig. 2C) proliferated more
markedly to residues 28 - 40 and 25 - 37 respectively, whereas
AC2 (Fig. 2B) responded equally to both peptides. This implies
that these three clones recognize epitopes within residues
22 - 40, but, there may be slight differences in the fine epitope
specificity. The dominance of the response to peptide Der p
2-(28-40) by AC1 implies that this clone may recognize an
epitope towards the C-terminus of.this region. On the other hand.
AC3 may recognize an epitope located more towards the
N-terminus as peptide Der p 2-(25-37) induces greater
proliferation. However, the similar response of AC2 to both
peptides may imply that there is a third epitope within residues
22 - 40. Peptides 19-31 and 16 - 28, but none of the flanking
sequences activated T cell clone AC5 (Fig. 2D), whereas T cell
clone AC28 responded only to the C-terminal region peptide,
amino acids 111-129 (Fig. 2E). Peptide 85-97 induced
maximal proliferation of T cell clone AC29 (Fig. 2F), and
responses were also observed to the flanking sequences 82 - 94
and 88-100. Collectively, these results demonstrate the
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Fig. 3. Polyclonal T cell responses of a HDM atopic individual to
overlapping peptides of Der p 2. measured 8 weeKs apart.
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Inhibition of the antigen-dependent responses of Der p 2 specific
T cell clones
In order to define the subsets of HLA class II molecules restricting
antigen recognition by the Der p 2 specific T cell clones, mAbs
reactive with conserved sequences of HLA-D region molecules
were aoded over a concentration range to T cell proliferation
assays. Each individual T cell clone was cultured with its specific
peptide (Fig. 2) at the optimal concentration to induce maximal
proliferation. Antigen-dependent responses of the T cell clones
AC1, AC2. and AC29 were inhibited in the presence of the anti-
HLA-DR antibody (L243), whereas the anti-HLA-DQ (SPV-L3) and
anti-HLA-DP (87/21) antibodies had minimal effects (Fig. 4A-C).
These results suggest that T cell clones AC1, AC2. and AC29
recognize HDM peptides in association with HLA-DR molecules.
In contrast, the T cell clones AC3. AC5, and AC28 were blocked
maximally by the anti-HLA-DQ antibody and no inhibition
occurred in the presence of the anti-HLA-DP or anti-HLA-CR
antibodies (Fig. 4D - F). The anti-DP antibody used in this study
has been snown to block antigen presentation to other HLA-QP
restricted clones (21). The results of these experiments imply that
100 , 1 r-
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Fig. 4. Anti-HLA class II antibody inhibition of peptide induced proliferation by Der p 2 specific T cell clones. A, AC1; B. AC2; C. AC29; D. AC3;
E. AC5; and F, AC28. Cloned T cells were incubated with peptide and APCs in the presence ana absence of antiboaies specific for HLA-DR (L243)
(•), HLA-DP (B7/21) (C). and HL4-DQ (SPV-L3) (A).
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DRB1 DRB3 DRB4 DRB5 DQA1 DQB1
YAR DR4 Dw4 DR53 0402 0101 DQ8(3) 0301 0302
SSTO DR4 Dw13 DR53 0403 — 0101 — DQ8(3) 03 0302
HIN-ND DR4 Dw15 DR53 0405 — 0101 — DQ4 03 0401
DBB DR7 DR53 07 — 0101 — DQ9(3) 0201 03032
SWEIG DR11(5) Dw5 DR52 Dw25 1101 0202 — DQ7(3) 0501 0301
SPOH DR11(5) Dw'DB2' DR52 Dw25 1101 0202 — — DQ5(1) 0102 0502
JVM DR11(5) Dw'JVM' DR52 Dw25 1102 0202 — — DQ7(3) 0501 • 0301
RML DR16(2) Dw22 1602 — — 0202 DQ7(3) 0501 0301
COX DR17(3) Dw3 DR52 Dw24 0301 0101 — — DQ2 0501 0201
HLA-DQ class II molecules may restrict antigen recognition by
the Der p 2 reactive T ceil clones AC3, AC5 and AC28.
HLA class II restriction specificity of Der p 2 reactive Tcell clones
Based on the results of the serological inhibition studies described
above, the HLA class II restriction specificity of the Der p 2 T
cell clones was further investigated using APC panels consisting
of HLA-typed, EBV-B cell lines selected for their expression of
either HLA-DR or -DQ molecules (Table 1). In order to control
for differences in the antigen concentration required to induce
maximum proliferation of the individual T cell clones to their
specific peptides, the dose ranges used in these HLA class II
restriction experiments (Figs 5 and 6) were varied. The T cell
clones AC1, AC2. and AC29 which were inhibited by the anti-
HLA-DR antibody, showed similar patterns of proliferation to the
APC panel (Fig. 5A-C). They responded in a dose-dependent
manner to peptide presented by the autologous EBV-B cell lines
[ACE: DR7, DR11 (5), DQ2. DQ7(3)J or the EBV-B cell line
homozygous for DR11 Dw5 (SWEIG; DRB1 *1101). The other
B cell lines tested, including JVM (DR11(5) Dw'JVM'; DRB1"
1102) and OBB (DR7) failed to present antigen to the three T
cell clones (Fig. 5). In the absence of both antigen and cloned
T cells background proliferation by the B cell line JVM exceeded
4000 c.p.m. Nevertheless, this B cell line served as a valuable
control for cross'reactivity between the DR11 alleles.
Those T cell clones AC3. AC5, and AC28, inhibited by the
anti-DQ antibody, were also investigated for their ability to
respond to antigen using selected EBV-B cell lines. Dose
dependent proliferation of the T cell clones AC3, AC5, and AC28
was induced to peptide presented by SWEIG, RML and ACE
or FME, all of which have the DQB1 *0301 allele (Fig. 6A-C).
For the T cell clone AC28 the EBV-B cell line FME was used as
positive control (Fig. 6C). This B cell line is histocomoatible with
SWEIG and ACE at the DR and DQ loci. Although ACE, FME,
and SWEIG express the same DRB1 gene product (DRB1 *1101),
RML differs in that it expressed DRB1 "1602. This supports the
serological inhibition studies that these T cell clones may be
'estricted by HLA-DQ class II molecules. None of the T cell clones
'esponded to antigen in the presence of the B cell line, COX,
which shares the other DQB1 allele (DQB1 *0201) expressed by
VSE but differs in its expression of DR (DRB1 *0301). However.
:ne failure of COX to present peptide despite expressing the same
DQa chain as SWEIG and RML (DQA1 *0501) suggests that the
a: chain alone does not determine recognition. The B cell line
SPOH which expresses DQA1 *0102 and DQB1 *0502 failed to
present peptide to the T cell clones, although at a supraoptimal
peptide concentration (10 jig/ml) limited proliferation of the T cell
done AC28 was induced (Fig. 6). SPOH and SWEIG share the
same DRB1"1101 allele and are defined serologically as
DR11(5). However, SROH failed to present antigen to the T ceil
clones AC3, ACS. and AC28 (Fig. 6), but was able to induce
antigen-dependent proliferation of the DRB1 *1101 restricted T
cell done AC2 (data not shown). Coilectively the results of the
APC panel experiments and the ability to inhibit antigen-
dependent proliferation with anti-HLA-DQ antibody suggest that
DQ class II moiecuies function as restriction elements in T cell
recognition of Der p 2.
Molecular models for the 3 chains of HLA-DRB1 '1101 and
HLA-DOB 1 '0301
The primary amino acid sequences of HLA-DRB1 *1101 and
HLA-DQB1 *0301 are shown in Fig. 7. Molecular modeling of
the 8 chains of these HLA-D molecules demonstrated that there
are 15 amino acid differences between these two alleles located
in the antigen combining site. In HLA-DQB1 "0301 tnese residues
are: Tyr9, Phe11, Ala13, Thr28. Ala38, Tyr47. Va!67, Arg70.
Thr71, Glu74, Leu75, Val78, Glu86, Leu87, and Thr90. In HLA-
DRB1"110l these residues are: Glu9, Ser11, Ser13. Aso28.
Val38, Phe47. Phe67. Asp70, Arg71. Ala74, Val75, Tyr78. Gly86.
Glu87, and Phe90. In addition to these potentially functional
differences there are 25 further amino acid changes between
these two alleles in the first 90 amino acids of the mature 8 cnain
(55.5% amino acid identity).
Discussion
The analysis of allergen specific IgE antibodies and T cell
responses in the periphery of HDM atopic individuals nas
demonstrated that the group 2 allergens (Der p 2 and Der f 2)
of HDM are a major target of immune recognition (4,8,7,14). The
study reported here was designed to investigate in detail the
heterogeneity of the Der p 2 reactive T cell repertoire in a HDM
allergic patient. Analysing the antigen and restriction specificity
of cloned T cells we have identified HLA-DR and -DQ restricted
T cell epitopes, one of which is able to bind to both DR and DQ
molecules.
Extending the population study in which we demonstrated that
the major T cell epitopes of Der p 2 are located in the regions
T cell epitopes of house dust mite 1595
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Fig. 5. HLA-DR class II restricted recognition of Der p 2 reactive T cell
clones. The restriction of the T cell clones (A, AC1: B. AC2; and C. AC29)
was determined using a panel of HIA-typed EBV B ceils as APCs: DBB
(A), SWEIG (A), JVM (□). YAR (■), SSTO ( + ), and HIN-ND (ffl). Control
responses of antigen-dependent proliferation in the presence of the
autologous EBV-B ceil line. ACE (O), and the T ceil clone to antigen alone
(•) were determined.
Antigen [pg/mi]
Fig. 6. HLA-DQ class II restricted recognition of Der p 2 specific T cell
clones. The restriction of the T cell clones (A, AC3; B. AC5; and C. AC28)
was determined using a panel of HLA-typed E3V-8 cells as APCs: ACE
(O). FME ( + ). RML (A). SWEIG (A), SPOH (■), and COX (C). The
background response of cionea T ceils to peptide in the absence of APCs
was also measured (•).
11 - 35 and 61 - 104 (14), a panel of T ceil ciones reactive with
Der p 2 was isolated from the peripheral blood of a HDM atopic
individual and their fine antigen specificity mapped using nested
sets of peptides. The T cell clones (AC1, AC2. and AC3) ail
resDonded to residues 22 - 40. but there were minor differences
in their pattern of proliferation to the peptides 25 - 37 and 28 - 40.
This suggests that they recognize closely related epitopes in this
region of the molecule. Three additional T cell epitopes were
located within the regions covered by residues 16 - 31, 82 -100.
and 111 - 129. Analysis of the polyclonal T cells to overlapping
peptides for the entire Der p 2 protein suggests that the epitopes
identified by the T cell clones represent many of the antigen
specificities of the overall peripheral T cell repertoire. However,
comparison with the polyclonal response reveals the presence
of additional epitopes. Therefore, it is important to include analysis
of the specificity of polyclonal T cells in the investigation of the
overall repertoire reactive with HDM. The practical application
of developing peptide-based immunotherapy reguires both
mapping of the major T cell epitopes and identification of the HLA
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DRB1-1101 GDTRPRFLEY STSECHFFNG TERVRFLDRY FYNQEEYVRF DSDVGEFRAV
DQBT0301 R. SPED . VYQ FKAM.Y.T. YVT . . I..R...A EVY...
DRB1-1101 TELGRPDEEY WNSQKDFLED RRAAVDTYCR HNYGVGESFT VQRR
OQB1"0301 . P . . P . . A EV . . R T . . EL . . V QLELRT . L . . .
Fig. 7. Primary amino acid seauences of tne first domains of DRB1 "1101 and DQB1 '0301.
prompted us to investigate the HLA class II restriction specificity
of the Der p 2 reactive T cell clones in addition to antigen
recognition by the polyclonal T cells. In serological inhibition
studies we observed that antigen-dependent proliferation of the
Der p 2 (22 - 40) specific T cell clones AC1 and AC2 was inhibited
by the anti-HLA-DR framework antibody, whereas the T cell clone
AC3, also specific for residues 22-40, was blocked by the
anti-HLA-DQ antibody. Likewise, the T cell epitopes 16-31 and
111 - 129 recognized by T cell clones AC5 and AC28 respect¬
ively were inhibited by the HLA-DQ specific antibody. The
remaining T cell epitope defined in this study, Der p 2-(82 - 100),
recognized by clone AC29, appeared to be HLA-DR restricted.
EBV-B cell lines selected for their expression of specific HLA-D
region gene products were used as APCs and the class II
restriction specificity of the Der p 2 reactive T cell clones was
further analysed. Using this approach it was confirmed that T
cell recognition of Der p 2-(16 — 31) and Der p 2-(111 -129) is
restricted by HLA-DQB1 "0301 and Der p 2-(82-100) by
HLA-DRB1 "1101, whereas it appears that Der p 2-(22-40) is
presented by both OR and DQ molecules of these specificities.
The relevance of the DRBT1101 class II molecules in the
regulation of HDM allergic inflammation is not only limited to the
recognition of Der p 2 as it has been reported that residues
94-104 of Der p 1 may be presented by this allele (20). The
possibility of an identical epitope restricted by HLA-DRB1 *1101
and HL4-DQB1 "0301 is of considerable interest. However, due
to the length of this region and the highly dissimilar chemical
nature of the peptide binding clefts of these aiieles it would appear
unlikely that an identical epitope would bind to these two alleles.
In the antigen combining site alone, there are amino-acid
substitutions at 15 positions between HLA-DRB1 *1101 and
HLA-DQB1 "0301 B chains. When the dissimilarity of the
monomorphic HLA-DR ct chain and the polymorphic HLA-DQ
a cnain are also considered (reviewed in 26), the differences
between these two molecules make it unlikely that they are both
able to bind an identical epitope. It is more likely that this region
fortuitously contains two epitopes, one of which conforms to the
HLA-DRB1 "1101 motif, the other to the HLA-DQB1 *0301 motif.
This phenomenon of overlapping epitopes bound by different
MHC molecules has recently been observed in the MHC class
I restricted cytotoxic T lymphocyte response to the influenza virus
nucleoprotein in an HLA-B*2702/B8 individual (27) in a highly
promiscuous HLA-DR binding malarial peptide (28) and also in
epitopes observed in a highly immunogenic region of the Der p 1
protein (21).
There are reports of associations between the expression of
particular HLA-DQ class II molecules and responaer status to
specific allergens (29-31). From a genetic epidemiological study
on cedar pollinosis in Japanese subjects it was revealed that the
lack of specific IgE in the nonatopics is in linkage with HLA-DQw3
and that non-responsiveness is mediated by cedar pollen specific
CD8* T cells (29). Similarly, a decrease in HLA-DR4 and
HLA-DQw3 alleles has been observed in individuals who develop
IgE antibodies to melittin or phospholipase A2 (30). Therefore,
it appears that DQw3 may have a protective role in controlling
IgE responses. However, an independent analysis, also in the
Japanese population, reported that the frequency of HLA-DQw3
was increased in patients with rhinitis induced by cedar pollen
and O. farinae (31), but as yet no HLA-DQ class II linkage with
HDM allergic immune responses has been established for Cauca¬
sians (32.33).
The results reported here demonstrate that for a given HDM
atopic individual a minimum of four T cell epitopes are recognizee
in Der p 2. Furthermore, these T cell epitopes appear to bind
to either HLA-DR or -DQTnolecules and, in the case of residues
22 - 40, binding to both subsets of HLA class II proteins was
observed. Over a period of 8 weeks, we have examined
polyclonal T cell responses to Der p 2 for this same individual
chronically exposed to allergen and have failed to detect major
differences in the pattern of peptide recognition. Plasticity in the
T cell repertoire reactive with HDM allergens and the ability of
major T cell sites to bind to both HLA-DR and -DQ moiecuies
suggests that selected peptides may have a potential application
in reguiating the seventy of the clinical symptoms of HDM allergic
disease.
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Summary
Two human helper T cell determinants in influenza
have been identified, one in the hemagglutinin and the
other in the matrix protein (M1). Both were shown to
be DR1 restricted by using transfected L cells to pres¬
ent antigen. Comparison of the sequences of the two
peptides revealed a similar pattern that could account
for their DR1 specificity if the peptides adopt a helical
conformation. The model was supported by the
demonstration that hybrid peptides, composed of the
amino acids that interact with DR1 from one deter¬
minant and the residues that interact with the T cell
receptor from the other, were recognized by each
clone. The generality of the motif was confirmed by
the finding that DR1 individuals respond to a ragweed
peptide containing the defined pattern.
Introduction
A unified model for T cell recognition of proteins has de¬
veloped from recent experimental results from several
laboratories. The observation that histocompatible cells
are lysed when incubated with peptide fragments of in¬
fluenza virus by both human and murine cytotoxic T cells
(Townsend et al„ 1986) demonstrated that cytotoxic T cells
as well as helper T cells recognize processed antigens in
conjunction with a MHC molecule. The many similar fea¬
tures in the response of CTLs to peptides with those of
helper T cells taken together with the shared usage of
identical genetic elements by the T cell receptors on the
two populations of lymphocytes (Davis, 1985) argue that
helper and cytotoxic T cells recognize protein antigens by
a common mechanism.
Our understanding of the molecular basis of antigen
recognition has been greatly enhanced by the finding that
MHC class II proteins specifically bind peptides. Babbitt
et al. (1985) demonstrated this by using a purified murine
MHC class II molecule and a lysozyme peptide in equilib¬
rium dialysis experiments; the class II—peptide complexes
were subsequently shown to be sufficiently stable to be
separated by using gel filtration techniques (Buus et al.,
1986). This method has been used to extend the original
observations to include several different MHC class II al¬
leles (Buus et al., 1987) and, recently, human MHC class
II proteins (Jardetzky, unpublished data).
Once formed, the complex between class II and peptide
is believed to be the entity specifically recognized by the
antigen receptor on the T cell. Competition studies, ini¬
tially performed on the cellular level (Guillet et al., 1986)
and subsequently with purified class II proteins (Guillet et
al., 1987), have implied that the class II and class I mole¬
cules examined have a single antigen-combining site. In
addition, the ability of the MHC proteins to bind fragments
of proteins appears to correlate with antigen-specific re¬
sponsiveness, for the generation of both helper (Guillet et
al., 1987) and cytotoxic (McMichael et al., 1986) T cells.
The recent solution of the three-dimensional structure
of HLA-A2 has revealed further details ofMHC-peptide in¬
teractions (Bjorkman et al., 1987a, 1987b). Polymorphic
residues of MHC class I molecules are concentrated in a
proposed peptide binding site whose sides are composed
of two a-helices, with the strands of the 3-pleated sheet
forming the base. MHC class II molecules can be modeled
by sequence homology to adopt a similar structure. How¬
ever, in the latter case, the site is composed of residues
of the helices and strands of the amino-terminal regions
of both the a and 3 subunits.
Consistent with the model of MHC proteins acting as
receptors for peptide antigens, the areas in proteins that
are recognized by T cells have a number of common struc¬
tural features. Berzofsky and DeLisi have analyzed the
known helper epitopes and have postulated that helper T
cells preferentially recognize amphipathic helices (DeLisi
and Berzofsky, 1985; Spouge et al., 1987). Independently,
we have noted that the majority of both helper and cyto¬
toxic T cell epitopes contain two adjacent hydrophobic
residues preceded by a charged residue or a glycine that
appears to be necessary for recognition (Rothbard, 1986).
Although differing in emphasis the two observations are
not necessarily mutually exclusive, and provide additional
evidence for similarities in the details of the antigen bind¬
ing sites of the MHC molecules. The merit of each analy¬
sis has been demonstrated by their ability to identify previ¬
ously undefined T cell determinants successfully (Cease
et al., 1987; Lamb et al., 1987; Rothbard and Taylor, 1988).
Several groups have commented on similar features in
the sequences of the determinants when the latter are








































































Figure 1. Definition of Matrix Protein Determinant Recognized by
Clone TLC 72
(A) Localization of antigenic determinant to sequence 17-31 within ma¬
trix protein. (B) Definition of amino terminus of the minimai pepiide
capable of maximum stimulation. (C) Determination of the carboxyl ter¬
minus of the peptide capable of maximum stimulation. T cells (5 x
K^/ml) of clone TLC 72 were cultured with irradiated histocompatible
PBMC (1.25 x 105/ml), with antigen at the concentrations indicated.
Proliferation as correlated with pHJTdR incorporation was determined
after 72 hr. The control proliferative responses of the T cells to A/Texas
influenza virus (5 HAU/ml) and to presenting cells alone were deter¬
mined.















Figure 2. Definition of Hemagglutinin Determinant Recognized by
Clone HA 1.7
(A) Definition of the amino terminus of the minimal hemagglutinin pep¬
tide capable of maximum stimulation. (B) Determination of carboxyl
terminus of the minimal hemagglutinin peptide capable of maximum
stimulation. T cells (5 x KJVml) of clone HA 1.7 were cultured with ir¬
radiated histocompatible PBMC (1.25 x 105/ml), with antigen at the
concentrations indicated. Proliferation was determined as described in
the legend to Figure 1. The control proliferative responses of the T
cells to A/Texas influenza virus (5 HAU/ml) and to presenting cells
alone were determined.
acids that interact with DR1 from one determinant and the
residues that interact with the T cell receptor from the
other. Finally, the generality of the pattern was examined
by analyzing the ability of DR1 individuals to respond to
a ragweed peptide containing the motif.
sible for their specific binding to the MHC protein (Guillet
et al., 1986; Buus et al., 1987; Rothbard and Taylor, 1988).
However, as provocative as such allele-specific subpat-
terns are, they have yet to be demonstrated experimen¬
tally.
In this paper we have defined two DR1-restricted helper
T cell epitopes in influenza, one in the hemagglutinin and
the other in the matrix protein. The restriction was estab¬
lished by demonstrating that each clone was stimulated
when the peptide antigens were presented by L cells
transfected with the a and (3 chains of DR1. Comparison
of the sequences of the two peptides revealed a similar
pattern that could account for their specific binding by
DR1. The model was successfully tested by demonstrat¬
ing that hybrid peptides stimulated the appropriate T cell
clone. The hybrid peptides were composed of the amino
Results
Definition of Two DR1-Restricted T Cell Determinants
Seven peptides containing motifs characteristic of the
majority of T cell epitopes (Rothbard and Taylor, 1988)
within the sequence of the matrix protein (M1) of influenza
were screened for their ability to stimulate a matrix-
specific human helper T cell clone. The specificity of the
clone, TLC 72, for the matrix protein has been previously
described (Lamb et al., 1982b). Clone TLC 72 was stimu¬
lated only by the peptide corresponding to residues 17-31
(Figure 1A). The minimum sequence necessary for maxi¬
mum stimulation was defined by testing nested sets of
peptides that differed in length. Peptides with a common
carboxyl terminus, but differing at their amino terminus,
were used to stimulate the clone. Residues 18 and 19 were
DR1 Binding of Antigen
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Table 1. Proliferative Response of DR1-Restricted T Cell Clones to Antigen Presented by L Cells Expressing DR1
Response
T Cell Clone Antigen-Presenting Cells Antigen (cpm ± % SEM)
HA 1.7® — — 520 ± 31°
DR1+ PBMC - 304 ± 10
DR1+ PBMC HA 306-324 19,051 ± 2
EBV-transformed DR1 + B cells — 732 ± 23
EBV-transformed DR1 + B cells HA 306-324 11,771 ± 7
DRla DR1p-transfected L cells — 253 ± 23
DR1a DR1p-transfected L cells HA 306-324 9,396 ± 2
L cells — 200 ± 15
L cells HA 306-324 285 ± 12
TLC 72° — — 112 ± 5
DR1 + PBMC — 176 ± 9
DR1+ PBMC MAT 18-30 6,022 ± 8
EBV-transformed DR1 + cells — 633 ± 3
EBV-transformed DR1 + cells MAT 18-30 8,668 ± 5
DR1a DRip-transfected L cells — 607 ± 4
DRla DRip-transfected L cells MAT 18-30 15,751 ± 4
L cells — 281 ± 4
L cells MAT 18-30 144 ± 9
' Clone HA 1.7 (5 x 104 cells/ml) was cultured with and without HA peptide 306-324 (0.3 ugyml) in the presence of irradiated histocompatible
PBMC (1.25 x 10s/ml), autologous EBV-transformed B cells (105/ml), or mitomycin C-treated murine L cells transfected with DR1c DRip.
" Proliferation was measured as described in Figure 1.
c Similar culture conditions were used for clone TLC 72 except that matrix 18-30 (3 ug/ml) was the stimulating antigen.
shown to be required for maximal stimulation (Figure 1B).
Serine-17 is not essential. Similar experiments examining
the oarboxy-terminal residues reveal that glutamic acid-29
is necessary but residues 30 and 31 are not, defining the
minimum epitope to be 18-29 (Figure 1C).
Previous experiments with panels of antigen-presenting
cells have suggested that clone TLC 72 was restricted by
DR1 (Eckels et al., 1982). Another clone, HA 1.7, reactive
with the hemagglutinin of influenza and isolated from the
same individual, was shown to be restricted by the class
II determinants DR1/DQw1 on panel studies (Eckels et al.,
1984). The determinant for clone HA 1.7 had been partially
characterized in earlier experiments to be present be¬
tween residues 306 and 329 (Lamb et al., 1982a). This se¬
quence contained two potential T cell recognition motifs
(Rothbard, 1986), between residues 308 and 311 and 316
and 319. To test whether either or both of these areas are
necessary for stimulation of the clone, we initially syn¬
thesized 306-324. This peptide contains all possible
decamers containing the patterns. As seen in Figure 2A,
306-324 was fully stimulatory. The cysteine at 306 was not
necessary for recognition because 307-324 was equally
recognized. However, removal of proline-307 and, more ef¬
fectively, lysine-308 results in the loss of stimulation (Fig¬
ure 2A). The carboxyl terminus could be reduced to in¬
clude alanine-318 without any loss of recognition (Figure
2B), allowing us to localize the determinant to residues
307-318, which contained the pattern from 308-311.
Presentation of Peptide Antigens to DR1-Restricted T
Cells by L Cells Expressing Human Class II Antigens
The identification of restriction elements for human T cell
clones is complicated because of the microheterogeneity
of the HLA-D region products and the shortage of locus-
specific monoclonal antibodies. To overcome this prob¬
lem, we used murine fibroblasts transfected with the a and
(3 chains of DR1 to prove unequivocably that both clones
are stimulated by the appropriate antigen in the presence
of DR1 (Table 1). The matrix-specific clone TLC 72 prolifer¬
ated when the peptide was presented by autologous B
cells transformed with Epstein-Barr virus, DR1-positive
peripheral blood mononuclear cells, and DR1-transfected
L cells (Table 1). Similar results were obtained with the
hemagglutinin-specific clone by using 306-324 of the
hemagglutinin (Table 1). The proliferative responses were
in all cases inhibited by monoclonal antibodies directed at
monomorphic DR determinants (R. Lechler, V. Bal, J.
Rothbard, E. Long, R. Sekaly, R. Germain, and J. Lamb,
submitted). From the results of these experiments, we
conclude that both clones are DR1 restricted.
Analysis, Synthesis, and Testing of Hybrid
Hemagglutinin-Matrix Peptides
Previous analysis of known T cell epitopes has revealed
the presence of both general and allele-specific subpat-
terns that have been used for successful prediction of sev¬
eral previously undefined determinants (Rothbard and
Taylor, 1988). The two DR1-restricted epitopes can be
aligned in a similar manner based on the two adjacent hy¬
drophobic residues (Figure 3A). Such an alignment re¬
veals additional similarities at other positions. Most strik¬
ingly, lysine-21 is aligned with lysine-311. Also, a third pair
of hydrophobic residues occurs at a fourth position,
leucine-28 and alanine-318. These residues, whose rela¬
tive positions are 1, 4, 5, and 8, would be juxtaposed if the
peptides were to adopt a helical conformation, and would
form a conserved face of the helix (Figure 3B).
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Figure 3. Sequence ana Alignment of the Known DR1, Ed, and Ek T
Cell Determinants
(A) Alignment of the two DR1-restricted peptides based on two adjacent
hydrophobic amino acids. Boxed residues are those postulated to in¬
teract with DR1. (B) The two seouences displayed in a helical wheel.
(C) Alignment of the defined E*-restncted determinants, revealing
their similarity with the DR1-restricted sequences. In the lower portion
of the figure, the staphylococcal nuclease determinant has been
reversed (•) to improve the alignment. (D) Alignment of the defined
Ea-restricted determinants, reveaiing their similarity with the DR1-
restricted sequences. As in (C), certain sequences have been reversed
(•) to improve alignment.
in the two determinants constitute the principal residues
interacting with DR1, while the amino acids composing
the opposite face of the helix would interact with the T cell
receptor. If true, this hypothesis would predict that those
residues that interact with the restriction element could be
exchanged between the epitopes without affecting recog¬
nition by either clone. Only those residues that are bound
by the T cell receptorwill be clonally specific. In Figure 3B,
the area recognized by the restriction element would be
the lower half of the helix, whereas the residues compos¬
ing the upper facade would interact with the antigen
receptor of the T cell. To test this hypothesis and to deter¬
mine exactly which residues interact with DR1 and which
are bound by the T cell receptor, two sets of peptides were
synthesized and tested for their ability to be recognized by
the T cell clones. In one set, the HAMAT series, amino
acids from the hemagglutinin epitope were substituted
into the matrix sequence. In the other set, MATHA pep¬
tides, amino acids from the matrix epitope replaced corre¬
sponding residues in the hemagglutinin determinant. The
HAMAT series begins with three substitutions (HAMAT 1)
and continues to HAMAT 9, which is identical to the origi¬
nal HA epitope except for one residue (Table 2A). The
MATHA series is less extensive (Table 2B). MATHA 3 con¬
Table 2. Sequences of Hybrid Peptides Composed of Residues from
the Two DR1-Restncted Epitopes
A The HAMAT series
Matrix 17-29 S Q P L K A E I A Q R L E
HAMAT 1 S G Y L K A N I A K R L E
HAMAT 2 S G Y L K Q N I A K R L E
HAMAT 3 S G Y L K Q N I A K L L E
HAMAT 4 S K Y L K Q N I A K L L E
HAMAT 5 S K Y L K Q N I A K L L T
HAMAT 6 P K Y L K Q N I A K L L T
HAMAT 7 P K Y V K Q N I A K L L T
HAMAT 8 P K Y V K Q N HA K L L T
HAMAT 9 P K Y V K Q -N 00 K L L T
HA 307-319 P K Y V K Q N T L K L A T
B The MATHA series
CUV Matrix 17-29 s g
MATHA 3 p k
MATHA 4 p g]
MATHA 5 p g
MATHA 6 p g
MltMl.lHi MATHA 4 A-17 A g
0 U>l>4tUM, 1M1
lwuni.1113 MATHA 4 A-19 p g
buull. 1111 MATHA 4 V-19 p g
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A E T L Q R A T
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A E T L Q R A T
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A E T L Q R A T
A E T L Q R A T
Q N T L K L A T
Residues enclosed in boxes correspond to the hemagglutinin sequence
in the HAMAT series and the matrix sequence in the MATHA series.
tains five substitutions, while MATHA 4 and 5 contain six
and seven, respectively. The seven substitutions within
MATHA 6 differ from those of MATHA 5 at two positions.
The peptides were individually titrated with each clone
and analyzed for their ability to stimulate. As seen in Fig¬
ure 4A, HAMAT 1-3 were not recognized by HA 1.7, even
at 100 g.g/ml. In contrast, HAMAT 4 did stimulate the clone
as well as the natural peptide at high concentrations, but
was less efficient as the concentration of the peptide was
decreased. Interestingly, HAMAT 5, 6, and 7 were not rec¬
ognized even though they contained more of the HA se¬
quence than HAMAT 4. HAMAT 8 and 9 were both recog¬
nized almost as well as the natural sequence.
To confirm that this result was not simply characteristic
of HA 1.7, the reciprocal experiment was performed. How¬
ever, TLC 72 did not proliferate in response to MATHA 3-6,
including MATHA 4, which contains the reciprocal ex¬
changes with HAMAT 4. One possible explanation for the
failure of MATHA 4 to stimulate TLC 72 is that it contains
the sequence of proline, glycine, proline, at the amino ter¬
minus. Proline is often stated to be incompatible with a he¬
lical conformation because the side chain is bonded to the
backbone nitrogen, preventing its participation in hydro¬
gen bonding and sterically preventing the correct confor¬
mational angles from being adopted (Richardson, 1981).
This is not completely correct, because in the first three
positions of a helix these hydrogen bonds are not formed.
Therefore, although not favored, a proline can exist in the
first turn of an a helix. However, in MATHA 4, the introduc¬
tion of two prolines in the first three residues may have
been sufficiently destabilizing to prevent an a-helical con¬
formation from being adopted. To test this hypothesis, we
synthesized three-analogs of MATHA 4. One contained an
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eral blood mononuclear cells (PBMC) from three DR1 indi¬
viduals. We selected this peptide because not only did it
contain the pattern, it also was immunogenic in H-2K ant?'
H-2D mice. As seen in Table 3, each of the individuals who
recognized antigen E also responded to this peptide.
PBMC from DR1 individuals whose T cells fail to prolifer¬
ate in response to this protein also did not recognize the
peptide, demonstrating that T cell proliferation was not
due to a nonspecific mitogenic effect of the sequence.
ANTIGEN CONCENTRATION (UG/ML)
Figure 4. Response of Clones HA 1.7 (A)andTLC 72(B) to Hemagglu¬
tinin and Matrix Hybrid Peptides
T cells (5 x 10*/mi) were cultured with irradiated histocompatible
PBMC (1.25 x 10s/ml), with antigen at the concentrations indicated.
Proliferation was determined as described in the legend to Figure 1.
alanine in place of proline-17, while the other two sub¬
stituted an alanine and a valine for proline-19. If the pep¬
tide binds DR1 in the orientation we propose, then the
substitution of an alanine at 17 will allow the peptide to
adopt a helix and still retain the proline at 19, which we pre¬
dict is recognized by the T cell receptor.
As seen in Figure 4B, only MATHA 4 with alanine-17 was
stimulatory. As with HAMAT 4, it was not as efficient as the
natural matrix sequence but it was, nonetheless, clearly
recognized. In addition, the failure of the peptides contain¬
ing alanine and valine at 19 is consistent with the pro¬
posed model. Finally, none of the HAMAT peptides were
recognized by the matrix-specific T cell clone, nor did any
of the MATHA peptides stimulate the hemagglutinin-spe-
cific clone (data not shown).
Identification of a DR1-Restricted T Cell Epitope
in Ragweed Antigen E
To test the generality of the motif, we used a peptide from
antigen E of ragweed, residues 54-61, to stimulate periph-
The recent demonstration that MHC class U molecules
specifically bind peptide antigens has provided a molecu¬
lar explanation for empirical analyses of the defined T cell
epitopes, revealing that theysbare several features. Taken
together, these ideas imply that there will be allele-specific
patterns that correspond to the regions in each deter¬
minant that interact with the MHC proteins. To test these
ideas, we have identified two DR1-restricted epitopes in in¬
fluenza. The restriction element to which they bound was
demonstrated by using L cells transfected with both chains
of DR1 to present antigen. The details of the MHC-pep-
tide interactions were examined by comparing the ability
of mutated peptides to stimulate the clones relative to the
natural sequences.
Assuming that the peptides share a common binding
site, we examined the two DR1-restricted. epitopes for,
common structural features! As seen in Figure 3, align¬
ment of the two epitopes by the two adjacent hydrophobic
residues revealed a similarity in the flanking residues. If
the two lysines are considered to be residue 1, then there
is similarity at relative positions 1,4,5, and 8. If the peptide
adopted a helical conformation, these residues would be
juxtaposed and would compose a common facade that
could be characteristic of a DR1 binding site.
To determine whether the similarity in the epitopes had
any structural validity and to analyze the conformation in
which the peptide might bind MHC, we synthesized a fam¬
ily of peptides composed of residues from one deter¬
minant substituted into the other. The successful use of
this strategy to produce a stimulatory peptide for each
clone provides strong support for the proposal that both
peptides bind DR1 in a helical conformation. The recog¬
nition of the hybrid peptides, which contained six modi¬
fications in each determinant, is especially remarkable
considering the sensitivity of these and other peptide
determinants to point mutations (data not shown; Sette et
al„ 1987; Allen et al„ 1987).
The three-dimensional structure of the proposed anti¬
gen-combining site of histocompatibility antigens can ac-
Table 3. Proliferative Response of PBMC from HLA-DR1 Individuals to Ragweed Peptide 54-65
Donor RaE 54-65 RaE Medium PHA
575 DR1.3 3,993 ± 21
224 DR1,— 2,524 ± 10










PBMC (5 x 104/well) were cultured with Ra peptide 54-65 (10 pg/ml), RaE (5 pg/ml), PHA, or medium. Proliferation as correlated with 3HTdR
incorporation was determined at 6 days.
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Figure 5. Space Filling Models of the Defined DR1-Restricted Determinants and the Stimulatory Hybrid Peptides in Helical Conformations
(A) Comparison of hemagglutinin 307-319 (left) with HAMAT 4 (right) viewed along the helical axes (z axis), with amino termini in the foreground.
The orientation of the side chains is identical to that displayed in the helical wheel in Figure 3B. The residues proposed to interact with DR1 compose
the lower facade of the helix, while those that interact with the T cell receptor are above (see text). (B) An orthogonal view of hemagglutinin 307-319
(left) and HAMAT 4 (right) to that of (A) (y axis), emphasizing the areas of the two peptides proposed to interact with the antigen receptor of HA
1.7 (see text). Relative to the orientation of the peptides in (A) and in Figure 4B. this view is from above. (C) Comparison of matrix 17-29 (left) with
MATHA 4, with alanine (yellow) at position 17 (right), viewed along the helical axis (z axis) as in (A). (D) An orthogonal view of matrix 17-29 (left)
and MATHA 4, with alanine (yellow) at position 17 (right), to that of (A) (y axis). As in (B), this view reveals that the residues necessary to interact
with the antigen receptor of TLC 72 compose the face of the helix in the foreground. In each picture, residues corresponding to the hemagglutinin
determinant 307-319 are red, while those of the matrix epitope, residues 17-29, are blue.
commodate a peptide in a helical conformation without
any significant conformational changes in the protein
(Bjorkman et al., 1987b). If we interpret our data in this con¬
text, the residues composing the described pattern would
interact with the side chains of the amino acids of the HLA
molecule pointing upwards from the |i-pleated sheet,
while the residues on the opposite face of the helix would
point outward from the cleft and would interact with the T
cell receptor. The amino acids of the epitope that are on
the sides of the helix may, or may not, interact with the cor¬
responding residues on the MHC helices depending on
their length, polarity, and the complementary residues in
the HLA protein. Consequently, even though the stimula¬
tory hybrid peptide for each clone contained an identical
number of substitutions on the upper facade of the helix,
they do not necessarily make similar molecular contacts
when bound by both receptors. For instance, the hemag-
glutinin-specific clone requires lysine-308 for stimulation,
which had to be substituted by glycine in the stimulatory
MATHA peptide. However, from its position on the helical
wheel and space filling models (Figures 3B and 5), we be¬
lieve that glycine-19 interacts with the restriction element
and not the T cell receptor. Lysine is of sufficient length
to extend out of the binding site and interact with the T cell
receptor, while glycine's lack of a side chain would prevent
any interaction.
The space filling models also provide a possible expla¬
nation as to why glutamic acid-29 and threonine-319 are
not required for recognition even though from their posi¬
tion on helical wheels (Figure 3B) they appear to have a
suitable orientation to interact with the T cell receptor.
Both are the carboxy-terminal residues of the peptide and
can be seen to be remote from the other clonal-specific
residues. The diameter of an a helix is approximately 10
A. If we assume that the T cell receptor combining site is
geometrically similar to that of an antibody, and the area
of interaction is equivalent to that defined by the cocrys-
tals of lysozyme and an antibody (30 x 20 A) (Amit et-al.,
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1986), then the receptor could contact the upper facades
of all three helices, that of the epitope and the two of the
MHC molecule. The length of the interaction along the
helices would then be of the order of 20 A, consistent with
the results with the hybrid peptides (Figure 5).
The space filling models also reveal that the shapes of
the areas proposed to be recognized by the two receptors
are distinctly different. As expected from the sequences
of the two peptides, the faces of the helices interacting
with the restriction element are quite similar (Figure 5). We
expect, as with other instances of helices packing onto
3-pieated sheets (Cohen et ai., 1982), that the turns of the
helical peptide will interdigitate with the four central strands
of the MHC molecule. Consequently, we expect that vari¬
ations in binding wiil occur, particularly if peptides can
bind in either direction (vide infra). However, the two inde¬
pendently derived determinants described in this report
appear to interact with the identical residues in 0R1, sug¬
gesting that variations in binding might not be as large as
one would initially expect.
That the hybrid peptides are not as effective in stimu¬
lating the clones is not surprising, primarily because
residues from one helix cannot necessarily be substituted
into another and still guarantee a helical conformation.
This is vividly demonstrated by the failure of MATHA 4 to
be recognized by the matrix-specific done. Even though
each peptide contained a proline in its first three amino
acids, the hybrid synthesis resulted in two prolines in the
same sequencewhich, as we discussed earlier, is unlikely
to form a helix. In addition, in such an unprecedented situ¬
ation where two macromolecular receptors bind the same
llgand, subtle sequence-specific interactions may be im¬
portant. These experiments also emphasize the potential
diversity of molecular contacts with different T cell recep¬
tors. For although we predict a constant MHC-peptide in¬
teraction, the T cell receptor is still free to interact to vary¬
ing degrees with residues exposed on the upper facade
of the bound helical peptide. This would be consistentwith
the known differences and the fine specificity of T ceil
clones recognizing the identical peptide (Fink et ai., 1986).
We have also provided preliminary evidence on the
generality of the pattern of a positive residue—and three
hydrophobic amino acids wiil be characteristic of DR1 re¬
sponsiveness (Table 3)—by demonstrating that a ragweed
peptide can stimulate peripheral blood lymphocytes from
0R1 individuals. We were attracted to this peptide for sev¬
eral reasons. Ragweed was a useful system because a
large number of individuals are known to respond to it. In
addition to containing the pattern, this peptide was previ¬
ously shown to be stimulatory in BALB/c and C3H.OH
mice. A similar analysis of the defined l-E* and l-Ea re¬
stricted epitopes (Rothbard and Taylor, 1988; Figures 3C
and 3D) revealed a potential similarity to the two 0R1-
restricted determinants. These sequences could also be
aligned to have a positively charged residue (either a ly¬
sine or an arginine) and two residues from a pair of hydro¬
phobic amino acids, and be separated by sue residues
from a third. Conceivably, the similarity in the sequences
of the determinants reflects common features in the
antigen-combining site of the 0R1, l-£a, and l-E* mole¬
cules. However, in order for the murine class II proteins to
bind each of the known determinants in a manner similar
to 0R1, not only must each peptide adopt a helix, but in
several cases the direction of the helix in the binding site
is reversed. Such a situation would not necessarily violate
the chirai nature of other known ligand-receptor interac¬
tions, because in a helical conformation the main chain
amide nitrogens and the carbonyl oxygens are internally
hydrogen bonded. Consequently, they would not interact
with either the MHC molecule or the T cell receptor. In ad¬
dition, the flexibility of the amino acid side chains on both
the antigen and the two receptors could be sufficiently
great to allow similar interactions to occur regardless of
the relative orientation of the helix. Our results on the rec¬
ognition of this peptide by OR1 individuals support these
ideas and have prompted us to investigate further the
similarities between DR1 and la Ea and E* (Lechler et ai.,
submitted).
We would not have identified many of these features if
we had adopted the experimental strategy of point muta¬
tions used by the other two groups that have published
analyses of peptide-MHC-T cell receptor interactions (Al¬
len et ai., 1987; Sette et ai., 1987). As useful as these
modifications have been to identify critical residues in
MHC and T ceil receptor binding, their interpretation is dif¬
ficult. Ambiguity can arise because the two receptors bind
a structure that results from the interactions between the
amino acids of the antigen, and those interactions are
not necessarily independent of each other. As we have
shown, a single substitution at one position can remove
ail recognition, but a compensating change at another
residue will restore binding. Our assumption that the pep¬
tide can be divided into two halves, one that is critical for
binding to class II and one that binds to the T cell receptor,
appears to be valid. Either half can be viewed as a recog¬
nition site that may be moved between determinants; how¬
ever, mutations within each set often result in dramatic
reduction in binding to either receptor.
The strategy of substituting alanine for the individual
residues of the determinant has an additional shortcom¬
ing: only if the replaced amino acid dramatically differs in
either size or polarity from alanine wiil a clear-cut distinc¬
tion be seen (Allen at ai., 1987; our unpublished data). For
instance, with the hemagglutinin determinant, alanine can
be successfully substituted at each position except for
lysine-311 without significantly affecting recognition (data
not shown). Consequently, certain residues appear not to
interact with either receptor by this analysis. In contrast,
our results indicate that each amino acid is involved in
binding to DR1, the T cell receptor, or both.
We are currently attempting to identify the exact interac¬
tions the peptides make with DR1 by measuring binding
constants of these and other analogs to purified DR1 and
by crystailographic studies of both DR1 and DR1-peptide
complexes. Detailed structural information from an HLA
atomic model combined with similar sequence analyses
of both helper and cytotoxic epitopes wiil lead to similar
allele-specrfic subpatterns that can be used to- develop





Peripheral blood mononuclear cells-(PBMC) obtained from healthy
adults were isolated by centrifugation on a discontinuous gradient of
RcolLHypaque (Pharmacia) and were cryopreserved. For use in ex¬
periments. lymphocytes were resuspended in complete medium:
RPM11640 supplemented with A* serum. 2 mM L-giutamine. and 100
lU/ml of penicillin/streptomycin.
Isolation of Antigen-Reactive T Cell Clones
The isolation and characterization of human T lymphocyte clones HA
1.7 and TLC 72 have been described previously (Lamb et al., 1982a.
1982b). Briefly, PBMC were stimulated for 6 days with influenza
hemagglutinin (H3) or intact virus (H3N2) for HA 1.7 and TLC 72.
respectively. Lymphobiasts were enriched on a Percoil density gra¬
dient (Pharmacia, Uppsala) and cloned by limiting dilution (013 cells
per well in Microtest II plates. Falcon) in the presence of autologous
irradiated (3000 rads) PBMC, viral antigen, and intorleukin 2. At day
7, growing dones were transferred to 96-weil flat bottom microtiter
plates and subsequently, to 24-well plates. At each transfer the clones
received filler cells, antigen, and IL-2. The dones were expanded and
maintained by the addition of fresh IL-2 every 3—4 days, and filler cells
togetherwith specific antigen every 7 days. Prior to use in proliferation
assays, the T cell dones were rested for 6 to 8 days after the last addi¬
tion of filler cells.
Proliferation Assays
Cloned T cells (5 x 104 per ml) were cultured with soluble antigen in
the presence of irradiated histocompatible PBMC (1.25 x 105 per
ml), autologous EBV-transformed B cells (10s per ml), or mitomycin
C-treated transteeled munne L ceils (105 per ml) in a total volume of
200 ul of complete medium in 96-well round bottom plates. Where L
cells were used as presenting cells, the assays were performed in 96-
well flat bottom plates. After 72 hr of incubation, tritiated methyl thymi¬
dine (1 nCi, pHJTdR; Amersham International, Amersham, IL K.) was
added to the cultures for 8-16 hr and then harvested onto glass fiber
filters. Proliferation as correlated with pHJTdR incorporation was mea¬
sured by liquid scintillation spectroscopy. The results are expressed as
mean counts per minute (cpm) plus or minus percentage error of the
mean for triplicate cultures.
Peptide Synthesis, Analysis, and Purification
Peptidss wars synthesized by using solid phase techniques (Baranv
and Merrtfield. 1979) on an Applied Blosystems Peptide Synthesizer
with commercially available Pam resins, t-8oc protected amino acids,
and commercially available reagents (Applied Biosystoms. Foster City,
CA). The peptides were deaved from the resin and the side chain pro¬
tecting groups were simultaneously removed with anhydrous hydro¬
fluoric acid with antsoie as a free radical trap. The side chain protecting
groups were extracted with ether. Subsequently, the peptides were dis¬
solved in 15% acetic acid, filtered from the resin, and lyophiiized. The
crude peptides were analyzed by HPLC on a C-8 reverse phase
column (Aquapore RP-300, Brownlee Labs) and by amino add analy¬
sis. Peptides that were not of greater than 90% purity as judged
by analytical HPLC analysis were purified by using a preparative RP-
300 column and a water-trifluoroacetic add-acetonitrile gradient.
Prindpal peaks were collected, lyophiiized, and analyzed by amino
add analysis.
Cloned Genes
The 0R1 a and 0 genes were full-length cONA gene clones, described
by Tonnelle et al. (1985). They were inserted into the pflSVS and
pRSV3 cONA expression vectors, respectively (Gorman et al.. 1983).
The pflSV5 vector contains the pSV2gpt gene (Mulligan and Berg,
1981).
□NA-Mediated Gene Transfer, Selection, and Ceil Sorting
The thymidine kinase (TK) negative munne L cell subline DAP-3 was
transfected with pairs of a and 0 genes together with a third plasmid
encoding either the xanthine-guanine phosphoribosyitransferase {gpt)
or the neomycin resistance gene. The standard calcium phosphate
precipitation techniquewas used (MarguJies et al., 1983) and success¬
fully transfected ceils selected in medium containing either MXH
(mycophenolic add, xanthine, and hypaxanthine) orG4ia Colonies of
transfectants were pooled, stained with appropnate monodonaJ anti¬
bodies, analyzed by microfluorimetry, and repeatedly sorted by prepa¬
rativemicrofluorimetry to achieve high levels of cell-surface MHC dass
II expression.
Mitomycin C Treatment of Mouse Fibroblast (L) Calls
After trypsinization, cells were washed in serum-free RPMI 1640. Up
to 107 calls were suspended per mi of serum-free medium. Mitomycin
C (Sigma) was added to a final concentration of 50 ug/ml. Cells were
incubated at 37*C for 45 min, washed extensively in A"7RPMl, and
used in the proliferation assays.
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Abstract
An assay for the binding of peptides to major histocompatibility complex (MHC) class II proteins
on the surface of cells has been used to determine the relative importance of the amino acids
composing an influenza haemagglutinin T cell determinant in binding. The important contact
residues were identified by the effect substitution of each residue with biotinylated lysine had on
the ability of the peptide to bind. The spacing of the critical residues within the peptide
sequence was consistent with the central core, of approximately eight amino acids, adopting a
helical conformation. The terminal residues were less constrained and might not be part of a
regular conformation. Increasing the helical propensity of the determinant, by simply acetylating
and amidating the peptide, resulted in an analogue that was able to stimulate a specific T cell
clone at significantly lower concentrations than the natural sequence. A potential location for the
peptide in the binding site was postulated based on the presence of complementary amino acids
in the class II molecule and supported by screening a large number of peptide analogues for
their ability either to bind the restriction element or to stimulate T cell proliferation.
Introduction
The antigen receptor of T lymphocytes recognizes a complex
formed between peptide fragments of protein immunogens and
cell surface glycoproteins encoded by either the class I or class
II major histocompatibility genes (reviewed in 1,2). Binding of
peptides to detergent-solubilized major histocompatibility complex
(MHC) class II molecules initially was demonstrated using
equilibrium dialysis (3), and subsequently the complex was shown
to be sufficiently stable to allow its isolation using gel filtration
chromatography (4-6). Recently, binding of biotinylated
analogues of T cell determinants to MHC class II proteins on the
surface of Epstein-8arr (EBV)-transformed 8 cells has been
shown using fluorescent streptavidin and flow cytometry (7).
Two groups have attempted to define the orientation of
peptide determinants when part of the complex by correlating
the inability of natural determinants containing point substitutions
to stimulate the T cell clone with their capacity to bind the
restriction element. Substitution of every position in a lysozyme
peptide with alanine generated a family of analogues whose
ability to bind purified l-Ak and/or stimulate a T cell clone
provided sufficient information to allow a helical conformation of
the bound peptide tp be postulated (8). However, the results of
a more extensive study using a similar strategy to dissect a helper
determinant in ovalbumin failed to identify residues unequivocally
interacting with either macromolecule (9). Consequently, a regular
conformation could not be identified, pnmariiy because the
maiority of peptides containing single substitutions were still able
to bind the class II protein.
An alternative method was used to examine the orientation of
two DR1-restricted determinants (10). Assuming the two peptides
bound in a similar location in the combining site and adopted
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identical conformations, residues from one sequence were
substituted for tne corresponding amino acid in the second to
generate hybrid peptides that were able to stimulate T cell
clones specific for each peptide. In addition to identifying residues
critical for clonally specific recognition, this approach provided
information on the structural requirements for binding and placed
constraints on the potential conformations the peptides could
adopt when part of the complex. However, this strategy had the
inherent weakness that the putative MHC contact residues were
identified on the basis of sequence homology between the two
peptides, and consequently, the hybrid peptides that were
stimulatory were quite similar to the natural determinant.
In this report the ability to detect binding of biotinylated peptides
to MHC class II proteins on cell surfaces was used to develop
a model for the relative orientation and conformation of an
influenza haemagglutinin (HA) peptide in the antigen-combining
site of HLA DR1. Only when an unnaturally large amino acid was
incorporated into each position of the peptide could important
residues for binding clearly be identified. The peptide was
placed in the binding site based on the presence of potential
complementary contact resTdues in the MHC molecule and the
effects of a number of analogues on T cell recognition and
binding. The ability of the MHC protein to bind a large variety
of peptides is discussed in the context of the model.
Methods
Peptides
The peptide representing residues 307-319 of HA (PKYVK-
QNTLKLAT in standard one-ietter code), which previously was
shown to be recognized by DR1-restricted T cells (10), was the
parent sequence for the analogues used in this study. Long-chain
biotin (11) was placed unambiguously at each position by
substituting lysine at the desired position, replacing lysines 308,
311, and 316 with arginine, and acetylating the cr-amino group.
The peptides were synthesized using standard solid-phase
methods as previously described (10) on an Applied Biosystems
430A synthesizer, and biotinylated with excess sulphosuccin-
imidyl-6-(biotinamido)hexanoate (Pierce). The biotinylated
peptides were purified by reversed-phase HPLC and analysed
by amino acid analysis and fast atom bombardment mass
spectrometry. Biotinylation was further confirmed by positive
reaction with dimethylaminocinnamaldehvde (12).
Binding assay
The assay has been described in detail elsewhere (7). Briefly,
two EBV-transforrned B cell lines homozygous for HLA-DR1 Dw1,
MAJA, and METTE, and the class II deficient EBV-B ceil line,
RJ 2.2.5 (13). were incubated at 3 x 105 cells per well with
eacn biotinylated peptide (50 /iM) in 96-well plates (200 /il) at
37°C for 4 h, followed by addition of fluorescein isothiocyanate
(FITC)-streptavidin (4.22 ng/ml; Calbiochem). Cell surface DR
expression was quantified by staining with fluoresceinated L243
anti-DR monoclonal antibody (14; Becton-Dickinson, 30 mm,
4°C). After each incubation, cells were washed with PBS
containing 0.1% bovine serum albumin. Stained cells were
analysed by flow cytometry using a FACScan analyser (Becton-
Dickinson). Only viable cells, identified on the analyser for their
ability to exclude propidium iodide, were included in the analysis.
In inhibition studies, competing peptides (6-fold molar excess;
300 nM) or unlabelled L243 (hybndoma supernatant, final dilution
2-fold) were included in the assay. To determine whether
differential proteolysis was a factor, a mixture of protease inhibitors
(TPCK, 10/ig/ml; PMSF, 50 /ig; leupeptin. 1 ^g/ml; aprotinin,
1 /ig/ml; soybean trypsin inhibitor, 10 ng/ml) were co-incubated
with cells and the biotinylated peptide.
-Measurement of helicity
The helicity of the natural peptide (HA 307-319) or derivatives
that were either acetylated or amidated, or both, was measured
by the magnitude of the negative Cotton effect at 222 nm in a
range of water - trifluoroethanol mixtures. On the scale shown,
10 M-' cm-' was taken to represent 100% helix. All peptides
underwent simple helix-coil transitions as judged by the
presence of isodichroic points around 203 nm and the minima
in the circular dichroism (CD) spectrum at 222 and 207 nm for
the helical, and at 196 nm for the unordered.conformation. CD
spectra were recorded on a Jasco J-600 spectropolarimeter at
—0.15 mg/ml of peptide in a 1 mm quartz cuvette. Absorption
spectra of peptide stocks were recorded on a Hewlett-Packard
diode array spectrophotometer. CD spectra of biotinylated
peptides were measured in 50% phosphate-buffered saline, pH
7.2/trifluoroethanol.
Isolation of antigen-reactive cloned T cells
The isolation and characterization of T ceil clone HA 1.7 reactive
with HA 307 -319 has been described in detail elsewhere (15).
Briefly peripheral blood mononuclear leukocytes (PBMC) were
stimulated with HA and cloned by limiting dilution in the presence
of autologous PBMC, antigen, and lL-2. Cloned T cells were
expanded by the addition of IL-2 every 3 - 4 days and filler cells
together with antigen every 7 days. Prior to use in proliferation
assays, the T cells were rested for 6 - 8 days after the iast addition
of filler cells.
Proliferation assays
Cloned HA 1.7 T cells (5 x 104/ml) were stimulated with peptide
antigens in the presence of histocompatible irradiated PBMC
(1.25 x 105/ml). After 60 h of incubation, tritiated thymidine
([3H]TdR; 1 /iCi/well; Amersham International, Bucks. UK) was
added and the cultures harvested onto glass fibre filters 8 -16 h
later. Proliferation as correlated with [3H]TdR incorporation was
measured by liquid scintillation spectroscopy. The results are
expressed as mean cpm for triplicate cultures. Background
response to accessory cells in the absence of antigen was <500
cpm and in all cases the SEM was <20%.
Results and discussion
Identification of amino acids critical for binding
Previous experiments exchanging amino acids between two
DR1-restricted determinants suggested that both peptides
adopted an a-helix when bound (10). In this model, the side
chains of the amino acids composing the upper face of a helical
peptide extend out of the antigen-combining site, and the
residues which form the opposite fapade and the sides of the
helix make important contacts with complementary residues of
the HLA molecule. Consequently, substitution of individual
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Fig. 1. Binding of a biotinylated analogue of HA 307-319 to
EBV-transformed B ceils. The DR1 Dw1 homozygous B ceil line. MAJA,
was incubated with an HA analogue containing LCB at the amino terminus
and stained with FITC - streptavidin ( ). Surface expression of class
II DR proteins was quantified by incubation with a fluoresoeinated anti
HLA-OR monoclonal antibody. L243 ( ). Background fluorescence
in the absence of biotinylated peptide was determined by incubation with
streotavidin only ( ). Co-incubation of the anti-OR monoclonal
antibody and the biotinyiated peptide resulted in a reduction of the
fluorescent signal ( ).
residues of the peptide by a bulky amino acid should differentially
affect the stability of the complex depending on the stenc
requirements of each contact and the relative importance of
each amino acid in binding. However, the structure of the
antigen-combining site of the MCH molecule has evolved to bind
multiple, unrelated peptides and therefcre is expected to tolerate
many point substitutions in a peptide with only slight effects on
the apparent affinity of binding. This might be why previous
studies (9) examining binding of ovalbumin peptide analcgues
to murine class II molecules have failed to define critical MHC
contact residues unambiguously. However, an unnaturally large
side chain might cause greater steric interference with binding
than substitution with any natural amino acid, thereby allowing
us to observe a greater reduction in binding upon altering a
critical residue.
To test this hypothesis, a set of peptides centaining a denvative
of biotinylated lysine with an additional hydrocarbon spacer,
long-chain biotin (LCB; 11), substituted for each residue of the
HA peptide was synthesized. Binding of the analogues to the
surfaces of DR homozygous EBV-transformed B cell lines was
assayed by incubating peptide-treated cells with fluorescently
labelled streptavidin and analysed by flow cytometry (7). When
the HA peptide, biotinylated at the amino terminus, was incubated
with the DR1-expressing cell line and exposed to FITC-
streptavidin, a fluorescent signal - 5 times that present when the
cells were incubated in the absence cf the peptide was apparent
(Fig. 1). Previous experiments have shown that the fluorescent
signal anses from the direct interaction between the peptide and
HLA-DR molecules on the surface of the cell and does not require
internalization (7).
In this paper, biotinyiated analogues have been used as
probes to examine the relative importance of each residue in





Fig. 2. Differential binding of analogues of HA 307-319. biotinyiated
at each position, to DR1-homozygous. EBV-transformed B cells. (A) Each
peptide (50 /*M) was incubated with transformed B cells homozygous
for 0R1 Dw1 (MAJA (■) and METTE (□)] or the DR-negative B cell line.
RJ 2.2.5 (0), stajned. and analysed by flow cytometry. The relative
amount of peptide bound to cells was judged by the intensity of green
fluorescence per cell, averaged over all viable cells. The background
as determined by the control incubations in the absence of biotinyiated
peptide was subtracted. The results shown are the average of three
assays, with the SD displayed with error bars. (8) Model of the
conformation adopted by the peptide when bound to DR1, deduced from
the binding results shown in (A). Residues 309-317 are folded into an
a-helix, with an orientation that permits residues 310. 313. and 316 to
point away from, while 309. 311, 312. 314, 315. and 317 would be
directed towards the antigen-combining site. The amino acids at both
termini, which tolerate biotinylation. are not drawn as part of the helix
because of their apparent conformational flexibility.
were incubated with the ceils, marked differences were seen in
the resultant fluorescent signal (Fig. 2A). Strong fluorescence was
present when lysine-LCB was placed either at the N terminus
or substituted for proline-307, lysine-308, vaiine-310. asparginine-
313, lysine-316, or aiamne-318. In contrast, no detectable
fluorescence was observed when peptides containing lysine-LCB
at residue 311 and 312 were used, while substitution at 309. 314.
315. or 317 resulted in reduced fluorescence.
A loss of the fluorescent signal upon biotinylating any residue
might occur because the ability of the peptide to bind to DR1
is reduced by the modification, or because the peptide still binds
but with the biotinyl group stencally unavailable to streptavidin.
In the latter case, no fluorescent signal should be apparent at
any concentration, because steric inaccessibility should not
depend on the amount of peptide in the assay. The appearance
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Fig. 3. Chemical modification of HA 307 -319 resulted in both greater helical propensity and increased antigenicity, (a) Helicity of the natural peptide
(HA 307-319). or derivatives that were either acetyiated (HA Ac), amidated (HA NH2). or Doth (HA Ac/NH2), measured in varying water - tntluoroethanol
mixtures, (b) Helicity of analogous HA 307-319 derivatives containing an arginine (R) residue at position 307. (c) T cell proliferation in response
to acetyiated and amidated analogues of HA 307-319. The response to the natural sequence is shown for comparison, (d) T cell proliferation to
R-307 substituted analogues.
of a fluorescent signal when analogues containing lysine-LCB
at 309. 311, and 312 were used at concentrations well above
50 jiM (data not shown) indicated that biotinylation affected the
apparent affinity of the analogues for DR1.
The ability of the analogues to bind to the restriction element
on cell surfaces could have been affected by the biotinylation
in a number of different ways: (i) by interfering with a critical
contact between the peptide and the class II proteins; (ii) by
altering the propensity of the peptide to adopt the conformation
in which it bound to DR1: or (iii) by changing the susceptibility
of the analogue to proteolytic degradation. The second possibility
was unlikely because each of the 14 peptide analogues had
indistinguishable CD spectra (data not shown) in trifluoroethanol
(TFE)-water mixtures containing TFE concentrations at which
the helical propensities of closely related, unbiotinylated HA
analogues were significantly different (vide infra). The third
possible explanation for the different fluorescent signals
generated by each analogue, differential proteolysis, was more
difficult to disprove. However, none of the low fluorescent signals
was increased in the presence of a cocktail of protease inhibitors
(TPCK, PMSF, leupeptin. aprotinin, and soybean trypsin inhibitor).
Therefore the differences in fluorescence appear to arise
from the varying capacity of the class II molecule to bind the
analbgues. reflecting the differential effect of biotinylation at each
position on the affinity of the interaction.
If this interpretation is true, then the assay provides a quantita¬
tive measure of the involvement of each amino acid of the pep¬
tide in the formation of the complex: the lower the signal, the more
important is the amino acid. Therefore we can conclude that
tyrosine-309, lysine-311, glutamine-312, and, to a lesser extent,
threonine-314, leucine-315, and leucine-317 contribute to the
formation of the complex.
The peptide might bind tb DR1 in a variety of ways. However,
the distinct variations in fluorescence observed when the different
analogues were assayed implied that the number of confor¬
mations and orientations of the bound peptide was limited. In
all possible modes of binding, residues 311 and 312 form critical
contacts with the restriction element, because biotinylation
at these positions eliminated the fluorescent signal at the
peptide concentration used. A further constraint on the possible
conformations of the bound peptide was that the fluorescent
profile peaked at every third residue (310. 313. and 316) within
the central portion of the peptide, with significantly less
fluorescence in between. The periodicity suggested that the
central core adopted a helical conformation. However, the results
were not consistent with the peptide being helical over its entire
length because analogues containing lysine-LCB at 308 and 318
resulted in a strong signal. If the peptide adopted a perfect helix
with 310, 313, and 316 pointing up. these residues sheuld point
down. The ability to tolerate substitution with biotinylated lysine
at both ends of the peptide might be explained by an increased
accessibility of the termini of the helix or by deviations from an
ideal a-helix. A model based on this interpretation of the pattern
of fluorescence is shown in Fig. 2B. consisting of a helical core
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Fig. 4. The ability of peptide analogues of HA 307-319 containing
substitutions to stimulate the HA-specific T cell clone. The proliferation
assays were performed as descnbed in the Methods. Proliferation to the
substituted peptides is expressed as a percentage of the response
observed to the natural sequence (HA 307-319) at the optimal
concentration (0.3 ng/ml), although each peptide was tested over a dose
range of 0.3 -30 ng/ml. The horizontal axis represents the sequence of
the natural determinant: monosubstitutions at each position are shown
above the histogram in order of decreasing proliferation. Where the two
peptides gave indistinguishable proliferation, they are shown on the same
line. A disubstituted peptide containing two lysines at positions 314 and
315 is also included. The proliferative response of cloned T cells cultured
with accessory cells in the absence of antigen is shown as a control.
(residues 309-317), with the two amino acids at each end of
the peptide exhibiting greater conformational freedom and not
modelled as part of the repeating structure.
Stabilization of a helical conformation results in increased
antigenicity
If the HA peptide binds the restriction element as an intact or
partial cr-helix, then stabilization of this conformation should
improve the potency of the peptide. Recent experiments have
demonstrated that stabilization of the macrodipole of an a-helix
can result in a significant increase in the helical content of relatively
short peptides (16). One way to stabilize the macrodipole is to
remove the charges at the amino and carboxyl termini of the
peptide by acetylation and amidation.
The natural HA peptide and several analogues were examined
for secondary structure content by CD in a range of water - TFE
mixtures. The unacetylated and unamidated HA peptide exhibited
only low helicity even at high TFE concentration (Fig. 3a), as
judged by absorption of circularly dipolarized light at 222 nm.
Amidation, acetylation and. to a greater extent, combined
acetylation and amidation substantially increased the helicity of
the HA peptide. Consistent with the hypothesis that the improved
helical content was due to stabilization of the macrodipole.
amidation and acetylation of an analogue with arginine at 307
also increased helical propensity, but less so than when the
positively charged arginine was not the first residue in the peptide
(Fig. 3b).
When tested in proliferation assays with the T cell clone, HA
1.7, the acetylated and amidated peptide stimulated the clone
at approximately two orders of magnitude lower concentrations
Fig. S. Percentage competition of monosubstituted HA peptides for
binding of the N-terminally biotinylated HA analogue to the DR1 Dwi
homozygous 8 cell line, MAJA. Cells were simultaneously incubated with
50 riM biotinylated peptide and 300 nM (6-fold molar excess) competitor
peptide, stained, and analysed as described in the legend to Fig. 1.
than the natural sequence (Fig. 3c). Replacement of the amino
terminal proline by either lysine or arginine also resulted in more
potent peptides (Fig. 3d), but the acetylated. amidated peptide
containing arginine at 307 was not recognized better than the
acetylated and amidated natural sequence. That the effects of
exchanging proline for a positive charged residue and blocking
the charged end groups were not additive indicated that the two
factors are acting by separate mechanisms. The most likely
explanation is that a positive charge at 307 results in a superior
interaction with a residue in the binding site of DR1, but does
not stabilize the macrodipole.
Recognition and competition by analogues containing point
substitutions
To begin to understand the physical and chemical requirements
at each position of the peptide for binding to OR 1 and recognition
by the T cell receptor of HA 1.7, sets of peptides containing point
substitutions at each position in the sequence were synthesized.
Each peptide was assayed over a concentration range of
0.03-30 rig/ml for its ability to stimulate the HA-specific clone.
The proliferative responses relative to the natural sequence at
0.3 iig/ml are shown in Fig. 4. As in previous studies on both
class I- and class ll-restricted T cell recognition (9.17), relatively
few substitutions resulted in peptides that were recognized better
than the natural sequence (R, K-307; Q-310; K-314).
Several peptides containing a point substitution, which resulted
in complete loss of recognition by HA 1.7, were tested for their
ability to displace the natural sequence containing an amino-
terminal LC8 from the antigen-combining site of DR1 on the
surface of an EBV-transformed B cell line (Fig. 5). Interestingly,
with the exception of a peptide containing serine at 309, they
all successfully competed to varying extents. Some of the best
competitors were analogues that contained substitutions at
positions shown to tolerate LCB and postulated to point outwards
from the site (307, 308, 310, 313. and 316). Surprisingly,
analogues containing substitutions at residues believed important
for binding (311, 312. and 314) also bound sufficiently well to
compete effectively.
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Rg. 6. Proposed model of ttie antigen-combining site of DR1 and the
complex formed between the HA peptide and the class II orotetn. (A) The
proposed antigen-combining site of DR1 modelled by homology to
the published structure of HLA-A2 (18,19). The model is consistent with
the alignment of class I and class II amino acid sequences by 8rown
el at. (20). The areas enclosed in dashed lines correspond to positions
with either additions or deletions of residues between consensus class I
or II sequences. (B) The proposed location of HA 307-319 in the
combining site. The peptide is modelled as two turns of a perfect a-nelix
and placed in the site parallel with the /S-chain helix. The flexibility at the
termini suggested by the binding experiments is indicated by the broken
lines connecting the terminal or-carbons of the peptide. The residues of
the peptide believed to be facing down in the site are enclosed in
diamonds.
Taken together with the earlier experiments on the ovalbumin
peptide (8) and related studies dn class l-restricted determinants
(17), these findings indicate that there is no absolute requirement
for a single amino acid in most positions in T cell determinants.
Monosubstitutions in the peptide may change the detailed
interactidns with the MHC protein or the surface of the peptide -
MHC complex as seen by the T cell receptor, but without
significantly reducing the amount of peptide bound to the
restnction element. Consequently, experiments using analogues
containing point substitutions to determine relative orientation of
the peptide can lead to results that are difficult to interpret. Only
if, as shown above using long-chain biotinylated lysine, the
substitutions are sufficiently drastic, wiii distinct variations in
binding be apparent. This high degree of tolerance to seguence
variation in the peptide might be expected for a binding site
containing several amino acids of different physical character in
close proximity to each residue of the agretope. In addition, the
flexibility of the side chains in the binding site might allow the
MHC protein to accommodate the stertc effects of mono-
substitutions.
Modelling a DRt-peptide complex
To identify a potential location of the peptide in the binding site,
a model of DR1 (Rg. 6A) was generated based on the published
HLA-A2 structure (18,19). As previously detailed (20). alignment
of the MHC class I and II alleles, whose sequence has been
determined, revealed that the two classes of proteins share a
number of structural features.
The results of the experiments using biotinylated analogues
indicated that the central core of the HA peptide bound in a
preferential orientation and conformation. The dimensions of the
proposed antigen-combining site are sufficient to allow a 13
amino acid peptide, folded as at least two turns of an a-helix,
to be placed in the site with its helical axis approximately parallel
with the helix of the a-chain of class II, as has been postulated
previously for a lysozyme peptide (20). In such a model, the
residues composing the lower facade of the helical peptide
would be expected to pack closely onto the four central strands
of the (3-pleated sheet ofjhe recognition element (Fig. 6B) as is
charactenstic of the helix - strand interactions in globular proteins
(21 -23). In this conformation, the amino acids composing the
sides of the helical peptide can interact with either the residues
of the helices of the MHC protein, those of the T cell receptor,
or both.
If the orientation of the peptide relative to the MHC protein and
the antigen receptor of the T cell was valid, as indicated by the
exchange experiments (10) and the binding of the biotinylated
analogues, then the proposed antigen-binding site should have
complementary features that might allow the identification of
contact residues in the iigand and its receptor.
The first position examined in the peptide was lysine-311.
Empirical analyses initially identified this residue as potentially
interesting (24) and the exchange experiments between
determinants (10) and the binding assays have confirmed
its importance. A positive amino acid at this position was
advantageous for binding because a peptide containing arginine
was recognized by the T cell clone, whereas substitution of lysine
by glutamic or aspartic acid or glutamine resulted in either
complete or significant loss of stimulatory activity. Biotinylation
of this lysine greatly affected the ability of the peptide to bind
DR1 and indicated that this residue most likely is buried in the
complex. Buried positive charges are often involved in salt
bridges in globular proteins (25), and together with the sensitivity
of this residue to substitution, suggested that the lysine
participates in an ionic interaction.
Two other positions in the peptide also exhibited a preference
for a positively charged amino acid, although not as clearly as
at 311. Of the nine amino acids substituted for lysine-308. arginine
was the best recognized. Substitution of the amino-terminal
proline at 307 with lysine or arginine resulted in more potent
peptide analogues, stimulating the clone at -10 times lower
concentration than the natural sequence (Fig. 4). The increased
potency was not simply due to the removal of the proline at this
position, because the other two substitutions (D and E) did not
increase the activity.
The molecular surface of the combining site was examined
for a pattern of buried negative charges that oeuld act as
counter-ions for positive charges at 311, 308, and 307 in the
peptide. Because of its demonstrated importance in binding.
lysine-311 was assigned a central position in the site near glutamic
acid-15 of the a-chain. If the amino terminus of the peptide was
orientated towards the strands of the 0-chain, as shown in Fig.
6B. then lysine-308 was located sd that it could interact with
glutamic acid-28 of the 0-chain. Alternatively, lysine-308 might
interact with glutamic acid-59 of the a-chain if the direction of
the peptide was reversed: however, only the orientation shown
in Fig. 6B can account for the preference for a positively charged
residue at position 307 because, in this configuration, residue
307 is near aspartic acid-70 of the a-chain.
The other residues shown to contribute to binding (314, 315,
309, and 312) were examined in the context of this tentative
model. As shown in Fig. 6B, residues 314 and 315 of the peptide
are located near the first and second strands of the a-chain.
Interestingly, lysine could be present at either position with no
deleterious effect on recognition. One possible rationalization for
the tolerance of both hydrophobic and hydrophilic amino acids
at these two positions is the diversity of interactions possible with
the receptor. For example, if a hydrophobic residue is present
at position 315 in the peptide, it can be tolerated because it could
form good contacts with several hydrophobic residues in the class
II binding site, namely phenylalanine-30 or -28. or isoleucine-11
of the a-chain, whereas if a polar residue is present it may bind
because it interacts with a distinctly different, polar amino acid.
glutamine-a13. However, there are limits to the ability of the
protein to tolerate substitutions in the determinant. A peptide
analogue containing lysine at both 314 and 315 did not compete
with the biotinylated native sequence for binding (Fig. 5) and was
not recognized by the T cell clone (Fig. 4), suggesting that some
hydrophobic character is required at these two positions.
In addition to 311, amino acids at 309 and 312 appear to be
critical for binding. When bound as shown in Fig. 6B, they are
both directed towards the 0-chain helix, with tyrosine-309 of the
peptide close to leucme-67 and glutamine-312 juxtaposed to
residue 71 in the model. Tyrosine-309 can be replaced by
phenylalanine and be recognized by the T cell clone, but
substitution with eight other amino acids resulted in significant
loss of stimulation (Fig. 4). Substitution with serine at 309 also
was the only point mutation that failed to compete with the
biotinylated natural sequence, demonstrating that tyrosine at this
position makes an important interaction with the restriction
element (Fig. 5). When glutamine-312 was substituted with
arginine all recognition was eliminated, whereas substitution with
either aspartic or glutamic acid retained the ability of the peptide
to stimulate the clone. The ability to tolerate a negative, but not
a positive, charge was consistent with position 312 in the peptide
interacting with arginine-71 of the B-chain. However, the limitations
to the monosubstitution approach are highlighted by the
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observation that a substitution with lysine at position 312 did not
eliminate recognition. While not necessarily disproving the
proposed model, this fact serves to emphasize the degree of
tolerance typical of the formation of the complex between the
HA peptide and DR1.
Due to the small number of substitutions and the variation with
which they differ from the native sequence at each position, only
limited conclusions can be made about the tolerance for amino
acid substitutions along the sequence. In addition, the ability of
analogues of the same peptide containing point substitutions to
compete with the natural sequence for binding demonstrated that
there was signifieant flexibility in the formation of the peptide -
MHC complex. Nevertheless, a tentative position for the peptide
was identified based on potential interactions with residues in
the site. The model has been constructed in which the peptide
adopts a conformation with its central core of approximately eight
amino acids as a fixed a-helix and the diversity of binding anses
from flexible side chain interactions. Such a central core of
residues in a T cell determinant is consistent with investigations
examining the minimal requirements for T cell recognition and
binding to MHC class I and II molecules (9.24). Outside of the
central core of the antigen, the conformation of the peptide
appears to be less constrained, which might contribute to
differences in fine specificity of T cell clones recognizing the
identical peptide sequence. The three most critical residues for
binding are centrally located, one pointing towards the pleated
sheet and two directed at the 0-chain helix. Lysine-311 on the
peptide was postulated to interact with glutamic acid-15 of the
a-chain while glutamine-312 and tyrosine-309 are believed to
contact arginine-71 and leucine-67 of the 8-chain helix. The
proposed contact residues in the MHC protein dramatically differ
in their polymorphism. The glutamic acid is present in all DR
proteins, whereas 67 and 71 of the 0-chain are highly variable
between alleles. Interestingly, positions 67 and 71 are two of the
three mutations found in the ASM'2 murine class II protein,
which are known to change T cell antigen recognition dramatically
(26.27). Also, position 71 has been identified as being associated
with susceptibility or resistance to rheumatoid arthntis and
pemphigus vulgaris (28). One possible explanation for their
importance is that they are located in a positidn on the side of
MHC helix where they contact not only the side chains on the
antigen, but also potentially the antigen receptor of the T cell.
Although the biochemical and functional data reported here
have permitted the generation of a working model, the true
structure of peptide - MHC class II complexes will remain elusive
until the crystal structure of a class II protein and of a pure class
II - peptide complex have been solved. The importance of a
working model is that it can be used as the basis for logical
mutagenesis of either the restriction element or the peptide ligand.
The results of such experiments, coupled with the data described
in this report, will not identify absolute requirements for individual
amino acids at the critical contact positions in the peptide, but
rather might lead to a hierarchy of amino acid preferences. Such
a ranking can be used to identify peptides from other protein
sequences that can bind MHC class II molecules with high affinity.
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EFFECT OF NATURAL POLYMORPHISM AT RESIDUE 86 OF THE HLA-DR 0
CHAIN ON PEPTIDE BINDING
ROBERT BUSCH. C. MARK HILL. JOHN D. HAYBALL. JONATHAN R. LAMB, and
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Class I and class II MHC glycoproteins are highly
polymorphicmolecules that bind antigenic peptides
and present them on cell surfaces for recognition
by T lymphocytes. Even though MHC polymorphism
has long been known to affect both peptide binding
and recognition by the TCR. the role of individual
amino acids of MHC proteins in these interactions
is poorly understood. To examine the effect of a
small number of amino acid residues on T cell stim¬
ulation. B lymphoblastoid cell lines homozygous for
the closely related DR1 subtypes. Dwl and Dw20.
and the DR4 subtypes. Dw4 and Dwl4. were com¬
pared for their ability to present an immunogenic
influenza hemagglutinin peptide (HA307-319) to an
Ag-specific. DR1.4-restricted T cell clone. B cell
lines expressing DR1 Dw20 and DR4 Dwl 4 pre¬
sented HA307-319 much less efficiently than DRI
Dwl and DR4 Dw4 and bound a biotinylated ana¬
logue of the same peptide less well. Analysis of
DRB1 gene sequences suggested that polymorphism
at residue 86 had a major effect on peptide binding.
Differences in binding of a set of HA307-319 ana¬
logues biotinylated at each residue to cells express¬
ing DRI Dwl and DRI Dw20 suggested that the
polymorphism affected the interactions of many
peptide residues with the class H molecule. In inhi¬
bition assays, DRI Dwl and DR4 Dw4 were shown
to differ from DRI Dw20 and DR4 Dwl4 in then-
length requirements for peptide binding. Using a
larger panel of homozygous B cell lines expressing
many class II haplotypes. a Ser-309 substituted
HA307-319 analogue was shown to bind to most B
cell lines expressing Vai-86 containing alleles (in¬
cluding DRI Dw20 and DR4 Dwl4) but failed to bind
most B cell lines expressing Gly-86 alleles (including
DRI Dwl and DR4 Dw4). The results indicated that
polymorphism at residue 86 influenced the specific¬
ity and affinity of peptide binding and affected the
conformation of peptide-DR protein complexes with¬
out completely eliminating T ceil recognition.
T cells recognize peptides bound to class I and class II
MHC proteins, and polymorphism in these proceins may
influence T cell recognition either by affecting the for¬
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mation of peptide-MHC protein complexes or by interfer¬
ing with their recognition by the TCR (1 -4). In the crystal
structure of the class I protein. HLA-A2. most of the
polymorphic residues either made direct contacts with
bound peptides or were located close to the proposed
peptide binding site at positions that might interact with
a TCR (5). Crystallography'has been used to examine
directly the effect of polymorphism on the structure of
the class I Ag combining site. Fifteen differences in pri¬
mary structure between HLA-A2.1 and Aw68 affected
the characteristics of individual specificity pockets but
not the overall shape and dimensions of the Ag binding
site (6). Homologies and conserved patterns of poly¬
morphic residues between class I and class II proteins
suggest that the binding site of class II MHC molecules
has a similar structure and that polymorphism affects
peptide binding and T ceil recognition by analogous
mechanisms (7).
The development of assays for peptide binding to affin¬
ity purified class II MHC proteins has permitted the effect
of polymorphism on these interactions to be measured
directly (8-10). Screening large numbers of peptides for
binding to murine I-A and I-E class II proteins confirmed
that the specificity was influenced by structural differ¬
ences between MHC proteins. In addition, alleles encoded
at the same locus were more similar in their structural
requirements for peptide binding than different class II
isotypes (11-13). Even though these studies demon¬
strated that polymorphism affected peptide binding, in¬
dividual important residues in the class II molecules were
not identified, primarily because a small number of al¬
leles were compared and these differed from each other
at multiple residues.
In this study, residue 86 of the HLA-DR 3 chain was
shown to be critical for binding of an influenza hemag¬
glutinin peptide. This was done by comparing structural
requirements for binding to DR alleles differing at a small
number of amino acid residues and by correlating HLA-
DR amino acid sequence with specificity across many
different DR types. Polymorphism at residue 86 appeared
to affect the structure of the peptide-DR complex as a
whole, rather than local interactions with an individual
peptide residue.
MATERIALS AND METHODS
Peptides. Peptides representing residues 307-319 of the influenza
A/Texas/1/77 H3 hemagglutinin protein (HA307-319. PKYVKQ
NTLKL AT] and analogues modified as shown in Table I were
synthesized and long chain biotlnylated as previously described (14).
Cells. 8 cell lines were grown in RPMI 1640 (GIBCO. Grand Island.
NY] supplemented with 10% FCS (Sigma Chemical Co.. St. Louis.
MO), penicillin, and streptomycin. The lines used co compare DRI
1292
PEPTIDE-DR INTERACTIONS AND 0 CHAIN POLYMORPHISM 1293
TABLE I cence intensities of duplicate samples usually were within 5% of the
Peptides used in this study mean.
Amino" ce^ Proliferation assay. B lymphoblastotd cells (I x 10®/2 ml/
N T ™ d well) were irradiated (5000 rad). incubated overnight at 37°C with
Group- sequence HA307-319 or HA LCB-NH and washed twice with PBS/BSA. AH-
: quots of ceils incubated with biotinvlated peptide were removed and
Truncated and substituted analogues of HA307-319 assayed for peptide binding. The remainder was incubated for 3
HA307-319 NH, PKYVKgNTL KL AT davs in triplicate cultures at 2 x 104/well with an equal number of
, . A NH _____ HA1.7 cloned T cells specific for HA307-319 (15). Tritlated thymi-
308-319 NH :::::::::::: dine (1 /iCl/well) was added during the last 16 h of culture. Cells
Ac309-319 AcNH L__________ were harvested onto glass fiber filters, and thymidine incorporation
309-319 NH, ___________ was measured by liquid scintillation counting. Background prolifer-
Ac310-319 AcNH __________ ation in the absence of peptide was subtracted.
310-319 NH, _____ _____
___ .... _ RESULTSScr-309 NH,
poaiuon of Presentation of influenza hemagglutinin peptide to T
Biounyuuon cells by different HLA-DR alleles. To examine the effect
Biotinviaied analogues of HA307-319 of structural differences between selected DR1 and DR4
PKYVKgNTL kl at subtypes (Table II) on T cell recognition, homozygous B
ThaiST3 lcb"nh - -- -- -- -- -- -- lymphoblastoid cell lines expressing these subtypes were
incubated with HA307-319. washed, and assayed for
Amino terminus lcb-nh - R- -R----R-_- their ability to stimulate proliferation of the HLA-DR
Residue 307 AcNH qr--r-_-_r__- restricted, hemagglutinin-specific Th cell clone. HA1.7
Residue 308 AcNH - 3_-r____r___ (15). DR1 Dw 1 -homozygous cells induced a strong prolif-
Residue 3?o AcNH I* R ' II I r I I ' erative response when pulsed with as little as 20 nM
Residue 311 AcNH - R- -B----R--- peptide (Fig. IA). In contrast, when the line expressing
DR1 Dw20 was used, about 104 times higher peptide
Residue 318 AcNH - R- -R----R-B- _ , .
Residue*319 AcNH - r- -r--_-r__b concentrations were required to stimulate similar leveis
■ Functional grouos a! the ammo terminus arc abbreviafed as follows: °f T ceil Proliferation (Fig. 1A). A difference also was
LCB. long chain biounvi (6-|biottnamido|hexanoyl): Ac. acetyl: NH.. free observed when B cell lines expressing the DR4 subtypes
a amino group. were compared (Fig. IB). CeUs expressing DR4 Dw4 pre-
"Sequences are shown In standard single letter code, except that B ] .... , , , . „ .F
denotes long chain blotlnylated lysine. Dashes indicate identity with sented the HA peptide almost as well as those expressing
HA307-319. DR1 Dwl. but presentation by cells expressing DR4
Dwl4 was much less^efficient. Similar numbers of DR
and DR4.subtypes are shown in Table II. and a larger panel covering molecules were expressed on ail ceil lines (data not
a range of haplotypes is shqjvn in Table ill. The T ceil clone. HA 1.7. shown), indicating that the observed differences were not
dcacrt^prevrotSvnsr11" °r antlgen' a"d 1L'2 aS due t0 differences in DR expression. Therefore. DR1
Binding of peptides to B lymphoblastoid cell lines. The assay Dw20 and DR4 Dwl4 molecules on B lymphoblastoid
was performed as described previousivf 16). Briefly. living B lvmpho- cells required much higher peptide concentrations for
blastoid cehs homozygous for HLADRprotcms. were incubated in equivalent T cell proliferation than DR1 Dwl or DR4duoiicate wells with HA LCB-NH or other biottnvlated analogues at M ^ , ~ ,
37°C in 200 WM PBS/2.5% FCS. After two washes in PBS/BSA. the moiecuies. indicating that the differences between
cells were stained in the cold with fluoresceinated avidin D (Vector the subtypes of'DRl and DR4 strongly influenced Ag
Laboratories. Inc.. Buriingame. CA) and analyzed by flow cytometry recognition
to determine relative amounts of bound biotlnylated peptide. Dead _ ® TT * r-,n r r\n <
cells were detected using propidlum iodide (Sigma) and excluded Binding of biotinylated HA307-319 to DR1 and DK4
from the analysis. HLA-DR expression was measured using saturat- molecules on B cell surfaces. An analogue of the HA307-
!nr£ ^r"?unts tfle Huoresceinaced anti-DR monoclonal antibody. 3^9 peptide containing a long chain biotinvl group at theL243 (Becton Dickinson. Mountain View. CA). To control for slight . ,TTA f_n -r- n * ^
variations in DR expression in quantitative comparisons of different ammo terminus (HA LCB-NH. Table I) was used to ex-
cell lines for peptide binding, the mean fluorescence obtained with amine whether the DR moiecuies expressed on the four
blotlnylated peptide and streptavidln was divided by the fluorescence 3 cell lines differed in their ability to bind the peptide.
obtained with L243 and the ratio expressed as a percentage. Inhibi- ~ , . .. _ . . _. ,
tion was measured by Incubating the ceils for 6 h with 25 or 50 uM Control experiments showed that biotinvlatlon did not
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TABLE m
Correlation between valine at residue 86 ofDRB1 chain and binding
ofSer-309 analogue"





DR1 Dwl IBW.4 86 0 0 (Y>S)
MLV 86 0 0 (Y> SI
DR4 Dw4 PRIESS 84 4 0.05 (Y > S)
BSM 99 10 0.1 (Y>S)
DR16 Dw21 AZH 88 0 0 (Y>S)
WT18 86 0 0 (Y > S)
DR4 Dwl5 SJAH 82 4.2 0.05 fY > S)
DR7 Dw7 MANN 79 14 0.18 fY > S)
MOU 99 11 0.11 fY > S)
DR8 Dw8.2 DLL 86 31 0.36 (Y > S)
DR11 Dw5 BM21 96 42 0.44 (Y > S)
DR14 Dwl6 AZL 75 0 0 fY > S)
DR16 Dw22 REM 88 0 .0 (Y > S)
Val-86 DRB1 alleles
DR1 Dw20 LWAGS 93 100 1.08 (Y-S)
DR4 Dwl4 BIN40 65 43 0.66 (Y-S)
DR4 DwlO
„
ALIO 96 54 0.56 (Y-S)
DR11 DwJVM JVM 98 92 0.94 (Y-S)
DR14 Dw9 WT52 68 62 0.91 (Y-S)
DR15 Dw2 PGF 86 0 0 (Y > S)
DR17 Dw3 WT20 94 65 0.69 (Y-S)
a Each of the ceil lines was analyzed for inhibition of binding of HA
LCB-NH by the two unblotlnvlated peptides as described InMaterials and
Methods. Binding of HA LCB-NH to these cell lines previously has been
shown to be specific for DR using mAb (16). The percentage competition
is shown for each ceil line in the presence of 1 mg/ml inhibitor and 50
mM HA LCB-NH. Y > S indicates that the percent inhibition with the
tyrosine substituted peptide is more than twice that seen with the senne
substituted peptide. Y - S Indicates that the percent inhibition with the
tyrosine substituted peptide is less than twice that seen with the senne
substituted peptide.
clone when presented by these B cell lines (data not
shown). Each cell line was incubated with HA LCB-NH at
37°C. stained with fluorescelnated avidln. and analyzed
by flow cytometry. This assay previously has been shown
to correlate well with binding to purified DR molecules
(10). At any one peptide concentration, cells expressing
DR1 Dwl gave the highest fluorescence, followed by DR4
Dw4 homozygous cells. DR1 Dw20 and DR4 Dwl4 homo¬
zygous cells bound the peptide much less well and re¬
quired very high peptide concentrations for a distinct
fluorescent signal to be observed (Fig. 2. A and B). Thus,
the alleles showed the same order of reactivity In the cell
surface binding and proliferation assays, although the
differences in Ag presentation between the B cell lines
were larger than the differences In peptide binding. On
all four cell lines, the specificity of binding previously
has been demonstrated using anti-class n mAb (16).
Therefore, at least some of the differences In presenta¬
tion of the HA peptide between the different DR1 and
DR4 subtypes could be attributed to differences in their
ability to form complexes with the peptide on the ceil
surface.
Mapping of differences in binding and T cell recog¬
nition between subtypes to residue 86 of DRBt chain.
The amino acid sequences of the DR1 and DR4 subtypes
were compared to identify residues that might cause the
observed differences in peptide binding (Table II). DR1
Dwl and DR1 Dw20 B chains differed from each other
only at residues 85 and 86. indicating that one or both of
these sequence differences influenced peptide binding.
The DR4 subtypes differed from each other at residues
2 T50O0
Peptide concentration, pM
Figure I. Presentation of HA307-319 to cloned T cells by B lympho-
blastoid cells expressing DR1 and DR4 subtypes. A. Comparison of cell
lines expressing the DR1 subtypes. Dwl (closed squares) and Dw20
(open squares). B. Comparison of lines expressing the DR4 subtypes.
Dw4 (closed mangles) and Dwl4 (open triangles). Irradiated B lympho-
blastold cell lines were incubated overnight at 37*C with the indicated
concentrations of HA307-319 and washed before adding the T cell clone.
HA1.7. A background of approximately 4000 cpm were subtracted from
each data point.
71 and 86. but both DR4 subtypes differed from DR1 at
multiple positions. The high binding alleles. DR1 Dwl
and DR4 Dw4. shared a glycine residue at position 86.
whereas the low binding alleles. DR1 Dw20 and DR4
Dwl4, shared a valine at this position. This showed that
polymorphism at residue 86 was sufficient to explain the
differences in binding of the HA peptide to the DR1 and
DR4 subtypes.
Effect of position of biotlnylatlon on peptide binding
to DR1 Dw20 homozygous cells. A set of HA307-319
analogues biotlnylated at each position (Table I) was used
to examine whether polymorphism at residue 86 (and/or
residue 85) affected the structural requirements for pep¬
tide binding to DR1 subtypes. Binding of these analogues
to DR1 Dwl homozygous ceils previously has been shown
to depend markedly on the position of biotlnylatlon (14).
None of these analogues bound to mutant B cells lacking
DR and DQ expression, and binding to DR1 Dwl homo¬
zygous B cells was inhibited by anti-DR mAb (14) (data
not shown). These studies also have provided evidence
that differences in fluorescence observed with these an¬
alogues were due to biotinylation interfering with peptide
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Peptide concentration, pM
Figure 2. Binding of HA LCB-NH to B-lymphobiastold cells expressing
DR1 and DR4 subtypes. A. Cells expressing the DR1 subtypes. DwL
(closed squares) and Dw20 (open squares) were incubated with HA LCB-
NH as described in the legend to Figure I. stained with fluorescemated
avtdln. and analyzed by flow cytometry. B. Ceils- expressing the DR4
subtypes. Dw4 (closed triangles) and Dwl4 (open triangles) were ana¬
lyzed for binding. To correct for slight variations in DR expression be¬
tween lines, the mean fluorescence due to peotlde binding was divided by
the fluorescence obtained with a fluorescemated antl-DR antibody and
expressed as a percentage.
binding to DR1 Dwl molecules, rather than effects of
biotlnylation on the conformational propensities of the
peptides or their susceptibility to proteases (14). The
variations in fluorescence therefore appeared to provide
information on the relative ability of each residue to
tolerate substitution with a bulky side chain and hence
on the conformation of the bound peptide.
When each analogue was examined for its ability to
give a fluorescent signal on ceils expressing DR1 Dw20
(Fig. 3A). the fluorescence intensities were, on average,
lower than on cells expressing DR1 Dwl (shown for
comparison in Fig. 35). In addition, the dependence of
the fluorescent signal on the position of blotlnyiation was
different on ceils expressing DR1 Dw20 than the pattern
of fluorescence previously seen on DR1 Dwl. Blotinyla-
tion at residues 309. 312. and 314. which greatly reduced
or eliminated the fluorescent signal on DR1 Dwl express¬
ing cells, did not drastically affect binding to DR1 Dw20
ceils. In contrast, biotlnylatton at residues 308. 315. and
316 reduced the fluorescence on cells expressing DR1
Dw20 more than on those expressing DR1 Dwl. Similar
Position of biotlnylatlon
Figure 3. Effect of the position of biotlnylatlon on binding of HA307-
319 analogues to cell surface DR1 Dwl and Dw20 molecules. Cells
expressing DR1 Dw20 (A) or DR1 Dwl (B) were incubated with a set of
HA307-319 analogues (50 ^M) substituted at each, residue with long chain
biotlnvlated lysine (see Table I). The data in B have been published
previously (14). The bar labeled NH2 refers to the analogue biotinvlated
on the a amino group.
results were obtained with two other cell lines expressing
DR 1 Dw 1 and one other line expressing DR 1 Dw20 (data
not shown). Taken together, the data suggested that the
contacts of many residues of the HA307-319 peptide were
affected by the differences between the DR1 subtypes.
Length requirementsfor peptide binding to DR1 and
DR4 subtypes. To confirm that subtype differences al¬
tered the way in which the peptide bound DR1 and DR4
molecules, truncated analogues of the HA307-319 pep¬
tide were analyzed for their ability to inhibit binding of
the biotinylated peptide to each of the cell lines (Table 1:
Fig. 4). Removal of residues 307 and 308 from the amino
terminus of the HA peptide had no effect on its ability to
interact with cell surface DR1 Dwl and DR4 Dw4 mole¬
cules in the competition assay, but removal of residue
309 resulted in complete loss of binding (Fig. 4. A and C).
A different pattern was observed when cell lines express¬
ing DR1 Dw20 or DR4 Dwl4 were examined. On these
ceils, removal of residues 307. 308. and 309 resulted in
a gradual loss of inhibition (Fig. 4. 5 and D). Acetylation
of the a amino group in these peptides had little effect on
binding, indicating that the results were not influenced
by effects of the amino terminal charge on the interaction
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Figure 4. Binding of truncated HA307-319 analogues to DRI and DR4 ■
Dw subtypes. Ceils expressing DR1 Dwl (A). Dw20 (B). DR4 Dw4 (C). or
DR4 Dwl4 (D) were assayed for binding of the truncated peptides in a
competition assay. Each cell line was incubated with HA307-319 or
truncated analogues (200 nM final concentration) and 25 uM HA LCB-NH
and stained with streptavldln. Results are expressed as percent inhibition
of the fluorescent signal compared to the signal obtained in the absence
of unblotlnylated peptide.
with the DR molecule. These results showed differences
In length requirements for peptide binding to DR1 Dwl
and DR4 Dw4 on the one hand and DR1 Dw20 and DR4
Dwl4 on the other and suggested that the way in which
the peptide bound was altered by polymorphism at resi¬
due 86 of the DR 8 chain.
Correlation between binding of substituted peptide
and residue 86 of DRBI chain. To confirm the validity of
the differences in peptide binding between DR 1 Dw 1 and
Dw20 observed using biotinylated peptides, residue 309
was examined in greater detail. This residue was chosen
for further investigation because previous experiments
have shown that it is critical for binding DRIDwl and
DR4Dw4 (14. 17) (unpublished observations). Deletion or
substitution of tyrosine 309 with amino acids with either
small or polar side chains resulted in analogs that were
unable to bind DRIDwl or DR4Dw4. In addition, all
residues other than tyrosine 309 and lysine 316 in this
determinant can be substituted with alanine without any
significant loss in apparent affinity for DRIDwl. Bioti-
nvlatlon at this residue also greatly reduced the fluores¬
cent signal on cells expressing DR1 Dwl but had little
effect on fluorescence when DR1 Dw20 expressing cells
were used (Fig. 3). The cell lines expressing DR1 and DR4
subtypes therefore were examined for binding of an
HA307-319 analogue containing a serine substitution at
residue 309 (Ser-309. Table I). The substitution greatly
reduced peptide binding to DR1 Dwl and DR4 Dw4 but
had no effect on binding to ceils expressing DR1 Dw20
or DR4 Dwl4 (Table III). This confirmed that the impor¬
tance of residue 309 of the peptide for the formation of
cell surface peptide-DR complexes was influenced by
polymorphism at residue 86 of the DR 8 chain.
The specificity of peptide binding was influenced in
similar ways by subtype differences in both DR1 and
DR4 alleles, even though DR1 and DR4 differ from each
other at multiple positions. This suggested that effects of
polymorphism at residue 86 on peptide binding might be
detected in haplotypes other than DR1 and DR4. There¬
fore. a larger panel of B cell lines, homozygous for HLA
DR proteins and representing many of the defined poly¬
morphisms among DRBI first domain sequences (18),
was analyzed for binding of the HA307-319 peptide and
the Ser-309 analogue. A striking correlation was ob¬
served between binding of the serine substituted peptide
and residue 86 of the DR B chain (Table III). All of the 13
B cell lines expressing 9 different DRBI genes coding for
Gly at residue 86 bound the natural HA307-319 peptide
but not the Ser-309 analogue. On these cell lines, residue
309 of the peptide appeared to make an important contact
with the DR molecule. In contrast, the substitution had
no effect on binding to most cell lines expressing Val-86
containing DRBI genes (6/7 lines, representing 6/7 hap¬
lotypes). indicating that residue 309 was not important
for binding to these ceil lines. Cell lines expressing sub¬
types of DR4 and DR6 differed in their reactivity with
the Ser-303 peptide despite sharing the DRw53 and
DRw52 genes, respectively. This confirmed that most of
the biotinylated peptide bound to the more abundant
DRordi molecule on these ceil lines, even though binding
of HA LCB-NH to DRw52 molecules has been observed
using transfected L cells2 (R. Busch. unpublished obser¬
vations). However, on cells expressing the DR2 Dw2 gene
(Val-86). the substituted peptide failed to compete, and
on DR11 Dw5 homozygous cells (Gly-86). the substitution
had no effect. On these cells, the HA peptide therefore
may either bind to the DRndl molecule in a different way
than to most other alleles, or the fluorescent signal may
be due to binding to products of the second DR 3 chain
gene. Nevertheless, the significant correlation between
the ability of the Ser-309 analogue to inhibit binding and
the presence of valine at residue 86 of the DRft chain
strongly suggested a role for residue 86 in determining
the specificity of peptide binding to many different DRodi
molecules.
Polymorphism at residue 86 of the DR 3 chain has been
shown in this report to influence recognition of an im¬
munogenic influenza virus HA peptide (residues 307-319)
by Ag-specific. DR1.4-restricted cloned T cells. This was
at least partly due to the effect of this polymorphism on
the amount of peptide binding to cell surface DR mole¬
cules. Structural variation at residue 86 correlated with
differences in the fine specificity of binding to closely
related DR1 and DR4 subtypes. This was shown by dif-
3 O'Hrhir. R. E-. R. BuscJa. J. B. Rotbbard. and J. R. Lamb. An in vitro
model of peptide-mediated hyposensitization of the human T cell response
to Dermatophagoldes spp. (house dust mite). Submittedfor publication.
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ferences in binding of monosubstltuted analogues and
peptides truncated at the amino terminus to B cell lines
homozygous for these DR alleles. Sensitivity of binding
to a substitution at residue 309 of the peptide correlated
with the presence of Gly at residue 86 of the DR .1 chain
in many different haplotypes. The polymorphism ap¬
peared to affect the contacts of multiple residues
throughout the entire peptide sequence with the DR mol¬
ecules, as suggested by differential effects of biotinyla-
tlon on binding to B cell lines expressing DR1 Dwl and
Dw20. Together, these observations showed that residue
86 affected the specificity of peptide binding to DR mol¬
ecules. possibly as a consequence of altering the shape
of the Ag combining site and consequently the contacts
made with bound peptides.
Even though residue 86 is not highly polymorphic,
being either a glycine or a valine in all reported HLA-DR
B chain sequences, and is located outside the three re¬
gions of greatest allelic variability (18). a growing body of
evidence indicates that polymorphism at this position
affects Ag recognition by T cells. In humans. DR subtypes
differing at residue 86 .or at residues 85 and 86 are
distinguishable by alloreactive T cells, and pairs of alleles
differing at these residues have been identified for many
different DR types (18. 19. 20). The homologous region
of murine class n molecules also has been shown to be
important for T cell recognition. Site-directed mutagene¬
sis of murine I-Ak B chain genes showed that substitu¬
tions at residues 85. 86. and 88 affected T cell recognition
(21). Susceptibility to type II collagen-induced arthritis in
DBA/1 mice has been mapped to residues 85-89 of the I-
Aq B chain (22). The data reported here raise the possibil¬
ity that polymorphism at residue 86 of class II B chains
may play a crucial role in each of these systems by
influencing the repertoire of bound peptides. However,
our results do not rule out the possibility that residue 86
may additionally interact with the TCR. as has been
suggested for the homologous region of the I-A" 8 chain
(21).
According to current models of the Ag combining site
of MHC class II proteins, based on similarities between
class I and class II proteins and the known crystal struc¬
ture of the class I molecule. HLA-A2. residue 86 is pre¬
dicted to be located ac the carboxyi-terminus of the 8
chain helical region that forms one wall of the Ag binding
site and to point Into the site (7). The polymorphism at
this residue not only affected local interactions between
the DR molecule and the amino terminus of the peptide,
but appeared to alter the structure of the entire peptide-
DR complex. This contrasts with a substitution affecting
a single pocket in the binding site, as was observed in
our previous experiments studying the possible interac¬
tions between residue 71 of the 0 chain and 312 of the
HA peptide (23). In these experiments. T ceil recognition
could be reversed by changing the residue at 312 in the
peptide to complement the charge characteristics of res¬
idue 71 of the DR protein. Effects of the substitution on
other residues in the peptide were not observed. In con¬
trast. modifications at residue 86 of the 0. chain resulted
in a more global effect than a modification of a single
pocket in the binding site. The strongest evidence sup¬
porting this hypothesis was the manifold differences ob¬
served in fluorescent patterns associated with the set of
peptides biotlnylated at each position when assayed on
DRIDwl compared with DRlDw20. Also the majority of
alleles with glysine at 86 required an amino acid at 309
with a bulky hydrocarbon sidechain. Substitution with
small or polar amino acids (i.e.. serine) obviated all bind¬
ing. In contrast, alleles with valine at 86 bound the
peptide with serine at 309. and also those with tyrosine
at this position. This lack of complementation indicates
that the results are not due to a simple interaction be¬
tween residue 86 of the B chain and 309 in the peptide.
The results could be explained in either of two ways. A
direct contact between residue 86 and the HA peptide
might alter the conformation of the remainder of the
peptide. Alternatively, residue 86 might affect the inter¬
action of the B chain helix with nearby a chain residues,
altering the geometry of the Ag combining site. The two
mechanisms could not be distinguished by our results
and may not be mutually exclusive.
None of the DR1 and DR4 subtypes studied failed to
present the peptide to cloned T cells, even though the T
cell clone used was exquisitely sensitive to structural
changes in the peptide and the DR protein (14. 15. 23).
This suggested that the differences in intermolecular
contacts observed using biotinylated HA analogues were
not a result of drastic changes in the way the peptide
bound, but rather the consequence of subtle adjustments
in the structure of the complex owing to the polymor¬
phism. The correlation between Val-86 and binding of
the Ser-309 analogue in many different DR haplotypes
also suggested that most DR alleles did not differ drasti¬
cally in the way they bound the peptide. These ideas are
consistent with our earlier observations on differences
in binding and T cell reactivity between DR4 Dw4 and
Dwl3 (JHF) on the onejiand and DR4 DwlO on the other
(23). The former two are Gly-86 alleles and. when tested
with the biotlnylated HA peptides, revealed a similar
conformation of the bound peptide as that shown in
Figure 3B. The latter allele contains Val at residue 86
and bound the HA peptide in a different way as measured
by differences in the pattern of biotinvlation. Neverthe¬
less. these conformational differences were not drastic
enough to prevent HA1.7 from recognizing an HA307-
319 analogue when presented by this restriction element.
In each case, the differences in sensitivity to biotinylating
each residue on these alleles could be explained by min¬
imal deviations from a common conformation (23). Crys-
tallographic studies of defined peptide-MHC class II com¬
plexes will be required to analyze the precise nature and
extent of the conformational differences.
Regardless of the exact way in which the Ag binding
site is altered by polymorphism at residue 86. our results
indicate that effects on the specificity of peptide binding
can be mapped to individual residues of class II proteins.
A peptide that has been shown to interact with many
different DR alleles has been converted by a single amino
acid change into one that binds a much smaller subset
of alleles. This strongly suggests a role for polymorphism
at residue 86 in altering and limiting the spectrum of
peptides bound to individual DR alleles. In addition, the
observation raises the possibility that allele specific pep¬
tides can be designed rationally, starting from degenerate
ones, by detailed empirical analyses of the effects of class
II polymorphism on the fine specificity of binding.
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Mapping T cell recognition: the identification of a
T cell receptor residue critical to the specific
interaction with an influenza hemagglutinin
peptide
The fine specificity of T cell receptor (TCR) interaction with the influenza
hemagglutinin peptide HA 307-319 in the context of the DR1 (DRA.
DRB1*0101) and DR4 (DRA, DRB1*0404) was studied in two human T cell
clones (HA1.7 and Cl-1) derived from different individuals. Sequencing of
amplified TCR transcripts revealed that these two clones express highly related
TCRa chains, with a conserved junctional motif, but very different TCRfJ
chains. Modeling studies led to the prediction that the conserved glutamic acid
residue in the TCRa chain could interact with the lysine at position 316 in the
peptide, a known TCR contact residue. HA1.7 TCR-CD3I; chimeric constructs
were expressed in the rat basophil line (RBL) and shown to confer specific anti¬
gen recognition. In two TCRa chain mutants, with the conserved glutamic acid
residue altered to alanine and lysine, respectively, peptide recognition was lost.
Specific recognition was not rescued by altered peptide ligands. Furthermore.
Jurkat derivatives expressing the related JurkatTCRa chain paired with the HA
1.7TCRP chain did not recognize the HA 307-319 /DR1 complex. These data
provide evidence for the critical interaction of a TCR residue with antigenic pep¬
tide.
1 Introduction
T ceils recognize antigen as short peptides presented by
MHC molecules [1, 2], using the highly variable, clonally
distributed T cell receptor (TCR). Elucidation of the crys¬
tal structures of the DR1 (DRA/DRB1*0101) class II mol¬
ecule [3] and several class I molecules [4, 5], have con¬
firmed that antigenic peptides are bound in a groove of the
MHC molecule, with certain amino acid side chains partic¬
ularly available for interaction with the antigen-specific
TCR. While the three-dimensional structure of the TCR is
still unknown, comparative modeling on the basis of
homology with the immunoglobulins has suggested the
presence of three highly variable complementarity-
determining regions (CDR1, 2 and 3) which are thought to
form the specific antigen binding site [6, 7]. Many studies
have suggested that particular MHC/peptide complexes
are recognized by a limited number of TCRa or TCR(3
gene segments in both murine and human T cells [8—12].
Fur¬
thermore, much evidence exists for the critical nature of
interactions between the proposed CDR3 regions of the
TCR chains and antigenic peptide, with many studies
showing conservation of TCRa orTCRp, or both, CDR3
amino acid sequences, when a particular peptide/MHC
complex is recognized [12-14]. Most compeilingly, in mice
transgenic for either the TCRa or TCR(3 chain of a TCR
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specific for moth cytochrome c, the alteration of a single
amino acid residue in the peptide resulted in specific TCR
showing reciprocal single-residue changes in the CDR3
regions of the nontransgenic chain in vivo [15].
The human CD4* T cell response to the influenza hemag¬
glutinin (HA) peptide 307-319 (PKYVKQNTLKLAT) in
the context of DR1 has been extensively studied [16-18].
Note that two alternative nomenclatures exist for this pro¬
tein, such that the same peptide is known as 306-318 in
some publications [3]. Functional studies have implicated
several residues in HA 307-319 as important TCR contact
residues: these are residues 308K. 311K, 316K and 319T
([17, 19, 20], and LRW and JRL. unpublished). In gen¬
eral, peptide analogs with substitutions at these positions
are not recognized by HA/DR1 specific T cell clones,
although these peptides still bind DR1 [17]. At position 316
of the HA peptide, most substitutions create a non-
stimulatory peptide. Two exceptions are the HA307-319
peptides with substitutions 316R and 316C. which stimu¬
late the HA1.7 clone, but only at far higher concentrations
than that required for native HA307-319 (LRW. and JRL,
unpublished observations). For another human clone spe¬
cific for HA307-319/DR1, Cl-1, several altered peptides
have been shown to act as potent antagonists at low con¬
centrations (for example HA307-319-316L) [19]. The
recent elucidation of the crystal structure of the
HA307-319/DR1 complex has confirmed that the residues
308K. 311K. 313N. 316K and 319T do indeed project away
from the MHC binding groove, and are available for inter¬
action with the TCR [3], However, residues in the TCR of
HA307-319/DRl-specific T cell clones which interact
directly with these amino acids in the peptide have not
been identified.
Here, we analyze the TCR of two HA307-319/DR1-
specific T cell clones, which also recognize peptide pre¬
sented by DR4 (DRB1*0404) class II molecules. The
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development of new methods for modeling the T cell
receptor has allowed the construction of a plausible model
of the ternary complex. Consideration of this model, in
combination with mutagenesis in viiro studies, have led to
the identification of a residue in the TCRa chain junctional
region that is essential for the interaction of the HA1.7
with its ligand.
2 Materials and methods
2.1 T cell clones and cell lines
The Cl-1 clone was a kind gift of Dr. H. Grey (Cytel, San
Diego) [18]. The HA1.7 and Cl-1 T cell clones were main¬
tained culture by addition of irradiated (2500 rad) feeder
cells and peptide every 7 days, and rIL-2 (10 ng/ml, Euro-
cetus. GB) every 3-4 days as described [16]. Prior to use
in proliferation assays, the clones were rested for 6-7 days
after the last addition of feeder cells and antigen. Irradi¬
ated PBMC from donors of DR1(DRB1*0101) or DR4
(DRB1*0404) haplotype were used as a source of APC for
the T cell clones. The mutant TCR-negative Jurkat cell
line JRT3T3.5, which lacks a full-length TCRp mRNA,
[21], was a gift of Prof. A. Weiss, (University of Califor¬
nia, San Fransisco). JRT3T3.5, and the HA1.7 TCR-
transfectants derived from it, including the clone CH7C17,
were cultured as described [22], The L cell transfectant
LDR1 (DRB1*0101 positive) was a gift from Dr. J. Bod-
mer, Imperial Cancer Research Fund, London. CTLL, a
murine IL-2-dependent T cell line [23], was used to assay
IL-2 release from Jurkat derived transfectants, as
described [22]. The rat basophil line RBL-2H3 was used
for transfections of TCR-CD3t chimeric constructs [24],
The EBV-transformed B cell line HOM-2 (DRB 1*0101
positive) was used as APC in the RBL stimulation assays.
2.2 Peptides, oligonucleotides and antibodies
The hemagglutinin peptide HA 307-319 (PKYVKQ-
NTLKLAT), mutant HA peptides with altered residues at
position 316, as well as the control DR1 binding matrix
peptide MAT 19-31 (PLKAEIAQRLEDV). were synthe¬
sized by the peptide synthesis laboratory. Imperial Cancer
Research Fund. Oligonucleotides were synthesized by
Dr. I. Goldsmith, Imperial Cancer Research Fund. The
JOVJ-1 (TCR CP specific) and JOV1-3 (TCRVP3 specific)
antibodies were as described [25]. The pan anti-TCRa
antibody aFl was purchased from T cell Diagnostics,
(Eurogenetics. GB). The anti-CD3 antibody UCHT1 was
a kind gift from Prof. Peter Beverley, Imperial Cancer
Research Fund. For cell staining, antibodies were used as
direct fluorescein isothiocyanate (FITC) conjugates, or
cells were counterstained with FITC-conjugated F(ab').
goat anti-mouse lgG, (Sigma, GB).
2.3 T cell clone proliferation assays
Cloned F1A1.7 and Cl-1 cells (10") were cultured in the
presence of 2.5 x Iff1 irradiated PBMC of the DR type
shown and HA peptide (dose range 0-3 pg/ml), in flat-
bottom 96-well plates for 72 h. Cells were pulsed with
[3H]dThd; 1 pCi/well (Amersham) for the last 16-18 h of
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the assay. Proliferation as [3H] dThd incorporation was
determined by liquid scintillation spectroscopy.
2.4 Sequencing of TCR
The TCRa and p sequences of the HA 1.7 clone have been
published [22]. The TCR sequences of Cl-1 were obtained
by anchored PCR (An PCR) as described [26]. Briefly,
5 pg of total RNA was used in first-strand cDNA synthesis,
using a dT(12-18) primer and AMV reverse transcriptase.
After precipitation, the product was G-tailed using termi¬
nal deoxynucleotidyltransferase. and 5 % of the tailed
cDNA was then used as template in An PCR reactions.
Primers, PCR conditions and M13mpl8 cloning were as
described [26]. M13 subclones (15-20) were sequenced by
the chain-termination method for each of the TCRa and
TCRP chains [27]. Sequences were compared to those
available in the EMBL data bank.
2.5 Modeling of the TCR-DR1-HA ternary complex
HA1.7 was modeled according to the method of Searle,
S.J. and Rees. A.R. (in preparation). Briefly, sequences of
naturally paired antibody VH and VL regions were aligned
with paired TCR Va and Vp regions from which frame¬
work and complementarity-determining regions (CDR)
were identified. To determine whether the TCR sequences
were more similar to VH or VL sequences, each set of Va
and Vp sequences were compared to both the VL and VH
sets, using the similarity score method described in [28]. In
addition, the structural environments of TCR residues
were compared to those of equivalent antibody residues by
calculating a normalized similarity score for each residue
in the context of neighboring residues within a 5A radius.
The results of these analyses showed that both Va and Vp
have greater similarity to VL domains than to VH
domains.
Given this VL preference, both Va and Vp framework
regions were modeled using the light chain dimer RBI [29]
and the CDR sequences were modeled using a modified
version of the antibody modeling program CAMAL
[30, 31], The final model was energy-minimized using Dis¬
cover (Biosym). Since there is. as yet. no TCR structure,
the accuracy of this method was tested by generating a
model of CD4, a member of the immunoglobulin super-
family more distantly related to antibodies than TCR.
When this model was compared with the x-ray structure of
CD4 [32], the CDR had the following backbone RMS
deviations: CDRd and_pi (1.6A), CDRa and p2 (2.4A)
and CDRa3 and P (1.3A). This close agreement with the x-
ray structure gave sufficient confidence to proceed to con¬
struction of the ternary complex.
The peptide-MHC complex was generated using the x-ray
corrdinates of the DR1 [33] and a peptide-docking pro¬
cedure in which the peptide was positioned in the MHC
groove in an extended orientation with its known TCR
contact residues solvent-exposed. This modeled complex
was subsequently modified to reflect the peptide twist
described in the x-ray structure of the DR1-HA307-319
complex [3].
T cell recognition of a hemagglutinin peptide/HLA-DR complex
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To generate the ternary complex, the TCR and MHC-
peptide complex were rotated onto each other in an
orientation that maximized the contact between CDR3
regions and the peptide contact residues. Two possible
orientations of the TCR were seen, differing by a rotation
of 180 ° with respect to the MHC-peptide complex. How¬
ever, only one of these (see Fig. 3) allowed acceptable
contacts to be made between CDR3 residues and the
known peptide contact residues. In this preferred orienta¬
tion, CDR1 and 2 of the TCRa chain and CDR2 of the
TCR(3 chain are in contact with the MHC helices, while
CDR1 of theTCRp chain probably has little or no contact.
A test of this procedure was carried out using the
TCR5C.C7 and the MHC class I complex, pigeon cyto¬
chrome c in the context of I-Ek described by Jorgensen
et al. [15]. Construction of the ternary complex in this sys¬
tem brought all the known TCR and peptide contact resi¬
dues to within less than 5A (Searle, S.J. and Rees, A.R.
unpublished).
2.6 Expression of HA1.7TCR chains in Jurkat lines
The HA1.7TCRap transfectant CH7C17 has been previ¬
ously described [22j. The expression of the HA TCRfi
chain with the Jurkat TCRa chain was achieved by co-
transfection of the HA1.7 TCRfi construct HA(3-pJ6f2
(35 pg) with the selection vector pJ6Qhygro (5 pg) carry¬
ing a hygromycin resistance gene into 1.5 x 107 JRT3T3.5
cells. Cells were electroporated on a Biorad Gene Pulser
using 250 V and 960 pF, and allowed to recover for 10 min
on ice. Cells were selected in hygromycin (Calbiochem) at
1 mg/mi 24 h after electroporation. Cells were analyzed
12-14 days later for TCRfi expression by flow cytometry
on a Becton Dickinson FASCcan using FITC-conjugated
JOVI-3 antibody, and positive clones were expanded.
2.7 TCR stimulation of Jurkat transfectants
T cells (5 x 10J) were co-cultured with equal numbers of
APC in the presence of native or altered HA peptides
(dose range 0-30 ug/ml), anti-TCR antibodies (1 pg/ml) in
the presence of PMA at 0.5 ng/ml, or PMA (0.5 ng/ml)
and ionomycin (0.5 pg/ml), in flat-bottom 96-well plates
for 48 h. Supernatants were harvested at 48 h and used to
stimulate 10J CTLL cells/well for 36 h. Proliferation was
measured by addition of 1 pCi/well [3H]dThd for the last
6 h of culture, as described above.
2.8 TCR-CD31; chimeric constructs and rat basophil line
transfections
The TCRVa-Ca and TCRVf5-CfS sequences of the HA 1.7
TCR terminating at the membrane-proximal cysteine resi¬
due. were cloned into the pCDL-SRa construct the CD31;
transmembrane and cytoplasmic sequences [24], a kind
gift of Dr. T. Ottenhoff. Site-directed mutagenesis of the
HA1.7 TCRa chain was performed using the
oligonucleotide-directed method in M13mpl9, according
to the manufacturer's instructions (Amersham, GB).
TCRa chain mutants containing alterations at the glutamic
acid at position 94, E-A and E-K, were constructed, and
cloned into the same chimeric constructs. All constructs
were checked by sequencing of both strands. RBL-2H3
cells (1.5 x 107) were co-transfected with 10 pg HA1.7
TCR(S-q construct. 10 pg of HA 1.7TCRa-q construct (wild
type or mutant), and 2 ug of the pH„APr-l-Neo vector to
confer neomycin resistance, with the electroporation con¬
ditions described above. Cells were selected in G418 at
1 mg/ml (Gibco, Life Technologies) and pools of transfect¬
ants were expanded. Cells were analyzed by flow cyto¬
metry 12 days after transfection for TCRa and TCRfi
expression by aFl and JOVI-3. respectively, and positive
ceils were sorted by JOVI-3 expression on the FACStar
(Becton Dickinson).
2.9 RBL-2H3 stimulation assays
HOM-2 cells were loaded with peptide by culturing in the
presence of wild-type or mutant peptides at the given con¬
centrations for 36—18 h, before use as APC. RBL-2H3
TCR transfectants were cultured for 18 h at 3 x 10J/well in
96-well flat-bottom plates in the presence of 0.2 pCi/well
of [1,2-3H] (N)-hydroxytryptamine binoxalate (5HT; NEN,
Dupont). Peptide-loaded HOM2 cells were washed once
and resuspended at a concentration of 3 x 10"/ml in
RPMI/2 dim glutamine/2 % FCS (assay medium). Labeled
RBL transfectants were washed 3 times in warm assay
medium, and then incubated for 1 h in the presence of
3 x UP loaded APC. or other stimuli as shown, in 100 pi.
The anti-TCR V|3 3 antibody JOVI-3 was used at a final
concentration of 5 pg/ml. An aliquot of the supernatant
was removed for estimation of released serotonin as a
measure of RBL stimulation. Cells were also lysed in
0.5% Triton X-100. Radioactivity released into the super¬
natants and in the ceil lysates was measured by liquid scin¬
tillation counting. The specific serotonin release was calcu¬
lated as: (cpm released/total lysate cpm + cpm relea¬
sed) x 100.
3 Results
3.1 Proliferation ofT cell clones to HA 307-319 on
DR1 and cross-reactivity on DR4
Two human CD4* class II restricted T ceil clones were
compared for proliferation to the HA 307-319 peptide in
the context of DRI and DR4 expressing APC (Fig. 1).
There was no significant difference in the response of
HAL7 to DRI (DRBl*0101) or DR4 (DRB1*0404) APC
and HA peptide, (Fig. la). However, CI-1 showed much
lower responses to HA in the context of DR4 than DRI
over the same dose range (Fig. lb), both clones responded
equally to IL-2 alone.
3.2 TCRa and (3 sequences of the two HA-specific
clones
An PCR and sequencing of 15-20 amplified TCR tran¬
scripts from the CI-1 T cell clone detected only one rear¬
ranged TCRa and one TCR(3 chain. The nucleotide and
predicted protein sequences of the CI-1 TCRa and TCR(3
chains spanning the VJa and VDJ(3 junctions are shown in
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Figure 1. Recognition of HA 307-319/DR1 and HA 307-319/
DR4 complexes by twoT cell clones, a) HA1.7 and b) Cl-1. Clo¬
nes were cultured with irradiated PBMC of the given MHC types
as APC. and HA 307-319 peptide at concentrations shown, for
72 h. and proliferation measured by tritiated thymidine incor¬
poration. Results are expressed as mean cpm ± SEM of triplicate
cells. White bars, response using DR1 APC: black bars, response
using DR4 APC; hatched bars, response to IL-2 only.
Fig. 2, with the equivalent sequences of the HA1.7TCRa
and TCR|3 and the JurkatTCRa for comparison. The Cl-1
TCRp chain was previously designated Vf313.2 [34] but
under the new WHO nomenclature for TCR [35] has the
name V|313.1 (TCRBV13S1) (Prof. J. Bell, personal com¬
munication). The HA1.7 clone expresses the V(33.1 seg¬
ment (TCRJ3V3S1), and the two clones use different Dp
and jp genes. Furthermore, these two TCRp chains show
no conservation of either protein sequence or length
across the presumed CDR3 region.
In contrast to the differences between the TCRP chains,
the TCRa chains utilized by these two clones are highly
related, and show remarkable sequence conservation
across the junctional region. The HA1.7TCRa chain uses
the Vol.2 gene segment (TCRAV1S2A2), while the Cl-1
TCRa chain uses a polymorphic variant of Val.3
(TCRAV1S3), with two nucleotide changes which alter
residues 57 and 58 such that they are the same as the equi¬
valent residues in the Val.2 segment. In the published
TCRAV1S3 gene segment, these residues are E-S while in
the Cl-1 TCRa chain they are replaced by K-G. which are
identical to the equivalent residues in the TCRAV1S2A2
segment. Furthermore, the clones have a conserved motif
across the presumed CDR3 region, as defined by Chothia
et al. [6], Thus, both clones have the protein sequence
V-S-E at the V/N/J junction, and this motif is followed by S
orT. respectively, and then a helix-breaking residue, P or
G. respectively. The highly related JurkatTCRa chain uses
the Val.2 segment (TCRAV1S2A2) and has the sequence
V-S-D-L-E at the equivalent positions. The J genes of all
three of the TCRa chains considered are different (Fig. 2).
3.3 Models of the TCR-HA-DR ternary complexes
Ternary complexes were generated in two orientations. In
the preferred orientation (Fig. 3a,b) the five known
peptide-contact residues (308K, 311K, 313N and 316K and
319T) are all in contact with various CDR residues. One of
the peptide residues (316K) is seen to be in contact with an
a-chain residue, 94E (see Fig. 2). This type of salt bridge
interaction has also been implicated in the study of Jorgen-
sen et al. [15]. In the second orientation (Fig. 3c), 316K is
seen to be outside the contact influence of the TCR CDR,
so this is therefore a less likely structure for the ternary
complex.
3.4 Expression of the HA1.7TCR chains in RBL and
JRT3T3.5
Previous studies with the HA1.7 and CI-1 T cell clones
have implicated the 316K as an important residue in T cell
recognition [17-19]. In order to test the prediction of the
modeling studies that the conserved glutamic acid at posi¬
tion 94 of the T cell clone TCRa chains is critical to pep¬
tide recognition, two mutants of the HA 1.7 TCRa chain
were constructed in which the glutamic acid at position 94
was mutated to alanine (HAaE94A) and lysine
(HAaE94K), respectively. Expression of the HA1.7TCRP
paired with the mutated HA1.7 TCRa chains was studied
in the RBL system. The extracellular domains of the
HA1.7 TCR|3 chain, and wild-type or mutant TCRa
chains, were fused to the transmembrane and cytoplasmic
domains of the CD3£ chain. TCRaP pairs were co-
transfected with a Neo-containing vector into RBL cells.
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Figure 2. TCR sequences spanning the
VJa and VDJp junctions ofT cell clones
HA 1.7 and Cl-1, and of the T cell line
JRT3T3.5 (Jurkat derivative). Nucleo¬
tide and predicted protein sequences of
a) TCRa and b) TCRp junctional regi¬
ons are shown. Spaces have been
inserted to allow alignment of con¬
served sequences.
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Figure ». Molecular models showing the predicted interaction between
TCR IIA 1.7 and the HA 307 319/DRI complex |3|. The Va and V\\
chains are shown in blue and orange, respectively and the MHC « and ji
chains in pink and yellow, respectively. The peptide is shown in white
and is orientated N terminus (right) toC terminus (Ici'l) in a) and b), and
in the reverse orientation in c). a) side view of the TCRMIIC complex
showing the proximity of residue TCRVot 94E (space-filled red) to pep¬
tide residue 3I6K; b) end view of the I C R Ml IC complex obtained hv
rotation of view a) by 00°. The CDR3 loops of the V<t and V|> chains can
be seen to be located above the peptide, while the CDRI and CDR2 re¬
gions arc positioned over the MHC helices, c) view of the ICR MIIC
complex in which the peptide-MHC complex has been rotated through
ISO" with respect to the TCR. Here, peptide residue 3I6K is seen
to be outside the interaction interlace. Figures were generated using
MOLSCRIPT [391.
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sorted by expression of the TCRp chain. All three RBL
transfectant lines, expressing wild-type HA1.7 TCR,
mutant HA TCRaE94A or HA TCRaE94K, were sorted
for identical levels of TCR|3 expression, which was stable
over many months in vitro. These lines also stained with
the same intensity with the TCRa-specific antibody aFl.
This antibody does not stain live T cells, but detects the
TCRa chain in Western analysis. The staining by aFl of
RBL transfectants, which express TCR in the absence of
CD3. suggests that the epitope recognized by aFl is usu¬
ally masked on T cells, perhaps by the CD3 complex.
Since the TCR-negative Jurkat line JRT3T3.5 is known to
have a functional mRNA for the Jurkat TCRa chain,
transfection of a TCRfl chain restores CD3 and TCR
expression to these cells [21]. We have therefore taken
advantage of the natural mutant of the Jurkat TCRa chain
in which the residue at position 94 is another charged
amino acid, aspartic acid 94D. similar to the E of the
HA1.7 and Cl-1 TCRa chains. The hybrid HA1.7 TCR(3-
Jurkat TCRa receptor was studied by transfection of the
HA1.7TCR|3 into JRT3T3.5. Transfectants were selected
in hygromycin. clones expressing CD3 and TCR|3 were
selected by flow cytometry, and compared to the HA1.7
wild-type transfectant CH7C17 by functional assays.
3.5 Recognition of the HA 307-319 peptide by wild-
type and mutant TCR
RBL transfectants expressing the HA1.7 wild-type and
mutant TCR were tested for their ability to respond to the
HA 307-319 peptide in the context of DR1, and to other
stimuli. All three lines responded equally well to the physi¬
ological stimulus of specific IgE and antigen (mediated by
the FceRI IgE receptor) or the nonspecific stimulus of
phorbol ester plus ionomycin (data not shown). All trans¬
fectants also showed equivalent responses to TCR stimula¬
tion by the JOVI-3 antibody, showing that TCR triggering
was functional in all three lines. The wild-type HA 1.7
TCR-positive cells responded specifically to HA 307-319
on DR1* APC, in a dose-dependent manner (Fig. 4), with
no response to the irrelevant DRl-binding peptide MAT
19-31. The response to maximal peptide concentrations
was equal to that obtained by triggering the TCR using the
specific anti-TCR antibodies JOV1-1 or JOVI-3. However,
TCR with mutant TCRa chains (HA TCRaE94A or HA
TCRaE94K) showed no responses to the HA peptide,
even at maximal doses, but were still able to respond well
to JOVI-3 antibody (Fig. 5). None of the transfectants
responded to an irrelevant isotype-matched control anti¬
body (data not shown), or to APC or medium alone
(Fig. 5).
The clone CH7C17. expressing the wild-type HA1.7TCR,
responds to HA peptide over the same dose range and with
the same specificity as the original T cell clone (LRW,
unpublished data, and [22]). We therefore tested transfect¬
ants of this cell line expressing the HA1.7 TCR|3 chain
paired with the Jurkat TCRa in the same way. Surprisingly,
out of 10 clones selected, none responded to wild-type HA
peptide in the context of DR1, although all could be stim¬
ulated by ligation of the TCR using low concentrations of
anti-TCR V|33 (JOVI-3), TCR C|3 (JOVI-1) or CD3
(UCHT1) antibodies (Fig. 6).
MAT 19-31, HA 307-319,
|iM R M
Figure 4. Stimulation of the wild-type HA1.7 TCRa(3 pair
expressed on RBL-2H3 cells. EBV-transformed B cells were
loaded with HA 307-319 or MAT 19-31 at the given concentra¬
tions and used to present to [3H] 5HT-labeled HA1.7-TCR-
transfected RBL-2H3 cells for 1 h. Results arc expressed as%
specific release = (cpm released/total Ivsate cpm + cpm relea¬
sed) x 100 ± SEM. of triplicate wells. Maximum cpm in lvsate =
10165 ±169.
3.6 Use of altered peptides to stimulate HA1.7 wild-
type and mutant TCR
HA307-319 analog peptides with one altered residue at
position 316 were tested in stimulation assays using RBL
and Jurkat transfectants expressing HA1.7 wild-type or
mutant TCR. The wild-type HA1.7 TCR-CD3 chimera
expressed in the RBL system showed the same fine speci¬
ficity for HA 307-319 altered peptides as the original
clone. Notably, a weak response was obtained to the
altered peptide 316C by wild-type TCR. However, other
substitutions at position 316 created non-stimulatory pep¬
tides (Fig. 7).
The mutant TCR complexes were also tested for responses
to altered peptides at this position. In particular, we
reasoned that if the 316K directly contacts the oppositely
charged 94E in the TCRa junctional region, then we might
Figure 5. Loss of HA 307-319 recognition in TCR mutants bear¬
ing one altered residue in the junctional region of TCRa chain.
The specific responses to maximal HA peptide (peptide loading
concentration 300 pM) plus APC. APC alone, culture medium
(CM) alone and anti-TCRp antibody JOVI-3 (5 pg/ml) are shown
for a) wild type HA1.7 TCR-transfectant. b) HAaE94A-TCR
transfectant. and c) HAaE94K-TCR transfectant. Results are
expressed as% specific release = (cpm released/total lysatc cpm
+ cpm released) x 100 ± SEM. of triplicate wells. The cpm in
total lvsates were as follows: for a). 30756 ± 3621: b)
31 275 ± 3043; c) 33201 ± 2276.
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Figure 6. The Jurkat TCRa chain cannot replace the HA 1.7
TCRa chain. T cell responses in Jurkat derivatives were measured
by lymphokine bioassay on CTLL cells. The responses of a) clone
CH7CI7 (HA1.7TCRct|3 transfectant). and b) clone Hll (Jurkat
TCRa. HA1.7TCR(5) are shown to: HA307-319 peptide on DRl
positive APC. APC alone. anti-TCR antibody JOVl-l (I ug/ml).
PMA (0.5 ng/ml). and JOVI-l plus PMA. Results are expressed
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Figure 7. Mutant HA1.7 TCR bearing one altered residue in
TCRa itre not rescued by analog peptides with substitutions at
position 316. The responses of RBL-transt'ected lines to HA
307-319 (HA WT) and 316-substituted peptides (HA 316E. etc.).
on DRl positive APC. as well as to APC alone, culture medium
alone (CM), and the anti-TCR antibody JOVt-3 (5 pg/ml). are
shown, a) wild type HA1.7 TCR transfectants. b) TCRa E94A
mutant, c) TCRa E94K mutant. Results are expressed as% spe¬
cific release = (cpm released/total Iysate cpm + cpm relea¬
sed) x 100 ± SEM. of triplicate wells. The cpm in total lysates
were as follows: for a). 34 701 ± 3701: b) 2S415 ± 477S: c)
30 572 ±2195.
be able to rescue peptide recognition by the E94KTCRa
mutant with a complementary mutation in the peptide.
However, none of the altered peptides tested were able to
rescue the response of the altered TCR to the HA peptide.
Specifically, no response was obtained from the HAa
E94K mutant TCR to the peptide analogs 316E or 316D
(Fig. 7).
4 Discussion
In this study, we compared the response of two human
T cell clones. HA1.7 and CI-L. both specific for the
influenza haemagglutinin peptide 307-319. on two differ¬
ent presenting MHC molecules. We found that HA 1.7 is
cross-reactive on DR4. while CI-L reacts only poorly to the
HA/DR4 complex. We also showed that these two clones
have TCR which use different TCR(3 chains with no con¬
servation of CDR3. In contrast, the TCRa chains of the
two clones are closely realted both in terms of the gene
segments used and in the presence of a highly conserved
motif in the CDR3.
The two TCRa chains are Val.2 (TCRAV1S2A2) for
HA1.7 and Val.3 (TCRAV1S3) for CI-L. respectively, but
the sequence of the Val.3 segment from CI-1 has two
amino acid changes just adjacent to the CDR2 region,
which are altered such that they are identical to the equi¬
valent residues in the Val.2. The conserved motif across
the junctional region V-S-E-S/T- P/G contains a charged
residue, glutamic acid. The highly related TCRa chain
(Val.2) of the Jurkat derivatives has the sequence V-S-D-
L-E over these five residues, with the related aspartic acid
in position 94. However, the hybrid TCR of the Jurkat
TCRa paired with the HA1.7 TCR|3 chain cannot recog¬
nize the HA 307-319 peptide in the context of D R1. At the
structural level, we cannot be sure of the conformational
differences between the Jurkat and HA1.7 or CI-L TCRa
CDR3 regions, since no structures are available. However,
the substitution of D for E and the presence of the hydro¬
phobic L immediately following the D would confer a dif¬
ferent packing preference for this part of the CDR. In
additon. this motif in the Jurkat sequence has an addi¬
tional E in the fifth position compared with either P or G
in the HA1.7 and CI-1 sequences, respectively. The com¬
bination of these apparently small differences could have
dramatic affects on the local CDR conformation and
would be sufficient to explain the loss of specificity. Taken
together, these data suggest that the TCRa chains of the
two T cell clones may confer precise peptide specificity,
but that even a small change in this region, such as that
created by the substitution of the Jurkat TCRa chain,
leads to a loss of recognition.
Several previous studies have implicated complementary
charge interactions as important in the interactions
between TCR and specific peptide, both in murine [15],
and human T cells [12. 36]. For example, in the analysis of
the TCR 5C.C7, specific for pigeon cytochrome c in the
context of HE*, a glutamic acid residue at position 93 of
the TCRa chain interacts with the residue 99K in the pep¬
tide (MCC 88-103). In mice transgenic for the TCR|3
chain of 5C. C7, immunization with the variant peptide
MCC 99E produced hybridomas expressing related TCRa
chains, in which position 93 was replaced by a lysine [15].
In the analysis of TCR specific for HA 307-319. previous
studies [17, 19, 20] and our own work (LRW and JRL.
unpublished) have characterized residues 308K, 3UK,
313N, 316K, and 319Tas important forTCR contacts. With
the availability of the crystal structure of the HA 307-319/
DRl complex, we have been able to model the TCR
described in this study, and have predicted that the TCRa
residue 94E lies close to 316K of the peptide. To test this,
we have constructed mutants at this position and
expressed these and the wild-type HA 1.7 TCR in the
RBL-2H3 system, using TCR-CD3C chimeric constructs.
In this cell line, stable and high cell-surface expression of
transfected constructs can be achieved. The CD3tj chain
allows heterodimerization of the two chains, and mediates
a signal which leads to basophil granule exocytosis. due to
its homology with the physiological signaling molecule in
the basophil, the FceRI [37].
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In this study, peptide-specific recognition byTCR has been
reconstituted in the RBL-2H3 cell line by transfection of
the wild-type HA 1.7TCR. Two mutantTCRa chains, with
residue 94 altered to A and K respectively, have also been
tested. Both TCR carrying mutant a chains have good
responses to TCR ligation by anti-TCR(3 antibody stimula¬
tion. As expected from the prediction, the TCRa E94A
and E94K mutants show an almost total loss of response to
HA 307-319. indicating the critical nature of the 94E resi¬
due in binding the peptide/MHC ligand.
In an attempt to obtain further evidence for the orienta¬
tion of the HA1.7 TCR on its ligand. we have tested the
responses of the wild-type and mutant TCR to altered pep¬
tides in which 316K has been substituted with other resi¬
dues. In parallel with the original HA 1.7 clone, the wild-
type TCR shows a weak response to the 316C analog, but
no response to 316R. The HA1.7T cell clone responds to
316R. albeit poorly: however, this requires very high con¬
centrations of peptide, and it is likely that the affinity of
the TCR for this peptide in the context of DR1 is too low
to produce a signal in the RBL system.
The use of altered peptides to stimulate the mutant TCR
could not rescue recognition. In particular, it was not pos¬
sible to restore the electrostatic partner of the TCRa E94K
mutant using the altered peptides 316E and 316D. This is
in contrast to the 5C.C7 TCR transgenic mice, where
reciprocal charge exchange restored responsiveness [15].
However, it is not always possible to introduce such recip¬
rocal mutations without some disruption of the surround¬
ing polypeptide chain, since the structural context in which
a charged residue is placed can be a critical determinant of
local conformation. In fact it has been suggested that ion-
pair reversal in proteins is "unlikely to succeed" [38]. The
difficulty of this type of charge engineering is shown by the
fact that even a conservative change can have a profound
biological effect, as shown by the greatly reduced response
of the wild type HA1.7TCR to the K316R peptide.
This study adds to the evidence that the CDR3 sequences
of TCR chains, in this case the TCRa chain, play a major
role in the specific recognition of antigenic peptide. Our
model also predicts that the difference in DR cross-
reactivity between the two clones could be explained by
the differing TCR(3 chains. The class II molecule
DRB1*0404 differs from DRB 1*0101 by only 10 residues.
The majority of the polymorphic residues which differ
between these two DR molecules lie in the base of the
peptide binding groove, such as 11. 13. 28. 30. 31. and 37h.
In DR1. these residues do not form direct interactions with
side chains of the peptide [3]. While the difference
between the clones may be mediated by direct interaction
between theTCRp chains and the polymorphic residues of
the DR molecule, it is also possible that the shape of the
HA peptide differs when presented in the context of DR4
instead of DR1. and that TCR(3 - peptide contacts are dif¬
ferent between the two ternary complexes. This has not
formally been tested in the present study, and further
experiments are in progress to address this issue.
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Supera.ntigens are proteins that in association with ciass II major
histocompatibility complex (MHC)-bearing cells can stimulate vir¬
tually all T ceils that express particular classes of the variable p-
domains of the T-cell receptor (TCR)1. This mechanism of T-cell
activation circumvents the usual requirement for peptide-specilic
MHC recognition. Staphylococcus aureus enterotoxin B (SEB) is
a bacterial superantigen that causes food poisoning and shock"-3.
We have characterized the tertiary complex of SEB. a soluble T-
cell receptor, and a soluble class II MHC molecule DR1, and the
three binary complexes TCR—SEB, SEB-DR1, and the peptide-
specific complex DR1-TCR. We report here that in each case the
specificity of the interaction among the soluble molecules is the
same as observed in biological assays. Native gel electrophoresis
and plasmon resonance affinity measurements indicate that SEB-
TCR complex can form in the absence of class II MHC and
that SEB-TCR interaction increases the binding of DR1. The
observation that a superantigen can form complexes with TCR in
both the absence and presence of class II MHC may provide a
mechanism for its ability to induce anergy in some circumstances
and activation in others6'7 (reviewed in ref. 8).
To investigate the interactions of TCR, class II MHC and
SEB, we used a soluble human TCR ap heterodimer (TCR
HA 1.7) which has specificity for influenza haemagglutinin HA
peptide (306-318) bound to the human ciass II MHC molecule
HLA-DR16. The variable (V) gene segment of the /?-chain of
TCR (HA 1.7) is V/33.1, which has specificity for SEB9. A native
gel-shift assay (Fig. 1) was used to examine formation of com¬
plexes between TCR, DR1 and SEB under non-denaturing con¬
ditions. TCR (lane 1), SEB (lane 4), and DR1-HA (HA peptide
306-318 bound to HLA-DR110) (lane 6), migrate through a
native polyacrylamide gel with distinct mobilities. Co-incubation
of TCR. DR1-HA and SEB resulted in a new band (lane 2.***),
indicating formation of a complex. The presence of TCR. DR1
and SEB in this band was confirmed by immunoblot analysis
using antibodies specific for each protein (Fig. 16). These data
confirm the existence of the predicted ternary complex3.
No complexes are observed under these conditions between
DR1 and SEB in the absence ofTCR (Fig. la, lane 3) or between
DR1-HA and TCR in the.absence of SEB (Fig. la, lane 5). This
could result from weaker affinities and/or fast dissociation rates
of these two binary complexes, which are beyond the sensitivity
of detection in native gels. Affinity of the TCR/ MHC class II
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interactions has been reported to be low (dissociation constant
k0 ~i0"4 to itr! mV1-'3.
The binary complex between SEB and TCR (in the absence
of DR1) is detected as a band on native gel electrophoresis (Fig.
2a. lane 6.*"') with mobility distinct from that of SEB (lane 7)
or TCR (lane 8).
The specificity of the interactions among soluble TCR, super¬
antigen and ciass II MHC molecules was also studied with native
gel electrophoresis. The ternary complex TCR-SEB-DR1 was
observed with four different peptides bound to DR1 (Fig. 2a;
compare lanes 1-4 to lanes 10-13). This indicates that in vitro,
as in vivo, superantigen circumvents the usual requirement for
peptide-specific MHC recognition by TCR. The slight variation
in mobility of the ternary complex bands (lanes 1-4.***) reflects
differences in the mobilities of HLA-DR1 bound to different
peptides (lanes 10-13). This observation, as well as the disap¬
pearance of the DR1 and TCR bands in lanes 1-4 (Fig. 2a),
provides additional evidence for the presence of all three protein
molecules in the ternary complex band.
The specificity of this TCR (HA 1.7, V/33.1) for the superanti¬
gen SEB14 but not SEA (S. aureus toxin A) or TSST-l (toxic-
shock-syndrome toxin l)15 was observed with native gel electro¬
phoresis. SEB formed a complex with TCR in both the absence
(Fig. 2a, lane 6; Fig. 26, lane 3) and presence (Fig. 2a, lane
4,*** and Fig. 26, lane 4) of DR1, whereas TSST-l (Fig. 26.
lanes 5. 6) and SEA (not shown) show no complex formation
with this TCR. Immunoblot analysis with a TCR antibody (Fig.
2c) confirmed that this TCR did not form a complex with TSST-
1 in the absence (lane 2) or presence (lane 3) of DR1.
We have also observed the ternary and binary complexes using
a BIAcore instrument16-17 that can detect the binding of one or
more soluble proteins to a protein immobilized on a dextran-
coated chip as a difference in refractive index18. Figure 3 shows
the binding of proteins to immobilized TCR. SEA (1 pM) shows
no significant binding, whereas SEB (1 pM) clearly forms a com¬
plex with TCR (Fig. 3). DR1-HA at high concentration (25 pM)
shows a small binding signal, whereas DR1-HA (1 pM) pre-
mixed with SEB (1 pM) binds to the TCR surface with a large
signal (much greater than additive), indicating formation of the
ternary complex (Fig. 3a). In control experiments, neither SEB
nor DR1-HA bound significantly to the dextran matrix alone;
and other proteins for which the TCR is not specific, such as
DR1-124 or HLA-A2 (class I MHC), did not bind to the immob¬
ilized TCR (Fig. 36, and data not shown). Although high DR1-
HA concentration (25 pM; Fig. 3) was required to observe
binding to immobilized TCR. the binding was peptide-specmc.
DR1 complexed with another peptide (124) showed no binding
at 25 pM (Fig. 36). On the basis of experiments using DR1-HA
concentrations up to 50 pM, we estimate that the KD of the
DR1-HA, TCR (HA1.7) interaction is greater than 25 pM in
vitro.
With SEB immobilized on a chip, both the binary complexes
DR1-SEB and TCR-SEB were readily detected (Fig. 4A. B). In
control experiments, neither DR1 (Fig. 4Aa. curve 2) nor TCR
(not shown) bound to the free dextran surface; and HLA-A2
(ciass I MHC). which does not have specificity for SEB, did not
bind to the immobilized SEB (not shown). In Fig. 4A a binary
complex between DR1 and SEB is observed, which was not
detectable by native gel electrophoresis (see above). Figure 4B
provides further evidence that SEB can form a stable binary
complex with TCR in the absence of MHC class II.
Equilibrium dissociation constants and kinetic on- and off-
rates were measured for the novel TCR-SEB complex. Kinetic
constants were calculated from the ascending rate of the BIAcore
signal during binding and the descending rate during wash-off
(Fig. 4, legend). For TCR binding to immobilized SEB, an on-
rate constant (kon = 1.30±0.12x 104 M"1 s"1) and off-rate con¬
stant (kolf= 1.06±0.05 x 10~2s~') were determined from tripli¬
cate experiments (Fig. 4B). From their ratio, the equilibrium
dissociation constant. £D = 0.82 pM, is estimated for the TCR-
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FIG. 1 Native gel shift assay, a. Co-incubation of DR1-HA (HLA-DR1
bound to HA 306-318 peptide), SEB and TCR (lane 2), results in the
appearance of a distinct band (•«*), not observed with TCR (lane 1), SEB
(lane 4) or DR1-HA (lane 6) alone, indicating TCR-SEB-DR1 complex
formation. Co-incubation of DR1-HA and SEB (lane 3) or of DR1-HA with
TCR (lane 5) did not result in any distinct mobility shift, b. Anti-TCR blot
(aFl mAb; T Cell Sciences) shows that TCR is shifted by incubation
with DR1-HA and SEB: anti-DRl blot (L243 mAb American Type Culture
Collection II HB55) snows that DR1-HA is shifted by incubation with
TCR and SEB: anti-SEB blot (polyclonal serum: Toxin Technology) snows
that SEB is shifted by incubation with TCR and DR1-HA. Thus all three
proteins are present in the band («•*).
METHODS. HLA-DR1 (DRBl'0101), was produced in insect cells as a
soluble protein, purified and complexed in vitro with peptides as
published10. A soluble human ap T-cell receptor (HA1.7, V/J3.1 Val.2)
was expressed ana isolated as previously described for a mouse TCR21
(I.E. and T.O., unpublished results). SEB was purchased from Sigma.
The TCR, peptide-complexed DR1 and SEB used in these experiments
appear homogeneous by gel-filtration HPLC and by SDS-PAGE. The
multiple SEB bands in native-PAGE may result from charge heterogen¬
eity. Non-denaturing native-PAGE was done by omitting SDS in a PAGE
system22. Proteins (15 pM TCR. 20 pM DR1. 35 pM SEB) were incubated
alone, or in combination, in PBS. with 1 mM pnenylmethylsuiphonyl
fluoride, 10 pg ml-1 leupeptin. pH 7.0. at 37 5C for 18 h before non-
reducing native polyacrylamide (10%) gel electrophoresis. No reducing
agents were added and samples were not heated. The resolving gel
buffer was 0.375 M Tris, pH 8.8. In native-PAGE the direction of migra¬
tion of the proteins will depend on the buffer pH relative to the iso¬
electric point (p/) of the protein23. The gels were run at 15 V cm-1.
Protein bands were visualized with a. Coomassie brilliant blue R250.
or b. were electropnoretically transferred to a polyvinylidene difluoride
(PVDF) membrane (Immobilon-P: Millipore), probed with specific anti¬
bodies. and the immune complexes visualized by alkaline
phosphatase24.
SEB complex. A similar value (ATD = 0.68pM) was obtained
from a Scatchard analysis (not shown) of equilibrium binding
at various TCR concentrations (Fig. 4Ba). The equilibrium dis¬
sociation constant for the DR1-SEB complex was also
measured. Scatchard analysis (Fig. 4Ac) of the data in Fig. 4Ab
gave a ATD = 1.7 pM. a value similar to that measured for SEB
binding to DR1 on cell surfaces19.
The kinetics of DR1-SEB association and dissociation were
too fast to be measured accurately in the experiments shown in
Fig. 4A. The fast dissociation kinetics may be the reason that
the DR1-SEB complex was not detectable in the native gel-shift
assay (see above).
Our native gel electrophoresis results indicate that DR1 with
peptide binds better to the SEB-TCR complex than to either
molecule separately. TCR-SEB-DR1 complexes could be
observed for four different DR1-peptide complexes under condi-
FIG. 2 Specificity of TCR-SEB and TCR-SEB-DR1 com¬
plex formation, a. In the presence of SEB. TCR migrates
with a mobility (lane 6. *«) intermediate between SEB
(lane 7) or TCR (lane 8) alone. Formation of the TCR-
SEB-DR1 complex (lanes 1-4, «•*) was independent of
the peptide bound to DR1 (peptide sequences listed
below), and was accompanied by a band shift relative
to peptide-Oound DR1 (lanes 10-13) and TCR alone
(lane 8). b. The interaction of TCR v/ith SEB was com¬
pared to the interaction of TCR with TSST-1. No com¬
plexes were detected when TCR was incubated with
TSST-1 (lanes 5 and 6) or SEA (data not shown), but
TCR-SEB (lane 3) and TCR-SEB-DR1 (lane 4, ***) com¬
plexes were observed. Neither TSST-1 nor SEA are
reported to interact with V/J3.1 (ref. 1). c. Anti-TCR
immunoblot of native gel with aFl mAb specifically con¬
firms that TCR is not shifted by incubation with TSST-
1 (lane 2) or TSST-1 -r-DRl (lane 3). but is shifted by
incubation with SEB and DR1 (lane 4).
METHODS. Proteins (10 pM each) were incuoated. sub¬
jected to native-PAGE (8%), and visualized as in Fig. 1.
a and b. Coomassie stained, c. Anti-TCR immunoblot.
Peptides: HA. influenza haemagglutinin (306-318)
PKYVKQNTLKLAT: 124. class ll-associated invariant
chain (9&-119), LPKPPKPVSKMRMATPLLMQALPM: 115,
class ll-associated invariant chain (105-119),
KMRMATPLLMQALPM; MA. influenza matrix (17-29),
SGPLKAEFAQRLE.
o* p^ p^Np*> J?
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FIG. 3 interaction of SEB. SEA. DR1 and pre-
mixed (DRl-t-SEB) to immobilized TCR. Pro¬
tein-protein interactions detected by surface
plasmon resonance (BIAcore instrument. Phar¬
macia), where increase in RU (resonance units)
indicates binding of injected protein to protein
immobilized on surface, a. SEB (1 pM) but not
SEA (1 pM) binds to immobilized TCR. Although
DR1-HA binds only weakly even at concentra¬
tions as high as 25 pM, premixing of SEB plus
DR1-HA at equimolar (1 pM) concentrations
before injection resulted in a more than addi¬
tive increase in binding signal, b. Overlaid sen-
sorgrams comparing binding of immobilized
TCR to 0R1 bound to the correct antigenic pep¬
tide (DR1-HA, 25 pM) versus DR1 bound to the
control peptide (DR1-I24, 25 pM).
METHODS. TCR was coupled to the dextran
matrix by standard amine chemistry25. A flow
of HBS (10 mM HEPES. 150 mM NaC!. 3.4 mM
EDTA, 0.5% surfactant P20 pH 7.4) was main¬
tained over the sensor surface at 5 pi min"1. Samples were injected at
5 pi min-1 for 5 min each. Between injections, the surface was regener¬
ated with HBS. The immobilization level was 3,000-4.000 RU. 'X'.















during the injection and towards the end of the wash. Although binding
of DR1 and SEB to the immobilized TCR is detectable, baseline drift
made kinetic and affinity measurements impractical.
tions where TCR-SEB complex formed, but DR1-SEB com¬
plexes were not stable (Figs I and 2). This suggests that either
soluble a (3TCR alters the conformation of SEB to a form which
has higher affinity for DR1. or that a [3TCR directly contacts
parts of the DR1 molecule in the TCR-SEB-DR1 complex.
Such a direct contact has previously been suggested based on
variations in T-cell responses with MHC class II polymorphism,
with the conformational state of MHC class II. and with the
type of TCRcr chain (for review see ref. 20); this contact could
occur on a DR1 surface adjacent to the bound peptide.
Two observations reported here indicate that TCR-SEB-DR1
complexes can be formed from soluble molecules. First, native
gel electrophoresis of mixtures of the three molecules reveals a
band with mobility distinct from the three individual constit¬
uents. or their binary complexes, and that band has been shown






























FIG. 4 Measurement of binding parameters for
DR1-SEB (A) and TCR-SEB (B) complexes. Aa.
DR1 binding to SEB surface (trace 1) versus
control surface (trace 2); b. Concentration-
dependent binding of DR1 to SEB surface: c.
Scatchard plot intercepts give R0 (maximum
DR1-HA bound) and Rq/K026, yielding a K0 of
1.7 pM. Sa. Bottom to top traces.
TCR-0.25 pM. 0.35 pM. 0.5 pM. 1.0 pM.
binding to SEB. 0. Binding rates dRU/dt at
these TCR concentrations versus relative
response in resonance units. RU. c. Association
rates (k,) versus TCR concentration (k, = slopes
from b). An apparent association rate constant
[kon = 1.30 = 0.12 x 104 M"ls'1; n = 3) was
calculated for TCR binding to SEB. d. Dissocia¬
tion of bound TCR (1 pM trace) from immobil¬
ized SEB. Assuming a single exponential decay,
koH= 1.06 = 0.05 x 10~2 s~l (n = 3). The ratio
of off- and on-rate constants gives an apparent
eauilibrium dissociation constant X0 = 0.8 uM.
The data shown here are from a typical experi¬
ment. The values for kinetic constants are
mean =s.d. from n independent experiments.
Methods as in Fig. 3.
Time (s)
0 100 200 300 400 500
3ourW [RU]
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2). Second, plasmon resonance measurements of SEB and DR1
binding to an immobilized TCR indicate that much more DR1
binds to the immobilized TCR in the presence of SEB than binds
under the same conditions in the absence of SEB (Fig. 3). We
also confirm the weak affinity for MHC class II with peptide to
TCR""13. demonstrating here that both soluble proteins interact
in a peptide-specific manner as required for MHC restriction.
Finally, we have observed direct binding of SEB to a (3TCR in
the absence of a class II MHC molecule (Ko = 0.S2 pM) which
exhibits kinetics (kon= 1.30 x 104 M"1 s~'; kolT= 1.06 * 10~2 s-1)
that suggest a half-life of the complex of 90 s. Although several
studies report that activation of T cells by superantigen requires
the presence of MHC class II molecules, under certain circum¬
stances (crossiinking of toxin and/or presence of co-stimulant)
superantigen can activate T cells in the absence of class II mol¬
ecules (reviewed in refs 1, 8. 15). In the absence of co-stimulants
or crossiinking, SEB alone appears to cause anergy6. The finding
that superantigen complexes with TCR in both the presence and
the absence of class II MHC in vitro may correlate with these
different activities in vivo. □
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Differential dependence ofTH-0, TH-1 and TH-2 CD4 4- T
cells on co-stimulatory activity provided by the accessory
molecule LFA-1
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Summary *
jBackground The adhesion molecule LFA-1 contributes to the activation response of
peripheral blood human CD4+ T ceils. Less is known of its contribution to stimulation
of long-term CD4-i- T cell lines and clones or of its potential to co-stimulate CD4-i- T
cells of different functional phenotype.
Objective This study was therefore performed to investigate co-stimulatory proper¬
ties of the LFA-1 (CD 1 la/CD 18) complex in the activation of human CD4+ T cell
lines and clones of TH-0, TH-1 and TH-2 subsets.
Methods Co-stimulatory activity was measured by cross-linking antibodies to CD1 la
or CD 18 with anti-CD3 antibodies to plastic and then measuring the proliferative
response of CD4-r T ceils to these antibodies.
Results A house duct mite allergen-specific CD4— T ceil line (TH-2) demonstrated
much greater dependence on both CDUa and CD 18 than a mycobacterial antigen-
specific CD4+ T cell line (TH-l). Co-stimulatory activity through LFA-1 was also
provided to a house dust mite-specific CD4+ T cell clone (DE-9; TH-2) but not to an
influenza haemagglutinin-specific CD4-f- T cell clone (HA1-7; TH-0). In contrast,
soluble antibodies to CD18 inhibited proliferative responses of both DE-9 and HA1-7
to an immunogenic challenge of antigen and to stimulation by anti-CD3 antibodies.
However, the allergen-specific T cells were more susceptible to inhibition. Signal
transduction was also observed from the T-cell receptor to LFA-1. Ligation of the
T-cell receptor modulated the phenotypic expression of LFA-1 and ICAM-1 on both
HA 1-7 and DE-9. Phenotypic modulation was observed as a result of both activation
and the induction of non-responsiveness.
Conclusion These experiments indicate that CD4+ T cells of TH-2 functional
phenotype may have a greater requirement for the co-stimulatory activity of LFA-1
than CD4-+- T cells of TH-0 or TH-1 phenotypes.
Keywords: CD4+ T cells. TH-0, TH-1. TH-2, functional phenotype. LFA-1, ICAM-1
Clinical and Experimental Allergy, Vol. 25, pp. 1163-1170. Submitted 20 May 1994:
accepted 11 October 1994.
Introduction
Antigenic peptides are presented to CD44- T cells by
MHC class II molecules expressed on the membrane of
accessory cells [1]. Accessory cells also bear several
Correspondence: Dr A. Faith. SIAF. Obere Strasse 22. Davos.
Switzerland.
ligands which interact with complementary receptors
on T cells. These molecular associations provide the
activation-dependent adhesion contributing to enhanced
responsiveness characteristic of CD4+ T cells. Several
major families of adhesion molecules have been
described [2], the best characterized of which are the
integrins and the immunoglobulin superfamily. The
C; 1995 Blackwell Science Ltd 1163
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integrins can be divided into several families of related
molecules, possessing a unique' a and common j3 chain.
The ffl integrin LFA-1 (CD1 la/CD18) [3] is present on T
cells and contributes to activation and proliferation. The
counter receptor for LFA-1 is a member of the immu¬
noglobulin superfamily ICAM-1 (CD54) [4], and is
expressed on a variety of tissues including peripheral
blood leucocytes, vascular endothelium and epithelial
cells. Recently the counter receptors ICAM-2 and
ICAM-3 have been described [5,6]. ICAM-2 is the pre¬
dominant LFA-1 binding Iigand on resting endothelium
while ICAM-3 although absent from endothelial cells is
strongly expressed on all leucocytes.
There is evidence to suggest that the role of the
adhesion molecules may not be limited to forming a
molecular bridge between accessory cells and T cells.
ICAM-1 has recently been shown to provide co-stimulation
in response to anti-CD3 antibodies by prolonging inosi¬
tol phospholipid hydrolysis [7],
Murine CD4^ T cells have been divided into two
mutually exclusive subsets, depending on their lympho-
kine profiles [8]. There is now strong evidence that
human CD4+ T cells, derived from atopic individuals
and responding to house dust mite (HDM) allergens,
belong to the TH-2 functional phenotype [9], secreting
cytokines such as IL-4, IL-5 and IL-10. However, most
human CD4+ T cell clones, derived from normal indi¬
viduals and responding to recall antigens, belong to the
TH-0 phenotype producing high levels of IFN7 as well as
TH-2 cytokines [10]. It is not known whether the role of
accessory molecules, in activation of human CD4 + T
cells belonging to different functional phenotype. differs.
We have, therefore, compared the function of LFA-1 in




Anti-CD3 antibodies, affinity purified by Protein-A
Sepharose chromatography, was the kind gift of Dr H.
Spits. Cancer Research Centre. Amsterdam, the Nether¬
lands. Purified anti-CD 11 a (38; IgG2a) and purified anti-
CD 18 antibodies (60.3; IgG2a) were kindly provided by
Dr N. Hogg. Imperial Cancer Research Fund. London,
UK and Dr J. Ledbetter. Bristol-Myers Squibb. Seattle.
USA, respectively.
Antigens
Staphylococcal enterotoxins (SE) B and E were pur¬
chased from Toxin Technology (Madison. WI. USA).
The HA307-319 (HA307) C-terminal peptide of the
influenza virus haemagglutinin antigen was prepared
using standard solid-phase methods. Lyopholized
extracts of the house dust mite Dermatophagoides pter-
onvssinus were kindly provided by SmithKline, Beecham
(Brentford. UK). Recombinant Der p II was kindly
provided by Dr W. R. Thomas, Princess Margaret
Hospital. Perth. Western Australia. Mycobacterial solu¬
ble extract (MTSE) was kindly provided by Professor D.
Young, Department of Microbiology, St Mary's Hospi¬
tal Medical School. London. UK.
T cell lines
Peripheral blood mononuclear cells (PBMC; 2 x 106/
mL) were stimulated with Der p II (10/rg/mL) or
MTSE (5 /tg/mL) for 10 days and viable cells recovered
from Ficoll-Hypaque gradients and restimulated
(1 x 106/mL) with antigen in the presence of auto¬
logous. irradiated PBMC (APC; 1 x 106/mL) and 5%
Lymphocult-T (Biotest Serum Institute, Frankfurt. Ger¬
many). T cells were expanded by alternate weekly cycles
of stimulation with antigen. APC and IL-2 or IL-2 alone.
The T cell lines were used in assays after 3 weeks
stimulation when CD4+ T cells represented >90% of
each population. The MTSE-specific line secreted
18250 pg/mL of IFTJ-y and 20pg/mL of IL-4 following
restimulation after 2 weeks in culture and was therefore
of TH-1 functional phenotype. The Der p II-specific line
was established from an atopic donor.
T cell proliferation assays
The isolation and characterization of the cloned human
T cells, HA1.7 and DE-9, reactive with HA307 and
Dermatophagoides pteronvssinus, respectively, have
been described elsewhere [11.12], HA1-7 and DE-9
(1 x 105/mL) were cultured with HA307 (2qg/mL) or
Dermatophagoides pteronyssinus (lO^tg/mL), respect¬
ively. with MHC class II matched, allogeneic, irradiated
PBMC (5 x 105/mL) (APC), in the presence or absence
of varying concentrations of antibodies to CD 11a and
CD 18. For assays of co-stimulatory activity, varying
concentrations of anti-CD3 antibodies and antibodies
to CD1 la or CD 18 (10 pgjmL) were co-immobilized by
coating round-bottomed 96-well microtitre plates, for 1 h
at 37°C. Anti-CD3 antibodies were added first for 1 h to
avoid competition with anti-LFA-1 antibodies for bind¬
ing to the plastic. The plates were then washed twice with
phosphate-buffered saline (PBS) and T cell clones or T
cell lines (1 x lCP/'mL) added to wells. T cell clones
(1 x 105/mL) were also stimulated with cross-linked
anti-CD3 antibodies (lOqg/mL) in the presence or
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absence of varying concentrations of soluble antibodies
to anti-CDlla and CD18. For all assays, T cells were
incubated for 66 h and proliferation measured by addi¬
tion of 3H-TdR during the final 16 h of culture. Prolif¬
eration is shown as the mean of triplicates ± standard
error of the mean.
The induction of non-responsiveness was achieved by
culturing HA 1.7 (2 x 106/mL) with HA307 peptide
(50/xg/mL) or SHB (0-5qg/mL) and DE-9 (2 x 106/mL)
with SEE (5 pig/mL) for 16 h. Cloned T cells were then
washed and restimulated with an immunogenic challenge
of their respctive antigens.
Fluorescence flow cytometry
T cells were stained directly with saturating concentra¬
tions of fiuorescein-conjugated murine monoclonal anti¬
bodies. anti-Leu 4 (CD3) and anti-IL-2 receptor (CD25)
antibodies (Becton Dickinson), using a mouse IgGl
fluorescein isothiocyanate (FITC)-conjugate control, or
indirectly with anti-CDlla, anti-CD 18, and anti-CD54
antibodies, and FITC-conjugated goat anti-mouse Ig
(DAKO). Viable cells, identified by their ability to
exclude propidium iodide, were analysed by flow cyto¬
metry using an Epics Prolife II (Coulter). The ceil
population was analysed by gating on the volume and
light scatter characteristics.
Results
Effects of antibodies to LFA-1/ICAM-1 on antigenic
responses of CD4 + T cell clones
Different functional populations of CD4+ T cells may
have selective requirements for adhesion molecules.
Therefore, we examined the role of these molecules in
antigen presentation to T cell clones representative of the
TH-0 and TH-2 functional phenotypes. The addition of
soluble antibodies to CD1 la and CD 18 resulted in dose-
dependent inhibition of the antigenic responses ofboth T
cell clones (Fig. 1) but whereas the response of DE-9 was
ablated at a concentration of 20 qg/mL of each antibody
that of HA1.7 was reduced by only 50%.
Effects of antibodies to CDllaiCD18 on CD4+ T cell
responses in the absence of accessory cells
Proliferation of polyclonal T cells, induced by cross-
linked anti-CD3 antibodies, has been reported to be
independent of the presence of accessory cells [13] and
therefore, the contribution of adhesion molecules
such as LFA-1 to CD4+ T cell activation can be
directly assessed. Soluble antibodies to anti-CD 18 gave
40 ooo r- , .I (a)
Anti-LFA-1 antibody concentration (iiq/mL;
Fig. 1. Effect of antibodies to CD1 la/CD18 on the response of
the T cell clones, HA1.7 and DE-9, to antigenic stimulation, (a)
DE-9 and (b) HA1.7 were stimulated with HA307 peptide and
D. Pter., respectively, in the presence ofMHC class II matched,
irradiated, allogeneic PBMC. Varying concentrations of anti¬
bodies to CD1 la and CD 18 (0-02-20 ug/mL) were added to the
culture system. Ceils were cultured for 66 h and tritiated
thymidine incorporation measured during the final 16 h of
culture. —. Anti-CDlla. —O—. Anti-CDI8.
dose-dependent inhibition of the responses of both DE-9
and HA1.7 to cross-linked anti-CD3 antibodies (Fig. 2),
but DE-9 was again much more susceptible to inhibition.
Soluble antibodies to CD 11a had no effect on the
responses of either T cell clone.
Co-immobilization of antibodies to adhesion mole¬
cules and anti-CD3 antibodies have been shown to
provide a co-stimulatory signal to polyclonal CD4-r T
cells [14]. Antibodies to CD 11a and CD 18, cross-linked
together with anti-CD3 antibodies, delivered a co-
stimulatory signal, resulting in enhanced proliferation, to
DE-9 at sub-optimal concentrations of anti-CD3
antibodies (Fig. 3a). In contrast, neither anti-CDlla or
© 1995 Blackwell Science Ltd. Clinical and Experimental Allergy, 25. 1163-1170
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Fig. 2. Effect of soluble antibodies to CD 11 a/CD 18 on the
response of DE-9 (a) and HA1.7 (b) to anti-CD3 antibodies.
Anti-CD3 antibodies (lOpg/mL) were immobilized on plastic
wells. T cells (1 x 105/mL) and varying concentrations of
antibodies to CDila and CD18 (0-02-20pg/mL) were added
to each well, and proliferation measured as in Fig. 1. —
Anti-CD3+ anti-CD18. -O—. Anti-CD3+ anti-CDUa,
CD 18 antibodies had any effect on the response of
HA1.7 (Fig. 3b). These results again indicated that
DE-9 was more dependent on LFA-1 than HA1.7. The
more general applicability of these results to CD4+ T
cell populations of different functional phenotype was
investigated by determining the co-stimulatory activity
of LFA-1 on TH-1 and TH-2 CD4+ T cell lines. Anti-
CD 1 la and anti-CD 18 antibodies, co-immobilized with
anti-CD3 antibodies, strongly enhanced the response of
the Der p II line (TH-2) to anti-CD3 antibodies alone,
whereas the response of the MTSE line (TH-1) was
unaffected bv the presence of the anti-LFA-1 antibodies
(Fig- 4).
Anti-CD3 antibody concentration ipg/mL)
Fig. 3. Effect of cross-linked antibodies to CD 1 la/CD 18 on the
response of DE-9 (a) and HA 1.7 (b) to anti-CD3 antibodies.
Varying concentrations of anti-CD3 antibodies were co-
immobilised on plastic wells with antibodies to CD1 la or CD 18
(10 pg/mL). T cells (1 x 105/mL) were added to each well and
proliferation measured as in Fig. 1.—. Anti-CD3. —A—. Anti-
CD3+ anti-CD18. -O-. Anti-CD3+ anu-CDlIa.
Activation and induction of non-responsiveness induces
phenotypic modulation of accessory molecules in T cell
clones
We have previously demonstrated phenotypic changes,
including downregulation of CD3 and upregulation of
CD25, in the T cell clone HA 1.7 associated with activa¬
tion [15]. Levels of CDUa. CD 18 and CD54 on both
HA1.7 and DE-9 were enhanced following activation by
a combination of cross-linked anti-CD3 antibodies and
IL-2 (Fig. 5). Exposure ofCD4+ T cells to supraoptimal
concentrations of peptide or superantigen in the absence
of accessory ceils induces non-responsiveness (anergy)
© 1995 Blackweil Science Ltd. Clinical and Experimental Allergy. 25. 1163-1170
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Fig. 4. Effect of cross-linked antibodies to CD 1 la/CD 18 on the
response ofDer p II (a) and MTSE (b) specific T cell lines to anti-
CD3 antibodies. Varying concentrations of anti-CD3 antibodies
were co-immobilized with antibodies to CD1 la or CD 18 (10 tig/
mL) on plastic wells. T cells (1 x 10"/mL) were added to each well
and proliferation measured as in Fig. 1. . Anti-CD3. -O-.
Anti-CD3+ anti-CDUa. - A—. Anti-CD3 + anii-CD18.
resulting in down-regulation of CD3 and increased
CD25 expression in HA1.7 [15]. This analysis was
extended to the changes in expression of adhesion mole¬
cules (Fig. 5). Anergizing concentrations of both peptide
or superantigen induced upregulation of CD 11 a, CD 18
and CD54 in both HA1.7 and DE-9. A parallel func¬
tional assay (Table 1) indicated that cloned T cells had
indeed been anergised by exposure to both peptide
and superantigen. In contrast, treatment with anti-CD3
antibodies and IL-2 does not impair the ability of the
T cell clones to respond to immunogenic challenge
(Table 1).








' T cells were exposed for 16 h to the designated treatments (see
Materials and methods). Cells were washed and restimulated
with HA307 peptide (2ug/mL) or D. pier. (10/ig/mL) in the
presence of APC.
" Mean proliferative response of triplicates (%SEM).
Discussion
In this study we have compared the function of LFA-1
in the activation of human CD4+ T cells belonging to
TH-0, TH-1 and TH-2 functional phenotypes. Immuno¬
genic challenge of cloned CD4+ T cells representative of
TH-0 and TH-2 phenotypes in the presence of soluble
antibodies to CD I la and CD 18 resulted in inhibition of
T cell proliferation, presumably due to abrogation of
interactions between LFA-1 and ICAM-1. House dust
mite-reactive T cells of clone DE-9 were more susceptible
than HA 1.7 to inhibition, suggesting greater dependence
on the accessory function of LFA-1. Although expression
ofCD 11 a and CD 18 was higher inHA 1.7 than DE-9, anti-
LFA-1 antibody concentrations of 20(tg/mL are likely to
be saturating. Previous experiments have shown that DE-9
is also more dependent than HA1.7 on the accessory
molecule, CD4, during antigenic stimulation [16].
Although it has been reported that cross-linked anti-
CD3 antibodies can induce proliferation in polyclonal
CD4+ T cells [13], it is probable that after rigorous
depletion of monocytes, a co-stimulatory signal is
required to induce proliferation [14]. CD4+ T cells
lines and clones, in contrast, proliferate to anti-CD3
antibodies in the absence of co-stimulation. Neverthe¬
less, optimal stimulation of CD4+ T cell lines has also
been reported to require co-stimulation through LFA-1
by the counter-receptors ICAM-1 and ICAM-2 [17]. T
cells of the TH-2 clone, DE-9, were optimally stimulated
only in the presence of antibodies to CDUa and CD 18.
The co-stimulatory activity transduced through LFA-1
may be a general property of TH-2 cells as a Der p II-
specific CD4 + T cell line, drived from an atopic donor,
also required signals through LFA-1 for optimal stimu¬
lation. In contrast, neither an MTSE-specific CD4- T
cell line ofTH-1 functional phenotype or the TH-0 clone.
10
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Fig. 5. Comparison of the effects of activation and induction of non-responsiveness (anergy) in HAI.7 and DE-9 on phenotypic
modulation of adhesion molecules. The T cell clones (2 x 106/mL), HA 1.7 (a) and DE-9 (b) were incubated in the presence of
medium alone or anti-CD3 antibodies (10 qg/mL) together with IL-2 (5% Lympocult-T). Additional aiiquots of HA1.7 were also
incubated with HA307 (50 qg/mL) or SEB (0-5 qg/mL). An aliquot ofDE-9 was also incubated with SEE (5 qg/mL). After overnight
incubation each aliquot of cells was washed and phenotypic expression of CD3, CD25. CD1 la. CD18 and CD54 determined by flow
cytometry.
HA 1.7, had any apparent requirement for co-stimulation
through LFA-1. It is probable that antibodies to
adhesion molecules increase adhesion and thus the affi¬
nity of interaction of co-immobilized anti-CD3 antibo¬
dies with the TCR. The observation that anti-CD 1 la and
anti-CD 18 antibodies provided similar levels of co-
stimulation to the Der p II-specific T cell line and DE-9
would support this postulate. A purified ICAM-1 anti¬
gen has recently been reported to provide co-stimulation
to polyclonal CD4+ T cells by prolonging inositol
phospholipid hydrolysis [7], an important signal trans¬
duction pathway in the activation of human CD4 + T
cells. Inositol phospholipid hydrolysis may be optimally
stimulated in TH-0 or TH-1 CD44- T ceils by anti-CD3
antibodies in the absence of accessory signals. Alter¬
natively, it is possible that ligand binding of LFA-1
antibodies may not completely reflect the binding of
ICAM. It is possible that different T cell subsets have
differential dependence on the three ICAM molecules
[18]. Another possibility is that TH-0 and TH-1 cells may
transduce signals through adhesion molecules other than
LFA-1. Murine TH-1 cells have been shown to use
different signalling pathways to TH-2 cells [19].
In contrast to the effects of co-immobilized anti-
CD 18 antibodies, soluble antibodies to CD 18 inhibited
the response of DE-9. Soluble anti-CD 18 antibodies
have previously been shown to inhibit anti-CD3
mediated stimulation of polyclonal T cells [13]. Soluble
3 1995 Blackwell Science Ltd, Clinical and Experimental Allergy, 25. 1163—1170
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anti-CD 1 la antibodies had no effect on the response and
therefore, anti-CD 18 antibodies were not inhibiting
interactions between opposing T cells. A negative
signal appeared to be transduced specifically through
CD 18. A strong intracellular calcium flux was induced
following ligation of CD 18 on polyclonal CD4+ T cells
by 60.3, the anti-CD 18 antibody used in this study [20],
and this may be associated with a negative signal to the
TCR. It seems probable that co-immobilization more
accurately reflects the distribution of MHC class II/
peptide complexes and adhesion molecules on the sur¬
face of the accessory ceil and, therefore, that a co-
stimulatory positive signal by adhesion molecules will
normally result from immunogenic challenge. Signal
transduction through the TCR is known to involve a
sequence of coordinated biochemical reactions trans¬
duced through the TCR multimeric complex [21].
Although there is no evidence of a physical association
of LFA-1 with the TCR, the observed npregulation of
CD1 la. CD18 and CD54 after stimulation ofHA1.7 and
DE-9 indicates that these molecules are linked to TCR
signalling.
Increased expression of adhesion molecules on
allergen-specific CD4 + T cells is related to recirculation
and extravasation of lymphocytes through endothelial
cells into tissue sites. The predominant T cell infiltrate in
skin sites sensitized to grass pollen allergens appeared to
be of TH-2 phenotype [22]. Desensitization to HDM
allergens might be attained by functionally inactivating,
or anergising, HDM-specific CD4— x cells of the TH-2
functional phenotype. Anergized HDM-specific CD4 —
T cells express high levels of LFA-l/ICAM-1 making it
probable that they could also extravasate into tissue
sites. The functional inactivation of peptide desensitized
HDM-specific CD4-1- T cells is not total since on
immunogenic challenge IFN7 production is maintained,
although IL-4 secretion is ablated [23]. Release of IFN7
by these cells might act to regulate and inhibit TH-2
cytokine production by other HDM-specific CD4+ T
ceils [24],
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Summary
Background It has been reported for the peripheral T cell repertoire that CD4
molecules may enhance adhesion between T cells and antigen presenting cells and,
through their physical association with T cell antigen receptors, contribute to signal
transduction.
Objective The aims of this study were to determine if the modulation of CD4
molecules had differential effects on T cell recognition, antigen induced cytokine (IL-
4 and IFN-/), release and the induction of specific anergy for human TH-0, TH-1 and
TH-2 cells.
Methods A panel of anti-CD4 antibodies was examined for its ability to modulate T
cell proliferation, cytokine production and tolerance induction in house dust mite (TH-
0 and TH-2) and influenza haemaggiutinin (TH-1) specific human CD4-t- T ceil clones
all restricted by DRBl'1101 and isolated from dust mite allergic individuals.
Results We observed that anti-CD4 antibodies may inhibit or enhance antigen
mediated T cell proliferation, which may reflect the differential requirements of T
cells for selective functions of CD4. Furthermore, IFN7 and IL-4 production was
differentially modulated depending on the specificity of the anti-CD4 antibody and the
clone ofT cells. However, pretreatment ofT cells with anti-CD4 antibody alone neither
induced nor enhanced the susceptibility of T cells to peptide mediated anergy.
Conclusion Antigen recognition by different subsets of human CD4+ T cells has
differential requirements on CD4, whereas the induction of specific anergy appeared to
be independent of the functions of CD4 molecules. Antigen induced IFN7 production
was more susceptible than IL-4 to the inhibitory effects of anti-CD4 antibodies.
Furthermore, it appeared that certain anti-CD4 antibodies can dissociate antigen
induced IFN7 and IL-4 production, and may downregulate IFN7 synthesis without
inhibiting antigen dependent proliferation.
Keywords: CD4, CD4-i-T cells subsets, house dust mite, haemaggiutinin, cytokines.
T ceil recognition, anergy
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Introduction
Different CD4-f- T subsets, termed TH-1 and TH-2.
promote either cell-mediated or humoral immunity
Correspondence: Dr J. Lamb. Department of Biology, Imperial College
of Science. Technology and Medicine. Prince Consort Road. London
SW7 LBB. UK.
C 1995 Blackwell Science Ltd
respectively, illustrating the functional heterogeneity of
the CD4+ T cell repertoire [1], This polarity in activity is
determined by the cytokines produced by each of CD4—
T cell subsets, with TH-2 cells characteristically secreting
(interleukin) IL-4, IL-5 and IL-6, whereas TH-1 cells
secrete IL-2 and interferon-gamma. (IFN7) [reviewed in
ref. 2]. An intermediate subset, TH-0 cells, which secrete
839
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both TH-1 and TH-2 cytokines have been identified [3]
and may form the major functional component of the
peripheral human T cell repertoire [4], In addition
kinetics and quantitative differences in the cytokine
response profiles will also contribute to the hetero¬
geneity of the CD4+ T cell responses.
The induction of protective or pathogenic immunity is
determined, in part, by which CD4-+- T cell subsets
dominate in the response to challenge with specific
antigens [5,6]. However, the factors which determine
the selective activation of these distinct immune path¬
ways have not been fully defined. There is evidence to
suggest that, in addition to the local cytokine environ¬
ment [7.8], the affinity of T cell antigen receptor (TcR)
[9.10], MHC class II and peptide interactions may
influence the functional phenotype of the CD4+ T cells
that are activated [11,12], with weak affinity interactions
and low antigen density favouring the induction ofTH-2
cells. When antigen is limiting or the TcR has a low
affinity for its ligand the interaction of accessory mol¬
ecules with their counter receptors on antigen presenting
cells (APC), such as CD4 with MHC class II molecules,
may increase the affinity of TcR for peptide/MHC class
II complexes. Therefore, activation of T cells with low
affinity TcR may depend more upon the accessory
function of CD4 mediating increased adhesion [13.14],
The role of CD4-f molecules on T cell effector function
extends beyond facilitating cell adhesion and contributes
to antigen recognition and T cell activation. Comodula-
tion of CD4 and TcR molecules on selected T cells with
anti-TcR antibodies or antigen implies that CD4 may be
a structural component of the antigen recognition com¬
plex on T cells [15,16]. The extracellular domains ofCD4
may serve to correct for variations in the flanking regions
of naturally processed peptides bound to MHC class II
molecules [17], Physical association of CD4 with the TcR
and consequent provision of tyrosine kinase activity by
the CD4 associated p56iac may be required for optimal
antigenic stimulation [18], Evidence that negative as well
as positive signals can be delivered through CD4 has
come from studies on the binding of the CD4 ligand,
HIV-gpl20 [19]. The administration of non-depleting
anti-CD4 antibodies together with antigen in mice
results in the induction of specific tolerance [reviewed
in ref. 20], demonstrating that the manipulation of CD4
may also result in the downregulation ofT cell responses.
Collectively these studies prompted us to investigate
the influence of CD4 molecules on antigen recognition,
cytokine production and the induction specific anergy by
CD4-i- human T cell clones respresentative of the TH-0.
TH-1 and TH-2 subsets. Our results demonstrate that
effects of anti-CD4 antibodies on antigen dependent T
cell responses are heterogeneous. They may either inhibit
or enhance proliferation, but fail to induce or to mod¬
ulate peptide-mediated T cell anergy. We observe that
IFN7 production is more susceptible than that of IL-4 to
the inhibitory effects of anti-CD4 antibodies. Further¬
more, anti-CD4 mediated downregulation of IFN7




Purified murine monoclonal IgG antibodies (ADP 372
(D4003), ADP 318 (Q4120) and ADP 302 (RFT4)
specific for different epitopes of human CD4 were
obtained from the MRC AIDS Directed Programme.
The anti-CD4 antibody L200 was the kind of gift of Dr
G. Fathman. Department of Immunology and Micro¬
biology, Stanford Medical Center. Palo Alto. CA. USA.
The anti-HLA class I antibody (W6/32) was used as a
control. The amount of antibody required to maximally
stain CD4+ T cell clones as assessed by FACS analysis
has been used as the initial starting concentration in the
functional assays and is termed 1 : 100 dilution.
The Der p II peptides spanning residues 28-40 and HA
peptide (255-270) were synthesized by standard solid
phase methods as previously described [21] on an
Applied Biosystem 431A synthesizer. Lyophilized
unfractionated extracts of Dermatophagoides pteronyssi-
nus (house dust mite; HDM) were generously provided
by Dr A. Wheeler. SmithKline and Beecham. UK.
Purified influenza virus haemaggiutinin (HA) from the
recombinant X31 virus was kindly provided by Dr J.
Skehel, NIMR, Mill Hill, London. UK.
Subjects and separation ofperipheral blood mononuclear
leucocytes
Both the HDM and HA reactive T cell clones used in this
study were isolated from the peripheral blood of dust
mite allergic individuals. Feeder cells required for the
maintenance and expansion of the T cell clones were
isolated from non-atopic control subjects. Atopic status
and house dustmite allergy were defined by positive skin-
prick tests of ^3 mm diameter weal to the standard
panel of common environmental aeroallergens in the
presence of a positive histamine and negative saline
control, together with the presence of HDM specific
serum IgE antibodies and clinical history.
Peripheral venous blood was collected in preservative
free heparin (CP Pharmaceuticals Ltd. Wrexham. UK).
Mononuclear cells (PBMC) were separated by densitv
gradient centrifugation on FicolL-Hypaque (Pharmacia.
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UK) and resuspended in complete medium (RPMI 1640
supplemented with 2mM l-giutamine. lOOIU/mL peni¬
cillin/streptomycin and 5% screened, heat inactivated
human A+ serum) and used in proliferation assays.
Isolation and characterization of T cell clones
The HDM reactive (Der p II) and HA reactive T cell
clones were isolated from HDM reactive individuals by
limiting dilution cloning [21,22]. Briefly, PBMC
(105/mL) were stimulated with an optimal concentra¬
tion of antigen (10/xg/mL) for 7 days in complete
medium. A long-term line was established by enriching
lymphoblasts on Ficoll-Paque (Pharmacia) in the pre¬
sence of irradiated autologous PBMC (5 x lO^/mL:
2500 Rads), antigen (10/ig/mL) and interleukin 2 (IL-
2, 5% v/v; Lymphocult T, Biotest Folex. Frankfurt.
Germany). Cells from the T cell line (0-3 cells/well)
were cloned by limiting dilution in complete medium
and plated in Microtest II plates together with irradiated
autologous PBMC, antigen and IL-2. After 7 days,
growing T cell clones were transferred to flat-bottom
96 well microtitre plates and then to 24 well plates. The T
cell clones were maintained with IL-2 every 7 days and
were used in experiments 7-8 days after the last addition
of antigen and APCs. The T cell clones AC1 and AC2
recognize residues 25-40 of the group II allergen (Der p
II) of HDM and the T cell clone, PF5, was reactive with
residues 255-270 of HA. All three T cell clones recognize
antigen in association with HLA-DRBl*l 101 class II
molecules.
Proliferation assays
T ceil clones (103/mL) were cultured with peptides
(Der p II, 3qg/mL: HA, 1 /ig/mL) in the presence of
irradiated autologous PBMC (1-25 x 106/mL; 2500
Rads) and increasing dilutions of antibody. After 48 h
the cultures were pulsed with tritiated methyl thymidine
([JH]-TdR; I qCi/well. [3H]-TdR: Amersham Interna¬
tional pic, Amersham. UK) and harvested 8-16 h later.
Proliferation as measured by [3H]-TdR incorporation
was determined by liquid scintillation spectroscopy. The
results are expressed as mean cpm for triplicate cultures
with sem< 25%.
Induction of T cell anergy
T cell clones (AC1 and PF5; 106/mL) were pretreated
with anti-CD4 antibody (L200 at 1: 100 dilution), anti-
MHC class I antibody (W6/32) or medium for 1 h at
37°C and then cultured in the presence of increasing
concentrations of peptide for 18 h as previously
described [23]. The T cells were then washed extensively
and restimulated with either an optimal concentration of
peptide in the presence of. APCs or IL-2 alone and
proliferation measured by the incorporation of 3[H]-
TdR.
Cytokine assays
T cell clones (103/mL) were stimulated with and without
peptides in the presence of irradiated autologous PBMC
(1-25 x 106/mL; 2500 Rads), either alone or together
with antibody. The supernatants from these cultures
were collected at 24 h for the determination of cytokine
levels. IFN-/ and IL-4 were measured in ELISA assays
(Eurogenetics, Teddington, UK).
Results
Modulation of antigen dependent T cell proliferation by
anti-CD4 antibodies of human T cell clones representative
of the TH-0, TH-I and TH-2 functional phenotypes
The functional characteristics of the human T cell clones
used in this study are summarized in Table I. The T cell
clones AC1 and AC2 both reactive with Der p II residues
25—1-0 and restricted by DRBPtlOl have the cytokine
profiles of the TH-0 and TH-2 functional phenotypes
respectively. PF5 reactive with influenza virus HA resi¬
dues 255-270 and restricted by DRB1*1101 secretes
IFN7 but undetectable levels of IL-4 and, therefore, is
designated in the TH-1 subset. The T cells were stimulated
Table 1. Functional characterisation of T ceil clones
AC1 AC2 PF5
TH-0/TH-1 /TH-2 TH0 TH2 TH1
MHC class II restriction DRBl'l 101 DRB1*1101 DRB1*1101
Antigen specificity Der p II. 25-40 Der p II. 25-40 HA. 255-270
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with specific antigen and APCs in the presence and
absence of anti-CD4 antibodies (Fig. 1 a-c). Antigen
mediated proliferation of the T cell clone AC1 was
inhibited in a dose dependent manner by the anti-CD4
antibodies 302, 318 and L200, although they differed in
potency (Fig. la). The control anti-HLA class I antibody
W632 had minimal inhibitory effects on the response of
AC1 to antigen. In the presence of the same panel of anti-
CD4 antibodies a similar pattern of inhibition of antigen
dependent proliferation was observed for T cells of AC2,
with L200 being the most effective antibody (Fig. lb).
Again no inhibition was induced by the anti-class I anti¬
body. In contrast, the anti-CD4 antibodies failed to inhibit
the response of the HA reactive T cells, PF5 to antigen
(Fig. lc). Indeed, the anti-CD4 antibody 318 enhanced the
antigen specific proliferation. The other antibodies had
neither inhibitory nor stimulatory effects on the response
of the PF5 T cells (Fig. lc). These results indicate hetero¬
geneity in the effects of anti-CD4 antibodies on antigen
mediated proliferation of different CD4+ T cells, which
may reflect the functional phenotype of the T cells or
variable affinities of the HDM and HA peptides for
binding to DRB1*1101 class II molecules.
Effect of anti-CD4 antibodies on cytokine production by
cloned TH-0, TH-1 and TH-2 cells
Supernatants were collected from T cell clones AC1,
AC2 and PF5 stimulated with specific antigen and
APCs in the presence of anti-CD4 antibodies and the
levels of IL-4 and IFN7 determined (Figs 2—4). In the
presence of the anti-CD4 antibodies (318 and L200) both
IL-4 and IFN7 production by the TH-0 cells (AC1) was
inhibited in a dose dependent manner (Figs 2a and c).
However, although able to inhibit antigen dependent
IFN7 production, the anti-CD4 antibody 302 (Fig. 2b)
failed to downregulate IL-4 secretion. No modulation of
either IL-4 or IFN7 production was observed in the
presence of the control antibody W632 (Fig. 2d). In the
presence of the panel of anti-CD4 antibodies IL-4
production by AC2 (TH-2) was inhibited by the anti¬
bodies 318 and L200 but not 302 or W6/32 (Fig. 3).
Fig. 1. Modulation of antigen dependent proliferation of
human TH-0, TH-1 and TH-2 cell clones by anti-CD4 anti¬
bodies. T cell clones were stimulated with specific peptide and
APCs (EBV-B cells) in the presence and absence of a panel of
anti-CD4 (302, •; 318, O; L200, □) and anti-HLA class I
(W632. ■) antibodies at different dilutions. 3[H]-TdR incor¬
poration was measured at 72 h. Results are expressed as mean
of triplicate cultures. In all experiments sem<25%. (a) AC1. (b)
AC2. (c) PF5.
IFN7 secretion by the influenza HA reactive TH-1
clone PF5 was reduced by the addition of the antibodies
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production was observed when 302 orW6/32 were added
to the cultures (Fig. 4).
The failure ofanti-CD4 antibodies to induce, enhance or
prevent the induction ofpeptide-mediated T cell anergy
In the presence of antigen, non-depleting anti-CD4
antibodies will induce specific tolerance in vivo [20].
Therefore, we investigated if signalling via CD4 alone
will induce or enhance peptide-mediated T cell anergy. T
cells of clones AC1 and PF5 were cultured with L200
alone or in the presence of increasing concentrations of
peptide and the response to rechallenge with peptide and
APCs or IL-2 determined. The proliferative responses of
control cultures of cells exposed to peptide alone or
peptide in the presence of W6/32 were compared (Fig.
5). Pretreatment of AC1 and PF5 with medium or
antibodies (anti-CD4 or anti-MHC class I) alone in the
absence of peptide failed to induce T cell anergy in that
the T cells still responded when restimulated with peptide
and APCs (Figs 5a and c). Furthermore, exposure of
AC1 to high doses of peptide resulted in the induction of
anergy that was neither enhanced nor inhibited by the
addition of anti-CD4 antibody (Fig. 5a). The TH-1 cells
(PF5) were also rendered anergic by high antigen con¬
centrations in a similar fashion, although the threshold
of peptide required to induce anergy was lower than that
observed for AC1 (Fig. 5c). Enhanced responsiveness to
IL-2, characteristic of anergic T cells, was observed in all
the groups of T cells (Figs 5b and d).
Discussion
In this study we have investigated the contribution of
CD4 molecules in antigen recognition and effector func¬
tion of human T cell clones representative of the TH-0.
TH-1 and TH-2 functional phenotypes. Previous studies
have reported that inhibition of the effector function of
CD4+ T cells with anti-CD4 antibodies correlates with
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Fig. 2. Effect of anti-CD4 antibodies on antigen mediated IL-4 and IFN7 production by cloned TH-0 ceils. T ceils (clone AC1) were
stimulated under the conditions described in the legend to Fig. 1. Supernatants were collected at 24 h and the levels of IL-4 (O) and
IFN7 (•) measured by ELISA. In the absence of antigen T cells cultured with APCs and antibody produced undetectable levels of
IL-4 or IFN-v.
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APCs [13,14], The avidity of the interaction appears to
be influenced by the orientation of the TcR thus deter¬
mining its capacity to associate with CD4 [24], Using
anti-CD4 antibodies specific for different epitopes on
CD4 we observed that the same pattern of inhibition of
antigen proliferation was induced in both clones of
DRB1*1101 restricted T cells specific for Der P II,
residues 25-40 [21], However, despite having the func¬
tional characteristics of either the TH-0 or TH-2 pheno-
types there was no apparent difference in their
dependency on CD4 accessory function. The loss of
antigen mediated proliferation may result from disrup¬
ting the function of CD4 as an adhesion molecule and
may occur by preventing the formation of complexes
between TcR. MHC class II and peptide. The ability of
CD4 to stabilize class JI molecules in dimeric form and
increase the density of MHC class II/peptide complexes
may be inhibited in the presence of the anti-CD4 anti¬
bodies. Alternatively, the inhibitory effects of the anti-
CD4 antibodies may arise from the delivery of a negative
signal directly to the T cells, since it has been reported
that crosslinking of CD4 molecules with specific mono¬
clonal antibodies before activation through TcR results
in the loss of T ceil responses [26]. Contrary to these
results we observed that pretreatment of the T cell clones
with the anti-CD4 antibodies had no inhibitory effects on
antigen recognition. The role of CD4 in signal transduc¬
tion is indicated by the enhancement of antigen induced
proliferation by the influenza HA reactive TH-1 cells
following the addition of the anti-CD4 antibodies. 318
and L200. Earlier studies have established that cross-
linking both CD4 and TcR/CD3 with antibodies may
induce synergistic proliferative responses [15.27] and one
explanation offered for this observation is that the anti-
CD4 antibodies are stabilizing the interaction between
CD4 and the TcR complex. Orientation of the different
chains of the TcR determines the association with CD4
[24].
The different effects of CD4 on antigen induced
proliferation by the TH-0, TH-1 and TH-2 clones
studied here prompted us to investigate the effect of the
modulation of CD4 on the cytokine response profiles.
The addition of anti-CD4 antibodies, 318 and L200. to
antigen stimulated cultures of the TH-1 cells inhibited
both IL-4 and IFNy production. However, the anti-CD4
antibody 302, although able to downregulate IFNy
syntheses failed to inhibit IL-4 production. Likewise,
Der p II dependent IL-4 production by the TH-2 cells
(AC2) was not inhibited by the antibody 302. whereas
the other anti-CD4 antibodies downregulated IL-4







Fig. 3. Effect of anti-CD4 antibodies on antigen mediated IL-4
production by cloned TH-2 cells. T cells (clone AC2) were
stimulated with anti-CD4 (302. •: 318. O: L200. □) and anti-
HLA class I (W6/32, ■) antibodies under the conditions
described in the legend to Fig. 1. Supernatants were collected
at 24 h and the levels of IL-4 measured by ELISA. In the
absence of antigen T cells cultured with APCs and antibody
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Fig. 4. Effect of anti-CD4 antibodies on antigen mediated IFN~.
production by cloned TH-1 cells. T cells (clone PF5) were
stimulated with anti-CD4 (302. •: 318. O: L200, □) and anti-
HLA class I (W6/32. ■) antibodies under the conditions
described in the legend to Fig. 1. Supernatants were collected
at 24 h and the levels of IFN7 measured by £LISA. In the
absence of antigen T cells cultured with APCs and antibody
produced 19 pg/mL of IFN7.
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response of the TH-1 clone (PF5), presumably by indu¬
cing IL-2 secretion, the antibodies L200 and 318 inhib¬
ited IFN-/ production. Our observations suggest that
certain anti-CD4 antibodies have variable effects on T
cell recognition and antigen dependent cytokine produc¬
tion by different CD4+ T cell subsets. In some instances
the effector functions determined by differences in the
biological activity of the cytokines they produce, such as
IL-4 and IFN7, can be dissociated by selectively regula¬
ting or inhibiting their synthesis. Depending on which
cytokines dominate the immune response they may
determine whether the immune response to antigen is
protective or pathogenic. For example, exposure of
atopic individuals to environmental allergens induces
TH-2 cells and the formation of allergen specific IgE.
while in non-atopic subjects. T cell responses of TH-1
phenotype generate no pathological changes [5,6]. There¬
fore. the ability to inhibit IL-4 production or promote
IFN7 synthesis through the action of anti-CD4 anti¬
bodies may result in reduced specific IgE levels and so
contribute to the treatment of allergic diseases. The anti-
CD4 antibodies may mediate their differential effects on
cytokine production by altering the affinity of the inter¬
action of the TcRs with MHC class II/peptide complexes
and subsequently changing the threshold of signalling via
the TcR [17,28]. Studies on murine CD4— T cell clones
have demonstrated that different dose thresholds are
required for distinct effector function [29]. It is possible
that similar changes in the threshold of signalling and
selective regulation of cytokine release by anti-CD4
0 0-05 5 50 0 0-05 5 50
Peptide pretreatment ipg/mL) Peptide pretreatment (pg/mL)
Fig. 5. Anti-CD4 antibodies fail to induce or prevent the induction ofmediated T cell anergy. Cloned T cells (AC1 and PF5) were
cultured in medium (O), anci-CD4 (L200, •) or anti-HLA class I (W6/32. G) antibodies alone or in the presence of increasing
concentrations of specific peptide. After overnight incubation the T ceils were restimulated with optimal concentrations of peptide
(Der p II or HA) in the presence of APCs (A. AC1: C, PF5) or IL-2 alone (B. AC1; D. PF5) and 3[H]-TdR measured.
1995 Blackwel! Science Ltd. Clinical and Experimental Allergy. 25. 839-847
846 J. R. Lamb et al.
antibodies may contribute to the mechanisms by which
'non-depeleting' anti-CD4 antibodies in the presence of
specific antigen are able to induce infectious intolerance
in vivo [20].
The exposure of human CD4+ T cells to supraoptimal
concentrations of peptide in the absence of appropriate
costimulatory signals results in the induction of T cell
anergy, which is characterized by the loss of antigen
dependent proliferation, phenotypic modulation and
cytokine dysreguiation [30]. Anti-CD4 antibodies, in
the presence of specific antigen, will induce tolerance in
vivo and this prompted us to examine the role of CD4 in
the induction of peptide-mediated anergy in human T
cells. We observed that crossiinking CD4 neither induced
anergy nor reduced the threshold of peptide required for
the state of anergy to be achieved in contrast to the
effects of HIV-gpl20 [19] and this may reflect the use of
different signalling pathways. In these experiments the
capacity of CD4 to modulate anergy was investigated
using fully differentiated T cells, however, naive CD4+ T
cell populations may be more susceptible to manipula¬
tion.
The relevance of our findings in relation to allergic
disease suggest that certain anti-CD4 antibodies can
induce selective regulation of cytokines and in some
cases have the ability to downregulate IL-4 production.
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An in vitro mode! of peptide-mediated
immunomodulation of the human T cell
response to Dermatophagoides spp
(house dust mite)
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Allergic sensitivity of Desmatophagoides spp (house dust mites) is mediated by specific IgE
antibody, the production of which requires the presence of CD4* helper T cells. Atiempts to
hyposensitize this response in allergic individuals have depended on the administration of
extracts of specific allergen. However, the ability of peptides derived from unrelated antigens to
inhibit specific immune responses offers an alternative approach to therapy. We have addressed
this question by examining the ability of a nonstimulatory peptide analogue derived from
influenza virus hemagglutinin to modulate T cell recognition of house dust mite. The peptide
inhibited the response of mite-specific CD4* T cell clones restricted by either the HLA-DRAB I
or DRAB3 gene products. Furthermore, mite-induced polyclonal T cell responses were
negatively modulated by the peptide, whereas recognition of common recall antigens remained
intact. The inhibitory effects were mediated at the level of the antigen-presenting cell, since no
inhibition of mitogen or anti-CD3 antibody-driven T cell proliferation was observed. In direct
binding assays, the peptide analogue bound to selected HLA-DR molecules expressed on the
membrane of antigen-presenting cells, with specificity predominantly for those class II proteins
capable of restricting house dust mite-allergen T cell recognition. (J ALLERGY CLIN IMMUNOL
1991:87:1120-7.)
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Inhibition of T cell response to HDM 1121
The importance of CD4~ T-lymphocytes in the
pathogenesis of allergic diseases is clearly established
with the synthesis of specific Ig£ and the differentia¬
tion and growth of effector ceils, such as mast cells
and eosinophils being dependent on CD4" T cells and
their products.1-6 The activation of CD4~ T cells is
dependent on antigen receptors on T ceils recognizing
peptidic fragments of foreign proteins in association
with self-gene products of the MHC expressed on the
surface membranes of antigen-presenting ceils.7"® It
has been proposed that the ability of MHC class E
molecules to bind only selected peptide fragments of
antigens in part determines immune responsiveness.10
The recent results of functional experiments and direct
binding assays suggest that gene products of specific
MHC class E molecules are capable of binding a large
number of different peptides, and, similarly, a single
peptide may bind to more than one MHC class U
protein.""16 Despite the apparent permissiveness in
binding, variation in class E MHC molecules may
regulate T cell recognition by influencing both peptide
binding and interaction with T cell receptors.7-®'16 The
preferential binding, and capacity of peptides to com¬
pete one with another for occupancy of the antigen-
combining site of MHC class E proteins'7"'® introduce
the potential of nonstimuiatory peptides as immuno-
reguiatory molecules in the treatment of allergic dis¬
eases. Clearly, if competitive inhibition were to have
a role in the regulation of allergic immune responses,
then specificity of the blocking peptide for the partic¬
ular allergen-associated MHC class E alleles would
be necessary.
The aim of this study was to investigate the ability
of a nonallergen-denved. nonstimuiatory peptide to
modulate the response of T cells from atopic individ¬
uals with the commonly observed allergy to HDMs
(.Dermaiophagoides sppl. Analysis of the MHC class
E restriction specificity has suggested that HLA-
DRAB3 gene products (DRw52b. the supertypic spec¬
ificity) were the major restriction elements, rather than
the classical HLA-DR specificities encoded by the
DRAB 1 genes.J0-21 A peptide analogue derived from
the natural sequence of the carboxyi terminus of the
HA-1 molecule of influenza HA (residues 307 to 319
with the naturally occurring tyrosine residue at posi¬
tion 309 substituted by serine) was demonstrated to
be able to bind to selected class E molecules and




Lyophilized extracts of D. farinae and D. pteronyssinus
were the generous gifts of Drs. H. Lawenstein and C. Schou
(ALK. Horshoim. Denmark) and Bencard (Brentford, Mid¬
Abbreviaiions used
MHC: Major histocompatibility complex ■
HA: Hemagglutinin
IL-2: Interieukin-2
HDM: House dust mite
PBMC: Peripheral blood mononuclear ceil
PH]TdR: Tritiated methylthymidine
dlesex, U.K.), respectively. A soluble extract of Mycobac¬
terium tuberculosis (MTSE)'was generously provided by
Dr. A. Rees tMedical Research Council Tuberculosis Unit.
Hammersmith Hospital. U.K.). The HA peptide analogue
(residues 307 to 319: serine at 309) and the keratin peptide
(residues 1 to 9) were synthesized with solid-phase
techniques- on an Applied Biosystems (Foster City, Calif.)
peptide synthesizer with Pam resins, iV-t-Boc-protected
amino acids, and commercially available reagents (Applied
Biosystems). The T cell mitogen PHA-P was purchased
from Sigma Chemical Co. (St. Louis, Mo.), and the murine
monoclonal anti-CD3 antibody (OKT3). purified from the
hvbridoma cell line, was purchased from the American Type
Culture Collection (Rockviile. Md.).
Preparation of lymphocytes and
donor characterization
PBMCs obtained from unmedicated atopic adults with
symptomatic HDM allergy (perennial rhinitis) were isolated
by centrirugation on a discontinuous gradient of Ficoil-
Paque (Pharmacia Ltd.. Milton Keynes. U.K.). All subjects
had positive skin prick tests to Dermaiophagoides spp. and
positive HDM RASTs. PBMCs were resuspended in com¬
plete medium. RPMI 1640 supplemented with A — or AB —
serum. 2 mmoi/L of L-glutamine. and 100 IU/ml of pen¬
icillin/streptomycin.
Isolation of antigen-reactive T cell clones
HDM-specific T cell clones were isolated as described
previously.23 Briefly, PBMCs (2.5 x lCP/ml) were sumu-
lated with an optimal concentration of D. farinae for 7 days
in complete medium. Lymphobiasts enriched on Ficoll-
Paque were maintained as a long-term line in the presence
of irradiated (2500 rad) autologous PBMCs. D. farinae. ana
IL-2 (10% vol/ vol; Lymphocult-T. Biotest Folex. Frankfurt.
Germany) and then cloned by limiting dilution from the T
cell line. For cloning, viable cells (0.3 cells per well) were
plated in Microtest II (Nuncion: Nunc. Roskilde, Denmark)
trays together with irradiated autologous PBMCs (5 x
HP/ml), D. farinae, and IL-2. After 7 days, growing clones
were transferred to flat-bottom. 96-well microtiter trays and.
subsequently, to 24-weil trays. At each transfer the clones
received filler cells, antigen, and IL-2. The clones were
maintained and expanded by the addition of IL-2 every 3
to 4 days and antigen together with filler cells every 7 days.
Before their use in proliferation assays, the T cell clones
were rested for 6 to 8 days after the last addition of filler
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FIG. 1. Inhibition of polvcionai T cell response of dust mite-
allergic individuals to specific allergen. PBMCs were stim-
uiatea with HDM in the presence (stippled bar) or aosence
(open bar) of the HA peptide analogue (residues 307-319
and S-309), both proteins being administered over a
concentration range. Proliferation as correlated with
[3H|TdR incorporation was measured at day 7, and in all
experiments. SEM for triplicate cultures was <25%. Re-
suits presented are the percentage proliferation as com¬
pared to the maximal HDM response expressed as 100%.
Murine fibroblasts transfected with HLA-D
region genes
The cloning of the DRlDwl. DR2Dw2B5. and DRw52b
genes and their cotranstection with the DRA gene into the
Ltk" fibroblast ceil line (DAP3) have been described else¬
where.34*" The transfected fibroblasts were the generous
gifts of Drs. R. Lecnier. J. Trowsaaie. and B. Mach.
Binding assays
Murine fibroblasts transfected with the HLA-D region
genes. DRw52b. DR1. and DR2Dw2B5 were examined for
their capacity to bind the HA analogue, as described else¬
where.3-21 After incubauon with peptide, containing long-
chain biotin at the amino terminus, over a concentrauon
range, the fibroblasts were then washed and stained with
fluorescein avidin D (Vector Laboratories. Buriingame.
Calif.). To amplify the signal a polyclonal antiavidin anti¬
body (Vector Laboratoriesi was added to the ceils before
additional incubauon with fluorescein avidin D. To control
for differential expression of HLA ciass II molecules on the
fibroblasts, ceils were incubated with a fluoresceinated mon-
omorphic anti-HLA-DR antibody (L243, Becton Dickinson.
Mountain View. Calif.).39 Stained cells were analyzed by
flow cytometry with a FACS anaivzer i Becton Dickinson».
Only viable ceils, identified by their ability to exclude pro-
pidium iodide, were analyzed.
cells and anugen. A number of T ceil clones specific for
D. farinae and other clones cross-reactive with D. farinae
and D. pteronyssinus were isolated, and the MHC ciass II
restriction specificities of these clones were mapped.:0-3:
Proliferation assays
Polyclonal responses. PBMCs <'2.5 x 103/ml) were cul¬
tured with soluble antigen in a total voiume of 200 p.i of
complete medium in 96-weil round-bottom piates. Peptides
were added at various concentrations to selected weils at
the initiation of cultures. After 6 days. 1 jjlCI of [3H]TdR
per weil (Amersham International. Amersham. U.K.J was
added to the cultures for 8 to 16 hours, and then the ceils
were harvested onto glass fiber filters. Proliferation as cor¬
related with [3H]TdR incorporation was measured by iiquid
scintillation spectroscopy. The results are expressed as mean
counts per minute for triplicate cultures with SEM < 25%
for all experiments with PBMCs. Ln those experiments in
which T cell clones were used, the SEM was <10%.
Monoclonal responses. Cloned T ceils (5 x lOVmi)
were cultured with soluble antigen in the presence of irra¬
diated autologous PBMCs (1.25 x KP/ml) in a total voi¬
ume of 200 |xi of complete medium in 96-weil round-bottom
piates. Peptides were added to selected weils as described
for polyclonal responses. After 60 hours of incubation.
[3H]TdR was added to the cultures for 8 to 16 hours and
then harvested as described for the polyclonal T ceil pro¬
liferation assays.
RESULTS
Peptide inhibition of polyclonal
T cell responses
Stimulation induced with D. pteronyssinus. Marked
proliferation was induced in all cases when PBMCs.
isolated from five atopic individuals with symptom¬
atic perennial rhinitis, were stimulated with D. pter¬
onyssinus at an optimal concentration (range. 3 to 12
fj.g.'mi). The magnitude of the response of these in¬
dividuals to HDM extracts ranged from 17 to 50 x
10J cpm with background responses of <1 x 103
cpm. The addition of the HA peptide analogue, with
the tyrosine at position 309 substituted by serine, to
the cultures resulted in marked inhibition of the pro¬
liferative response over a concentration range (0.5 to
100 fxg/mi) with maximal inhibition mediated by the
HA peptide at 50 to 100 pLg/mi. In the presence of
the HA peptide, the percentage proliferation, as com¬
pared to the maximal HDM response achieved, vanea
from 10% to 34% (Fig. 1). The inhibition indicated
in Fig. I is that mediated in the presence of maximal
stimulation by HDM extract. In contrast, coculture of
the keratm peptide and D. pteronyssinus over the same
concentration range faiied to decrease the observed
response (Fig. 2. A). The keratin peptide was added
as a control to all experiments, and in no instance was
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RG. 2. Modulation of polyclonal T-cell responses. A, HDM. B, M. tuberculosis. C, PHA. PBMCs
from HDM-ailergic individuals. B. S. (i) and M. R. (Hi. A, Stimulated with antigen D. pteronyssinus
(3 j&g /m I). B, Stimulated with M. tuberculosis 13 p-g/rnll. C. Stimulated with PHA (1 u.g / m I).
Stimulation was in the presence of the HA S-309 (O) or keratin (•) peptides over a concentration
range. Proliferation as correlated with PHlTdR incorporation was measured at day 7 and ex¬
pressed as counts per minute, being the mean of triplicate cultures. The SEM was <25% in all
experiments.
inhibition observed. Investigation of the kinetics re¬
vealed that preincubation with the HA peptide results
in minimal enhancement of inhibition. Addition of
HA 307-319, up to 24 hours after stimulation with
HDM extract, is able to mediate inhibition that is not
observed with the control keratin peptide (data not
presented). In all cases PBMCs failed to proliferate
to either of the peptides alone. Truncated analogues
of the HA peptide (309-318NHJ bind to class II mol¬
ecules with the same efficiency as the native HA pep-
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RG. 3. Peptide modulation of monoclonal T cell responses to insoiubiiized anti-C03 antibody
(i) and HDM (ii). A, Cloned T cells (DE9) were stimulated with insoluoiiized anti-C03 (12
M.g/ml) and IL-2 (10% voi/vol) (i) or D. pteronyssinus (3 (xg/ml) (ii) with accessory ceils in the
presence of HA (o) or keratin (•) peptides over a concentration range. Proliferation was deter¬
mined by (3H)TdR incorporation at 72 hours. B, inhibition of HDM-reactive T cell clones by the
HA peptide. Cloned T ceils DE47 (i), DE12 (ii), and DE9 (iii) were stimulated with increasing
concentrations of HDM in the presence (o) or absence (•) of the HA peptide at a fixed concen¬
tration (100 jxg/ml). The SEM was <10% in these experiments.
ICQ
tide.;s thus indicating that the keratin peptide, al¬
though it is shorter, provides an appropriate control
to assess both biologic function and possible toxicity
of residual by-products of peptide synthesis.
Stimulation induced with M. tuberculosis soluble
extract. Polyclonal T cell proliferation observed in re¬
sponse to stimulation withM. tuberculosis soluble ex¬
tract. MTSE (3 (jLg/mi), was only minimally inhibited
by the HA analogue. The maximal inhibitory effect
obtained was only 25% (B. S.) (Fig. 2. A) and 40%
(M. R.) (Fig. 2. A) at 100 (eg/ml. with 13% (B. S.)
and 28% (M. R.) inhibition at 10 p.g/mi. No inhi¬
bition of the antimycobacterial T ceil response was
observed in the presence of the control keratin peotide
(Fig. 2. B).
PHA- and anti-CD3-induced activation. PHA at a
concentration of 1 p.g/mi induced marked prolifera¬
tion in each subject (Fig. 2. C.i and ii). No inhibitory
effect was observed with the addition of either pep¬
tide. Similarly, both peptides failed to inhibit the pro¬
liferative response of T ceils stimulated directly with
immobilized anti-CD3 antibody ana IL-2 that mimics
the recognition of peptide/MHC class II complexes
(Fig. 3. A.i).
Peptide inhibition of monoclonal
T cell responses
Cloned T ceils (DE9: cross-reactive for both
D. pteronyssinus and D. farinae. restricted by prod¬
ucts of the B1 gene locus. DRwl2. and degenerate
in its restriction specificity for DR2 subtypes and
DR8)20-:l proliferated markedly to D. pteronyssinus
(3 (xg/mll presented by autologous irradiated PBMCs
as accessory ceils. The addition of the HA analogue
resulted in marked inhibition of the proliferative re¬
sponse in a dose-dependent manner, with 60% inhi-
volume 37
number 6
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biuon at 100 tig/ml. In contrast, coculture with the
keratin peptide failed to inhibit the HDM-inauced pro¬
liferation (Fig. 3. A.ii).
D. farmae-specihc T cell clones (DE12 and DE47)
restricted by the DRAB3 gene product. DRw52b.:0,2'
and T cell clone DE9 were stimulated with increas¬
ing concentrations of stimulating antigen (D. farinae)
in the presence of autologous irradiated PBMCs as a
source of antigen-presenting ceils. To these cultures,
the HA analogue was added at a fixed concentration
(100 |j.g/ml). and T cell proliferation was determined.
The HA peptide was able to compete with HDM for
presentation to the cloned T cells and effectively in¬
hibited the proliferation (Fig. 3, B.i to Hi). However,
increasing the concentration of HDM in the assays
was associated with a decrease in the inhibition me¬
diated by the HA peptide in each case. In contrast,
in similar experiments, the HA analogue failed to in¬
hibit the proliferative response of a panel of ragweed-
specific T cell clones (Amb a reactive; DR5 re¬
stricted) stimulated by their native ligands. (Garman
R. O'Hehir R. Lamb J. Unpublished results.)
Binding of the HA peptide to
antigen-presenting ceils expressing DRw52b
HLA class II molecules
To examine the binding of the HA peptide to
DRw52b in isolation from other HLA class II mole¬
cules. the appropriate genes'were transfected in mu¬
rine fibroblasts. Murine fibroblasts transfected with
the DRw52b gene were able to bind the HA peptide
in a dose-dependent manner in contrast to the control
fibroblasts expressing DR1 or the untransfected ceil
line (DAP3). as determined by the level of fluores¬
cence (Fig. 4). Similarly, the HA peptide was able to
bind in a dose-dependent manner to murine fibroblasts
transfected with DR2Dw2B5 genes, which were func¬
tionally able to present HDM to clone DE9.:i
DISCUSSION
The realization that CD4* T cells play a critical
role in allergic responses allows the reassessment and
development of novel therapeutic approaches. The
practice of hyposensitization has been widely used,
but the results have been variable30"32 and the immu¬
nologic mechanisms remain ill denned. Potentially,
the capacity of nonallergen components to compete
with allergenic peptides themseives for occupancy of
the anugen-combining site of MHC ciass II moiecules
could prevent the activation of allergen-specific T cells
and the subsequent induction of Ig£ synthesis. The
observation that a nonstimuiatory peptide analogue of
influenza HA (residues 307-319, with the tyrosine at
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FIG. 4. Binding of the HA peDtiae to DRw52b HLA class II
molecules expressed on the surface of murine fibroblasts.
Murine fibroblasts exDressing DRw52b (■> or DR1 (□) were
incubated with biotinylatea peptide, stained, ana analyzed
by flow cytometry. Backgrounas as determined bv incu¬
bation of the peptide with untransfected fibroblasts were
subtracted. Results are expressed as the percentage of
peptide bound relative to the binding of the anti-HLA-DR
antiboay (L243) to normalize for differential HLA ciass II
expression.
to murine fibroblasts expressing the DRAB3 gene
product, DRw52b. prompted us to investigate the po-
tennal of this peptide to inhibit recognition of specific
antigen by immune T cells isolated from the peripheral
blood of symptomatic HDM-allergic individuals. For
the management of specific allergic responses by ma¬
nipulation of the immune system, consideration of
antigen and HLA-restriction specificity of T cell rec¬
ognition is necessary. In contrast to the serologic re¬
sponse that is predominantly cross-reactive.!3 :"i T cell
recognition of dust mite is also directed toward com¬
ponents of either of the two main species of HDM
(D. pteronyssinus and D. farinae)P The HA peptide
inhibits both polyclonal T cell responses to HDM and
that of individual T cell clones of different specific¬
ities. suggesting that the competing peptide prevents
activation of most dust mite-reactive T cells. How¬
ever. the observation of only partial inhibition of the
antimvcobactenai and anttragweed T cell responses
demonstrates that there is a certain degree of speci¬
ficity and that overall T cell responsiveness is not
ablated. The HDM and mycobacterial T cell responses
could be restricted by the same MHC class II mole¬
cules but with most mycobacterial epitopes binding
at higher affinity, such that the S-309 peptide was
unable to compete. Alternatively, only a minor com¬
ponent of the T cell responses to HDM and myco¬
bacteria might have overlapping restriction specifici-
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ties. The failure to block either the PHA or anti-CD3
antibody-induced proliferation, acting directly on T
cells via CD2 and T cell-specific antigen receptor,
respectively, suggests that antigen competition for
MHC class II binding is the mechanism involved.
The apparently high concentration of the HA pep¬
tide required to inhibit HDM-induced proliferation
may be a function of antigen processing in that the
peptide fails to associate with the class II molecules
as efficiently as the HDM extract. As a result the
peptide may be competing for occupancy of the
antigen-combining site of the appropriate class E mol¬
ecules expressed only on the cell membrane and not
in the intracellular compartment of the antigen-
presenting cells. However, caution must be used in
extrapolating from these in vitro studies on the po¬
tential efficacy of peptide inhibition in vivo.
Nevertheless, pepririe engineering and examination
of different routes of drug delivery may enhance the
immunomodulatory effects. Additionally, the ability
to inhibit the proliferative response of T cell clones
indicates that the induction of additional regulatory T
cells-12-33 does not need to be a prerequisite for hy¬
posensitization. Although the administration of com¬
ponents of HDM may appear to be the most appro¬
priate means of achieving dust mite hyposensitiza¬
tion.3' the use of nonstimulatorv peptides, such as the
derivative of the naturally occurring influenza HA. as
we have described here, minimizes the risk of trig¬
gering an allergic response and therefore may prove
to be the preferable therapeutic approach.
Examination of the genetic restriction of polyclonal
and monoclonal T cell responses to HDM has revealed
that products of HLA-DRAB3 class E genes (DRw52)
function as a dominant restriction element. The
DRw52 class E molecules, which are associated with
the HLA-DR 3, 5, 6. and 3 alleles, may contribute
to the high frequency of dust mite allergy. However,
the polygenic nature of allergic responses36 suggests
that specific responsiveness to HDM may not be reg¬
ulated by the DRB3 gene products alone but involves
other genes, such as the "atopy gene" recently mapped
to chromosome 1 lq.37 Interestingly, the HA peptide
was able to bind to DRw52b expressed on the surface
of accessory ceils and to inhibit the antigen-dependent
response of cloned HDM-specific T cells with that
restriction specificity. A minor component of the
T cell repertoire reactive with HDM appears to
be restricted by DRAB1 gene products and. in
some cases, this has been mapped to the locus of
DRwl2.:o"21 Clone DE9 is restricted by DRwl2 and
degenerate on accessory cells expressing DR2Dw2B5.
DR2Dw21Bl. and DR8. These HLA-DR molecules
have identity at positions 70 and 71 in the third vari¬
able region of the (3-1 domain that forms the a-helicai
wail of the antigen-combining site of class E histo¬
compatibility antigens.33 This suggests that residues
70 and 71 are able to regulate T ceil antigen recog-
nirion independent of those polymorphic residues
forming the floor of the antigen-combining site."
Binding studies with murine fibroblasts expressing
DR2Dw2B5 molecules demonstrated that the HA an¬
alogue was able to bind to this HLA-DR molecule
and accounted for the ability of the peptide to compete
for recognition of HDM by this clone of T ceils. Ad¬
ditional binding studies on a panel of Epstein-Barr
virus-transformed B ceil lines have compared binding
of the native HA peptide (tyrosine at 309) and the
monosubstituted analogue with serine at position 309.
The results of these experiments demonstrated a very
restricted binding of the S-309 HA analogue as com¬
pared with the highly permissive binding of the native
HA peptide (Y-309).38 Interestingly, most B' cell
lines that bound HA S-309 expressed both B1 and B3
gene products. Further analysis with murine fibro¬
blasts confirmed the high binding to DRw52b and
DR2Dw2B5, consistent with the ability of the peptide
to compete with HDM recognition in the polyclonal
and monoclonal T ceil responses.
As precedent for the use of a nonstimuiatory peptide
to regulate immune responsiveness. Adorini et al.18
demonstrated that a self-peptide derived from murine
lvsozyme. and differing by only three ammo acid res¬
idues from hen egg white lysozyme. was able to in¬
hibit presentation of hen egg white lysozyme in vivo
in high-responder strains. Competitive inhibition with
"nondisease-related" peptides has also been demon¬
strated to prevent the development of experimental
allergic encephalomyelitis.40 An approach such as this
may be of clinical benefit in the treatment of localized
allergic disease, such as perennial rhinitis. The im¬
mune responsiveness of atopic individuals to allergen
is clearly an aberrant response, and a therapeutic reg¬
imen that down regulated the specific reactivity would
be beneficial.
We thank Dr. B. Mach for helpful scientific discussions.
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Brief communications
T-ceil receptor peptides that inhibit the T-ceil
response to allergen induce transforming
growth factor-^ production
Catherine M. Hawrylowicz, PhD," Elizabeth R. Jarman, PhD,a
Laura Guida, PhO,a Robyn E. O'Henir, MD, PhD,a and
Jonathan R. Lamb, PhD" London. England
Abbreviations used
HDM: House dust mite
IFN-v: Interferon-y
MTSE: Mycobactenum tuberculosis soluble ex¬
tract
PBMCs: Peripheral blood mononuclear cells
TcR: T-cell receptor
TGF-3,: Transforming growth fac:or-j3.
V(3: Variable region of the |3 chain of the
T-ee!l receptor
Recent findings indicate restricted usage of T-
ceil receptor (TcR) (3 chain variable region 3
fV(33) gene elements in the human polyclonal
T-cell response to the allergens of house dust mite
(HDM).'-2 Furthermore, we have reported that a
peptide analog of TcR-V(33 CDR2 specifically
inhibits the polyclonal proliferative response of
human V(33—T cells to unfractionated Dennato-
phagoides pteronyssinus extract.2 Although the
mechanism of inhibition remains to be defined,
there is increasing evidence that immunosuppres¬
sive cytokines may piav an important role in the
downregulation of immune responsiveness in a
number of experimental systems.-'"5 In this study
we reveal that the V(33-CDR2 peptide induces the
production of the inhibitory cytokine transforming
growth factor-'p, (TGF-(3t) but that no IL-4. IL-tO.
or interferon-v (IFN-y) activity was detectable in
the same culture supernatants.
METHODS
Separation of peripheral blood mononuclear ceils
(PBMCs) from healthy adults by Ficoil-Hypaque density
centrifugation and CD4~ and CDS" T-cell depletion
protocols (routinely <3"o contamination) has recently
been described.2 PBMCs (5 -< 10") were cultured in 1 ml
of supplemented RPMI-1640 media2 (Gi'oco. Paisley.
Scotland) and 5% AB" human serum with 10 p.g'mi
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Mycobactenum tuberculosis soluble extract (MTSE).2 25
Ag/ml HDM extract.2 25 to 100 p.g/mi VJ33-CDR2
peptide (GLGLRLIYFSYDVKMKEKGDI), V36.7a-
CDR2 peptide (SPLGSKDPASNG), murine V(3S-
CDR2 peptide (IDGKETSDAVYSYHIL),2 or 10 jig/ml
phytohemaggluuntn plus 10 ng/mi pnorbol mvristate
(PHA/PMA: Sigma Chemical Co.. St. Louis. Mo.). Su¬
pernatants from these cultures were harvested after 5
days and frozen at -20° C until they were tested for
cytokine activity as described below.
IL-4 and IFN-y activity were measured with ELISAs
(Eurogenetics. Teddington. U.K.). IL-10was measured
by ELISA with antibodies kindly provided by Dr. Anne
O'Garra (DNAX. Palo Alto. Calif.). The VlvlLu bioas-
sav was used to measure TGF-J, activity." Latent
TGF-jS, was converted to the active form by reducing
the pH to less than 3.0 for 30 minutes at room temper¬
ature. TGF-0, activity was inversely proportional to
MvlLu ceil growth, as determined by tritiated thymidine
incorporation.2 when tests were performed in replicates
of 3 to 6 wells, with standard deviations routinely iess
than 20%.
RESULTS
Supernatants harvested from PBMCs cultured
with 25 to 100 ixg/ml Vp53-CDRE peptide were
tested in the MviLu growth inhibition assay for
TGF-3, bioactivitv. The V(33-CDR2 peptide in¬
duced a dose-dependent production of active
707
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FIG. 1. Induction of TGF-0, activity by TcR peptides. Unfractionated human PBMCs (A-DI or
CD4- and CD8-depieted PBMCs IDI were cultured at 5 x 106 cells/ml in medium, with 10 |j.g/ml
PHA plus 10 ng/ml PMA, 10 ug/ml MTSE, or tne indicated concentrations (25 to 100 ug/ml: 50
ug/ml in D) of TcR peptides for 5 days. Culture supernatants were then harvested and assayed
for TGF-0, bioactivity as described in Methods. Data are presented in A as mean counts per
minute r standard deviation of replicate cultures and B, C, and D as units per milliliter of TGF-j3,
activity as extrapolated from a standard curve obtained with recombinant human TGF-0,. A and
B represent data from the same experiment.
TGF-3,, with levels comparable to those induced
by PHA plus PMA, a potent stimulus of TGF-p,
production, but more than those induced by anti¬
gen (Fig. 1, A and B). Comparable results were
observed in all nine individuals tested (mean —
SD): TGF-P, in medium, 0.31 ± 0.24 U/mi; PHA/
PMA. 1.52 r 0.85 U/mi; TcR-V33 CDR2 peptide.
1.43 = 0.79 U/ml; and HDM. 0.585 = 0.53 U/ml. A
second CDR2 peptide derived from the human
Vp6.7a gene element induced lower but detectable
levels of TGF-P, in rwo individuals tested (Fig. 1,
C. and data not shown). This was particularly
interesting because Vf36.7a-TcR usage was de¬
tected. albeit at a lower level than TcR-Vp3, in a
panel of HDM-specinc T-cell clones.1 A control
murine CDR2 peptide, derived from murine TcR-
Vp8. failed to stimulate TGF-P, production (Fig.
1, C).
To demonstrate that the TGF-P, bioactivity
detected in our cultures was directly synthesized
after peptide stimulation of PBMCs and not
caused by serum contaminants, cells were cultured
for 24 hours with various stimuli in serum contain¬
ing medium, washed extensively, and then recui-
tured in the absence of serum for an additional 3
days. Serum-free supernatants were harvested and
assayed for active versus total (latent plus active)
TGF-p, content after in vitro conversion of latent
TGF-P, by acid treatment. Supernatants from
PBMCs cultured in medium alone or with Vp3-
CDR2 peptide contained less than 0.3 and 2.4
active total U/ml TGF-P, compared with 1.4 and
13 U/ml TGF-P,, respectively.
Cell depletion studies previously suggested that
CD8- T cells play a central role in mediating
CDR2 peptide inhibition of the T-cell response to
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HDM allergens.2 The induction of active TGF-p,
in unfractionated. CD^-depleted. and CD8-de-
pleted PBtvlCs was therefore compared. As shown
in F:g. 1. D. a representative experiment of four
performed, high levels of TGF-p, bioactivity were
detectable in all three groups after PHA/PMA
stimulation. In contrast. Vp3-CDR2 peptide in¬
duced TGF-p, production in unfractionated and
CD4-depleted. but not in CD8-depleted. PBMC
cultures, suggesting that the CD8" T-cell fraction
is the major cell type responding to this TcR
peptide. When IL-10 levels were measured in the
same supernatants. only PHA/PMA stimulation
resulted in marked cytokine production, as mea¬
sured by ELISA. Furthermore, induction of IL-10
by PHA/PMA was readily detected in unfraction¬
ated and CD8-depieted (6.7 and 4.1 U/ml respec¬
tively), but not CD4-depleted cultures (0.6 U/ml:
medium control. HDM. or CDR2 peptide for ail
groups <1.0 U/ml).
The Vp3-CDR2 peptide preparation also failed
to induce IFN-y (/; = 6: medium. 3.8 ~ 4.5:
PHA/PMA. 329 r 47.8: CDR2. 2.8 = 2.8: HDM.
8.2 ~ 9.5: MTSE [n = 4), 247.5 r 129 pg/mi) or
IL-4 (medium. HDM. or CDR2 peptide <6 pg/mi:
PHA/PMA. 40 pa/mi) production as measured by
specific EL1SA. 1L-2 activiiy, measured in the
CTLL growth assay, was also not detected in
24-hour culture supernatants of ceils cultured in
medium or peptide, but was found in the control
HDM and PHA/PMA supernatants (data not
shown).
DISCUSSION
In this report we demonstrate that peptides
derived from the human TcR-VS3 CDR2 region
induce production of active TGF-p, by PBMCs in
culture. IL-10. IFN-v, IL-4. or IL-2 activity in the
same cultures was below the limits of detection.
Strong induction of all cytokines was observed
after stimulation with PHA/PMA. Furthermore,
depletion of CD8"~ T cells resulted in loss of
TGF-P, production, suggesting that CD8" T ceils
were responsible for TGF-p, production after TcR
peptide stimulation. Similarly, inhibition of the
proliferative response of human PBMCs to HDM
allergens by Vp3-CDR2 peptide required the
presence of CD8 T ceils. Our findings suggest
that this inhibition may. in part, be mediated
through the induction of immunosuppressive
cytokines, such as TGF-p,. Nevertheless, neu¬
tralizing anti-TGF-p, antibody failed to reverse
CDR2 peptide-mediated inhibition of the HDM
response. This observation is not surprising,
given the likely requirement for close interaction
of two different ceil types, in this case the
putative CDS" regulatory T ceils with CD4".
TcR-Vg3~ HDM-reactive cells, for the conver¬
sion of latent to active TGF-P, activity as pro¬
posed in other experimental systems." If this is
so. it is unlikely that 'free'' cytokine would be
available for antibody neutralization.
TGF-p, acts directly on T cells by inhibiting IL-L
and IL-2 receptor expression and cytokine produc¬
tion. as well as indirecilv by inhibiting T-ceil acti¬
vation by modulation of antigen-presenting ceil
function.2 In addition. TGF-p, inhibits the switch
to germline s transcription and Ig£ production,
while selectively inducing a switch to a. chain and
IgA transcription. A number of inhibitory media¬
tors induce production of TGF-p,, including evcio-
sponne.5 the synthetic glucocorticoid dexametha-
sone/ and. most recently in this report. TcR
peptides. These observations have led to growing
recognition of an important role for this immuno¬
suppressive cytokine in the modulation of allergic
and other immune phenomena.
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Altered T Cell Ligands Derived from a Major House Dust Mite
Allergen Enhance IFN-y but Not IL-4 Production by Human
CD4+ T Cells1
Daphne C. Tsitoura,* Adrienne Verhoer,* Colin M. Gelder,* Robvn E. O'Hehir/ and
Jonathan R. Lamb2*
Changes in the affinity of the interaction between T cell Ag receptors and their iigands can moduiate selected T cell effector
functions. Since both allergen-specific Th2 and ThO cells are present in the peripheral CD4^ T cell pool of atopic individuals,
the potential to inhibit cytokine production by Th2 cells and promote Thl-type cytokines from ThO ceils mav contribute to the
down-regulation of allergic inflammation. The aim of this study was to investigate the effects of peptide analogues of a dominant
T ceil epitope of the group II allergen derived from house dust mite, residues 28 to 40, on proliferation and cytokine production
by human Th2 and ThO ceils. From both functional competition and proliferation assays, using analogues substituted with
alanine or charged amino acids, the influence of different positions in p28-40 on TCR recognition and/or MHC class II binding
was determined. For the specific ThO ceils, generally those analogues that lead to a reduction in proliferation also decreased
both IL-4 and IFN-y production. However, the p28-40 analogues with alanine residues at positions 34 and 36 altered the
IFN-y:lL-4 ratio by selectively enhancing IFN-y secretion. In the case of Th2 cells, stimulation with the peptide analogues
induced different patterns of effector function- Selected analogues were capable of inducing IL-4 production in the absence of
proliferation, whereas in response to other peptide variants of p28—*0, both IL-4 production and proliferation were inhibited.
The Journal of Immunology, 1996, 157: 2160-2165.
The qualitative nature of allergen-specific immune re¬sponses in sensitized individuals, based on the analysis ofperipheral T ceils (1-3) and clinical biopsies (4), suggests
that both Th2 and ThO ceils contribute to the functional phenotype
of the peripheral CD4" T cell repertoire (5). The functional ac¬
tivity of these T cell subsets is characterized by their cytokine
response profiles, with Th2 ceils producing IL-4. IL-5. IL-10. and
IL-13. and ThO ceils synthesizing IL-2. IFN-y, and TGF-/3 in ad¬
dition to Th2 cytokines (6-9). The induction of ailergen-specific
IgE requires the presence of Th2-type cytokines, and it is in pan
the balance between the agonist and antagonist effects of IL-4 and
IFN-y that reguiates IgE synthesis (10). Therefore, the potential to
inhibit IL-4 production and/or promote IFN-y secretion may con¬
tribute in the long term to the down-reguiauon of IgE and be of
clinical benefit to individuals with atopic allergy.
In the presence of cosumulatory signals, recognition of peptide
fragments of allergen bound to MHC class II molecules by TCR is
required for the activauon of all CD4~ T cell subsets (11. 12).
However, there is evidence indicating that altering the affinity of
the interactions between TCRs and their cognate ligands can lead
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to the selective activation of T ceil effector functions (13-18). This
is illustrated by the finding that murine Thl cells, when stimulated
with an altered T ceil ligand. failed to produce cytokines or pro¬
liferate. yet retained cytolytic activity and up-reguiated their IL-2
receptors (13). Furthermore, stimulation of murine Th2 ceils with
analogues of an immunogenic pepude in which a secondary TCR
contact residue had been altered by conservative ammo acid sub¬
stitutions was sufficient to induce IL-4 production and provide B
ceil help, but not clonal expansion (14). Peptide analogues with
partial agonist activity have been reported that are capable, in the
present of live APC. of inducing anergy in both Thl and Th2 ceils.
These cells fail to proliferate when restimuiated with their natural
ligand. although in the case of Th2 ceils, their ability to produce
IL-4 is retained (15. 16). Moreover, observations made in vivo in
mice revealed that structural differences in antigenic peptides or
class II molecules of different MHC hapiotypes can influence the
development of Thi or Th2 responses (17). In particular, it ap¬
peared that high affinity MHC/pepnae interactions with the TCR
favored the induction of Thl responses, while interactions of low
affinity resulted in the activauon of Th2 ceils. In a recent report it
has been demonstrated that sumuiauon of T cells in vitro with
an altered peptide ligand derived from the mveiin proteolipid
protein induces Th2 and ThO ceils, which, when adoptively
transferred to mice, confer protection from experimental auto¬
immune encephalomyelitis (19).
The aim of the experiments reported here was to determine
whether peptide analogues of a major human T cell epitope of the
group II allergen of house dust mite (HDM)-5 Der p II (20). resi¬
dues 28 to 40. with single amino substitutions introduced at each
position can modulate T ceil proliferation and cytokine producuon
1 Abbreviations usea in this oaoer: HDM. house oust mite: Der o ll. tne grouo II
allergen or Dermatopnagoiaes pteronvssinus: iJH|dTha. trmatea tnvrmatne.
Copyright © 1996 bv The American Association or Immunoiogists 0022-1 767/96/S02.00
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Table i. Ammo acid seouence or wiid type and analogues or
P28-40
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The Der p II peptides, residues 81 to 96 (VKGQQYDIKYTWNVPK) and
28 to 40 (IIHRGKPFQLEAV). and analogues of p28-40 were synthesized
on a Multipeptide Synthesis block BT7400 (Cambridge Research Bio-
cnemicais. Noithwich. U.K.) using 4-(2'.4'-dimethoxypnenyl F-moc ami-
nomethvDphenoxy resins (Novasyn Chemicals Ltd.. Nottingham. U.K.) as
previously described (21). Couplings were performed using F-moc side
chain protected pentahuoropnenyi or oxo-oenzoteiazine amino acid esters.
Full-length peptides were cieaved from the resin and deblocked by treat¬
ment with TFA/thioanisoie/ethanedithiol (94/5/2.5. v/v/vi for 1 h and then
precipitated and washed twice with ether. The precipitates were dissolved
in 10% formic acid (v/v) and freeze-<ined for 48 h. Each peptide produced
a singie peak by reverse phase HPLC. The pcpude analogues used in this
study are iisted in Table I.
Isolation of Der p ll-reactive, ORBTil 01 -restricted, cloned
human ThO and Th2 cells
Cloned T cells of AC1 (ThO) and AC2 (Th2) were isolated from a HDM
atopic individual (DRB1-0701. DRBI * 1101: DQ2. DQ7 (3): DPB 1*0101/
0402) by iimiung dilution cloning from a long term T ceil line as described
previously (20). The T cell clones were maintained in RPMI 1640 medium
supplemented with 2 mM L-giutamme. 100 IU/ml penicillin/streptomycin
(Life Technoiogies. Paisiey. Scotland), and 5% inactivated human A" se¬
rum (National Blood Transfusion Service. Edgware. U.K.) by stimulation
with the p28-40 pepude at optimal concentrauons and irradiated nisto-
compatibie PBMC (5 x 105/ml: 3000 rad) as a source of APCs together
with IL-2 (10%. v/v: Lympnocult T. Biotest Folex. Frankfurt. Germany). In
ail experiments. T cell clones were rested for 7 to 8 days after the last
addition of Ag and APCs.
T cell proliferation assays
Cloned T ceils (2 x 10"7well) were cultured in flat-bottom 96-weil micro¬
liter trays (Nunc. Life Technologies) with native pepude or analogues of
p28—U) (3 and 30 jAg/mi) in the presence of APCs. Mitomycin C-treated
murine fibroblasts expressing HLA-DRB1"! 101 (2 X 10* cells/well) were
used for Ag presentation. Cultures were puised with tnuated thymidine (1
^tCi/weil: ('H]dThd: Amersnam International. Ayiesbury. U.K.) after 48 h
and harvested 8 to 16 h later. Proliferation was determined by (JHldThd
incorporation by iiquid scintiliauon spectroscopy. The results are expressed
as mean counts per minute for tnpiicate cultures, with an SEM < 20%.
Cellular competition assays
The binding or native p2S-40 pepude and analogues to DRB1*1101 was
assessed by their capacity to innibit tne proiiferauon of a DRB 1*1101-
restncted T ceil clone <AC29) reacuve with p85-97 (20). Peptide ana¬
logues of p28-40 (50 M.g/mi) togetner with the pepude p81—96 (5 jig/mi)
were added to mitomycin C-treated murine fibroblasts expressing
DRB 1*1101. To these cuitures T cells of clone AC29 were added, and
proliferation was measured by (3H|dThd incorporation. AC29 ceils were
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isolated and expanded as described above. The results are expressed as the
percentage of inhibition of AC29 proliferation reiauve to that induced by
the native p28-40 peptide.
Measurement of IFN-y and IL-4
Supernatants were collected at 48 h from T cells sumuiated with peptide or
cultured in medium alone. Triplicate wells were pooled, and IFN-y and
DL-4 were measured by ELISA kits as described previously (22).
Results
Effect of stimulation with p28-40 peptide analogues on Ag
recognition by specific T cell clones representative of the
ThO and Th2 functional phenotypes
The T ceil clones AC1 and AC2. both of which are reactive with
residues 28-40 of Der p H and restricted by HLA-DRB1*1101.
exhibit the cytokine profiles of ThO and Th2 ceils, respectively (20,
23). Initially, AC1 and AC2 T ceils were stimulated with pepude
analogues of p28-40 synthesized with alanine substituted sequen¬
tially at each position (Table I), and the proliferative responses
were determined (Fig. 1, A and B). The anugenicitv of the ana¬
logues with subsutuuons at positions 31. 32. and 33 was markedly
reduced compared with that of the native peptide for both T ceil
clones, although minor differences in the pattern of proliferation in
response to these analogues were observed. For example, the re¬
sponse of AC1 T cells was more susceptible to the alanine sub-
sutuuon at position 31, whereas A32 had a greater inhibitory effect
on T ceil recognition by AC2 T cells. The patterns of responsive¬
ness and effector function were not differenuaily affected by van-
auons in the concentrauons of pepudes (data not shown). The pres¬
ence at alanine at other positions in p28-40 had minimal or no
effect on the proliferauve* responses of either of the T cell clones.
To further examine the relative importance of different residues
in p28 -40 on T cell recognition, in particular those at positions 31.
32, and 33. peptides with charged amino acids were synthesized
(24). Arginine (R) occurs at position 31 in the nauve pepude. but
when replaced with either a conservative (K31) or a radical (E31)
substituuon. a reduction in the proliferative response of both AC1
(Fig. 1C) and AC2 (Fig. ID) was observed. Similarly, both T cell
clones responded weakly to the peptide analogue in which glycine
at position 32 had been replaced with lysine (K32). In contrast,
although AC2 (Fig. ID) failed to recognize the analogue E32. the
response of AC1 was oniv parually inhibited (Fig. 1C). The con-
servauve substitution of R33 for K33 induced proliferation similar
to that of the nauve peptide, whereas E33 was only weakly anu-
genic for both T cell clones. With the exception of E30, the mtro-
ducuon of charged residues at posiuons 30. 34. and 35 markedly
reduced T cell proliferation.
The modulatory effect of the analogues on T cell recognition
may occur as the result of altering either the binding of the pepude
to HLA-DRB1* 1101 or the affinity of the pepude-TCR interaction.
To test the first of these possibilities, nauve peptide and analogues
of p28—U) were investigated for the ability to competitively inhibit
presentation of p81—96 to the T cell clone AC29 (Fig. 2). If the
binding capacity of a Der p II 28-40 analogue to DRB 1*1101 is
not affected by the introduced substitution, it wouid be expected to
equally inhibit proliferation of AC29 cells to the nauve 28-40
peptide. Indeed, this was the case with analogues substituted at
positions 28. 31. 32. 34. 36. 37. ana 40. In contrast. A29. E33. ana
A38 were more efficient at inhibiting the proliferation of AC29
cells, suggesting that they bind with higher affinity to DRB 1*1101
than the native pepude. However, since A30, R33. and A35 were
less effecuve than nauve pepude at inhibiting AC29 proiiferauon.
it is likely that they bind with lower affinity to DRB 1*1101. From
the combined results of proiiferauon and funcuonal competition
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FIGURE 1. The proliferative response of Derp II (p28-40)-specific ThO and Th2 cells to peptide analogues of p28-40. T cells of clone AC! (ThO)
and AC2 (Th2) were stimulated with p28—*0 peptide analogues in the presence of mitomycin C-treated murine fibroblasts expressing HLA-
DRB1*1101 as a source of APCs. Proliferation was determined by [3HldThd incorporation. Background responses of T cells cultured with APO
in the absence of Ag were <450 cpm. ~
assays, it appears that amino acids at positions 31 and 32 are crit¬
ical for T ceil recognition by both AC1 and AC2 T ceils. In con¬
trast, due to the different capacities of A33. E33. and R33 to com¬
petitively inhibit AC29 T ceil proliferation, position 33 appears to
affect T ceil recognition as well as binding to MHC class II
molecules.
Effect or p28-40 peptide analogues on cytokine production
by the T cell clones AC1 (ThO) and AC2 (Th2)
The p28 -40 analogues were investigated for their ability to mod¬
ulate cytokine production by AC1 (ThO) and AC2 (Th2) cells. In
response to stimulation by the p28-40 analogues with alanine at
positions 28, 31, 32, 33. and 40, the production of IL-4 by AC1
cells was markedly reduced compared with that elicited by the
native peptide (Fig. 3A). Stimulation with A29 and A30 also re¬
sulted in diminished levels of IL-4 secretion. Although the ana¬
logues A31. A32, and A33 markedly down-regulated the prolifera¬
tive response of the Th2 ceils (AC2). their inhibitory effects on
IL-4 secretion were minimal (Fig. 35), demonstrating that IL-4
producuon and proliferation could be dissociated. Background re¬
lease of IL-4 by both AC1 and AC2 ceils in the absence of peptide
was <10 pg/rni. The additional analogues with charged amino acid
substitutions were also tested for their ability to stimulate IL-4
production by AC1 and AC2 ceils. Compared with the native pep¬
tide glutamic acid or lysine at positions 31. 32. 34. and 35 as well
as E33 reduced the capacity of AC1 cells to produce IL-4 by 35%
<<<W56<Ui*<L
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FIGURE 2. Assessment of the binding of p28-40 peptide analogues
to HLA-ORB1"1101. Peptide analogues of p28-40 (50 /xg/ml) were
added with the stimulating peptide p81-96 (5 jig/ml) to mitomycin
C-treated murine fibroblasts expressing DRB1 "1101 (2 x 104/well). To
these and control cultures containing no p28-40-derived peptides,
AC29 T cells (p82-96 specific and DRB1 *1101 restricted) were added
(2 X 104/we!l), and proliferation was determined by (JH|dThd incor¬
poration. The results are expressed as the percentage of inhibition rel¬
ative to that induced by the native p28-40 peptide.
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FIGURE 3. The eifects of peptide analogues on IL-4 proauction bv Der p II (p28-40)-speciric ThO and Th2 cells. T cells of done AC! (ThO) ana
AC2 (Th2) were stimulated with p28-40 peptide analogues in the presence or mitomycin C-treated murine fibroblasts expressing HLA-DRB1 "1101
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FIGURE 4. The eifects of Deptide analogues on IFN-y production bv Der p II (p28-40)-speciric ThO ceils. T cells of clone AC1 (ThO) were
stimulated with o28-40 peptide analogues in the presence of mitomycin C-treatea murine fibroblasts expressing HLA-DRBl'l 101 as a source of
APCs. Suoernatants were collected at 48 h, and the levels of IFN-v were determined by EL1SA.
or more (Fig. 30. The analogues E30 and K30 induced IL-4 pro¬
duction by both T ceil clones, although for Th2 ceils. E30 was tne
most potent of these two peptides (Fig. 3. C and D). Analogues
with charged amino acids at positions 31. 32. and 33 reduced IL-4
production by AC2 cells, although in the case of R33. IL-4 secre¬
tion was diminished by oniy 33% (Fig. 3D).
The ability of p28-40 peptide analogues to sumuiate IFN-y
production by ThO cells (AC1) was also investigated. The ana¬
logues A31. A32, and A33 all failed to induce IFN-y production
(Fig. 4/4). and similarly, stimulation by peptides with charged res¬
idues at these positions was also unable to eiicit the release of
IFN-y. Substitutions with alanine at positions 28. 29. 30. 35. 37.
2164 ENHANCED IFN-y SECRETION INDUCED BY ALTERED TCR LJGANDS
38. and 40 induced the same ievei of IFN-y secretion as the native
peptide (Fig. 4A). In contrast. A"'4 and A36 increased IFN-y se¬
cretion compared with native p28—4). with enhancements of five-
and fourfoid. respectively (Fig. 4A). None of the analogues with
charged residue substitutions was as potent as the native peptide at
inducing IFN-y secretion (Fig. 4B): however, the IFN-y response
profile of AC1 cells was similar to that observed for IL-4 in re¬
sponse to stimulation with these analogues. Undetectable levels of
IFN-y were produced by AC1 ceils cultured with APCs in the
absence of peptide.
Discussion
The potential to modulate the qualitative nature of immune re¬
sponses with structural analogues of anugenic peptides was inves¬
tigated in vitro forT cell responses to a major human T cell epitope
of the HDM. In atopic disorders it may be possible to achieve
clinical improvement by decreasing the ratio of Th2 to Th 1 cyto¬
kines. This change could be accomplished by either a quantitative
reduction in ailergen-specific Th2 responses or the selective in¬
duction of Thl cytokines by allergen-reactive ThO cells, both
present in the T cell repertoire of atopic individuals (25). This
prompted us to analyze peptide analogues of Der p II. residues 28
to 40. for their anugenicitv and ability to stimulate cytokine pro¬
duction by DRBl*l 101-restncted T ceil clones representative of
the ThO and Th2 functional phenotypes (20).
The substitution of singie ammo acids with alanine at each po¬
sition in p28—4) had similar effects on the pattern of proliferation
of both ThO- and Th2-specific cells ana markedly reduced the re¬
sponse only when introduced at each of three positions (31, 32. and
33). In contrast, analogues containing positively and negatively
charged ammo acid substitutions had consistently negauve effects
on Ag recognition, although this was less pronounced when the
substituted natural amino acid was of a similar charge. These re¬
sults taken together with the MHC-peptide binding studies suggest
that the residues at positions 31 and 32 are critical for TCR rec¬
ognition. The capacity of analogues with different amino acid sub¬
stitutions at position 33 to bind with varying affinities to class II
MHC implies that this position makes contact with DRB1*1101.
However, the residue at this position may also contact TCR. since
the analogue A33 appears to bind to DRB1*1101 with an affinity
similar to chat of the native peptide, but is less antigenic. These
conclusions are consistent with eariier findings suggesting chat for
both AC1 and AC2 T ceils, the peptide core for TCR recognition
may be located between residues 28 and 35. whereas sequences 22
to 28 or 35 to 40 may be implicated mainly in binding to HLA-D
region molecules (20). Results from the functional competition
assays imply that, in addition to residue 33. those amino acids at
positions 29. 30. 35..and 38 in p28-40 contribute to peptide bind¬
ing to DRB1*1101. These residues either directly contact MHC or
influence the binding capacity of the peptide indirectly by altering
the conformation of the side chains of adjacent amino acids. For
peptides bound to HLA-DRBl*l 101. a potential motif has been
suggested, consisting of three mam anchoring positions, an aro¬
matic residue at position I followed by a hydrophobic and a pos¬
itively charged amino acid at positions 4 and 6. respectively (26.
27). Assuming that the aromatic residue H-'0 in p28—4) corre¬
sponds to the relative position 1. the residues implicated in MHC
binding found at positions 4 and 6 would be K33 ana F35. How¬
ever. although the residues at these positions appear to contact
MHC. their natures would not comply with the proposed binding
mouf for DRB1* 1101. and this may account for the ability of Der
p II 28—4) to bind to other class II molecules, including HLA-DQ
(20). MHC class II-restncted T cell recognition of peptides not
exhibiting the binding requirements for that particular MHC class
II specificity have been described (28).
Rules analogous to those governing MHC class II-peptiae bind¬
ing also appear to influence the outcome of TCR interactions with
altered peptide ligands. It has been demonstrated that analogues of
an anagenic peptide with the primary TCR contact unaltered but
containing selected subsdtutions at secondary TCR contact resi¬
dues could act as agonists or partial agonists for specific Th ceils
(13, 14). Furthermore, unrelated peptides wtth sequence similari¬
ties at these positions were found to be capable of eliciting similar
functional activity. Nevertheless. TCR recognition remains a
uniquely specific phenomenon, since Th ceils with different tine
specificities presented a variable pattern of responsiveness to the
same ligands (29).
In addition to the effects of alterations in the structure of the
p28-40 peptide on Ag recognition, the effects on cytokine pro¬
duction by both ThO ceils and Th2 ceils were analyzed. Despite the
similarity in the proliferative responses of both subsets of specific
Th ceils to the p28—4) analogues, the pattern of IL-4 secretion
varied markedly. In response to the p28-40 analogues. ThO ceils
induced IL-4 production, which generally reflected the pattern of
clonal expansion, although minor quantitative differences were
noted. In contrast, stimulation of Th2 cells with selected p28—4)
analogues induced IL-4 secretion in the absence of proliferation.
Although differences in the fine specificity of the two T ceil clones
may account for this disparity, it cannot be excluded that stimu¬
lation with the altered T ceil ligands may have different effects on
the signaling pathways that induce IL-4 production in both ThO
and Th2 cells. Stimulation of ThO cells with p28—4) analogues
containing alanine at position 34 or 36 resulted in a selective en¬
hancement of IFN-y secretion that was independent of IL-4 pro¬
duction and the degree of proliferation. Previous reports have dem¬
onstrated that proliferation and cytokine production in murine Th2
ceils have distinct thresholds of induction and can be selectively
triggered (16). In particular. IL-4 synthesis appears to be favorea
by signals provided by less potent TCR-ligana interactions, as in
the case of reduced ligand density (30) or by stimulation with
peptides of low affinity for TCR or MHC class II (13. 17. 18).
Furthermore. IL-4 secretion by Th2 ceils seems to have less strin¬
gent requirements for coreceptor or accessory moiecuie-mediated
costimuiation. It has been observed that murine Th2 ceils retained
their capacity to secrete IL-4 when stimulated by specific peptide
on chemically fixed APCs (16). It appears also chat certain anti-
CD4 Abs that inhibited Ag-dependent proliferation of p28—4)-
specific Th2 cells failed to down-regulate IL-4 secretion (23).
Moreover, when activated in the absence of cosumulatory signals
from APCs. ThO cells adopted the cytokine profile of Th2 celis.
implying that the Th2 pnenotvpe correlates with the induction of
anergy in ThO cells (31).
The potential use of altered T ceil ligands to modulate the ef¬
fector function of Th2 ceils may be of limited vaiue. since selective
inhibition of IL-4 production has not been achieved. However,
when Der p Il-specmc ThO ceils were stimulated with p28—4)
analogues (A34 and A36). IFN-y production was enhanced fivefold
compared with that of the native ligand. whereas IL-4 production
remained unchanged. The importance of regulating the balance
between Thl- ana Th2-denved cytokines was demonstrated in a
recent clinical study, in which it was reported that successful de-
sensitizauon with bee venom was accompanied by alterations in
the IFN-y:IL-4 ratios (32). Increased expression of mRNA for
Thl-type cytokines at the sue of late phase cutaneous reactions
was described in successfully treated individuals i4). Therefore, an
alternative strategy to beneficially intervene in atopic disorders
The Journal of Immunology 2165
may be by targeting ThO cells in an attempt to alter the IL-4:IFN-y
rauo in favor of EFN-y.
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Regulation of cytokine production by human ThO cells following stimulation with
peptide analogues: differential expression of TGF-P in activation and anergy
D. C. TSITOURA, C. M. GELDER, D. M. KEMENY* & J. R. LAMB Department ofBiology, Imperial College ofScience,
Technology andMedicine and *Department of Immunology, King 's College School ofMedicine and Dentistry, London
SUMMARY
The different biological activities of T-cell-derived cytokines and their level of production influences
the qualitative nature of immune responses and, in certain forms of T-ceil tolerance, the lack of
antigen responsiveness is associated with the production of transforming growth factor-0 (TGF-
(3) and interieukin-4 (IL-4). In this study we have investigated the effects of T-ceil receptor (TCR)
ligation with peptide analogues and the native peptide, in the presence and absence ofcostimulation.
dtt cytokine production by human T-helper type 0 (ThO) ceils reactive with influenza virus
haemagglutinin (HA) peptide (HA306-318) and restricted by HLA-DRBl*010l. We observed
that resting ThO cells constitutiveiy produced TGF-(3, but when stimulated with peptide and
antigen-presenting cells (APC) under conditions that induce clonal expansion, TGF-{3 secretion
was abrogated. Furthermore, exposure of the T cells to the wild-type HA peptide under conditions
that induce T-ceil anergy resulted in the secretion of TGF-(3, and subsequent antigenic rechallenge
was unable to override this signal and down-regulate TGF-{3 production. Stimulation with altered
TCR ligands that failed to induce proliferation also resulted in marked production of TGF-P,
although in many instances the levels were less than those observed in the total absence of antigen,
suggesting that partial signalling has occurred. Although in general, there was a direct positive
correlation between proliferation and the production of IL-2, IL-4 and interferon-y (IFN-y)
following stimulation with certain analogues, the production of selected cytokines was dissociated.
INTRODUCTION
CD4"'" T ceils may be divided into functional subsets with
distinct cytokine secretion profiles and, therefore, exhibit
different biological properties, which contribute to the qualitat¬
ive nature of immune responses (reviewed in ref. 1). In a
variety of experimental models it has been demonstrated that
the activation ofT-heiper (Th) ceils representative of a particu¬
lar functional phenotype may be necessary for generating
effective immunity.-"4 In contrast, either failure to secrete
cytokines with the required biological functions or expansion
of Th ceil subsets eliciting inappropriate activities may result
in immunopathoiogical reactions, such as those observed in
autoimmunity, allergic disorders and chronic infections
(reviewed in ref. 5). Consequently, the potential to induce or
inhibit the production of cytokines derived from specific Th
ceils in order to promote protective immunity in vaccination
or to down-regulate pathogenic responses in immunotherapy
has attracted considerable interest.6*7
There is now evidence from murine systems suggesting that
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modulation of T-ceil effector functions, and selective cytokine
production can be achieved by changing the affinity of the
interaction between T-cell receptor (TCR) and its cognate
ligand8"11 or, alternatively, through the induction of regulatory
T cells.12*13 The failure of T ceils to proliferate on antigenic
restimulation following ligation of the TCR with native pep¬
tide14-15 or altered T-cell ligands11*16 in either the presence or
absence of costimulation is, in many instances, associated with
dysregulation of cytokine production.15*17"19 In general, the
secretion of Thl-type cytokines appears to be readily inhibited
in anergy, whereas Th2 and ThO ceils retain the ability to
secrete selected cytokines, such as interieukin-4 (IL-4), even
though their capacity to proliferate on antigen restimulation
is abrogated.18*19 Furthermore, the analysis of the cellular
basis of oral tolerance has revealed that both CD8^ and
CD4' T cells capable of synthesizing transforming growth
factor-p (TGF-0) as well as IL-4, may be induced.12*13 In this
model it is proposed that the negative effects of IL-* are
elicited through the cross-inhibition of Thl ceils, whereas
TGF-p has more generalized immunosuppressive activities.
Collectively these observations prompted us to investigate
the effect on cytokine production by human ThO ceils on
stimulation, in the presence of antigen-presenting cells (APC),
with wild-type peptide [influenza haemaggiutinin (HA) resi¬
dues 306-318] and HA analogues in which the TCR contact
10 3 1997 Blackweil Science Ltd
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residues had been substituted. The production of IL-2, IL-4,
interferon-y (IFN-y) and TGF-f3 was studied in relation to
clonal expansion. In addition, we examined the ability of Th
cells to secrete TGF-P in absence of costimulatory signals
during the induction phase of anergy and on restimulation of




The influenza virus haemagglutinin peptide residues 306-318
(PKYVKQNTLKLAT) and analogues with substitutions at
the TCR contact residues were synthesized on a Multipeptide
Synthesis block BT7400 (Cambridge Research Biochemicals,
Northwich, UK) using 4-(2'f 4' dlmethoxyphenyl FMOC
aminomethyl) phenoxy resins (Novasyn Chemicals Ltd,
Nottingham, UK). Couplings were performed using FMOC
side chain-protected pentaflurophenyl or oxo-benzoteiazine
amino acid esters. Full-length peptides were cleaved from the
resin and deblocked by treatment with trifluroacetic acid/
thioanisole/ethanedithiol (94/5/2-5 v/v) for 1 hr, precipitated
and then washed twice with ether. The precipitates were
dissolved in 10% formic acid (v/v) and freeze dried for 48 hr.
Each peptide produced a single peak by reverse-phase high-
performance liquid chromatography (HPLC). The peptide
analogues used in this study are listed in Table 1.
Table 1. Amino acid sequences of peptide analogues of HA 306-318































Isolation ofHA 306-318-reactive DRB1 *0101-restricted cloned
human ThO cells
T cells of HA1.7 were isolated by limiting dilution cloning as
described previously.14 The T-cell clone was maintained in
RPMI-1640 medium supplemented with 2 mM L-glutamine,
100 IU/ml penicillin/streptomycin (Gibco, Life Technologies,
Paisley, UK) and 5% inactivated human A"1" serum (National
Blood Transfusion Service, Edgware, UK) by stimulation with
the HA 306-318 peptide and irradiated histocompatible peri¬
pheral blood mononuclear cells (PBMC) (5 x 105/nil; 3000
rads) as a source of APC, together with IL-2 (10% v/v;
Lymphocult T, Biotest Folex, Frankfurt. Germany). In all
experiments, clones were tested 7-8 days after the last addition
of antigen and APC.
Proliferation assays
Goned T cells (HA1.7; 2-0 x 104/well) were cultured in flat-
bottomed 96-well nricrotitre trays (Nunc. Gibco Life
Technologies) with analogues of HA 306-318 (3 or 10 pg/ml)
in the presence of APC. Mitomycin C-treated murine fibro¬
blasts expressing HLA-DRB1*0101 (2X104 cells/well) were
used for antigen presentation. In some experiments irradiated
histocompatible PMBC (2-5 x 104 cells/well) or Epstein-Barr
virus (EBV)-transformed B cells (2 x 104 cells/well) were used
as APC. Cultures were pulsed with tritiated thymidine
(1 pCi/well; [3H]TdR; Amersham International Pic,
Amersham, UK) after 48 hr and harvested 8-16 hr later.
Proliferation was determined by [3H]TdR incorporation by
liquid scintillation spectroscopy. The results are expressed as
mean c.p.m. for triplicate cultures with SEM<20%.
Induction of T-cell anergy
T cells (106/nil) were cultured in the presence of peptide
(100 pg/ml) or in medium alone for 18 hr and supernatants
collected for the measurement of TGF-p. The T cells were
then washed extensively before being rechallenged with either
an optimal concentration of native peptide in the presence of
APC (DR1-expressing murine fibroblasts) or IL-2 alone, as
described previously.14 Supernatants were also collected from
these cultures for the measurement of TGF-p. Proliferation
was measured by the incorporation of 3[H]TdR.
Measurement of IL-2. IL-4. IFN-y and TGF-P
Supernatants were collected at 48 hr from cultures of HA 1.7
cells stimulated with peptides in the presence of APC. Triplicate
wells were pooled and IL-2 was measured using the CTLL-2
line, whereas IFN-y and IL-4 were measured by enzyme-linked
immunosorbent assay (ELISA) kits.11 TGF-p was assayed
using the cell line Mv 1 Lu (NBL-7), as described previously.20
TGF-P was measured in supernatants collected during the
induction phase of anergy and following antigenic restimuia-
tion of the anergic T cells as described above.
RESULTS
The effect of amino acid substitutions at the TCR contact
residues in the HA peptide 306-318 on cytokine (IL-2, IL-4,
IFN-y aQd TGF-P) production by human ThO cells
Resolution of the crystal structure ofDRB1*0101/HA 306-318
complexes suggests that residues at positions 307, 309, 310.
312, 315 and 318 may interact with the TCR.21 Therefore.
© 1997 Blackwell Science Ltd, Immunology, 92. 10-19
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peptide analogues with substitutions at these positions were
synthesized (Table 1) and analysed for their ability to induce
selected T-cell effector functions and/or anergy, with the
exception of 318, since we have reported in a previous study
that threonine (318) is not required for recognition of the HA
peptide by HA 1.7 cells.22 Initially the activity of the HA
analogues was tested in T-cell proliferation assays and, sub¬
sequently, analogues with different potencies were analysed
for their ability to induce IL-2, IL-4, IFN-y and TGF-P
production or anergy in the absence of costimulation.
Substitutions atposition 307. The analogue R307 stimulated
proliferation similar in magnitude to the wild-type HA peptide
(K307), whereas for F307, H307 and Q307 proliferation was
reduced to the order of 50% (Fig. la). In general, the pro¬
duction of TGF-P by HA1.7 cells was inversely correlated
with proliferation, such that native peptide and R307, which
stimulated clonal expansion, failed fo induce TGF-P pro¬
duction (Fig. lb). In cultures of the T cells with APC and
E307 or APC alone, the highest levels of TGF-P were detected.
In order to exclude the possibility that incomplete costimula¬
tion was being provided by the HLA-DRl-transfected murine
fibroblasts and that human accessory molecules were required
for TGF-p production by the HA 1.7 cells, histocompatible
PBMC or EBV-transformed B cells were used as a source of
APC. In the presence of additional costimulation similar
results were observed and proliferating T cells failed to secrete
TGF-P (data not shown). In contrast to TGF-P, IL-4 (Fig. lc)
and IFN-y (Fig. Id) production paralleled the proliferative
response, but IL-2 was only detected in the supernatant of
cultures stimulated with wild-type peptide and R307 (Fig. le).
TGF-P production was measured at 48 hr; however, in kinetic
studies sampling supematants at 24, 48 and 72 hr an inverse
relationship between proliferation and TFG-P was still
observed. We have observed that other ThO cells, in addition
to HA1.7 cells, constitutively produce TGF-P, which is abro¬
gated by antigenic stimulation (results not shown).
Substitutions at position 309. The analogues with Ala, Gly,
His or Pro at position 309 induced proliferation but at a lower
level than the native peptide, V309 (Fig. 2a). Minimal prolifer¬
ation was observed by T cells stimulated with F309 or K30'.
Of the analogues tested. A309, G309, H309, P309 and V309 all
failed to induce the synthesis of TGF-P (Fig. 2b). In contrast,
neither proliferation nor TGF-P production was induced by
F309 IL-4 levels were comparable following stimulation with
G309, H309 and V309, whereas for P309, A309 and D309 levels
were reduced by 22%, 75% and 87%, respectively, and no IL-t
was induced by F309 or K309. Minimal levels or no detectable
IFN-y was found in cultures stimulated with the analogues
P309, D309, F309 or K309. However, for A309 and G309 the levels
were equal to or greater than V309 (Fig. 2d). IL-2 production
had a similar response profile to IFN-y, except that D309, F309
and K309 induced very low but detectable levels (Fig. 2e).
Substitutions at position 310. The amino aaid at position
310 appears to be a primary TCR contact residue in that all
the analogues tested, with the exception of the conservative
substitution of Arg for Lys, ablated the effector functions of
HA1.7 cells (Fig. 3). However, despite their inability to induce
proliferation (Fig. 3a) or the production of IL-2 (Fig. 3e),
IL-4 (Fig. 3c) and IFN-y (Fig. 3d) in the presence of the
analogues A310, Q310 and S310, the T cells secreted TGF-P,
although at reduced levels compared to D310 and the medium
control (Fig. 3b).
Substitutions at position 312. Analogues with the naturally
occurring residue Asn at position 312 substituted with His,
Ala, Gly, or Phe stimulated T-cell proliferation, although
reduced in magnitude (Fig. 4a) compared to the native peptide,
while in response to H312 the proliferation was marginally
increased (14%). No proliferation of the HA1.7 cells was
induced by Q312 or P312, but both of these analogues stimulated
the production of TGF-P (Fig. 4b), although the amount
secreted was less than the constitutive production. Low levels
of TGF-P'were detected in cultures of the T cells with A312
and H312. For IL-4 (Fig. 4c), IFN-y (Fig. 4d) and IL-2
(Fig. 4e), in general cytokine production reflected clonal
expansion. Nevertheless, stimulation with A312 induced
enhanced IFN-y (Fig. 4d) and reduced IL-2 (Fig. 4e) secretion
compared to the natural ligand.
Substitutions at position 315. All the analogues tested with
substitutions at positions 315 stimulated less proliferation
(Fig. 5a) than the native peptide (K315). TGF-P production
was inversely correlated with the proliferative response
(Fig. 5b). IL-4 (Fig. 5c), IFN-y (Fig. 5d) and IL-2 (Fig. 5e)
secretion mirrored proliferation, except for S315 which failed
to stimulate levels of IL-l or IFN-y that were detectable in
the culture supernatants.
TGF-P production by anergic ThO cells
We have previously reported that HA1.7 cells exposed to
supraimmunogenic concentrations of native peptide or ana¬
logues in the absence of costimulation become anergic to
restimulation with antigen.""4 These studies have been
extended to investigate the effects of high doses of wild-type
peptide and selected analogues on TGF-P secretion during the
induction phase of anergy and when anergic T cells are
restimulated (Fig. 6). Exposure of HA1.7 cells to native pep¬
tide (100 ug/ml) induced TGF-P release, and on rechallenge
of the anergic cells with an antigenic concentration of the
wild-type peptide in the presence of APC the cytokine was
still produced. Pretreatment of HA1.7 cells with F307, H307,
H309, G312 and H315 had similar effects to the native peptide.
K312 also induced a similar pattern of TGF-P production but
reduced in magnitude. Exposure to the analogues Q312 and
P312 in the absence of APC induced some TGF-P release,
similar to the medium control, but on restimulation no further
production of TGF-P was observed.
DISCUSSION
The results of this study provide further evidence that selective
cytokine production by human ThO cells can be achieved by
modulating the conditions of T-eell activation, namely by
using altered peptide ligands or inducing T-cell anergy. This
analysis is an extension of our previous work in which the
effects of altered T-cell ligands on proliferation and cytokine
production, namely IL-2, IL-4 and IFN-y, during the induction
of T-cell anergy was investigated." Here we report that certain
human ThO cells constitutiveiy produce TGF-P and that this
secretion is inhibited when the T cells are stimulated with
antigenic concentrations of peptide in the presence of APC.
The use of peptide analogues with altered affinities for the
TCR also revealed an inverse correlation between the ability
to induce clonal expansion and TGF-P production. In contrast,
Q 1997 Blackwell Science Ltd, Immunology, 92. 10-19
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Figure 1. Effects of amino acid substitutions at position 307 in HA 306-318 on T-cell proliferation and the induction of cytokines,
(a) cloned T ceils were stimulated with the HA307 analogues indicated at 3 and 10 pg/ml in the presence of APC (mitomycin
C-treated HLA-DRB1*0101 expressing murine fibroblasts). 3[H]TdR incorporation was determined at 72 hr. The response of
cultures containing 3 pg/ml of peptide are presented. The background proliferation of T cells cultured with APC in the absence of
peptide was measured (Med). HA 1.7 cells were cultured with peptide analogues in the presence of APC and culture supernatants
were harvested at 48 hr for the measurement of (b) TGF-0, (c) IL-4, (d) IFN-y and (e) IL-2.
IL-2, IL-4 and IFN-y synthesis occurred only after TCR
ligation and, for themajority of the HA analogues, the amount
of cytokine produced paralleled the magnitude ofproliferation.
However, for selective analogues, such as A309 and A312,
differences in the ratio of IL-4 to IFN-y favouring the Thl
pathway were observed, while in response to P309 preferential
© 1997 Blackweil Science Ltd, Immunology, 92, 10-19
secretion of EL-4 without significant amounts of IFN-y was
noticed. Anergy induced by exposure of the T cells to supra-
immunogenic concentrations of wild-type peptide and selected
analogues in the absence of costimulation resulted in TGF-(3
production that was not overridden by antigenicTestimulation.
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Figure 2. Effects of amino acid substitutions at position 309 in HA 306-318 on T-ccil proliferation and the induction of cytokines.
The HA309 analogues examined are indicated on the figure. The results presented are as described in the legend to Fig. 1.
cells may be associated with down-regulation of the IL-2
signalling pathway that characterizes both states.15
Antagonism between the actions of the two cytokines has been
documented.23 Furthermore, it has been shown that the
mRNA for TGF-P and IL-2 is differentially regulated in
human T cells, with the immunosuppressant cyclosporine A
selectively inducing mRNA specific for TGF-P and down-
regulating that for IL-2.24 Secretion of TGF-p from resting
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Figure 3. Effects of amino acid substitutions at position 310 in HA 306-318 on T-ceU proliferation and the induction of cytokines.
The HA310 analogues examined are indicated on the figure. The results presented are as described in the legend to Fig. 1.
T cells in the absence of TCR-mediated stimulation may also
be triggered by IL-2 through translational and/or post trans¬
lations! mechanisms." TGF-P reported to be a potent inhibitor
of cell grwoth by blocking cell cycle transition from G1 to S
phase (reviewed in ref. 26). As regards CD4* T cells, TGF-P
can suppress proliferation as well as effector functions, includ¬
ing Thl- and Th2-type cytokine synthesis,27,28 although under
certain conditions stimulatory effects have been observed.2' In.
an attempt to explain these contradictory findings it has been
suggested that the effects of TGF-P may depend on the
maturation stage of the T cells and their functional character-
© 1997 Blackwell Science Ltd, Immunology, 92, 10-19
istics and activation requirements, such as the nature of
costimulatory signals required for clonal expansion.30
In general, in response to altered T-cell ligands the HA1-7
cells produced TGF-P only when significant proliferation was
not included. However, quantitative differences in the levels
of TGF-P between unstimulated T-cell cultures and those
containing the non-stimulatory HA analogues were observed,
e.g. K309 and H315. Furthermore, stimulation with H307 and
H312 induced both TGF-P release and proliferation, whereas
the analogues F309 and A315, which are non-antigenic, failed
to trigger TGF-P synthesis. The disparities may be due to
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Figure 4. Effects of amino acid substitutions at position 312 in HA 306-318 on T-cell proliferation and the induction of cytokines.
The HA312 analogues examined are indicated on the figure. The results presented are as described in the legend to Fig. 1.
partial agonist effects of the analogues resulting in the acti¬
vation of some but not all of the effector functions of the
T cells. These findings suggest that pathways regulating TGF-
P production may also be affected by alterations in the
intracellular signalling generated by lowering the affinity of
TCR/ligand interactions. It has recently been reported that
stimulation of cloned myelin basic protein (residues 85-99)-
reactive ThO cells with a partial agonist peptide resulted in
selective TGF-p production.3] However, the authors con¬
sidered TGF-p production to be a consequence of the action
of the peptide analogue and not due to the intrinsic ability of
the specific ThO cells to generate TGF-P in the absence of full
activation signalling, although low levels of secretion of the
cytokine by resting cells was observed.
In contrast to TGF-p, the amounts of IL-2, IL-4 and IFN-
7 present in supernatants collected from cultures of the Th
cells stimulated with the HA analogues reflected, in general,
the degree of clonal expansion. None the less, in response to
© 1997 Blackwell Science Ltd, Immunology, 92, 10-19
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Figure 5. Effects of amino acid substitutions at position 315 in HA 306-318 on T-cell proliferation and the induction of cytokines.
The HA315 analogues examined are indicated on the figure. The results presented are as described in the legend to Fig. 1.
certain analogues the cytokine production was dissociated
from proliferation. IL-2 was not detected in some T-cell
cultures (e.g. F312), although proliferation and secretion of
both IFN-y and IL-4 occurred. Levels of IL-2 disproportionate
to the magnitude of the proliferative response may result from
a failure of the HA analogue to induce IL-2 production or
enhanced up-regulation of IL-2 receptors leading to increased
IL-2 consumption. Studies in which T cells were stimulated
with anti-TCR antibody32 or a mutated MHC-peptide ligand10
have revealed that the pathways for activation of IL-2 secretion
and CD25 expression can be dissociated.
Quantitative differences were noticed in the levels of IFN-
y and IL-4 secreted by the T ceils in response to selected
analogues, e.g. A309 induced low levels of IL-4 with levels of
IFN-y similar to the wild-type peptide. A312 selectively trig¬
gered enhanced IFN-y production, while P309 failed to stimu¬
late secretion of IFN-y although the synthesis of IL-4 remained
intact. These results suggest that the effector activities of ThO
cells have different thresholds and can be triggered either
selectively or quantitatively. The signalling pathways that
regulate Thl-type cytokine production overall appear to be
more sensitive to the effects of altered peptide ligands than
£> 1997 Blackwell Science Ltd, Immunology, 92. 10-19
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Figure 6. TGF-P production by ThO ceils during the induction phase
of anergy and when anergic T cells are subjected to immunogenic
restimuiation. HA1.7 cells were stimulated with native peptide and
selected analogues in the absence of APC and the supernatants
collected at 18 hr for the measurement of TGF-(3 (stippled bars). The
T ceils were washed and then restimulated with APC and native
peptide and TGF-fi was measured in supernatants collected at 48 hr
(cross-hatched bars).
those of IL-4 and this difference may result from IL-2, IL-4
and IFN-y gene transcription being under the control of
separate regulatory elements. It has recently been demonstrated
that activation of both NF-ATp and AP-l is required for Thl
cytokines gene induction, whereas the IL-4 gene involves only
NF-ATp.33 Moreover, the differential effect of activation of
the protein kinase A pathway on the expression of IL-2 and
IL-4 gene was shown to be mediated by a site in the IL-2
promoter, which is absent from the IL-4 promoter.34 The
intracellular signalling pathways leading to secretion of Thl
and Th2 cytokines also have different sensitivities to inhibitory
stimuli, such as immunosuppressive agents35 or anergy
induction.18-19
Ligation of TCR with peptide ligands in the absence of
costimulation results in the induction of T-cell anergy.11-14-15
Human cloned ThO cells exposed to high concentrations of
the native peptide and selected analogues, in the absence of
APC. exhibit dysregulated cytokine production and fail to
proliferate on antigenic restimuiation.17 In this study we report
that during the induction phase of anergy TGF-|3 was released
by T cells incubated with the wild-type peptide or analogues
capable of inducing anergy (e.g. H307 and H309). When the
anergized T cells were rechallenged with the native peptide in
the presence ofAPC they retained their ability to secrete TGF-
(3. The delivery of an antigenic signal to the anergic T cells
was unable to override TGF-(3 production initiated during the
induction phase of anergy. Reduced levels of TGF-(3, similar
to those generated in the control cultures, were also noticed
for T cells exposed to analogues that were unable to induce
anergy (e.g. Q312). However, restimuiation of these T ceils
under immunogenic conditions resulted in inhibition of the
cytokine production. This observation implies that although
the HA1.7 cells can produce TGF-{3 in the absence of a signal
inducing proliferation, this production can be further enhanced
by an anergic stimuli. In models of oral tolerance it has been
demonstrated that T cells secreting TGF-p alone or together
with IL-4 and IL-10 are induced and that these cells are
capable of actively suppressing specific responses.12-13-36
Furthermore, it has been concluded that these T-cell popu¬
lations constitute an independent Th cell subset, termed Th3.
However, certain anergic ThO cells could also have the same
functional phenotype.
Clearly the ability to alter the affinity of TCR-ligand
interactions and promote the production of growth inhibitory
and anti-inflammatory cytokines may be relevant to the devel¬
opment of specific immunotherapy for allergic and auto¬
immune diseases.
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INDUCTION. OF TOLERANCE EN INFLUENZA VIRUS-IMMUNE
T LYMPHOCYTE CLONES WITH SYNTHETIC
PEPTIDES OF INFLUENZA HEMAGGLUTININ*
by jonathan r. lamb j: barry j. skidmore, nicola green,
jacques m. chiller, and marc feldmann
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T cell clones have been highly useful for investigating various aspects of T cell-
mediated immunity and immunoregulation. For example, they have been useful for
analyzing the genetic restriction of lymphoid cell interactions, soluble mediators ofT
cell function, and the T cell repertoire (reviewed in references 1 and 2). Furthermore,
T cell clones have also been useful as homogeneous populations to examine mecha¬
nisms of T cell activation (1-4), and also offer the opportunity to examine regulation
of the immune system in more detail. Thus we have recently developed a suppressor
cell clone that specifically recognizes an antigen-specific helper cell and inhibits its
helper function (5). This will permit a detailed analysis of regulation by suppressor
effector cells.
Regulation of the immune response by antigen is a well documented phenomenon.
Mitchison (6) reported that antigen administered in either supraoptimal concentra¬
tions or repeated suboptimal doses, may induce the state of antigen-specific, antigen-
induced unresponsiveness commonly termed immunological tolerance. Further anal¬
ysis by Chiller and Weigle (8), Mitchison (7), Rajewsky (9), and others located the
cellular sites of unresponsiveness and revealed that although B cell tolerance occurred
transiently, tolerance ofT cells was more persistent and was the major lesion in high
zone tolerance and the only one in low zone tolerance (7-9).
Further research into the cellular mechanisms of tolerance has involved the analysis
of tolerance induced in vitro. Thus, Diener and Feldmann (10, 11) found that B cell
tolerance was induced in vitro by incubation with a high dose of antigen for 3-6 h at
37°C, a process that depended critically on the nature of the antigen used and its
polymeric interaction with B cell surface receptors. This process was reversible with
enzyme treatment for the first few days (12). In contrast, the induction of T cell
tolerance in vitro has not been reproducible, so its molecular basis has been difficult
to study. However, the cellular mechanism of tolerance has been investigated in vivo,
and it has been suggested that suppressor T cells play a critical role, especially in T
* Supported by contract N000-14-77C-0748 from the U. S. Office of Naval Research.
£ Present address is Imperial Cancer Research Fund, Human Tumor Immunology Group, University
College Hospital, London WCIE 6JJ.
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cell tolerance (13-16), although suppressor cells were not always detected, and when
found, did not correlate exactly with the tolerant state.
These results however, did not exclude the possibility that T cell tolerance could
occur in the absence of suppressor cells (e.g., 17, 18). The existence of cloned
populations of helper T cells offers the opportunity of determining whether antigen,
by itself, can tolerize helper T cells in the absence of suppressor T cells or their
precursors. The present report indicates that brief incubation with synthetic peptides
of the hemagglutinin (HA)1 molecule may specifically inhibit the proliferation of
cloned human helper T cells, suggesting that tolerance can be induced by high
concentrations of anrigen without the mediation of suppressor T cells.
Materials and Methods
Antigens. Formalin-inactivated influenza viruses of the strains "*A/Texas (A/Texas/1/
77X49(1-131^2); lot 53142) and B/Singapore (B/Sing) (B/Singapore/222/79; lot 71719) were
obtained from-Merck Sharp & Dohme, Rahway, NJ. Immunochemically purified influenza A
virus HA (A/Bangkok/1/79; H3N2) was generously provided by Dr R. G. Webster, St. Jude
Children's Research Hospital, Memphis, TN. The peptides of the HA1 molecule of influenza
hemagglutinin were synthesized according to the amino acid sequence of A/Hong/Kong/X47
(H3N2) (19) as predicted from the nucleotide sequence (20). In this study peptides 4 (amino
acid sequence 39-65), 11 (105-140), and 20 (306-329) were used.
Lymphocyte Preparation and Fractionation. The preparation and fractionation of peripheral
blood mononuclear leukoytes (PBL) have been described in detail elsewhere (21, 22). Briefly,
cryopreserved PBL from a healthy adult volunteer isolated on a Ficoll-Hypaque density
gradient were used throughout these experiments. T cell-enriched populations (IT) were isolated
from PBL by resetting with S-2-aminoethylisothiouronium bromide hydrobromide (AET)
(Calbiochem-Behring Corp., San Diego, CA)-treated sheep erythrocytes. After centrifugation
over Percoll (d = 1.080 g/ml; Pharmacia Fine Chemicals, Uppsala, Sweden), the non-rosette-
forming cell (E~) fraction, which contained <1% E"1" cells, was recovered from the interface and
the E+ fraction was recovered from the pellet by lysis of the erythrocytes with Gey's hemolytic
solution.
Production o/T Cell Growth Factor (TCGF). TCGF was prepared by culturing normal human
PBL (1 X 10 /ml) with 0.1% purified phytohemagglutinin (PHA) (Difco Laboratories, Detroit,
MI) in RPMI 1640 (Gibco laboratories, Grand Island, NY) supplemented with 2 mM l-
glutamine, 1 mM Na pyruvate, 10 IU/ml Na heparin, 25 mM Hepes, and 50 fig/ml gentamicin,
and containing 1% autologous plasma (23). After 48 h, supematants were harvested and assayed
for their ability to support the growth of a TCGF-dependent cell line (22).
Isolation ofAntigen-specific T Lymphocyte Clones (TLC). Antigen-specific TLC were isolated as
described previously (22). Briefly, normal PBL (2.5 X 105/ml) were cultured with purified HA
(0.1 fig/ml) in supplemented RPMI 1640 containing 10% screened pooled A* serum. At 6 d the
lymphoblasts were enriched on a 35-40% discontinuous Percoll gradient, resuspended at 33%
cells/ml and plated at one cell every third well in Microtest II trays (Falcon Division, Becton,
Dickinson & Co., Cockeysville, MD) with 10* irradiated (2,500 rad) autologous PBL and HA
(0.1 /ig/ml) in the presence of 20% TCGF. After 7 d, growing clones were transferred to flat-
bottomed 96-well microliter trays (Costar, Data Packaging, Cambridge, MA) and subsequently
to 24-well trays (Costar). At each transfer the TLC received fresh TCGF (20%) and irradiated
autologous PBL (5 X 105/ml) together with specific antigen (HA; 0.1 pg/m1). TLC were
maintained with fresh TCGF every 3-4 d and irradiated autologous PBL and HA were added
every 7 d. Before use in proliferation or helper assays the TLC were rested 7 d after the addition
1 Abbreviations used in this paper: AET, S-2-aminoethylisothiouronium bromide hydrobromide; BSA,
bovine serum albumin; B/Sing, B/Singapore; DNP, dinitrophenyl; E"*, sheep erythrocyte rosette-forming
lymphocytes; E", sheep erythrocyte non-rosette-forming lymphocytes; ELISA enzyme-linked immunosor¬
bent assay; FCS, fetal calf serum; HA, hemagglutinin; HAU, hemagglutinating units; [3H]TdR, tritiated
methyl thymidine; PBL, peripheral blood mononuclear leukocytes; PBS, phosphate-buffered saline; PHA,
phytohemagglutinin; TCGF, T cell growth factor; TLC, T lymphocyte clone.
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of irradiated filler cells. In these studies, the following HA-specific clones were used, HA1.7
(specific for peptide 20) and HA2.61 (specific for peptide 11).
Proliferation Assays. TLC (2.5 X 10*/mi) were cultured with HA (1.0 /ig/ml) in the presence
of irradiated autologous E~ cells (2.5 X 10*/ml) in a total volume of 200 jtil of supplemented
RPMI 1640 containing 10% A* serum. In some experiments, as indicated, E~ cells were cultured
for 18 h with antigen (1.0 /tg/ml) and washed before the addition of cloned T cells. After 72 h
incubation the cultures were pulsed for 8-12 h with 1.0 /tCi of tritiated methyl thymidine
([3H]TdR) (New England Nuclear, Boston, MA) and harvested onto glass fibre filters. Prolif¬
eration, as correlated with [3H]TdR incorporation, was measured by liquid scintillation
spectroscopy. The results are expressed as mean counts per minute ± standard error of the
mean for triplicate cultures.
Culture Conditions for In Vitro Antibody Production. The methodology for the T cell-dependent
production of specific anti-influenza antibody was based on that previously reported (24-27).
TLC (HA1.7, 5 X 102) or E"1" cells (1 X 10s) were cultured with autologous E~ cells (1 X 10s) in
round-bottomed 96-well microtiter trays (Linbro Chemical Co., Hamden, CT) in a total volume
of 200 ill in RPMI 1640 containing 10% fetal calf serum (FCS) (Gibco Laboratories). To these
cultures intact virus A/Texas or B/Sing (0.5 hemagglutinating units [HAU]/mi) were added.
After 6 d incubation, the cells were washed and recultured in 100 jil ofRPMI 1640 containing
5% FCS. Supernatants from triplicate cultures were collected at 24 h and stored at —20°C
before assay for anti-influenza virus antibody.
Enzyme-linked Immunosorbent Assay (ELISA) for Anti-influenza Virus Antibody. Anti-influenza
antibody was detected using an ELISA as described previously (25, 26). Flat-bottomed 96-well
microtiter trays (Dynatech Laboratories Inc., Alexandria, VA) were coated with 100 /xl of 500
HAU/ml of A/Texas or B/Sing in saline with 0.02% sodium azide for 1 h at 37°C in a
humidified atmosphere. After blocking nonspecific binding sites with phosphate-buffered saline
(PBS) containing 1% bovine serum albumin (BSA) (Pentex Grade V; Miles Laboratories Inc.,
Elkhart, IN), 50 fil samples of culture supernatants were added to each well. After a further 1
h incubation, the trays were washed and to each well 100 id of goat anti-human IgG conjugated
to alkaline phosphatase (Miles Laboratories Inc.) diluted 1:1,000 in PBS-BSA was added.
Before developing the reaction with 100 /il/ml of 1 mg/ml p-nitrophenyl phosphate (Sigma
Chemical Co., St Louis, MO) in carbonate buffer (pH 9.8, 10~3 M MgCh) the tray was washed
once with PBS-BSA and three times with the carbonate buffer. Absorbance was measured at
405 nm with a multichannel spectrophotometer (Dynatech Instruments Inc., Santa Monica,
CA); from a standard curve of logit-transformed absorbance against log concentration of
antibody of a reference serum, the actual amount of antibody was calculated (25). Backgrounds
determined by replacing the test supernatant with RPMI 1640 containing 5% FCS were
subtracted from the test values. The results are expressed as nanograms per milliliter.
Results
The Helper Activity of Clone HA 1.7 in the Production of Anti-influenza Antibody. From
previous studies, it was known that clone HA 1.7 recognized peptide 20 of the HA1
molecule of the influenza Haemagglutinin, amino acid sequence 305-329 (28). The
helper activity of HA1.7 was assayed on autologous E~ cells (a source of B cells and
monocytes) in the presence of influenza A virus (A/Texas/1/77). The addition of
5 X 102 cloned T cells per culture was able to induce levels of specific antibody in
excess of that induced by 10s unseiected autologous E"1" cells (Table I). To determine
the antigen specificity of the helper function, clone HA 1.7 and autologous E~ cells
were stimulated with A/Texas or B/Sing and then assayed for the production of anti-
A/Texas or anti-B/Sing antibody (Table I). HA1.7 was able to induce anti-A/Texas
antibody only when stimulated with A/Texas and not B/Sing. Furthermore, in the
presence of B/Sing or A/Texas, HA1.7 was unable to cooperate with E~ cells in the
production of B/Sing-specific antibodies (Table I). This could not be explained by
the inability of the E- cells to respond to B/Sing, since the addition of autologous E~
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Table I
Helper Activity of Clone HA1.7*
Co-culture Antibody response
Helper cells E~ cells Antigen Ann-A/Texas Anti-B/Sing
ng/ml
E* + A/Texas 147 ± 24 2± 1
+ — + 0 0
- + + 2 ± 2 0
+ + B/Sing I + 1 115 ± 33
+ — + 0 0
— + + 0 5 ± 3
HA1.7 + A/Texas 193 ± 17 0
+ — + 0 0
+ + B/Sing 0 4 ± 2
+ — + o "" • 0
* Cloned helper T cells (HA1.7; 5 X 102) or E* (10s) ceils were cultured with autologous E~
(10s) cells in the presence ofA/Texas/1/77 or B/Singapore/222/79 (0.5 hemagglutinating
U/ml). Anti-A/Texas and anti-B/Singapore antibody were determined in the supematants
of 7-d cultures. Background responses ofTLC HA1.7, E*, and E~ cells cultured alone with
virus were measured.
ceils leads to the production of anti-B/Sing antibody (Table I). Thus, the interaction
of HA1.7 with autologous E~ cells is specific for A/Texas/1/77, as is the antibody
synthesized.
Effect of Antigen Concentration on the Proliferative Response. The effect of antigen
concentration on the proliferative response of TLC cells co-cultured with irradiated
autologous E~ cells is shown in Fig. 1. The addition of HA-1 peptides 11 and 20 to
clones HA2.61 and HA1.7, respectively, induced maximum proliferation over the
concentration range of 0.3-3.0 jug/ml. The lower concentrations tested (0.01-0.3 fig/
ml) were able to induce proliferation but at a suboptimal level. However, doses of
peptide >10 /tg/ml (10-300 jig/ml) diminished the response dramatically.
Antigen-induced Tolerance of TLC. To determine the cellular level at which high
concentrations of antigen mediated their inhibitory effects, cells from HA1.7 were
preincubated with differing concentrations of peptide 20 (0.01-300 /rg/ml) in the
absence of accessory cells. After 16 h incubation, the TLC were washed extensively
and the viable cells (5 X 103) added to irradiated antigen-pulsed autologous E- cells.
Cloned helper cells (HA1.7) incubated in the presence of concentrations of peptide 20
>10 /tg/ml were subsequently unable to respond when co-cultured with E- cells
pulsed with peptide 20 (Fig. 2). The effect was antigen specific in that preincubating
HA1.7 cells with peptide 4 (300 fig/ml) did not inhibit the proliferative response of
HA1.7 cells when added to E_ cells pulsed with peptide 20 (Fig. 2). Furthermore,
after preincubation with any concentration of peptide 20 (over the range of 0.01-300
/ig/ml), TLC were still fully capable of proliferating in the presence of TCGF,
suggesting that the anergic state did not reflect a general inability of the cells to
proliferate as a result of toxicity. To exclude the possibility that the unresponsiveness
of the TLC was due to the carry over of irradiated T cells and/or accessory cells with
suppressor function, TLC were cultured in the presence ofTCGF alone for 7 d before
pretreatment with antigen. It has been noted previously, using alloreactive TLC
maintained on stimulator cells of unrelated HLA specificities, that after 7 d stimulator
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Preincubation with Paptida (/jg/ml)
Fic. 1. Inactivation of antigen-induced proliferation of TLC with high concentration of specific
antigen. TLC cells (HA1.7 [9|> HA2.61 [■!; 5 X 103) were cultured with irradiated autologous E~
cells (5 X 103) in the presence of differing concentrations of antigen (0.01-300 pg/ml of peptides 20
and 11, respectively, for HA1.7 and HA2.61). Proliferation as correlated with [3H]TdR incorporation
was determined for 72-h cultures. The results are expressed as the mean counts per minute (cpm)
± SEM of triplicate cultures. Background responses of HA1.7 and HA2.61 in the absence of
irradiated E~ cells for any of the antigen concentrations used was <50 cpm as was that of E~ cells
alone cultured with antigen. The response of HA1.7 and HA2.61 cultured with E~ cells in the
absence of antigen were 29 ±»4«and 21 ± 6 cpm, respectively.
cells were no longer detectable as determined by HLA phenotypic analysis (A. H.
Johnson, Lombardi Cancer Research Center, personal communication). We have
confirmed that in- populations of irradiated filler ceils cultured alone stimulator ceils
do not survive >7 d in vitro.
The duration of the exposure of helper T cells to antigen for tolerance induction
was also investigated. TLC ofHA 1.7 were not rendered unresponsive during the first
60 min of incubation with specific antigen (peptide 20; Fig. 3). However, after 3 and
6 h pretreatment with antigen the ability of TLC to proliferate in the presence of
antigen-pulsed E- cells was reduced by 55 and 28%, respectively, and after 18 h the
response was reduced to 4% of that seen with untreated T cells (Fig. 3). At each time
point of preincubation with antigen, the response of the T cells when cultured in
TCGF was not markedly different from that of the untreated population (Fig. 3).
Although these results suggest that incubation with antigen for a duration of >3 h is
required to induce unresponsiveness of >50%, ceil density and the geometry of the
wells in which the cells were cultured may influence the kinetics of tolerance induction,
and these remain to be investigated in more detail.
The Influence of Accessory Cells on the Expression of Tolerance. It was considered that
the number of accessory cells present in the assay culture may influence the expression
of unresponsiveness in the pretreated T cells. However, variations in the number of
accessory cells from 102 to 5 X 104 E~ cells per well did not appear to influence the
state of unresponsiveness induced in the T cells of clone HA1.7 (Fig: 4). Furthermore,
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Fic. 2. Dose dependency of tolerance induced by preincubating T cells with specific antigen.
Clone HA1.7 (105 cells/ml) was incubated in the presence or absence of varying concentrations of
specific peptide (peptide 20; 0.01-300 fig/ml). The pretreatment was performed in round-bottomed
96-well microtiter plates for 16 h at 37°C. The plates were washed twice and 5 X 103 viable TLC
cells were added to 5 X 103 irradiated antigen-pulsed E~ ceils. Cells from each group were assayed
for their ability to proliferate in the absence of TCGF alone. Proliferation was determined by
[aH]TdR incorporation as described in legend to Fig. 1.0, HA1.7 preincubated with specific antigen
(HA peptide 20) and then tested for the response to peptide 20 in the presence of accessory cells.
□, HA 1.7 preincubated with specific antigen (HA peptide 20) and then tested for the response to
TCGF in the absence of accessory cells. •, HA1.7 preincubated with non-cross-reactive antigen
(HA peptide 4; 300 /ig/ml) and then tested for the response to peptide 20 in the presence of
accessory cells. ■. HA1.7 preincubated with non-cross-reactive antigen (HA peptide 4; 300 fig/ml)
and then tested for the response to TCGF in the absence of accessory cells.
the unresponsiveness observed in the T cells pretreated with specific peptide could
not be accounted for by a shift in the kinetics of the response since tolerized T cells co-
cultured with varying numbers of irradiated E~ cells for 48, 72, and 96 h remained
unresponsive (data not shown). In contrast, the initial rapid increase in the magnitude
of the proliferative response of untreated cells of HA1.7 reached a plateau as the ratio
of E~ cells to clone exceeded 1:1 (Fig. 4). Whether this plateau effect is due to
inhibitory signals in the presenting cell population, or that the critical number of cells
for maximal stimulation of the clone has been achieved, cannot be determined from
these experiments, but it is clear that the usual 1:1 ratio used in the other experiments
reported here is in the optimal range.
Antigen Specificity of Tolerance Induction. The antigen specificity of the induction of
tolerance suggested in Fig. 2 was more fully analyzed using the combination of two
T cell clones, HA1.7 and HA2.61, and the peptides 20 and 11 to which they are
respectively specific. After preincubation with peptide (50 jag/ml), the cells were
added to irradiated autologous E- cells pulsed with peptide 20, 11, or both, and the
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Fig. 3. TLC of HAI.7 (105/ml) were preincubated with 50 fig/mi of peptide 20 in the absence of
E ceils for 30 min, I, 3, 6, and 18 h, chen washed and assayed for proliferation as described in the
legend to Fig. 2. •, HA1.7 preincubated with HA peptide 20 and then tested for response on peptide
20-puised E" ceils. O, HA1.7 preincubated with HA peptide 20 and then tested for response to
TCGF in the absence of E~ cells.
proliferative response was determined. In addition, all experimental groups were
evaluated for their ability to proliferate in the presence ofTCGF alone. Clone HA1.7,
specific for peptide 20, (group A, Table II) is rendered unresponsive by preincubation
with peptide 20 (group BJ, but not by preincubation with the unrelated peptide 11
(group C). The reciprocal can be seen with HA2.61, which is specific for peptide 11
(group D), and can be tolerized by preincubation with peptide 11 (group E), but not
with peptide 20 (group F). In contrast, ail pretreated cells respond to TCGF to an
extent identical to that of cells not pretreated with antigen (Table II).
In a more demanding test of specificity, the combination of the two test clones was
incubated with peptide 11, 20, or both. The recovered cells were then assayed for
their proliferative response on irradiated autologous E~ cells pulsed with peptide 11,
20 or both together. The data in Table III reveal that when the combination of clones
HA1.7 and HA2.61 was preincubated with either peptide 11 or 20, the proliferative
response was limited to peptide 20 or 11, respectively (groups B and C), compared
with the normal response to each peptide observed in the group where the cells were
preincubated in medium alone. However, when the cells were preincubated with both
peptides, no response was seen when such cells were stimulated with accessory cells
pulsed with 11, 20 or both peptides (group D). As before, a normal response to TCGF
was seen in all groups regardless of the type of pretreatment experienced.
Duration of Tolerance. T helper cells of clone HA 1.7 were tolerized with peptide 20
and then maintained in TCGF alone without the addition of filler cells for up to 96
h. The responses of these ceils in the presence of antigen (peptide 20)-pulsed E~ ceils
or TCGF alone after various time in culture (16, 48, 72, 96, 168 h) were compared
with those of untreated cells. The T cells remained unresponsive to stimulation with
specific antigen in the presence of autologous E~ cells 168 h after being tolerized
(Table IV). This unresponsiveness was not due to cytolytic effects since the T ceils
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Fig. 4. The influence of accessory cell number on the expression of tolerance. Untreated and
tolerized cells of HA1.7 (5 X i03/weil) were assayed for responsiveness on irradiated antigen-pulsed
E~ cells ranging in number from 102 to 5 X Iff4/well. The protocols for tolerance induction and the
proliferative assay are described in the legend to Fig. 2. •, HA1.7 preincubated with HA peptide 20
and then assayed for response on peptide 20-pulsed E~ cells. O, untreated HA1.7 assayed for
response on peptide 20-pulsed E" cells. ■, HA1.7 preincubated with HA peptide 20 and then
assayed for response to TCGF in the absence of E~ cells. Q untreated HA1.7 assayed for response
to TCGF in the absence of E~ cells.
were able to proliferate in response to TCGF, and this response was not markedly
different from that of untreated T cells maintained under the same culture conditions
(Table IV). In contrast, the latter were able to respond to specific antigen (Table IV).
Discussion
There has been relatively little progress in the field of immunological tolerance in
recent years. The reasons for this are not clear, but the lack of in vitro systems whereby
the most significant form of tolerance, T cell tolerance, may be induced, has presum¬
ably contributed. The recent developments in cloning T cells has made it possible to
envisage an in vitro model of tolerance induction, which may make it possible to
discriminate between various possible mechanisms of tolerance induction as reviewed
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Table II
Specificity of Tolerance Induced by the Preincubation of Individual TLC with Antigen"
Tolerance Induction Response
Antigen
Group Clone Antigen TCGF
11 20 11 + 20
cpm + SEM
A HA1.7 None 129 ±31 19,373 ± 1,257 18,638 ± 998 5,591 ± 292
B HA1.7 20 135 ± 30 897 ± 145 918 ±229 5,424 ± 221
C HA1.7 11 86 ±25 16,902 ± 1,369 19,293 ± 923 5,163 ± 187
D HA2.61 None 6,548 ± 848 105 ± 12 7,591 ± 505 2,540 ± 176
E HA2.61 11 237 ± 68 398 ± 52 495 ± 50 2,609 ± 230
F HA2.61 20 7,055 ± 236 216 ± 13 7,256,± 753 2,368 ± 100
* Cells from clone HA 1.7 (specific for peptide 20) or HA2.61 (specific for peptide 11) were incubated for
16 h with either peptide 11 or 20 (50 itg/ml). Recovered cells (5 X 103/weil) were assayed for proliferation
in the presence of irradiated autologous E~ cells (5 X 103/well) that had been pulsed with peptide 11, 20,
or both in the absence of E~ cells but in the presence of TCGF. Background responses of E~ cells in the
presence or absence of antigen are <80 cpm. Results are expressed as described in the legend to Fig. 1.
Table III
























18,474 * 1,424 29,201 ± 1,637
16,446 * 1,124 17,671 * 2,702
485 * 56 7,386 * 595





• The protocol is identical to that described in the legend to Table II with the exception chat combinations of cells from clones HA1.7 and
H2.61 were incubated with antigens.
by Weigle, Howard, and Mitchison (30-32). Two groups of mechanisms may be
envisaged. Either antigen at supraoptimal concentrations acts to initiate the pathways
that generate suppressor cells (reviewed in references 33, 34), or antigen may act
directly on effector T cells, to modulate in some way their capacity to respond to
antigen.
Recently suppressor T ceils were cloned from a mouse rendered tolerant to BSA
(35). This coupled to the general similarities between the conditions for tolerance and
suppressor cell induction (e.g., in high antigen dose, accessory cell requirement [36,
37]) suggests that suppressor cells are often responsible for immunological tolerance as
proposed by several authors (13-16). However, these results do not exclude the
existence of tolerance induced by antigen in the absence of suppressor cells (e.g., 17).
We thus performed experiments to determine whether antigen administered by itself
will modulate the responsiveness of a clone of helper T cells in vitro. The results
indicated that it is possible in vitro to induce specific immunological tolerance in a
helper clone.
To determine whether antigen in excess would regulate the antigen-specific proiif-
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Table IV
Duration of Tolerance*
Response of Cloned T helper cells
Time (post-anu- Tolerized Untreated
gen treatment)
E~ + Peptide 20 TCGF E~ + Peptide 20 TCGF
ft cpm ± SEM
16 13 ±7 3,960 ±210 11,277 ± 1,275 4,082 ± 491
48 153 ±13 3,512 ± 308 10^331 ± 1,151 3,783 ± 375
72 179 ± 25 2,835 ± 435 14,068 ± 1,378 3,406 ± 455
96 127 ±21 3,271 ±227 9,517 ± 524 4,584 ± 339
168 488 ± 34 2,912 ± 354 12,485 ± 358 3,522 ± 210
* Cells from clone HA 1.7 pretreated with peptide 20 were assayed for proliferation on E~ cells pulsed with
specific peptide or in the presence of TCGF alone as detailed in the legend to Fig. 2. T cells were
maintained at a concentration of 5 X 10s/ml in TCGF alone for 16, 48, 72, 96, and 168 h after tolerance
induction before use in the proliferation assay. In the proliferation assay both pretreated and normal T
cells were added at 5 X 10 viable ceils/well. As a control untreated cells were maintained under the
same culture conditions. Background responses of E~ cells in the presence or absence of antigen at any of
the time points taken are <100 cpm. Results are expressed as described in the legend to Fig. 1.
erative response, a dose-response analysis was performed, with the antigen present for
the entire duration of the culture period. Supraoptimal concentrations yielded reduced
proliferative responses to their respective immunogens, peptide 20 for clone HA 1.7
and peptide 11 for clone HA2.61 (Fig. 1). From the literature on mouse T cell clones,
it is clear that some clones do not yield this type of dose-response curve (e.g., 38).
Since it was determined that supraoptimal concentrations of synthetic peptide yield
greatly reduced responses, preincubation experiments as previously described for the
analysis of B cell tolerance were performed (10, 11). Because the presence of accessory
cells or macrophages has been shown to inhibit or reduce the degree of tolerance (36)
and of suppressor cell induction (37) these experiments were performed with T cell
clones 7 d after the last irradiated filler cells were added. From previous work it is
known that 2,500 rad-irradiated filler cells cannot be detected in our culture conditions
after 7 d (A. H. Johnson, Lombardi Cancer Research Center, unpublished data).
It is observed that concentrations >3 /ig/ml of the appropriate synthetic peptide
(20) inhibited the proliferation of clone HA1.7 (Fig. 2), which is an HA-specific helper
T cell (Table I). These concentrations of antigen are comparable to those required to
induce B ceil tolerance, for example in the polymeric flagellin system (10, 11) where
10-100 fig/ml was needed. The time course of antigen pretreatment was investigated,
using 50 /xg/ml of peptide 20 in the absence of E~ cells. Inhibition was detectable
within 3 h, appreciable (~50%) by 6 h, and virtually complete by 18 h. Thus
inhibition of T cells by antigen took 3-6 h or more, a result comparable to the case
with B cells in vitro (10, 11).
The key criterion of immunological tolerance is that it is antigen induced, antigen
specific and not immediately reversible. This aspect was investigated using two clones
derived from the same individual, HA1.7, a helper cell that recognizes peptide 20,
and HA2.61, which recognizes peptide 11. The findings reported here indicate that
these clones are inhibited by the appropriate peptide only (Table I), even if a mixture
of ceils is used (Table II). This establishes the antigen specificity of the effect, and also
excludes the possibility that a nonspecific diffusible inhibitor is released by cells
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(43, 44). This is because .effector cell blockade requires highly polymeric antigen (43),
in contrast to the small synthetic oligopeptide we are using to tolerize T cells, and
because efFector cell blockade is fully recoverable within 24 h, unlike the stability of
complete tolerance for at least 7 d noted here. Moorhead (45) has reported that
dinitrophenyl (DNP)-specific delayed hypersensitivity T cells are blocked by preex¬
posure to free DNP lysine (45). This phenomenon is different from the one described
here, in that blocking by DNP lysine occurred rapidly (1 h at 4°C), and reversed
rapidly (1 h at 37°C), whereas the tolerance induced by peptide 20 was unaltered by
7-d incubation at 37°C before challenge in vitro, and took much longer to induce
(~16 h for 99% inhibition). ,
By developing a system for T cell tolerance within a T cell clone, we have a system
for analyzing whether the nature of'offsignals', such as tolerance, differ quantitatively
or qualitatively from the 'on signals'. Particularly relevant here is the question as to
whether the induction of tolerance is MHC restricted (discussed in references 46, 47),
which can be~ analyzed in this system and is under investigation.
Summary
Antigen-specific human T cell clones specific for defined peptides of influenza A
hemagglutinin were found to be rendered unresponsive by incubation with moderately
high concentrations of antigen. This was the case whether the synthetic peptide
antigen was present for the duration of the culture or the cloned T cells were
preincubated with antigen for 3-18 h at 37°C, before stimulation with T-depleted
irradiated sheep erythrocyte non-rosette-forming lymphocytes (E~) pulsed with the
optimal dose of peptide. Tolerance could not be overcome by culture with various
numbers of E- cells and antigen. The induction of unresponsiveness was antigen
specific, since it depended upon incubation with the appropriate peptide recognized
by that clone. In addition, the tolerant T cells remained unresponsive to stimulation
with the specific peptide for at least 7 d after induction even though maintained in
culture in the presence of T cell growth factor. This state of antigen-specific unre¬
sponsiveness is akin to immunological tolerance. Furthermore, the experiments re¬
ported here demonstrate that the helper T cell clone can be inhibited by the relevant
peptide in the absence of any suppressor cells or their precursors. This suggests that
antigen-induced unresponsiveness need not always depend on the presence of sup¬
pressor T cells. The induction of tolerance in T cell clones does not result in early T
cell death, since cells that no longer proliferate in response to the specific antigen and
accessory cells still proliferate in response to T cell growth factor.
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Induction of Anergy in Human T Helper 0 Cells by
Stimulation with Altered T Cell Antigen Receptor Ligands1
Daphne C. Tsitoura,* Wolfgang Holter/ Adefheid Cerwenka/ Colin M. Gelder,* and
Jonathan R. Lamb2*
CD4"* T cells may become profoundly unresponsive to antigenic restimulation following ligation of TCR by immunogenic peptides
bound to MHC class II molecules in the absence of costimuiation. Furthermore, it has been reported that anergy can be induced as
a consequence of engagement of TCR by analogues of antigenic peptides presented by live APCs. In this study, based on resolution
of the crystal structure of an influenza virus hemagglutinin (HA) peptide (HA 306-318) bound to HLA-DR8T0101, we investigated
the potential of analogues with amino acid substitutions at those positions predicted to form interactions with TCR to differentially
activate and/or anergize HA-specific human ThO ceils restricted by OR1 class II molecules. For some analogues altering the affinity
of peptide/TCR interactions revealed a direct positive correlation between antigenicity and their ability to induce anergy. Neverthe¬
less, certain HA peptide analogues functioned as partial agonists, which although they failed to stimulate clonal expansion, were
capable of rendering the ThO cells unresponsive to immunogenic rechailenge. Furthermore, differences were noticed in the charac¬
teristics of the anergic phenotype induced by selected analogues. Restimulation with the native peptide of ThO cells pre-exposed to
the HA analogues in the absence of costimulatory signals failed to uncouple IL-4 and IFN-y secretion; however, in some instances,
dissociation of proliferation from cytokine production was observed. The ability to differentially signal T cells through changing the
affinity of peptide/TCR interactions may have implications in the potential use of altered TCR ligands in immunotherapy. The
Journal of Immunology, 1996, 156: 2801-2808.
Engagement of TCR by antigenic peptides bound to class IImolecules encoded by the MHC. together with costimu¬latory signals provided by APC. initiate the effector func¬
tions of CD4"" T cells (e.g.; 1-4). In contrast, altered signaling of
T cells by ligation of the TCR. in the absence of costimuiation.
leads to a state of functional unresponsiveness termed anergy,
which is characterized by a failure of the T cells to proliferate
when restimuiated (e.g.; 4-9). From the analysis of in vitro sys¬
tems. using either human or murine CD4"" T cells, it has been
reported that anergy may be achieved by stimulation with native
peptide under the appropriate conditions. For example, human
CD4"" T cells when exposed to supraimmunogenic concentrations
of peptide, in the presence or absence ofAPCs. become anergic to
immunogenic restimulation (5). whereas for murine T cells unre¬
sponsiveness can be induced by stimulation with antigenic con¬
centrations ofmative peptide presented by chemically modified
APCs (e.g.. Refs. 6. 10). The early studies on murine T ceil anergy
focused on the Thl functional phenotype and established that im¬
paired IL-2 transcription in the anergic T cells resulted in the loss
of Ag-dependent proliferation (5). From the analysis of the kinetics
of cytokine-specific mRNA induction it has been demonstrated
that human T cells become hvperactivated during the initial expo¬
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sure to toierizirig concentrations of peptide (11); however, when
the anergic human T cells were restimuiated. a defect in IL-2 pro¬
duction was observed (12).
Attempts to induce anergy in murine Th2 cells by ligation of the
TCR with native peptide in the absence of costimuiation. in gen¬
eral. have been unsuccessful (4. 13, 14). However, recently the
ability of peptide analogues with partial agonist effects to modulate
the effector functions of both murine Thl and Th2 cells has been
studied (9, 10. 15. 16). These analogues of immunogenic peptides,
termed altered peptide ligands. bind with comparable affinity to
class II MHC molecules but have altered affinities for TCR. The
presentation of altered peptide ligands by live APCs can induce
murine Th2 (10) ceils, as well as Thl (9) ceils, to become pro¬
foundly unresponsive to restimuiation with wild-type peptide, sug¬
gesting that the regulation of clonal expansion is fundamental to
the induction of anergy in both Thl and Th2 ceils. However, the
Th2 cells retained the capacity to secrete IL-4. which raises the
possibility that the presence of IL-4 may confer resistance to the
. induction of complete anergy in Th2 and ThO cells or that tran¬
scriptional regulation of IL-4 is not subject to modulation during
anergy induction (7. 10).
These observations prompted us to investigate the potential to an¬
ergize human ThO ceils, as weil as to inhibit or dissociate the pro¬
duction of Thl (IFN-yj- and Th2 (IL-A)-derived cytokines on restimu-
lauon of native peptide by using altered peptide ligands with the
properties of agonists or partial agonists. The resolution of the crystal
structure of hemagglutinin (HA)3 306-318/DRJ31*0101 complexes
(17. 18) and the interaction of the native HA peptide and analogues
with affinity purified and membrane-expressed DRB 1*0101 mole¬
cules in binding studies (19. 20) imply that residues at positions 307.
309. 310. 312. 315. and 318 interact with the TCR. Based on this
prediction we have generated a panel of peptide analogues with amino
1 Abbreviation used in this paper: HA. hemagglutinin.
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acid substitutions at these positions and investigated their effects on
the induction ofanergy in cloned human ThO cells of the appropriate
Ag and restriction specificity (21).
Materials and Methods
Antigens
The influenza virus HA peptide residues 306-318 (PKYVKQNTLKLAT)
and analogues with substitutions at the TCR contact residues were synthe¬
sized on a Multipeptide Synthesis block BT74(X) (Cambridge Research
Biochemicals. Northwich. U.K.) using 4-(2'. 4' dimethoxyphenyl F-moc
aminomethvDphenoxy resins (Novasyn Chemicals. NtHtingham. UK) as
previously described (22). Couplings were performed using F-moc side
chain-protected pentalluorophenyl or oxobenzoteiazine amino acid esters.
Full-length peptides were cleaved from the resin and deblocked by treat¬
ment with trifluoroacctic acid-thioanisole-ethanedithiol (94:5:2.5. v/v) for
1 h and then precipitated and washed twice with ether. The precipitares
were dissolved in 10% formic acid (v/v) and freeze dried for 48 h. Each
peptide produced a single peak by reverse-phase HPLC. The peptide an¬
alogues used in this study are listed later in Table I.
Cell surface binding assays
The binding affinities of native and peptide analogues of HA 306-318 were
compared by their ability to compete with biotinyiated HA 306-318 for
binding to DRB I *0101 expressed on murine fibroblasts as previously de¬
scribed (19). DRB 1*0101 -positive fibroblasts were co-incubated with NH-
long chain biotinyiated HA peptide (25 /ig/ml) and selected analogues (500
/xg/ml). washed, and incubated with fluoresceinated avidin D (Vector Lab¬
oratories. Peterborough. U.K.) followed by biotinyiated anti-avidin D. The
cells were then incubated again with fluoresceinated avidin D and fluores¬
cence intensity was determined by flow cytometry.
Isolation of HA 306-318 reactive DRB1 *0101 -restricted
cloned human ThO cells
Cloned T cells of HA 1.7 were isolated by limiting dilution cloning method
as described previously (21). The T cell clone was maintained in RPMI
1640 medium supplemented with 2 mM L-glutamine. 100 lU/ml penicillin/
streptomycin (Life Technologies. Paisley. Scotland) and 5% inactivated
human A* serum (National Blood Transfusion Service. Edgwarc. U.K.) by
stimulating with HA 306—318 peptide and irradiated hisiocompatible PBMC
(5 x lOVml: 3CXX) rad) as a source of APCs together with 1L-2 (10% v/v:
Lymphocult T. Biotest Folex. Frankfurt. Germany). In all experiments, clones
were tested 7 to 8 days after the last addition of Ag and APCs.
Proliferation assays
Cloned T cells (HA 1.7: 2.0 X KfVwell) were cultured in flat-bottom. 96-
well microliter trays (Nunc. Roskilde. Denmark, and Life Technologies)
with analogues of HA 306-318 <0.(X)3 to MX) /ig/mi) in the presence
of APCs. Mitomycin C-treated murine fibroblasts expressing HLA-
DRBI*0I0I (2 x |(j4 cells/well), irradiated (50(H) rad) homozygous
DRB I *0101 expressing EBV-transformcd B cells lines (2 X 10' cells/
well), or irradiated (3CHM) rad) hisiocontpaiihle PBMCs were used lor Ag
presentation. From selected cultures, siipcrnuianis were collected at 48 h
and the levels of 1L-4 determined. Cultures were pulsed with |*H|TdR
(I /iCi/well) (Amersham. Amersham. U.K.) after 48 h and harvested 8 to
16 h later. Proliferation was determined by | %H(TdR incorporation by liq¬
uid scintillation spectroscopy. The results are expressed as mean cpm for
triplicate cultures with SEM <20%.
Induction of T cell anergy
T cells (lO'Vmi) were cultured with peptide (MX) /xg/ml) or in medium
alone or in the presence of APCs for 18 h and then washed extensively
before being rechallenged with either an optimal concentration of native
peptide in the presence of APCs (DRI-expressing murine fibroblasts) or
IL-2 alone as described previously (5). Proliferation was measured by the
incorporation of | "H|TdR.
Measurement of IFN-y and IL-4
Supcmatams were collected at 48 h from cultures of peptidc-pretreatcd or
untreated T cells rechallenged with immunogenic peptide. Triplicate wells
were pooled and IFN-y and IL-4 were measured by EL1SA as described
previously (23).
Cytofluoromctric ana Ivs is
T cells were stained for cell-surface phenotype by standard methods using
mAbs (CD2. CD3. and CD25) directly conjugated to FITC and analyzed on
an EPICS IV (Coulter. Hialeah. FL) (24).
Results
Effect of amino acid substitutions at the TCR contact residues
on the ability of the HA 306-318 peptide to stimulate
proliferation, induce anergy. or modulate cytokine (IL-4 and
IFN-y) production by anergic T cells
Peptide analogues of HA 306-318. with amino acid substitutions
at positions 307. 309. 310. 312. and 315. but not 318. since the
threonine at this position is not required for recognition by HA 1.7
cells (25). were investigated for agonist effects. The MHC class
11-binding characteristics of the HA peptide analogues used in this
study have been investigated in detail by others (19. 20). However,
to confirm their previous observations that substitutions at these
positions had minimal effects on MHC class Il-binding. selected
analogues were investigated in cell surface binding assays. The
HA analogues tested with substitutions at positions 307. 309. 310,
312. and 315 (Table I) inhibited the binding of biotinyiated native
peptide to a similar degree as the unlabeled native HA 306-318
(Fig. 1). As an additional control, binding was determined for an
analogue in which tyrosine at position 308. a residue critical for
MHC class II binding (17-20). had been substituted by serine
(S3C,H). The binding of labeled peptide was only weakly inhibited
by S3<)s suggesting that it has a lower affinity for DRB I *0101 than
either native peptide or the other analogues tested.
Substitutions at position 307. Compared with the native peptide,
which has a lysine at position 307 (K307). the magnitude and shape
of the dose-response curve of proliferation induced by the ana¬
logue with a conservative substitution (R307) was similar. Over the
concentration range of 3 to 30 /xg/ml. the analogues E3"7. G307.
H3"7. and Q3"7 stimulated proliferation at reduced levels compared
with the native peptide. However, at 30 /xg/ml proliferation in¬
duced by H3"7 and Q3°7 was greater than that of K3"7 (Fig. 2A).
Since it has been reported that altered T cell ligands are able to
dissociate proliferation from IL-4 production (15). the supernatants
from cultures in which the analogues induced only minimal or no
proliferation were analyzed for the presence of IL-4 (Fig. 3). The
analogues E;o7 and G3"7. which stimulated reduced proliferation,
also induced only low levels of IL-4 compared with native peptide.
Only the levels of IL-4 induced by peptide at concentrations that
stimulate maximum proliferation are presented.
in order to determine whether the analogues were able to induce
anergy. T cells were cultured with each peptide (100 /xg/ml) in the
absence of APCs and both proliferation and cytokine production
measured on restimuiation by APCs pulsed with an antigenic con¬
centration of native peptide. HA 1.7 cells failed to proliferate (Fig.
28) or produce IL-4 and IFN-y (Fig. 2C) on restimuiation after
incubation with the native peptide or the analogues R3"7. G3"7. and
H307 as compared with the control of cells maintained in medium
alone. HA-E307 partially inhibited Ag-induced proliferation, but
had less of an effect on cytokine production. In contrast. Q3<)7
failed to induce anergy. As previously described for the native HA.
peptide responsiveness of anergic T cells to exogenous IL-2 was
enhanced (24). This effect was also observed for the HA3"7 ana¬
logues. which induced anergy. with the exception ofG3"7 in which
no enhancement of IL-2 responsiveness was observed (Fig. 28).
Substitutions at position 309. When valine (V3,H>) in the native
peptide was substituted by phenylalanine (F30l>) or lysine (K3,w).
minimal or no proliferation was observed (Fig. 4A). Neither did
these analogues induce IL-4 production (Fig. 3). The shape of the
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FIGURE 1. 8inding of native HA 306—318 peptide and analogues to
DRBT0101. DRB1"0101 transfectants were cocultured with unla¬
beled native peptide and analogues together with biotinyiated HA
306-318 and the level of binding was analyzed by flow cytometry.
dose-response curves of the proliferation induced by the substitu¬
tions A309, G309. and H309 was similar to that of V309. but reduced
in magnitude with H309, least potent of the analogues (Fig. 4A).
Pretreatment with F309 or PC309 failed to reduce either prolifer¬
ation (Fig. 45) or cytokine production (Fig. 4O on restimulation.
In contrast, these T cell functions were down-reguiaied by the
A309. G309. and H309. Although H309 was markedly less antigenic
than native peptide, it had similar potency in terms of inducing
anergy. Enhanced IL-2 responsiveness paralleled loss of Ag-de-
pendent proliferation (Fig. 45).
Substitutions at position 310. The capacity of HA310 analogues to
induce anergy paralleled their antigenicity. Of the analogues
screened (A310. D310. E3'0, G3I°, and R310) only the conservative
substitution of arginine for lysine stimulated proliferation and IL-4
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FIGURE 2. Effects of amino acid substitutions at position 307 in HA
306-318 on T cell recognition and the induction of anergy. A, Cloned
T cells were stimulated with the following HA307 analogues: O, R307;
■. Q307; □, E307; A, G307; A. H307; and native peptide (HA-K307), • in
the presence of APCs (mitomycin C-treated HLA-DR8T0101 express¬
ing murine fibroblasts). [JHlTdR incorporation was determined at
72 h. B, HA1.7 ceils were stimulated with native peptide (HA-K307),
R307, Q307, E307. G3°7, and H307 in the absence of APCs and then
restimulated with APCs and native peptide (cross-hatched bars) or IL-2
alone (stippled bars), and proliferation was determined by the incor¬
poration of [3H|TdR. C. Cloned T ceils were stimulated with native
peptide (HA-K307). R307, Q307, E307, G307, and H307 in the absence of
APCs and restimulated with APCs and native peptide, and IL-4 (solid
bars) and IFN-y (cross-hatched bars) were measured in supernatants
collected at t-8 h.
(Fig. 5A). Pretreatment with R310 induced anergy, inhibited pro¬
liferation (Fg. 55) and cytokine production (Fig. 50, and en¬
hanced responsiveness to exogenous IL-2.'
Substitutions at position 312. In the native peptide, asparagine
(N312) was found at position 312. The analogues A312 and S312
were antigenic but reduced compared with N312 (Fg. 6A). Stim¬
ulation with S312 also induced low levels of IL-4 production as
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FIGURE 3. IL-4 production by T cells stimulated with HA analogues
in the presence of APCs. T cells of HA1.7 were cultured with the native
peptide and analogues in the presence of APCs. and the level of IL-4
was measured in 48-h supernatants.
compared with the native peptide (Fig. 3). E312. V312. and the
conservative substitution Q3'2 all failed to induce proliferation.
A312, similar to N3'2, induced anergy (Fig. 6B) and inhibited
cytokine production (Fig. 6O on restimulation. in contrast to Q312.
Pretreatment with S312 induced modulation of IL-4 and IFN-y pro¬
duction but failed to inhibit the proliferative response on restimu¬
lation. E312 failed to stimulate proliferation but. nevertheless, in¬
duced partial anergy of Ag-dependent proliferation and inhibited
both IL-4 and IFN-y production without increasing responsiveness
to IL-2. Stimulation with V312 resulted in down-regulation of cy¬
tokine production but Ag-dependent proliferation was only par¬
tially anergized and no increase in IL-2 responsiveness was ob¬
served (Fig. 6. B and C).
Substitutions at position 315. None of the analogues substituted
at position 315 was as efficient as the native peptide (K313) in
stimulating proliferation of HA 1.7 cells (Fig. 7A). The conserva¬
tive substitution. R313. was antigenic at 0.3 /xg/ml and greater but
was three logs less potent. A315. V3'5, and D313 induced limited
proliferation, whereas H313 failed to stimulate the T cells. Stimu¬
lation with H313 failed to induce IL-4 production, although A315
was able to stimulate suboptimal levels (Fig. 3).
After pretreatment with A313. V3'5. and D'15. the T cells re¬
sponded by proliferation (Fig. IB) and cytokine release (Fig. 7C)
when rechallenged with the native peptide. R'13. similar to K313.
ancrgized the proliferative response and both IL-4 and IFN-y pro¬
duction. H"*13. which failed to stimulate HA 1.7 cells, induced com¬
plete anergy (Fig. 7. B and C). The induction of unresponsiveness
by H3'5 was dose dependent (Fig. 8A). However, unlike K313 and
R3'5. exposure to H313 did not enhance responsiveness to exoge¬
nous IL-2. Pretreatment of the T cells with H313 or native peptide
in the presence of APCs resulted in the induction of T cell anergy
(Table II).
Increasing the concentration of native peptide used to rechal-
lenge anergic T cells failed to stimulate clonal expansion or cyto¬
kine production. Results are presented for the proliferative re¬
sponse of HA 1.7 cells anergized by native peptide or the analogues
G307. E312. or H313 (Fig. 85). Furthermore, stimulation of HA 1.7
cells in the presence of different types of APCs (DRB 1*0101 ex¬
pressing murine fibroblasts. EBV-transformed B cells, or PBMC)
did not alter the pattern of response in the proliferation assays.
Likewise, the degree and characteristics of anergy induced by na¬
tive peptide or HA analogues were not affected by APCs present at
the time of restimulation (data not shown).
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FIGURE 4. The eife. ts of amino acid substitutions at position 309 in
HA 306-318 on T cell recognition and the induction of anergy. The
following HA1"' analogues: O. A'""; ■. G'""; Z. H'""; A. K'""'; Z.
F1"*'; and the native peptide (HA-V'""* i#» were investigated. The re¬
sults are presented as descril>ed in the legend to Figure 1.
Phenotyfjic modulation ut anergic Tin) cell*
Pcptide-tncdiatcd anergy modulates the cell surface phenotypc of
human CD4"* T cells, and as previously reported (24). the expres¬
sion of the TCR/CD3 receptor complex was down-regulated while
membrane levels of CD2 and CD25 were elevated (Fig. 9). The
effect of preincubation of the T cells with selected HA analogues
of HA 306-318 was also analyzed. The HA-307 analogues (G307.
H3"7, and R3"7). which induced anergy. also down-regulated CD3
expression. However, although membrane levels of both CD2 and
CD25 were enhanced by R3"7. expression of CD2 but not CD25
was elevated following stimulation with G3"7. On|v minimal up-
regulation of CD25 was observed following incubation with H3°7
(Fig. 9). The partial anergy induced by E312 was accompanied by
marginal reduction in CD3 expression and enhancement of CD25.
with CD2 unaltered. In contrast, Q3'" enhanced CD2 and CD25
cell surface levels, but had limited effect on CD3. As regards the
HA-315 analogues, for D313 the phenotypic modulation paralleled
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FIGURE 5. Effects of amino acid substitutions at position 310 in HA
306-318 on T cell recognition and the induction of anergy. The fol¬
lowing HA3,° analogues: O. A3,°; ■. R310; Q, 03,°; A, EJ,°; A. F3,°;
and the native peptide (HA-Ki,u) (•) were investigated. The results are
presented as described in the legend to Figure 1.
functional responses to Ag rechailenge or exogenous IL-2. H3'3.
which induced anergy. paniaily down-regulated CD3. up-regu¬
lated CD2. but had little effect on CD25 membrane expression,
which was in agreement with the lack of enhanced responsiveness
to exogenous IL-2. A similar pattern of phenotypic modulation
was observed when the T cells were exposed to anergizing con¬
centrations of H315 or native peptide with APCs present in the
primary cultures.
Discussion
In this report we have investigated the ability of peptide analogues
of HA 306-318 with altered affinities for the TCR to induce pro¬
liferation and anergy in human HA-specific ThO cells. For the ma¬
jority of analogues we have demonstrated a direct positive corre¬
lation between immunogenicity and their ability to induce anergy.
However, for selected peptides, such as Q3"7. E3'2, and H3'3. we
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FIGURE 6. Effects of amino acid substitutions at position 312 in HA
306-318 on T cell recognition and the induction of anergy. The fol¬
lowing HA31- analogues: O. A312; ■. Q312; □, E312; ▲. V3'2; A. S3'2;
and the native peptide (HA-N3'2) {•) were investigated. The results are
presented as described in the legend to Figure I.
duction of anergy (Table III). We have previously reported that
stimulation of human CD*"* T cells with supraimmunogenic con¬
centrations of wild-type peptide, in the absence of cosrimuiatory
signals, can render the cells unresponsive to further immunogenic
challenge (5. 24). Here we extended those findings and demon¬
strated that exposure of ThO cells to certain HA analogues (e.g..
S312), under similar conditions, may modulate their effector activ¬
ity as regards their capacity to proliferate and secrete cytokines
when subjected to immunogenic restimuiation.
Analyzing the patterns of proliferation of HA1.7 ceils, in the
presence of APCs. revealed that lysine at position 310 in the HA
peptide was critical for Ag recognition since substitutions of this
residue, including a conservative change to arginine. were poorly
tolerated. It would appear, therefore, that position 310 is a primary
A: 312
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FIGURE 7. Effects or amino acid substitutions at position 315 in HA
306-318 on T cell recognition and the induction of anergy. The fol¬
lowing HA315 analogues: O, A31S; ■. R3'5; □, Dns; a. H3'5; a. v3,s;
and the native peptide (HA-K315) (•) were investigated. The results are
presented as described in the legend to Figure 1.
TCR contact residue (26). In contrast, the residues at positions 307.
309, 312. and 315 have the characteristics of secondary TCR con¬
tact residues, as a variety of changes in the nature of the amino
acids at these positions were accepted and this confirmed our ear¬
lier observations on the contribution of positions 309 and 312 to
Ag recognition by HA1.7 cells (27). In general, peptide/MHC class
II complexes formed with the HA analogues substituted at either
the primary or secondary TCR contact sites revealed a direct cor¬
relation between immunogenicity, both in terms of proliferation
and IL-4 production and their ability to induce anergy. Similar
observations have been reported for other in vivo experimental
systems (e.g., 28, 29). The capacity of amino acid substitutions at
secondary TCR contacts to modulate selected effector functions
has been studied in most detail formurine T ceil clones specific for
A.
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FIGURE 8. Effect of Ag concentration on anergy induction and re-
stimulation. A. Dose response curve of H3,5-induced T cell anergy.
HA1.7 cells were cultured in medium or with increasing concentra¬
tions of H315 (cross-hatched bars) or native (solid bars) peptide in the
absence of APCs. T cells were restimulated with APCs and native pep¬
tide and proliferation measured. B. Effect of Ag concentration on the
restimulation of anergic T cells. HA1.7 cells were cultured in medium
(C) or with G307 (□); E3'" (■); H3'5 (A), or the native peptide (•) at 100
fig/m\ in the absence of APCs and then restimuiated with increasing
concentrations of native peptide in the presence of APCs. Proliferation
was determined by the incorporation of [3HlTdR.
Table II. Induction of T cell anergy in the presence of APCs
Surtace Phenotvpe
Peptide Ag Recnallenge
Prctreatmenr* HA 306 -r APC CD3 CD25
Medium 19.350 55 13
HA 1.876 38 315
H-315 2.012 41 100
J T cells were culiured with APCs (DRB1 "0101 expressing murine fibroblasts)
alone or in the presence of native peptide or H11'1 (100 jigfml) for 38 h. Phe-
notypic expression of CD3 and CD25 was determined and the proliferative re¬
sponse of the T cells to restimuiation with native peptide in the presence or APCs
assessed as described in the legend to Figure 1.
hemagiobin peptide Hb/3^ (64—76) (9, 10, 15, 16). It has been
demonstrated that one analogue of this peptide with a conservative
substitution (S—*-A at position 70), although unable to stimulate
Thl cells either to proliferate or produce cytokines, when pre¬
sented by live APCs was able to render them unresponsive to chal¬
lenge with wild-type peptide (9). Similarly, we observed that stim¬
ulation of HA 1.7 ceils with selected analogues, in which the
secondary TCR contacts had been substituted (e.g., E307. G307,
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FIGURE 9. Phenotypic modulation or HA1.7 cells stimulated with
HA analogues in the absence of costimulation. HA1.7 cells were cul¬
tured in medium. Rm\ Hwr. G"'7, Q1'-. E"2 0"\ H,,s. and the
native peptide all at 100 /xg/ml in the absence of APCs and cell-surface
expression of CD2 (cross-hatched bars). CD3 (solid bars), and CD25
(stippled bars) measured by fluorescence. «
£312 v312. S3,2t H315) interfered with qualitative and quantitative
aspects of proliferation and anergy induction in the presence and
absence of APCs.
Peptide-mediated anergy of HA 1.7 cells was characterized by
modulation of the cell-surface phenotype with reduced expression
of TCR-CD3 receptor complexes and enhanced membrane levels
of CD2 and CD25 (24. 30). Nevertheless, different patterns of
modulation were observed following exposure to selected ana¬
logues: for example, anergy induced by G307 had minimal effect on
ceil-surface expression of CD25. Therefore, changes in the affinity
of TCR/ligand interactions appeared to affect not only the capacity
to stimulate clonal expansion or induce anergy but also qualitative
differences in these functional outcomes. This was further illus¬
trated by analysis of the activity elicited by certain HA peptides
with substitutions at positions 312 and 315. In the presence of
APCs. stimulation with S312 induces proliferation, albeit reduced
in magnitude when compared with the native peptide. Neverthe¬
less. this analogue induces partial anergy affecting only cytokine
production on restimuiation. Without costimuiation exposure to
E"*'2 or V312. nonimmunogenic analogues resulted in inhibition of
both IFN-y and 1L-4 production on rcchallenge. whereas the pro¬
liferative response was only partially inhibited. The H315 peptide
analogue appeared to form partial agonist complexes with DRI
that were able to inhibit both cytokine production and prolifera¬
tion. although in the presence of APCs they failed to induce T cell
proliferation. The induction of anergy by H3'5 and E3'2. in contrast
to anergy mediated by the native peptide, was not accompanied by
enhanced responsiveness to exogenous IL-2. suggesting that dis¬
tinct elements of the anergic phenotype may have different quali¬
tative thresholds for^elicitation. From a molecular model of the
predicted interactions between the TCR of HA 1.7 (31) and the
HA306-3IS/DRB I *0101 complex (17, 18) K315 appears to contact
glutamic acid at position 94 in the TCR a-chain. Mutation of 594
to either alanine or lysine resulted in the loss of recognition of the
wiid-tvpe peptide, and stimulation with HA313 analogues, includ¬
ing D315 and E3'5. failed to restore recognition. The introduction
of these reciprocal mutations at position 315 may result in struc¬
tural modification at a distant site in the peptide. Similarly, the
effects of the amino acid substitution at position 315. which we
report here, may also arise by modifying contacts between other
positions in the peptide and the TCR.
Since the HA analogues used in this study bind with similar
affinity to cell-surface DRB 1*0101 molecules (19, 20), either al¬
tered intracellular signaling mediated through ligation of the TCR
or a lack of costimulaiory activity could account for the failure of
certain HA analogues to stimulate proliferation in the presence of
APCs (32-34). It has been suggested that quantitative differences
in the threshold requirements for IL-2 and IL-3 production are
influenced by costimuiatory signals (32). This is also supported by
the observation that the addition of IL-l was able to restore the loss
of proliferation in Th2 cells induced by an altered peptide ligand
(15). In contrast, since anergy in our system is generated in the
absence of costimuiation. it is likely that the qualitative differences
in the anergic phenotype induced by the altered TCR ligands oc¬
curs as a consequence of changes in the threshold of TCR-medi-
ated signal transduction. Two independent studies have identified
a common biochemical mechanism for modified TCR signaling by
altered peptide ligands (33. 34). The altered peptide ligands failed
to induce £ chain phosphorylation, which resulted in the inability
of ZAP-70 to associate with the TCR complex following trans¬
duction of signals from the TCR. Activation of selective intracel¬
lular signaling pathways may arise as a consequence of increased
peptide concentration and this is indirectly supported by the dose-
dependent induction of anergy by H3,"\ In this case increasing the
density of the ligand for TCR a "null" signal changes to one
capable of inducing partial activation that is not overridden by
restimulating with native peptide at higher concentrations or in the
presence of different types of APCs. Alternatively, alterations in
the affinity or conformation of the ligand, either by the substituted
amino acid itself adopting a different orientation or modifying the
interaction between TCR at a remote residue, may lead to differ¬
ential siuna! inn.
2808 ALTERED TCR UGAND-MEDIATED ANERGY IN HUMAN ThO CELLS
Differences in the susceptibility of murine Th2 cells to tolerance
induction in terms of Ag-dependent proliferation and responsive¬
ness to IL-4 have been reported (e.g., 8, 10, 13, 14). However,
even those Th2 cells that can be rendered anergic retain the ca¬
pacity to produce IL-4 on restimulation (10). Similarly, anergic
murine ThO cells can still produce IL-4. despite losing the ability
to secrete IL-2 (7). This finding may be explained by in vitro
experiments in which it was observed that increased protein kinase
A activity stimulated IL-4 but inhibited IL-2 expression through
suppression of the EL-2 promoter via a binding site that is absent
in the IL-4 promoter (35-37). However, for the human ThO cells
studied in this report we failed to observe selective down-regula¬
tion of either Thl or Th2 cytokine production in response to stim¬
ulation with any of the peptide analogues in the absence of co-
stimuiadon. The inability of changes in the threshold of signaling
to uncouple IL-4 and IFN-y production suggests that the regulation
of these genes may be under muldple control pathways or have
less stringent requirements for cosdmulauon. In support of this is
the report that EFN-y production was only partially inhibited in
anergic murine Thl clones"(4)..
Our results demonstrate that some peptide analogues containing
substitutions that alter the affinity of the interaction between pep¬
tide and TCR behaved as incomplete agonists for ThO cells, failing
to stimulate clonal expansion, but capable of delivering signals
such that they become anergic to restimuiation with the native
peptide. Different thresholds of signaling failed to uncouple IL-4
and IFN-y secretion, nevertheless, in response to stimulation with
altered TCR ligands, in the absence of costimulation, dissociation
of proliferation from cytokine production was achieved. These
findings have implications in peptide-based immunotherapy where
it may be desirable to alter qualitative parameters of immune re¬
sponses. such as those that occur in allergic or autoimmune dis¬
eases, by the inhibition or modulation of selected effector functions
mediated by specific T cell subsets (e.g.. 38-40).
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ABSTRACT The exotoxins produced by certain strains of
Staphylococcus aureus are able to stimulate powerful polyclonal
proliferative responses and to induce nonresponsiveness by
clonal deletion of T lymphocytes expressing the appropriate
T-cell antigen receptor Vf} gene products. This paper examines
the ability of S. aureus enterotoxins to modulate the respon¬
siveness of human CD4+ T lymphocytes with defined antigen
specificity. It was observed that certain 5. aureus toxins were
able to activate and induce anergy in hemagglutinin-reactive T
cells expressing ~Vp3* elements. After exposure to S. aureus
enterotoxins A, B, and D in the absence of antigen-presenting
cells, the T cells failed to respond to their natural ligand
presented in an immunogenic form, despite enhanced prolif¬
eration to exogenous interieukin 2. The 5. aureus toxin-induced
anergy was associated with modulation of T-cell membrane
receptors; down-regulation of the T-cell antigen receptor was
concomitant with enhanced expression of CD2 and CD2S.
Interestingly, CD28 was increased only on stimulation, sug¬
gesting this protein may be differentially expressed by activated
and anergic T ceils. These results indicate that bacterial toxins
are able to induce antigen-specific nonresponsiveness in human
T cells, the application of which may be relevant in the
regulation of T cells expressing a particular family of V/I gene
products.
The staphylococcal enterotoxins (1, 2) and certain endoge-
nously derived proteins such as Mis (3, 4) are members of a
family of antigens termed "superantigens." based on their
ability to stimulate powerful polyclonal proliferative re¬
sponses of murine and human T lymphocytes bearing par¬
ticular T-cell antigen receptor (TCR) V/3 gene products (4-7).
Additionally, superantigens are also able to induce nonre¬
sponsiveness in murine T cells either by clonal deletion (5) or
functional inactivation (8). With the development of in vitro
experimental systems, it has been possible to demonstrate
that occupancy of the TCR by peptidic fragments of antigen
complexed with class II major histocompatibility complex
(MHC) molecules, in the absence of additional signals (co-
stimulatory activity), is able to induce antigen-specific anergy
(9-12). However, direct evidence to support clonal anergy as
an operational mechanism in the development and mainte¬
nance of tolerance to either self or extrinsic antigens in vivo
has been difficult to obtain. The results of recent experiments
examining T-cell tolerance to noniymphoid-expressed MHC
molecules (13, 14) or to the self superantigen Mls-la (8)
suggest that nonresponsiveness, in certain instances, may be
accounted for by functional inactivation. Similarity between
the functional characteristics of these in vivo experimental
models and those of peptide-specific T-cell anergy induced in
vitro (9-12) prompted us to investigate the ability of Staphy¬
lococcus aureus enterotoxins to induce antigen-specific non-
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responsiveness in cloned human cd4" T cells specific for the
carboxyl terminus of influenza virus hemagglutinin (HA),
residues 307-319 [HA-(307-319)] (15, 16). In this report we
demonstrate that the S. aureus toxins which were able to
stimulate proliferation could also render the HA-reactive T
cells rionresponsive to an immunogenic challenge of viral
antigen and that the mechanism of nonresponsiveness is
associated with modulation of T-cell membrane proteins.
MATERIALS AND METHODS
Antigens. Staphylococcal enterotoxins A, B, CI, C2, C3,
and D (SEA, SEB, SEC1, SEC2, SEC3, and SED) were
purchased from Toxin Technology (Madison. WI) or Serva
Fine Biochemicals (New York). The HA peptide (residues
307-319) was synthesized using standard solid-phase meth¬
ods on an Applied Biosystems model 430A synthesizer,
purified by reversed-phase HPLC, and analyzed by amino
acid analysis as described (16). This peptide was generously
provided by J. Rothbard (ImmuLogic).
Antibodies. For flow cytometric analysis, fluorescein-
conjugated murine monoclonal antibodies, anti-Leu5b
(CD2), anti-Leu4 (CD3), anti-Leu3a (CD4), anti-interleukin 2
(IL-2) receptor (CD25), and fluorescein isothiocyanate-
conjugated mouse IgGl control were purchased from Becton
Dickinson. The murine monoclonal antibodies anti-CD28
(9.3: ref. 17) and anti-CD3 were generously provided by J.
Ledbetter (Oncogen, Seattle. WA) and H. Spits (DNAX),
respectively.
Cloned Human Antigen-Reactive T Lymphocytes. The iso¬
lation and characterization of the cloned human T cells
reactive with HA-(307-319) have been reported in detail
elsewhere (15). Briefly, T cells activated with immunocnem-
ically purified HA were resuspended in RPMI 1640 medium
(GIBCO) supplemented'with penicillin (100 units/ml), strep¬
tomycin (100 jig/ml), 2 mM L-glutamine. and 5% (vol/vol)
screened human AB~ serum and cloned by limiting dilution
in the presence of autologous irradiated peripheral blood
mononuclear leukocytes. IL-2 [10% (vol/vol) Lymphocuit T:
Biotest Folex. Frankfurt. F.R.G.], and antigen. Growing T
cells were expanded by cyclic stimulation with antigen and
filler cells every 7 days and with IL-2 every 3 or 4 days. Prior
to their use in experiments the T ceils were allowed to rest for
7 days after the last exposure to antigen and filler cells.
Induction ofT-Cell Nonresponsiveness. T cells (106 cells per
ml) were incubated for 16 hr with the S. aureus toxins (0.5
jig/ml) or HA-(307-319) (50 /ig/mU ref. 9). Control cultures
Abbreviations: APC. antigen-presenting cell: HA. influenza virus
hemagglutinin: MHC. major histocompatibility complex: TCR.
T-cell antigen receptor: IL-2. interieukin 2; SE. staphylococcal
enterotoxin.
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ofT cells in medium or ofT cells activated with insolubiiized
anti-CD3 antibody (12 /xg/ml) and IL-2 were performed in
parallel. The cells were washed extensively after the pre-
treaunent before determining their ability to respond to either
an immunogenic challenge of antigen [HA-(307-319)J and
antigen-presenting cells (APCs) or IL-2 (10%).
Proliferation Assays. Cloned T cells (10" cells per ml) were
stimulated with HA-(307-319) (1.0 p.g/'mi) or the S. aureus
toxins at the concentrations as indicated in the figures, in the
presence of mitomycin C-treated murine fibroblasts express¬
ing HLA-DR1 (105 cells per ml; ref. 16) as a source of APCs,
or in IL-2 alone. After 60 hr of incubation, [methyl-
3H]thymidine (1 /xCi/mi; 1 Ci = 37 GBq; Amersham) was
added and the cultures were harvested onto glass fiber filters
8-16 hr later. Proliferation as correlated with [3H]thymidine
incorporation was measured by liquid scintillation spectros¬
copy. The results are expressed as mean cpm for triplicate
cultures. In all cases the standard error of the mean was
<20%.
Fluorescence Flow Cytometry. T cells were stained directly
with saturating concentrations of fluorescein-conjugated mu¬
rine monoclonal antibodies. anti-Leu5b (CD2), anti-Leu4
(CD3), anti-Leu3a (CD4),"or anti-IL-2 receptor (CD25) using
a mouse IgGl fluorescein isothiocyanate-conjugated control,
or indirectly with 9.3 (CD28). Viable cells, identified by their
ability to exclude propidium iodide, were analyzed by flow
cytometry using a FACScan (Becton Dickinson). The cell
population was analyzed by gating on the volume and light-
scatter characteristics.
RESULTS
The Proliferative Response of Cloned HA-Reactive T Cells
(HA1.7) to the S. aureus Enterotoxins. Distinct patterns of
responsiveness were observed when T ceils of clone HA1.7
were cultured alone or with APCs or IL-2 in the presence of
the 5. aureus enterotoxins, over a broad concentration range
(Fig. 1). These cloned cells express a/3 TCRs bearing V/33
gene products (M. J. Owen, personal communication). SEA
at 0.5 /tg/ml in the presence of APCs induced a weak but
reproducible proliferative response (Fig. la). Although me¬
diated at different concentrations, with SED (Fig. If) being
two orders ofmagnitude more potent, the effects of this toxin
and SEB (Fig. 16) on the T cells were simitar. Interestingly,
proliferation in response to the natural ligand HA-(307-319),
in association with DR1, was always at least 5-fold greater
than that induced by any of the S. aureus toxins tested. At the
appropriate concentration, SEB or SED alone induced T-ceil
proliferation in the absence of APCs; nevertheless, the re¬
sponse was decreased compared to that observed when APCs
were present. In parallel the doses of toxin capable of
inducing proliferation decreased responsiveness to exoge¬
nous IL-2. The patterns of response to SEC1, -2, and -3 were
generally similar in that these toxins failed to induce T-cell
proliferation even in the presence of APCs (Fig. 1 c-e).
Induction of HA-Specific Nonresponsiveness After Exposure
to S. aureus Toxins. Preincubation with SEA, SEB, and SED
for 16 hr in the absence of APCs induced nonresponsiveness
in the T cells such that they were unable to proliferate in
response to an immunogenic challenge of HA presented by
murine fibroblasts expressing HLA-DR1 (Fig. 2). When
peripheral blood mononuclear leukocytes or Epstein-Barr
virus-transformed B cells were used as a source of APCs, the
enterotoxin-pretreated T cells also failed to respond to spe¬
cific antigen. This suggests that the nonresponsiveness ob¬
served in the presence of the DR1+ transfectants is not the
result ofa lack ofaccessory-cell costimulatory activity. In the




Fig. 1. Effect of S. aureus toxins on the proliferative response of HA1.7. Cloned T cells were stimulated with increasing concentrations
of staphylococcal enterotoxins. SEA (a). SEB (b), SEC1 (c). SEC2 (d), SEC3 (e), and SED if) alone (solid bars), with IL-2 (open bars), or with
mitomycin C-treated murine fibroblasts expressing HLA-DR1 (stippled bars). The control response of the T ceils to HA-(307-319) at an optimum
concentration of 1 ^tg/ml was 96,070 cpm (± 5%) (mean c: SEM).
























Pretreatment of T Cells
Fig. 2. Functional inactivation of T-ceil clone HA1.7 after ex¬
posure to S. aureus toxins. T ceils were exposed to the 5. aureus
toxins under conditions that induce unresponsiveness (as indicated).
In the control cultures, T cells were incubated in medium alone or
with the HA peptide oranti-CD3 antibody and IL-2. From each group
of treatments T cells were assayed for their ability to respond to an
immunogenic challenge of HA-(307-319) 2nd accessory cells (mito¬
mycin C-treated murine fibroblasts expressing HLA-DR1; solid
bars), accessory cells alone (hatched bars), or IL-2 (stippled bars).
response of the T cells to specific antigen, although higher
concentrations are required. A similar state of specific anergy
resulted when the T cells were exposed to a supraimmuno-
genic concentration of free HA peptide but not to a peptide
of unrelated sequence (e.g., see Fig. 4c). Unlike the activated
T cells, both HA-peptide- and toxin-tolerized cells were
refractory to an immunogenic challenge for up to 5 days.
Concomitant with the loss of antigen-specific nonrespon-
siveness, a reciprocal enhancement of the proliferative re¬
sponse to IL-2 was demonstrated. As observed in activation,
the tolerogenic effects of the toxins could be ranked as SED
> SEB > SEA. In contrast, neither antigen- nor IL-2-
dependent proliferation was modulated by exposure of the T
cells to SEC1, -2, or -3 (Fig. 2).
Phenotypic Modulation Accompanying S. aureus Toxin and
HA-Peptide-Induced Nonresponsiveness. To determine wheth¬
er or not nonresponsiveness was due to receptor modulation,
the T cells were analyzed by flow cytometry. Changes in
phenotype observed after exposure to SEA. SEB, and SED
were comparable (Fig. 3). "Hie reduced expression of CD3
(Fig. 3a) was accompanied by up-regulation of CD2 (Fig. 3b)
and CD25 (Fig. 3c). The TCR was modulated in parallel with
CD3, as determined by staining with the monoclonal antibody
WT31, which recognizes the a/3 TCR (data not shown).
Activation with insolubilized anti-CD3 antibody and IL-2- or
HA-peptide-induced anergy revealed similar changes in the
phenotype. Membrane levels of CD4 were unaltered by ex¬
posure to HA-(307-319) ormost of the S. aureus toxins tested.
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the exception being SEA, which enhanced CD4 expression,
although the efFect was marginal (Fig. 3d). The level of CD28
was marginally, but reproducibly, down-regulated (20-35%, n
= 6) in toxin- and HA-peptide-induced anergy, whereas acti¬
vation with anti-CD3 antibody and IL-2 markedly enhanced
the expression (Fig. 3e). The phenotype of the T cells after
pretreatment with SEC1, -2, and -3 were indistinguishable
from the medium control.
To determine whether or not functional inactivation par¬
alleled phenotypic modulation, the T cells were exposed to
increasing concentrations of SEB and the loss of antigen-
dependent proliferation was compared to the expression of
CD3 and CD25. At concentrations of SEB >0.05 /xg/ml, the
down-regulation of CD3 (Fig. 4a) correlated with functional
inactivation (Fig. 4c). Similarly, no changes in the expression
of CD25 (Fig. 4b) were observed in the presence of SEB at
concentrations that failed to induce anergy. Control cultures
of T cells tolerized with HA-(307-319) revealed the same
phenotypic modulation, whereas an irrelevant peptide de¬
rived from the group II allergen of dust mite, residues 36-60.
had no effect.
DISCUSSION
The present study demonstrates that human T cells ofdefined
antigen specificity exposed to certain S. aureus toxins, in the
absence of accessory cells, become anergic to an immuno¬
genic challenge by their natural ligand but retain responsive¬
ness to IL-2. Distinct patterns of proliferation were observed
when cloned human V/33+ T cells specific for HA were
cultured with the 5. aureus toxins (SEA to -D) under stim¬
ulatory conditions. SEA. SEB, and SED induced prolifera¬
tion in the presence of APCs, albeit with different potencies.
Murine and human T cells expressing V/33 elements are able
to interact specifically with SEB (6, 7); therefore, it was not
surprising that this toxin is able to stimulate the HA-specific
T cells. Human CD4' and CD8"1" T-cell clones activated by
SEA and SEB have been identified (18), and since these
toxins have =30% sequence identity (19, 20), a common
sequence may be present that allows binding to the V/3 gene
products expressed by the two subsets ofT ceils. An immu¬
nologically related functional site has tentatively been local¬
ized at the amino terminus of SEA within residues 1-27 (ref.
21). However, the comparable region in SEB shows only
limited homology and, therefore, it is unlikely that this
sequence contains the active site that triggers the T cells used
in this study. Although, of the 5. aureus toxins, SEC1 and
SEB (22) are the most homologous, the V/33' T cells would
appear to bind only the latter. Weak stimulation of the T ceils
by SEB and SED in the absence of APCs was observed.
Although bacterial toxins appear to require no cellular pro¬
cessing to stimulate T cells (1,18) and activated human T cells
express class II MHC molecules, the inability of the T cells
to provide adequate accessory signals may account for the
suboptimal activation.
Interestingly, in the absence of APCs, those S. aureus
toxins capable of inducing proliferation were able to modu¬
late antigen recognition by the cloned T cells, such that the
T cells failed to respond to an immunogenic challenge of the
appropriate ligand. The failure to respond to antigen was not
due to cytolysis since IL-2 responsiveness was enhanced.
This phenomenon of T-cell nonresponsiveness is similar to
that induced by free antigen in peptidic form (9) or antigen
presented by chemically modified accessory cells (10-12).
This finding demonstrates that extrinsic superantigens are
able to functionally inactivate the response of human T cells
to their natural ligand, in this case HA. Our observations
parallel those reported for specific tolerance to MIs-1", the
self superantigen in adult MIs-lb mice (8). The observation
that V/36' peripheral T cells are excluded after stimulation
IS a
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Fig. 3. Phenotypic modulation of the T ceils functionally inactivated by S. aureus toxins. T cells were exposed to the 5. aureus toxins under
conditions that induce unresponsiveness. Membrane expression of CD3 (a). CD2 (b), CD25 (c), CD4 id), and CD28 (e) was examined by flow
cytometry and compared to control cultures of T cells in medium alone, tolenzed with HA-1307-319). or activated with anti-CD3 antibody and
IL-2.
with SED is compatible with the ability of enterotoxins to
induce nonresponsiveness of human T cells (61. In experi¬
mental animal models, tolerance to SEB may also result from
the physical elimination of T cells (5). The direct interaction
of SEB with the TCR (4, 18) or through MHC class II
molecules on APCs could account for the clonal deletion.
From serological inhibition studies, it appears that, in con¬
trast to the HA peptide (23), under conditions that induce
anergy, the toxins bind to TCR independently ofMHC class
II molecules and transduce negative signals directly to the T
cells (unpublished observations). However, whether or not
bacterial superantigens bind directly to TCR remains con¬
troversial (1, 4, 18).
The induction of anergy by the 5. aureus toxins resulted in
changes in the phenotype of the T cells. The Ti-CD3 antigen
receptor complex was modulated from the cell surface after
exposure to SEA, SEB. or SED and correlated with the
failure of the T cells to proliferate in response to specific
peptides. However, after overnight activation with anti-CD3
and IL-2, unlike the HA peptide (24) and despite the down-
regulation of membrane Ti-CD3, an immunogenic challenge
still elicited proliferation. The rapid recovery ofTi-CD3 after
activation may account for the antigen-dependent response.
The longevity of anergy (9, 10) and the lack ofTi-CD3 on the
cells tolerized by chemically modified APCs and antigen (121
indicate that anergy is associated with complex molecular
regulation and is not solely the result of TCR modulation. In
the nonresponsive T cells, the expression of TCR and CD25
is reciprocal. The up-regulation of CD25 and the subsequent
increased IL-2 responsiveness of the anergic T cells may
lower the effective IL-2 concentration and account for the
apparent suppressor activity of SEA (25) without invoking
the generation of an additional regulatory cell type.
There was no comodulation of CD4 with CD3 from the
T-cell membrane in the anergic T ceils, which suggests that
for these cloned T cells CD4 is not structurally part of the
antigen-recognition complex (26). However, the interactions
between Ti-CD3 and CD2 appear to be considerably more
complex. Coprecipitation studies have demonstrated that
=40% of membrane CD2 is physically associated with Ti-
CD3 (27). Interestingly, in the experiments reported here the
expression of CD2 and Ti-CD3 are reciprocal in both toxin-
mediated anergy and activation. Their relationship is further
complicated by the observation that cholera toxin modulates
only Ti-CD3 on the human T-cell lymphoma Jurkat (28).
Collectively, these findings suggest that two populations of
CD2 may exist that are modulated independently and may
have different functional roles in the regulation of T-cell
activation. The regulation of CD28 expression was intriguing
by virtue of its association with an alternative pathway of
activation independent of antigen recognition by the Ti-CD3
complex (29). Although, marginally down-regulated in an¬
ergy, enhancement occurred in activation. It has been pos¬
tulated that CD28 may be the receptor for costimulatory
activity that determines the outcome of tolerance or activa¬
tion after occupancy of the TCR, based on the molecular
analysis of peptide-induced anergy (12). Our experiments
were not designed to address this issue; nevertheless they
demonstrate that CD28 is differentially expressed in acti¬
vated (anti-CD3) and anergic [HA-(307-319), SEA, SEB. and
SED] T cells (Fig. 3).
5. aureus toxins react with particular V/3 gene products of
TCRs (4—7) and, as is reported here, are also able to inacti¬
vate T cells such that they fail to respond to their natural
ligand. It has been observed that carboxymethylation, al¬
though not altering antigenicity, which remains equal to that
of the native molecule, removes the enterotoxic properties of
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Fig. 4. Dose dependence of functional inactivation and pheno-
typic modulation. After exposure to SEB at increasing concentra¬
tions. T-cell membrane expression of CD3 (a) and CD25 (b) were
compared to their responsiveness to an immunogenic challenge (c) of
HA-(307-319) and DR1* APCs (open bits) or DR1"*" APCs alone
(solid bars). Control cultures of T cells in medium alone, activated
with anti-CD3 or pretreated with tolerogenic concentrations of
HA-<307-319) or an irrelevant peptide derived from dust mite (Der
pi I 36-60) were examined.
SEA (32). The ability of the enterotoxins to induce nonre-
sponsiveness ofT cells in the presence ofAPCs, although less
efficiently than in their absence, suggests they will retain this
property in vivo (8). This raises the possibility of using
superantigens as tolerogens to inactivate subpopulations ofT
cells that express TCR with common features. This approach
would be of particular relevance in certain autoimmune
diseases where the diversity of TCR is limited (30, 31).
Furthermore, by genetic manipulation both the tolerogenic
activity and affinity of enterotoxins for TCRs may be en¬
hanced and. therefore, have potential as an alternative
method of therapeutic intervention.
We are grateful to Dr. Ronald Schwartz for his suggestion to
investigate the modulation of CD28 in T-ceil anergy. Helpful scien¬
tific discussions with Drs. G. Fathman. M. Getter, and H. McDevitt
are acknowledged. R.E.O'H. is the recipient of a Wellcome Senior
Fellowship in the Clinical Sciences. This research was supported in
part by the Medical Research Council, London.
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The induction of T-cell responses involves the recognition of
extrinsic antigen in association with antigens of the major his¬
tocompatibility complex (MHO. in mice and man. with differ¬
ent T cells recognizing antigen in association with either class
I (H-2K/D, HLA-A.B, C) or class H (la. HLA-D/DR) MHC
antigens1"5. However, the requirement of MHC recognition in
the indnction- of immnnologicai tolerance remains ill defined.
With human T helper dones recognizing synthetic peptides of
• influenza haemagglnrinin (HA-1), we have investigated the
nature of antigen-induced stimulation6, and antigen-indnced
antigen-specific unresponsiveness, immunological tolerance7.
Tolerance is not dne to ceil death, as the ceils remain responsive
to interlenitin-2 and is associated with the loss of T3 antigen
from the cell surface3. Using monoclonal antibodies to the
non-polymorphic regions of human dass II antigens to inhibit
the indnction of T-cell tolerance we report here that indnction
of tolerance requires the recognition of MHC antigens.
Since T lymphocyte dqjieS can be maintained in long-term
culture it is now possible to analyse their mechanisms of antigen
recognition and regulation in more detail than previously. We
have produced a number of human influenza-specific T-ceil
dones with a diversity of function, such as help9, suppression10
and lymphokine production11. They have been analysed for the
fine specificity of their response to antigen. Clones HA1.4 and
HA1.7 used in this study respond to a 24 ammo acid peptide
derived from the C-terminai region of HA-1 (residues 306-329)
termed peptide 20, orp20t (ref. 12). This is an immunodominant
region, as many dones raised with the intact haemaggiurimn
molecule react to this region13.
Depending on the nature and concentration of specific anti¬
gen, duration of culture and the presence of antigen-presenting
ceils, these clones can be either induced to proliferate, or can
be rendered unresponsive7. Hence these clones are suitable for
investigating the nature of the 'signals' necessary for T-cell
activation or tolerance induction. Since recognition of MHC is
of paramount importance for activation of T ceils, we wanted
to determine whether or not this was also the case for the
induction of tolerance.
The buman HLA-D region, corresponding to the mouse
H—2I region, controls a number of different products, which
have been described serologically under a variety of names.
There are three HLA-D groups (reviewed in rets 2. 14, 15).
HLA-DR and HLA-SB correspond to the mouse l-E region,
as judged by sequence homology and serological cross-reac¬
tivity. HLA-DCIDS (also known asMT and MB. LB), corres¬
ponds to the murine L-A subregion. There is evidence that
HLA-DR (ref. L6), SB (ref. 17) and DC (D. D. Eckeis. personal
communication) ail act as MHC targets of T-ceil recognition by
various clones.
The requirement for class II MHC determinants in T-cell
activation can be demonstrated either by the addition of antigen-
0.1 143 5
Anubody diluuon-ugjni"'
Fig. 1 Inhibition of antigen-induced proliferative response of
cloned helper T cells reactive with HA peptide 20 by ann-HLA
class II antibodies. Cells of HA1.7 (2~5 x 10* per mi) were stimu¬
lated with p20 (1.0 ml"1) in the presence of irradiated E~ ceils
(2-5 x 10* per ml) in 96-weil round-bottom culture plates. Anti¬
bodies (2A1. Q* DA-i ▲; UCHT1. ■: and SG465. O) were
added at the start of the cultures in the concentrations as indicated
(0.15-20 M-g ml"1 in doubling dilution) and left in for the duration
of the culture. Proliferation was assayed as described in.the legend
to Table 1. The background responses of cloned T ceils in the
absence of irradiated E~ ceils was < 150 c.p.m. as was that of E~
ceils alone cultured with antigen.
presenting ceils bearing the appropriate MHC specificities or
by the inhibition ofT-ceil proliferation by anti-class II antibodies
specific for the various subregions18. The former approach can¬
not be used as tolerance is more readily induced in the absence
◦f antigen-presenting ceils7, and so serological inhibition, using
rabbit anti-human la. andmousemonoclonal antibodies directed
against class II antigens, either HLA-DC/DS or HLA-DR. was
used. Aa controls, monoclonal anti-HLA-A. B, C, anti-£2-
microgiobulin. anti-T4 and anti-T3 antibodies were used.
The proliferative response of clone HA1.7 is inhibited by
anti-ciass II. especially anti-DC/DS and thus involves recogni¬
tion of HLA-DC/DS (Fig. I). Anti-HLA-A. B. C had no effect,
anti-HLA-DR had a minimal effect. This is presumably because
there is a degree of cross-reactivity between the non-polymor¬
phic components of HLA-DR and HLA-DC, as has been.pre¬
viously demonstrated biochemically19 "0.
One possible interpretation of the inhibition mediated by
anti-HLA-DC was chat it was due to a direct effect on T cells
in the absence of antigen. This was excluded by experiments in
which T ceils were pretreated with antibodies and then washed
before an antigenic challenge (Table I). In these conditions,
only anti-T3 inhibited T-ceil proliferation. No enhancement or
inhibition of proliferation was detected with either monoclonal
or rabbit anti-class II antibodies. Therefore it would seem that
the anti-ciass II antibodies mediated their effects by inhibiting
antigen-induced activation18, and not by direct effect on the T
ceils.
Since human T-ceil clones express class II antigens1 l-zl-22 it
was possible to investigate whether anti-class II antibodies could
inhibit the induction of tolerance. Pretreannent of the clones
with anti-HLA-DC/DS and rabbit anti-la blocked tolerance
induction completely, whereas ana-HLA-DR had only a mar¬
ginal effect (Table 2). Anti-MHC class I had no effect. These
results indicate that tolerance involves recognition ofMHC class
H antigens. To determine more precisely which MHC class II
antigens were involved, dose—response curves of ann-HLA-
DC/DS and ann-HLA-DR antibodies on tolerance induction
are compared. This was necessary as immunoprecipitation analy¬
sis has shown that the anti-DR monoclonal DA2 cross reacts
weakly with DC/DS molecules19,20, which would explain its
partial effects on the induction-of proliferation and tolerance.
However, at lower concentrations (1.25 p.gml"1), only the ann-
Table 1 Effect of antibodies on the induction of unresponsiveness in Table 2 Ann-la antibody inhibits tolerance induction
the absence of specific antigen
Pretreatment Response of cloned
Pretreatment Response, of cloned T helper cells
T helper cells. (c-p.m. =s.ejn.)
(c.p.m.= s.e.m.) Antibody Anugen E~ +Peptide 20 TCGF
Antibody Antigen E" 4 peptide 20 TCGF p20 674= 90 5,730*437
— — 11.454 * 856 3.751=497 — pll 9.210*524 4.461*428
— p20 506=104 5.677= 566 Anti-HLA (2A1) p20 456= 82 4.150 * 773
— pll 10.924 = 1.103 32356= 331 Anti-DC (SG 465) p20 8.542*267 2.368*409
Anti-HLA (2A1) 8.881=804 42309= 499 Anti-DR (DA2) p20 2.7.25*226 1712*276
Anu-DC (SG465) — 12.453 = 1.862 1264 = 226 Raia p20 9,700*972 1697*160
Anti-DR (DA2) — 8.790 = 329 2.744 = 340 Anti-T3 (UCHTI) p20 728*137 5,141*1016
Raia — 8,478*1.123 2.994 = 445 Anti-0,M (M8) p20 964*258 3,589= 773
Anti-T3 (UCHTI) — 698=138 52179= 267 Anti-T4 (MT 321) p20 880*123 4.547*71
Anti-/3-»M (M8) — 11.926= 634 4.018= 482 — — 10.591 *785 3.966=486
Anu-T4 (MT321) — 7.408 = 612 3.406=675
T lymphocyte clones reactive with the synthetic peptides of influenza
virus haemaggiudnin (HA) were isolated as described previously0.
Briefly, peripheral blood mononuclear leukocytes (PBL) were stimu¬
lated for 6 days with HA (0.1 ngml"1). Following enrichment on a
discontinuous Percoll gradient (Pharmacia) the lvmphoblasts were
resuspenaed in RPMI-1640 (Gibco) supplemented with 10% pooled
A" serum and 20% T-ceil growth factor (TCGF) and cloned by limiting
dilution. Lymphobiasts were plated one cell every third well in sterile
60-well Microtest II trays (Falcon) with 10* irradiated (2^00 rad)
autologous (PBL) and 0.1 y.gmi-1 of HA. At 7 days, growing clones
were transferred to 96-weil microtitre trays and subsequently to 24-weli
platesL At each transfer the clones received fresh TCGF every 3-4 days
and irradiated histocompatibie PBLand influenza virus (A/Tcxas/1 /77)
every 7 days. TCGF was prepared from tonsillar lymphocytes (1 x
10° ml"1) stimulated with 0.1% purified phytohacmaggiunnin (Difco)
in complete culture medium supplemented with 2.5% pooled A" serum.
Before use in experiments the clones were rested for 7 days after the
addition of filler cells. To induce tolerance, cloned T cells were cultured
at 105 perml in round bottom 96-well plates for 16 h with HAjjeptides
(50 u.gmi"') ormonoclonal antibodies (5 ugmT"1) for 16 h. Intact virus
or haemaggiutinin at high concentrations are toxic in culture and do
not induce tolerance. Rabbit anti-la was used at a 1:50 dilution. After
washing the cloned T ceils (2~5 x 10* per mi) were cultured with irradi¬
ated histocompatibie sheep erythrocyte rosette negative (E~) lym¬
phocytes (2-5 x 10* per ml) that had been pulsed overnight with
1.0 ng ml"1 of p20. Following 60 h incubation the cultures were pulsed
for 8-16 h with l.OnG of *H-thymidine (3HTdR) (Amersham) and
collected onto glass fibre filters. Proliferation as correlated with 3H-TdR
incorporation was measured by liquid sontillauon spectroscopy. The
results are expressed as mean counts per nun (c.p.m.)ss.e. of the mean
of triplicate cultures. UCHT1 is specific for the T3 antigen present on
all mature funcnonal T cells31. 2A1 is against a nonpoiymorphic deter¬
minant of HLA class I32. M8 is against microglobulin33. MT321 is
against the helper/inducer.subset (P. Richer, personal communication),
and rabbit anti-la is broadly reactive with human la-like antigens3*.
DA-2 is reactive with a monomorphic determinant of HLA-DR (ref.
23) and SG465 is an antibody reactive with HLA-DC determinants27.
HLA-DC/DS monoclonal inhibits tolerance induction (Fig. 2),
and thus the type of class II molecule recognized is the same
for both immunity and tolerance.
Analogous results have been obtained with two anti-HLA-DR
reagents, DA2 (ref. 23), CA2.06 (ref. 24), and three anti-HLA-
DC reagents. SDR 4.1 (ref. 25), HIG 78 (ref. 26) and SG 465
(ref. 27). To confirm thatMHC involvement in tolerance induc¬
tion was not unique to done HA1.7, a second p20 specific done
HA1.4 was also investigated, and showed similar inhibition by
the same anti-dass II reagents. Questions of cross-reactivity
between monomorphic anti-DR or anti-DC antibodies do not
affect the major point of this communication, that recognition
of MHC class II antigens is of importance in tolerance induction.
However, the experiments reported here do not resolve
whether the class II molecules involved in tolerance induction
are present on the same T ceil, or adjacent T ceils. Our previous
results have indicated that cloned T. cells can present antigen
to other T ceils, using an 'anti-idiotype' (anti-receptor) clone10.
Cloned T cells were preincubated with either peptide or antibody
prior to assay or antigen-pulsed E~ ceils as described in Table 1 legend.
Antibody was added 6 h prior to the addition of antigen, and left in for
the 16 h of antigen exposure before washing the ceils three rimes,
Proliferation was determined as described in the legend to Table 1.
Studies in vivo have attempted to examine whether tolerance
to minor transplantation antigens is MHC restricted. Matzmger
and Waterfield28 used F<-parent bone marrow chimaeras, but
due to the possibility of antigen reprocessing by Fx macrophages
could not make a definitive assessment. More recently Groves
and Singer29 have used parent-Pi irradiation chimaeras. Their
results suggest that tolerance of cytotoxic T-ceil precursors
involves MHC recogninon, in keeping with the in vitro cionai
analysis reported here.
The observation that T-ceil tolerance involves MHC recogni¬
tion is compatible with either a single or dual T-cell receptor
concept. However, it is not consistent with the concept that
T-ceil immunization involves recognition of antigen in associ¬
ation with MHC, whereas tolerance involves recognition of
antigen alone30. If 'positive' induction of a helper clone, to
proliferate and help, and 'negative' induction to be tolerant both
depend on recognition of the same antigen and MHC product,
it is pertinent to ask what factors discriminate between these
opposite tendencies. At present antigen concentration and anti¬
gen-presenting ceils have been shown to be relevant. However,
the role of other signals, such as interieukin-1, remain to be
elucidated.
We thank J. Knight and S. Smith for technical assistance, Drs
P. C. L. Beverley, J. Bodmer, M. Crumpton. S. Goyert, J. Silver,
V. van Heyningen for the gift of monoclonal antibodies, Drs N.
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Fig. 2 Dose-response curve of the inhibition of tolerance induc¬
tion by anti-HLA-DC and anti-HLA-DR antibodies. Ceils of
HA1.7 were pretreated with various concentrations of antibody
(anti-HLA-DC. SG 46527 #, O; anti-HLA-DR,DAI22 ▲. A) and
the anugen specific (•. ▲) and TCGF (O. A) responses assayed
as described in the legend to Table 1.
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Peptide-induced nonresponsiveness of HLA-DP
restricted human T cells reactive with
Dermatophagoides spp. (house dust mite)
Juiie A. Higgins, PhD, Jonathan R. Lamb, PhD, Steven G. E. Marsh, BSc,a
Susan Tonks, BSc,* John D. Haybail, BSc, Sandra Rosert-Bronson, PhD,b
Julia G. Bodmer, DSc,* and Robyn E. O'Hehir, MD, PhDc London. England,
and Washington, D.C.
The activation of CD4 ■+■ T lymphocytes. which play a central role in allergic inflammation,
depends■ on the recognition of allergen-derived peptides in association with major
histocompatibility complex class II gene products. In this report we demonstrate, at a clonal
level. that a component of the T-cell repertoire reactive with Dermatophagoides spp. (house dust
mite) in atopic individuals, is restricted by HLA-DP class II molecules. This supports the recent
w results emerging from genetic epidemiologic studies that indicate positive associanons between
the HLA-DP phenotype and immune responsiveness to a variety of common allergens. Our
findings also reveal that the T cells restricted by HLA-DP recognize a species-specific epitope
located in the group I allergen of Dermatophagoides pteronyssinus (residues 101-119).
Furthermore, we report that the pretreatment of the T cells restricted by HLA-DP with the Der
p I peptide renders them nonresponsive to an immunogenic challenge with house dust mite
allergen, and the loss of antigen-dependent proliferation is associated with downregulation of
membrane expression of the T-cell antigen, receptor. The ability to functionally inactivate T cells
restricted by HLA-DP. as well as those that recognize allergen in association with HL.\-DR
class II molecules, suggests that desensitization with allergen-derived peptides may have
therapeutic potential in the management of allergic diseases irrespective of their HLA class II
association. (J allergy Cun immunol 1992:90:749-56.)
Key words: Peptide^T cells. MHC, HLA-DP. Dermatophagoides spp.. house dust mite. Der p I.
desensitization
It is now well documented that CD4 + T lympho¬
cytes are critical for the induction of both the spe¬
cific (Ig£) and nonspecific (polymorphonuclear
granulocytes) effector mechanisms of allergic iniiam-
macion.1*3 The activation of CD4-F T ceils requires
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MHC: Major histocompatibility complex
IL-2: Interleukin-2
HDM: House dust mite
PBMC: Peripheral blood mononuclear cell
['HlTdR: Tritiated methyl thymidine
EBV: Epstein-Barr virus
cpm: Counts per minute
Der p I: Group 1 allergen of Dermatophagoides
pteronyssinus
APC: Antigen presenting cell
the formation of molecular interactions between T-
ceil receptor, peptide fragments of antigen, and major
histocompatibility complex (MHC) class II gene prod¬
ucts."1"6 Therefore the importance of MHC molecules
in the regulation of immune responses prompted ge¬
netic epidemiologic studies in an attempt to establish
an association between human leucocyte antigen
(HLA) phenotype and allergic immune responses to
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environmental allergens. The initial analyses concen¬
trated on pollen antigens, and consequently it was
demonstrated that the production of IgE after exposure
to the ragweed pollen antigens Amb a V, Amb t V,
Amb p V, and Amb a VI occurred in individuals ex¬
pressing DRB1*1501 and DRB5*0101 (DR2 Dw2,
DR51*) gene products.7'10 With the combined ap¬
proaches of sequence-specific oligonucleotide typing
and antigen-specific T-cell clones,l<M: these HLA as¬
sociations for ragweed pollen have been confirmed.
The extension of these studies on the linkage between
HLA and atopic disease established that specific im¬
mune responses to the rye grass antigens of Lolium
perenne (Lol p) I, H, and HI, are associated with DR3
and DR5 alleles.'3-14 As regards allergic immune re¬
sponses to house dust mite (HDM), from the analysis
of antigen-specific T-cell clones it has also.been es¬
tablished that HLA-DRB1, HLA-DRB3, and HLA-
DRB5 gene products (principally DR2. DR5. DR52b.
DR5 1) are all able to restrict the recognition of HDM
determinants.15- "
The combined results of these studies, in agreement
with many others, indicate that HLA-DR molecules
restrict T-cell recognition of the majority of nominal
antigens. However, in humans there are two additional
families of MHC class II molecules (HLA-DP and
HLA-DQ) encoded by the HLA gene complex, both
of which may function as restriction elements. As
regards HLA-DP, documentation exists that T-cell
recognition of viral and alloantigens may be restricted
by these class n molecules but may contribute to a
minor component of the T-cell repertoire. "■ 18 How¬
ever. more recently a dominant HLA-DP restricted
response to a mycobacterial heat shock protein 65
epitope has been reported in a patient with rheumatoid
and arthritis."
The ability to induce nonresponsiveness in allergen-
specific T cells offers an approach to the modulation
of allergic immune responses, ana recently it has been
demonstrated that peptide-mediated desensitization of
T-cell clones reactive to HDM is accompanied by
changes in the cytokine pattern from predominantly
interieukin (IL)-4 secretion to that of interferon (IFN)-
y, which may contribute to the downreguiation of IgE
production.30 Evidence exists to support that, similar
to activation, MHC class II molecules of the appro¬
priate specificity are required for peptide-mediated T-
cell anergy,3' although this analysis is limited to
T cells restricted by HLA-DR. Here we extend our
findings to report the first isolation of cloned CD4 —
T cells that are reactive with a peptide determinant of
the group I allergen of Dermawphagoides pteronys-
•Nomcnciature used is from the WHO Nomenclature Committee,
XI International Histocompatibility Workshop. 1991.
sinus (D. pteronyssinus [Der p I]) in the context of
HLA-DPB 1*0401 class II molecules. This supports
the recent population analyses that demonstrate as¬
sociations between responsiveness to allergens, in¬
cluding HDM, and expression of the HLA-DP phe-
notype. Furthermore, the results of experiments de¬
scribed here indicate that it is possible to desensitize
T cells reactive with. HDM and restricted by HLA-
DP with specific peptide.
MATERIAL AND METHODS
Antigens
Lyophilized extracts of D. pteronyssinus and D. farinae
were the generous gift of Bencard (Brentford. Middlesex.
England) and Pharmacia (Uppsala, Sweden). Residues 101-
119 (Der p I 101-119) of Der p I were synthesized by use
of standard solid-phase methods, purified by high-perfor¬
mance liquid chromatography (HPLC), and identified by
amino acid analysis.33
Antibodies
The monoclonal antibodies L243 (anti-HLA-DR)33 anc
B7/21 (anii-HLA-DP)34 were isolated from the culture su-
pematants of the respective hybridoma cell lines and purifiec
by use of protein A sepharose.
isolation of human HDM reactive clones
Cloned T cells reactive with Der p I 101-119 were iso¬
lated from a subject allergic to HDM by limiting dilution
cloning, as published elsewhere.33 In brief, peripheral blood
mononuclear cells (PBMCs; lOVml) were stimulated with
an optimal concentration of D. pteronyssinus (20 p.g/ml)
for 7 days in RPMI-1640 medium supplemented with 2
p-mol/L L-giutamine. 100 RJ/ml penicillin/streptomycin
(Gibco. Life Technologies. Paisley, Scotland), and 5%
screened, inactivated human A" serum (Blood Transfusion
Service. Edgeware England). Lymphobiasts enriched on Fi-
coll-Paque (Pharmacia) were established as a long-term line
in the presence of irradiated autologous PBMCs (5 x
105/ml: 2500 rad), D. pteronyssinus (20 M-g/ ml). and IL-2
(10% vol/ vol. Lympnocuit T. Biotest Folex. Frankfurt. Ger¬
many) and subsequently cloned by limiting dilution. For
cloning, viable cells (0.3 cells/well) were resuspenaed in
supplemented medium and plated in Microtest II (Nunclon:
Nunc. Roskilde. Denmark) plates together with irradiated
autologous PBMCs. D. pteronyssinus. and IL-2. After 7
days, growing clones were transferred to flat-bottom 96-
well microtiter plates and subsequently transferred to 24-
well plates. The clones were maintained with IL-2 every 3
to 4 davs and with irradiated autologous PBMCs and D.
preronysstnus every 7 days. Before use in assay systems,
clones were rested for 7 to 8 days after the last addition of
antigen presenting cells (APCs) and antigen.
Proliferation assays
Cloned T cells (103 cells/ml) were stimulated with Der
p I 101-119 (1 p.g/ml) orD. pteronyssinus (20 iLg/ml) in
the presence of an equal number of either irradiated autol-
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Concentration (pg/ml)
RG. 1. Antigen specificity of cloned T cells (KS2.12) in¬
duced with O. pteronyssinus. T cells 110s/ml) were stim¬
ulated with antigen in the presence of irradiated autolo¬
gous PBMCs as APCs. Proliferation as correlated with
[3H]TdR incorporation was measured at 72 hours. Marked
dose-dependent stimulation was observed with the pep¬
tide epitope Oer p I 101-119 (o) and with unfractionated
O. pteronyssinus extract (C). No response was observed
to the related HDM species. D. farinae (a).
mAb concentration (pg/mi)
RG. 2. Anti-HLA-OP class II antibody inhibits the antigen-
dependent proliferative response of T-cell clone KS2.12.
The blocking effects of murine monoclonal antibodies
against human MHC class II molecules were determined
in proliferation assays with clone KS2.12 and irradiated
autologous PBMCs as accessory cells with O. pteronys¬
sinus (20 jj.grml). Marked inhibition was observed with
the anti-HLA-DP antibody, B7/21 (c) in contrast to the anti-
HLA-QR antibody, L243 (o).
ogous PBMC (2500 rad) Epstein-Barr vims (EBV)-trans-
formed B cells (5000 rad), or mitomycin C-treated murine
fibroblasts expressing HLA-D region gene products, as
APCs. The murine fibroblasts (DAP3). transfected with
DRB 1-OfOl or DPB1 *0401 genes were kindly provided by
Dr. J. Trowsdale, (Imperial Cancer Research Fund), Dr.
S. Rosen-Bronson. Georgetown University. Washington
D.C.. and Dr. H. Inoko. Tokai University School of Med¬
icine. Bosheida Isehara Kanagawa. Japan, respectively. In
serologic inhibition assays, antibodies were added over a
concentration range at the initiation of cultures. After 60
hours of incubatton the cultures were pulsed with tritiated
methyl thymidine (1 p.Ci/well. [3H]TdR: Amersham Inter¬
national Inc.. Amersham. U.K.) and the cultures harvested
8 to 16 hours later. Proliferation as correlated with ['HITdR
incorporation was measured by liquid scintillation spec¬
troscopy. The results are expressed as mean counts per min¬
ute (cpm) for triplicate cultures. The standard error of the
mean for ail experiments was <20%. The data plotted in
each of the figures and tables are from one experiment:
however, each experiment was repeated three times or more
with consistent results.
Induction of T-cell nonresponsiveness
The inducnon of pepnde-mediated nonresponsiveness
was performed as previously reported for T cells restricted
by HLA-DR.36 In brief, cloned T ceils (10s/ml) were in¬
cubated with Der p I 101-119 (100 p.g/ml) for 16 hours in
the absence of .APCs. Control cultures of cells in medium
alone were performed in parallel. The cells were washed
extensively after the pretreatment before determining their
ability to respond to either an immunogenic challenge of
antigen (D. pteronyssinus or Der p I 101-119) and APCs.
or IL-2 or APC alone.
RESULTS
Antigen specificity of T-ceil clone
T cells of clone, ECS 2.12. in the presence of ac¬
cessory ceils, proliferated in a dose-dependent manner
to the inducing antigen. D. pteronyssinus whole ex¬
tract but not a closely related member of the same
genus. D . farinae (Fig. 1). With use of overlapping
synthetic peptides, the reactivity of the T cells was
mapped to residues 101-119 of Der p I.
Serologic inhibition of the
antigen-dependent response of T-cell
clone KS2.12
To define initially the subsets of MHC class II mol¬
ecules acting as restriction elements, monoclonal an¬
tibodies directed against framework anngens of HLA-
D region molecules were added over a concentration
range at the initiation of the proliferation assays con¬
taining the cloned T ceils (Fig. 2). Maximal inhibition
of antigen-dependent proliferation was obtained with
anti-HLA-DP antibody (B7/21), whereas the anti-
HLA-DR antibody (L243), which recognizes a deter¬
minant on OR a chains, faiied to modulate the
proliferative response. The activity of L243 was con¬
firmed by its ability to block antigen-dependent pro¬
liferation of other cloned T cells. The anti-HLA-DP
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TABLE I. HLA-D region specificities of the panel of EBV-transformed B cells used as APCs
HLA alleles
Cell line HLA-D specificities DRB1 DRB3 DRB4 DRB5 DQA1 DQB1 DPA1 DPB1
PGF DR15 DW2 1501 O101 O102 0602 01 0401
HOM2 DRi'Dwl 0101 — — — O101 O501 ND 0401
YAR Dr4 DwlO 0402 — 0101 — O301 0302 Ol 0401
SWEIG DR 11(51 Dw5 DR52 Dw25 1101 0202 — — O50l O301 ND O402
AMAI DR15(2) Dw2 1501 — — 0101 O102 0602 01 0402
TOKONAGA DR15(21 Dwl2 1502 — — O102 O103 O601 02 0901
WT24 DR16(2) Dw21 1601 — — O201 O102 0502 01 0301
RML DR16(2) Dw22 1602 — — 0202 O501 O301 01 0402
JVM DR11(51 Dw'JVM' DR52 Dw25 1102 0202 — — O501 O301 01 0201
TISI DR11 DR52 Dw25 1103 0202 — — O50l O301 01 O402
FPF DR1K5) Dw'FS' DR52 Dw25 1104 0202 — — O103 06 01 0201
BM16 DR12(5) Dw'DB6' DR52 Dw25 1201 0202 — — O501 O301 01 0201
TER-ND DR103 Dw'BON' .0103 — — — O101 O501 Ol 0201. 0401
PMG075 DR1 Dw20 O102 — — — O101 O501 01.02 0301.0401
ND. Not determined.
TABLE II. The T-cell clone KS2.12 (10s/ml) was cultured with 3nd without D. pteronyssinus in the
presence of HLA-D region typed EBV-transformed B cells (106/ml) described in Table I, including
the autologous EBV-B cells
3H-thymidine incorporation
(epm)




PGF DR15 Dw2 5430 23904
HOM2 DR1 Dwl 2949 46887
YAR Dr4 DwlO 2911 45938
SWEIG DR11(5) Dw5 DR52 Dw25 2901 27255
AMAI DR 15(21 Dw2 2352 2880
TOKONAGA Drl5(21 Dwl2 1580 1458
WT24 DR 16(21 Dw21 1054 2204
RML DR16f21 Dw22 2381 23051
JVM DR11(5) Dw'JVM' DR52 Dw25 7772 8546
TISI DR11 DR52 Dw25 1285 22851
FPF DR11(5) Dw'FS' DR52 Dw25 1840 1870
BM16 DR12(5) Dw'DB6' DR52 Dw25 3027 3517
TER-ND DR103 Dw'BON'- 4470 25904
PMG075 DR1 Dw20 854 26182
Dpter: D. pleronyssinus.
Proliferation as correlated with ['H]TdR incorporation measured at 72 hours. Results expressed as mean cpm for triplicate cultures. In
both test and control groups SE of the mean <20%.
antibody also gave marked inhibition of a D. ptero¬
nyssinus-specific T-ceil line derived from KS showing
that a major component of the T-cell repertoire for
D. pteronyssinus was restricted by HLA-DP (data not
shown).
Restriction pattern of cloned T cells with
use of panels of B-cell lines transformed
by EBV
On the basis of the serologic inhibition data, the
cloned T cells were further examined for responsive-
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Antigen concentration (ng/ml) Antigen concentration (jig/ml)
RG. 3. E3V-transformed B-cell lines expressing HLA-OP class II molecules restrict the recognition
of Der p I by the T-cell clone KS2.12. Cloned T lymphocytes (KS2.12: 10Vml) were cultured with
unfractionated O. pteronyssinus extract over a concentration range in the presence of an equal
number.of HLA typed, irradiated E3V-transformed 3 cells as a source APCs. Strong proliferative
responses (A) were observed with KSE. the autologous control EBV line (o). PGF (□), YAR (•),
and HOM2 (a). Moderate proliferation (B) was also induced in the presence of SWEIG (o), PMG075
(c), and TER-ND (a). Weak proliferation (CI was observed with RML (c) and TISI (a) at high
antigen concentration (50 jig/ml), but AMAI (o) failed to present HDM. No stimulation (D) was






ness by use of an APC panel consisting ofHLA-typed.
EBV-transformed. B-cell lines (Table I), including the
autologous EBV B-cell line, KSE (DR1, DR2) as a
positive control (Table II). A dose-dependent prolif¬
erative response was induced to D. pteronyssinus
when presented by those EBV-B cells homozygous
for the DPB1 gene product *0401 (PGF, HOM2, and
YAR; Fig. 3, A). The B-cell lines PMG075 and TER-
ND, which express the DPB1 gene products *0301,
*0401, and *0201, *0401, respectively, also pre¬
sented antigen to the T-cell clone in a dose-dependent
manner (Fig. 3, B). The level of proliferation was
lower in these cultures than that induced by either the
HLA-DPB 1*0401 homozygous or autologous B-ceil
lines. SWEIG, which expresses DPB 1*0402. also in¬
duced a lower dose-dependent proliferation than that
observed with the autologous B-cell line. At supraop-
timai antigen concentrations (50 p.g/mi), RML and
TISI (DPB 1*0402) induced marked proliferation.
However, the other EBV-B-ceil line expressing *0402
(AMAI) failed to present antigen effectively to the
cloned T cells (Fig. 3. O. Those EBV-B-cell lines
expressing the DPB1 products *0201 (JVM. FPF,
BM16), *0301 (WT24), and *0901 (TOKUNAGA)
failed to induce proliferation (Fig. 3, D).
Antigen presentation by murine fibroblasts
expressing HLA-DPB1*0401
class II moiecuies
To confirm the functional role of DPB 1*0401 in
antigen presentation to T ceils of clone KS2.12, mu¬
rine fibroblasts transfected with the DPB 1*0401 gene
were used as APCs in proliferation assays with whole
D. pteronyssinus extract and peptide (Der p 1 101-




FIG. 4. Recognition of Der p I 101 -119 by T-cell clone
KS2.12 is restricted by the HLA-DP8* 0401 specificity.
Cloned T cells (10r/ml) were cultured with the peptide Der
p I 101-119 (0.5 to 50 u.g'ml) in the presence of different
APCs (lOVmll; autologous EBV-8 cells (o) or mitomycin-
C-treated murine fibroblasts expressing DPB1*0401 (•),
-DRB1*0101 (a), and DAP3 (untransfected control murine
fibroblast G).
119). The transfected fibroblasts induced strong, dose-
.dependent proliferative responses in the presence of
the peptide in a manner analogous to those observed
with autologous EBV-transformed B cells as APCs
(Fig. 4). In contrast, the nontransfected fibroblast
line, DAP3, and a DRB 1*0101 transfectant, when
used as APCs failed to induce marked antigen-depen¬
dent proliferation. Unfractionated HDM extract was
only presented to T cells of clone KS2.12 by the
DPBI*0401 transfectant at high concentrations (50
p-g/ml), and proliferation was decreased compared




Preincubation of the HDM-reactive T cells
(KS2.12) with specific peptide (Der p I 101-119) at
100 p.g/ml for 16 hours, in the absence of APCs,
induced nonresponsiveness, such that the T cells failed
to proliferate when rechallenged with an immunogenic
challenge of D. pteronyssinus extract or with peptide
in the presence of autologous PBMCs (Fig. 5). Re¬
sponsiveness to exogenous IL-2. however, was en¬
hanced. The presence of anergy was associated with
downmodulation of CD3 expression and upregu-
lation of CD25 expression (data not shown), as
has been described previously in antigen-induced non¬
responsiveness in T-cell clones restricted bv HLA-
DR.=°
medium 101-119 looinyml
PrBtrearment of T calls
RG. 5. Peptide-induced inhibition of T-cell proliferation.
T cells of clone KS2.12 were cultured for 16 hours in the
presence of Der p I 101-119 (100 ug/ml) in the absence
of accessory cells or in medium alone. The T cells were
then washed thoroughly and rechallenged with an im¬
munogenic concentration of Der p I 101-119 (1 n.g/ml;
hatched histogramI or crude HDM extract, D. pteronys-
sinus (20 M-g/ml; stippled histogram) in the presence of
irradiated autologous PBMCs as accessory cells, or with
medium alone /solid histogram), accessory cells alone
/feathered histogram), or with IL-2 /open histogram). Pro¬
liferation as correlated with PHlTdR incorporation was de¬
termined at 72 hours. Results are expressed as mean com
for triplicate culture's. In both test and control groups the
SE of the mean was <20%.
DISCUSSION
In this report we demonstrate, in the periphery of
an atopic individual, the presence of T cells that re¬
spond to the group I allergen of D. pteronyssinus
(residues 101-119) in association with HLA-DP mol¬
ecules. Furthermore, the results of the experiments
reported here indicate that the administration of a su-
praoptimal concentration of Der p I 101-119 is able
to functionally inactivate the T cells such that they
are unresponsive to an immunogenic challenge of an¬
tigen.
The inhibition of antigen-dependent proliferation
with anti-HLA-DP, but not anti-HLA-DR framework
antibodies, provided the initial evidence that T-cell
recognition was restricted by HLA-DP molecules.
This contrasts with previous anti-MHC class 0 anti¬
body blocking studies examining HDM-specific T-cell
lines and clones.13'17 which suggested that HLA-DR
molecules were the major restriction elements. The
subsequent detailed analysis of the restriction speci¬
ficity of HDM-reactive T-cell clones with use of mu¬
rine fibroblasts expressing the appropriate HLA-D re¬
gion molecules confirmed that HLA-DRB1. HLA-
DRB3, and HLA-DRB5 MHC class II molecules are
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functional in the presentation of HDM.'6 The multi-
determinant nature of HDM may account for this het¬
erogeneity in the HLA class H restriction specificity
of the T-ceil repertoire reactive with dust mite aller¬
gens and, in part, may explain the failure of many
genetic epidemiologic studies to establish an HLA
linkage. To explore further the HLA-DP restriction of
the Der p I 101-119 specific T ceils, a panel of HLA-
typed, EBV-transformed B cells was used as APCs.
Antigen-dependent proliferation was observed in the
presence of EBV-B cells known to express HLA-
DPB 1*0401 (PGF, HOM2, YAR, PMG075, and
TER-ND). The ability of the DPB 1*0402 expressing
EBV-8-ceil lines SWEIG, RML, and TISI. but not
AMAi, to induce proliferation, suggests that different
allelic forms of DPB 1*0402 may exist with varying
structural homology to DPB 1*0401. The HLA-DPB1
restriction was confirmed with murine fibroblasts ex¬
pressing DPBi*0401, which were able to present Der
p I 101-119 with comparable efficiency to autologous
EBV-B cells. In agreement with previous reports ex¬
amining T-ceil recognition of other antigens.17 our
observations demonstrate that HLA-DP molecules are
able to restrict T-cell responses to dust mite allergen.
It is interesting to note that it has been reported that
HLA-DP restricted T-cell clones specific for heat
shock protein 65 expressed CD4", CD8~, TCR delta
phenotype," whereas the Der p I 101-119 reactive
T cells described here show positive membrane stain¬
ing with antibodies specific forTCR-aB heterodimers.
Furthermore, their lymphokine profile was that of the
"allergen phenotype,"78 displaying enhanced mRNA
levels for IL-4 and IL-5, but not 1L-2 and IFN-y,
which is consistent with the ability to support Ig£
synthesis (data not shown).
The importance of our findings with respect to the
role of HLA-DP molecules in atopy is highlighted by
recent epidemiologic studies that suggest positive cor¬
relations between specific IgE against common aller¬
gens and phenotypic expression of HLA-DP. Using
the polymerase chain reaction. Eura et al.79 observe
increases in DPB 1*0401 and *0201 frequencies in the
response to the group II allergen of D. farinae. The
findings in this report, based on the class II restriction
specificity of cloned T cells reactive with HDM, sup¬
port these epidemiologic smdies. In parallel studies.
Young et al.30 using population analyses report an in¬
crease in DPB 1*0401 frequencies in atopic individu¬
als, as compared with controls, for a number of im¬
portant allergens (Fel d I; Can/I;Alt a I: Phi p V; Der
p I, Der p IT). The expression of DPB 1*0401 is 55%
in normal individuals, and therefore extension of the
population studies combined with the use of ceil cul¬
ture systems is required to dissect the MHC class II
restriction of HDM responsiveness. Nevertheless, to¬
gether these reports suggest a possible important role
for HLA-DP as well as HLA-DR gene products in the
regulation of allergic immune responses.
The tissue distribution of HLA-DP class II mole¬
cules may be as important as their specificity in al¬
lergic immune responses. In 5% of adults and 10%
of children atopic disease is manifest as extrinsic
asthma. Thus increased expression of HLA-D region
molecules, including HLA-DP, on lung dendritic
ceils, the primary APCs in the airway, may have both
qualitative and quantitative effects on local immune
responses, as has been suggested for dendritic cells
isolated from the synovial fluid of patients with in¬
flammatory-arthritis. 31 Similarities in the inflammatory
components of asthma and inflammatory arthritis im¬
ply that studies on the expression of class II molecules
on airway APCs may be rewarding.
The ability to render peripheral T-ceils nonrespon-
sive to specific antigen forms the theoretic basis of
allergen-mediated desensitization. It has been reported
that peptides and superantigens of the appropriate
specificity are able to induce tolerance and modulate
the lymphokine production ofT ceils reactive to HDM
toward that of Thl type cells.70 The in vivo potential
of peptide-mediated anergy is suggested by the ob¬
servation that high doses of peptide are able to induce
T-cell nonresponsiveness in the presence of APCs.70
Nevertheless, this analysis has been limited to only
those T cells that are restricted by HLA-DR and
prompted us to investigate whether or not it was pos¬
sible to induce tolerance in T cells restricted by HLA-
DP molecules. The findings reported here establish
that exposure to specific peptide may functionally in¬
activate T cells restricted by HLA-DP, and that the
loss of antigen-dependent proliferation is associated
with the transient modulation of the T-cell receptor
from the cell surface.70
Our findings demonstrate at a clonal level that a
component of the T-cell repertoire reactive with
HDM, in atopic individuals, may be restricted by
HLA-DP class H molecules and support the recent
experimental data on HLA associations in allergy that
are emerging from the population studies.79, 30 The
ability to functionally inactivate the T cells with use
of allergen-derived peptides suggests that such an ap¬
proach may have therapeutic potential in the man¬
agement of allergic diseases where T-ceil allergen rec¬
ognition is in the control of HLA-DR and/or HLA-
DP molecules.
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Major Histocompatibility Complex Independent
Clonal T Cell Anergy by Direct Interaction of
Staphylococcus aureus Enterotoxin B with the T Cell
Antigen Receptor
By Colin R. A. Hewitt,*! Jonathan R. Lamb,! John Hayball,!
Mark Hill,§ Michael J. Owen,*" and Robyn E. O'Hehir!
Front the "Imperial Cancer Research Fund, London WC2A 3PXt UK; the *Department of
Immunology, St. Mary's Hospital Medical School, Imperial College of Science, Technology and
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California 94306
The Staphylococcal enterotoxin superantigens stimulate vigorous responses in T cells bearing
certain T cell antigen receptor (TCR) V/3 regions. In addition to activation, these superantigens
also impart negative signals to T cells resulting in a profound state of unresponsiveness or anergy.
The Staphylococcus aureus enterotoxins (SE) D and C2 bind to a closely related site on major
histocompatibility complex (MHC) human leukocyte antigen (HLA)-DRl molecules. Only SEB,
however, interacts with the TCR V/33 region of HA1.7, a human HLA-DR1 restricted T cell
clone specific for influenza haemagglutinin. In competition experiments, we demonstrated that
the induction of anergy in HA1.7 by SEB is unaffected by the presence of SEC2. These results
suggest that SEB-induced anergy is MHC independent and involves a direct interaction between
the TCR and SEB. To resolve definitively whether SEB binds directly to T cells in the absence
ofMHC class II molecules, the cDNAs encoding the HA1.7 TCR were transfected into anMHC
class II-negative human T cell line. The addition of SEB to these transfectants resulted in the
downregulation of cell surface TCR expression, an increase in the concentration of intracellular
calcium ions, the production oflymphokines, and reduced responsiveness to a subsequent challenge
with SEB. We conclude that SEB interacts directly with the TCR in the absence of cointeraction
with MHC class II molecules, and that this interaction may induce anergy in HA1.7.
Agroup of exotoxins produced by certain strains of Staph¬ylococcus aureus induce vigorous responses in T cells ex¬
pressing particular TCR V/3 elements (1^1). Such exotoxins
have thus been termed superantigens. In common with en¬
dogenous murine retroviral superantigens, bacterial superan¬
tigens also have the capacity to shape the TCR repertoire
by clonal deletion (2, 5) or the induction of anergy (6-8).
Since thymic deletion alone fails to explain self-tolerance to
antigens expressed exclusively by adults or in sites remote
from the neonatal thymus, anergy, which can be induced in
mature T cells, is proposed to account for T cell unrespon¬
siveness to these antigens both in in vivo (6-9) and in vitro
models (10-12).
Incubation of human T cell clones with supraoptimal con¬
centrations ofnominal peptide antigen renders the cells anergic
to a subsequent immunogenic challenge (10, 11, 13). In
common with antigen-specific T cell activation, antigen-
induced anergy is initiated by MHC class II-restricted an¬
tigen presentation (14).
More recently, it has been demonstrated that Staphylococcus
aureus enterotoxin (SE)1 superantigens, are also able to in¬
duce T cell anergy to their native ligand (12, 15). Unlike
peptide antigen-induced anergy, however, enterotaxm-induced
anergy was not inhibited by anti-MHC class II mAbs (R. E.
O'Hehir and ]. R. Lamb, unpublished observations).
The aim of the present study was, therefore, to determine
whether a Staphylococcal enterotoxin superantigen was able
to interact directly with the TCR and induce clonal anergy
in the absence of MHC-dependent antigen presentation.
Materials and Methods
Reagents and Cell Lines. HA1.7 is a human.CD4* T cell clone
specific for influenza haemagglutinin (HA) peptide 307-319 in the
1 Abbreviations used in this paper. AnPCR, anchored polymerase chain re¬
action; HA, inflnrn7a harmagglurinin; SE, Staphylococcus aureus enterotoxin.
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contact of HLA-DR1. LNAT is an autologous EBV-transformed
B cell line used as an APC (16). JRT3T3.5, a CD3-TCR negative,
MHC class Il-negative mutant ofJurkat (17), was a gift from Dr.
A. Weiss (University ofCalifornia, San Francisco). CTLLM, a mu¬
rine IL-2-dependent T cell line used for the bioassay ofJurkat-derived
supernatants (18), was obtained from the European Collection of
Animal Cell Cultures (EACC) (Forton Down, UK). Oligonucle¬
otides were synthesized by Dr. Ian Goldsmith (Imperial Cancer
Research Fund). The HA peptide 307-319 was synthesized by Dr.
J. Rothbard (ImmuLogic Pharmaceutical Corp.). FITC-conjugated
goat antibodies specific formouse Igs and anti-CD3 were obtained
from Becton Dickinson & Co. (Mountain View, CA). MX6, an
anti-TCR V/38 mAb was obtained from Dr. S. Carrel (Ludwig In¬
stitute, Epalinges, Switzerland). SEB, SECi, and SECa were ob¬
tained from Sigma Chemical Co., (Poole Dorset, UK) or Toxin
Technology, Inc. (Madison, WI).
Cloning ofTCR a and/3 chain cDNA. HA1.7 was purified free
ofAPC and stimulated for 6 h with 1 /xg/ml phytohaemagglutinin-P
(Sigma Chemical Co.) and 10 ng/ml PMA (Sigma Chemical Co.)
to increase TCR a and /3 chain mRNA expression (19). RNA was
purified from 5 x 106 cells by the guanidine isothiocyanate-acid
phenol method (20). cDNA was synthesized by a standard oligo-
dT primed method (21). cDNAs encoding the HA1.7 TCR a and
13 chains were then amplified using the anchored PCR (AnPCR)
(22) as modified by Dr. P. Marche andDr. O. Acuto (Institut Pasteur,
Paris, France).
For amplification of TCR a chain cDNA, an antisense primer
was designed to include pan of the C region (bold type), and
EcoRJ, and Bglll sites: 5' GCGAA1TCAGATCTlAGGCAGA-
CAGACTTGTCACTGG. 3'; the sense primer for the TCR a
rhain contained a dC anchor, Xhol, NotI, and Sail sites: 5' CACTC-
GAGCGGCCGCGTCGACCCCCCCCCC 3'. The antisense
primer used to amplify the TCR /3 chain contained pan of the
C region (bold type), Kpnl, Sail, and Clal sites: 5' GGTACC-
GTCGACATCGATCCACCAGCTCAGCTCCACGTGGTCG
3'. The sense primer for the TCR /S chain included a dC anchor,
SphI, NotI, and SacII sites: 5' GCATGCGCGCGGCCGCGGA-
GGCCCCCCCCCCCCCC 3'. 25 cycles of AnPCR were per¬
formed, each cycle consisting of 1 min at 94°C, 2 min at 55°C,
3 min at 72°C, and a single final extension of 6 min at 72°C.
AnPCR products were isolated, cloned, and sequenced by stan¬
dard methods. Full a and jS coding sequences were constructed
using constant region cDNAs derived from the Jurkat TCR a and
(3 chains.
Functional Expression ofTCR. The HA1.7 TCR a and /3 con¬
structs (UBal4/4 and CUB/31.5) were cloned into the eucaryotic
expression vector PJ6G, in which cDNA is transcribed under the
control of the rat actin promoter (23). pj6Q expression vectors con¬
taining the hygromycin B (pJ6GhygTo) or puromycin (pJ6Qpuro)
resistance genes, were made available by Dr. H. Land (Imperial
Cancer Research Fund).
The HA1.7 TCR /3 expression-construct (50 /xg/ml) was cotrans-
feeted with pJ6Q hygro (25 /xg/ml) into 2 x 107 JRT3T3.5 by
electroporation (450 V at 125 /xF). Cells were immediately placed
on ice and resuspended in RPMI1640 containing 10% FCS. After
3 d of culture, the medium was supplemented with 400 /xg/ml
hygromycin-B (Sigma Chemical Co.).
After 3 wk, the a chain expression construct was cotransfected
with pJ60 puro into the 3 chain transfected line by electropora¬
tion. Cells were selected in medium containing 400 /xg/ml of
hygromycin-B, and 4 /xg/ml of puromycin (Sigma Chemical Co.),
and the resulting cell line assessed for CD3 expression by flow cytom-
eter analysis. Cells were sorted for high CD3 expression three times
and then cloned by limiting dilution. Clones were screened for re¬
sponses to peptide 307-319 and SEB in the presence ofLNAT APC.
One particularly efficient clone CH7C17 was used for themajority
of these studies.
A mock transfected subline designated OGSL1 was also gener¬
ated. This line underwent all the procedures outlined above, but
was electroporated in the absence of plasmid DNA.
Functional Assays. Anergy was induced by incubation ofT cells
(lOVml) with HA peptide 307-319 (up to 100 /xg/ml) or SEB (up
to 100 /xg/ml) for 16 h at 37°C. Cells were thoroughly washed
and then challenged with an immunogenic concentration of HA
peptide 307-319 or SEB in the presence of irradiated (6,000 rad)
LNAT APC. Experiments with HA1.7 were pulsed with 1/xCi
of [3H] thymidine (Amersham International, Amersham, Bucks,
UK) for the last 16 h of a 72-h culture. For experiments with
CH7C17, culture supernatants were taken at 72 h and used to stimu¬
late CTLL-M cells for 24 h. Proliferation was then measured by
[3H] thymidine incorporation for the last 8 h of culture.
Assay of Intracellular Calcium. Cells were washed three times
with serum-free RPMI, then incubated with 1 /xg/ml Fura-2 in
RPMI at 37°C for 15 min. Cells were washed twice with HBSS
containing 20 mM Hepes at pH 7.3, and resuspended at lOVml.
Two ml of cells were placed in a cuvette and warmed to 37°C with
stirring in a fluorimeter (The Perkin-Elmer Corp., Norwalk, CT)
set to excite at 325 nm and measure fluorescence at 510 nm. The
stimulus was added and the fluorescence recorded for 5 min.
Immunofluorescence. Cells were stained for sorting or cell sur¬
face phenotype analysis by standard methods using mAb directly
conjugated to FITC, or a primary mAb followed by a second layer
of FITC-conjugated goat antibodies specific for mouse Ig.
SEB and SEC2 Competition Binding Assay. SEB was biotiny-
lated by incubating a twofold molar excess ofN-hydroxysuccinimide
active ester of long chain biotin with SEB (1 mg/ml) overnight
at 4°C. Unbound biotin ^vas removed by Sephadex G-25 gel filtra¬
tion. Biotinylated SEB (50 /xg/ml) was incubated with 1BW4, an
HLA-DRl-Dwl EBV-transformed B cell line, for 2 h at 4°C in
the presence of various concentrations of unlabeled SEB or SEC2.
Cells were washed with PBSA containing 0.1% BSA and incubated
at 4°C with FITC-avidin D (Vector Labs., Inc., Burlingame, CA)
at 10 /xg/ml for 30 min. Cells were washed and resuspended in
PBSA containing 0.1% BSA for flow cytometer analysis.
Results
SEC2 Fails to Compete with SEB during the Induction of
Anergy. The Staphylococcal enterotoxins SEC2 and SEB are
known to bind to the same site on MHC class II antigens
(24). Unlike SEC2, however, SEB stimulates T cells ex¬
pressing TCR V/33.1 elements (12). To confirm the identity
of the SEB and SEC2 binding sites on HLA-DR1, bi¬
otinylated SEB was incubated with HLA-DR1"1" B cells in
competition with unlabeled SEB and SEC2. Consistent with
the report that the two enterotoxins bind to a closely related
site on the HLA-DR1 molecule, the binding ofSEB to HLA-
DR1* B cells was specifically competed with both by unla¬
beled SEB and SEC2 (Fig. 1 A).
If SEB-induced anergy occurs by a mechanism indepen¬
dent of MHC class II binding, then it should be possible
to anergize HA1.7 with SEB after pretreatment with an excess
of SEC2. A 100-fold molar excess of SEC2 failed to inhibit
the induction of anergy in HA1.7 by either SEB or the HA
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Figure 1. SEC 2 interacts with'
the SEB binding site on HLA-
DR1, but Bails to inhibit anergy
induction by SEB or HA peptide
307-319 in HA1.7. (A). Bi-
otinylated SEB at 50 /xg/ml was
incubated with EBW4, HLA
-DRl-Dwl EBV-transformed B
cells for 2 h at 4°C in the pres¬
ence of various concentrations of
unlabeled SEB {filled squares) or
SEC: (open squares). Biotinylated
SEB bound to the cell surface was
detected using FITC-conjugated
avidin and flow cytometer analysis.
(B) HA1.7 was treated with 50
/ag/ral of SEC2 for 1 h at 37°C
then incubated with an anergizing
concentration ofSEB (0.5 /zg/ml)
or peptide 307-319 (50 /ig/ral) for
16 h at 37°C. Cells were washed
and stained with mAb specific for
CD3 (hatched bars) or CD25
(shaded bars).
peptide 307-319 (Kg. 1 B). The fall in CD3 expression, and
rise in CD25 expression, both characteristics of anergy (12),
combined with the failure of HA1.7 to incorporate thymi¬
dine after a subsequent immunogenic challenge with HA pep¬
tide 307-319 and APC (data not shown), suggested that anergy
induction by SEB may not require MHC class II molecules.
Generation ofMHC Class II Antigen-negative T Cells Ex¬
pressing the HA1.7 ICR. The TCR a and 0 chain cDNAs
encoding the HA1.7 TCR were cloned from HA1.7 RNA
using AnPCR. 20 clones containing a PCR fragment of the
correct size for TCR a were sequenced. All 20 clones con¬
sisted of an identical sequence with i^o evidence for a second
TCR a transcript. The HA1.7 Va region differed from the
Val.2 subfamily sequence by a single, conservative base change
(25). The N region consisted of twelve nucleotides, and was
unique to HA1.7 (Kg. 2 A). The core sequence of the HA1.7
Jot region was identical to that used by clone AA13 (26),
and was most similar, but not identical, to a member of the
M jet family (27).
20 clones of the single TCR 0 chain PCR fragment were
also sequenced. All 20 clones consisted of a V/33.1 region
identical to that used by the clone PL4.4 (28), a unique 9-bp
N region, and a D/3 region with the conserved core sequence
Gly, Leu, Pro (Kg. 2 B). The J region was identical to the
J/31.2 region used by the cell line JM (29).
Full-length coding sequences of the TCR a and 0 chains
were constructed by ligation with the TCR a and 0 con¬
stant regions ofJurkat. Constructs were sequenced to ensure
the correct joining of the constant regions. Each TCR cDNA
was recloned into expression vectors and transfected into the
CD3-TCR negative, MHC class II-negative mutant T cell
line JRT3T3.5. The transfected line was cloned by limiting
dilution, and the clone CH7C17 was characterized further.
A mock transfected line OGSL1 was also characterized in
parallel.
The mock transfected subline OGSL1 and the HA1.7 trans-
fectant CH7C17 were examined for surface expression ofCD3,
TCR-cr/0 and TCR V/38 by immunofluorescence. OGSL1
was completely CD3, TCR-a/0, and V/38 negative, and
CH7C17 expressed high levels of CD3 and the TCR-a/ft
but no TCR V/38, demonstrating that the TCR expressed
by CH7C17 was not derived from the native TCR V/38 posi¬
tive Jurkat cell line (data not shown). CH7C17 was also as¬
sayed for the expression ofMHC antigens. Immunofluores¬
cence analysis usingmAbs, specific for monomorphic epitopes
of HLA-DR antigens, HLA-DP antigens, all MHC class II
antigens (including HLA-DQ), and all HLA class I antigens
showed that both the native Jurkat cell line, OGSL1, and
CH7C17 expressed no detectable MHC class II antigens (Kg.
3). All cell lines however, were strongly positive for MHC
class I antigens (data not shown; Kg. 4 A). This confirms
results from independent laboratories which demonstrate the
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Figure 2. Sequence of HA1.7TCR at and (3 chain V-N-(D)-J-C junc¬
tional regions, (a) TCR a chain. (b) TCR £ chain. These sequence data
are available from EMBL/Genbank/DDBJ under accession numbers X63455
(HA1.7 TCR alpha chain) and X63456 (HA1.7 TCR beta chain).
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Figure 3. Jurkat transfectants Bail to express surface MHC class II an¬
tigens. CH7C17 (solid line) and LNAT {dotted line) were stained with {A)
goat anti-mouse Igs conjugated with FITC (GaMFITC); {B) FITC-
coniugated ann-HLA-DR (Becton Dickinson 8c Co., Mountain View. CA);
(C) anti-HLA-DP (B7/21/2) and GaMFITC and (D) anti-HLA-DQ +
DR +• DP (CA2.11) + GaMFITC, then analyzed by flow cytometry.
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Figure 4. Rrcomatution of
HA1.7 TCR. intigen-MHC spec-
maty. JRT3T3.5 was transacted
by electropotation with cDNAs
encoding the TCR a and 3 chain
of HA1.7. Transttctcd cells were
cloned (CH7C17) and stimulated
with LNAT APC and peptide
307-319 (fitted quarts) or SEB
(filled triangles). T cell activation
was assessed by lymphokine pro¬
duction.
complete absence of both cell surface MHC class II antigens
on various sublines ofJurkat, (S. Marsh and J. Bodmer, per¬
sonal communication), and mRNA for HLA-DP, DQ, and
DR (45).
Unequivocal evidence that the TCR expressed by CH7C17
was identical to that expressed by HA1.7, was obtained by
functional analysis. CH7C17 and OGSL1 were challenged
with various concentrations ofHA peptide 307-319 and SEB
in the presence of LNAT.APC. After 24 h of culture, super-
natants were assayed for lymphokine content in a CTLL-M
bioassay.
As shown in Kg. 4, CH7C17 responded to both HA pep¬
tide 307-319 and SEB with a concentration-dependent re¬
sponse, demonstrating that the specificity of the HA1.7 TCR
had been reconstituted in CH7C17. The mock transfected
cell line, OGSL1, was completely unresponsive to HA pep¬
tide 307-319 and SEB presented by LNAT APC. Neither of
the cell lines responded to SECi (data not shown).
MHC Class U Independent SEB-mediated Signaling in
CH7C17. CH7C17 was incubated in the complete absence
of MHC class II-positive APC with SEB at concentrations
up to 100 /rg/ml. After overnight incubation, cells were
washed and assessed for the level of CD3 expression. The
culture supernatants were taken for lymphokine assay.
The level of cell surface CD3 on CH7C17 cells decreased
in an SEB concentration-dependent manner, such that higher
concentrations of SEB resulted in lower cell surface expres¬
sion of CD3 (Kg. 5 A). In contrast to CD3, the level of
MHC class I antigen expression was increased -with the con¬
centration of SEB (Kg. 5 A). MHC class II expression, how¬
ever, was not induced after incubation with SEB. Using
CA2.11, a mAb specific for HLA-DR + DP + DQ antigens,
no change was observed in the mean fluorescence intensity
of CH7C17 after incubation in medium alone, or in the pres¬
ence of SEB. A mean fluorescence intensity of 3.4 was ob¬
served with CA2.11 and secondary antibody in both the pres¬
ence and absence of 20 /rg/ml SEB. Downregulation ofCD3
was specifically due to SEB as SEA, SECi, SEC2, and SEE
failed to induce any change in CD3 expression (data not
shown). Lymphokine production by CH7C17 cells also in¬
creased with the concentration ofSEB. This increase was not
due to the direct interaction of SEB with the CTLL-M cells
(Kg. 5 B).
CH7C17 Pretncubatedwith SEB in the Absence ofMHC Class
IIAntigens Fails to Respond to a Subsequent Immunogenic Chal¬
lenge with SEB. CH7C17 was incubated without MHC class
Figure 5. SEB induces down-
regulation ofCD3, and stimulates
lympholrine production by CH7-
C17 in the absence ofMHC class
II antigens (A) CH7C17 was in¬
cubated for 16 h with various con¬
centrations ofSEB in the absence
of APC, cells were washed and
stained with anti-CD3 (filled
squares, left hand scale) or anti-
MHC class I (filled triangles, right
hand scale) and analyzed by flow
cytometry. CH7C17 was stimu¬
lated for 16 h with various con¬
centrations of SEB in the absence
of APC (filled squares); superna¬
tants were taken and assayed for
lymphokines. Various concentra¬
tions of SEB (filled triangles) were
incubated for 16 h in the absence
of cells. Supernatants were then
tested for the direct activation of
CTLL-M cells.
-positive Witn 5H13 at various concentrations up to
100 /ig/ml. After overnight incubation, cells were washed
and loaded with Fura-2 for assay of changes in intracellular
calcium ion concentration. Fura-2-loaded cells were then
stimulated with SEB (15 fig/ral) in the absence of APC in
stirred cultures. Changes in intracellular calcium ion concen¬
tration upon stimulation were measured using a fluorimeter.
Within 10 s of restiiuulation with SEB, the concentration
of intracellular calcium increased, peaking at a level depen¬
dent upon the concentration of SEB used in the overnight
incubation, such that preincubation with higher concentra¬
tions of SEB rendered CH7C17 less responsive to the subse¬
quent exposure (Fig. 6). This effect was specific to SEB, as
cells incubated overnight with various concentrations of
SECi (which does not activate HA1.7) had no effect on the
increase in intracellular calcium ions stimulated by 15 fig/ml
SEB. Neither SEB nor SECi was able to increase intracel¬
lular calcium above basal levels in the TCR-negative cell line
Figure 6. SEB induces un¬
responsiveness in CH7C17 cells.
CH7C17 was incubated for 16 h
with various concentrations of
SEB (filled squares) or SECi (filled
triangles). Cells were washed and
loaded with Fura-2, then stimu¬
lated in the absence of APC with
15 fig/rol of SEB. Changes in
fluorescence induced by an increase
in intracellular calcium ion con¬
centration were measured, and the
concentration of intracellular cal¬
cium calculated.
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Discussion
This study demonstrates that a TCR of defined antigen
specificity is able to interact with SEB in the absence ofMHC
class II antigens. Furthermore, the direct interaction of SEB
with the TCR was able to stimulate a program of events
leading to clonal anergy in the T cell clone HA1.7.
Characteristically, superantigens are able to bind to all TCRs
using particular V/3 regions irrespective of the antigen-MHC
specificity of the TCR (3). This implies that the superan-
tigen binding region shared by certain TCR V/3 regions is
remote from the CDRs involved in MHC-restricted peptide-
antigen recognition. In support of this, two recent studies
have analyzed the reactivity of TCR mutants and close V/3
family members with different reactivities, and predicted that
superantigen binding sites lie on the side of the TCR mole¬
cule, away from the peptide antigen-MHC binding site (30,
31). Similar studies on the MHC requirement of superan¬
tigen recognition have shown that many MHC class II an¬
tigen isoforms are able to present a particular superantigen
to TCR. This suggests that superantigens bind to common
sites on MHC class II antigens remote from the peptide an¬
tigen binding groove.
The present results demonstrating anergy induction by pep¬
tide 307-319 in the presence of SEC2 (Fig. 1 B) support this
conclusion. Others have characterized this binding site using
cell lines that expressMHC molecules with mutations in the
peptide antigen binding groove (32), or by demonstrating
the binding of labeled superantigens to structurally similar
MHC class II molecules (33).
In a recent study of clonal T cell anergy in HA1.7, we
demonstrated that human T cells of defined antigen-MHC
specificity, when exposed to high concentration of SEB, Be¬
come anergic to a subsequent immunogenic stimulus with
their natural peptide ligand and APC (12). The present re¬
port demonstrates that, in contrast to peptide-mediated anergy,
SEB-induced anergy in HA1.7 is notMHC dependent. Thus,
pretreatment of HA1.7 with anti-MHC class II mAb or
SEC2, which binds to an identical site on HLA-DR1, but
fails to interact with the HA1.7 TCR, is unable to inhibit
SEB-induced anergy.
To demonstrate directly that SEB interacts with the TCR
in the absence ofMHC antigens, cDNAs encoding the HA1.7
TCR were introduced into a T cell tumor line which ex¬
pressed no cell surface TCR and MHC class II. Incubation
of these cells with SEB in the absence of APC resulted in
SEB concentration-dependent T cell activation, as measured
by a rapid increase in the concentration of intracellular cal¬
cium ions and lymphokine production. In common with
HA1.7, incubation of CH7C17 with SEB in the absence of
APC reduced cell surface CD3 expression in a dose-dependent
manner. This downregulation was of functional significance,
as the cells mounted a reduced Ca2+ response to a subse¬
quent exposure to an optimal concentration of SEB. Studies
in vivo (34) support the conclusion that the level of TCR- -
CD3 expression is of fundamental importance in the mecha¬
nism of both T cell activation and anergy.
The absence of cell surface MHC class II expression by
the transfectedmutant odl line derived from Jurkat is ofcentral
importance to this study. In addition to immunofluorescence
results reported here, (Fig. 3), and those by independent groups
(S. Marsh and J. Bodmer, personal communication) analysis
ofmRNA specific for KLA-DP, DQ, andDR has determined
that the parental cell line of CH7C17, Jurkat, does not pro¬
duce mRNA for HLA-DP, DQ, or DR (45). Furthermore,
J. D. Fraser (35), reports that SEA and SEB are unable to
bind to the surface ofJurkat cells, confirming that these cells
are MHC class II negative. The completeMHC class II nega¬
tivity ofJurkat was also shown functionally by demonstrating
the inability of Jurkat cells to present enterotoxins to un-
primed human PBLs (35). ,
There is a single report that small amounts ofMHC class
IH chain can be immunoprecipitated fromMHC class H-posi-
tive cells pulsed with enterotoxin. This study concludes that
a small amount of class 1 H chain might interact with preex¬
isting enterotoxin-MHC class II complexes (35). There is no
evidence, however, thatMHC class I antigens are able to bind
directly to, or present enterotoxins to T cells (36). Indeed,
even CD8 positive, class I-restricted CTL TCRs interact
with SE only when bound to MHC class II (37). We there¬
fore conclude that SEB-induced downregulation of CD3 in
CH7C17 and anergy in HA1.7 is MHC independent and in¬
volves a direct interaction between the TCR and SEB.
Other groups have also obtained circumstantial evidence
that superantigens might bind directly to the TCR (37-40).
Immobilized or cross-linked Streptococcal M toxin has been
shown to stimulate native Jurkat cells to produce IL-2 (41).
T cells may also be stimulated in the absence ofAPC by con¬
jugation of a T cell-surface antigen-specificmAb to the same
solid support as an enterotoxin (42). There is also a report
that enterotoxins may behave in a similar manner to soluble
anti-CD3 mAb in their ability to induce early activation events
in T cells (38).
The ability to anergize T cells in the absence ofMHC class
II antigens using enterotoxins has clinical implications in,
for example, autoimmune and allergic diseases, where there
may be restricted TCR V0 usage in the harmful T cell re¬
sponses, but where the antigen is either not determined or
extremely complex, and involvement of MHC antigens is
ill-defined. In these cases, enterotoxins modified to separate
the enterotoxic (emetic) from TCR binding activity (43),
and possibly the TCR fromMHC binding activity (44), could
be used to anergize T cells expressing particular V/3 regions
implicated in disease processes.
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It is possible to regulate the activity of human influenza virus
specific helper T-cell clones either by high concentrations of
antigen1 or by anti-idiotypic suppressor T cells'. In the absence
of accessory ceils, the appropriate peptide antigen recognized
by the clones induces specific unresponsiveness. This
phenomenon, hpwever, is not the result of cytolysis as respon¬
siveness to EL-2 remained unaltered. This suggests that high-
dose immunological tolerance need not involve suppressor T
cells, and that peptide antigens can interact directly with the
T-cell surface. As recent reports suggest that the T-cell surface
antigen T3 is involved in the triggering of T lymphocytes and
possibly in antigen recognition3** we have investigated the
expression of T3 and other ceil surface antigens following the
induction of T-ceil tolerance. We report here that when a T-cell
done is exposed to a tolerizing concentration of the appropriate
peptide antigen, surface T3 antigen is lost in a dose-dependent
manner. As loss of surface T3 induced by anti-T3 antibody also
results in unresponsiveness to antigen, we condude that T3 is
involved in the process of T-ceil triggering by antigen.
The capacity to produce and maintain long-term T-
lymphocyte clones has made it possible to analyse T-cell
heterogeneity and function with much greater precision than
before. We have generated a number of human influenza
spedfic T-cell dones and lines which show diversity of function,
such as help3 suppression2 and lymphokine production6. Some
of these have been analysed for the fine sperifirity of their
response to antigen. Clone HA1.7 has been shown to proliferate
in culture in response to HLA-DR1 and a 24 amino add peptide
derived from the C-terminal of the HA1 portion of the influenza
haemagglutinin (residues 306-329; termed peptide 20)7.
We have shown that when clone HA1.7 was cultured for
several hours at 37 °C with a supraoptimal dose of peptide 20
(p. 20) in the absence of antigen presenting cells, the clone
failed to respond by proliferation when subsequently exposed
to an immunogenic dose with antigen presenting ceils. This
unresponsiveness is a form of immunological tolerance and is
antigen spedfic, since the HA1.7 cells which cannot respond
to antigen still proliferate in response to optimal concentrations
of TCGF. Other T-cell clones in the same culture vessel remain
unaffected indicating that this is a specific effect. The cells
remain unresponsive for at least one week but during this period
are alive and capable of responding to TCGF. These results
exclude certain hypotheses for the mechanism of tolerance1.
Since the T3 antigen is assodated with lymphocyte triggering
its expression was investigated in clone HA1.7 cultured for
16 h at 37 °C in the absence of feeder cells, or with the relevant
influenza A haemaggiutinin peptide, p. 20, or an irrelevant
haemagglutinin peptide, p. 11. TTie cells were examined for the
expression of T3 antigen by indirect immunofluorescence using
a fluorescence activated ceil sorter (FACS IV, Becton Dick¬
inson) and for their capadty to respond by proliferation with
antigen (p. 20) in the presence of histocompatible irradiated
antigen presenting ceils (Fig. 1). When ceils have been pre-
incubated in medium or with p. 11, the majority of the ceils
are brightly stained by UCHT1 (anti-T3) and far to the right
of the scale, but after exposure to p. 20 the fluorescence is
much reduced. A dose-response curve with p. 20 shows that
the diminution of T3 is dependent on antigen dose, increasing
up to the highest concentration used. The phenotypic effects
observed following the exposure of HA1.7 to p. 20 are specific
in that an irrelevant peptide (p. 11) does not induce the modula¬









Fig. 1 Indirect immunofluorescent staining with UCHT1 mono¬
clonal antibody of control and peptide antigen modulated clone
HA 1.7. T lymphocyte clones specific for the synthetic peptides of
influenza haemagglutinin7 were isolated as previously
described1,18. Briefly, peripheral blood lymphocytes (PBL) were
cultured for 6 days with 0.1 ngml7' of HA (gift of Dr R. G.
Webster). The lymphobiasts were enriched on a discontinuous
Percoll (Pharmacia) gradient and resuspended in RPMI-1640
(Gibco) containing 10% A-t-serum and 20% T-cell growth factor
(TCGF), and plated at one cell every third well in Teraski trays
with 10* irradiated (2,500 rad) autologous PBL and 0.1 ngml"1
HA. After 7 d, growing clones were transferred to 96-well micro¬
ti tre trays and then to 24-well trays. At each transfer the clones
received fresh TCGF and irradiated autologous PBLs together
with specific antigen. The clones were expanded in 25 cm2 tissue
culture flasks receiving 20% TCGF every 3-4 d and irradiated
autologous PBL and intact virus (A/Texas/1/77) every 7 d. TCGF
was prepared from 48 h supernatants of PBL (1 x 106 perml)
cultured with 0.1% purified phytohaemaggiutinin (PHA-P; Difco)
in complete culture medium containing 1% autologous serum.
Before use in tolerance induction or modulation assays, the clones
were rested for 6-7 d after the addition of filler cells. Modulation
was induced by exposing 2xl03 clone cells in round bottom
microtitre trays in the absence of filler cells for 16 h to HA peptides
at the concentrations shown in the figure. In these experiments
the peptides used were p. 11 (amino arid residues 105-140) and
p. 20 (residues 306-329). Following exposure to peptide or control
medium the cells were washed and stained for indirect
immunofluorescence with UCHT1 monoclonal antibody and FTTC
conjugated and immunoabsorbent purified sheep anti-mouse
immunoglobulin antiserum10. Stained cells were analysed for for¬
ward angle light scattering (ceil size) and scatter gated fluorescence
on a FACS IV.
Light scatter I Fluorescence
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unique property of either clone HA1.7 or p. 20 in that clone
HA2.43, also specific for p. 20, was modulated in a similar
manner (Table 1). Secondly clone HA2.61, specific for p. 11
(ref. 1), showed modulation of T3 only after exposure to p. 11
and not p. 20 (Table 1). Exposure of clones HA1.7, HA2.43
and HA2.61 to UCHT1 antibody under similar conditions also
leads to a loss of surface T3 antigen (Table 1, Fig. 2) alone,
but not other surface markers studied. Preliminary data suggests
that significant changes in phenotype and function can be detec¬
ted after 3 to 4 hours exposure to antigen or UCHT1 antibody.
We have not yet investigated in detail the kinetics of re-
expression of T3 antigen on modulated cells but other data
suggests that modulated TCGF dependent T cells re-express
T3 after approximately 48 h8.
The functional effects of pretreatmentwith antigen or various
antibodies are shown in Table 2. When clone HA1.7 is used,
p. 20 but not p. 11 markedly inhibits the response to its specific
antigen p. 20, but not to TCGF, indicating that it is an antigen
specific effect. UCHT1 causes similar abrogation of the
response to antigen. Of the other antibodies, anti-Tl (Leu 1,
UCHT2) was weakly inhibitory but not any of the others. It
may be relevant that the antigen T1 was partly modulated by
p. 20 but not p. 11 (Fig. 2) and can be readily modulated by
exposure to anti-Tl antibody (data not shown and reference
8). All the other antibodies shown in Table 2 stained HA 1.7
but the level of staining was not decreased by pre-exposure to
p. 20.
We have previously shown that exposure of T cell clones to
a high dose of peptide antigen in the absence of accessory cells
induces a state of specific immunological tolerance implying
that T lymphocytes can recognise soluble antigen without pro¬
cessing1. TTie results presented here lend support to this view
as, in addition to the functional effects, we have shown that the
cells undergo profound phenotypic changes. The data also impiy
that the loss of T3 antigen is intimately associated with the loss
of responsiveness since both the phenotypic and functional
Table 1 Modulation of T3 antigen in control clones
Pre-incubation







p. 11 29 31 40
p. 20 4 13 83
UCHT1 63 25 12
p. 11 8 11 81
p. 20 18 25 57
UCHT1 53 26 21
T-ceil clone 2.61 responds by proliferation to p. 11 and T-ceil clone
2.43 to p. 20. Both clones were incubated for 16 h at 37 °C with
20^gml_1 of p. 11 or p. 20 or Sugml-1 of UCHT1 monoclonal
antibody. They were then washed and stained with UCHT1 monoclonal
antibody for FACS analysis (see Fig. 1). Results are expressed as the
percentage of cells (103) analysed appearing in fluorescence channels.
Cells appearing in channels 1-100 are unstained or very dim, those in
channels 101-200 are of intermediate brightness and those in channels
201-255 are brightly stained.
changes can be induced by exposure to antigen or anti-T3
antibody and have the same antigen dosage requirements. It is
conceivable, however, that HA1.7 recognizes antigen in associ¬
ation with its own la molecules, but fails to proliferate in the
absence of other stimulating signals. This question can only be
answered by direct binding studies using labelled antigen.
Our results resemble the recent observations of Schlossman
and his colleagues who have reported that the T3 antigen of
cloned human cytotoxic cells was modulated by exposure to
anti-T3 or antibody to clonal specific (clonotypic) molecules4.
Comodulation suggested that the T3 antigen was closely associ¬
ated with the clonotypic marker which was considered to be
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Fig. 2 Modulation of surface antigens by exposure to antibody
or peptide antigen. Gone HA1.7 cells were cultured for 16 h in
medium alone, in the presence of 5 p.gml-1 of purified UCHT1
immunoglobulin or with 20 M.gml-1 of p. 11 or p. 20 (see legend
to Fig. 1). Following treatment cells were washed and stained with
either UCHT1 (anti-T3) or UCHT2 (anti-Tl) monoclonal anti¬
bodies followed by FITC sheep anti-mouse immunoglobulin anti¬
serum.
Table 2 Effect of monoclonal antibodies reactive with lymphocyte anngens on
the induction of antigen specific unresponsiveness
Tolerance induction Response (c.p.m.±s.e.m.)
Antibody (specificity) Antigen Antigen TCGF
8.821 ±585 3,981 ±499
— p. 20 270±67 4,353 = 479
UCHT1 (T3) — 431 =70 4,597= 412
Leu 1 (Tl) — 6.209±1.251 4,726 = 442
UCHT1 (Tl) — 4.700 ±567 4,233 = 507
9.6 (E receptor) — 8.271 ±197 3.968 = 390
3A1 (most T ceils) — 7,787 ±1,026 4,593 = 391
M-T321 (T4) — 7,885±731 3.951 = 522
2A1 (HLA Qass I) — 8,995 ±869 4.871 = 254
M8 (/32M) — 9,275 ±178 4.730=497
Rala (HLA Class II) — 7,291 ±562 4,103=451
HLe-1 (leukocyte common) — 6.803 ±522 4.182=169
— p. 11 7,984 ±937 4,144*536
Tolerance was induced as described in detail elsewhere1. Cloned T cells
(10s per ml) were incubated for 16 h with haemaggludnin (HA) peptides or
antibodies in the absence of anugen presenting ceils. HA peptides were used at
50 u8ml"', the monoclonal antibodies UCHT1 and Leu 1 at 5 ug ml-1 of purified
immunoglobulin and other monoclonal antibodies as whole ascites or serum at
concentrations at least fivefold greater than the minimum required to give
maximal staining by indirect immunofluorescence. After washing, the T cells
(2.5 x 104 perml) were added to irradiated autologous sheep erythrocyte rosette
negative (E-) ceils (2.5 x 104 perml) that had been pulsed with antigen. Following
72 h incubation the cultures were pulsed for 8-16 h with 1.0 u.G JH TdR (Radio¬
chemicals Inc.. Amersham) and collected on to glass fibre filters. Proliferation as
correlated with 3HTdR incorporation was measured by liquid scintillation spec¬
troscopy. UCHT1 is specific for the T3 antigen present on all mature functional
T cells10, UCHT2 and Leu 1 are against the 67K T1 antigen11-", 9.6 binds to
the sheep red blood cell receptor", 3A1 stains the majority of T cells14, M-T321
is against the heiper/inducer subset (P. Richer, personal communicationj, 2A1
is against a non-polymorphic determinant of HLA Class I", M8 is against
beta-2M16, anu-HLe-1 is against a common leukocyte antigen" and the rabbit
anti-la is broadly reactive with human la-like antigens". HA1.7 expresses the
phenotype characteristic of human heiper cells (Tl, 3, 4 and 11 positive) and is
stained by all the reagents listed above.
merits imply that T3 is associated with T-ceil antigen recogni¬
tion. However, certain differences are apparent that influence
our hypothesis as to the functional role of T3 and its precise
association with the antigen specific T-ceil receptor. It has
been suggested, based on the comoduiation of phenotype and
function that T3 represents the constant region of the antigen
recognition structure. However, it is unlikely that T3 by itself
represents the entire constant region $ince serological evidence
indicates differences between the constant region of the recep¬
tors of helper and suppressor T-ceil subpopuiations9.
The induction of unresponsiveness by anti-T3 or p. 20 resul¬
ted in no enhancement of the EL-2 response, implying that
although T3 may be required for antigen-specific signal trans¬
mission it is not a prerequisite for EL-2 signal transmission.
Furthermore, pretreatment with antigen (or anti-Tl) induced
phenotypic changes not seen with anti-Tj, namely modulation
of the T1 antigen. This suggests that although T3 may be linked
to the antigen specific receptor it is uniikeiy that the two are
identical since anti-T3 and specific antigen modulate T ceils in
a different manner. It is our view therefore that T3 is not a
structural component of the T-ceil receptor but is necessary for
transmission of an activation signal following antigen binding.
This hypothesis is compatible with ail the reported immunologi¬
cal effects of anti-T3.
We are grateful to those who have provided us with mono¬
clonal and other antibodies and to the Department of
Haematoiogy, Faculty of Clinical Sciences, University College,
London, for permission to use the FACS IV. We thank Dr T.
Davies and his colleagues at the National Blood Transfusion
Centre, Hdgware. for their assistance and Dr R. A. Lerner for
helpful discussions. ILD.Z. is supported by the Arthritis and
Rheumatism Council.
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Antigen-specific T cell unresponsiveness in cioned
helper T ceils mediated via the CD2 or CD3/TI receptor
pathways
We have investigated the role of the CD2 protein in the negative regulation of
immune function and report that similar to antigen and anti-CD3, the monocionai
anti-CD2 antibodies (Till and Til,) can induce specific unresponsiveness. Anngen
and and-CD2 tolerogenic signals both down-reguiated the phenotypic expression of
CD3-Ti. In contrast CD2 surface expression was up-reguiated after exposure to pep¬
tide and down-regulated after ann-Tll. and Til, preincubation. However, in both
instances interieuidn-Z receptor surface leveis were increased. These phenotypic
changes could oniv be partly explained by variations in the leveis of the transcripts
encoding the CD3-TI and CD2 molecules.
1 Introduction
Human T lymphocytes can be activated through either the
CD3-Ti receptor complex following co-recogmtion of antigen
and major histocompatibility complex (MHC1 gene produtns
[1| or the sheep erythrocyte receptor, the CD2 differennation
anngen [2]. Additionally the CD3-TI receptor complex can
transmit a negative growth or tolerogenic signai. in that the
exposure of cloned helper T ceils to supraopnmal concentra¬
tions of the relevant pepnde antigen or ann-CD3 antibody in
the absence of accessory ceils fAO can induce unresponsive¬
ness to an immunogenic challenge of specific anngen [31. This
state of anergy results from the modulation of CD3-Ti from
the ceil surface with reciprocal enhancement of imerieukin 2
receptor (IL2R) ana CDZ expression [4]. Therefore, it was of
interest to determine if the sumuianon of T cells via the "licer-
nanve" pathway (CD2 protein) is either able to induce or to
reverse anngen-specific T cell unresponsiveness.
2 Materials and methods
2.1 Antigens
Pepnde 14 ( residues 306-319) and RB635 (residues 310-329)
of the carboxvl cenmnus of the HA-L moiecuie of influenza
virus (H2N2) hemaggiunmn (HA) were the girt of Dr. R. A.
Lemer. Scnnps Research Insutute. La loila. CA.
2.2 Antibodies and cytofluorometric analysis
Monocionai anti-CD2 annbodies Tllt, Til, and TII3 were
provided by Dr. E. L. Remheiz. Dana-Farber Cancer Insn-
(162231
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tute. Boston. MA. Monocionai anti-CD3-{Leu4) and and-3r
microglobulin were purchased from Becron Dickinson. Moun¬
tain View. CA. Ann-EL2R antibody (ann-Tac) was the girt or'
Dr. T. A. Waidmann. NCI. Berhesda. MD. For FAC3 analy¬
sis cioned T ceils preincubated with anngen or annbodv were
washed and stained for indirect immunofluorescence with the
monocionai annbodies (mAb) Leu4, ann-Tac, Tilt, Til? ana
Til3 mAb and fluorescein isothiocyanate-conjugaced and
immunosorbent-purmed sheep ana-mouse immunoglobulin
andsera as previously described. Stained ceils were analyzed
on EPICS C (Coulter Electronics. Harpenden. G3). Resuits
are expressed as percentage or ceils analyzed appearing in
channel no. 1-256.
2.3 Generation of human cloned helper T cells
Coned heiper T ceils (HA1.7) reaenve with pi.4 were isolated
and characterized as described previously (31. Bneflv.
peripheral blood mononuclear leukocytes (PBMC) were- cul¬
tured for 6 days with HA (0.1 ug/rai). Lvmphobiasts isoiatea
on a disconnnuous Percoil gradient (Pharmacia. Uppsaia.
Sweden) were resuspended in RPMI 1640 (Gibco. Grand
Island. NY) supplemented with 10% A" serum ana EL 2 (20%.
Lympnocuit T, Biotest Serum Insutut. Frankfurt. FRG) ana
cioned by limiting dilution (0.3 ceils/weil) in Terasaki trays
with irradiated autologous PBMC (lOYweil) ana HA (0.1 ug/
mi). Clones were expanded in EL2 every 3—4 days and irraai-
ated histocompatibie peripheral blood lymphocytes together
with anngen every 7 days. Before use in experiments the
clones were rested for 6- days after the last addition of oiler
ceils.
2.4 Induction of T ceil unresponsiveness
To induce toierance. cioned T ceils were cultured at 10° ceils/
mi in tubes (Falcon 2058. Oxnard. CA) in the absence of Slier
ceils for 16 h at 37 °C with HA peptides or mAb (3|. Pepnaes
pi.4 and RB6B5 were used at 50 ug/mi in these experiments.
Anri-j3?-M mAb was added at 5 ug/mi and the ann-Tll? ana
TII3 were added together at a finai dilution of L/200. .After
washing, the T ceils were cultured in proliferation assays.
0014-2980/87/1111-641S02.50/0
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2.5. Proliferation assays
Cloned T cells (5 x 107ml) were cultured together with inadi-
ated histocompanbie PBMC (1.25 x KP/mi) and pl4 (0.3 tig/
mi) or cultured alone with IL2 in a total volume of 200 ui in
96-weil round-bottom micronter plates. Following 60 h incu¬
bation the cultures were puised for 8-16 h with
0.1 uCi = 37 kBa of tritiated methyl thymidine ([JH]dThd:
Amersham Radiochemicals Inc., Ametsham. GB) and har¬
vested onto glass Sbet filters. Proiiferadon as coneiated with
[JH]dThd incorporation was measured by liquid santillanon
spectrometry. The results are expressed as mean counts per
minute (cpm) = % SEM of triplicate cultures.
2.6 Northern hybridization analysis
Total ceiluiar RNA was prepared tram ceils premcubated
overnight in medium or with anti-Til; and Til; (ann-CD2),
anu-CD3-Sepharose (anti-CD3) or p!4. Equal amounts of
total RNA (10 ug) were eiectropnoresed on a 1.1% formai-
dehyde-agarose gel and transferred to nitrocellulose as
described [5]. The filter was sequentially hybridized with 32P-
labeied 11 aipha. beta. CD3 delta. CD2 [6] ana actin probes as
described previously [7], A different Northern filter was
hybridized with the IL2R probe. This blot was renvbndized
with' an actin probe (not shown) for quanntation. Several
exposures were taken after each hvbridizanon to ensure
linearity of response and autoradiographs were quantitated by
densitometry. The levels of mRNA were assessed reianve to
that of acnn on the assumption that changes in the actin
mRNA level under the different incubation conditions
reflected any general varianon in mRNA level relative to that
of ribosomai RNA. Functional assays on each of the test
groups were always performed in parallel. -
Table 1. Anti-CD2 annbodv-induced T ceil acuvauon and tolerance
inaucuon'"
Tolerance: inaucnon Resptmv rrnn —%t'SEM- ~~ '
T ceils. ..Antigen/ Antigen/ 7 AC "r77a_ '. ■ 2E2V
i antibody antibody
— —r : gx-—- -Q4— ^ - -




is- Pi4 ., ni4»-£-fe;-"inr-rn; ■"
-
RB6B5 ."'.I- pi* T^,02S76=alib.~IT562i=il8
THi.-t-THj; pl4- '~ .■ '.2.41.±2Drzi371(P±rn.
■ -.Ann-tL-iVi" . pt—q^Al9-7u—~74"
a) Gone HA1.7 (I07mll was incubated with pl4 (50 ugtml). RB6B5
(50 ua/mil. Til; and Til) (1/2001 or anu-£—M (5 ugimi) in the
absence of AC for 16 h. T ceils (5 x 107mi) were then snmuiateo
with irradiated histocomDauble PBMC 1.25 x 107mil and pl4
(0.3 ug/ml) or alone with IL2. Proliferation was detennmed by
FHldThd mcorporauon. The results are exoressed as mean counts
per minute (cpmI = % SEM of tnpiicate cultures. Control spea-
mens of T ceils and PBMC in the absence of anngen. PBMC and T
cells alone are shown as is the mnogemc effect ofTil. and Til. in
the presence of PBMC (line 2).
3 Results and discussion
In this study we have investigated the effects of ann-Tll; and
TII3 antibodies on the phenotvpic expression and mRNA
levels of CD3-Ti. CD2 and IL2R in the induction of T cell
unresponsiveness. For this analysis we have used T ceils of
done HAi.7 which are reactive with residues 306-519 of the
HA-1 molecule of influenza virus (pl4; [3]). These cells when
cultured overnight in the absence of AC with pl4. but not with
an irrelevant HA peptide RB6B5 (residues 310-329). failed to
respond to an immunogenic challenge of pl4 (Tabie 1). Simi¬
larly. preincubation with anti-Til; and ann-Tll; antibodies m
the absence of AC-induced unresponsiveness to pl4. whereas
the control antibody anti-fi—microglobulin had no effect
(Table 1). In contrast, both pl4 and the combination of anh-
Tll; and Til; enhanced the response to IL2. In the presence
of AC. however. HAi.7 proliferated in response to ann-Tll;
andTil; (Tabie 1). These results suggest that the CD2 protein
can deliver a negative signal that is functionally idenncal to
that of supraopnmal antigen. To determine if both forms of
unresponsiveness operate through similar mechanism the ceils
were firstly examined for CD3-H, CDZand IL2R expression
by indirect immunofluorescence using FACS. In comparison
to the medium control, preincubation with pl4 or anti-Til;
and Til; down-regulated CD3-T1 whereas IL2R expression
was enhanced (Tabie 2 and Fig. 1). However, wniie expres¬
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Figure 1. Expression of CD3-TI. CD2 and IL2R genes. The incuba¬
tion conditions used for tolerance or activation and the Northern blot¬
ting conditions are as described in Sect. 2.6.
ceils to pl4. in contrast anti-Til? and Tllronoduiated CD2
from the ceil surface. T cell membrane antigen changes follow¬
ing activation with anri-CD3-Sepharose. which mimics the im¬
munogenic effects of anngen/MHC and was included as a con¬
trol. .-is observed with the tolerogenic concentrations of p!4
and the anti-CD2 antibodies. CD3-T1 was down-reguiated ana
the EL2R reciprocally up-reguiated. There was. however, no
change in CD2 expression (Tabie 2).-
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Table 2. Phenorypic modulation of peptide and inn-CD2 annboay-
induced T ceil unresponsiveness"
'ToieiajULr-indnrnbirr -r 9ae ot'cells stained! -/,4m
Anngen/annbods*^ MICSi?-Ami,- Ami- • --I?AWr^
~ CDZ •• - CD3" "-lEZar
Mcdmnn^^- -.;.r^; .;- : JL f,.~ 95" ^^S.f-- r .
4--:- S3^.V'94^-12".
TIDw-TII^ . 9£*3fe*3Sb '5."-.9*^i
CDSVSepiiamsea^'r" 72^ '
«... * I "' —hlTt'ii iThBM I " " 'm- n-'-' Ti" '--- ■■'• '--"-•■•■••■"*r£r\^" 'ri*"
a) Gone HA1.7 (10*/mi) was- prerreated wicH pl4, Til, and Til,,
CD3-Sepharose (500 beads/10* ceils) or in meoium alone. The ceils
were washed, stained and anaivzed on FACS as descnbed in
Seer. 2.2.
Since pi.4 and anti-Til'; and Tllj-tnduced unresponsiveness
was accompanied by phenotvpic changes (Table 2 and Fig. 1)
the possibility was investigated chat these changes were
reflected by an alteration in the levels of mRNA encoding the
receptor components. When anti-Til; and Tllj was used as a
tolerogenic signal Ti beta ana CDS aeita mRNAs were
reduced by 3-5-fold (compared to the medium control)
whereas the level of alpha transcripts remained unchanged
although an additional 1.2 kb alpha transcnDt was observed
(Fig. 2). This transcript is most probably a result of transcrip¬
tion from promoter elements upstream of the J alpha elements
[8j. In contrast, after preincubation with plA aloha, beta and
delta mRNA levels were not significantly altered although the
l.2-kb alpha species was again induced. CD2 mRNA leveis
were increased by about 2-foid after preincubation 'with pi.4.
but were unchanged by ana-Tll;-and Til? treatment. In both
instances EL2R mRNA 4eveis were increased by at least
10-20-foid. When HAi.7 was activated by an 18-h incubation
with ann-CD3-Sepnarose Ti alpha and beta. CD2 and EL2R
mRNA levels were essentially unaltered whereas CD3 delta
mRNA was decreased by about 4-fold. It is emphasized that
these changes in transcript levels are relative to the level of
actin mRNA and were measured at a single tune point. How¬
ever. changes in the leveis of these transcripts may occur at a
different time during activation than that which is optimal for
the induction of unresponsiveness.
Thus, there was no evidence tor a tight coupling of CD3-Ti
ana CD2 surface expression and steady state RNA leveis after
the overnight preincubation of HAi.7 with pl4 or anti-Til;






Figure 1. Modulation ot CD3 (A). CD2 (B) una IL2R (CI exuression
after exposure to toienzmg concentrations of tne mAb Til, una Til,
f .1, pic (•'•) or medium f—). Cjntroi staining with unu-mouse [g
fluorescent antiboov ( ).
extensive changes in mRNA leveis encoding these surface
components occur during snorter incubation penods with old
or anti-Til, and TII3. They do, however, suggest that the
phenotypic changes observed cannot be wholly explained by
transcriptional regulation of receptor genes. A transladonai
or, more likely, post-translationai control most probably con¬
tributes to the cell surface changes. The mechanism of sucn
post-cranslanonai control is unclear but may involve the level
of intracellular transport, internalization and degradation, or
both.
After preincubation with pl4 or anti-Til, and Tllj, HAi.7
exhibits increased IL 2R mRNA and surface expression, a pro¬
cess which is most probably the result of transcriptional con¬
trol mechanisms. The observed inachvauon is. therefore, pre¬
sumably due to the lack of IL2 expression since the addition of
exogenous IL2 results in proliferation (Table 1). Consistent
with this observation was the failure to detect IL2 mRNA
after the 24-h preincubation of HAI.7 with pic or Til, and
TII3 (data not shown) and that the clone appears to synthesize
only low leveis of EL 2 [9J.
This study extends our earlier observations on the tolerogenic
effects of anngen via CD3-T1 [j. 4] to the altemauve pathway
of T ceil activation [2] and demonstrates that ann-CD2 anti¬
bodies in the absence of AC can induce antigen-specific unre¬
sponsiveness through down-reguianon of CD3-Ti. In comoa-
rabie studies it has been reported that activation by CD3-
Sepharose is not inhibited by modulanon of CD2. whereas
preincubation with ann-CD3 antibody did inhibit anti-Til,
and Till activation although the expression of CD2 was not
altered [101. Other reports suggest that some anti-CD2 ann-
bodies are able to inhibit antigen and mitogen-induced prolif¬
eration [11] and that this may operate by suppressing EL 2
secretion and receptor expression [121. In contrast, we and
others observed that IL2R expression 'was enhanced. The
implications of these observations for the CD2 and CD3-TI
pathways of activation will most probably require unequivocal
elucidation of the physiological role for CD2. This elucidation
will be aided by the recent identification of the CD2 ligand as
the surface glycoprotein LFA-3 [13!. Various models for the
function of CD2 in the thymus have been postulated including
a roie in inducing the ininai expansion of thymocyte immig¬
rants (via IL2R expression! and in the induction of toierance
to seif-MHC [10). In the periphery, a possi'oie roie might be 1
synergistic one. "hat is. to provide the predominant prolifera¬
tion signal for a T ceil after antigen/MHC recognition via the T
ceil receptor [14|. Thus, the transducnon of both positive and
negative signals might be of crucial imnonance in CD2 func-
non and the results reported here snouid be interpreted in this
context.
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Abstract
A failure of T lymphocytes to produce interleukin 2 (IL-2) on restlmulation may, in part, account
for the specific, unresponsiveness that accompanies incomplete activation. The evidence to
support this has been derived predominantly from the investigation of the molecular basis of
anergy in murine type 1 T ceils. In this study, the effects of different tolerogenic signals
delivered by specific peptide or Staphylococcus aureus enterotoxin on the ability of antigen-
specific human T ceils to produce lymphokines, both in the induction phase and in established
antigen-specific non-responsiveness, have been examined. Although T cell proliferation was
decreased by supraoptimai concentrations of specific peptide in the presence or absence of
antigen presenting cells, IL-2, IL-4, and interferon gamma (IFN-y) synthesis were comparable to
that of activated T ceils. The different tolerogenic signals, ail capable of inhibiting proliferation,
had selective effects on the secretion of these lymphokines during the induction phase of
unresponsiveness. Restimiilation of anergic T ceils with an antigenic challenge failed to induce
iymphokine production, with the exception of allergen-reactive T cells that secreted IFN-y. This
latter observation is relevant to the desensitization of specific responsiveness in allergic disease.
Introduction
The ability to discriminate seif from non-self is acquired in the
thymus and aopears to be mediated both by deletion (1.2) and
functional inactivation of seif-reactive T cells (3.4). Direct evidence
for clonal anergy is derived from the results of recent in vivo
experiments examining the induction of tolerance to exogenously
administered self antigens (5). and the extrathymic expression
of non-lymphoid-associated MHC class i and class II molecules
m transgenic mice (6.7). These findings parallel those of the
previously established human and murine in vitro systems of
non-resoonsiveness. wnich demonstrated that occupancy of the
TCR by peptide fragments of antigen bound to class II MHC
molecules, in the absence of costimulatory activity, resulted in
functional inactivation of the T cells (8-10). Specific non-
resoonsiveness may be achieved by a variety of different stimuli
(8- 15). including exposure of T cells to free antigen in peptide
form (8). Peptides of the appropnate specificity, in the presence
of antigen-presenting cells (APCs). were able to inhibit T cell
proliferation, although in their absence the concentration of
antigen required to achieve a comparable degree of anergy was
less (8). Similarly, negative signals delivered by Staonylococcus
aureus enterotoxins inhibit antigen-dependent but not
IL-2-deoenoent proliferation of T cells expressing particular TCR
Vj gene elements (16).
The molecular basis of anergy has been examined predom¬
inantly for murine Tj type cells, in ccntrast to the T„2 ceils, that
provide B cell help (17), where little is known of the underlying
mechanisms (11.18). However, recent analysis of Tni ano T„2
cells of the same antigen specificity has indicated that botn
subsets may be tolenzed. althougn they exnibit distinct differences
(19). The failure of Th1 ceils to respond after exoosure to antigen
presented by chemically modified APCs (9). or by nign concentra¬
tions of IL-2 (15), was attributed primarily to a lack of IL-2
production, althougn the activity of other lympnokines was also
modulated in the non-responsive T cells (11.12.20.21).
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In this report, we have examined the effects of different
tolerogenic signals delivered by specific peptide or S. aureus
enterotoxin on the ability of human CD4 • T cells to proliferate
and produce lymonokihes. The modulation of lymphokine
production was investigated both ounng the induction phase and
in estaolisned anergy. in the presence of APCs. althougn T cell
proliferation was decreased by supraoptimal concentrations of
specific peptide, the production of mterleukin 2 (IL-2). IL-4. and
interferon gamma (IFN-y) was equal to or enhanced as compared
with activated T cells. During the induction phase of anergy.
different tolerogenic signals that were all caoaole of inhibiting
proliferation had selective effects on the secretion of these
lympnokines. Restimulation of the anergic T cells with an antigenic
challenge failed to induce lympnokme production, with the
exception of allergen-reactive T cells that secreted IFN-7.
Methods
Antigens
Staonyiococcai enterotoxins 5. C2. and D (SE3. SEC2. and SED)
were purcnased from Toxin Tecnnology (Madison. Wl). Residues
307 - 319 (HA 307 - 3T9) of the C-iermmus of the HA-1 molecule
of influenza virus naemagglutimn and residues 89-117 (p I
89 - 117) of the group I allergen. Der p I, of Dermatophagoides
pteronyssinus were synthesized using standard solid-phase
methods. The peptides were punfied by HPLC and identified by
amino acid analysis (22). Recombinant Derp I was obtained after
expression in Escnenchia coli of the genomic DNA. cooing for
Der p I (a kino gift of Dr W. Thomas. Princess Margaret Children's
Hospital. Penh. Australia), as a fusion protein with glutathione
transferase (23).
Cloned antigen-specific T iympnocytes
The isolation of cloned T cells reactive with HA 307-319 has
been reponec in aetaii previously (24). Briefly, peripheral biooo
mononuclear leukocytes (P3MC) were stimulated with an optimal
concentration of punfied HA in RPMI 1640 (Gibco Laboratories.
Grand Island. NY) supplemented with 100 U/ml penicillin.
100 ^g/mi streptomycin. 2 mM L-glutamine. and 5% screened
human AB- serum. The activated T cells were cloned by
limiting dilution m the presence of irradiated autologous PBMC.
IL-2 (10% v/v. Lymphocult T. Biotest Folex. Frankfurt. Germany),
and antigen. The cloned T ceil populations specific for Der p I.
NP-12 and NP-14, were generated from the blood of a house
dust mite allergic patient by stimulating PBMC with a lyopnilized
extract of D. pteronyssinus (1 /tgTni; Diepnuis Laboratories.
Groningen. The Netherlands) and have been described
elsewnere (25). Growing HA-reactive T cells were expanded by
stimulation with antigen and filler cells every 7 days. The Der p
l-specific T cells were cultured ano expanded by stimulation with
feeder cefls every 14 days in the absence of antigen. After stimula¬
tion. the T cell clones were expanded with IL-2 every 3-4 days.
Prior to their use in experiments the T cells were rested. 7-8
days for HA1.7 and 10-14 aays for NP-12 and NP-14. after the
last addition of filler ceils and antigen.
Induction of T cell anergy
HA-reactive T cells (106/mi) were incubated with HA 307 -319
or the S. aureus toxins, ano tne house dust mite specific T cells
with recombinant Der p I or p I 89 -117 for 16 h in the absence
of APCs. Control cultures of T cells resting in medium or with
Concanavann A (Con A: 30 ^g/ml) were performed in parallel.
The supernatants were harvested for the determination of
lympnokines ano the cells then wasned extensively before
being assayed for their ability to respond to an immunogenic
challenge of specific antigen ano APCs or IL-2.
Proliferation assays
Cloned T cells (l05/m!) were stimulated with HA 307-319
(1.0 uglml) m the presence of mitomycin C-treated murine
fibroblasts expressing HLA-DR1Dw1 (lOVml: ret. 22) as a
source of APCs. or in IL-2 alone. The Der p l-soecific T cells were
stimulated with recombinant Der p I or p I 86 -117. in the
presence of mitomycin C-treated (50 pg/ml for 45 min).
autologous. Epstein - Barr virus (EBV)-transformed B cells as
APCs. After 60 h incubation, tritiated methyl thymidine (pHJTdR:
1 pCi/well: Amersnam International. Arlington Heights. IL) was
added and the cultures harvested 8 - 16 h later. Proliferation as
correlated with pH]TdR incorporation was measured by liquid
scintillation spectroscopy. The results are expressed as mean
c.p.m. for triplicate cultures. In all experiments the standard error
of the mean was <20%.
Generation of lymphokmes
T cells (106/ml) were cultured for 24 h with HA 307 - 319 (at 0.5
ano 50 pg/ml), SE3. SEC2. or SED (all at 0.5 /tg/ml). ano
recombinant Der p I or p I 89-117 (1 and 100 pg/mi
respectively), and the supernatants harvested. Control suoer-
natants from T cells in medium alone or activated with Con A
(30 jtg/ml) were also assayed for the presence of lympnoKines.
T cells (105/well) exposed to the different pretreatments were
restimuiateo with DR1 * fibroblasts (10s/weil) and HA 307 -319
(1 Mg/ml) in 96-well flat-Qottom plates in a total voiume of 200 nl.
The Der p l-specific T cell clones were restimulated with
recombinant Der p I or p I 89 -117 in the presence of autologous
E3V-transrormeo B cells. Control cultures contained T cells alone.
APCs alone, or T cells together with APCs but without acoeo
antigen. After 60 h incubation the suoernatants were harvestec
and the levels of lymphokines determined.
Measurement of lympnokines
IL-2 levels were determined using the IL-2-deoendent mouse T
cell line CTLL-2 (26). IL-4 (27) and IFN-7 (28) were determined
by ELISA. as described previously. The assays were performed
in duplicate and eacn experiment was repeated on four separate
occasions and yielded similar results. In ail experiments the
standard error of the mean was <25%.
Fluorescence activated flow cytometry
For flow cytometric analysis, fluorescem-coniugated murine
monoclonal antibodies. Leu 5b (anti-CD2). Leu 4 (anti-CD3).
Leu 3a (anti-CD4). and anti-IL-2 receptor (anti-CD25). and mouse
igGl fluorescein isothiocyanate control (anti-KLH) were
purchased from Becton Dickinson (Mountain View. CA). T cells
were stained directly with saturating concentrations of antibodies.
ViaDle cells, identified by the ability to exclude propidium iodide,
were analyzed by flow cytometry using a FACScan (Becton
Dickinson). The cell population was analyzed by gating on the
voiume and light scatter characteristics.
Results
Inhibition ot antigen-dependent T cell proliferation and phenotypic
modulation after exposure to S. aureus enterotoxin or HA peptide
Preincubation of the HA-reactive T cells (HA 1.7) with specific
peptide (HA 307-319) at 50 /xg'ml for 16 h, in the aosence of
APCs. induced non-responsiveness such that the 7 cells faiied
to proliferate when rechailenged with HA 307 -319 presented
by HLA-0R1 * murine fibroblasts (Fig. 1). Lower concentrations
of peotioe (0.5 /ig/ml). that are immunogenic in the-presence of
APCs. failed to anergize the T cells as compared to the medium
control.
After exposure to the appropriate S. aureus enterotoxins. SE3
and ScD. the T ceil clone HAi.7 was also unable to
proliferate when restimulated with its natural ligand (Fig. 1).
Inhibition of the antigen-depencent response of the T ceils
induced by both the HA peptide and enterotoxins was associated
with ennanced responsiveness to IL-2. thus confirming that the
anergy induced was not the result of cytolysis.
T cell non-responsiveness arising from pretreatment with either
the S. aureus enterotoxins or HA 307-319 induced similar
changes in the T cell pnenotype as determined by flow cytometry
(Fig. 2). Down-regulation of membrane cD3 (Fig. 2A) was
accompanied by enhanced expression of cD25 (Fig. 2C) as
compared to the medium control. No modulation of the T ceil
pnenotype was Observed after incubation with SEC2 or HA 307
at 0.5 nQiml (Fig. 2). Similarly, none of the pretreatments was
able to modulate cell surface CD4 (Fig. 2B).
Pratreatment of T calls
Fig. 1. Peotide and staDhylococcal enterotoxin induced inhibition of T
ceil Qroiiferation. T ceils of clone HA1.7 (l05/mi) were cultured overmgnt
with HA 307-319 (0.5 and 50 jiQ/ml) and SE3. SEC2. or SED (all at
0.5 /ig/ml). or in medium alone. The treated T ceils were rechailenged
with HA 307-319 (1.0 MQ/mf) in the presence of mitomycin C-treatea
Hl_A-QRiOwl * murine fibroblasts (solid histogram). 0R1 * fibroblasts
(open histogram), medium (stippled histogram), or IL-2 (cross-natcned
histogram). Proliferation as correlated with (3H]TdR incorporation was
determined at 72 h. Results are expressed as mean c.p.m. for tnolicate
cultures. In both test and control groups the 5E of the mean was <20%.
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Lymphokine production following exposure of the HA-reactive
T ceils to tolerogenic signals
The relationship between lymphokine production and the loss
of proliferative response was examined. The HA-reactive T ceils
were exposed to different immunogenic or tolerogenic signals
in the aosence of APCs. The supernatants from these 2* n
cultures were analyzed for the presence of lymphokmes. in
parallel, the T cells were assayed for their aoiiity to respond to
restimulation with antigen presented by DR1 *-transferee
murine fibroblasts, to confirm that anergy had been .ncucec.
Pretreatment of the cloned T cells (HA1.7) overmgnt witn HA
307-319 at 50 Ag/mt. in the absence ot APCs. induced IL-2
production (Fig. 3A). even though at this concentration the
peptide rendered the T cells anergic to an immunogenic
challenge (Fg. 1). The level of IL-2 produced was greater than
or egual to that observed following stimulation with Con A or
anti-CD3 antibody and PMA under mitogenic conditions (Fg. 3A).
The HA-reactive * T ceils faiied to produce detectable leveis
of IL-2 when incubated with SE3 or SED under conditions that
have been demonstrated to induce non-resoonsiveness (Fg. 1).
Neither HA 307-319 at 0.5 Mg/ml nor those enterotoxins that
interact with TCR V3 gene products of different specificities
stimulated measurable IL-2 release (Fg. 3A).
The production of IL-4 by the T cells was determined after
identical conditions of activation and tolerance induction as
described above. Negative signalling by either the specific
peotioe or appropriate toxins was accompanied by the induction
of IL-4 production, and eaualled or exceeded that secreted after
stimulation with Con A or anti-CD3 and PMA. Detectable IL-4
production was not observed after incubation of the T ceils in
the medium or in the presence of the control toxins (Fg. 53).
Under conditions that inhibit proliferation, the effect of peotioe
and toxin on IFN-7 production were similar to that observed for
IL-4. m that supraoptimal concentrations of specific peptide or
staphylococcal enterotoxin induced levels of IFN-7 eaual to or
greater than that following activation with Con A or PMA and
anti-CD3 antibody (Fg. 3C). The relationship between tolerogenic
signals and lymphokine production were similar in four separate
sets of experiments.
Effect of antigen restimulation on the production of lympnoxines
by anergic T ceils
T cells rendered non-responsive by peotioe or enterotoxin
were restimulated with HA 307-319 in the presence of
DR1 • -transfecteo L ceils and the supernatants were harvested
to determine if the anergic T ceils were still capable of producing
lymphokines. Restimulation with an antigenic challenge faiiec to
induce detectable IL-2 production by those T cells that were
tolerized by SE3. SED. or HA (Fig. 4A). In contrast, i cells
pretreated with the control superantigen SEC2 or the low
concentration of HA peptide (0.5 pg/mt) synthesized comoaraote
amounts of IL-2 to the medium control. When rechailenged. the
HA-reactive T ceils, irrespective of their pretreatment. faiiec to
secrete IL-4 that could be detected in the culture supernatants
(Fg. 48).
Effect of antigen concentration on T cell proliferation and
lymphoKine production by house dust mite-reactive Tceil clones
The Oer p I allergen-reactive T cell clones. NP-12 and NP-14.
proliferated in a cose-dependent manner to the Oer p I-derived
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Pretreaiment of T cells
Rg. 2. Phenotypic modulation of HA peotide and staonylococcai enterotoxin anergized T cells. Cloned Tceiis (HA1.7) were exoosed to HA 307 - 319
or tne S. aureus toxins for 16 h unaer conditions tnat induce non-resDonsiveness. Memorane exoression of (A) CD3. (B) CD4. and (C) CD25 was
aeterminea by flow cytometry and compared to control cultures of T cells in meaium aione or oretreatea wirn a non-ioierizing concentration of tne
HA peotide.
peotide residues 89-117, reacmng maximal proliferation at
1 >*g/ml (Fig. 5). However, when p I 89-117 was added at a
concentration of 100 /tg/ml in the presence of autologous
ESV-transformed B cells, the proliferative response of the T cell
clones was decreased. In contrast, despite the decreased
proliferative resoonse. the T cells in the presence of supraoptimal
doses of antigen (100 ^g/ml) produced lympnokines in the
supernatants. Exposure of the Der p i-specific T cell clones NP-12
and NP-14 to tolerizing concentrations of specific peptide or
mitogenic concentrations of Con A, in the presence of APCs.
induced comparaoie amounts of IL-2. IL-4. and lFN-y secretion
(Rg. 6). The results presented in Fig. 6 are representative of
the patterns of lymphokine production ooserved in repeated
experiments.
Regulation of lymphokine production by house dust mite-reaczve
T cells in established anergy
The house dust mite-reactive T cell clone NP-14, which produces
mucn greater concentrations of IL-4 under normal immunogenic
cnallenge than the HA-reactive T ceils, was no longer aole to
secrete measurable levels of IL-4 on restimulation of the
non-responsive T cells (Rg. 7A). Exposure to low amounts of p
I 89-117 resulted in the production of IL-4. whereas exposure
to supraimmunogenic concentrations of peptide followed oy
recnailenge did not lead to detectaDle IL-4 release (Fig. 7A). In
contrast, the production of IFN-y was not inhibited by hign-oose-
sbecific peptide-mduced non-resbonsiveness of the allergen-
reactive T cells (Fig. 7B).
Discussion
The present study examines the differential regulation of
lymphokine secretion by human CD3~ T cells during tne
induction pnase of antigen specific anergy and in estaoiisnea
T cell non-responsiveness.
The proliferative response of T cells reactive with residues
89 -117 of the group I allergen of D. pteronyssinus (Derp I) was
markedly decreased by supraobtimaJ concentrations of antigen
even in the presence of APCs. similar to that described for
HA-specific T ceils (8). However, in the exoenments reported here
the lack of proliferation by the Der p l-specific T ceils was
accompanied by secretion of IL-2. IL-4. and IFN-y in quantities
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Pretreatment of T cells
Fig. 3. Effect of activation and the induction of anergy on the oroduction
of IL-2. IL-4. and IFN-7. Cloned T ceils of HA1.7 (l06/mi) were cultured
witn S. aureus toxins. HA oeotide. Con A, anti-CD3 antibody, and PMA,
or with medium alone. The suoematants were narvested after 24 h and
the levels of (A) IL-2. (B) IL-4. and (C) IFN-7 determined as described
in Methods. In both test and control grouos the SE of the mean was
<25%.
which equalled or exceeded that produced during T cell
activation. Specialization in function associated with the Thi
(IL-2*. IFN-7) and Tn2 (IL-4*) subsets is reflected in their
Pretreatment of T cells
Fig. 4. The failure of anergic T cells to produce lymohokmes on
resnmuianon with an immunogenic challenge. Cloned T ceils (HA 1 7) were
cultured with the HA peotide or S. aureus toxins under conditions tnat
induce soecific anergy. Additional cultures of the T ceils m medium or
with the HA oeotide at a non-tolenzing concentration served as controls.
The treated T ceils were restimulated with HA 307-319 in the oresence
of OR 1 - transfectants (solid histogram) and DR1 * transfectants (ooen
histogram) or medium alone (stippled histogram) for 72 h. The
suoernatants from these cultures were assayed for the oresence of (A)
IL-2 and (B) IL-4. In both test and control grouos the SE of the mean
was <25%.
lymphokine profiles (29). However, the relationship is not so
clearly delineated for human T cells (30.31) and. as describea
here, the Oer p l-specific T cells, which are able to support IgE
synthesis, also produce IL-2 and IFN-7 (24). However, the amount
of IL-4 produced by these CD4* T cells, in comparison to the
HA specific T cells, for example, was elevated. The HA-reactive
CD4* T ceils examined here, although fully differentiated ana
capable of supporting Ig synthesis (8). appeared from their
lymphokine profiles to be similar to Th0 cells (32). The transient
mnibition of proliferation in murine Th1 type cells, mediated by
high doses of peotide. resulted from blocking the action but not
the synthesis of IL-2 (33). In contrast, analysis of the supernatants
of T cells, made unresponsive by antigen presented on
chemically modified APCs. revealed that during the mauction
phase of anergy no IL-2 or IFN-7 was produced (12.34).
Therefore, from these different systems, it would appear that
antigen delivered in a non-immunogenic form may have
opposing effects on the secretion of lymphokines during the



















Fig. 5. Inmoition of tne Droiiferative response of house oust mtte-soec:fic
T cell clones in the presence of hign aoses of the Der p I peotiae. p I
89- 117. T ceils of clones NP-12 (C) and NP-14 (•) ooth at 2x IC/wetl
were stimulated with antigen in tne presence of 3.1 autologous mitomycin
C-treated 53V-transformed B ceils. Proliferation as correlated with
[3H)TdR mcorDoration was determined at 72 h.
induction pnase of anergy. The moae of antigen presentation
ana the signalling reauirements of the different T cells investigated
may contnoute to these differences.
The induction of anergy in human T cells by free peptide is
more efficient in the apsence of APCs (8) but. as observed in
the murine moaeis. non-responsiveness is dependent upon MHC
class II molecules, in this case expressed on the memorane of
the activated T cells themselves (10). Similar to specific peptide,
exoosure of T cells with the appropriate TCR V3 gene products
to S. aureus enterotoxins results in functional inactivation such
that they fail to respond to their natural ligano but retain
responsiveness to exogenous IL-2 (16.35).
These observations prompted us to investigate the relation¬
ship between different tolerogenic signals and the production of
lymphokines without the potential influence of other cell types.
During the induction phase of peptide-meoiated anergy. HA
307-319. at toierizing concentrations, stimulated the produc¬
tion of IL-2. IL-4. and iFN-7 which exceeded that in activation.
The effect was similar to that observed for the Der p l-specitic
T cells in the presence of APCs. but contrasted with murine Th1
ceils toienzed by antigen and modified APCs (18). However,
murine T ceils anergized with immobilized anti-CD3 antibody
appeared capable of synthesizing some IL-2 (36). IL-4 ana IFN-
7 secretion were induced after pretreatment with the enterotoxins
SE3 ana SED under conditions that inhibit antigen-depenaent
T ceil proliferation, whereas there was minimal secretion of IL-2.
Despite similar expression of CD25 after exoosure to the different
tolerogenic signals, it is possible that variation in the level of IL-2
in the supernatants is due to .differential consumption by the T
cells. The engagement of different regions of the TCR may deliver
negative signals that are subtly different in their effects on
lympnokine production. The ability of SED to stimulate IL-4 and
IFN-7 but not IL-2 production essentially altered the functional
pnenotype of the T cells. Toroett and Glaseorook (37) observed
that the exposure of murine T„0 cells to fixed APCs innibited the
production of IL-2 but not IL-4. It is not possible from these
expenments to resolve whether fixation is influencing APC-denved
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Fig. 6. Lymonokine oroduction by Der p l-reac:ive T cell ciones :n tne
oresence of hign concentrations of specific oeDtiae. SuDernatants from
72 h cultures of clones NP-12 (cross-natcned histogram) and NP-14 (ooen
histogram) stimulated with p I 89 - 117 (1 or 100 ug/mi). meaium or Con
A were assayea for the presence of (A) IL-2. (B) IL-A ana (C) IFN-, as
aescrioea in Metnods. In botn test and control groups tne SE of tne mean
was <25%.
negative signal. Comparison of tolerance induction in murine
Thl and T„2 cells of the same antigen specificity indicated that
proliferation response but not the helper function of the T_2
subset was resistant to concentrations of antigen caoabie of
toierizing the Tni cells (19). Differences between the human and
murine moaeis of in vitro T cell anergy are not limited to the effects
of negative signalling on lympnokine production. Phenotypic
modulation, with the down-regulation of Ti-CD3 (14) ana
reciprocal ennancement of CD25 (39). occurs during the
















Pretreatment of T cells
Rg. 7. The differential effects of peptide mediated anergy on IL-4 and
IFN-y production by the Oer p i-reactive T ceils. Cloned T ceils (NP-14)
after preincubation in meaium or specific peptide (1 or 100 jig/ml) were
restimuiatea with p I 89 -117 in the oresence of autologous E3V-
transtormed 8 cells (stiopied histogram) or E3V-8 ceils alone (cross
hatched histogram) for 72 h. The subernatants from these cultures were
assayed for the oresence of (a) IL-4 ana (b) lFN-7. In both test and control
groups the SE of the mean was <25%.
for murine T cells no alteration in TCR expression is odservea
between normal and anergic T cells.
T cells tolerized with either specific pepttce or toxin failed to
recover the capacity to synthesize 11-2 on restimulation with
antigen under immunogenic conditions, ano suoporrs the finding
that murine T cells tolenzed by chemically modified APCs or hign
concentrations of IL-2 (11.21) have reduced transcripts for IL-2
(11.21). The activity of other fymphokines is modulated in anergic
T ceils: nevertheless, it would appear that IL-2 regulation is critical
in the development and reversal (40) of anergy. The failure of
T cells from adult mice toierized to Mls-1 m vivo to produce IL-2
on restimuiation (5) ano the ability of !L-2 to break neonatal
tolerance in grart rejection (41) support a central role for IL-2 in
activation and non-responsiveness.
Uoon rechailenge. IL-4 could not be detected in either the
anergized or control cultures of the HA-reactive T cells. As an
alternative to IL-4 production being inhibited, these findings may
reflect lymphokine consumption by both the activated ano
anergic T cells. In contrast, only in establisned non-
resoonsiveness did the Der p l-reactive T cells fail to secrete IL-4.
There was reciprocal regulation of IFN-7 production, sucn that
the anergic allergen-specific T cells when restimulated with
peptide or wnoie extract of house dust mites secreted IFN-7 .n
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comparaole amounts to the normal T cells. IL-4 is required for
IgE synthesis by 8 ceils (42). wnereas IFN-7 inhibits IgE synthesis
(43). Thus, the level of IgE produced is dependent, in part, on
the balance between these two lymphokines. Clearly, the ability
to selectively modulate lymphokines secreted by the house dust
mite-reactive T cells such that IL-4 production is inhibited and
IFN-7 is maintained or enhanced would be an advantage in
down-regulating the aberrant responses in allergic disease. The
findings reported here demonstrate that different signals that are
all capable of inhibiting proliferation mignt have a differential effect
on lymphokine production. This information may be relevant in
the design of immunomodulatory agents for potential use in the
treatment of allergic and autoimmune diseases.
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Abbreviations
APC antigen-presenting cells
Con A Concanavann A
E3V Epstein - 3arr virus
IFN-y interferon gamma
IL mterleukin
P9MC penpheral blood mononuclear ceils
ToR thymidine
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UNCOUPLING OF CYTOKINE mRNA EXPRESSION AND PROTEIN SECRETION
DURING THE INDUCTION PHASE OF T CELL ANERGY1
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Tie CD4* T cell clone HA1.7 may be made specif¬
ically nonresponsive. or anergic, to its cognate Ag.
an influenza hemagglutinin peptide (HA), by pre-
treatment with the superantigen Staphylococcus
aureus enterotoxin B or with high concentrations
of HA itself. We compare the patterns of mRNA
expression and protein production of selected T cell
cytokines during the first 24 h after treatments that
induce anergy in HA1.7 and during the same period
after treatments that simulate normal cellular ac¬
tivation. The cytokines examined include TNF-a. IL-
8/neutrophil activating protein-1 and the RANTES/
SIS cytokines, a family of small secreted proteins
with inflammatory and potential antiproliferative
and leukocyte regulating activities. Messenger RNA
for TNF-a. human MIP-la. human MlP-ld. and EL-S
are all induced during the development of clonal
anergy in HA1.7, and these levels are significantly
higher than those seen during activation of the
clone using an anti-CD3 antibody and IL-2. These
high levels of mRNA also persist longer than those
seen after anti-CD3 and IL-2 activation. However,
the increased levels of mRNA are not typically ac¬
companied by increased protein secretion. In all
cases but one. the amount of cytokine secreted by
HA1.7 cells was greater after. anti-CD3 and IL-2
treatments than after anergy- inducing treatments.
Thus, the induction of T cell anergy in HA1.7 does
not appear to require a general inhibition of T cell
cytokine mRNA expression, and. in fact, anergy
treatments appear to superinduce certain cytokine
transcripts, but anergy-specific posttranscriptional
mechanisms may exist by which cytokine release is
regulated.
The process of clonal deletion appears to eliminate
most T ceils reactive to "self" tissues during maturation
In the thymus. Nevertheless, additional mechanisms are
thought to exist that Insure tolerance to host tissues by
self reactive T cells in the peripheral circulation. Al¬
though these mechanisms are at present largely un¬
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known, experiments In vitro have shown that certain
populations of human T cells may be tolerlzed by su-
praimmunogenic doses of antigenic peptide such that
subsequent exposure to the Ag In the context of MHC
does not result in clonal proliferation. IL-2 responsive¬
ness remains Intact, however, despite the failure to re¬
spond to specific Ag. This type of nonresponsive state,
clonal anergy, has been postulated to somehow play a
role In extrathymlc tolerance of lymphocytes to self mol¬
ecules In vivo (1-4). Experimental models of nondeie-
tlonal mechanisms of T cell tolerance established from
In vitro systems have been supported by experiments
showing the induction of tolerance to exogenously admin¬
istered self Ag (5) and nonlymphoid-associated MHC class
H molecules In transgenic mice (6-8). Inhibition of pro¬
duction of T cell cytokines has been postulated as a
mechanism by which clonal anergy is induced (9-11): a
lack of production of IL-2 In anergic clones has been
reported (9. 10) and nonresponsive T cell clones have also
been reported to be poor producers of IL-3 (11).
Activated T cells are known to regulate the transcrip¬
tion of other cytokines Including TNF-a. IL-8. and some
of the RANTES/S1S3 cytokines, a newly emerging class
of potential leukocyte regulatory factors in the platelet
factor 4 superfamily (12-14). RANTES/SIS cytokines are
small peptides (Mr 8-16 kDa) secreted primarily by hu¬
man T cells and monocytes and related by primary struc¬
ture. Including a conserved four cysteine motif (14). This
family includes RANTES (15). monocyte chemotactlc pro-
tein-1 (16-18). 1-309 (19). and the human homologs (des¬
ignated HuMIP-la. HuMIP-ld) of the murine macrophage
Inflammatory proteins MIP-la and MIP-Id (14. 20-23).
RANTES/SIS* cytokines and their murine counterparts
have recently been implicated In a number of important
potential immunoregulatory and inflammatory processes
(14. 22. 24-26). IL-8 (neutrophil activating protein 1).
also a member of the platelet factor 4 superfamlly. has
been reported to have effects on both neutrophils and T
lymphocytes (27-29). To test the ability of the T cell clone
HA1.7 to produce these cytokines, and to assess if a
general Inhibition of T ceil cytokine production was a
feature of T cell anergy Inducdon. we performed an
analysis of the mRNA and protein profiles of selected T
cell cytokines In HA1.7 during induction of the nonres¬
ponsive state.
MATERIALS AND METHODS
Ag. SEB and SEC2 were purchased from Toxin Technology (Mad¬
ison. wp. The influenza virus hemagglutinin (residues 307-319) and
3 Abbrevladons used In this paper: SIS. small. Inducible, secreted: NAP-
1. neutrophll-acdvatlng protem-1: HA. hemagglutinin: SEB. Staphylo¬
coccus aureus enterotoxin B: SEC2. S. aureus enerotaxln C2; MIP. mac¬
rophage Inflammatory protein: HDM: House dust mite.
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HDM (Der p II: residues 36-60) peptides were synthesized using
standard solid-phase methods on an Applied Blosystems 430A syn¬
thesizer (Foster City. CA) purified by reversed phase HPLC and
analyzed by amino acids analysis as previously described (30).
Anttbodtes. For flow cytometric analysis fluorescein conjugated
murine monoclonal antibodies. antl-Leu 5a (CD2). anti-Leu 4 (CD3).
anti-Leu 3a (CD4). antl-IL-2R (CD25). and mouse IgG, FTTC control
were purchased from Beeton Dickinson (Mountain View. CA).
Cloned. HA reactive T lymphocytes. The Isolation and character¬
ization of the cloned human T cells reactive HA 307-319 have been
reported elsewhere (31). Briefly. T cells activated with iramunochem-
lcally purified HA were resuspended In RPMJ 1640 (GIBCO. Grand
Island. NY) supplemented with 100 U/mi penicillin. 100 ml/ml strep¬
tomycin. 2 mM L-glutamlne. and 5% screened human AB~ serum
and cloned by limiting dilution In the presence of autologous Irradi¬
ated PBMC. IL- 2 (Lymphocult T. Blotest Folex. Frank. FRG). and Ag.
Growing T ceils were expanded by cyclic stimulation with Ag and
filler cells every 7 days and IL-2 every 3 to 4 days. Before their use
in experiments the T cells were rested for 7 days after the last
exposure to Ag and filler cells.
Induction of T cell non responsiveness. T ceils (10*/ml) were
incubated for 16 h with the Staphylococcus aureus toxins (0.5 mg/
ml). Control cultures of T cells in medium or activated with insolu-
billzed antl-CD3 antibody (12 mg/ml) and IL-2 were examined in
parallel. The cells were washed extensively after the pretreatment
before determining their ability to respond to either an immunogenic
challenge of Ag (HA 307-319) and APC or IL-2.
Proliferation assays. Cloned T ceils (lOVml) were stimulated with
HA 307-319 (1.0 mg/ml) or the S. aureus toxins at concentrations
indicated In the figures. In the presence of mitomycin C-treated
murine fibroblasts expressing HLA-DR1 (10a/ml) (31) as a source of
APC. or in IL-2 alone. After 60 h of Incubation. (3H]TdR (1 mCl/ml:
Amersham International. Arlington Heights. IL) was added and the
cultures harvested onto glass fibre filters 8 to 16 h later. Proliferation
as correlated with (3H)TdR incorporation was measured by liquid
scintillation spectroscopy. The results are expressed as mean cpm
for triplicate cultures. In all cases the SE of the mean was <20%.
Fluorescence flow cytometry. T ceils were stained directly with
saturating concentrations of fluorescein-conjugated murine mAb.
anti-Leu 5a (CD2). anti-Leu 4 (CD3). anti-Leu 3a (CD4). antl-IL-2R
(CD25) using a mouse IgG! FITC control. Viable cells, identified by
their ability to exclude propidium iodide, were analyzed by flow
cytometry using a FACScan (Becton Dickinson). The cell population
was analyzed by gating on the volume and light scatter characteris¬
tics.
Northern blot analysts: solid phase EL1SA. RNA was extracted
at 0. 2. 4. and 24 h after treatment described above from 5 million
cells/time point using the method of Chomzynskl and Sacchl (32). A
total of 10 Mg of cytoplasmic RNA per time point was fractionated on
a 1% agarose/formaidehyde gel and transferred to a nylon membrane
(Genescreen. Du Pont. Wilmington. DE) per the manufacturer's rec¬
ommendation. Probes representing.the coding regions of the cDNA
listed in Figure 3 were labeled with "P-dATP using the random
hexamer method, and applied to the blot in 50% Formamlde hybrid¬
ization solution at 42*C for 16 h per the membrane manufacturer s
recommendation. Blots were washed in 0.2X SSC; 1.0% SDS at 55°C
and exposed at -70°C on Kodak XAR5 film. The same blot was
serially hybridized with each probe listed. Probes were stripped by
boiling the blot in water for 5 mln before subsequent hybridization.
Densitometry quantitation of Northern blots was performed using a
laser densitometer manufactured by Molecular Devices Corporation
(Menio Park. CA) using the Image Quant 3.0 software package. IL-8
and TNF concentrations in HA1.7 supernatants were assayed by
solid phase ELISA by the Genentech Immunology Research and
Assay Technology section: the results shown represent mean values
of two assays each comprised of triplicate determinations for each
data point. In all cases the SE of the mean was less than 10%.
Western blot analysts. Antlsera for Western analysis were gen¬
erated by immunizing female NZW rabbits with the synthetic
peptides CYTO 1 (PMGSDPPTAC) and CYTO 3 (CADPSEEWVgKY-
VSDLELSA) representing the amino terminus of HuMIP-ld and the
carboxy terminus of HuMIP-la. respectively, which were conjugated
to the earner protein soybean trypsin inhibitor via their cysteine
residues. Preimmune sera were collected from rabbits before im¬
munization. Immunologic blot analysis were performed as described
(33) with both antlsera (each diluted 1/2000) combined to detect
HuMIP-la and HuMIP-l/S proteins on the same blot. Experiments
with recombinant HuMIP-1 proteins have shown that HuMIP-la
migrates as a lower band relative to HuMIP-18 due to presumed
glycosylation differences (14). Background staining was assessed by
incubating a duplicate blot in pooled preimmune serum.
HA1.7 is a CD4* T ceil clone that recognizes the car-
boxyi-terminus of influenza virus HA (peptide HA: resi¬
dues 307-319) (30. 31). To test its cytokine mRNA and
protein production profiles during tolerance induction.
HA1.7 was tolerized to this Ag by preincubation for 16 h
with high doses of HA or by exposure to the superantigen
SEB in the absence of APC (Fig. 1) (34). Cells so pretreated
are unable to proliferate, as measured by [3H]TdR incor¬
poration. to subsequent immunogenic challenge of HA
presented by murine fibroblasts expressing HLA-DR1.
but retain their ability to proliferate in response to IL-2
(Fig. 1). Cells pretreated with control conditions medium
alone, anti-CD3 mAb. antl-CD3 mAb plus IL-2. SEC2. or
a HDM peptide proliferate well to both subsequent chal¬
lenge with HA plus APCs and to IL-2 stimulation (Fig. 1).
No proliferation is seen under any of the conditions to
APC alone. Induction of tolerance in response to HA or
SEB is accompanied by cell surface phenotypic changes
that mimic those seen with T cell activation (Fig. 2).
Analysis of cell surface markers by flow cytometry indi¬
cates an increase in the levels of CD2 and CD25 in
response to HA. SEB, and anti-CD3 antibodies alone or
with IL-2. but a reduction of CD3 by the same treatments
(Fig. 2). These cell surface molecules are unaffected by
the control conditions, and levels of CD4 are not signifi¬
cantly affected by any of the treatments (Fig. 2).
Northern blot analysis of RNA extracted from HA1.7
cells after various treatments reveals little mRNA for
most of the cytokines tested in untreated cells but a
striking induction and accumulation of mRNA for many
of these molecules af£er the HA or SEB tolerizing treat¬
ment. Only RANTES mRNA is present in untreated
HA 1.7 ceils, and its levels are not greatly changed by
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Figure 1. Induction of T cell anergy in the T cell clone HA1.7 after
exposure to SEB or HA peptide. T cells were exposed to SEB or HA 307-
319 under conditions which induce nonresponslveness (34). Control T
cells populations were pretreated by cuihiring in medium alone. antl-CD3
antibody alone and In combination with IL-2. SEC2.. or HDM. After
pretreatment the T cells were assayed for their ability to respond to
restlmulatlon with HA 307-319 and accessory cells (mitomycin C-treated
murine fibroblasts expressing HLA-DR1: stripped bars), accessory ceils
alone (solid bars), or IL-2 (open bars\. Proliferation as correlated with
[3H|TdR Incorporation was determined at 72 h.




Figure 2. Phenotyplc modulation of T ceils
anerglzed wtth SEB or HA peptide. Membrane
expression of CD2. CD3. CD4. and CD23 of the
anergic T ceils was examined by flow cytometry
and compared to control cultures or those acti¬
vated with antl-CD3 and IL-2. Phenotyplc
changes in response to toiertzlng treatments
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either tolerizlng (HA or SEB) or activation (antl-CD3 an¬
tibody with or without IL-2) treatments (Fig. 3A). This is
in contrast to observations In other T ceil populations
where levels of RANTES mRNA are markedly reduced
after activation via the TCR (IS). We do not know if the
lack of reduction of RANTES mRNA In these ceils after
stimulation is a specific property of tolerlzable T cells. In
contrast to RANTES. monocyte chemotactlc protein
mRNA is not detected in the HA1.7 clone (Fig. 3A). The
HuMIP-1 genes, however, typify the pattern of inducible
cytokine mRNA investigated in this T cell clone. HuMIP-
1 a mRNA accumulates dramatically after tolerlzlng treat¬
ments (Fig. 3A). and these levels of HuMIP-la mRNA are
higher, and persist longer, than levels induced by antl-
CD3 activation in the presence or absence of IL-2 (Fig.
3A). Laser densitometry measurements (Fig. 3B) reveal
that peak levels of HuMIP-la mRNA expression after
antl-CD3 stimulation are at least 10-fold less than peak
levels seen after SEB treatment ofHA1.7. The expression
of the mRNA for HuMIP-1/3. a cytokine nearly 7035 Iden¬
tical to HuMIP-la in primary structure, is similar to that
seen wtth HuMIP-1 a (Fig. 3A) except the levels of HuMIP-
10 RNA are not as abundant and do not persist as long
as HuMIP-1 a mRNA. Neither HuMIP-1 a nor HuMIP-10 are
appreciably Induced by treatmentwith HDM peptide (Fig.
3A) or with SEC2 (data not shown), indicating that
HuMIP-1 mRNA induction in HAI.7 cells is specific to
activation or tolerizlng signals. Thus, although related in
primary structure and clustered on human chromosome
17 (35. 36). the RANTES/SIS cytokines are differentially
transcriptionally regulated in HA1.7 during cellular ac¬
tivation and during the induction of clonal anergy.
To assess whether the release of HuMIP-1 proteins into
HA1.7 culture supematants correlated with mRNA levels
during anergy induction and activation treatments. West¬
ern blot analysis was performed using antlpeptlde anti-
sera that would discriminate between HuMIP-la and
HuMIP-10. Although there is significantly greater mRNA
accumulation during anergy induction than during antl-
CD3 antibody treatment in the presence or absence of IL-
2 (Figs. 3. A and B). the amount of HuMIP-la and -10
protein secreted does not necessarily mirror the mRNA
pattern (Fig. 3C). For example. SEB anergy induction
treatments result in the highest levels of HuMIP-la
mRNA in HA1.7 (Figs. 3. A and B), but the secretion of
HuMIP-1 proteins from SEB-treated cells appears no
greater than that detected from antl-CD3-activated cells
(Fig. 3C). which express less than one-tenth the mRNA.
Moreover, even though the greatest amount of protein is
detected in supematants collected from ceils 24 h after
treatment with HA peptide, corresponding with the fact
that these cells contain high levels of both HuMIP-1a and
-10 mRNA. titration experiments reveal that the level of
protein secretion is only two to three times that of the
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Figure 3. A. Northern blot analysis of .
RANTES/SIS cytokine expression in HA1.7. HuMIP-lCt
HA 1.7 ceils were treated as in Figure 2 and cy¬
toplasmic RNA was harvested after 2. 4. and 24
h incubation for each treatment. RNA from un¬
treated control cells is in lanes designated C.
Ethldlum bromide staining and approximately
equivalent intensities with an actln probe con¬
firmed equal amounts of RNA were loaded in
each lane (not shown). The same blot was
stripped and reprobed with a labeled cDNA frag- HuMIP-1 0
ment representing the coding region of each cy¬
tokine listed in the left margin. B. Laser densi¬
tometry quantitation of HuMIP- la RNA. C. West¬
ern blot analysis of HuMIP-la and -1/3 proteins
in HA 1.7 cell supernatants after activation and
anergy induction treatments. Supernatants. col¬
lected from cells treated as described above, were
fractionated on a 10 to 20% trtcene-Trls SDS-
PAGE and immunoblotted. Plus (+) lanes repre¬
sent positive control sample consisting of recom¬
binant HuMIP-la. Mr lane is migration of M, a) F
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anti-CD3 treated ceils, which express considerably less
HuMIP-1 mRNA. Thus, the secretion of the HuMIP-1
cytokines appears to be posttranscriptionally regulated
during anergy induction. In addition, posttranscrtptional
regulation mechanisms may differentially control the se¬
cretion of HuMIP-la and -lfi during Ag-speclfic anergy
induction (HA treatment) as compared to superantigen-
HuMIP-1(3
HuMIP-1 a
Induced anergy (SEB treatment).
Posttranscrlptlonai regulation may be controlling the
secretion of RANTES protein as well In HA1.7. We were
also unable to detect RANTES. as assayed by Western
blot. In the supematants of these cells, although abun¬
dant mRNA levels exist.
IL-8/neutrophll-actlvatlng protein-1 is related to the
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RANTES/SIS cytokines by a modification of the four
cysteine structural motif (13. 14. 27, 28). As with HuMIP-
la and HuMIP- id. IL-8 mRNA Is detected In HA1.7 during
cellular activation and the Induction of anergy. Treat¬
ment of HA1.7 with antl-CD3 and antl-CD3 plus IL-2
results In detectable levels of IL-8 mRNA. and higher
levels sure seen after HA and SEB anergy treatment (Fig.
4. top panel). No IL-8 mRNA Is seen after SEC2 or HDM
treatment. However, although mRNA levels appear
higher In response to the tolerance Inducing signals than
the antl-CD3 activation signals, this does not correlate
with the amount of 1L-8 protein secreted Into the ceil
culture medium. A solid phase ELISA using two antl-IL-
8 mAb reveals concentrations of secreted IL-8 are mark¬
edly higher with antl-CD3 +■ IL-2. treatment (-55 ng/mi
after 24 h) (Fig. 4. lower panel), with levels present after
HA. SEB. and antl-CD3 alone being approximately 10-
foid less (—5 ng/ml after 24 h of HA treatment) (Fig. 4).
No IL-8 was detected In the supematants of unstimulated
ceils or cells treated with SEC2 or HDM. Thus, although
HA1.7 cells express IL-8 mRNA and release IL-8 protein
specifically In response to activation or toierizlng treat¬
ments. protein secretion appears to be posttranscrlption-
aily regulated In anerglzed cells. The production of IL-8
by HA1.7 Is consistent with the observation that these
cells produce a neutrophil chemotacdc activity (37). and
demonstrates that at least some T ceils have the capabil¬
ity to actively secrete IL-8.
The expression of TNF-a mRNA and secretion of this
cytokine was also examined, and the pattern found mim¬
ics that seen with the HuMIF-1 and IL-8 cytokines. Al¬
though much more TNF-a mRNA accumulates after HA
or SEB treatment than with antl-CD3 In the presence or
absence of IL-2 (Fig. 5). the amount of TNF-a released
into the culture medium Is significantly higher in the
cultures treated with antl-CD3 and IL-2 (-5800 pg/ml
after 24 h) than In the T cells undergoing anergy Induc¬
tion (-3350 pg/mi 24 h after HA treatments and -2600
385
pg/ml 24 h after SEB treatments) (Fig. 5). Finally, we
have also noted increased levels of IL-4 mRNA after
anergy-inducing treatments relative to antl- CD3 activa¬
tion with or without IL-2 (Fig. 6).
DISCUSSION
This study shows that the tolerlzableT cell clone HA1.7
expresses high levels of mRNA for several cytokines dur¬
ing the induction of the nonresponsive state of clonal
anergy. In fact, tolertzlng signals (treatment with either
HA peptide 307-319 or the superantlgen SEB) appear to
be stronger and longer lasting inducers ofmRNA formost
of the cytokines examined than is cellular activationwith
antl-CD3 In the presenceor absence of IL-2. Interestingly,
however, although more mRNA accumulates after toler-
izlng treatments than after antl-CD3 and IL-2 activation,
the amount of secreted cytokines is typically less after
tolerance induction signals than after activation treat¬
ments. This suggests that specific posttranscrlptlonal
mechanisms of regulating the secretion of T cell cyto¬
kines may be In place during anergy induction. This
appears to be the case not only for HA1.7. but for another
tolerizabie T cell clone. DE9. which, for the cytokines
examined In this study, exhibits similar patterns of cy¬
tokine mRNA expression and protein production during
anergy induction and cellular activation (ourunpublished
observations).
The data obtained raise several issues. Our findings
provide definitive evidence that at least some T cells not
only transcribe but also secrete IL-8. In contrast. Smyth
et al. (12) have recently reported that purified T cells from
PBL transcribe but do not secrete IL-8. The data in thac
report, coupled with the data presented suggests that T
ceils have the capacity to regulate IL-8 production post-
transcriptlonally and that some differentiation event
may be necessary to enable T cells to actively secrete this
cytokine.
Of more particular relevance to T cell anergy, the data
HA SEB SEC
C 2 4 24 2 4 24 2 4 24
Figure 4. IL-8 mRNA expression and protein produc¬
tion by HA 1.7 cells during anergy induction and acti¬
vation. Upper panel depicts Northern blot analysis of
IL-8 mRNA expression by HA1.7 cells In response to
activation and toleming treatments listed at the top of
the panel and as described for Figure 3. Lower panel
represents ELISA analysis of secretion of IL-8 protein
into the medium of HA1.7 cultures during the same
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demonstrate that complete inhibition of T cell cytokine
mRNA expression Is not a general feature of T cell anergy
Induction, but there may exist specific mechanisms by
which T cells undergoing anergy induction regulate cy¬
tokine secretion. These mechanisms are at present
largely unclear, but the data are likely indicative of post-
transcrlptlonal control of cytokine production during the
induction of anergy. Two possibilities are the formation
of a "transiatlonal block" inhibiting cytokine protein syn¬
thesis in T cells undergoing tolerance induction, and
increased degradation of cytokines in cells after tolerance
Induction relative to cells activated with antl-CD3 and IL-
2. Inasmuch as the induction of tolerance appears to
require new protein synthesis (38). the existence of spe¬
cific "anergens" could be postulated to provide for such
mechanisms.
It is possible that some of the cytokines examined may
have roles in T cell regulation, and that the altering of
their normal transcription and secretion could play a role
in the process of anergy Induction. It is likely that T cells
express specific receptors for at least some of the cytor
klnes examined in this study, based on chemotaxis data
(26. 29), so autocrine or paracrine mechanisms of regu¬
lation might be envisaged to play a role during the induc¬
tion of T cell anergy. The murine homolog of HuMIP-la.
MlP-lcr (20), has been shown by Graham et al. (25) to be
an inhibitor of hematopoietic stem cell proliferation. Be¬
cause HuMIP-la mRNA is superinduced during anergy
treatments, and because HA-treated cells secrete the
highest levels of HuMIP-1 proteins, it seems possible that
HuMIP-1 a could have an antiproliferative effect on HA1.7
during the induction of anergy or could, perhaps, inhibit
T cells in the same microenvlronment. However. HA 1.7
cells anerglzed with SEB. although superinduced with
respect to the amount ofHuMIP-1 mRNA. secrete no more
HuMIP-1 proteins than do HA1.7 cells activated with
antl-CD3 treatment in the presence or absence of IL-2.
This suggests that different interactions of HA and SEB
ligands with the TCR. whereas both inducing,anergy in
HA1.7. also result in differential regulation of the secre¬
tion of the HuMIP-1 proteins. Differential production of
IL-2 in response to HA and SEB stimulation has also been
observed in HA1.7 (our unpublished observations).
The data in this study suggest that the induction phase
of T cell anergy. the first 24 h after treatment with
superantlgen or supraimmunogenic doses of specific Ag.
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Is accompanied by changes in the profiles of cytokine
transcripdon and secretion as compared to the same
period after activation of these T cells with antl-CD3 and
IL-2. Investigation of the molecular events underlying
these changes, as well as further experimentation with
recombinant cytokines such as IL-8 and the RANTES/
SIS molecules may provide insight into the workings of
immune tolerance.
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SUMMARY
The exposure of human T-ceil clones to supra-immunogenic concentrations of peptide antigen in the
absence of accessory cells induces antigen-specific unresponsiveness. Using this model we have
investigated the ability ofcytokines to modulate the induction of. or reversal of. T-cell tolerance. Our
findings demonstrate that interieukin-2 (IL-2), but nut interferon-gamma (IFN-y) or interleukin-1
(1L-1). is able to inhibit the induction of T-cell unresponsiveness in a dose-dependent fashion.
Moreover. IL-2 was able to reverse established antigen-dependent T-cell unresponsiveness. In order
to determine if modulation of IL-2 receptors is able to induce or abrogate unresponsiveness, the T
cells were treated with anti-Tac antibody alone or together with tolerizing concentrations of antigen.
Anti-Tac antibody was neither able to induce nor inhibit the induction of tolerance. The application
of this model in the manipulation of immune responses is discussed here.
INTRODUCTION
The presentation of antigenic determinants in an immunogenic
form to T-helper cells is critical in the generation of immune
responses (Lamb et al.. 1983). Although there are many reports
describing components necessary for the successful activation of
T-helper cells (Schwartz. 1985), far less is known about the
events regulating and preventing responses to potentially immu¬
nogenic antigen. For this reason we have been interested in
investigating the mechanism by which antigen may abrogate
antigen-induced responses, a process that has been termed
"immunological tolerance'. Useful model systems have
abounded for studying immunological tolerance in B cells
(reviewed by Nossal. 1984) but not for T cells, until it was
possible to generate T-cell clones that recognize specific pep¬
tides.
With human T-ceil clones recognizing peptides sequences
derived from influenza virus haemagglutinin (HA), it was
observed that the incubation of the clones with the appropriate
peptide antigen in the absence of accessory cells inhibited
proliferation to subsequent stimulation with an immunogenic
concentration of peptide and accessory cells (Lamb et al.. 1983).
The underlying mechanism of this phenomenon was asso¬
ciated with changes in the expression of differentiation antigens
on the T-cell membrane (Zanders et al.. 1983). Concomitant
Abbreviations: APC. accessory cells: I FN-;, interferon-gamma: IL-
l. inierleukin-l; IL-2. interieukin-2; PBM. peripheral biood mononuc¬
lear cells.
Correspondence: Professor M. Feldmann. Charing Cross
Suniev Research Centre. I Lurgan Avenue. Hammersmith. London
W6 SLW. U.K.
with the down-regulation of the antigen recognition-receptor
complex. "CD3/Ti\ is the enhanced expression of the CD2 and
IL-2 receptor proteins (reviewed by Feldmann, Zanders &
Lamb. 1985). However, the changes in membrane CD3;Ti
following tolerizing concentrations of peptide are not reflected
by an alteration in their mRNA levels: whereas, in contrast,
transcripts ofCD2 and IL-2 receptor are enhanced (Lamb et al..
1987). Since the tolerized T cells expressed IL-2 receptors and
proliferated in response to exogenous IL-2, lack of endogenous
IL-2 production, as suggested by the failure to detect IL-2
mRNA, may account for the unresponsiveness in vitro. A key
role for IL-2 in tolerance has also been identified in studies with
neonatally tolenzed mice where IL-2 breaks tolerance, inducing
graft rejection (Malkovskv et al.. 1985).
In this study we have investigated the potential of cytokines
IL-1. IL-2 and IFN-y to inhibit the induction and to reverse
antigen-dependent T-cell unresponsiveness. The results
reported here indicate that IL-2 but not IL-1 or IFN-y prevents
the induction of tolerance and also reverses it once induced.




Synthetic peptides ofHA 1: p 14 (residues 306-320) was obtained
from Peninsula Laboratories (Belmont. CA): p 17 (residues 174-
196) and p20 (306-329) were the kind gift of Dr R. A. Lerner.
Scripps Research Institute. La Jolla. CA. The peptide pi 12
(residues 112-132) was from the 65.000 MW protein of
mycobacteria and was the generous gift of Dr J. B. Rothbara.
Imperial Cancer Research Fund. London.
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Antibodies
Murine monoclonal antibodies. anti-IL-2 receptor (Tac). anti-
CD3 (UCHT1) and anti-HLA class I (2A-1) were the generous
gifts of Drs T. A. Waldmann. NCI. Bethesda. P. Beverley.
1CRF. London, and M. Crumpton.TCRF. London, respect¬
ively.
Recombinant cytokines
Purified recombinant human IL-2 was obtained from Sandoz.
Vienna. Austria, by courtesy ofDr E. Liehl. It had an activity of
- 10" U/mg. Purified recombinant (IFN-y) was supplied by Dr
G. Adolf of Boenringer-Ingelheim. Austria. It had an activity of
2x 10 U/mg. Purified recombinant human IL-la and fi were
supplied by Dr P. Lomedico (Roche. NJ). IL-1 a had an activity
of 2 x 10" U mg assayed in the thymocyte co-mitogenesis assay.
IL- 1/f had an activity of 2 x 10" U/mg.
Isolation of antigen-specific T-lymplwcyte clones
Influenza virus haemogglunnin (HA) reactive T-ccll helper
cionc (HA 1-7. CD4+) was isolated as described previously
(Lambet al.. 1982. 1983). Briefly. Tcells from a 6-dav culture of
peripheral blood mononuclear leucocytes (PBM: 1-5 x 10' ml)
stimulated with immunopurified HA (01 wg/ml) in RPMI-1640
containing 10% human A' serum (Edgewarc Blood Trans¬
fusion Centre. London) were cloned by limiting dilution (0-3
cells well) in microtest II iravs (Falcon. Oxnard. CA) with
irradiated autologous PBM (5 x 105/ml). HA (01 /ig/ml) and
IL-2. Clones were expanded with fresh IL-2 every 3-4 days and
irradiated PBM and influenza virus every 7 days. Prior to use in
proliferation assays, the cloned T cells were rested 6-8 days after
the addition of accessory cells.
Induction of unresponsiveness
In order to induce unresponsiveness, cloned T cells (5 x 10J,ml)
were cultured in 96-well round-bottomed plates for 16 hr with
peptides or monoclonal antibody al different concentrations as
indicated, alone or together, and then washed extensively before
adding to the proliferation assays (Lamb et al.. 1982). In some
cultures cytokines were added together with, or 30 min prior to.
the tolerizing antigen.
In order to elute IL-2 from its receptor and so prevent carry
over of IL-2. the T cells were incubated with 0-2 m glycine buffer
(pH 3-8) for 10 min on ice (Fujii et al.. 1986). and then washed
five times in RPMI-1640 supplemented with 10% human A"
serum before addition to proliferation assays.
Proliferation assays
Cloned T cells (5x K^/ml), after pretreatmenl in tolerance-
induction cultures, were incubated with p 14 (1 -0 /ig/ml) together
with irradiated histocompatiblc PBM (1-25 x 105/m 1) or with
recombinant IL-2 in 96-well round-bottomed microtitrc plates.
In cultures designed to investigate the reversal of tolerance. IL-2
(1 /ig/ml) was added to the cells after washing. At 60 hr of
incubation, tritiated methyl thymidine (pHjTdR. 1 /iCi'well:
Amersham International. Amersham. Bucks), was added and
the cultures harvested onto glass-fibre filters 8-16 hr later.
Proliferation was correlated with [?H]TdR incorporation, as
measured by liquid scintillation spectroscopy. The results are
expressed as mean counts per minute (c.p.m.) ± SEM for
triplicate cultures.
:OOr
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Figure I. Ability of IL-2 to inhibit the induction ofT-cell unresponsive¬
ness. Clone HA 1-7. 1 x I04. was tolerized ± varying concentrations oi
antigen (Ag), pl4. in the presence of IL-2: • no IL-2: O 01 /ig/ml IL-2: ♦
0-3/ig/ml IL-2: ▲ 10 /ig/ml IL-2. for 16 hr. Cells were washed
extensively with acidic buffer to elute IL-2 from its receptor, then
challenged with 2-5 x 10J accessory cells pius the activating dose of pl4
(10 /ig/ml) for 3 days.
RESULTS
Ability of recombinant IL-2 to prevent the induction of T-cell
unresponsiveness
Exposure to increasing concentrations (0-3—30 /ig/ml) of p 14
rendered T cells of clone HA I-7 unresponsive to an immuno¬
genic challenge of p 14 in the presence of accessory cells (Fig. 1).
However, the addition of rIL-2 to the tolerance-induction
culture inhibited the development of antigen-dependent unres¬
ponsiveness. The inhibition was dose-dependent since T cells
incubated with 0-1 //g/ml were only partially resistant to the
tolerizing effects of peptide, whereas 0-3 and 1 /ig/ml of rIL-2
had marked effects (Fig. 1). It seemed unlikely that the
proliferation observed was merely IL-2 carry over, since T cells
pretreated with IL-2 were washed with an acidic buffer. pH 3-8.
to elute IL-2 from its receptor (Fujii et al.. 1986). T cells pre-
incubated with IL-2 alone and washed in this way failed to
proliferate alone in culture or in the presence of accessory cells
(Table 1. line 5. 727 c.p.m.). The specificity of this unresponsive¬
ness was confirmed (Table 1), as pl4 was effective but an
unrelated peptide (pi 12) from the 65.000 MW protein of
mycobacteria was not.
IL-1 and IFN-y fail to inhibit the development of T-ceii unrespon¬
siveness
IL-1 is a growth factor involved in the activation of T cells.
Therefore, it was of interest to determine whether or not IL-1
has the capacity to abrogate T-cell unresponsiveness. The
addition of recombinant IL-1 a at concentrations ranging from 1
to 1000 U/ml had no appreciable effect in the induction of
tolerance with supra-immunogenic concentrations of pl4
(Fig. 2. Table 2). Although incubation with IL-la at 1000 U/ml
overnight in the absence of peptide reduced the capacity of the T
cells to respond to an immunogenic challenge with pi4. this was
not observed when peptide (10 or 100 /ig/ml) was added to the
cultures (Fig. 2). In addition. \L-\[i had no inhibitory effect on
antigen-induced unresponsiveness (data not shown).
The effects of IFN-y on antigen-induced T-cell tolerance
were similar to those of IL-1. While exposure to IFN-y alone
appeared to partially inhibit the response when challenged with
pi4. howeverwith p!4 present in the induction culture at 10 and
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Table I. IL-2 can inhibit the induction of T-ccll unresponsiveness
Toierance induction Response (c.p.m.)
T ceils Antigen IL-2 APC APC — p 14 IL-2
HA 1.7 _ _ 192 14.131 7206
- pi4 (30 /ig/mi) — 283 1624 9431
- pi 12 (30 /ig/ml) — 311 10.768 8826
- p 14 (30 /ig/mi) 1 ug/ml 820 8713 11.473
- - -t- 727 17.215 12.762
- - - 241 326 —
Cloned T ceils of HAl-7 (5x 104,mi) were precuitured in medium.
IL-2. antigen (30 /ig/ml) or the combination of antigen and IL-2
overnight and then washed prior to the addition to proliferation assays.
In the proliferation assays. T cells (5 x I04'mi) were added to histocom-
patible irradiated PBM (1-25 x 105'ml) in the presence or absence of p 14
(I /zg/ml) or cultured in IL-2 alone. Proliferation as correlated with
[}H]TdR incorporation was determined at 72 hr. Results are expressed




Figure 3. Failure of IFNy to inhibit the induction ot'T cell unresponsiv e¬
ness. Clone HA 1-7. I x 104 was tolerized± varying concentrations ofAg
pl4. in the presence of IFN-y: □ no IFN-y: □ 100 U.mi: 23 1000 U ml for
16 hr. Cells were washed, then challenged with 2-5 x 104 accessory ceils
plus activating dose of pl4 (I ,ug/mi) for 3 days.
0 10 100
Tolerance induction Aq /xq/mL
Figure 2. Faiiure of IL-I to inhibit the induction of T-cell responsive¬
ness. Clone HA 1-7. 1 x l()4. was tolerized ± varying concentrations of
Ag p 14. in the presence of recombinant IL-Ix: □ no IL-I; □ 1 U mi: 3
1000 U mi. for 16 hr. Cells were washed, then challenged with 2 5 x !04







Figure 4. Ability of IL-2 to reverse antigen-specific unresponsiveness.
Clone HAI-7. I x 104. was toienzed ± varying concentrations ofAg pi 4.
Toierance induction is indicated by ♦. Cells were washed, then
challenged with 10 /ig.mi IL-2. indicated by a. The normal controi
activation curve of I x 104 HAT7-r2-5x I04 accessory cells varying
doses of Ag. pi4. is indicate by •.
Table 3. Anti-IL-2 receptor (Tac) antibody neither
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Cloned T cells of HA IT were preircaied with
antibody (5 /ig/ml). antigen (30 ug ml) or both together
and after washing assayed as described in iegend to
Table 1.
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100 ug/ml no difference was observed between the control
cultures without antigen (Fig. 3. Table 2). These preparations of
recombinant IL-1 and IFN-y were effective in the thymocyte
assay (IL-1) and monocyte HLA-DR induction (IFN-y) in our
laboratory (data not shown).
Reversal of antigen-induced unresponsiveness by IL-2
The presence of IL-2 during the initial incubation of peptide
abrogates the induction of T-cell unresponsiveness (Fig. 1).
Therefore, it was of interest to determine if IL-2 could reverse
tolerance once established. Thus experiments were performed
cultunng T cells with IL-2 after the induction of unresponsive¬
ness. Indeed, adding IL-2 to cultures containing T cells tolerized
over a range of antigen concentrations, it was able to restore to
ability to respond to p 14 (Fig. 4). As theT cells were treated with
acidic buffer to dissociate IL-2 from its receptor, it would appear
that IL-2 is able to reverse the antigen-dependent unresponsive¬
ness and that IL-2 carry over does not account for the
proliferation observed. The apparent high concentration of IL-2
required to reverse tolerance 1 ^g/ml (1000 U/ml) is due to its
low biological activity.
Effect of anti-IL-2 receptor antibody (Tac) on the induction and
reversal of antigen-specific unresponsiveness
Although anti-Tac antibody interacts with the binding site for
IL-2. blocking both high and low affinity binding of IL-2. it does
not stimulate IL-2 receptors or otherwise mimic IL-2. (Miva-
waki et al.. 1982). Anti-Tac was used to determine whether or
not the modulation of IL-2 receptors could interfere with the
induction of antigen-dependent tolerance or induce unrespon¬
siveness itself. The anti-Tac antibody, similar to the control
anti-HLA class I antibody, was unable to inhibit p20-induced
unresponsiveness (Table 3). Furthermore, pretreatment of the
T cells with anti-Tac antibody alone did not induce unres¬
ponsiveness. As a specificity control for p20 induced tolerance.
T cells were exposed to the unrelated HA peptide pi7 and no
unresponsiveness resulted (Table 3).
DISCUSSION
Although some of the mechanisms of T-cell activation in the
induction of an immune response are becoming understood,
there is little information on those regulating unresponsiveness.
In human systems there could be significant clinical benefit in
autoimmune or infectious diseases from understanding mecha¬
nisms of unresponsiveness in more detail (Feldmann. 1987b;
Nath. 1983).
Neither is self non-responsiveness well understood. It is
considered to be acquired in large part, during fetal develop¬
ment in the thymus. Recent studies of T-cell receptor V/? gene
expression in murine thymus have suggested that during T-ccll
maturation there may be deletion of clones using certain V/?
genes, as judged by their presence in the immature (CD4"
CDS*) cells but absence from the mature (CD44 or CD8")
T cells (Kappler. Roenm &. Marrack. 1987). A role for suppres¬
sor cells in self non-responsiveness has been asserted on the basis
of a variety of studies, but the relative inability to clone
suppressor T cells (Lamb & Feldmann. 1982) makes it difficult
to evaluate their role in self non-responsiveness. The process of
antigen-induced non-responsiveness of T-cell clones has been
reported by ourselves using human class II-expressing T cells
(Feldmann et al.. 1985). and more recently a murine model using
class II-negative T cells and fixed class II-expressing APC has
been developed (Jenkins &. Schwartz. 1987). Although both the
human and murine systems appear analogous, there is insuffi¬
cient data to relate these m vitro processes to the mechanisms of
immunological tolerance' as they occur during fetal develop¬
ment and subsequently in vivo, although the MHC restriction
both in vivo and in vitro is suggestive of similarities (Matzinger.
Zamovska & Waldmann. 1984; Lamb &. Feldmann. 1984).
The addition of a tolenzing concentration of antigen down-
regulates the CD3/Ti-receptor complex concomitant with
enhanced expression of IL-2 receptor (Zanders et al.. 1983;
Feldmann et al.. 1985; Lamb et al.. 1987). Therefore, we tested
whether or not engaging the IL-2 receptorwith IL-2 or anti-IL-2
receptor antibodies was able to block the induction of. or
reverse, tolerance. The results presented here indicate that IL-2.
but not IL-1 or IFN-y. al concentrations effective in bio-assavs.
can abrogate the induction of unresponsiveness at concentra¬
tions effective in bio-assavs. The difference between the effect of
IL-2 and the ineffectiveness of anti-Tac may be due to the much
greater affinity of the former (kD 10~i: mole/litre) compared
to the latter (kD — 10~v mole/litre), or to the need lor IL-2 to be
internalized (reviewed by Leonard et al.. 1982). IL-2 can also
reverse the unresponsiveness, if added after the tolerance-
induction phase. Although murine T-cell clones tolerized in vitro
are unable to secrete IL-2. the addition of IL-2 during the
induction phase fails to prevent unresponsiveness developing
(Jenkins et al.. 1987). However, it has been reported that IL-2
injected into neonatally tolerant mice can induce graft rejection
(Malkovsky et al.. 1985).
From our findings, based on the control experiments and
dose responses, it is possible that IL-2 acts at both stages.
Particularly telling is the fact that reversal requires high
concentrations of IL-2. being optimal at 1 //g/ml (1000 U/ml).
whereas blocking of the induction occurs at lower levels
(300 U/ml). In comparison, maximum proliferation of the cells
was induced with approximately 30 U/ml. Thus it seems unlikely
that the breaking is due to IL-2 carry over, as the cells were
washed, reducing considerably the IL-2 carry over to the
'breaking or reversal" time.
The effect of IL-2 on antigen-induced unresponsiveness has
certain implications for other systems. An obvious example is
the induction of human autoimmunity. It is conceivable that
activation of T cells by viruses or parasites may provide
sufficient IL-2 in a local site to overcome unresponsive status
and generate helper cells to certain autoantigens. The relevance
of this to the classical autoimmune diseases is not known,
however, we have found that there is abundant IL-2 mRNA in
tissue biopsies of active autoimmune sites such as rheumatoid
arthritis (Buchan et al.. 1988). There is the development of a
number of autoantibodies in individuals parasitized with
schistosomes and conceivably the pathway described above may
be of relevance (reviewed by Feldmann. 1987a).
Recently. IL-2 has been used in tumour immunotherapy. By
cultunng blood mononuclear cells with 1000 U/ml of IL-2.
activated killer cells are generated. These are known as lym-
phokinc-activated killer cells or LAK cells (Muul &. Rosenberg.
1986). Therapy with such cells causes considerable side-effects.
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It is possible that some of the side-effects may be due to
abrogation of self-tolerance in some T cells.
Our interest in analysing the effects of lympnokines and
cytokines on the induction of T-cell unresponsiveness was
primarily because of the possible insights that may be shed on
the mechanisms, and consequently their potential for immune
manipulation. Taken together, our results suggest that supra-
immunogenic concentrations of antigen in the absence of
accessory cells may prevent the production of IL-2. perhaps by
switching off the IL-2 gene. It was proposed that the molecular
basis for this may be an increase in intracellular calcium (Jenkins
et al., 1987). From in vitro studies with murine T-cell clones it
appears that IL-2 is the only lymphokine that is switched off
during tolerance induction (Jenkins et al., 1987), and it remains
to be determined whether human T cells are regulated in the
same way.
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Abstract
The induction of non-responsiveness in specific clones of T cells in vivo might be expected to
reverse immunologically mediated disease processes. With this goal in mind, experiments in vitro
with cloned T cells have investigated the mechanisms of induction of anergy. Resting T cells can
be functionally inactivated in vitro by high doses of appropriate peptide in either the presence or
absence of antigen presenting cells. During the induction of anergy, the modulation of the
surface phenotype of T cells is similar to that of cells proliferating in response to an
immunogenic stimulus. The amount of T cell receptor at the cell surface is down regulated,
whereas the C02 and CD25 receptors are increased in density. In contrast, CD28 has been
identified as a membrane protein that is differentially regulated during activation and the
induction of non-responsiveness. Ligation of CD28 provides an efficient costlmulatory signal for
activation of T cells. In this report, we show that not only resting cells, but also fully activated
T cells can be rendered non-responsive and that this process is accompanied by profound
downregulation of CD28, both at the level of cytoplasmic mRNA and surface expression of the
mature protein. This observation anticipates clinical intervention in immunologically mediated
disease, where the target T cells are more likely to be activated than in a resting state.
Introduction
The phenomenon of immunological tolerance is well described:
it results from both deletions of sets of T lymphocytes in the
thymus and from the maintenance of some sets in a state of
anergy in the periphery. The mechanisms of post-thymic T cell
tolerance have been studied in vitro and several model systems
have now been well characterized (reviewed in 1). For human
CD4* T cells it has been established that stimulation with high
doses of appropriate peptide, in either the presence or aDsence
of antigen presenting ceils (APC), will inhibit subsequent antigen
dependent proliferation (2). The phenotype of T cells during the
induction pnase of anergy parallels that of cells which received
an activating signal. Transcription of several genes is hyper-
induced during this period: however, the ability of anergized
T cells when rechallenged to release a range of cytokines is
curtailed (3). Anergic T cells fail to produce enough IL-2 by the
normal autocrine pathway to deliver a growth signal that permits
clonal expansion and so anergy may be considered as abortive
activation. However, the cells remain viable and they will
proliferate, in resDonse to exogenous IL-2 (4). In humans, both
T„1 and Th2 subtypes of CD4* T cells are susceptible to
CorresDondence to: R. A. Lake
Transmitting editor- M. Neuberger
peptide-mediated anergy. Interestingly, anergized T.,2 type
T cell clones do not produce IL-4, but release interferon (IFN)--y
when rechallenged (5). This observation suggests that a strategy
of peptide vaccination for desensitization of allergic individuals
may divert the overall immune response towards the T„1 type
and thus away from Igt synthesis. In contrast, this study also
revealed that T cell clones of the Tn1 type did not release
IFN-y when rechallenged. Murine CD4* T cell ciones cannot be
anergized by high doses of peptide, probably because these
T cells do not express MHC class II molecules. However, these
cells do not proliferate when stimulated with antigen and
chemicaily modified APC and they remain refractory to a
subsequent immunogenic rechallenge (6). Unlike the human
system, murine T cell anergy is immediate and not characterized
by a change in surface phenotype.
After an activating signal, T cells upregulate their exDression
of the C028 antigen. In contrast. T cells that receive a tolerizing
signal downregulate their expression of the antigen (7). This
reduction of CD28 has been reproducibly seen in human T cells
representative of the T„1- and Tn2-like subsets. A signal through
Received 9 November 1992. accepted 22 January f 993
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Fig. 1. Phenotypic moauiation oi activated T ceils exposed to anergizing concentration of specific peptide. Membrane expression of CD3 (A). CD23
(B) and CD25 (C) of activated T ceils exDOsed to hign concentrations of HA 307-319 (cross-natcned bars) or HDM 1 -15 (stippieo bars) were
compared by flow cytometry at 2.4 ano 24 h after activation. Expression of CD3. CD28. and CD25 for resting 7 cells and those activated by anti-CD3
antioody was also determined (solid bars in A, B, and C).
CD28 is a pleiotropic event: it is costimulatory for T cell prolifera¬
tion (8) and results in the uoregulation of several T cell derived
cytokines by stabilizing their mRNAs (9.10). Ligation of CD28
affects IL-2 synthesis by the generation of a nuclear complex that
increases transcription from the IL-2 gene promoter (11). It is now
clear that faiiure to iigate CD28 is the tolerogenic event wnen
T ceils are stimulated by antigen and chemically modified APC
(12), probably because the natural ligand of CD2B, the activa¬
tion antigen B7/BB-1 (present on dendritic cells, activated B cells,
and monocytes), is denatured in the fixation process. It seems
possible then, that tolerance induced by high dose peptide
antigen is similar to tolerance induced by chemically modified
APC. In the former, absence of a costimulatory signal can be
ascnoed to low receptor expression, in the latter to lack of ligand.
High doses of peptide cause down regulation of CD28 so that
no second signal can be delivered on rechallenge whereas
fixation of APC causes the disruption of the natural ligand with
the same conseouence. The present report extends these obser¬
vations. We show that aownregulation of CD28 after a tolerogenic
signal occurs rapidly and by post-transcriptionai mechanisms.
Furthermore, we establish that activated T cells, involved in an
ongoing immune response, can oe anergized by high concentra¬
tions of free peptide.
Methods
Peptides
The influenza haemagglutinin peptide (residues 307-319: HA
307- 319) and control peptide from the group II allergen of the
house dust mite (residues 1-15: HDM 1-15) were synthesized
using standard solid-phase tecnnology on an Applied Biosystems
model 431A synthesizer, purified by reverse-phase HPLC. The
constitution of the peptides was confirmed by amino acid anaiysis
as previously described (13).
Antibodies
Flow cytometric analysis was performed using fluorescem-
conjugated murine mAbs. Anti-Leu4 (CD3), anti-IL-2 receptor
(CD25) and a mouse lgG1 control were bought from Becton-





Fig. 2. Ability of specific peptide to inauce anergy in activated T ceils.
In (A), cloned T ceils of HA1.7 (l0°/mi) were pretreatea by culturing in
medium alone (stippied bars) or with insoluoiiizeo anti-CD3 antibody and
IL-2 (cross-hatched bars) for 24 h. After preTreatment the T ceils (iCP/ml)
were assayed for their aoility to respond to restimuiation with HA 307-319
(0.3 ug/ml) and HLA-0R1 " APC (irradiated PBMC) or IL-2 alone. Control
responses of the pretreated T cells to APC alone or medium alone were
measured. Proliferation as correlated with [3H]TdR incorporation was
determined at 72 h. In (B), T ceils initially stimuiated with anti-CD3 antibody
and IL-2 for 24 h were exposed either to HA 307-319 (solid bars) or
HDM 1-15 (cross-hatched bars), both at 50 u.glml. for a further 24 h.
The T ceils were then assayed for their acility to respond to restimuiation
as described above.
Dickinson (Oxford. UK). Anti-CD28 antibody was bought from
Janssen (Aide, Germany). The murine anti-CD3 antibody used
for cell activation was a kind gift from H. Spits (DNAX, Palo Alto.
CA).
HA reactive cloned T lymphocytes
The isolation of HA 1.7, a clone of T cells reactive with HA
307-319. has been reporteo in detail previously (2.7). Briefly,
peripheral blood mononuclear leukocytes (PBMC) were
stimulated with purified HA in RPMI 1640 (Gibco. Uxbriage, UK)
supplemented with 100 U/ml penicillin. 100 ng/ml streptomycin.
2 mM L-glutamine, and 5% human A8" serum. The activated
T cells were cloned by limiting dilution in the presence of
irradiated autologous PBMC. IL-2. and antigen. Growing HA1.7
cells were expanded by stimuiation with antigen and filler ceils
every 7 days. After stimulation, the cells were expanded with IL-2
every 3-4 days. The cells were rested 7-3 days after the last
addition of filler cells and antigen before their use in experiments.
Experimental protocol
Resting cloned T cells (106/mi) were activated by incubation with
anti-CD3 antibody insolubilized on tissue culture plates (12 pgiml)
together with 10% IL-2. Activated T cells were washed, then
incubated with HA 307 -319 (50 yglm\). Control cultures were
treated with the same concentration of an irrelevant peptide (HDM
1-15). After 24 h the cells were washed three times and then
assessed for their ability (105/ml) to respond to an immunogenic
challenge by APC [irradiated nistocompatible (DR1 *) PBMC
1.25 x 105/ml] and antigen (HA 307-319: 0.3 )ig/ml).
Proliferation assays
After a further 60 h incubation, tritiated methyl thymidine
([3H]TdR: 1 ^Ci/well: Amersnam International. Amersham. UK)
was added and the cultures harvested 12 h later. Proliferation
as correlated with [3H]TdR incorporation was measured by
liquid scintillation spectroscopy. The results are expressed as
mean counts per minute (c.p.m.) for triplicate cultures. In all
experiments the ScM was <20%.
Determination of phenotypic expression by fluorescence flow
cytometry
T cells were stained directly using saturating concentrations of
fluorescein-conjugated murine monoclonal antibodies. Propidium
iodide exclusion was used to identify viable cells. Cell popula¬
tions were analyzed by flow cytometry using an Epics-Profile II
(Coulter, Luton, UK). Mean fluorescence intensity was measured
on a linear scale. All viable cells were included in each deter¬
mination and in each case the fluorescence profile was unimodal.
Oligonucleotide synthesis
Oligonucleotides were synthesized using an Appiied Biosystems
(Cheshire, UK) PCR-mate-EP 391 DNA synthesizer, and purified
using oligonucleotide purification columns (Applied Biosystems),
according to the manufacturers general instructions. The
sequences used were:
CD28 forward 5'-CTT GTA GCG TAC GAC AAT GCG GT-3'
CD28 reverse 5'-AGG GCT GGT AAT GCT TGC GGG-3'
Actin forward 5;-GTG GGG CGC CCC AGG CAC CA-3'
Actin reverse 5'-CTC CTT AAT GTC ACG CAC GAT TTC-3'
Analysis of specific mRNA levels by polymerase chain reaction
(PCR)
Total celluiar RNA was prepared by guanidinium thiocyanate-
phenol/chloroform extraction (14). The RNA from each sample
was then transcribed to cDNA using 20 U AMV reverse
transcriptase (IBI. Cambridge. UK) and ollgo(dT)12_.a as a
primer. Transcripts were amplified througn 25 cycles of PCR us¬
ing appropriate primers at a final concentration of 0.25 ^M.
Amplification reactions were carrieo out in a Perkin Eimer thermal
cycler (Cetus: denaturation, 1 min, 94°C: annealing, 1 min, 55^,
extension. 2 min, 72°C). Reaction products were extracted with
chioroform and 25 were blotted onto Hybond nylon
memoranes (Amersnam) using a slot blot apparatus (Schliecner
& Schuell, Dassei, Germany) ano hybridized as previously
described (15). Probes were selected from areas internal to the
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Fig. 3. Cytopiasmic mRNA levels in activated T cells exposed to
anergizing concentration of specific peptide. Slot blotting and densito-
metnc analysis of PCR products was used to measure the amount of
mRNA encoding CD28 (upper panel) and cytopiasmic /3-actin (lower
panel). Resting T cells (lane 1) were pretreatea by culturing with
insolubiiized anti-CD3 antibody and IL-2 for 24 h (lane 2). After pretreat-
ment the T cells were exposed to either HA 307-319 (lanes 3, 5. and
7) or HDM 1-15 (lanes 4. 6, and 8), both at 50 ^g/ml. and the T cells
were harvested 2 h (lanes 3 and 4), 4 h (lanes 5 and 6), and 24 h (lanes
7 and 8) later
two primers used in tne amplification step and were laDelleo
(specific activity >108 d.p.m./^g) using the random hexa-
nucleotide priming method (16). The amount of mRNA in the
original sample was tnen quantified by radiography and densito¬
metry. Each sample was amplified with /3-actin primers and
processed in the same way to allow the starting levels of cDNA
to be compared.
Nuclear run off analysis
Nascent RNA was lapelleo using [a-32P]UTP (Amersnam) as
described (17) and hybridized to immobilized complementary
sequences as cetailed above. 1053/1, 1100/1. and 1057/1 are
genomic clones covering the CD28 locus. These clones were
a kind gift from K Lee (University of Michigan) [see (18) for
aetaiis). Giyceraloenyae-3-onospnate dehydrogenase (GAPDH),











Fig. 4. Nuclear run off analysis, showing de novo transcription in isolated
nuclei from cloned T cells, either untreated (Medium) or 24 h after
inauction of activation or tolerance. Nascent RNA was labelled and
hybridized to immobilized complementary seouences: 1053/1, 1100/1
ana 1057/1 are genomic clones covering the C028 locus (see 18 for
oetails).
Results
Phenotypic modulation o? activated T cells after treatment with
HA 307-319
The pnenotypic modulation of resting HA 307-319 reactive
CD4~ T cells (HA 1.7) after treatment with activating and toleriz-
ing regimens has been reported elsewhere (19). T cells were
rested for 7 days after the last cycle of expansion, then activated
with anti-CD3 antibody and IL-2. Twenty-four hours later, aliquots
of cells were exposed to a tolerizing concentration of HA
307-319 or an irrelevant HDM peptide, and samples were
analysed by fluorescence flow cytometry to determine the level
of surface CD3, C025. and CD28 after a further 2, 4. and 24 h
(Fig. 1). Consistent with our previous findings, the cells had
markedly downreguiated membrane CD3 expression 24 h after
an activating signal ano. in the aosence of any otner signal CDS
expression slowly recovered over the following 24 h period. In
contrast, CD3 expression on the cells that were treated with a
toierizing concentration of HA 307 - 319 was further reduced over
the course of the experiment (Fig. 1A). IL-2 (CD25) expression
was unremarkable: cells that received an activating signal showed
an increase in receptor expression and this increase was not
modulated by subsequent exposure to a tolerogenic signal (Fig.
1C). CD28 was upregulated after an activating signal and in the
aosence of any additional signal the expression of CD28 at the
cell surface continued to increase (Fig. 1B). The activated cells
treated with tolerogenic HA 307-319 downreguiated CD28 from
tne surface, so that 24 h after a toierizing signal the amount of
CD28 was similar to the resting cell level. This rapid loss of CD28
from the cell surface indicates that the protein has a high turnover
rate.
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Induction of i ceil anergy by treatment of activated cells with HA
307-319
The T cells were tested for their ability to respond to specific
peptide, 24 h after receiving an activating signal deliverea
through the T cell receptor (Fig. 2A). The data show that pre¬
servation does not affect the ability of cells to proliferate in
response to peptide presented in an immunogenic form, indeed
the activated cells are hyperresponsive to challenge. This
phenomenon is due to the induction of CD25 and the manifest
hyper-responsiveness of activated cells to IL-2 (Fig. 2A). These
experiments were designed to test whether activated cells subse-
auently treated with a high dose of specific peptide could be
functionally inactivated. After incubation with HA 307-319
(50 (tg/ml) for 24 h, the T ceils failed to proliferate when
restimulated with HA 307 -319 presented in an immunogenic
form (Fig. 2B). In contrast. T cells incubated with HDM 1-15
responded to rechallenge with specific peptide appropriately
presented. The addition of exogenous IL-2 caused proliferation
of anergized cells, confirming functional inactivation was not the
result of cytolysis. To our knowledge this is the first demonstra¬
tion that activated human T cells can be rendered functionally
non-responsive.
CD28 transcripts after activation and superinduction of T cell
anergy
In order to examine the kinetics of CD28 mRNA production during
the induction of non-responsiveness, levels were determined at
2, 4 and 24 h after exposure to the anergizing signal (Fig. 3).
Quantitative PCR analysis was used to measure the level of CD28
mRNA in cells that were treated with a high dose of peptide
antigen or irrelevant peptide as a control. CD28 mRNA
accumulated in T cell clones after activation and continued to
accumulate when the cells were treated with an irrelevant peptide.
In contrast, cells treated with a tolenzmg dose of HA 307 -319
had markedly less CD28 message 2 h later, and 4 h after
treatment CD28 mRNA was virtually undetectable. These data
correlate well with expression of CD28 at the cell surface after
the various treatments. Clearly, CD28 mRNA is rapidly degraded
during the induction phase of tolerance. However, it is not clear
from these experiments whether CD28 downregulation occurs
at the level of transcription or because of increased specific
catabolic activity.
Nuclear transcripts of CD28 after activation and induction of T cell
anergy
Nuclear run off assays were performed to investigate transcrip¬
tional activity in cells that received either an activating signal or
a tolerizing signal. The data suggest that increased expression
of CD28 after activation is a consequence of transcriptional
upregulation (Fig. 4). It is important to note that these data do
not rule out attenuation as the primary mechanism of transcrip¬
tional control. On the contrary, it is noteworthy that X clone 1100/1
(Fig. 4) contained DNA from the most 3' end of the gene and
is apparently unrepresented as a transcript in the nucleus of ceils
cultured in medium alone. This suggests that transcription is
attenuated in unstimulated ceils and that a positive signal permits
full length transcription through the remainder of the gene. Our
results also show that cells that received a tolerizing signai
transcribe the CD28 gene at the same rate as cells undergoing
activation. Different levels of CD28 mRNA accumulate in the two
populations, probably because of differential rates of degrada¬
tion after treatment. The biological importance of post-
iranscnptional mechanisms of gene regulation is now being
generally recognized (20). Variations in the steady state level of
cytoplasmic mRNA can be attributed to regulation at any point
in the pathway between nuclear transcription and degradation
in the cytoplasm, e.g. changes in RNA processing and transport.
However, mRNA stability is the best candidate mechanism: it is
a known target for regulatory mechanisms in T ceils and inaeed
CD28 signalling affects mRNA stability itself.
Discussion
T cell activation is usually a prelude to proliferation, which is driven
at least in part by growth factors, notably IL-2. During the activa¬
tion of T cells, occupancy of the T cell receptor is conventionally
referred to as signal 1 and a growth signal referred to as signal
2. Bretscher and Cohn (31) first proposed this nomenclature to
expiam self - non-seif discrimination and their model demanded
that signal 2 be antigen specific and able to distinguish seif from
non-self. Signal 2 is, therefore, necessarily a function of an
immune effector population. The T cell growth factors fulfil this
requirement so long as they are produced in an antigen depend¬
ent manner. A costimulatory signal for T cell activation is provided
by ligation of C28 on the T cell to the accessory molecule B7/BB-1
on the surface of dendritic cells, B cells, and monocytes. It is
likely, though it is not yet known whether other receptors can
transduce an effective costimulatory signal. The net effect of
appropriate stimulation of T cells is the synthesis and release of
IL-2 and it has been suggested that signal 1 in the absence of
costimulation leads to anergy because IL-2 is not released
(22,23). However, it is clear from work with human T cell clones
that an enhanced signal 1, delivered through the T cell receptor,
even in the presence of antigen presenting cells and therefore
a costimulatory signal, is sufficient to induce non-responsiveness
(5). These experiments clearly snowed that the optimum cose
of peptide for the induction of anergy was increased in the
presence of APC. It is possible that T ceils are rendered
susceptible to the induction of anergy after stimulation through
the T cell receotor by the production of factors that have been
termed anergens (3). These are likely to be a diverse group of
molecules that may affect processes in distinct cellular compart¬
ments (see below). Rescue from anergy may occur by the
transduction of an appropriate signal 2, whicn at its most simplistic
might be a costimulatory signal that is sufficient to upregulate
IL-2 production. Anergic T cells will proliferate in response to
exogenous IL-2 (4,23) and it has been suggested that this growth
dilutes anergens to a level low enough to allow a normal
proliferative response on rechallenge (23). An ennanced signai
1 by stimulation of T cells with a high density of antigen might
therefore be expected to result in a high level of anergens, which,
beyond a certain level, a costimulatory signal cannot override.
This suggests that costimulation must act negatively on the
induction of anergens as well as positively on the production of
signal 2.
Induction of anergy is an active process that requires protein
synthesis (24,25). Anergens will include some of these molecules
as well as activation or translocation of other effector molecules.
For example, de novo protein synthesis prooably requires
transcription of the relevant genes and would therefore be
466 CD28 and T cell anergy
characterized by changes in the distribution of various transcrip¬
tion factors. One conseauence of a tolerogenic signal, aescribed
in the present report, is the raDid oecay of CD28 mRNA. It follows
therefore, that one member of the family of anergens is a factor
that can differentially control mRNA stability. Such a factor mignt
oe a sequence specific RNase or a factor that displaced a SDecific
RNA protecting molecule. Future work will investigate these
possibilities, ask whether the degradation accelerating factor is
a newiy synthesized protein, and examine the range of mRNA
species affected by a tolerogenic signal. In addition, we will test
other T cell clones to snow whether the phenomenon is general
or restricted to the Th1-like pnenotype. Interestingly. Takahana
and Singer (26) have recently identified a post-transcriptional
mechanism that regulates eariy thymocyte development. The
mechanism is influenced by signals througn the TCR and has
similar characteristics to the decay accelerating factor described
in this paoer. However accomplished, down modulation of CD28
from the cell surface could contribute to a mechanism wnereby
cells can be rendered anergic. Ligation of CD28 results in the
upregulation of IL-2 by stabilizing its mRNA (9) and througn the
generation of a nuclear complex that increases transcription from
tne IL-2 gene promoter (11). Thus, the loss of CD28 from the
surface of the T cell will render the costimuiatory pathway
ineffective. The rapid kinetics of CD28 down modulation is
consistent with the short time (24 h) required for the induction
of anergy.
The findings reported here demonstrate that immunogenic
peptides, appropriately presented at high density, can inactivate
SDecific clones of T cells that have oeen activatec through the
T ceil receptor for antigen. The practical value of this observation
is in the development of DeDtide-based approaches to immuno-
:herapeutic intervention during the acute pnase of autoimmune
disease and specific allergic inflammatory responses.
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Biochemical events initiated by exposure of human T
lymphocyte clones to immunogenic and tolerogenic
concentrations of antigen*
Interieukin 2-dependent helper T ceils, cloned from human peripheral blood Ivmpno-
cvtes activated with strain A influenza virus hemagglutinin, proliferate in response to
a 24-residue synthetic peptide (p20) of hemagglutinin, but become unresponsive to a
subsequent immunogenic challenge when pretreated with a high concentration of p20.
This phenomenon is associated with a loss of the T3 antigen complex, presumabiv in
association with the T ceil receptor. We have examined this phenomenon in more
detaii and show that in addition to changes in the expression of T3 molecules on the
cell surface, high doses of p20 cause changes in the expression of certain biosvntheti-
callv and surface-labeled proteins, although total DNA and protein synthesis was
unaltered. Thus, by examining these biochemical phenomena we can begin to define
some of the processes which occur during antigen activation of human T lymphocytes
at the clonal level.
1 Introduction
Recent technical advances have made it possible to clone T
lymphocytes and perform experiments which would have been
uninternrerable using heterogeneous populations containing
rare antigen-specific cells. We have used human T cell clones
induced with the hemagglutinin-1 molecule of influenza which
recognize a 24 amino acid peptide (p20. ref. [1]) to study the
induction of antigen-specific, antigen-induced nonresponsive-
ness in vitro, a form of immunological tolerance. Optimal
tolerance required 18 h exposure to high concentrations of
antigen, and was more profoundly induced in the absence of
antigen-presenting cells [2|. During the process of antigen-
induced tolerance, the surface antigen T3 was selectively lost
from the cell surface in proportion to the concentration of p20
used for incubation [3], Functional tolerance (lack of response
to antigen) was mimicked by pretreatment with anti-T3 which
removed it from the ceil surface. .Since Meuer et al. have
shown that "clonotvpic" molecuies corresponding to the T cell
receptors for antigen are comoduiated with T3 [4|, our current
concept is that during tolerance antigen at high doses down
regulates the antigen receptor and takes the T3 complex with
it.
Although this is a simple mode! for antigen-driven unrespon¬
siveness at the clonal level, it is evident that other changes
occur during exposure of HA1.7 to p20. We wished to charac¬
terize these changes by using standard biochemical techniques
to study the fate of macromoiecuies during the period of prein¬
cubation with antigen and to evaluate this system as a model
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for anrigen-T cell interactions. We show here that several
changes in the expression of proteins occur, although the rele¬
vance of this to T cell activation phenomena in general is stiil
unknown,
2 Materials and methods
2.1 Ceils, antigens and antisera
Clone HA 1.7 was isolated and cultured as previously
described [1], For the expenments reported here, ceils were
used between 4 and 7 days after feeding with irradiated pre¬
senting ceils and specific antigen. Peptides of the hemaggluti¬
nin-! (HA-L) molecuie of influenza virus hemagglutinin were
synthesized according to the ammo acid sequence of A Hong
Kong'.K47 (H3N2) [5) as predicted from the nucleotide se¬
quence [6j. p20 corresponded to residues 306-329. and oil to
105-l-tO. Both were kind gifts of Dr. R. A. Lerner. Researcn
Institute of ScriDDS. La loila. CA.
2.2 Biosvnthetic labeling of protein and DNA
For determining the effects of p20 concentration on DNA and
protein synthesis, ceils were washed once in HEPES-buffered
RPMI 1640 (Gibco. Grand Island. NY) containing 10% A"
serum and cultured in 200 ul wells of microtest piates i Faicon
Plastics. Oxnard. CA) in the same medium. Increasing con¬
centrations of peptide dissolved in phosphate-buffered saiine
(PBS) were added, followed by radioisotope, (a) For DNA
synthesis 2.5 x 10" cells were cultured overnight with
1 uCi = 37 kBq [JH|thvmidine (Radiochemical Centre. Amer-
sham. GB) and harvested onto glass fiber filters. Incorpora¬
tion was measured by liquid scintillation spectrometry. <b)
Protein synthesis was measured by labeling 5 x 104 ceils with
5 uCi ["S]methiomne (Amersham. >800 Ci/mmoi) for 18 h.
Labeled ceils were Ivsed with 0.5% Nomdet-P40 (NP40).
0.15 M NaCI. 50 mM Tris chloride. pH 8.0. and 1 mM phenyi-
methyisuifonvi fluoride ( PMSF). Aliauots of total ceil lysates
were spotted onto Whatman 3 MM filter paper, boned in 10%
trichloroacetic acid (TCA) for 10 min and washed in cold TCA
followed by ethanoi and ether. Air-dried filters were then
counted in a liquid scintillation counter.
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2.3 Analysis of surface and biosynthetically labeled proteins
I a) HA1.7 was surface labeled with I25I using the dipnenvl
givcoiuril procedure (iodogen) [7]. Briefly, the cells were
washed twice in PBS. resuspended in PBS to lO'/ml and
labeled with 1 mCi ;25I (Amersham) for 20 mm. They were
then washed twice in PBS and Ivsed in 0.5% NP40. 0.15 M
NaCl. 50 m.M Tris chloride. pH 8.0. 1 mM PMSF ana 50 mM
iodoacetamide. Cell debris was removed bv centrifugatton for
1 mm in an Eppendorf microfuge and the cell extracts were
analyzed by two-dimensional gel electrophoresis using the
isoelectric focusing system described by O'Farrell [8]. (b)
HA1.7 was washed once in methionine-free RPMI 1640
fSelectamine kit. Gibco) and cultured in 96-well plates at
2 x 103 cells/well in the presence of 10 u.Ci [35S]methionine.
After labeiing overnight, the cells were washed once in com¬
plete medium and lvsed as described above, (c) Proteins
labeled using either method were analyzed by SDS-PAGE in
10-15% exponential gradients of acrviamide. After staining
with Coomassie blue to locate the molecular weight markers,
the geis were dried and autoradiograpned using Kodak SB-5
or XAR5 film for 3JS and lsI. respectively.
11.
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Figure 1. HA1.7 was cultured in round-bottom tissue culture weils for
18 h with PHlthymiaine for DNA and [33S]methionine for protein
synthesis. The quantities of cells and isotopes used were as described
in Sect. 2.2. Each point represents the mean of two determinations,
with standard errors being less than 10%. The top graph indicates the
incorporation of [3H]thvmidine in a standard proliferation assay after
clones were treated with the indicated amounts of peptide and repre¬
sents functional tolerance with p20 [2].
3 Results
3.1 Effect of p20 on synthesis of protein and DNA
To observe the effect of increased doses of p20 on mac-
romolecuiar synthesis. HA1.7 was cultured under similar con¬
ditions to those described in Fig. 1. but in the presence of
radioactive precursors of DNA and protein. Fig. 1 shows the
ability of increased p20 concentrations to inhibit the subse¬
quent proliferation of HA1.7 when challenged in the presence
of an immunogenic concentration of p20 (1 ug/ml) and irradi¬
ated presenting cells (ref. [2], top graph). Total DNA and
protein synthesis, as measured by [3H]thvmidine and
[35S]methionine uptake, respectively, was unaffected and
remained at the same level as that of the control peptide pll.
3.2 Biosynthetic labeiing of HA1.7
Although total protein synthesis in HA1.7 appeared to be
unaffected by high doses of p20. it was possible that the syn¬
thesis of a small number of individual polypeptides might be
altered under these conditions. Ceils were therefore labeled
with [35S]methionme in methiomne-free medium for 18 n.
lvsed to extract proteins from the cell membrane and cyto¬
plasm and analyzed by SDS-PAGE. Labeiing in this medium
has previously been shown not to affect the ability ofHA1.7 to
be functionally tolerant to antigen. Fig. 2 shows the gei
obtained after such a protocol. The lanes derived from cul¬
tures without peptide were duplicated to show the reproduci¬
bility of sample preparation and electrophoresis. A control
peptide, pll, gave identical patterns to these zero controls
(data not shown). As the peptide concentration was increased,
however, several changes in the proteins synthesized became
Figure 2. HA;.7 was
labeled at 1 x 10°/ml in
200 ui RPMI 16-10 minus
methionine containing
50 uCi/ml ["Sjmethio-




for 18 h. The cells were
washed once in complete
medium, extracted in
NP40 buffer as described
in Sect. 2.3 and the entire
sample was analyzed by
SDS-PAGE using a
10-15% exponential gra¬
dient of acryiamiae be¬








304 E. D. Zanders. M. Feldmann and J. R. Lamb Eur. J. Immunol. 1985.15: 302-305
apparent. Thus proteins of apparent molecular masses 24. 29.
44. 47, 60 . 70 and 135 kDa were enhanced, whiie two species
of 42 and 92 kDa were diminished. Similar profiles were
obtained when [35S(cysteine was substituted tor methionine
(data not shown). Thus even reiativeiv low levels of p20 (e.g.
0.1 ug/mi) were capable-of enhancing the synthesis of some
proteins.
3.3 Surface iodination of HA1.7
HA1.7 was cultured overnight with either 0 or LOO ug/mi of
p20. followed by surface iodination with l~I using the ioaogen
method. NP^O Ivsates were prepared and analyzed by isoelec¬
tric focusing followed by SDS-PAGE. Fig. 3 shows the resuit
obtained. Some spots were induced [relative to 0 and irrele¬
vant peptide (pll) controls! with high doses of p20. most
prominently those with a molecular mass of 50. 83 and
87 kDa. Initially we had hoped to detect putative T cell recep¬
tor molecules using this technique. These have been described
as having molecular masses between 80 ana 90 kDa under
nonreducing conditions which can be cleaved by reduction to
two molecules of 30-40 and 45-50 kDa. respectively [10].
Tnese were not observed using standard two-dimensional geis
and therefore represent a very smail fraction of the total sur-
face-labeied proteins.
4 Discussion
We have examined the changes in protein synthesis which
occur when cioned human T helper cells are exposed to
tolerogenic doses of peptide antigen. Functional unresponsive¬
ness is generated exclusively by specific antigen (either p20 or
pii according to the clone used") in the absence of accessory
ceils [2]. p20 itseif has no effect on other clones tor which it is
not specific. In addition. moauiatio« of the T3 antigen was






Figure 3. HA1.7 cells (2.5 x 10°) were incubated with or without
100 ug/ml p20 tor 18 h in RPMI 1640containing J.0% A" serum. They
were then washed once in PBS and iodinated with 0.5 mCi '~I using
the :oaogen method. After two washes with PBS the ceils were Ivsed
in NPao buffer, made 9.5 m in urea ana mixed with an equal volume of
O'Farreil solution A [6). Isoelectric focusing was periormed exactly as
described (6) ana the geis were run in the second dimension througn
10-15% gradient geis. The dried geis were autoradiograpned with
intensifying screens. The arrows indicate peptides enhanced upon
stimulation of HA 1.7 with p20.
vations wouid suggest that the clones "present" specific anti¬
gen to themselves in the absence of accessory ceils, and that
the most likeiv site of peptide interaction other than the
specific receptors is with the HLA-DC molecules expressed on
the cell surface. It is uniikelv that this unresponsiveness is due
to a shut off of macromoiecular synthesis since the clones are
still responsive to interieukin 2 (IL2) [2j. Thus we have shown
in this report that DNA and protein synthesis is unaffected by
increasing doses of p20. However, examination of total surface
or biosvntheticaily labeled proteins by SDS-PAGE revealed
several changes. At present, little is known about the moiecu-
lar mechamsms of lymphocyte proliferation although studies
using uncioned peripheral blood lymphocytes and mitogens
have indicated that new proteins are induced [11]. In that
study, proteins recognized by antisera to HLA. A.B.C ana
DR antigens were induced, whereas the cioned T ceils
described here already express these antigens at the same level
regardless of the amount of peptide used in preincubation as
judged by pnenotvpic analysis [3]. In addition, the molecular
weights of the induced proteins described by these inves¬
tigators differ from those obtained here, although this couid
partly be due to differences in gel systems. We have observed
the increased expression of the IL 2 receptor, detected by the
anti-Tac monoclonal antibody, upon p20 stimulation [12). ana
it is possible that the biosyntheticailv labeled 60-kDa species
(Fig. 2) corresponds to this receptor [13]. The newiv synthe¬
sized proteins could also be cytoskeietai in origin, since recep¬
tor down regulation by internalization or shedding presumably
involves some rearrangements of the cvtoskeieton. Finally,
some of these proteins may be regulators of gene expression
although if they interact directly with nucleic acids their copy
number wouid be expected to be very low. A definite answer
to these questions can only be made when each moiecuie
involved is identified: this will probably require screening of
intracellular antigens with a battery of antisera against known
lymphocyte proteins.
Analysis of the cell surface proteins induced by p20 has been
iess revealing, since of the protein changes observed, none
corresponded to the T3 and T1 antigens known to be down
regulated by using serological techniques [3]. Thus the number
of bands changed with high doses of p20 is cieariv an under¬
estimate.
The system we have described offer a means of reducing the
complexity of the analysis of interacting ceils and molecules
within the immune system by using cloned ceils ana minimal
antigenic units. It offers the additional prospect of analyzing
two opposing functional states, immunity and tolerance [21. In
the initial functional studies, we found that tolerance T ceils
were still aiive and responded to IL2 after 7 days culture [2].
suggesting that tolerance was not due to antigen-induced dam¬
age of T ceils. Subsequent membrane stuaies confirmed that
toierance was an active state, since there was selective loss of
ceil surface antigens, not only the T3 complex [3]. Here we
present further data that the process is complex with selec¬
tively enhanced protein synthesis. The function of the newiv
synthesized proteins, however, is unknown at present.
We wish co (hank Dr. R. A. Lerner for the gift ofpeptides. Drs. 3ever-
lev and Silver for antisera. Dr. \t. Contreras and colleagues at :he
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Differential Induction of the NF-AT Complex During
Restimulation and the Induction of T-Cell Anergv
David Wotton, Julie A. Higgins, Robyn E. O'Hehir,
Jonathan R. Lamb, and Richard A. Lake
ABSTRACT: Stimulation of human CD4"1" T-cell
clones through che T-cell receptor (TcR) by high doses of
specific peptide results in che induction of a long-lived
state of nonresponsiveness chat has been called anergy.
During the induction of anergy, T cells «uc phenotypicaily
similar co cells responding co an immunogenic stimulus.
The amount of TcR at che ceil surface is downmodulated,
whereas che CD2 and CD25 receptors are increased.
When restimuiated, however, anergic T ceils fail co up-
regulate transcription of the IL-2 gene and in consequence
do not produce IL-2. In chis study, we have compared che
ability of various cranscription factors co bind co cheir
appropriate site on DNA. Facrors were isolated from che
nuclei of T cells chac were in che induction phase of anergy
or were undergoing activation. The pattern of binding
activity in restimuiated T ceils is consistent with che
pattern chat has previously been shown co regulate T-ceil-
specinc expression of che IL-2 and che (3 chain of che TcR
genes. The measured binding co a TCF-1 sice is che same
in che nuclei of resting, activated, and anergized ceils.
The inducible factors NK-kB, £ E2, CD28RC, and AP-1
are not expressed in resting cells and are cwofoid lower in
anergized as compared wich activated ceils. In contrast,
anergic T cells express approximated eightfold lower
amounts of NF-AT, a member of che class of inducible
factors chac regulates IL-2 gene transcription. The failure
co induce NF-AT completely may be a consequence of a
diminished calcium flux, since che PKC pathway was
apparently intact. It was found chat che calcium iono-
phore ionomycin could either induce anergy or abrogate
che induction of nonresponsiveness according co che dose,
also suggestive of differences in calcium signaling. The
pattern of expression of cranscription factors during che
induction of T-ceil anergy is consistent wich che inability
ofanergic ceils co produce IL-2. These results demonstrate
chac chere are differences in che early nuclear events char¬
acteristic of stimuli, che outcome of which leads co cells
chac are phenocypically similar, but are functionally dif¬
ferent. Human Immunology 42, 95—102 (1995)
ABBREVIATIONS
APC ancigen-presencing ceil
[Ca'""f"]j intracellular calcium concentration
dT deoxychymidine
HA hemagglutinin
MHC major histocompatibility complex
NF-AT nuclear factor activated T ceils
PBMC peripheral blood mononuclear ceil
PHA phytohemagglucinin
PKC procein kinase C
TcR T-cell receptor
INTRODUCTION
Immunologic tolerance results from deletion of some
self-reactive T lymphocytes in the thymus; other self-
reactive T cells that escape deletion can be rendered non-
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responsive or anergic (reviewed by Kroemer and Mar¬
tinez [1]). The second process is of particular interest
because the ability to render specific clones of T ceils
nonresponsive in vivo may contribute to attempts to
control immunologically mediated disease processes. To¬
ward this end, we have investigated the mechanisms of
induction of anergy with cloned T ceils in vitro. T-cell
activation and interleukin-2 (IL-2) production are regu¬
lated by several signals, including those generated
through the T-ceil antigen receptor (TcR), protein ki¬
nase C (PKC), and changes in the intracellular free cai-
0198-8859/95/S9.50
SSDI 0198-8859(94)00004-A
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cium concentration ([Ca2*],). Additionally, other co-
stimulatorv signals can act synergistically to cause syn¬
thesis of IL-2 and proliferation of the cells. The best-
documented costimulatory pathway is mediated through
CD28 on the T cell and the activation antigen B7/BB-1
present on the antigen-presenting cell (APC) [2—4].
Stimulation through the TcR without a costimulatory
signal results in anergy[5], and under some circum¬
stances a signal through CD28 can block the induction of
anergy in murine T-cell clones [6]. For human CD4~ T
cells, however, stimulation through the TcR with high
doses of appropriate peptide, in either the presence or
absence of APCs, will inhibit subsequent antigen-
dependent proliferation [7], These experiments clearly
show that the optimum dose of peptide for the induction
of anergy is higher in the presence of APCs. Thus, it
seems that the magnitude of the signal received through
the TcR can override an otherwise immunogenic stimu¬
lus and induce anergy. Fully activated T cells can also be
rendered nonresponsive [8]. And these observations an¬
ticipate clinical intervention in immunologically medi¬
ated diseases, where the target T cells are more likely to
be activated than in a resting state and the T cells will
certainly be in the presence of APCs.
The phenotype of T cells during the induction phase
of anergy is similar to the phenotype of cells undergoing
stimulation. Key changes at the cell surface include
downmodulation of the TcR complex and upregulation
of CD2 and CD25 receptors. Interestingly, signals
through the TcR upregulate transcription of the (3 chain
of the TcR gene [9], whereas transcription of the CD2
gene is not inducible. Howevet, a complex array of post-
transcriptional mechanisms regulates TcR gene expres¬
sion [10], such chat the overall effect of activating or
anergizing signals is downmodulation of cell surface
TcR. After an activating signal, T cells upregulate their
expression of the CD28 antigen. In contrast, T cells that
receive a high dose of specific peptide as a colerizing
signal do not [8, 11]. A signal through CD28 is a pleio-
tropic event: it is costimulatory for T-cell proliferation
and results in the upreguiation of several T-cell-derived
cytokines by stabilizing their mRNAs [12]. Ligation of
CD28 affects IL-2 synthesis by the generation of a nu¬
clear complex (CD28RC) chat increases transcription
from the IL-2 gene promoter [13]. The induction of the
CD28RC is, however, clearly not specific for signals
through the CD28 receptor as the complex is induced by
the mitogenic combination of PMA and anti-CD3 anti¬
bodies [14],
In this report, we have analyzed the effect of activat¬
ing and anergizing regimens on the induction of some
selected transcription factors that regulate expression of
the |3 chain of the TcR and the IL-2 gene. These factors
are well characterized and both T-cell-specific and gen¬
eral transcription factors are represented. The IL-2 pro¬
moter contains binding sites for nuclear factors including
NF-AT, Oct. NF-kB, and AP-1, which are ail poten¬
tially sensitive to activation of PKC. Members of a fam¬
ily that include the nuclear oncogenes Fos and Jun bind
as a heterodimeric complex to an AP-1 DNA-binding
site. Dimenzation occurs by the interaction of leucine
zipper domains in the two proteins and is a prerequisite
for DNA binding. The AP-1 site is the major target of
transcriptional induction after PKC activation in the
IL-2 gene promoter [15].
NF-AT is an inducible factor that is restricted to T
cells and is also a major regulator of IL-2 gene transcrip¬
tion. NF-AT is formed when a preexisting cytoplasmic
subunit translocates to the nucleus and combines with
newly synthesized Fos and Jun proteins [16]. FK506 and
cyclosporin A block translocation of the cytoplasmic
component without affecting synthesis of the nuclear
subunit [17], suggesting that the translocation is a cal¬
cium-dependent event. In nonstimulated cells, NF-kB
resides in the cytoplasm in an inactive complex with the
inhibitor I-kB. Stimulation causes release of 1-kB and
allows NF-kB to enter the nucleus, bind to DNA control
elements and, thereby, aid transcription. Activation is
triggered by a variety of agents including IL-1, TNF,
and phorbol esters. The TcR (3-chain enhancer responds
to PKC-mediated activation signals through a functional
domain that includes*the 3E2 element [18]. Multimer-
ized (3E2 can act in isolation as a phorbol-ester-
responsive element; it contains a consensus Ets-binding
site and binds directly to the product of the c-ets-1
ptotooncogene. 3E2 can also bind a second family of
nuclear factors, the core-binding factors [9]. TCF-1 is a
noninducible T-cell-specific transcription factor: it is
known to bind within the CD3 6 enhancer and in the
TcR a enhancer. It shares a region of homology with
other transcription factors termed the high-mobility
group 1 (HMG) box [19].
MATERIALS AND METHODS
Peptides. The influenza hemagglutinin peptide (residues
307—319; HA 307—319) was synthesized using standard
solid-phase technology and further purified by reverse-
phase HPLC. The constitution of the peptide was con¬
firmed by amino acid analysis as previously described
[20],
Antibodies. Flow-cycomerric analysis was performed us¬
ing fluorescem-conjugated murine monoclonal antibod¬
ies. Anti-Leu4 (CD3), anti-IL-2 receptor (CD25), and a
mouse IgG, control were purchased from Becton Dick¬
inson (Oxford, UK). The murine anti-CD3 antibody
used for cell activation was a kind gift from H. Spits
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(The Netherlands Cancer Research Institute, Amster¬
dam).
Cloned T lymphocytes. The isolacion of HA 1.7, a clone of
T cells reactive with HA 307-319 has been reported in
detail previously [7]. Briefly, peripheral blood mononu¬
clear leukocytes (PBMCs) were stimulated with purified
HA 307—319 in RPMI-1640 (Gibco Laboratories, Ux-
bridge, UK) supplemented with 100 U/ml penicillin,
100 p.g/ml streptomycin, 2 mM L-glutamine, and 5%
human AB serum. The activated T cells were cloned by
limiting dilution in the presence of irradiated autologous
PBMCs, IL-2 (10% Lymphocult T; Biotest Folex, Frank¬
furt; i.e. 10 U/ml) and antigen. Growing HA1.7 cells
were expanded by stimulation with antigen and filler
cells every 7 days. After stimulation, the cells were ex¬
panded with 10% Lymphocult T every 3-4 days. The
ceils were rested 7-8 days after the last addition of filler
cells and antigen prior to their use in experiments. Rest¬
ing cloned T cells (2 X 105/well) were activated by
incubation with anti-CD3 antibody insolubilized on tis¬
sue culture plates (12 p.g/ml) together with 10% Lym¬
phocult T. To induce anergy, T ceils were incubated
with HA 307-319 (50 |xg/ml). In some experiments,
the calcium ionophore, ionomvein (0.2-1 p-g/ml) was
added. After 24 hours, che cells were pooled and washed
chree times. The majority were used to make nuclear
extracts, whereas some were assessed for their ability (2
X 10~*/weli) to respond to an immunogenic challenge:
either by APCs (irradiated histocompatible [DR1+]
PBMCs 2 X 104/well) and antigefi (HA 307—319, 0.3
(Ag/'mi) or by incubation with anti-CD3 antibody insol¬
ubilized on tissue culture plates (12 p.g/ml).
T-cell proliferation assays. After a further 60 hours of in¬
cubation ('H]methyi chvmidine (1 p.Ci/'welI; Amersham
International, Amersham, UK) was added and the cul¬
tures harvested 8—16 hours later. Proliferation as corre¬
lated with ['H]methyl thymidine incorporation was
measured by liquid scintillation spectroscopy. The re¬
sults are expressed as mean counts per minute (cpm) for
triplicate cultures.
Flow cytometry. T cells (3 X L05) were stained directly by
using saturating concentrations of fluorescein-conjugated
murine monoclonal antibodies. Forward and side scatter
was used to identify viable cells. Cell populations were
analyzed by flow cytometry using an Epics-Profile II
(Coulter. Luton, UK). Data are expressed as the channel
number representing mean fluorescence intensity.
Oligonucleotides. Oligonucleotides were synthesized using
an Applied Biosystems DNA synthesizer and purified
using OPC (oligonucleotide purification columns, Ap¬
plied Biosystems), according to the manufacturers' gen¬
eral instructions. The sequences used were
se2: 5'-gatccacaacaggatgtggtttgacattta-3'
mf-at: 5' -gatctaaggaggaaaaactgtttcatcg-3 '
NF-kB: 5'-gatccagtgggaaattcctcg-3'
tcf-1: 5' -gatcctgggagactcagaacaaagcgctctcacacggga- 3'
cd28rc: 5' -gtctgatgactctttggaatttcttt-3'
AP-1: 5'-gatctatctctgagtcaatcagcg-3'
The reverse and complement of each sequence was also
synthesized with a noncomplemencary 5' dG and with¬
out the 3'dC.
Electrophorettc mobility-shift assay. Nuclear extracts were
prepared by a rapid method as described by Dignam et
al. {21], with several modifications. Cells (2 x 106) were
washed in ice cold PBS, pelleted and resuspended in lysis
buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl2, and 10
mM KC1). The mixture was vortexed and left on ice for
5 minuccs. Cell nuclei were pelleted by centrifugation
and resuspended in glycerol buffer (25% vol/vol glycerol,
20 mM Hepes pH 7.9, 0.42 M NaCl, 1.5 mxM MgCl,,
and 0.2 mM EDTA). The nuclear lysate was left on ice
for 1 hour with occasional vortexing. The nuclear debris
was pelleted and the extract retained. Protein concentra¬
tions were estimated using the Biorad protein assay kit.
All buffers contained 0.5 mM PMSF, 1.0 mM benzami-
dine, 5 p.g/mi aprotinin, 5 p-g/ml pepstatin, 30 (Xg/ml
leupeptin, and 0.5 mM DTT.
Oligonucleotides were radiolabeled with '2P [dCTP]
by filling in a dG overhang using AMV-RT, and the
probes were then purified by separation on 7.5% poiy-
acrylamide gels. Binding reactions contained 20 fJ-g
acetylated BSA, 2 p-g poly(dI—dC) • poly(dI—dC), 0.5
jxg salmon sperm DNA, 0.005% NP40, 5 mM MgCl2,
80 mM NaCl, 10 mM Hepes pH 7.9, 2.5 |ug of nuclear
extract, and 0.5 ng of probe with an activity of around
10,000 cpm. Oligonucleotide competitors were prein-
cubated with the nuclear extract for 5 minutes before the
addition of probe. Nonspecific oligonucleotides were
used in che final analysis as an indication that complexes
were not being retarded through a general capacity to
stick to DNA. In each case, the nonspecific oligonucle¬
otide was TCF-1, except in the TCF-1 gel shift, where
the AP-1 oligonucleotide was used. Reactions were in¬
cubated at room temperature for 20 minutes and then
separated on 5% polyacrylamide gels. Gels were dried for
autoradiography or were quanritated directly from che
dried gels by using an Ambis scanner.
RESULTS
Phenotypic changes during activation and the induction of an¬
ergy. The phenotypic modulation of the HA 307—3 19-
reactive CD4~ T cells (HA 1.7) after treatment with
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activating and tolerizing regimens has already been re¬
ported in detail [22]. T cells were rested for 7 days after
the last cycle of expansion and then activated with anti-
CD? antibody and 10% Lymphocuit T, or exposed to a
tolerizing concentration of HA 307—319- Cells were
analysed by fluorescence flow cytometry to determine the
level of surface CD3, CD25, and CD2 (Fig. 1). Consis¬
tent with our previous findings, both treatments resulted
in cells that had markedly downregulated membrane
CD3 expression. In contrast, IL-2 receptor (CD25) and
CD2 expression were upregulated.
Induction of T-cell anergy by treatment of cells with HA 307—
379. The T ceils were tested for their ability to respond
to specific peptide, 24 hours after receiving an activating
or anergizing signal (Fig. 2). The data show that pre-
activation enhances the ability of cells to proliferate in
response to an immunogenic challenge when compared
with cells incubated in medium alone. This phenomenon
FIGURE 1 Phenotypic modulation of T ceils exposed to
activating and anergizing signals. Membrane expression of
CD2 (solid bars), CD3 (cross-batched bars), and CD25 (stippled
bars) of T cells exposed to different conditions were compared
by flow cytometry at 24 hours after stimulation.
30000
5
Meeium Anti-CD3 * IL-2 HA (50ug/ml)
Pretreatment of T cells
Medium Anti-CD3 - IL-2 HA (50ug/ml)
Pretreatment of T cells
FIGURE 2 The ability of specific peptide to induce anergy
in activated T cells. Cloned T ceils (HA 1.7; 106/ml) were
pretreated by cukuring with insolubilized anti-CD3 antibody
and IL-2, with HA 307—319 at 50 (ag/mi or in medium alone
tor 24 hours. After pretreatment, the T cells (105/ml) were
assayed for their ability to respond to restimulation with HLA-
DR1 — APCs (irradiated PBMCs) alone (solid bars), HA 307—
319 (0.3 p-g/ml) — APCs (cross-hatched bars), or IL-2 alone
(suppled bars). Proliferation as correlated with [ H]methvi thy¬
midine incorporation was determined 72 hours later.
is probably due to the induction of CD25 and the man¬
ifest hyperresponsiveness of activated cells to IL-2 (Fig.
2). After incubation with HA 307-319 (50 p.g/ml) for
24 hours, the T cells failed to proliferate when restim-
ulatea with HA 307—3 19 presented in an immunogenic
form (Fig. 2). The addition of exogenous IL-2 caused
proliferation of the anergized cells, confirming func¬
tional inactivation was not the result of cytolysis.
Differential expression of the NF-AT complex in activated and
tolerized T cells. Nuclear extracts were incubated with
radiolabeled double-stranded DNA probes that con¬
tained known dr-acting sequences to determine which
transcription-factor-binding activities were expressed af¬
ter treatment of cells with activating or tolenzing stim-
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uii. Two independent characteristics divide the factors
into four groups, chree of which were chosen for study:
T-cell-specific inducible factors include NFkB, NF-AT,
(3E2, and the CD28RC; AP-1 is a general and inducible
molecular complex, whereas TCF-1 [19] is an example of
a T-cell-specific noninducible factor. TCF-1 and pE2 are
involved in the regulation of transcription of the (3 chain
of the TcR, whereas che others have a role in transcrip¬
tion of the IL-2 gene. As expected, the noninducible
factor, TCF-1, is the only factor clearly present in the
nuclei of untreated cells and its concentration does not
vary in activation and anergy (Fig. 3). All six probes
formed complexes with extract from activated cells that
were competed by specific, but not by nonspecific, oli¬
gonucleotide competitors. The lower band in the NF-kB
shift is a nonspecific complex, whereas the upper is au¬
thentic NF-kB. Equal amounts of protein were used
from each nuclear lysate, and this is substantiated by the
observation that binding to the TCF-1 site is the same in
the nuclei of resting, activated, and anergized cells. Dif¬
ferences in the pattern of induction of specific transcrip¬
tion factors were quantified using an Ambis scanner;
radioactivity was measured directly from che dried gels.
These results confirm a relative failure of anergic T cells
to upregulace NF-AT (Table 1). The inducible factors
NF-kB, |3E2, CD28RC, and AP-1 are not expressed in
rescmg cells, and are 1.6- to 2.2-fold lower in anergized
as compared with activated cells. In contrast, anergic T
cells express approximately eightfold lower amounts of
NF-AT than cells that received an activating signal.
Functional inactivation in the presence of calcium iono-
phore. The failure to establish good NF-AT expression in
the induction phase of anergy suggesced that chese T
ceils may be missing some biochemical aspect of an ac¬
tivating signal. The observation that AP-1 and 3E2
binding were relatively well induced in anergized T ceils
suggested that the pathway through PKC was intact.
There is an approximate fourfold difference between the
induction of AP-1 and NF-AT when activated cells are
compared with anergized cells, and boch of these treat¬
ments involve stimulation through the TcR. Since NF-
AT consists of AP-1 plus a second component that trans¬
locates to the nucleus as a result of calcium-dependent
FIGURE 3 Electropnoretic mo¬
bility shift assay. Nuclear extracts
were prepared from resting T cells
incubated in medium alone (M),
and from activated (A) or rolerized
(21 cells. Double-stranded DNA
probes (as indicated) were incu¬
bated with che extracts in che
presence of 100-fold excess of ei-
cher a specific (S) or nonspecific
(N) oligonucleotide competitor
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TABLE 1 Ratio of transcription factor










Retarded complexes were quantified directly from the dried
gel using an Ambis scanner.
phosphorylation, it seemed logical to investigate the
Ca"~ pathway further. It is noteworthy in this regard
that both core-binding factor (CBF) and the ets tran¬
scription factors bind to the (3E2 element: ets is induc¬
ible whereas CBF is not [9]; this explains the small shift
of the (3E2 element when using the extract from resting
T cells (Fig. 3). (3E2 activity is inducible principally
through PKC and not the Ca*'1" pathway [23], thus
providing further evidence that the PKC pathway is rel¬
atively intact during the induction of anergy. T ceils
were therefore treated with calcium ionophore at the
time that they received an anergizing dose of peptide to
establish whether an additional calcium flux could abro¬
gate the induction ofT-cell anergy. T cells were restim-
ulated with either msolubilized anti-CD3 or HA 307—
319 presented on irradiated histocompatible (DR1*")
PBMCs. The results (Table 2) show that ionomycin itself
can induce anergy in a dose-dependent manner, but that
peptide-induced anergy is abrogated only by a low dose
of ionomycin. This applies both to restimulation with
peptide and APCs and with anti-CD3-
DISCUSSION
Several groups have developed systems to study T cell
anergy in vitro. Each method includes a signal through
the TcR, though this can be delivered specifically, for
example with peptides, or nonspecifically, using anti-
CD3 antibodies or lectins. T-cell proliferation is aug¬
mented by costimulatory signals, and anergy can be in¬
duced in murine T cells by antigen receptor stimulation
in the absence of costimulation. The costimuiatory mol¬
ecule B7/BB-1 is functionally inactivated by a chemical
fixation process, and the use of such cells to present
antigen results in anergy. This mechanism does not re¬
sult in the phenotvpic changes that characterize high-
dose peptide anergy of human T cells, but the cells have
in common a reduced ability to release IL-2 on rechal-
lenge. Go and Miller examined the expression of a series
of transcription factors after stimulation ofmurine T-cell
clones with normal and with chemically modified APCs
[24], The tolerogenic stimulus induced less NF-AT and
lower amounts of one of the two NF-xB-binding factors.
The AP-1 transcription factor was induced and was not
obviously differentially regulated. These results are in
very close accord with the results presented here, but
differ markedly from a third independent study [25].
This group showed that anergic T cells, generated by
exposing the cells to concanavalin A, did not make IL-2.
However, this was associated with a specific downregu-
lation of the AP-1 complex. These experiments showed
no differences in the NF-AT complex, a surprising find¬
ing since NF-AT contains AP-1. Collectively, these data
indicate that the control of IL-2 gene expression during
anergy induction and during normal stimulation of an-
ergized cells is distinct, and suggest the presence of ad¬
ditional regulatory elements that control synthesis and
release of IL-2.
TABLE 2 Proliferative capacity of the human T-cell clone HA 1.7 after
various pretreatments
Restimutation"
Pretreatment APC APC + peptide' IL-2 Anti-CD3 Anti-CD3 - IL-2
Medium 109 .(22) 17.959 (4) 12.855 (7) 3422 (18) 22,565 (5)
HA50* 1041 (30) 8250 (34) 27,620 (23) 1084 (30) 33,502 (4)
HA50 + I'd |i,g/ml) 616 (31) 1770 (9) 20.936 (12) 441 (24) 24.317 (3)
HA50 -r I' (0.2 fig/ml) 7254 (11) 18,344 (10) 34.092 (12) 6774 (21) 45,441 (7)
I' (1 fxg/ml) 167 (34) 1602 (9) 14,313 (12) 212 (38) 17,286 (10)
I' (0.2 pLg/ml) 105 (19) 6033 (12) 13.183 (6) 1768 (10) 20.557 (10)
Anti-CD3 202 (58) 16,896 (55) 13.306 (8) 7270 (24) 30.651 (14)
" Cells were rescimulated 24 hours after prerreacmenc and proliferation as correlated with [5H)methvl thymidine incor¬
poration was determined 72 hours later in duplicate. The numbers in parentheses refer to SEM.
' APC. irradiated DR1 + PBMC.
Peptide, HA 307-319 (0.3 (xg/ml).
"
HA50, HA 307-319 (50 ixg/'ml).
' I, lonomycm (concentration as shown).
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In an interesting series of experiments designed to
investigate the relationship between NF-AT and gene
expression, the lacZ gene was placed under the control of
tandem copies of the NF-AT-binding site in transfected
T ceils. Following exposure of the cloned stably trans¬
fected T cells to TcR-specific stimuli, a bimodal pattern
of gene expression was noted. Increasing concentrations
of the stimulus increased the fraction of lacZ ^ cells, but
not the level of lacZ activity per cell (26]. The pattern of
expression was not dependent upon cell-cycle position or
heritable variation. And the results, therefore, suggest
that the concentration of NF-AT must exceed a critical
threshold before transcription of a linked gene is in¬
duced. Other transfected T cells, in which lacZ is con¬
trolled by NF-kB or the entire IL-2 promoter, also show
bimodal expression patterns after stimulation (27}. It
seems likely then that cranscription factors have concen¬
tration thresholds below which they cannot initiate tran¬
scription of linked genes. A completely different pheno-
type might, therefore, occur with only a partial loss of an
inducible factor.
T-ceil anergy is mediated, at least in part, by a loss of
the costimulatory pathway, and the CD28 receptor is
only one component of a complex system regulating
T-cell activation. There are several surface molecules that
transmit costimulatory signals, and these might substi¬
tute if the CD28 pathway were blocked. For example,
superantigen-induced proliferation of human T cells is
not dependent on costimuiation through CD28, but is
affected by interactions between the CDl la—CD 18 com¬
plex and its counter receptors ICAM1—3 [28]. The re¬
sults reported here show that the induction of T-ceil
anergy, when compared with T-ceil stimulation, is char¬
acterized by a reduced expression of the NF-AT complex.
NF-AT is induced in T ceils stimulated through the TcR
and is required for IL-2 gene induction. The induction of
NF-AT probably requires two activation-dependent
events: the translocation of a preexisting cytoplasmic
component and the synthesis of a nuclear component.
The newly synthesized nuclear component of NF-AT is
the transcription factor AP-1, and it contains the Fos and
Jun proteins [16], whereas the translocation depends on
dephosphorylation by caicineurin (29]. Our results show
no primary failure in the ability of toierized ceils to
produce AP-L; it therefore seems likely that the differ¬
ence lies in the ability of these ceils to translocate the
cytoplasmic component of the complex to the nucleus.
Maximal expression of NF-AT in T ceils requires at least
two signals: triggering of the TcR in association with
either PKC activation or a (Ca"^}; flux. Activation
through the TcR has many downstream biochemical ef¬
fects, and signals other than a calcium flux or PKC can
regulate NF-AT expression in peripheral blood-derived
T ceils (30}. The TcR can regulate multiple intracellular
signals in T cells, and the biochemical events following
ligation of the receptor may depend upon ligand density
as well as the nature of additional signals. We have
shown that the combination of these signals, generated
by the addition of ionomvcin during the induction of
anergy, leads to a different end state according to the
concentration of ionomycin. And this suggests that the
triggering of particular downstream events is sensitive to
different thresholds of (Ca~ }{.
Molecules associated with the induction of anergy (an-
ergens) are likely to be a diverse group that may affect
processes in distinct cellular compartments. Induction of
anergy is an active process that requires protein synthesis
(22}. Therefore, some anergens will be newly synthe¬
sized molecules and others may be activated by phos¬
phorylation or translocated to an active site. While this
study has not directly identified any potential anergen,
the observation that the amount of NF-AT available in
the nucleus for transcription is different in activation and
anergy shows that the cells have taken alternative devel¬
opmental steps.
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Summary
Antigen-specific CD4"" T cells play an important role in the allergic immune response to house
dust mite (HDM) allergens in humans. The group 1 allergen of Dermatophagoides spp. is a major
target antigen in both B and T ceil recognition of HDM. In vitro studies have shown that the
presentation of peptides to human T cells under appropriate conditions may lead to a state of
specific nonresponsiveness. Therefore, to determine if peptides are able to modulate the function
of allergen-reactive T cells in vivo, we have used a murine model of T cell recognition of the
HDM ailergen Der p 1. The results demonstrate that inhalation of low concentrations of peptide
containing the major T cell epitope of Der p 1 (residues 111-139), induces tolerance in naive
C57BL/6J mice such that they become profoundly unresponsive to an immunogenic challenge
with the intact allergen. When restimulated in vitro with antigen, lymph node T cells isolated
from tolerant mice secrete very low levels of interleukin 2, proliferate poorly, and are unable
to provide cognate help to stimulate specific antibody production. Furthermore, intranasal peptide
therapy was able to inhibit an ongoing immune response to the allergen in mice and this has
potential implications in the development of allergen-based immunotherapy.
Approximately 10% of the population suffers from allergy, t house dust mite (HDM) and CD4* T cells are
known to play an important role in allergic sensitization (1).
In vitro studies have shown that human HDM-reactive
CD4* T cell clones can be rendered unresponsive by ex¬
posure to either high doses of their specific peptide epitope
or to superantigens (2-6). Therefore, by modulating the func¬
tion of allergen-reactive T cells in vivo it may be possible
to control an established allergic immune response in humans.
Independent studies have shown that immunogenic peptides
can preferentially induce antigen-specific T cell tolerance in
naive mice when administered either intraperitoneallv in IFA
or intravenously (7-9). Experimental animals may also be ren¬
dered immunologically tolerant by feeding or inhaling an¬
tigens, and this state of nonresponsiveness is usually long-
lasting and antigen specific (10-13). Experimental allergic ence¬
phalomyelitis (EAE) is a demyelinating autoimmune disease
of rodents, and CD4" T cells specific for myelin basic pro¬
tein (MBP) are responsible for the development of disease.
Rats can be protected from developing EAE by oral adminis¬
tration of MBP before an encephalitogenic challenge from
the autoantigen (14, 15). Similarly, susceptible H2U mice can
be protected from developing EAE by inhalation but not oral
administration of a peptide containing the immunodominant
T cell epitope on MBP (Ac 1-9, 1-11) (16). In a previous
study, we have shown, using a murine model, that T cell
responses to the Der p 1 allergen were inhibited by feeding
recombinant peptides containing either major or minor T
cell epitopes (Hovne, G. F„ M. G. Callow, M.-C. Kuo, and
W. R. Thomas, manuscript submitted for publication). The
induction of tolerance resulted in decreased responses in LN
T cells to the whole antigen in vitro, and a loss of reactivity
to all T cell epitopes on the antigen was observed.
In this study, we show that if naive C57BL/6J mice inhale
small quantities of synthetic peptides containing T cell epi¬
topes, they become profoundly unresponsive to a powerful
immunogenic challenge with the allergen. LN T cells from
tolerized mice secrete low levels of IL-2 and proliferate poorly
when restimulated with antigen. They are also unable to pro¬
vide help for antibody production in vitro. Furthermore, in-
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tranasal peptide therapy inhibited T cell responses in mice
that had been previously sensitized to the Der p 1 allergen.
These studies indicate that administering immunogenic pep¬
tides intranasally may be an effective way to control aberrant
immune responses that give rise to specific disease states in
humans.
Materials and Methods
Animals. Inbred C57BL/6J mice were purchased from the An¬
imal Resource Centre (Murdoch, Western Australia) at 6-8 wk
of age and were kept under specific pathogen-free conditions.
Antigens. The house dust mite allergen Der p 1 was affinity
purified from spent mite medium (17). Synthetic peptides derived
from the Der p 1 sequence were synthesized using standard F-moc
chemistry, peptides were purified by reverse-phase HPLC. and the
sequence of individual peptides were confirmed by sequencing. The
peptides used in this study were pi 111-139, pi 156-168 of the
group 1 allergen of Dermatophagoides pteronyssinus (Der p 1) and
p2 21-35 from the group 2 allergen (Der p 2).
Prevaration of Recombinant Proteins. A cDNA insert encoding
the 57-130 fragment of the Der p 1 protein was iigated to the pGEX
vector which expresses the fusion proteins with glutathione-S-
transferase in Escherichia coli. (18). The procedures for the cloning
and expression of the fragments have been described (19). Log phase
E. coli cells transformed with the pGEX-based construct were in¬
duced to express the recombinant protein by adding 0.1 mM
isopropylthiogalactosidase (Promega Corp., Madison, WI). The
fusion protein was purified to homogeneity using glutathione-
coupled agarose (Sigma Chemical Co., St. Louis, MO) following
the techniques previously described by Smith and Johnson (18),
ana eventually lyophilized.
Induction of Intranasal Tolerance. Mice were lightly anesthesized
under ether and peptides dissolved in PBS were administered in¬
tranasally in a total volume of 10 /zl using a micropipette on three
consecutive days. Mice were immunized subcutaneousiy at the base
of tail 7 d after the last treatment with 100 /ig ofDer p 1 emulsified
in CFA (Difco, Detroit, MI) in a volume of 0.2 ml. To inhibit
ongoing responses, mice were immunized intraperitoneally with
Der p 1 in CFA, and 10 d later received 100 /ig of pi 111-139 in¬
tranasally on five consecutive days. Mice were then reimmunized
7 d later with 100 /ig of Der p 1 in IFA (Difco) subcutaneousiy
at the base of tail.
Culture Medium. LN cells were cultured inDME (GIBCO BRL,
Gaithersburg, MD) supplemented with 2% FCS (Commonwealth
Serum Laboratories [CSL], Parkville, Victoria. Australia), 50 /iM
2-ME (Sigma Chemical Co.), 2 mM L-glutamine (CSL), and 20
/tg/ml gentamycin (David Bull Laboratories, Muigrave, Victoria.
Australia). CTLL-2 cells were maintained in RPMI (GIBCO BRL)
plus 10% FCS.
T Cell Assays. The periaortic and inguinal LNs were expressed
through a stainless steel wire mesh, washed, and cultured at 4 x
105 cells in a volume of 0.2 ml in culture medium in a 96-weil fiat-
bottom tissue culture plate (Becton Dickinson Labware, Lincoln
Park, NJ). Protein or peptide antigens were added at various con¬
centrations and the cells were incubated at 37°C for 24 h. Super-
natants were collected and stored at - 20°C until required for the
assay.
Lymphokine Assays. The CTLL-2 cell line proliferates maximally
with IL-2 but only poorly in the presence of IL-4 (20). 5 x 103
CTLL-2 cells per weil were cultured in supernatants for 24 h at
37°C and pulsed with 1 /iCi of [3H]thymidine. Cells were har¬
vested onto glass fiber filters and the proliferation determined by
incorporation of [3H] thymidine which was assessed using a direct
beta counter (Packard Matrix 9600; Packard Instruments, Meriden,
CT).
In Vitro Antibody Production. Mice were immunized with 100
/ig ofDer p 1 in CFA and 10 d later, the spleens of two mice were
pooled and RBCs were lysed with sterile distilled water. Periaortic
and inguinal LN cells were isolated 7 d after immunization from
mice that had been treated on three consecutive days with either
PBS (control) or pi 111-139 (tolerant) intranasally and immunized
subcutaneousiv 7 d later with Der p 1/CFA. 2 x 106 spleen or
LN cells were cultured alone in the presence ofDer p 1 in a volume
of 1 ml culture medium in a 24-well tissue culture plate. Alterna¬
tively, 106 spleen cells were mixed with 106 LN cells from con¬
trol or tolerant mice and cultured in a 1-ml volume with the addi¬
tion of antigen. Cells were cultured for 7 d at 37°C and the
supernatants were assayed for the presence ofDer p 1-specific Abs
using an ELISA.
ELISA. Affinity-purified protein was diluted in 50 mM Na
HCO3 buffer, pH 9.6, and coated onto an ELISA plate at 100
/xg/'ml in a volume of 50 /ti/'well. The plate was incubated over¬
night at 4°C and the next day was washed three times with PBS
plus 0.05% Tween 20. Nonspecific binding sites were blocked by
incubating the plate with a solution of PBS containing 1% BSA
for 1 h at room temperature. After three washes, serum was added
to the plate at appropriate dilutions and incubated for 2 h at room
temperature. The plate was washed as described and a 1/1,000 di¬
lution of goat anti-mouse Ig conjugated to horseradish peroxidase
was added and incubated for 1 h at room temperature. After a final
wash, the color was developed with ABTS containing 1% hydrogen
peroxide for 20 min at room temperature. The reaction was stopped
bv addition of 0.1 M citric acid plus 0.01% sodium aziae, ana the
OD of the plate was measured at 405 nm using an ELISA plate
reader. Results are expressed as ELISA OD units.
Results and Discussion
C57BL/6J mice are high responders to the HDM allergen
Der p 1 and T cells recognize three different epitopes that
are located within the following sequences: 110-131, 78-100.
and 21-49 (Hovne, G. F., et al., manuscript submitted for
publication). The ability of purified recombinant GEX
p57-130 and a synthetic peptide that contains the im¬
munodominant determinant, pi 111-139 to induce tolerance
when administered intranasally were compared. This epitope
was chosen for study because it represents a major T cell epi¬
tope recognized by human Der p 1-specific T cell clones (6).
Mice received 100 /ig of either peptide or PBS intranasally
on three consecutive days and 1 wk later, all mice were chal¬
lenged with Der p 1 in CFA. LN cells draining the site of
injection were collected 7 d later and stimulated in vitro with
either protein or peptide for 24 h and the supernatants were
assayed for IL-2. LN cells from mice treated with either pi
111-139 or GEX p57-130 failed to respond with either Der
p 1 (Fig. 1 A) or the T cell epitopes pi 111-139, pi 78-100
and pi 21-49 (Fig. 1, B-D). Control mice that received PBS
intranasally developed strong IL-2 responses to both the in¬
tact protein and the peptides (Fig. 1).
In addition, mice received either PBS or pi 111-139 in¬
tranasally and 1 wk later were challenged subcutaneousiy with
an immunogenic concentration of pi 111-139. LN cells were
cultured in vitro with pi 111-139 and IL-2 secretion and T
1784 Peptide-inauced T Cell Tolerance
1 10 100 1000
pi 111-139 (Wg/ml)
10 100 1000 .1
pi 78-100 (|ig/mi)
1 10 100 1000
pi 21-49 (ug/ml)
Figure 1. Peptides given intranasaily to mice can inhibit T ceil responses.
Mice were created with either PBS (□), 100 /xg of GEX p57-130 (A),
or pi 111-139 (•) intranasaily on three consecutive days and 1 wk later
ail mice were immunized with 100 /xg of Der p 1/CFA. LN cells were
coilected 7 d later and cultured in vitro with (A) Der p 1 protein. (B)
pi 111-139. (C) pi 78-100. or (D) pi 21-49 for 24 h. Data shows the
mean IL-2 response of five mice per group ± SD.
ceil proliferation were determined. LN cells from control mice
proliferated strongly to the peptide in vitro and produced
IL-2 in a dose-dependent manner. However, T cells from
peptide-treated mice proliferated only poorly and secreted only
very low leveis of IL-2 when rechallenged with the peptide
in vitro (data not shown). Thus the induction of tolerance
results in a state of nonresponsivenefs to the whole antigen
as a result of the failure of antigen-specific T cells to secrete
IL-2 and to proliferate when restimulated. Tolerance to the
immunodominant epitope also downregulated the response
ofT cells directed to other epitopes on the antigen. Recently
it has been reported that susceptible H2U mice are protected
from developing EAE by inhalation of a synthetic peptide
containing the immunodominant epitope MBP Ac 1-9 or
Ac 1-11 before encephalitogenic challenge with MBP or pep¬
tide (16). In this study (16), the authors also observed that
after the induction of tolerance to Ac 1-9 T cell responses
to subdominant epitopes on MBP were equally downreguiated.
To determine the concentration of peptide required to in¬
duce peripheral tolerance, mice were treated intranasaily on
three consecutive days with either PBS or 1, 10, or 100 /xg
of pi 111-139 and then challenged 1 wk later with Der p
1 in CFA. LN cells were collected 7 d after immunization
and cultured in vitro with either Der p 1 or pi 111-139. T
cell responses from each of the test groups after in vitro stim¬
ulation with Der p 1 or pi 111-139 were markedly down-
regulated (Table 1), whereas T cells from control mice secreted
large amounts of IL-2 when stimulated in vitro with either
Der p 1 or peptide (Table 1). The immunodominant peptide
at concentrations as low as 3 x 1 /xg induced peripheral toler¬
ance when given intranasaily. It is interesting to note that
inhalation of similar levels of an intact protein in mice can
induce immunological tolerance (12). Therefore mucosa of
the respiratory tract appears to provide a highly efficient route
for the induction of tolerance.
Mice tolerized with pi 111-139 also failed to produce specific
Abs. To demonstrate this, spleen cells collected from Der p
1 immune mice were cultured in vitro either alone or with
LN cells from mice that had been treated intranasaily with
PBS or pi 111-139 and immunized subcutaneouslv with Der
p 1 in CFA. Lymphocytes from both the test and control
groups were cultured with Der p 1 for 7 d and the presence
of anti-Der p 1 Abs in the culture supernatants were exam¬
ined by ELISA. Der p 1-specific Abs were present in the su¬
pernatants of both immune spleen cells and LN ceils from
PBS-created mice, but no Abs were detected in the suDerna-
Table 1. Intranasal Tolerance Induced with Microgram Quantities oj Peptide
PBS
Intranasal dose of antigen




















C57BL/6J mice were treated on three consecutive days with pi 111-139 intranasaily with the doses indicated or with PBS. 1 wk later mice were
immunized with Der p 1 in CFA and the periaortic and inguinal LN were coilected 7 d later and cultured in vitro with either Der p 1 or pi 111-139.
Data shows the mean response of five mice per group z SD.
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Figure 2. Inhibition of antibody production in vitro. Spleens were re¬
moved from Der p 1 immune mice and the periaortic and inguinal LN
were collected from control or tolerized mice who had been immunized
with Der p 1/CFA. 4 x 10s spleen or LN cells were cultured alone or
2 x 10s spleen cells were mixed with equal numbers of LN cells from
either control or tolerized mice. Ail cells were cultured for 7 d at 37°C
and supernatants were assayed for Der p 1-specific Abs using an ELISA
assav. Data show the mean response from hve mice per group and is presented
as ELISA OD units at 405 nm.
tants of LN cells from mice tolerized with pi 111-139. When
LN cells from PBS-treated mice were mixed with immune
spleen cells, Ab production was unaffected (Fig. 2). How¬
ever. addition of LN cells from pi 111-139-treated mice to
spleen cell cultures completely inhibited antibody produc¬
tion in vitro (Fig. 2). The mechanisms which lead to inhibi¬
tion of antibody synthesis have all the hallmarks of being
classical suppression. That is, not only do tolerized T cells
fail to provide cognate help to primed B cells in vitro, but
the tolerized cells also have the capacity to suppress the effector
function of primed CD4" Th cells in the spleen.
Since allergy to HDM reflects a chronic disease, we wished
to examine whether it were possible to inhibit an on-going
T cell response using intranasal peptide therapy (16). Mice
were immunized with Der p 1 in CFA and 10 d later they
received either 100 /xg of pi 111-139 or an irrelevant peptide
from the Der p 2 allergen, p2 21-35, intranasally on five con¬
secutive days. After 7 d the mice were reimmunized with
Der p 1 in IFA. 1 wk later, LN cells were cultured in vitro
with the Der p 1 protein and IL-2 production was measured
in supernatants of 24-h cultures. LN cells from control mice
treated with the nonimmunogenic peptide p2 21-35 were
able to produce IL-2 responses when stimulated with the al¬
lergen in vitro (Fig. 3), whereas IL-2 secretion was completely
abrogated in LN cells from mice receiving pi 111-139 (Fig.
3). Equivalent results were obtained ifmice were immunized
with Der p 1/CFA and then 6 mo later received pi 111-139
on five consecutive days and then were rechallenged with Der
p 1/IFA 7 d after therapy (Fig. 4). Therefore intranasal pep¬
tide therapy will induce tolerance not only in naive mice but
also will inhibit the function of T cells previously sensitized
to the antigen.
The studies reported here demonstrate that inhalation of
peptides in low concentrations will induce peripheral toler¬
Der p I (^ig/ml)
Figure 3. Peptide therapy inhibits ongoing immune responses to the
Der p 1 allergen. Mice were treated on hve consecutive days with pi 111-139
(O) or a control peptide (■) 10 d after sensitization with Der p 1. 1 wk
after the completion of therapy mice were reimmunized with Der p 1/IFA
and LN cells were collected 7 d later. The data shows the mean IL-2 re¬
sponse of individual mice r SD. The number of animals per group used
in each experiment were control (p2 21-35) n - 5, and tolerized (pi 111-139)
n « 10. This experiment has been repeated with over 20 animals with
eauivalent results.
ance in mice such that they become profoundly unresponsive
to a powerful subcutaneous challenge with the antigen. Pep¬
tides containing a dominant T cell epitope were more effec¬
tive tolerogens than tlfose containing only minor epitopes,
since tolerance could be induced in naive mice with only one
exposure to pi 111-139, whereas a minimum of three doses
were required to induce tolerance to a peptide containing a




Der p 1 (ng/ml)
Figure 4. Inhibition of long-term immune responses to Der p 1.
C57BL/6J mice were immunized with 100 jig of Der p 1/CFA i.p. and
3 wk later mice were rechallenged with 100 fig of Der p 1/IFA i.p. 6
mo later, half the mice were given 100 fig of pi 111-139 mtranasailv for
5 d. whereas the other half received p2 21-35 over the same period, and
1 wk later all mice were immunized with 100 fig Der p 1/CFA s.c. at
the base of tail and LN ceils were cultured 1 wk 'later. Data shows the
mean IL-2 response of five mice per group ± SD.
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we found chat intranasal peptide therapy does inhibit an on¬
going immune response in mice previously sensitized to the
HDM allergen. Clearly these results have important impli¬
cations showing that peptides could be effective immunother-
apeutic agents in allergic conditions.
It should be emphasized from these studies that although
only one peptide epitope was used for treatment, T cell re¬
sponses to the other epitopes of the antigen were subsequently
downregulated. This spreading of tolerance to encompass all
epitopes of a protein antigen shares some similarities to the
model of "infectious" tolerance (21). However, we cannot
exclude other regulatory mechanisms operating within the
lung that may be active in modulating the response antigen-
reactive T cells. There is precedence in the literature for a
role of CD8 * T suppressor cells in immunological tolerance
after inhalation of OVA in rats (13). Therefore, there maybe
more than one mechanism operating to control T cell re¬
sponses to foreign antigens encountered within the nasal
mucosa and the lung. Finally, the HDM response in mice
provides a promising model for studying further the peptide-
induced modulation of allergen-reactive T cells.
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Abstract
We have previously demonstrated that intranasal (i.n.) administration of an immunodominant
peptide (p1 111-139) derived from the house dust mite (HDM) allergen Der p 1 inhibits antigen-
specific CD4* T ceil responses in H-2° mice. Here we report that i.n. peptide induced a rapid but
transient activation of MHC class II restricted CD4"* T cells that peaked 4 days after peptide
treatment and was of similar magnitude to that induced by parenteral immunization with antigen in
adjuvant. During the early phase of the response lymph node and splenic T cells secreted a range
of lymphokines when re-stimulated in vitro with p1 111-139; however, by day 14 IL-2 and IFN^y
secretion by T cells were down-regulated. Mice deficient in CD8^ T cells became tolerant by i.n.
treatment with peptide, suggesting that CD8" T cells are not involved in down-regulating the CD4 +
T cell response. Rechallenging mice with a single dose of p1 111-139 21 days after the initial
treatment elicited a further transient T cell response, which was subsequently down-regulated over
time. Although the i.n. peptide indbced a strong transient CD4+ T cell response, only low levels of
peptide-specific antibodies were detected either after the initial or subsequent i.n. exposures to p1
111-139. Our findings address the mechanisms underlying peripheral T cell tolerance following i.n.
administration of a high dose of immunogenic peptide and have implications for understanding the
consequences of peptide immunotherapy.
Introduction
Antigen-specific CD4^ T cells play an important role in allergic
sensitization by secreting lymphokines that promote IgE syn¬
thesis and support the growth or maturation of effector cells
such as eosinophils and mast cells (1). Protein antigens
derived from the house dust mite (HDM), Dermatoodagoides
preronyssinus are a common source of aeroallergens in the
environment. -10% of the population develop allergies to
HDM resulting in clinical symptoms including perennial rhinitis,
atopic dermatitis or asthma (1). At present desensitization
therapy is not successful for most HDM allergic patients and
more effective methods of modulating the allergic immune
response are required. Recently it has been shown that
human HDM-reactive CD4~ T cells can be inactivated in vitro




cognate peptide (2.3). Furthermore, it is possible to inhibit
the function of allergen-reactive T cells in vivo by either
intranasal (i.n.) or oral administration of a peptide containing
the immunodominant T cell epitope derived from the HDM
allergen Der p 1 in H-2° mice (4,5). These results suggest
that peptide-mediated immune regulation may be useful in
allergen immunotherapy as has been demonstrated in the
prevention of experimental autoimmune diseases (6-9).
Administration of antigens via mucosal surfaces is an
effective way of inhibiting antigen-specific T cell responses
in vivo. Oral tolerance to protein antigens results in the
inhibition of antigen-specific 004^ T cell responses in vitro
by either clonal deletion, clonal anergy or active suppression
depending on the dose of antigen administered (10.11).
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Little is known about the mechanisms that reguiate immune
responses following high-aose antigen treatment through the
reSDiratory tract. In rats continuously exposed to low doses
of nebulized protein, CD4T T cells become primed to the
antigen and secrete 11-2 and IL-4 (12). The CD4" T cell
response, however, is then suppressed oy the activation of
IFN-y-secreting CD8T T cells and these suppressor cells
abrogate the induction of IgE synthesis in naive recipients
upon adoptive transfer (12-14). In this paper we have begun
to elucidate the cellular mechanisms which give rise to the
development of antigen-specific T cell tolerance following i.n.
administration of peptide. We examined the nature of the
primary T cell response elicited by high doses of i.n. peptide
and investigated the role of CD8* T cells in the induction of
toierance. We also demonstrate that rechallenging mice with
i.n. peptide after 3 weeks after the initial treatment elicits a
further transient T cell response to the oeotide. These studies
nave important implications in understanding the reSDonse to
mucosally delivered peptides in immunotherapy.
Methods
Animals
inbred female C57BL/6J mice were purchased from Harlan
OLAC (Bicester, UK) at 6-8 weeks of age and were kept in
isolators. CD8"~ mice were obtained as a fifth generation
backcross on the C57BL/6J background and bred under
conventional conditions. The mice were kindly provided by
Dr Dimitri Kioussis (National Institute of Medical Research,
The Ridgeway, Mill Hill, UK).
Antigens
The synthetic peptide p1 111-139 was derived from the Der
p 1 sequence and was synthesized using standard f-moc
chemistry.
Antibodies
Monocional antibodies specific for murine CD4 (YTS.191.2.1)
and CD8 (Lyt2. 53.5.) were obtained from the European Tissue
Culture Collections. The murine anti-l-Ae mAb (M5/114) was
a kind gift from Dr R. Lechler. Cervical lymph node (LN)
cells from peotide-treated mice were cultured with mAb
supernatants or a control rat anti-mouse IgG at 1/20 and 1/
100 dilution in the presence or absence of peptide for 24 h
at 37°C. Supernatants were collected and assayed for the
presence of lymphokines.
Induction of Tcell non-responsiveness by inhalation ofpeptide
Mice were lightly anaesthetized with ether and the peptide
p1 111-139 (100 ng) dissolved in 20 pi of PBS was adminis¬
tered i.n. using a micropioette on three consecutive days.
Mice were immunized s.c. at the base of the tail 14 days after
the iast treatment with 50 tig of Der p 1 emulsified in complete
Freund's adjuvant (CFA). (Difco, Detroit, Ml) in a volume of
0.2 ml.
Culture medium
LN or spleen cells were cultured in RPMI 1640 (Gibco
Laboratories, Grand Island. NY) supplemented with 2% FCS
(Gibco), 50 pM 2-mercaptoethanol (Sigma, St Louis. MO).
2 mM L-giutamine (Sigma) and 20 ug/ml penicillin/streDto-
mycin. CTLL-2 cells were maintained in RPMI 1640 (Gibco)
and 10% FCS. wniie FDC-Pl ceils were cultured in DMEM
plus 5% FCS.
T cell assays
The cervical LNs were pressed through a stainless steel wire
mesh, washed and cultured at 4x10s cells in 0.2 ml culture
medium in 96-well flat-bottom tissue culture plates (Becton
Dickinson Labware, Lincoln Park. NJ) at 37°C. Protein or
peptide antigen was adoeo at various concentrations and
supernatants were collected at 24 or 48 h and stored at
-20°C until assayed.
Lymphokine assays
The CTLL-2 cell line proliferates maximally with IL-2 but only
poorly in the presence of IL-4 (15). Test supernatants (50 pi)
were added in tripiicate to 5x103 CTLL-2 cells (50 pi) per
well and cultured for 24 h at 37°C. Tritiated methyl thymidine
(3[H]TdR; IpCi. Amersham, Amersnam, UK) was added
during the iast 6 h of culture.
FDC-P1 cells proliferate in response to IL-3 and granulocyte
macrophage colony stimulating factor (GM-CSF) (15). FDC-
Pl cells (2X103 in 50 pi) were cultured with the test super¬
natants in triplicate wells for 40-48 h and then pulsed with
1 pCi 3[H]TdR for the last 6 h.
CT.4S cells proliferate in response to IL-4, but only poorly
to IL-2. Cells (2X103) were cultured with test supernatants
for 96 h and pulsed arith [3H]TdR for 6 h. The level of
radioactivity incorporated by lymphokine dependent cell lines
was determined by harvesting cells onto glass fibre filter mats
and counted using a Beta Plate Liquid Scintillation counter
(Wallac).
IFN-y was measured using an ELISA assay. Briefly, rat anti-
mouse IFN-y mAb (R4-5A2; PharMingen) was coated onto
lmmuion-2 plates overnight and washed with PBS containing
0.05% Tween 20 (Sigma). Plates were blocked with 10% BSA
dissolved in PBS. After washing, culture supernatants were
added to the plates and incubated for 2 h at room temperature.
Plates were washed and the presence of bound IFN-y
detected by biotinylated anti-mouse IFN-y (XMG1.2.
PharMingen). Plates were developed using streptavidin-alkal-
ine phosphatase (Sigma) with 3,3'-5.5'-tetramethyl benzidine
(Sigma) as the substrate. Plates were read at 405 nm.
Antibody measurements
The p1 111-139 peptide was coated onto lmmulon-4 microtitre
plates at 10 ng/ml overnight at 4°C. Plates were blocked with
PBS containing 10% BSA. After washing, serum dilutions
were adoed to the plate and incubated for 2 h at room
temperature. Plates were wasneo and the presence of bound
antibody was detected isotype-specific biotinylated anti¬
bodies (Southern Biotechnology Associates). Plates were
washed and developed using streptavidin-alkaline peroxid¬
ase (Sigma) with 3.3'-5.5'-tetramethyl benzidine (Sigma) as
the substrate. Results expressed as OD absorbance units at
405 nm.
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Results
T cells undergo transient activation during the induction phase
of non-resoonsiveness
In oraer to investigate the effect of i.n. peptide on the effector
function of antigen-specific T cells in vivo, C578LV6J mice
were treated i.n. on three consecutive days with 100 ,ug of
p1 111-139. This regime has previously been shown to be
effective in inducing peripheral tolerance to Der p 1 in naive
mice. The response of T cells in the draining cervical LN and
spleen of i.n. treated mice was examined at various times
over a 28 day period and their capacity to secrete iympnokines
following antigenic challenge in vitro was determined. When
T cells are re-stimulated with peptide in vitro on day 2 they
secrete high levels of IL-3/GM-CSF but only low levels of IFN-
V and IL-2 (Fig. 1). By day 4. p1 111—139-specific T cells in
the LN and spleen display their highest level of secretion of
IL-2, IL-3/GM-CSF and IFN-y (Fig. 1) with little or no IL-4 (not
shown). By day 8 T cell responses in the cervical LN and
spleen had begun to decline, and on day 14 and day 28
peptide-specific T ceils secreted only low levels of IL-3/GM-
C3F and no IL-2 or IFN-y wnen stimulated in vitro (Fig. 1).
During the first 4 days after peptide inhalation there was a
raoio increase in the cellularity of the cervical LN that declined
over time (Fig. 1 d). Spleen cell numbers, however, did not
change significantly over the same period. Thus it would
apDear that by day 14 antigen-specific T cells were anergic
as defined by their inaoility to secrete IL-2 when stimulateo
in vitro.
Identification of the phenotype of the cell responding to
peptide
It was important to identify the phenotype of the T cells which
responded to the i.n. peptide. Mice were treated i.n. with 100
iig of p1 111-139 on three consecutive days and 4 days iater
the cervical LN were cultured with 10gg/mip1 111-139 either
in the presence or absence of mAbs against CD4, CD8. class
II MHC or a control antibody (rat anti-IgG). Cells treated with
the control antibody responded strongly to the peptide in vitro
secreting IL-2, IL-3/GM-CSF (Fig, 2) and IFN-y (not shown).
Treating cells with a 1/20 dilution of anti-CD4 mAb inhibited
lymphokine secretion in response to the peptide, wniie anti-
CD8 antibody had no effect (Fig. 2). Treating cells with an
antibody to class II MHC (anti-l-A°) also abrogated the
secretion of lymphokines in response to peptiae stimulation
in vitro (Fig. 2). These results indicate that the cells responaing






Fig. 1. LymphoKine production by T cells following i.n. administration of peptide. Mice were treated with 100 ug pi 111-139 on three
consecutive days, and (A) the cervical LN and (B) spleen were cultured in vitro on days 2. 4, 8 . 14 and 28 post-i.n. treatment and stimulated
with the peptide. (A and 8) Suoernatants were collected ana assayed for the presence of IL-3/GM-CSF (C) and IL-2 (•>. (C) Cervical LN (C)
and spleen (■) cells were cultured in vitro with p 1 111-139 and the secretion of IFN-y was detected in 48 h suoernatants. The data show the
mean response of five mice per time point r SD. The data presented is representative of three separate experiments. LN or spleen cells in
these experiments were cultured in the presence of varying concentrations of pi 111-139. but only results for 10 ug/ml are shown since this
is the dose of peptide that gives optimal T cell activation in vitro. Responses from naive T cells stimulated with p1 111-139 (10 ug/ml) on day
0 are usually <1000 c.p.m. for IL-2 and <800 c.p.m. for IL-3/GM-CSF. (D) Data show the average ceil yields from the cervical LN and is from
one representative experiment.














Fig. 2. CD4"r T cells respond to the i.n. peptide. Mice were treated with p1 111-139 i.n. and 4 days later the cervical LN were cultured in vitro
with the peptide at 10 ug/ml. Cells were treated with a control rat anti-IgG (■) or mAbs against either CD4 (a). CD8 (B) or l-A° (H) (see
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Fig. 3. The induction of tolerance leads to an equivalent level of T cell activation. Mice were treated with 3x100 ug of pi 111-139 i.n. or 50 ug
Der o 1/CFA s.c. at the scruff of the neck and the cervical LN (■) and spleen (□) cell responses were examined in vitro 4, 8 and 14 days
after the final challenge. Data snow the mean (A—C)"IL-2 and (D—F) IFN-y response from five mice per time point = SD.
to high-dose HDM peptide are class II MHC restricted and
express CD4 co-receptor.
Comparison of antigen-specific T cell responses following an
activating or tolerizing cnallenge with antigen
Mice were treated i.n. with 3x100 ug of p1 111-139 or were
immunized at the scruff of the neck with 50 ug Der p 1/CFA.
T cell responses were measured in the cervical LN on days
4. 8 and 14 after both forms of challenge, and production of
IL-2 and IFN-y was examined. On day 4 there was little
difference in the T cell responses of mice receiving the
tolerizing or activating challenges with antigen. T cells from
both groups secreted equivalent levels of IL-2 and IFN-v
(Fig. 3). However, by day 8 T cells from the peptide-treated
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Fig. 4. CD8"" T cells do not play a role in tolerance to i.n peotiae. CD8"'~ mice were treated with either PBS or p1 111-139 i.n. in a typical
tolerance experiment. At 10 days after parenteral challenge with Oer p l/CFA LN cells were cultured in vitro in the presence or (A) Oer p 1 or
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Fig. 5. Antigen-soecitic T calls display a further transient response after -ecnallenge with i.n. pi 111-139. Mice were treated with 100 ug p1
111-139 on three consecutive days and 21 days later mice were given a single 100 irg dose of pi 111-139 i.n., while other mice were left
untreated. Four days post-challenge, tne cervical LN and spleen ceils were cultured in vitro with p1 111-139 and the 24 h suoernatants were
assayed for the presence of (A) IL-2 and i.B) IL-3/GM-CSF. Data shows the mean response of five mice per grouo c SD. The data are
representative of three separate experiments.
mice had begun to down-regulate their cytokine secretion,
and this was most'noticeable by day 14 (Fig. 3).
CDS" T cells do not play a role in the maintenance of
penpneral tolerance to inhaled peptide
To examine whether regulatory CD8T T cells play a role in
inhibiting the function or antigen-specific CD4" T cells follow¬
ing i.n. peptide treatment we used mice deficient in CD8' T
ceils. The CD8~'~mice were treated with PBS or with p1 111—
139 i.n. using the standard tolerance protocol. Following Der
p 1 immunization, LN cells from PBS treated animais were
still responsive and could secrete IL-2 when stimulated in vitro
with either Der p 1 or the dominant peptide (Fig. 4). CD8"
mice that had been pretreateo with p1 111-139 i.n. had down-
regulated antigen-specific T ceil responses to both the protein
and the peptide, typical of wild-type mice (Fig. 4).
Intranasal peptide challenge in vivo after anergy induction
results in further transient antigen-specific IL-2 production
Twenty-one days after i.n. peptide, antigen-specific T ceils in
the regional LN and spleen fail to secrete IL-2 when stimulated
in vitro with p1 111-139. Thus we wished to examine If
peptide-specific T cells would remain anergic after a further
.n. challenge with p1 111-139. Four days after the m vivo
recnalienge. T cells from the cervical LN ana spleen secreted
IL-2 and IL-3/GM-CSF in an antigen-specific manner wnen
stimulated in vitro with peptide (Fig. 5.). In comparison, T ceils
from unchallenged mice failed to secrete IL-2 and only low
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levels of IL-3/GM-CSF (Fig. 5). However, the secretion of
IL-2 by peDtiae-specific T cells was only transient, ana by
day 14, T cells had again down-regulated IL-2 production. It
should be noted that despite the transient release of IL-2 from
T cells upon rechallenge with peptide in vivo mice remained
unresponsive to a challenge with Der p 1/CFA.
We were interested in determining if the same effect would
be seen after parenteral cnallenge with Der p 1. Mice were
treated with PBS or p1 111-139 and cnallenged 2 weeks later
with Der p 1/CFA s.c. at the base of tail. LN cells were
collected either on day 4 or 10 post-challenge and examined
for their capacity to secrete IL-2 following in vitro stimulation
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Fig. 6. Intranasally treated mice remain unresponsive following
cnallenge with HDM protein. Mice were treated with PBS or pt tn-
139 ana immunized 2 weeks later with Der D 1/CFA. LN cells were
tested for their capacity to secrete IL-2 on days 4 and 10 post-
challenge. The results show the 24 h IL-2 response from T cells of
individual mice.
IL-2 at high levels on both days 4 and 10 post-challenge
(Fig. 6), whereas on the other hand T cells from peptide-
treated mice failed to secrete IL-2 at either time point (Fig. 6).
Peptide inhalation does not elicit a significant antibody
response
Since inhalation of peptide inauced a vigorous T cell response
we wanted to determine if there were any serum antibodies
produced to the peptide. Mice were treated with 3x100 ug
p1 111-139 i.n. and bled on day 14 after the last treatment
(Group 1, Fig. 7). The level of peptide-specific antibodies in
the serum was low and predominantly of the igM isotype with
a small amount of lgG2a (Fig. 7). Unlike the T cell response
we did not observe any significant rise either in the level of
peptide-specific antibodies or a switch to the IgG isotype in
mice who were rechallenged twice with p1 111-139 i.n. at
fortnightly intervals (Group 2. Fig. 7).
Discussion
We report here that i.n. administration of a high dose of HDM-
derived peptide elicits a strong but transient activation of
CD4" T cells that eventually gives rise to a state of antigen-
specific T cell non-responsiveness. Responses to the i.n.
peptide spread systemically into various lymphoid tissues
within 48 h, but are strongest in the draining cervical LN. The
peptide elicited a vigorous response in vivo as indicated by
a 3- to 4-fold increase in the cellularity of the cervical LN over
the first 4 days. The T cell responses peaked on day 4 after
the completion of treatment, at which time the cells were
capable of secreting IL-2, IL-3/GM-CSF and IFN-y but with
little or no IL-4 when stimulated with p1 111-139 in vitro. By
2 weeks, peptide-specific T cells had down-regulated IL-2
and IFN-y secretion but there was residuai antigen-specific
secretion of IL-3/GM-CSF responses even on day 28. In
addition we noticed that the activation of T cells following
peptide inhalation appeared to be of the same magnitude as
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Fig. 7. Intranasaliy administered peotide induces minimal antibcdy resocnses in vivo. Graup 1 mice were treated with 100 ug pi 111-139 i.n.
cn three ccnsecutive days anc 14 days later were bled. Grcup 2 mice received the same initial treatment but alsc were recnallengec with d1
111-139 on days 17 and 31, and were Died on day 45. The serum from individual mice of both groups was analysed for the presence of IgM.
IgG 1 and lgG2a peotide-SDecific antibodies by ELISA. GrouD 3 refers to control resDonses obtained with normal mouse serum.
The failure of T cells to secrete IL-2 following antigenic
stimulation has been usea as a definition for clonal anergy
(16). However, from our studies it would appear that the
development of anergy in vivo occurring as a consequence
of i.n. peptide is mediated by a different mechanism to that
proposed for anergy in-vitro (17,18). After peptide i.n. CD4~
T cells still secrete IL-2 , and therefore, must have received
costimulation from antigen-presenting cells (APCs). Neverthe¬
less, the signals which mucosal APCs deliver to the naive T
ceils must in some way prime these cells to become non-
responsive (anergic). Studies to date have suggested that
mucosal APCs do not have an intrinsic tolerogenic capacity
(19). Whether or not certain populations of APCs are able to
deliver inhibitory signals that override the known positive co-
stimuiatory signals such as those mediated by the B7 family
of molecuies is not known.
Our findings are consistent with previous studies which
have also demonstrated that CD4+ or CD8'' Tcells responding
to various tolerogens undergo a state of transient activation
prior to the development of non-responsiveness (20-24).
However, we have obtained no direct evidence for a shift in
cytokine production by CD4' T cells over time following the
Induction of toierance to i.n. peptide. This is in contrast to
recent findings which snow that the development of peripheral
CD4' T cell toierance following immunization of mice with
ovalbumin in incomplete Freund's adjuvant (25). Others sug¬
gest a role of CD8' Ts cells in the regulation of IgE responses
in mice and rats exposed to nebulized antigen (13.14,26).
However, we failed to demonstrate that CDS' T cells regulate
either the induction or maintenance of tolerance to peptide
administered i.n., similar to that described for the induction
of oral toierance (27). There is a possibility that CD8' Ts cells
may function when low doses of antigen are encountered by
the immune system, such as in the maintenance of oral
toierance induced by feeding iow doses of protein antigen
(10). It should be noted that we have only examined responses
to high doses of peptide given i.n., which may occur via
distinct mechanisms.
Two weeks after peptide treatment. T cells in the draining
cervical LN failed to secrete IL-2 when challenged in vitro.
However, if mice were challenged 21 days after their initial
treatment with a single 100 pg dose of peptide i.n.. then
within 4 days of the challenge, antigen-specific T cells capable
of secreting IL-2 were detected in the cervical LN and spleen.
The capacity of these T cells to secrete IL-2 was only transient
and was down-reguiated by 2 weeks. It wouid appear that
IL-2 production on peptide rechallenge in vivo did not abro¬
gate peripheral tolerance to the HDM protein, since these
same animals were still unresponsive to a parenteral challenge
with Der p 1/CFA if given 14 days after the i.n. rechallenge.
Furthermore, if mice are continuously rechallenged with pep¬
tide i.n. once every 2 weeks then by day 4 after the last
rechallenge the presence of IL-2 secreting cells in the cervical
LN and spleen is observed. Similar responses have also been
shown to occur with periodic feeding of high doses of
antigen to mice (28) and with tolerance to the suoerantigen
staphylococcal enterotoxin 8 (SE3) (29). Following the induc¬
tion of peripheral tolerance to SE3 Vp3' CD4' and CD8' T
cells appear to be anergic when stimulated with antigen
m vitro. However, on rechallenge with SE3 in vivo VpS" TCR~
Regulation of CD4r T cells responses with peptide 341
T cells regain the capacity to secrete IL-2 but only CD8" T
cells were shown to undergo clonal expansion (29). It is
unclear at this stage why the transient IL-2 response is not
ooserveo following parenteral challenge with Der p 1 n
peptide treated mice. This may be due to differences ;n
epitope concentration or may involve different APCs. Despite
the strong transient CD4' T cell response that occurs to the
i.n. peptide these cells fail to provide effector heip to 8 ceils
to induce Ig class switching. Although some IgM peptide-
specific antibodies are present, no IgG antibodies can be
detected in the serum of mice. Our findings suggest that the
transient IL-2 response observed after peptide rechallenge
is from naive T cells that have not yet been tolerized to the
peptide. What is clear from these experiments is that the
development of peripheral tolerance to i.n. administered, or
fed. antigens is not complete after the first encounter with
antigen, but instead the immune system continuously
responds to these antigens.in a negative way that acts to
preserve tolerance.
It is possible that the development of mucosal tolerance
involves more than one mechanism in order to control
responses to common dietary or inhaled antigens. For
exampie, following nigh-dose antigen treatment some T ceils
may undergo apoptosis as a result of antigen recognition
(11,30), a subset of cells may escape death but become
anergic (31). In addition, negative responses mediated by
regulatory Ts cells may be superimposed on these effects
(14,26). Therefore, different overlapping mechanisms of
immune regulation at mucosal surfaces may provide for an
efficient control over immune responses to normal environ¬
mental antigens.
Our results have important implications for the use of
peptides in immunotherapy. Currently a clinical trial is in
progress investigating the efficacy of synthetic peotiaes
derived from the Fel day 1 allergen to ameliorate allergic
symptoms in cat allergic individuals (32). Our results are likely
to provide an insight into the mechanisms of how mucosally
delivered peptides induce peripheral tolerance in CD4" T
cells in vivo. In addition we have demonstrated that the
immune system continuously responds to the peptide toier-
ogen on periodic challenge in vivo. This is an important
observation since patients undergoing peptide immunother¬
apy are expected to receive peptide injections every 3-4
weeks over an extended period of time. Clearly information
is required to better understand the cellular and molecular
basis for tolerance induction by peptides delivered througn
mucosal surfaces. This will require examination of the nature
of mucosal APCs and the nature of the signals delivered to
the T cells.
Acknowledgements
This work was supported by grants from the Wellcome Trust and the
Medical Research Council. UK.
Abbreviations
APC antigen-presenting cells
CFA complete Freuna's adjuvant
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GM-CSF granulocyte macropnage colony stimulating factor
HDM house oust mite
i.n. intranasal
LN lymph node
SE3 staphylococcal enterotoxin B
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Abstract
Mucosal administration of antigens in experimental animals leads to the induction of peripheral
T cell tolerance. We have previously reported that in H-2b mice, intranasal (i.n.) or oral
administration of a peptide containing the immunodominant T cell epitope will down-regulate the
function of CD4* T ceils reactive with Der p 1, a major target antigen in both B and T cell
responses to house dust mite. In the present study we have investigated the tolerogenicity of
peptides containing both dominant and subdominant determinants when given i.n. to naive mice.
Induction of tolerance by the nasally administered immunodominant peptide leads to a diminution
in all T cell-derived cytokines and modulation of deiayed-type hypersensitivity responses, but IgE
production did not seem to be affected, furthermore the induction of T cell tolerance was stable,
lasting beyond 6 months. We have also examined the specificity of intramolecular epitope
suppression which is a feature of mucosal tolerance induced by nasally administered peptides and
demonstrate that regulatory CD4+-T cells may exert their suppressive effect by linked recognition
of epitopes on the same or neighbouring antigen-presenting cells.
Introduction
Soluble protein antigens encountered through the respiratory
or gastrointestinal tracts do not elicit strong systemic immune
responses but induce a state of antigen-specific unrespons¬
iveness which is commonly referred to as mucosal tolerance.
It is characterized by a diminution of T cell effector responses
and consequently antibody synthesis. As regards the cellular
mechanisms responsible for the development of tolerance, it
appears that feeding high doses of antigen can lead to the
deletion of antigen-specific T cells (1), anergy (2-4) or a shift
in the cytokine production of T ceils (5). Similarly, tolerance
to inhaled antigens can arise as a result of anergy or immune
deviation (6,7).
Early studies on mucosal tolerance were restricted to
analysis of cellular responses to whole protein antigens, but
it now appears that immunogenic peptides which contain
T cell epitopes can also act as potent tolerogens in vivo
(8-12). Peptides derived from self antigens delivered in
tolerogenic form through mucosal surfaces can prevent the
induction of, or reduce the seventy of, clinical symptoms
associated with various autoimmune diseases (12-14).
Furthermore, we have previously reported that the intranasal
(i.n.) or oral administration of a single immunodominant
peptide derived from the house dust mite (HDM) protein Der
p 1, when given prior to immunization with the whole protein,
can induce peripheral tolerance in both naive (15,16) or
sensitized mice (15). The non-responsiveness is character¬
ized by a reduction in IL-2 production by both lymph noae
and splenic T cells, and their failure to provide cognate help
for antibody production (15).
A feature of peptioe-inouced mucosal tolerance is that
treatment with a singie immunogenic peptide can abrogate
T cell responses to all the epitopes on an antigen
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(13-16). Such intramolecular, and presumably intermolecular
(or bystander), epitope suppression seems to be effective in
inhibiting the onset of clinical symptoms in different auto¬
immune disease models (13.14,17), where immunological
resDonses to multideterminant self antigens are typically
involved. These studies and others (18.19) have suggested
that peripheral T cell tolerance can occur through linked
recognition of tolerogenic antigen which helps to block an
antigen-specific immune response. In the present study we
have investigated further the specificity and duration of the
T cell tolerance to peptides delivered i.n. to mice.
Methods
Animals
Inored C57BL/6J mice were purchased from Harlan Olac
(Bicester, UK) or Murdoch Univeristy (Western Australia) at
6-8 weeks of age and were kept in isolators. All experiments
were performed in accordance to the animal ethics regulations
of the Home Office in the UK and the NH&MRC guidelines in
Australia.
Antigens
The HDM allergen Der p 1 was affinity purified from spent
mite medium (16). Synthetic peptides p81-102, pi 11—139
and p197-212 derived from the Der p 1 seouence were
synthesized using standard f-moc chemistry.
Induction of tolerance by i.n. administered peptides
Mice were lightly anaesthetized under ether and peptides
dissolved in PBS were administered i.n. in a total volume of
20 |il using a micropipette on three consecutive days. Mice
were immunized s.c. at the base of the tail 14 days after the
last treatment with 50 ug of Der p 1 emulsified in complete
Freund's adjuvant (CFA; Difco, Detroit, Ml) in a volume of
0.2 mi. Ten days later the para-aortic and inguinal lymph
nodes were collected and cell suspensions made. To examine
bystander suppression to an unrelated antigen, peptide-
treated or control mice were co-immunized with 50 ug Der
p 1 and ovalbumin (OVA) in CFA.
Culture medium
Lymph node (LN) or spleen cells were cultured in RPMI
1640 (Gibco, Grand Island, NY) supplemented with 2% FCS
(Gibco), 50 )iM 2-mercaptoethanoi (Sigma. St Louis. MO),
2 mM L-glutamine (Sigma) and 20 |ig/ml penicillin/streptomy¬
cin. CTLL-2 and MV1-Lu cells were maintained in RPMI 1640
and 10% FCS. and FDC-P1 cells were cultured in DMEM
(Gibco) plus 5% FCS.
T cell assays
LN cells were pressed through a stainless steel wire mesh,
washed and cultured at 4x10s cells in a volume of 0.2 ml in
culture medium in a 96-well flat-bottom tissue culture plate
(Nunc. Copenhagen, Denmark). Peptide antigen was added
at various concentrations and the ceils were incubated at
37°C for 24 or 48 h. Supernatants were collected anc stored
at -20°C until required for the assay.
Lymphokine assays
Cytokine measurements were made with the use of either
Pioassays [IL-2. IL-4 and transforming growth factor (TGF)-pl ]
or ELISA (IFN-y and IL-5). All cytokines were measured in
culture supernatants taken at 24 h intervals over a 96 h
period. IL-2 and IL-3 were usually measured at 24 h, IL-5,
IFN-y and TGF-(3 at 48 h. and IL-4 at 96 h.
The CTLL-2 cell line proliferates maximally with IL-2 but
only poorly in the presence of IL-4 (20). Test supernatants
(50 |il volumes) were added to 5x103 CTLL-2 cells (50 |il)
per well and cultured for 24 h. at 37°C and pulsed for 6 h with
[3Hlthymidine (1 ixCi: Amersham, Amersham, UK).
FDC-P1 cells proliferate maximally to IL-3 and granulocyte
macrophage colony stimulating factor but poorly to IFN-y
Cells (2x103) were cultured with test supernatants for 24 h
for FDC-P1 cells and 96 h for CT.4S cells and pulsed with
[3H]thymidine.
CT.4S cells proliferate in response to IL-4, but only poorly
to IL-2 (20). Cells (2x103) were cultured with test supernatants
for 24 h for FDC-P1 cells and 96 h for CT.4S cells and pulsed
with [3H]thymidine.
IFN-y was measured using an ELISA assay. Briefly, rat anti-
mouse IFN-y mAb (R4-6A2; PharMingen, San Diego. CA) was
coated onto lmmulon-2 plates overnight and washed with
PBS containing 0.05% Tween 20 (Sigma). Plates were blockec
with 10% BSA dissolved in PBS. After washing, culture
supernatants were added to the plates and incubated for 2 h
at room temperature. Plates were washed and the presence
of bound IFN-y detected by blotinylated anti-mouse IFN-y
(XMG1.2; PharMingen)..Plates were developed using strepta-
vidin-alkaiine phosphatase (Sigma) with 3,3'-5,5'-tetratmethy.
benzidine (Sigma) as the substrate and plates were read at
405 nm. The concentration of IFN-y was measured from a
standard curve using recombinant IFN-y (PharMingen).
IL-5 was measured in 48 h culture supernatants by ELISA
using a commercially available kit (Endogen IL-5) and was
performed following the manufacturer's directions. Standard
recombinant IL-5 preparations were included in eacn assays.
TGF-P 1
The growth of the mink lung epithelial cell line MV-1Lu is
arrested in the presence of TGF-(51. Test supernatants (50 ul
volumes) were aaoed to 2X103 MV-1Lu cells (50 ul) per well
and cultured for 24 h at 37°C and pulsed for 6 h with
[3H]thymidine. The concentration of TGF-j31 in supernatants
was determined from a standard curve using purified TGF-p 1.
Skin testing for delayed-type hypersensitivity (DTH) responses
Mice received either PBS or p111-139 nasally on three
consecutive days and 9 days later mice were immunized with
100 ug Der p 1/CFA. After 7 days mice were injected
intradermally with 10 ug Der p 1 in 10 ul PBS. Ear swelling
was measured after 24 h and the increments were obtained
by subtracting values of the test groups from those control
mice who received either PBS or p111-139 alone.
Passive cutaneous anaphylaxis (PCA) assay
Mice were treated nasally with PBS or a tolerogenic dose of
peptide 111-139 and then immunized 9 days later with Der
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0 1/CFA. After 21 days mice were died and the serum was
serially diluted in doubling dilutions in PBS. Serum was
injected intradermally into the back of an adult male Sprague-
Dawiey rat. After 24 h the rat was anaethetizeo and injected
with 10 tig of Der p 1 in saline containing Evans blue. Serum
from Oer p 1 hyperimmunized mice was used as a positive
control. A positive result was scored at the serum dilution
which gave a wheal of 10 mm or larger.
Statistical analysis
The Student's t-test and the Mann-Whitney U-test was used
to analyse the statistical significance of the experimental data
where appropriate.
Results
Comparison of peripheral non-responsiveness in H-2° mice
induced by i.n. administration ofpeptides containing immuno¬
dominant or minor T cell epitopes of Der p 1
We have previously described the dominant or subdominant
T cell epitopes of the HDM allergen Der p 1 which are
recognized following immunization of H-2° mice with affinity-
purified protein emulsified in CFA (16). Peak responses are
observed to peptide 110-131, whiie weaker responses are
observed to 81-102. 197-212 and 21-49. The ability of Der
p 1-derived peptides containing either the immunodominant
(pi 11—139) or a minor (81-102) epitope to inhibit antigen-
specific CD4'* T cell responses when administered nasally
was investigated. In all the experiments performed in this
report, control mice received PBS i.n., but the specificity of
tolerance induction of this model has been previously reported
(15). Mice were treated with either PBS or with 100 u.g
of p 111—139 or p81-102 on three consecutive days and
immunized with Der p 1/CFA 14 days after the last peptide
treatment. The capacity of LN T cells to secrete various
cytokines following in vitro stimulation with the Der p 1 protein
10 days after the parenteral challenge was examined. All
cytokines were measured at various time points from 24 to
96 h in order to determine the optimal secretion and for
simplicity cytokines shown in Fig. 1 are only from the peak
response. T cells from control mice were still highly responsive
to the Der p 1 protein in vitro and could secrete IL-2, IL-3,
11—-5. IFN-y but with little or no IL-4, while T cells from mice
treated with HDM peptide displayed down-regulated cytokine
responses in vitro for all the cytokines measured (Fig. 1). In
addition, we did not observe any increase in TGF-lil secretion
following tolerance induction to nasally administered peptides
(Fig. 1). The level of tolerance achieved with the minor epitope
was not as complete as that obtained with the dominant
peptide, with the minor epitope only reducing responses to
50-60% of that observed in the control animals (Fig. 1). In all
of the remaining experiments we have focused on the secre¬
tion of IL-2 by LN T cells since this is the cytokine that is most
markedly inhibited in T cells following mucosal tolerance and
is a general feature of peripheral T cell tolerance.
Peptide tolerance affects DTH responses but not IgE
responses
The above results indicate that T cell responses are markedly
reduced following induction of tolerance to nasally adminis¬
tered peptide. To determine if this can be correlated with an'
in vivo response, we compared DTH responses in mice
receiving either PBS or p 111-139 nasaily. Mice were tolerized
as usual and after 9 days were immunized with 100 ,ug
Der p 1/CFA. One week later all mice were immunized
intradermally in the ear with 10 u.g of Der p 1. Specific skin
swelling was measured 24 h later. To determine background
swelling responses, mice were pretreated with PBS or p 111 —
139 alone and received no Der p 1/CFA injection. The data
presented in Fig. 2(A) show that pretreatment with mice with
the immunodominant peptide 111-139 couid inhibit specific
DTH responses to a skin test challenge with Der p 1 in vivo.
these findings were statistically significant at P < 0.05 using
both Student's r-test and the Mann-Whiney U-test.
Serum from the same mice were measured for the presence
of specific IgE antibodies against Der p 1 (Fig. 2B). Although
peptide tolerized mice displayed markedly reduced CD4~
T cell responses in vitro, and in vivo, antibody responses did
not appear to be affected when IgE levels were measured
by PCA (Fig. 2B).
Duration of unresponsiveness induced by pi 11-139
In order to determine if the state of antigen-soecific T ceil non-
responsiveness is long lasting in vivo. C57BL'6J mice were
treated i.n. with pi 11-139 or PBS and immunized with Der p 1/
CFA 14 days later. Alternatively, mice were treated with 100 ug
of pill—139 i.n. on 3 consecutive days and immunized
6 months after the initial treatment and responses examined
in vitro 10 days after immunization with Der p 1/CFA. T ceils
from PBS-treated control mice responded well to pil 1—139
in vitro and were capable of secreting IL-2 (Fig. 3), whereas LN
cells from peptide-treated animals, i.e. from 2 week or 6 month
groups, were still unresponsive to the antigen in vitro (Fig. 3).
Characterization of intramolecular epitope suppression
A feature of peripheral tolerance induced by mucosaliy
delivered peptide is that treating mice with a single peptide
can inhibit T cell responses to all epitopes on the antigen
(13,15), which we define here as intramoiecular epitope
suppression. We wanted to examine therefore the antigenic
requirements that were necessary for this phenomenon to be
observed in vivo. Mice were treated with either PBS or p 111 —
139 i.n. and 2 weeks later immunized with either 50 ug of Der
p 1/CFA, p111-139/CFA or p81-102/CFA. LN T cells from
control mice were responsive to each of the immunogens
wnen stimulated in vitro (Fig. 4A-C). T cells from mice treated
with p111-139 i.n. failed to secrete IL-2 wnen stimulated
in v/'frowith Der p 1 or p 111—139 (Fig. 4D and E). However,
tolerance could not be demonstrated to the minor peptide
in vitro if mice pretreated with pi 11—139 i.n. were immunized
with p81-102/CFA (Fig. 4F).
The previous results suggest that the intact protein is
required in order to observe intramoiecular epitope suppres¬
sion. The temporal relationship of tolerance to the dominant
and minor epitopes was investigated. Mice were treated i.n.
with PBS or p111-139 and 14 days later immunized with Der
p 1/CFA. In one group in vitro T cell responses to the protein
and to a minor epitope were examined after the usual 10 day
period. T cells from control mice responded well to both Der
p 1 and to the minor epitope, p 197-212 (Fig. 5A and S).
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Fig. 1. Modulation in tne secretion of T cell-derived cytokines following tolerance induction to nasally administered peptiaes. Mice were treatec
i.n. with either PBS (•), pi 11—139 (A) or p81-102 (G) and 14 days later challenged with Der p 1/CFA. !_N cells from five mice Der group were
cultured in vitro with Der p 1 and cytokines measured after 24 or 48 h. Data snows the mean response c: SD for eacn of the cytokines. Data
nave been compiled from at least three experiments.
However, mice that were pretreated with pi 11—139 showed
down-regulated responses to the protein and to p197-212
(Fig. 5A and B). The remaining mice were immunized with 50
ug of 197-212/incomplete Freund's adjuvant (IFA) 3 weeks
after the Der p 1 cnallenge, and after a further 10 days LN
cells from both groups were tested for resDonses to the
dominant and minor epitopes. When analysed. T cells from
control mice and peptioe-tolerated mice displayed equivalent
responses to the minor epitope 197-212 (Fig. 5C and D),
while T cell responses in both groups to the dominant epitope
were still down-regulated.
Bystander suppression
The previous experiments demonstrate that the nasally admin¬
istered immunodominant peptide can induce regulatory T cells
that can block T cell responses to epitooes linked on the
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A
Fig. 2. Tolerance affects T but not 8 cell responses to Der p 1. (A) Mice were treated with PBS (n = 5) or a tolerogenic dose of P111-139
(n = 6) i.n. and 9 days later mice were immunized with Der p 1/CFA. One week later mice were injected intradermally in the ear with 10 ug
Der p 1 in saline. Twenty four hours later skin swelling was measured with a micrometer on the ear injected with antigen and that uninfected.
The two values were subtracted from each other to give increments of ear swelling. Control animals received either PBS or p 111—f 39 i.n. only
in order to establish background swelling responses. (B) Sera from control or peptide toierized mice were measured for the presence of
allergen-specific IgE by PCA. Serial dilutions of serum were injected intradermal^ into the back of a Sprague-Dawiey male rat and 24 h later
the rat was injected with a solution containing 10 ug Der p 1 in Evans Blue. Wheal respenses were measured and scored positive responses
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Fig. 3. Peripheral tolerance induced by i.n. peptide persists for long
periods m vivo. Mice were treated with either PBS (•) or p 111—139
and immunized after 2 weeks (A) or received p111-139 i.n. and
rested for 6 months before being immunized with Der p 1/CFA (□).
Ten days after the immunization LN ceils from eacn group were
cultured in vitro with the p 111—139. Data shows the mean IL-2
response from five mice per group — SD.
same protein. We wanted to examine if these regulatory T cells
may also block immune responses to unrelated antigens
in vivo. Mice were tolerated with the dominant peptide as
usual but on day 14 post-treatment mice were co-immunized
with Der p 1 and OVA in CFA. Ten days later LN cells were
cultured in vitro and responses tested to Der p 1 or OVA
seoarately. As shown in Fig. 6. T cell responses to Der p 1 were
clearly abrogated (P < 0.05) but although some decrease in
T cell responses was observed to the bystander antigen OVA.
this was not statistically significant (P > 0.1).
Discussion
"he delivery of antigens through mucosal surfaces is an
efficient way of inducing antigen-specific T cell non-respons¬
iveness, which is referred to as mucosal toierance. We have
previously reported that i.n. administration of the immunodom¬
inant peptide (residues 111-139) derived from the Der p 1
allergen of HDM can specifically inhibit CD4~ T cell responses
to the whole antigen when administered to naive or sensitized
H-2° mice (15). Several mechanisms have been identified to
explain the loss of T cell antigen-reactivity following the
induction of mucosal tolerance. Clonal deletion of antigen-
reactive T cells has been observed following hign-dose
feeding of protein antigens to TCR transgenic mice (1), while
others have suggested a role for clonal anergy of CD4" T ceils
(2,3). In addition there is evidence for active suppression in
oral tolerance mediated by TGF-|31 CD8" T suppressor (Ts)
and, more recently, immunoregulatory CD4~ T cells that
secrete Th2-type cytokines (e.g. IL-4, IL-10 and TGF-(51) have
been isolated from the Peyer's patch and mesenteric lymph
node following feeding with iow doses of myelin basic protein
(MBP) (5). However, the role for CD8+ Ts cells in oral tolerance
is controversial, since several groups have failed to observe
a role for such ceils in the induction or maintenance of oral
tolerance (2,3,21).
Studies on the immune response to nebulized antigens
have revealed that allergic sensitization is naturally avoided
through a shift in cytokine production (or immune deviation)
by specific CD4" T cells during the course of a primary
immune response to the antigen (7). There is evidence that
regulatory CD8" Ts cells become activated following inhalation
of protein antigen in experimental animals which can block
antigen-specific IgE synthesis in vivo (22-25). However, it
was recently shown that CD8'1' T ceils activated by inhaled
antigen may play a role in mediating airway hypersensitivity
(26). In addition immune deviation was shown to be respons¬
ible for the protection of non-obese diabetic mice from
autoimmune diabetes following nasal administration of a
cocktail of GAD65 peptides (27).
Induction of tolerance to high-dose nasally administered
peptide is preceded by a transient response by CD4'r T ceils
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Fig. 4. Moiecuiar reauirements for intramolecular eDitope suppression. Mice were treated with either PBS (A-C) or p111-139 (D-F), i.n. ana 2
weeKs later mice were challenged with either Der p 1/CFA (A and D). pni-139/CFA (B and E) or O81-102/CFA (C and F). Data shows the 24
n IL-2 response from LN cultures of individual mice.
□ PBSun -> Oer d 1/CFA
• pi 11-139 ui -> Der d 1/CFA
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• pi 11-139 i-n. •> Oerp 1/CFA









□ P8S i.n -> Der p 1/CFA ->197-212/1FA
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pl 97-212 (Mfl/ml)
» pll 1-1 39 i.n. -> Derp 1/CFA-> 197-212/IFA
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Fig. 5. T cells specific for minor epitopes are not aeieteo or anergized following i.n. treatment with the immunoaominant peptide. Mice were
treated i.n. with either PBS (G) or p 111—139 (•) and 2 weeKs later immunized with Der p 1/CFA. After 10 days half the mice of eacn group
were sacrificed and LN ceils tested for responses to (A) Der p 1 and (B) p 197-212. The remaining mice were tnen immunized with p 197-2121
iFA 3 weeks later and after a further 7 days LN cells were cultured in vitro with p197-212 (C and D). Data snows the IL-2 response from
individual mice.
(6). We have not identified a role for CD8" T cells in this
model (6) and interestingly ao not observe any shift in cytokine
production or increased secretion of TGF-[31 by regulatory
T cells following i.n. peptiae tolerance. This ciearly is in
contrast to studies on oral tolerance to MBP where TGF-P
secretion seems to be an important mecnanism for regulating
responses of self-reactive CD4' T cells. In the model studied
here, the production of all T-cell-derived cytokines was down-












Fig. 5. To examine bystander suppression to a unrelated antigen. Mice were treated with PBS or the dominant peptide i.n. and 14 days later
co-immunized with SO Lig Der p 1 +■ OVA in CFA. Ten days later draining LN ceils were cultured in vitro with either (A) Der p 1 or (B) OVA.
The data show the production of IL-2 in culture supernatants from individual mice stimulated with 20 AS/ml Der p 1 or 400 ug/ml of OVA.
Statistical analysis of the data using a Student's f-test revealed that the induction of T ceil non-responsiveness to Der p 1 is significant at P <
0.05 between PBS- and peptide-treated animals, while tne lowered OVA responses were not statistically significant between PBS- or plll-
139-treated animals (P >0.1).
regulated following tolerance induction with a peptide con¬
taining either the dominant or a minor T cell epitope. Although
the level of T cell inhibition achieved with the minor T cell
epitope was not as profound as that obtained with the
immunodominant epitope, our results are in agreement with
other reports (9.13) that demonstrate a hierarchy of potency
of peptides as tolerogens which reflects their immunogenicity
in vivo. The finding that there is a loss of cytokine production
by antigen-specific T cells following tolerance induction is
consistent with a previous study on peptide-inouced peri¬
pheral tolerance (28). However, there may be distinct mechan¬
isms which operate in the induction of mucosal tolerance
through the respiratory tract and this may be dependent
upon the dose, the frequency and the nature of the antigen
administered, as has been shown for oral tolerance (29).
Although the nasal administration of soluble peptide
appears to induce a strong primary immune response (6),
the functional outcome of this response is qualitatively different
had the same peptide been administered in conjunction
with adjuvant. We have previously suggested that mucosal
tolerance to high-dose peptide induces a population of regu¬
latory T cells which display an anergic phenotype in vitro (6).
The cells remain in the peripheral circulation but can no
longer act as classical Th cells (15,16) but instead adopt an
immunoregulatory role and function to modulate rather than
promote antigen-specific immune responses. Furthermore,
these regulatory T cells appear to be maintained in the
peripheral circulation for long periods, as evidenced by
their capacity to down-regulate T cell-dependent immune
responses, such as cytokine secretion and DTH responses
to Der p 1. Moreover, the regulatory T cells appear to be
functional even 6 months after the original peptide treatment.
This finding is in agreement with the stability of oral tolerance
in mice where a single feed of protein to a naive animal can
lead to life long antigen-specific T ceil non-responsiveness
(30).
Although antigen-specific T cell responses were modulated
following tolerance induction, the levels of specific IgE anti¬
body were not affected. The limitation to this study was that
most immunizations were made in CFA which snould bias for
a Thi dominant immune response. Nevertheless, we have
also observed similar findings wnen mice were also immun¬
ized under Th2-type conditions. Therefore, the mucosally
delivered peptide tolerogen appears to affect the function of
CD4~ Tt, cells while 8 ceil function in the short term does not
appear to be modulated. These findings are consistent with
studies which have examined immunological functions of
patients who have undergone conventional allergen immuno¬
therapy (31), where T cell functions were demonstrated to
have been modulated without affecting the levels of specific
serum IgE in the short term.
A feature of mucosal tolerance induced by nasally adminis¬
tered peptide is that a single peptide can inhibit responses
to all epitopes on an antigen (13-17). In the model system
studied here, the induction of tolerance to the immunodomin¬
ant peptide of Der p 1 can down-regulate T cell responses
to all four epitopes on the antigen when mice are immunized
with the whole protein in adjuvant (15). However, it was
possible to uncouple tolerance to the minor epitopes by
immunizing tolerant mice with a peptide containing only the
subdominant determinant, which is consistent with previous
studies on peripheral T cell tolerance (8). However, it was
possible to rescue a T cell response to a minor epitope of
Der o 1 in mice that had been rendered tolerant to the
dominant epitope and who had been previously immunized
with the whole protein (Fig. 5). If such mice were immunized
with the subdominant peptide in adjuvant. 3 weeks after the
initial protein immunization, then the previously tolerant mice
displayed equivalent responses to the subdominant epitope
as controls.
Taken together, these observations suggest that the T cells
specific for the minor epitopes are not deleted or anergizeo
after nasal administration of the immunodominant peptide,
but should be competent to respond to their epitopes following
immunization with the protein. Yet this is not the case. Thus
the intramolecular epitope suppression observed in our model
is prooably due to local suppression mediated by regulatory
CD4~ T cells through the recognition of linked epitopes on
the same antigen. However, rather than killing the T cells
specific for minor epitopes, we suggest that the regulatory
T cells may merely block their growth. Once the immune
response to the protein has waned, the regulatory T cells
wouid return to a resting state since their epitopes would
not be presented on APC. Thus when tolerant mice are
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reimmunized with a peDtide containing only the subdommant
determinant. T cells specific for the epitope would be allowed
to expand nprmally since they would no ionger be under the
control of the reguiatory CD4' T cells. The phenomenon of
linked suppression is not new and has been observed in
a murine model of mAb-induced transplantation tolerance
(18.19). Regulatory CD4^ T ceils induced by this tolerance
protocol can mediate local suppression of allo-reactive T cells
by linked recognition of antigen possibly on the same APC
and can generate some bystander suppression to a third
party antigen (18). Although we observed some inhibition of
T cell responses to a bystander antigen in our model of
peptide induced mucosal tolerance, the levei of inhibition was
not statistically significant.
We propose the following model to explain how intramolecu¬
lar epitope suppression might be induced in mucosal toler¬
ance. Following immunization of tolerant mice with the intact
protein, APC in the draining LN will present peptides specific
for the reguiatory T cells and for those T cells recognizing
the suboominant epitopes. The APC may therefore act as a
bridge to bring the regulatory cells into close vicinity with the
naive T cells of differing specificity. In such an environment
the regulatory T ceils may exert their inhibitory effects to other
T cells either througn the release of inhibitory cytokines or by
negative signalling via direct membrane interactions. Alternat¬
ively. the regulatory T cells may compete for the local produc¬
tion of IL-2 by 'mopping up' excess IL-2 and thus prevent
expansion of the naive T ceils specific for the subdominant
epitopes, as has been suggested by a human model of T cell
anergy (32). The induction of bystander suppression in this
model was not convincing, but this may be due to a problem
in Ipcal antigen presentation, in tnat different APC may present
the epitopes for the two antigens and these APC may be
separated by a sufficient distance in vivo that enables the
OVA-reactive T cells to escape the regulatory actions of tne
p111-139-specific T ceils in vivo.
The observation reported here that T cell tolerance to i.n.
peptide is long lasting may facilitate this route of antigen
delivery in immunotherapy (33). Since a single immunogenic
peptide alone can establish T cell tolerance by inducing a
population of regulatory T cells, it may not be necessary to
vaccinate with multipie T cell epitopes. In addition, further
studies may nelo identify the molecular basis for tolerance
induction and may also provide an insight into the functional
properties of mucosal APC that make them effective in
tolerance induction.
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APC antigen-presenting ceil
CPA complete Freund's adjuvant
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DTH delayed-type hypersensitivity
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IFA incomplete Freund's adjuvant
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SUMMARY
Grass poilen immunotherapy for the treatment of seasonal allergic rhinitis ('summer hayfever') results
in improvement in symptoms, a reduction in the early and late phase responses to allergen provocation
and decreased tissue eosinophilia. Immunotherapy may act by altering the pattern of cytokine
production by allergen-specific T cells from a 'Th2-type' (IL-4 and IL-5) profile to a 'Thl-type'
(interferon-gamma (EFN-7)) profile. We set out to determine whether clinical improvement following
specific allergen immunotherapy is accompanied by reduced production of the pro-eosinophilic and
archetypal 'Th2-type' cytokine, EL-5. Peripheral blood mononuclear cells (PBMC) were isolated from
(i) 13 patients who had received 6 or 7 years' continuous conventional immunotherapy with timothy
grass pollen (Phleum pratense); (ii) 14 patients who had received 3 or 4 years of conventional
immunotherapy followed by 3 years of placebo treatment; (iii) 12 matched seasonal rhinitic patients
who had never received immunotherapy; and (iv) 17 non-atopic normal controls. PBMC were
stimulated with 20 pg/mi and 200 /xg/mi P. pratense extract, or 10 fig/ml ofMycobacterium tuberculosis
purified protein derivative (PPD), at 2x 10° cells/ml and 5 x 106 cells/ml. EL-5 concentrations fn culture
supernatants collected after 6 days' culture were measured by ELISA. IL-5 production in response to
stimulation with P. pratense extract was highly reproducible and was elevated in both of the
immunotherapy treated groups and the untreated rhinitics relative to non-atopic controls CP <0005
for each group relative to non-atopic controls, under each of the four conditions tested). However, no
significant reduction was observed in IL-5 production when immunotherapy treated patients were
compared with untreated rhinitic controls. Moreover, abrogation of the cutaneous late-phase responses
to allergen following treatment was not associated with reduced IL-5 production by allergen-stimulated
peripheral blood T cells. Reduced IL-5 production by peripheral blood T ceils may not be necessary for
immunotherapy to be effective. Local immunodulation of T cell responses may play a role in this form
of treatment.
Keywords allergy immunotherapy T ceil cytokines IL-5
INTRODUCTION
Although grass pollen immunotherapy is a highly effective treat¬
ment for seasonal allergic rhinitis [1-4], the exact nature of the
mechanisms underlying its effects remains poorly defined. One
possibility is that so-called 'blocking' IgG antibodies produced
during immunotherapy may sequester allergen and thus prevent
IgE-mediated activation of mast cells or basophils [5]. A reduction
Correspondence: Dr S. R. Durham. Upper Respiratory Medicine.
Imperial College School of Medicine at National Heart and Lung Institute.
Dovehouse Street. London SW3 6LY. UK.
in the numbers of nasal metachromatic ceils [6], presumed to be
mast ceils or basophils, has also been described following grass
poilen immunotherapy. .Allergen exposure in atopic subjects is
characteristically associated with local expression of the Th2-type
cytokines. IL-4 and IL-5 [7-9]. In vitro studies have demonstrated
an association between allergic symptoms and production of IL-4
and IL-5 by allergen-specific T cells [10-12], and smce ailergen-
specific T ceils from non-atopic subjects are characterized by
the expression of Thl-type cytokines such as interferon-gamma
(IFN-y) [10,11], it has been proposed that immunotherapy with
aeroallergens may be associated with a shift in cytokine production
114 § 1997 Blackweil Science
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by allergen-specific T cells from a Th2-rype to a Thl-type profile.
In support of this hypothesis, Secrist et al. [13] observed a
reduction in EL-4 production by allergen-specific T cell lines
derived from peripheral blood of immunotherapy treated patients
relative to untreated controls, and we have previously reported
increased expression of IFN-7 mRNA-in skin and nasal biopsies of
successfully treated patients after local allergen provocation
[14,15]. A decrease in Th2-type and reciprocol increases in
Thl-type cytokine production following high-dose andgen admin¬
istration have also been described following insect venom desen-
sitization [16-18]. A further feature of successful immunotherapy
is a macroscopic inhibition of allergen-induced late-phase
responses and an attendant reduction in the numbers of infiltrating
eosinophils [15,19-21]. Since IL-5 acts specifically on eosinophils
to promote their maturation, endothelial adhesion, activation and
survival [22-24], and primes these cells for enhanced chemotactic
response to C-C chemokines such as RANTES [25], we hypothe¬
sized that clinical improvement following grass pollen immu¬
notherapy may be associated with a reduction in IL-5 production
by grass pollen allergen-specific T cells in response to allergen
-"posure. We have previously shown that in short-term cultures of
.use dust mite-stimulated peripheral blood mononuclear cells
fPBMC), IL-5 is secreted in a CD4""-dependent manner and that
the amounts produced are elevated in sensitized asthmatics and
rhinitics relative to atopic and non-atopic controls without symp¬
toms [12]. Thus, in order to test our hypothesis in the present study,
we compared grass pollen allergen-induced IL-5 production by
PBMC from immunotherapy treated patients, untreated rhimtics
and non-atopic normal controls. To investigate further the speci¬
ficity of any immunotherapy-induced changes in peripheral blood
T cell function, we also compared responses to grass pollen and
purified protein derivative (PPD; a ubiquitous antigen to which




Patients were selected for immunotherapy according to a history of
severe summer hay fever that was poorly controlled by conven¬
tional medication. All patients had a > 5 mm weal in response to
n testing with timothy grass pollen (Phleum pratense\ Soiu-
yiick. ALK. Horsholm. Denmark). Patients with other significant
medical conditions (including a history of chronic asthma) were
excluded. At the time of sample collection, 13 patients had
received 6 or 7 years' continuous immunotherapy, and a further
14 patients had received 3 or 4 years' immunotherapy followed by
3 years' placebo treatment. The induction phase of immunotherapy
was performed with twice weekly injections of Alutard SQ P.
pratense over 6—8 weeks before progressing to monthly maintenance
injections. Twelve matched atopic patients who had never received
immunotherapy ('rhinitic controls') and 17 non-atopic subjects
with a life-long absence of allergic symptoms were recruited as
controls in this study. Both immunotherapy treated groups showed
highly significant reductions in the sizes of cutaneous allergen-
induced late-phase reactions and improvement in symptoms com¬
pared with untreated rhinitic controls (data not shown). Details of
all subjects in the four clinical groups are shown in Table 1.
Peripheral blood samples collected from these subjects were
processed and cultured in the laboratory in a blinded fashion by
a single investigator. This study was performed with the approval
of the ethics committee of the Royal Brompton National Heart and
Lung Hospital and the written consent of all participants.
Preparation of cells
PBMC were isolated from heparinized blood samples by density
gradient centrifugation over Ficoll-Hypaque (Pharmacia, Uppsala,
Sweden), washed twice in HEPES-buffered RPMI 1640 (Sigma,
Poole, UK) and resuspended in RPMI 1640 (Sigma) supplemented
with 5% human AJB serum (Sigma), lOOU/ml penicillin/strepto¬
mycin (Gibco, Paisley, UK) and 2 mM L-glutamine (Gdbco).
Cell cultures
For cytokine production, PBMC were resuspended at 2x 106 and
5 x 106 cells/ml and incubated in 200 pi volumes (six replicates) in
the presence of 20 and 200 /zg/ml concentrations of P. pratense
('Aquagen' extract, kindly provided by ALK). Control cultures
were incubated with medium or lOjxg/m1 of Mycobacterium
tuberculosis PPD (Evans. Medical Limited, Leatherhead, UK) as
a non-allergen control. All cultures were performed in 96-weil flat-
bottomed microtitre tissue culture plates (Nunc, Roskilde, Den¬
mark). Supernatants were harvested from wells on day 6 and stored
at —80°C pending measurement of cytokine concentrations. For
proliferation, PBMC were resuspended at 0-5 x 106 cells/ml in the
presence of 20 and 200 /xg/ml concentrations of P. pratense, and
10 pg/ml of PPD. Cellular proliferation was measured on day 7 by
adding 0-5 pC'i of tritiated methyl-thymidine (Amersham. Ayles¬
bury, UK) per well for the last 16 h of culture, and assaying label
incorporation by liquid scintillation spectroscopy.
Cytokine assays
IL-5 concentrations in culture supernatants were measured using a
specific sandwich ELISA sensitive above 6-5 pg/ml, as previously
described [26]. IFN-y was measured using a commercially avail¬
able ELISA (CLB, Amsterdam, The Netherlands) sensitive above
1 pg/ml.
Table 1. Clinical details of subjects
IT 3-4 years -!-
IT 6-7 years placebo 3 years Rhinitic controls Non-atopic controls
Number 13 14 12 17
Age (years ± s.e.m.) 41-7 3-8) 43-7 (± 2-5) 37-6 (d 3-7) 39-2 3-9)
Gender (M:F) 8:5 7:7 8:4 11:6
IT, Immunotherapy.
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Statistical analysis
The distribution of proliferative-and cytokine responses was non-
parametric, and between group comparisons were therefore performed
using the Mann-Whitney U-test with the aid of a commercial
software package (Minitab Inc., PA). The Bonferroni correction was
applied for multiple comparisons. P < 005 was considered significant.
RESULTS
PBMC proliferation in response to P. pratense and PPD stimulation
In order to determine the concentration or allergen extract required
for optimal in vitro T cell activation, PBMC from 10 atopic donors
were incubated with varying concentrations of P. pratense. Antigen-
induced cellular proliferation increased in a concentration-
dependent fashion (Fig. 1). The optimal dose of P. pratense
required to illicit a proliferative response was between 20 and
200^g/ml. Phleum pratense- and PPD-induced PBMC prolifera¬
tion was statistically equivalent in both immunotherapy treated
groups, the untreated rhinitic group and the non-atopic control
group (Table 2).
Reproducibility of"?, pratense-induced IL-5 production
To confirm that allergen-induced IL-5 production by peripheral
blood T ceils was reproducible, PBMC were purified from three
P. pratense-sensiiive atopic donors on three separate occasions (to
ascertain interassay reproducibility). The first sample was also
divided into two aliquots, each of which was then processed in
parallel (to ascertain intra-assay reproducibility). EL-5 production
under the conditions described was highly reproducible (Fig. 2),
with all measurements in the order patient 3 >> patient 2> patient
1. As can be seen from the individual data, there was good intra-






Fig. 1. Effect of allergen concentration Phleum pratense-induced periph¬
eral blood mononuclear cell (PBMC) proliferation. Proliferauon was
assayed after 7 days. Data are from 10 atopic subjects and are represented
for clarity as mean -4-s.d. Act/min represents the counts per minute in
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Fig. 2. Reproducibility of Phleum pratense-induced IL-5 production in
three sensitized atopic subjects. Peripheral blood mononuclear cells
(PBMC) were stimulated for 6 days at 5x 10° cells/ml with 200ng/ml P.
pratense. IL-5 concentrations were measured in duplicate (shown as mean
-t- s.d.): 1 (a and b), 2 and 3 represent data generated from blood samples
collected on 3 different days. Data for la and lb were generated from a
single blood sample divided into two aliquots after collecuon. each of
which was processed separately.
Effects of immunotherapy on P. pratense-induced IL-5 production
IL-5 production by PBMC stimulated with 20 /xg/ml and 200 /ag/ml
P. pratense and lOjxg/mi PPD was determined in 13 immuno¬
therapy treated rhinitics (6-7 years' active treatment), 14 rhinitics
who previously received immunotherapy but were currently
receiving placebo (3-4 years active, 3 years placebo), 12 rhinitics
who had never received immunotherapy and 17 non-atopic normal
controls. .All measurements were performed on PBMC cultures
performed at 5 x 106 cells/mi (Fig. 3) and-2x 106 ceils/ml (Fig. 4).
Under all conditions tested, rhiniuc groups (irrespective ofwhether
they had previously received immunotherapy) were characterized
by elevated EL-5 production compared with non-atopic normal
controls. Nevertheless, no statistically significant differences
were observed in allergen-induced IL-5 production between
immunotherapy treated rhinitic groups and the untreated rhinitic
group. This was also the case when the two separate groups of
immunotherapy treated patients were combined and compared
with untreated controls. Moreover, abrogation or inhibition of
cutaneous late responses in immunotherapy treated patients was
not associated with reduced allergen-induced IL-5 production by T
cells within PBMC (Fig. 5). IL-5 production in PPD-stimulated
cultures was lower than in the allergen-stimulated cultures. No
significant differences were observed in IFN-7 production between
any of the groups under any of the conditions tested. Comparison
of ratios of IL-5 and IFN-y produced in response to P. pratense or
PPD (a prototypical Thl-type antigen; sumulation confirmed that
IL-5 production by P. prare/z^e-stimulated PBMC obtained from
atopic subjects (immunotherapy treated and untreated), but not
normal controls, occurred in the context of a Th2-like cytokine
response (Table 2).
As further confirmation of the validity of our EL-5 measure¬
ments, significant positive correlations were observed between
IL-5 production in response to 20 /xg/mi P. pratense and 200 /ig/ml
P. pratense. when ail atopic patients (immunotherapy treated and
untreated) were analysed together (r= 0-88, P< 0-0001 at 5 x 10°
cells/mi. and r= 0*92, P< 0-0001 at 2x 106 ceils/ml).
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Fig. 3. Comparison of Phleum pratense- and purified protein derivative (PPD)-induced IL-5 production in immunotherapy treated rhinitic
patients (aTT, pIT). untreated rhinitic controls (RC), and non-atopic normal controls (NC): alT patients had received a total of 6-7 years'
immunotherapy and were on active treatment at the time of the study. pIT patients had received a total of 3-4 years' immunotherapy but had
received piacebo treatment for the 3 years up to and including the time of the study. Peripheral blood mononuclear cells (PBMC) were
cultured at 5x 106 cells/ml. mmP <0-005 versus NC bv Mann-Whitnev U-test.
DISCUSSION
We have investigated the effects of specific allergen immuno¬
therapy for the treatment of severe seasonal allergic rhinitis on the
propensity of peripheral blood T cells to produce IL-5 in response
to ex vivo stimulation with grass pollen allergen (P. pratense). We
report that although P. pratense-induced IL-5 production by
PBMC is elevated in appropriately sensitized rhinitic patients
relative to non-atopic normal control subjects, treatment with a
conventional allergen immunotherapy protocol, which resulted in a
reduction in allergen-induced cutaneous late-phase responses and
clinical improvement [3] in an overwhelming majority of patients,
did not appear to decrease P. pratense-induced IL-5 production
relative to untreated controls. Based on our findings, we speculate
that a reduction in the ability of circulating peripheral blood T cells
to secrete IL-5 on allergen stimulation is not a prerequisite for this
form of immunotherapy to be effective.
Phi p 200 ug/ml
2x10 cells/ml
Phi p 20 ug/ml M. tuberculosis PPD










alT pIT RC NC alT pIT RC NC
Fig. 4. Comparison of Phleum pratense- and purified protein derivative (PPD)-induced IL-5 production in immunotherapy treated rhinitic
patients (alT, pIT), untreated rhinitic controls (RC), and non-atopic normal controls (NC): alT patients had received a total of 6-7 years'
immunotherapy and were on active treatment at the time of the study. pIT patients had received a total of 3-4 years' immunotherapy but had
received placebo treatment for the 3 years up to and including the time of the study. Peripheral blood mononuclear cells (PBMC) were cultured at
2x 106 cells/ml. mmP<0-005 versus NC. bv Mann-Whimev (7-tesL
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Fig. 5. Relationship between (a) size of cutaneous late-phase reactions
(LPR) 6h following intradermal injection with 30 BU of Phleum proteose,
and (b) P. proteose-induced EL-5 production by peripheral blood mono¬
nuclear cells (PBMC) (200 jig/ml P. proteose, 5 x 106 cells/ml). •. Pauents
who had received a total of 6-7 years' immunotherapy and were on active
treatment at the time of the study; O, pauents who had received a total of 3-
4 years' immunotherapy but had received placebo treatment for the 3 years
up to and including the time of the study. NT, Not tested.
The association between the production of Th2-tvpe cytokines
such as IL-4 and EL-5 by allergen-specific T cells and the presence
of atopic diseases, such as asthma or allergic rhinitis, is well
established. Although many of these studies have been based on
analyses of allergen-specific T cell lines or clones [10,27], a
number of more recent studies have also demonstrated elevated
IL-4 [11] or IL-5 [12] production by peripheral blood T cells from
atopic subjects stimulated by allergen in short-term primary
cultures of PBMC. Data generated in our group [12] have shown
that IL-5 production by allergen-stimulated PBMC is elevated in
symptomatic atopic patients (asthma or rhinitis) relative to atopic
and non-atopic subjects without any symptoms, and that EL-5
synthesis in this system is dependent on the presence of CD4"*"
but not CDS"*" T cells. We chose to use this primary culture system
to investigate the effects of immunotherapy on IL-5 production by
allergen-specific peripheral blood T cells, because it is highly
reproducible and generates data with clear cut differences between
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rhinitic patients and normal controls. Moreover, the sole stimulus
in these cultures is allergen extract: ceils are not subject to expan¬
sion in EL-2 or stimulation with non-specific mitogens, which may
distort the allergen-specific T cell repertoire or unphysioiogically
augment cytokine synthesis.
In the present study, we also observed T cell proliferative
responses and EFN-y (but not IL-5) production in normal controls.
These findings are consistent with those of Imada et al. [11], who
recently demonstrated that non-atopic individuals mounted in vitro
T cell responses to grass pollen, although in contrast to atopics,
these subjects' T cells favoured EFN-y, but not IL-4 production
under these conditions. While it may have been preferable to
perform the analyses described before and throughout the immu¬
notherapy course, this was impracticable in the present study.
Furthermore, we took a number of precautions to standardize
measurements in different subjects. First, in patients currently receiv¬
ing immunotherapy (or placebo treatment), all blood samples were
collected 3-4 weeks after the last injection of allergen. Second, all
blood samples were processed 1 -2 h after collection, and cultured
with identical batches of allergen extract and culture medium
supplements (AB-f- serum. L-glutamine and antibiotics). The
reproducibility of these assays was examined in initial experiments
performed on three subjects on three separate occasions (Fig. 1)
and subsequently confirmed in study subjects by virtue of the
strong linear correlation observed between IL-5 measurements
made using two different concentrations of allergen extract
Although studies performed on peripheral blood ceils have
yielded invaluable information, the relationship between cytokine
secretion by allergen-specific T cells within peripheral blood and
the target organ remains poorly defined. Previous work from our
group has shown that exposure of the nasal mucosa to grass pollen
is associated with recruitment and activation of T cells and
eosinophils [28] and preferential expression of mRNA for the
Th2-type cytokines, particularly EL-4 and IL-5 [15]. The principle
cell source of IL-5 was the T cell (83-2%), with minor contribu¬
tions from mast cells (11*3%) and eosinophils (5-4%) [8], We also
examined the influence of immunotherapy on these changes in the
target organ. Immunotherapy was not associated with statistically
significant reductions in the numbers of IL-4-exprcssing cells,
although there was a trend towards a decrease in EL-5 expression
[15], and increased numbers of IFN-y and IL-12 mRNA-
expressing cells were observed [14,15,29]. Moreover. EFN-y
expression within the nasal mucosa was found to correlate with
clinical improvement following immunotherapy [15]. More recent
functional studies suggest that the ability of allergen-specific T
cells to secrete IL-5 is markedly up-regulated at sites of allergen
exposure, since purified broncnoalveolar lavage T cells (collected
24 h after segmental allergen challenge) stimulated with allergen
and antigen-presenting cells secreted significantly higher amounts
of IL-5 than equivalent numbers of peripheral blood T cells from
the same subjects (unpublished observations). These observations
suggest that allergen-specific T cells may undergo differentiation
into a cytokine-producing 'effector' phenotype following in vivo
allergen exposure and recruitment to tissues.
Although peripheral blood T cells from atopic subjects are
predisposed to secrete IL-4 and IL-5 in the context of a Th2-type
cytokine profile on stimulation with allergen (but not with bacterial
antigens such as M. tuberculosis PPD, which favour IFN-7
production [30,31], see Table 2), the cytokine-producing pheno¬
type of these cells retains some flexibility, since production of IL-4
and EL-5 in vitro in response to activation by allergen can be
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inhibited by IL-12 and EFN-y [32-34]. We hypothesize that
expression of cytokines such as IL-12 and IFN-7 at the sites of
allergen exposure plays a key role in regulation of T ceil
cytokine responses following immunotherapy, by interceding in
up-regulauon of locai IL-5 (and possibly IL-4) production. This
hypothesis is consistent with our findings of IL-12 and IFN-y
mRNA expression in biopsies of allergen-induced late-phase
reactions in patients who have received immunotherapy
[14,15,29]. Although the numbers of EL-5 mRNA-transcribing
ceils in these biopsies did not change with immunotherapy,
in situ hybridization does not quantify the amount of mRNA
produced by a particular cell, and it is quite possible that in T
cells in which IL-5 production has been inhibited by IL-12/TFN-7,
complete extinction of IL-5 transcription may not occur.
There have been relatively few previous studies of the proper¬
ties of allergen-specific T ceils following conventional immu¬
notherapy with aeroallergen extracts. Secrist et aL [13] showed
that allergen-specific T cell lines propagated from the peripheral
blood of immunotherapy treated atopic patients and stimulated
with mitogen secreted markedly less IL-4 compared with a group
of untreated atopics. However, this study included patients that
were sensitive to both house dust mite and grass pollen, and
who had received immunotherapy for differing lengths of time.
Moreover, this smdy employed culture techniques that necessitated
expansion of cells in IL-2 and stimulation with non-specific
mitogens. Similar findings have also been reported following
rush desensiozanon for wasp and bee venom anaphylaxis [16-18].
In contrast, we did not identify either a reduction in EL-5 or an
increase in EFN-7 production in PBMC cultures following
immunotherapy, despite use of validated methods in a blinded
controlled clinical smdy. However, our previous findings of
'immune deviation' within the target organ (i.e. the nose), with a
non-significant trend for a reduction in IL-5 expression and
significant increases in IFN-7 and IL-12 mRNA expression, sup¬
port the concept that locai alterations inrT lymphocyte responses
upon subsequent allergen exposure may underlie the clinical
benefits following allergen immunotherapy.
In conclusion, we have investigated the effects of immunother¬
apy on the capacity of peripheral blood allergen-specific T
ceils (within PBMC) to produce EL-5 on ex vivo stimulation
with allergen extract. Our observations suggest that a profound
alteration of allergen-specific T cell function in the peripheral
circulation may not be a requirement for the clinical efficacy of this
form of treatment, and support the concept that local immuno-
modulation may be at least partly responsible for the effects of
immunotherapy.
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A human suppressor T cell clone
which recognizes an
autologous helper T cell clone
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Division of Immunologic Oncology, Lombardi Cancer
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Washington DC 20007, USA
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In contrast to the many reports of EL-2 dependent proliferat¬
ing, helper or killer cell clones1, there is only a single report of
an EL-2 dependent suppressor ceil done2, in the mouse.
However by the same doning procedures used to generate
human helper cells2, suppressor cell dones to influenza virus
could not be generated, and so another strategy was used.
Jerne's network hypothesis4 proposes that immune regulation
results from lymphoid ceil receptors recognizing determinants
on other lymphoid cell receptors. If this is the case it should
be possible to generate regulatory T cell dones against other
T cells and we report here the generation of an autologous
suppressor ceil done which recognizes and inhibits the function
of a human helper T ceil done. Such an autologous suppressor
cell done provides a new approach to understanding the path¬
ways and molecular events involved in immune regulation.
Mutual stimulation of the suppressor cell done and the target
helper ceil done in the absence of back stimulation, provides
direct experimental evidence for the existence of interactions
between T ceil receptors, and thus suggests that the specifirity
of the suppressor ceil done is for the antigen receptor of the
helper ceil.
Human immunoiogy, unlike mOuse immunology, is limited
by restricted access to genetically uniform ceils. In order to
circumvent this problem, ail the experiments reported here
*
address: Lmoenai Cancer Research Fund. Human Tumour [mraunoio^y Unit.
University College Hoaptul. London WCIE 6BT. UK.
were performed with cryopreserved cells from a single
individual. T lymphocyte clone 6 (TLC 6) is a heiper ceil which
recognized influenza A matrix protein in conjunction with
HLA-DR13"*. It was used to generate anti-idiotype suppressor
cells because it grows well in culture, and its heiper activity is
easy to measure in vitro using the influenza virus specific anti¬
body response and assay system developed by our colleagues,
Cailard, Beverley and Zanders7"*, using either the cells themsel¬
ves, or its antigen specific heiper factor.
To stimulate autologous peripheral blood cells (PBL) with
irradiated TLC6, a 10-day mixed lymphocyte culture was per¬
formed. The resulting blasts were purified on Ficoil-Hypaque
and restimuiated with irradiated TLC6. The ensuing lympho-
biasts purified on a Percoil gradient three days later, and cloned
as described in Table 1. Approximately 60 clones were grown
up, and tested for their specificity. For simplicity, proliferation
was used as the criterion of responsiveness, and ceils from
individual clones were cultured with irradiated autologous PBL
and either the immunogen TLC6, another heiper clone from
the same donor HA1.9, influenza A virus, or just PBL alone.
After 72 hours, cultures were pulsed with tritiated thymidine
and cells were collected 16 hours later. Several patterns of
reactivity were seen. Clones from these experiments were ter¬
med AC1 to 60. The most common response was to influenza
virus (for example clone AC10), which could have been still
present on the surface of washed TLC6 even after one week's
culture. Other clones showed no detectable response to any of
the stimuli used (for example AC57). This is paradoxical, as
only activated cells respond to TCGF and can be cloned1. It
seems likely that these clones were responding to TLC6, but
the response was not detectable by the assay used. Clone AC34
is presumably recognizing an antigen on PBL (or serum),
whereas clone AC5 is recognizing an activated cell antigen.
The specificity of clones AC19 and AC22. is not known.
The most relevant clone, chosen for further analysis, was
clone AC50. This proliferated in response to TLC6, but not
other clones. PBL or influenza virus. Thus it seemed to be
specific for TLC6, and was a candidate for an and TLC6 clone.
In the absence of any antibodies which unambiguously define
human T-ceil receptors, we used a functional assay to analyse
the specificity of clone AC50 further.
Table 1 Induction of anti-TLC 6 clones
Antigen
Gone no. 6-PBL HA1.9-PBL PBL Flu—PBL Medium TCGF
AC5 • 1.249 = 94 5.469 = 1.595 44=10 75=21 39=16 11.450 = 750
AC10 43 = 20 57=16 54=16 4,676= 404 31 = 11 5.063 = 162
AC19 2.534=367 2.794=366 2.457= 326 31=8 15= 4 3.164=243
AC22 1.518= 247 24=2 46=11 2.478=35 34=4 8.695 = 622
AC34 1.301 = 360 2.255 =304 1.655 = 68 3.005= 912 29 = 7 6.243 = 221
AC50 2.928 = 94 32=13 36=10 54=8 21 = 3 9,949= 216
ACS7 23 = 4 22=5 24=4 30=5 21 = 2 9,720=506
AGS 8 4.550=570 3.711 = 446 7.508=1.620 5,301 = 1.494 26 = 3 9,097= 208
Peripheral blood lymphocytes (PBL. 5x 10® per mi) were cultured with irradiated (2.500 rad: ,,7Cs) TLC5 (5x 10® per ml) in RPMI 1640 supplemented with
10% pooled A" serum in a 24 well plate (Costar). Both the responder (PBL) and stimulator (TLC6) cells were derived from the same donor. After 10 days of primary
culture the viable ceils were isolated on Ficoil-Hypaque and blast ceils (10® per ml) were restimuiated with irradiated TLC6 (10® per mi) in the presence of autologous
irradiated PBL (5x 10® per mi). Three days after resnmulation the lymphobiasts were enriched on a discontinuous Percoil (Pharmacia) density gradient (35-40%»
and plated at 0.3 ceils per well in sterile 60 well Microtest II trays (Faiconi in the presence of T ceils growth factor (TCGF or Interieuicin 2) irradiated snrauiator
ceils (TLC6: 5 x 10® per well) and autologous irradiated PBLs <5x 10® per ceil) as a source of antigen presenting cells iAPCs). TCGF was prepared from PBL (1x10*
per ml cultured with PHA (0.1%) in the presence of 1% autologous serum for 48 hours as described elsewhere®*11. The wells that showed positive growth (3.4% of
the total number of blast cell seeded) at 7 days were transferred to 96 well flat bottom microntre trays (Faicon) and cultured with irradiated TLC6 (5 x 10* per well)
and autologous irradiated PBL (5 x 10* perwell) in the presence of TCGF. Following a further 7 days in culture, the clones were transferred to 24 well trays containing.
TCGF. irradiated TLC6 (5 x 10* per well) and autologous irradiated PBL (1 x 10* per well). In the preliminary screen dones were examined for anogen speonaty in
a 72 hour array by using titrated methyl thymidine (®H-TdR; NEN). A 1:200 dilution of individual dones from 24 weii trays were cultured with autologous irradiated
PBL (25 x 10® per well) and irradiated TLC6 (5 x 10® per well) in a total volume of 200 ui. Gones T ceils from the same donor but with a different anagen speahary
(HA1.9) together with autologous PBL. PBL alone or induenza A virus (A Texas/1/77; 5 ha*wi«qghinn""f|g units (HAU) perml) in the presence of PBL were added
as controls. After 72 hours, cultures were pulsed with 1.0 p.C of JH-TdR and cells were collected 16 hours later. Incorporation of ®H-TdR was measured by liquid
scintillation spectroscopy. Results are expressed as mean c.p.ra.:=s.e.m. We have checked AG50 for its reactivity with other helper dones from the same individual
but with different fine specificities. It did not react with 2 other helper clones (HA1.7, HA1.9) as well as other autologous clones (37, 53. 72).
2
Table 2 Anri-idiotypic activity of clone AC50
Antigen
Clone AC50"
(5 x 103)Clone no. (5 x 102) (1 x 103) Medium TCGF
6 820=124 1.160=169 2.274=322 17 = 4 3,472=313
6^E~* 3,413=369 4,074= 254 5.328= 590 31 = 16
6t-E"fFlu 10.311 = 2,404 8,902= 866 7,386=1,063 9.360=495
37 43 = 9 59=8 65=16 35=3 8,551 = 1137
37 T-E" 38= 8 71 = 18 32=4 53 = 13
37-rE" -r Flu 13,569=1,861 9,978= 1.348 11.703 = 1,018 14,325 = 2.543
53 27=4 35 = 12 17= 6 25=6 6,217= 491
53 + E~ 33=5 18 = 2 24=2 12=1
53^E~ + Flu 4,261=434 4.954=129 6.203 = 631 4,829= 686
72 23=1 8 = 2 19=5 20=5 4,142=474
72 +E" 41=14 26= 3 13=2 29=3
72 Flu 7,443=1035 7.248=131 8.130=1076 7,055 = 360
HA1.7 17= 2 15 = 2 10=3 31 = 6 3,447=122
HAl.7—E" 33 = 1 43 = 8 18 = 2 12=1
HA1.7 +E" + Flu 3.625=329 4.288 = 372 4,100=105 3,814 = 261
CTLL 58 49=11 115 = 17 73=14 •10,361 = 1,895
CTLL-E" 101 146= 23 742=109 60= 8
CTLL-E"-Flu 20.183 17.081 = 3.036 15,622=U88 18,762=2^73
Various numbers of irradiated AG50 cells (5 x 102, 1 x 103 and 5 x 103 per well) were cultured with a panei of influenza A virus-specific TLCs
(5 x 103 per well) in the presence or absence of autologous irradiated sheep erythrocyte (SRBO rosette negative (E~) ceils (5 x 103 per well) and
Influenza A virus. E~ cells were separated from those cells forming rosettes with AET (aminoethyiisoethiouronium bromide hvdrobromide)-treated
SRBC by centrifugation over Percoll (1,080 gmi~l). Proliferative responses were determined by the incorporation of 3HTdR as described in the
legend to Table 1. Results are expressed as mean c.p.m. (=s.e.m.). CTLL. influenza specific T lymphocyte line.
' E~ and AC50 irradiated 2.500 rad. ^
We argued that if receptors on AC50 recognized anti-"I2-C6
receptors, then TLC6 might be stimulated to respond to irradi¬
ated AC50 in vitro, as its receptors would be bound. Thus a
variety of influenza specific clones (ail from the same donor)
were stimulated with irradiated clone AC50, or AC50 plus
irradiated E" ceils (T depleted cells) as a source of antigen
presenting cells. As a control the response to AC50, PBL and
influenza virus was assayed. As shown in Table 2, all the clones
responded to i nfluenza virus and TCGF, but only TLC6 respon¬
ded to AC50, with or without the addition of irradiated E~
cells. This result is compatible with the notion that AC50 is an
auto anti-idiotype clone, that is, recognizes antigen-specific
receptors on TLC6. The response in the absence of additional
antigen presenting ceils (APC) is of interest, implying that the
reaction between TLC6 and AC50 may not require antigen
presenting ceils. However, a few APC, which had not adhered
to the plastic in the week of culture since irradiated PBL were
added could still have been present, and this question needs to
be analysed in detail. It is of interest that Infante eral.10 recently
found that anti-idiotype antisera stimulate mouse T cell ciones
to proliferate even in the absence of added antigen presenting
cells, in analogy to the results shown here with anti-idiotype T
ceils.
Table 3 Lack of back sumuiauon in mixed cultures ofAC50 andTLC6
Responder Stimulation (c.p.m.= s.e.m.)
ceils AC50 6 AC50-r6 FluA Medium TCGF
CTLL 43 17 31 15 23 6.503
=7 =4 =9 =2 =6 =294
CTLL+E" 12 21 57 14,689 27 —
=5 =5 =8 =2^29 =4
Irradiated AC50 (5 x 103 cells per well) and TLC6 (5 x 103 cells per
well) were cultured alone or together with an influenza specific cultured
T lymphocyte line tnot the same as in Table 2) CTLL (5 x 103 cells per
well) in the presence or absence of autologous irradiated E" cells. As
controls CTLL cells were cultured with and without irradiated E~ cells
and influenzaA virus. Proliferative responses were measured and results
expressed as described in Table 1.
The results in Table 2 indicate that AC50 and TLC6 interact
in a specific manner. But they do not conclusively indicate that
the reaction is anti-receptor. An alternative interpretation is
that the proliferation of TLC6 is due to back stimulation3*11
with irradiated AC50 recognizing TLC6, and it is the release
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Cloned helper T ceils (TLC6; 2.5 x 103 per mi) or E" ceils (5 x 103
per mi) were cultured with autologous E~ cells in the presence of
influenza A virus (A/Texas/1/77; 05 HAU ml"1) in RPMI 1640
supplemented with 10% horse serum in 96 well round bottom micro¬
titre trays. TLC AC50 ceils were added at 50. 250 and 500 cells per mi
at the initiation of the cocultures each of 200 pi. After 6days incubation
at 37 °C. triplicate cultures were washed and recultured in 150 pi of
RPMI 1640 supplemented with 5% fetal calf serum (FCS). Supernatant*
were collected after 24 h and assayed for and-A/Texas/1/77 antibody
using a solid phase enzyme immunoassay. Antibody production was
determined by reading absorbance at 405 nm of the transformed sub¬
strate of alkaline phosphatase9. The actual amount of antibody
(ngmi"1)=standard error of triplicate cultures. Results are expressed
as the mean (ngmi"') and for each triplicate the s.e. was <20%.
Background responses of TLC6. E~ and E~ cultured alone or with
influenza A virus were measured. " 5 x 103 ml"'; * 2.5 x 103 mi"1.
Autol. E" A/Texas/1/77
Heiper (5 x 103 (0.5 HAU





of lymphokines from irradiated AC50 which causes TLC6 to
incorporate thymidine. This possibility was investigated, using
a cultured (not cloned). T lymphocyte line (CTLL) which
responds well to TCGF (Table 3). Amixture of irradiated AC50
and TLC6 could not stimulate CTLL to proliferate (31 c.p.m.1
in contrast.to TCGF (6,503 c.p.m.), as shown in Table 3. There
was no effect ofAC50 andTLCS even in the presence of E- ceils.
Thus the induction of thymidine incorporation in TLC6 by
AC50 was not due to back stimulation, and thus the bidirec¬
tional nature of the TLC6-AC50 interaction and its specificity
for TLC6, but no other autologous clones would appear to
indicate that AC50 recognizes antigen-specific receptors on
TLC6. Because the reaction is autologous, and specific for
TLC6 it cannot be directed against MHC or differentiation
antigens. The criteria we have used to define the anti-idiotype
nature of clone AG50 (that is, specificity, stimulatory effects)
are the same as used for anti-idiotypic antisera (discussed in
reis 10, 12).
The effects of done AC50 on the helper response of TLC6
were assessed in vitro (Table 4). Very small numbers of AC50
diminished the response. Only 10 done AC30 ceils inhibited
the helper response of 500TLC6 (to 100,000 E~ cells in a
200 pi culture volume) by 95%. Fifty cells of AC50 per culture
abolished the response altogether. These results indicate that
AC50 is a potent suppressor ceil. The mechanism of suppression
is unknown, but it is unlikely, due to the ratio of ceils used (1
suppressor to 50 helpers) and the capacity of irradiated AC50
to induce TLC6 to incorporate thymidine (Table 2), that AC50
is cytotoxic for TLC6. "Hie mechanism of suppression remains
to be eluddated. but because it occurs at the clonal level should
be amenable to predse analysis.
These results indicate that as in the mouse, it is possible to
generate a human spedfic suppressor T cell done dependent
on IL-2. In contrast to the mouse suppressor cell clone, specific
for antigen, the spedfidty of the human suppressor clone was
for the immunizing cell (and not oshei*autologous helpers). The
redprocai stimulation, in the absence of back stimulation, sug¬
gests that the target of AC50 is the receptor for antigen of
TLC6. This is a direct experimental test of the 'idiotvpe
network' at the T ceil level. The potency of the suppressor
erfect suggests that this type of suppressor ceil may be of major
importance in immune regulation.
The generation of suppressor T ceils recognizing heiper ceil
receptors resembles work reported by Binz and Wigzeil. who
injected antigen-spedfic lymphobiasts into autologous mice'3.
Spedfic unresponsiveness resulted, which was mediated by
either T killer, suppressor or heiper ceils, or B ceils13. Concep¬
tually the results are analogous, but the experiments reported
here were performed entirely in vitro, and at the donai rather
than the population level. There are reports of suppressor ceil
pathways to the haptens nitrophenyl (NP) or azobenzene arson-
ate (ABA) for delayed hypersensitivity which involve second
order suppressor ceils, which recognize idiotype bearing ceils14.
However, the final suppression was not idiotype spedfic15.
These experiments were also performed at the population level.
By possessing a clone of suppressor cells (AC50), spedfic for
a clone of heiper ceils (TLC6), we have a powerful system for
analysing the mechanism of T ceil suppression. There is no
reason to believe that the prindple demonstrated here will not
apply with other dones. Thus, situations with undesirable clones
of heiper (or killer) ceils such as autoimmunity or perhaps even
leukaemia may be controllable by suppressor ceils of this type,
generated in vitro.
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Inhibition of human T-cell responses to house
dust mite allergens by a T-cell
receptor peptide
Elizabeth R. Jarman, BSc, Catherine M. Hawrylowicz, PhD,
Elizabeth Panagiotopoiou, MD, Robyn E. O'Hehir, MD, PhD, and
Jonathan R. Lamb, PhD London, England
Recent analysis of the usage of T-cell receptor (TcR) /3 chain variable region (Vf3) gene
elements by house dust mite (HDM)-reactive T cells from an atopic donor suggested that
TcR-Vf33 gene products may form a major component of the human T-cell repertoire reactive
to this common allergen. In this study a peptide analog of the TcR-V/33 complementarity
determining region 2 (CDR2) is shown to inhibit the polyclonal human T-cell response to
HDM; this effect is specific because inhibition is dependent on the presence of V/33+ T cells.
This experimental approach has been used to determine whether the pattern seen in-T-cell
clones derived from one atopic donor reflects TcR-VR usage in the polyclonal response to
allergen in the general population. Inhibition ofmore than 50% of the polyclonal response to
allergen by Vf33-CDR2 peptide was observed in 16 of 21 donors tested, suggesting that
TcR-Vf33 gene usage may form a major component of the human HDM repertoire and as such
offer a suitable target for T cell-directed specific immunotherapy in HDM-ailergic individuals.
Depletion of CD8+ T cells abolishes peptide-mediated inhibition of CD4 •+■ T-cell proliferation
to HDM, suggesting that induction of a CDS+ regulatory T-cell subset by the CDR2 peptide
may modulate HDM-spccific allergic T-ceil responses. (JALLERGY CLIN IMMUNOL
1994:94:844-51)
Key words: House dust mite, T cells, TcR-CDR2 peptide
CD4 + T lymphocytes from atopic individuals
recognize processed fragments of allergens from
house dust mite (HDM) bounci to major histo¬
compatibility complex (MHC) class II molecules.
These T ceils become activated to induce and
regulate the effector mechanisms, including the
production of IgE and the activation of inflamma¬
tory cells, of the allergic immune response.1- 2 The
capacity to specifically downregulate antigen-
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Abbreviations used
CDR2: Complementarity determining re¬
gion 2
EAE: Experimental allergic encephalomy¬
elitis
HDM: House dust mite
IL-2: Interieukin-2
MHC Major histocompatibility complex
MTSE: Mycobacterium tuberculosis soluble
extract
PBMCs: Peripheral blood mononuclear cells
TcR: T cell-specific antigen receptor
VP: Variable region of the 3 chain of the
T-cell receptor
mediated stimulation of allergen-reactive CD4 +
T cells from atopic individuals may provide a
means to alleviate the symptoms of allergic disease
without the undesirable and long-term side effects
associated with the nonspecific immunosuppres¬
sive therapies currently in use. Evidence for the
344
J ALLERGY CLIN IMMUNOL
VOLUME 9*. NUMBER S
Jarman et al. 845
recognition of a limited array of HDM epitopes or
the recruitment to the disease site of T cells
expressing T cell-specific antigen receptor (TcR)
with shared characteristics would allow these cells
to be specifically targeted and facilitate the devel¬
opment of TcR-based immunotherapy.
Recent experiments in our laboratory have
demonstrated that T lymphocytes from an atopic
individual with allergy to HDM show a bias in
usage of TcR-V|3 gene elements. This was dem¬
onstrated with anchor polymerase chain reaction
analysis of T-ceil clones derived from peripheral
blood that were reactive with HDM. Of 10 clones
analyzed, six different TcRotfi chain combinations
were identified of which three, or 50%, used V(33
and the others used V(36.7a, V(39, and V(321. This
TcR-Vp gene usage appears to persist with time
because when the same individual was tested over
a period of several years, the HDM-reactive TcR
repertoire appeared unchanged,3 and dominant
long-lived clones could still be detected in the
periphery 6 years later. If the same pattern of
restricted Vp gene usage observed in T-cell clones
derived from a single atopic individual is repre¬
sentative of the polyclonal response observed in
the majority of HDM-allergic individuals, it may
be possible to design specific immunotherapy for
HDM-allergic individuals by targeting allergen-
reactive T cells with restricted»V(3 usage. In an
earlier study analysis of TcR-Vp usage by HDM-
reactive T cells at the population level was limited
by the requirement to, clone, confirm antigen
specificity, and perform anchor polymerase chain
reaction and sequence analysis of the TcR reper¬
toire of multiple T-cell clones derived from a
large number of individuals. We have circum¬
vented this approach by using an experimental
design that permits analysis of VP3 usage in the
polyclonal response to HDM.
The T cell-specific antigen receptor is a mem¬
ber of the immunoglobulin superfamily of mol¬
ecules, and the variable regions of both the a.
(Va) and p (Vp) chains of the TcR have four
hypervariabie loops, also known as complementa¬
rity determining regions (CDR1, 2, 3, and 4),
which form the antigen-binding regions.'* CDR3
appears to be the most diverse of these regions
and is believed to be involved in antigen contact.
The CDR1 and CDR2 regions are implicated in
MHC binding.3 The fourth hypervariabie region,
CDR4, appears to participate in superantigen
binding.3 Recent experiments in rodent models
suggest that these regions of the TcR not only
serve to promote antigen and MHC binding but
may also (in particular the VP-CDR2 region)
serve as an antigenic determinant or recognition
site for regulatory T cells.7"'
"Disease-associated" T cells that preferentially
use selected TcR gene products have been iden¬
tified in animal models of experimental allergic
encephalomyelitis' (EAE). Encephaiitogenic T
ceils in both rat and mouse EAE express pre¬
dominantly TcR-Vp8.2 genes, and immunization
with a synthetic peptide corresponding to the
CDR2 of TcR-V(38.2 prevents clinical signs of
disease.7"12 We have tested the capacity of a
CDR2 peptide derived from the'human TcR-V(33
to modulate the polyclonal human T-cell response
to HDM allergen. We demonstrate that this pep¬
tide specifically inhibits the antigen responsive¬
ness of Vp3-expressing T cells, and we have used
this observation to study the contribution of VB3
T cells to the HDM response in the population as
a whole. A panel of HDM-primed, genetically
unrelated individuals was chosen for this study.
Inhibition of more than 50% of the polyclonal
response to HDM by CDR2 peptide was observed
in 75% of all individuals tested; less than 10% of
donors showed no inhibition of CDR2. These
data suggest that TcR-V(33 usage may form a
major componenrwithin the HDM-reactive T-cell
population and may thus provide a target for
immunotherapy. Studies into the mechanism of
CDR2 inhibition are also presented.
METHODS
Patients
The atopic status of patients with HDM allergy was
defined by the presence of a positive skin prick test
responseu-14 (wheal diameter 2 3 mm) to Dermatopha-
goides pteronyssinus and D. fartnae extracts in the pres¬
ence of a negative saline control. Sixteen HDM-allergic
atopic subjects, aged 15 to 60 years, were included in
the study. All of these individuals had clinical symp¬
toms of HDM allergy (perennial rhinitis and/or asthma)
and had grade HI or IV serum-specific Ig£ for HDM as
measured by RAST.
Nonatopic status was defined in a subject who was
free of symptoms by the absence of positive skin prick
test responses to a panel of common environmental
allergens (D. pteronyssinus, D. farinae, mixed grass pol¬
len, birch pollen, plane tree, nettle, Aspergillus fumiga-
tus, Cladosporium herbarium) in the presence of a
positive wheal response to histamine hydrochloride
(1 mg/mi) of 3 mm or greater and a negative response
to a saline control. Five normal healthy nonatopic
individuals were used for this study. All had negative
skin prick test results and normal total IgE levels.
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Antigens
Lyophiiized, unfractionated extracts of D. pteronyssi¬
nus and D. farinae were generously provided by Dr.
A. Wheeler (SraithKline Beecham PLC Brentford.
Middlesex. U.K.) and Dr. H. Lowenstein (ALK Labo¬
ratories. Horsholm, Denmark), respectiveiy. Mycobacte¬
rium tuberculosis soluble extract (MTSE) was a kind gift
from the TB and Related Infections Unit at Hammer¬
smith Hospital, London.
Peptides
The CDR2 40-61 (GLGLRUYFSYDVKMKEK-
GDI) peptide used overlaps the predicted region for
the second hypervariable region of the TcR-Vf33 ex¬
pressed by the CD4+ T-cell clone HA1.7. Influenza
virus hemagglutinin peptide HA 307-319 (PKYVKQN-
TXKLAT), keratin peptide Kl-9 (QRQRPAEIK), and
CDR2 40-61 were synthesized by use of standard solid-
phase methods, purified by high-performance liquid
chromatography, and identified by amino acid sequence
analysis.'3
Antibodies
Jovi 1J ceils, which secrete a murine monoclonal
antibody specific for human TcR-V(33," were a kind
gift of Dr. I. Viney (Imperial Cancer Research Fund,
London. U.K.). Antibodies for cell staining and
population analysis were all purchased from Becton-
Dickinson (Oxford. U.K.).
T-cell prgliferation assays: Clonal
The T-cell clones used in these experiments were
isolated as previously described." HA1.7 was reac¬
tive to HA 307-319 peptide and expressed the V03
TcR, and the two HDM-reactive (responsive to both
D. pteronyssinus and D. farinae) clones DE26 and DE9
were TcR-V03 and TcR-V06.7a, respectively. For pro¬
liferation assays the ceils were cultured at 2 x 10* per
well in round-bottom 96-well microtiter plates in com¬
plete RPMI-1640 medium (Gibco. Paisley, Scotland)
supplemented with 2 mmol/L L-glutamine, 100 U/ml
penicillin/streptomycin and 5% screened, heat-inacti¬
vated. A- human serum (North London Blood Trans¬
fusion Service). An equal number of autologous Ep-
stein-Barr virus-transformed B cells (5000 rad) or pe¬
ripheral blood mononuclear cells (PBMCs) (2500 rad)
of the correct haplotype were used as antigen-present¬
ing ceils. HA 307-319 or D. fartnae and CDR2 40-61
were added at the concentrations indicated to the
apppropriate wells to produce a final volume of 200 pi.
As a control for toxicity, cells were incubated with
CDR2 40-61 and 10% interieukin-2 (IL-2) (Lympho-
cult-T; Biotest Foiex, Frankfurt. Germany) or in wells
coated with anti-CD3 (10 |ig/ml for 30 minutes at
37° C) and IL-2. After 72 hours of incubation, tritiated
methyithymidine (1 p,Ci/weil; Amersham International
Inc.. Ameisham, U.K.) was added to cultures, which
were harvested onto glass fiber filters 8 to 16 hours
later. Proliferation was measured as tritiated meth¬
yithymidine incorporation per culture by means of
liquid scintillation spectroscopy with the results ex¬
pressed as mean counts per minute for 3 to 9 replicate
wells. Standard deviation rarely exceeds 20%.
T-call proliferation assays: Polyclonal
PBMCs from nonatopic and atopic donors were
separated by discontinuous density centrifugation over
Ficoil-Hypaque (Pharmacia Ltd., Milton Keynes, U.K.).
PBMCs (1 x 103) were incubated in 96-well round-
bottom microtiter plates with various combinations of
HDM antigen (D. pteronyssinus extract) and CDR2 or
Kl-9 peptides at the concentrations Indicated. PBMCs
were also Cultured with 10% IL-2, on plates coated with
anti-CD3 antibody and IL-2, with the T-cell mitogen
phytohemaggiutinin protein (10 p.g/ml; Sigma Chemical
Co., St. Louis, Mo.), MTSE, or the bacterial superan-
tigen Staphylococcus aureus enterotoxin B (at 0.01 to
1 ii.g/mi, Sigma) in the presence or absence of CDR2
peptide. Complete RPMI-1640 medium was used at a
final volume of 200 pi. After 6 days, cells were pulsed
with 1 p.Ci/weil of tritiated methyithymidine for 8 to 16
hours, after which the cells were harvested and prolif¬
eration measured as described above for T-ceil clones.
Vp3+, CD4+, and CD8+ T-call depletions
PBMCs were depleted of V03 + , CD4+ , or CD8 —
T cells, respectiveiy by immunomagnetic separation
with Dynabeads (Dynal, New Ferry, U.K.) used ac¬
cording to the manufacturer's instructions. Briefly, to
deplete PBMCs of V03-t- cells, they were incubated
with Jovi 1J culture supernatant on ice for 30 minutes.
Cells were then washed in the cold, and sheep anti-
mouse Ig-conjugated magnetic beads were added at the
approximate ratio of 10:1 beads to V03 + T cells. The
beads were washed three times before use to ensure
complete removal of the azide in which the beads are
stored. The mixture was rotated in the cold for an
additional 30 minutes, and then V(33 — T cells were
removed by a magnet. PBMCs were depleted of more
than 90% CD4+ or CDS- T cells in a similar fashion
with commercially available Dynabeads coated with
monoclonal antibodies binding the CD4 or CD8 an¬
tigens on human T ceils. For CD8 depletion, two
rounds of magnetic depletion were performed to op¬
timize elimination of contaminating CD8 +■ T ceils. The
cells were analyzed by flow cytometry (Coulter EPICS
Profile II; Coulter Corp.. Hiaieah, Fla.) to ensure
purity.
RESULTS
Inhibition of polyclonal T-call responses to
HDM by VP3-CDR2 peptide
A peptide derived from the CDR2 region of
the TcR-V|33 has been tested for its capacity
to selectively inhibit the response of V(33-r,
HDM-reactive human T ceils. PBMCs from an
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atopic individual were stimulated with HDM
antigen, D. pteronyssinus extract over a concen¬
tration range of 5 to 20 fig/ml in the presence
or absence of CDR2 peptide, residues 40-61,
derived from the human TcR-V(33 sequence.
Addition of the V(33-CDR2 peptide resulted in
a dose-dependent inhibition of polyclonal T-cell
responses to D. pteronyssinus (Fig. 1, A). In a
second donor substantial inhibition of the poly¬
clonal response to HDM by the CDR2 pep¬
tide, but not by a control peptide derived from
keratin (residues 1-9; Fig. 1, B), was observed.
A second control peptide, overlapping the CDR2
region of a murine TcR-V[38 gene failed to in¬
hibit the HDM response in five individuals: mean
inhibition values in the presence of murine CDR2
TcR-Vp8 and human CDR2 TcR-Vp3 pep¬
tides were 4.4 * 8.6 versus 52.0 £ 22.0, respec¬
tively.
The effect of the CDR2 peptide on peripheral
T cells stimulated with either HDM or an irrel¬
evant antigen, MTSE was also compared, and in
contrast to HDM, the response to MTSE was not
inhibited by the CDR2 peptide (Fig. 1, C). Fur¬
thermore. when investigated at concentrations of
up to 300 n-g/'ml. the CDR2 peptide was not
mitogenic and unable to inhibit T-cell prolifera¬
tion stimulated by exogenous IL-2, by mitogens
such as phytohemagglutinin profpin, by cross-
linked anti-CD3 antibody plus IL-2, or by the
bacterial superantigen S. aureus enterotoxin B
(data not shown).
Specificity of V{$3-CDR2 peptide action
To demonstrate that CDR2 peptide inhibition
of the HDM response is VfS3-specific, the effects
on Vf33-depleted and unfractionated PBMCs
were compared. After greater than 90% depletion
of Vp3-expressing T cells from PBMCs with a
V(33-specific mononcional antibody, a vigorous
response to antigen was still observed, presumably
reflecting the contribution of other TcR-Vp re¬
gions, including V(36.7a and Vg21, to the HDM
response.3 However, after V03 - T-cell depletion,
the HDM response was completely refractory to
CDR2 peptide inhibition (Fig. 2,A and B). These
experiments confirm that inhibition by TcR-Vp3
CDR2 peptide of the polyclonal human T-cell
response to HDM is dependent on the presence
of VP3+T cells.
Population study
Because V(33-CDR2 peptide inhibition of the









FIG. 1. Modulation of antigen-dependent polyclonal hu¬
man T-cell responses by a synthetic peptide correspond¬
ing to the CDR2 region of the human TcR-Vp3. PBMCs
(1 x IQVwell) were stimulated in 96-weil microtiter piates
with (A) 5 to 20 M.g/ml HDM allergen I'D. pteronyssinus)
alone (open circles) or with 10 to 50 p^g/ml CDR2 peptide
(filled symbols), (B) 20 p^/ml HDM in medium or together
with 25 M-Q/ml CDR2 or keratin (K1-9) peptides, or (C)
jig/ml HDM or MTSE control antigen in medium or with 20
CDR2 peptide. The experiments shown in panels A to C
were performed with PBMCs derived from three separate
donors. T-ceil responses were assessed as tritiated meth-
ylthymidine uptake as described in the Methods section.
Data are presented as mean tritiated methylthymidine
incorporation from replicate (3 to 9) wells with a standard
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FIG. 2. Vg3-r T-cell depletion leads to loss of CDR2 inhi¬
bition of the HDM response. Unfractionated (A) or VB3-
depleted (B) PBMCs were cultured with HDM in the pres¬
ence or absence of 25 ng/ml CDR2 peptide as described in
the legend to Fig. 1 and in the Methods section.
cific, we have used this experimental approach to
determine what percentage of HDM-reactive in¬
dividuals have HDM responses inhibited by this
peptide. A population of HDM-reactive individu¬
als who were first seen with a wide range of
clinical symptoms, ranging from mild atopy to
severe asthma, was selected at random from the
allergy clinic. These individuals were unrelated
and assumed to show no skewing or bias in HLA
or other genetic haplotypes. Included in this study
were five unrelated, nonatopic individuals who
showed in vitro responsiveness to HDM. The
earlier data obtained in studies with a single
individual suggested that TcR-V(33-expressing
ceils may be dominant in the HDM-reacrive T-ceil.
repertoire,3 and this study of 21 donors suggests
that this may be true within the population as a
whole. Of 16 atopic donors tested, only two failed
to show substantial inhibition of the HDM re¬
sponse by the CDR2 peptide. The magnitude of
modulation varied considerably between donors
(range 9% to 92%), presumably reflecting differ¬
ences in the relative contribution of TcR-V(33 to
the HDM response between individuals. It seems
unlikely that when very high inhibition (> 90%) of
the HDM response occurs, the T-cell response of
that individual is solely represented by V(33-ex¬
pressing T cells. Rather, it seems probable that
regulatory mechanisms induced by the CDR2
peptide in culture may have bystander effects on
the polyclonal response to allergen.
There was no marked difference in the ability of
the CDR2 peptide to inhibit the HDM response of
either atopic (mean inhibition, 53.4% ± 25.0%) or
nonatopic- individuals (mean inhibition, 59.6% ±
9.3%) (Table I). Therefore although the same an¬
tigen appears to activate peripheral T cells hum
both atopic and nonatopic individuals, the func¬
tional consequences of T-cell activation differ be¬
tween the two groups.18
Effect of COR2 peptide on the response of
HDM-specific T-ceil clones
Two CD4-r V(33+ human T-cell clones, one
reactive with a peptide derived from influenza vi¬
rus hemagglutinin (HA 307-319), the other with
HDM, and a third Vj36.7a-I-, HDM-reactive T-cell
clone were all resistant to CDR2 peptide-induced
inhibition (Table I). This finding suggests that the
modulatory effect of the TcR peptide may not sim¬
ply be explained by a direct effect on the CD4-I-
V33 + antigen-responsive T-ceil population.
Role of CD8+ T cells
In animal studies it has been proposed that
CDR2 inhibition of antigen-induced EAE acts
through the induction of a CD8-r regulatory
T-cell population.8 To assess evidence for a simi¬
lar regulatory population in human beings, the
capacity of CDR2 peptide to inhibit the HDM
response in unfractionated or CD8 +-depleted
human PBMCs was compared. With the use of
antibody-conjugated magnetic beads, depletion of
CD4 or CD8 populations by more than 90% was
routinely achieved. The response to antigen was
only observed in the CD4 + T cell-enriched
population (Fig. 3, A). Nevertheless, after deple¬
tion of the CD8 — cells, the capacity to modulate
the response by TcR peptide was lost (Fig. 3, B
and C). CDS + T-cell depletion resulted not only
in loss of inhibition of the HDM response by the
CDR2 peptide, but led to an increased response
in the presence of the peptide. A similar increase
was also observed after depletion of V(33 + T ceils
from PBMCs (Fig. 2). The reason for this is as yet
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TABLE I. Inhibition of HDM allergen—dependent T-cell responses of HDM-allergic individuals
Tritiated thymidine incorporation (cpm)
Medium D. pter D. pter 4* CDR2 Inhibition (%)
Donor
Al 3,004 14,568 6,681 54
A2 1,031 32216 21,454 33
A3 428 37208 20265 46
A4 3,037 112067 20206 82
A5 324 25,400 7,956 69
A6 251 13289 4,320 68
A7 486 27.886 24,165 13
A8 265 22294 7,784 65
A9 881 63,035 51201 9
A10 5,988 16,246 7,993 51
All 679 23,363 7,610 67
A12 1227 73.281 33,716 54
A13 634 22117 13,241 41
A14 397 66,297 5,162 92
A15 947 45251 15,964 65
A16 3,798 27238 9,359 66
NA1 356 5275 1221 76
NA2 467 71,003 32354 55
NA3 759 15,629 6,731 57
NA4 378 26,703 12483 53
NA5 4,744 32415 13,763 57
T-cell clones -
HA1.7 (Vp 3; HA) 70 12800 13283 0
DE26 (Vp 3; HDM) 2,954 15265 15265 0
DH9 (Vp 6.7a; HDM) - 2275 27,788 27,179 2
PBMCs from 16 atopic (Al-16) and five nonatopic (NA1-5) donors were cultured as indicated in Fig. 1 in medium alone or with
20 y.g/ml HDM in the presence or absence of CDR2 peptide (data shown are for the concentration of CDR2 producing maximal
inhibition of the HDM response for each donor A2 10 p-g/mi, the rest 25 or 50 ng/ml). T-ceil clones (HA 1.7, DE26 and DE9)
were cultured at 2 x 104 ceils/well in the presence of an equal number of irradiated (2500 rad) histocompatible PBMCs in
medium. 1 jig/ml HA 307-319, or 20 p-g/mi D. format, respectively in the presence or absence of 25 p.g/mi CDR2 peptide; and
proliferation was measured on day 3 as described in the Methods section.
D. pter, D. pceronyssinus.
unclear, but it might reflect the presence of a
subpopulation of CD4+ T ceils that are also
CDR2-reactive (buf non inhibitory). It seems
likely that, as in the animal studies, a CD8 -
T-cell regulatory subset is induced by the CDR2
peptide that modulates the allergen responsive
CD4+ T-cell population.
DISCUSSION
In this report we demonstrate that a TcR pep¬
tide, based on the sequence of the CDR2 region
of the TcR-VflS gene segment, downregulates the
human polyclonal T-cell response to HDM. This
effect is specific because it is dependent on the
presence of Vf33+ cells in the stimulation culture.
In an earlier study we demonstrated, using anchor
polymerase chain reaction analysis, that T-cell
clones specific for HDM, derived from a single
atopic individual, showed a bias towards TcR-VS3
usage. In this study inhibition of the polyclonal
response to HDM by CDR2 TcR-Vf33 peptide in
the majority (16 of 21) of donors examined has
been used to demonstrate that a bias toward V|33
usage occurs not only in clones but, more rel¬
evantly, among the polyclonal responses of pe¬
ripheral blood derived, HDM-responsive T cells
within the population as a whole. Although T cells
expressing TcR other than Vp3 clearly contribute
to the overall HDM-reactive repertoire,3 our re¬
sults demonstrate that Vf33 + T cells are a major















FIG. 3. Effect of CD8+ cell depletion on CDH2 modulation of the HOM response. A. PMBCs were
depleted of either CD4+ or CD8 — cells with specific antibody directly conjugated to magnetic
beads, and the proliferative response to HOM of unfractionated. CD4-depieted. or CD8-depleted
PBMCs was compared. B, Unfractionated or (C) CD8-depleted PBMCs were cultured with HOM
and 25 pg/ml CDR2 peptide.
component of the HDM-reactive repertoire. Al¬
though the relative contribution of V(33 + T ceils
to the HDM response will vary between individu¬
als, because inhibition of up to 90% is achievable,
it is possible that once the regulatory mechanism
has been activated, nonspecific bystander mecha¬
nisms may operate to dampen the polyclonal
response to antigen.1®"21 An example of this has
been described in the model of murine responses
to the group I allergen ofD. pieronyssinus in which
intranasal administration of an immunodominant
peptide was able to toierize mice to subsequent
challenge with the intact protein.21
The goal in the treatment of immunologically
mediated diseases has been to design therapies
that specifically target T lymphocytes that induce
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or regulate the disease process and to avoid
nonspecific immunosuppressive regimens and the
long-term problems associated with their use. To
design such therapies, it is necessary to define the
dominant T-ceil epitope, the presence of limited
TcR usage or HLA restriction involved in the
disease inducing immune response, which can be
specifically targeted. The design of this study
demonstrates that it is possible to use peptide
analogs of the appropriate TcR-Vp region to
specifically target and significantly inhibit the pro¬
liferative response of allergen-reactive T cells.
Although these studies have as yet only demon¬
strated inhibition of the human T-cell response to
allergen in vitro, it is noteworthy that similar
studies have been performed in vivo in both rat
and mouse models of EAE, in which restricted
V|38.2 usage by encephalitogenic T cells was ob¬
served. In these studies the appropriate CDR2
peptides not only prevented the onset of clinical
disease but also, more practically, caused regres¬
sion of ongoing EAE.12
Initial studies to address the mechanism
whereby CDR2 peptides modulate the polyclonal
response to allergen suggest that induction of a
CD8- regulatory T-cell subset by the peptide,
which modulates the responsiveness of HDM-
responsive T cells, may occur. In experiments with
T-cell clones we find no evidence for a direct
effect of the peptide on HDM-ceactfve T ceils,
which suggests that the CDR2 peptide is not
directly binding the TcR, nor is it competing with
antigen at the level of MHC binding. Failure to
block phytohemagglutinin or anti-CD3-induced
T-cell proliferation suggests that the CDR2 pep¬
tide does not act through CD2 or the T cell-
specific antigen receptor. More direct evidence
comes from studies in which depletion of CD8 -
T cells from the HDM stimulation cultures leads
to loss of CDR2 peptide-mediated inhibition.
The antigenic peptide recognized by the putative
"regulatory" CD8+- T-ceil subset, which is pre¬
sumably derived from the sequence of TcR ex¬
pressed on Vp3+ HDM-reactive CD4-r T cells,
and the mechanism or mechanisms by which the
CD8-1- T cells modulate the response of these
cells remain to be clarified in future experiments.
TcR peptide-based therapy may have broader
applications in allergic and autoimmune diseases
in which TcR gene usage is reported to be re¬
stricted (e.g., multiple sclerosis and myasthenia
gravis in which VB5.2 and V(312, respectively, are
implicated).22"2* In certain diseases, however, such
as rheumatoid arthritis, the observed TcR expres¬
sion of cells infiltrating disease sites appears to be
patient-specific rather than disease-specific, and
involves multiple VP families.25-28 Nevertheless,
specific therapy based on TcR structure may have
a practical application in allergic disease. The
inactivation of selected components of the specific
T-cell repertoire, such as those T cells that ex¬
press the dominant TcR-Vp specificity and repre¬
sent long-lived allergen reactive clones,3 may be
sufficient to downregulate the severity of the
clinical phenotype.
We thank Drs. Brigitte Askonas and Richard Lake
for critical comments on the manuscript, and Mr. John
Hayball for the synthesis of peptides used in this study.
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Abstract
Background: Peripheral tolerance is required to main¬
tain balance within the immune system. A feature of
peripheral tolerance is linked suppression, in which
tolerance induced to a single T cell epitope inhibits the
response to all epitopes in the same protein. It is
suggested that this phenomenon is mediated by regula¬
tory T cells through either the activity of immunopres-
sive cytokines or direct cell contact. In previous experi¬
ments we failed to detect inhibitory cytokines when T
cells from mice rendered tolerant by intranasal delivery
of the immunodominant peptide of Der p 1 (p 1,
110-131) were restimulated with peptide in vitro. There¬
fore, the aim of this study was to determine if cognate
interactions between T cells mediated by Notch/Delta
signaling induce and maintain peripheral T cell toler¬
ance. Methods: Using in situ hybridization and viral me¬
diated gene transfer, the expression and function of
Deltal were investigated in a murine model of T cell tol¬
erance to Der p 1 in vivo. Results: Deltal expression is
increased on peripheral T cells during the induction of
tolerance with high-dose peptide delivered intranasally
and when tolerant animals are rechallenged under im¬
munogenic conditions. Peptide p 1, 110-131-specific
CD4+ T cells transfected with Deltal inhibited the
response of antigen-primed T cells and induced linked
suppression. Conclusions: High-dose peptide delivered
intranasally induces transient expression of Delta 1 on
inhibitory CD4+T cells. Ligation of the Notchl receptor
on neighbouring T cells by Delta1+ regulatory T cells in¬
hibits clonal expansion of the former and mediates
linked suppression.
Introduction
Immune responsiveness to inhaled and ingested antigens
that are non-pathogenic occurs through the induction of pe¬
ripheral tolerance [e.g., 1], Several studies have now been
described in which the mechanisms underlying tolerance
induction following the delivery of antigen via mucosal
surfaces have been investigated [e.g., 1, 2-4], We have
demonstrated that intranasal administration of the immun¬
odominant T ceil epitope (residues 110-131) of the group 1
allergen of Dermatophagoides pteronyssinus. Der p 1, at
high doses induces extreme and long-lasdng tolerance [2.5,
6]. Tolerance to the immunodominant epitope inhibited T
cell responses to all other epitopes in Derp 1, provided that
tolerant mice were challenged with the intact protein. Fur¬
thermore, this phenomenon, which is termed linked sup¬
pression, was mediated by CD4+ T cells [6]. Linked sup¬
pression has also been described in other models of
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peripheral tolerance to transplantation and self-antigens
[7—9]. The processing and presentation of multiple epitopes
originating from within the same protein (Derp 1) by a sin¬
gle or neighbouring antigen-presenting cell brings regulato¬
ry and naive T cells into close proximity and facilitates, the
transfer of inhibitory signals between the T cell populations.
It has been proposed that the. secretion of immunosuppres¬
sive cytokines, such as interleukins 4 and 10 and transform¬
ing growth factor beta, provides the negative signals that
mediate the inhibitory effects observed in linked suppres¬
sion [e.g., 1, 9], However, we have been unable to detect ei¬
ther transforming growth factor beta or Th2-type cytokine
production by T cells from tolerant mice when restimulated
with peptide in vitro. Therefore, it is possible that linked
suppression in our system uses an alternative mechanism
which requires direct cell contact between the regulatory
and naive T cells, similar to that reported for bystander sup¬
pression mediated by anergic human T cell clones in vitro
[10, 11],
The Notch signalling pathway regulates the differentia¬
tion and growth of a range of tissues [e.g.. 12], including the
immune system, where in the thymus, for example, it ap¬
pears to play a role in T ceil development [e.g., 13]. In stud¬
ies on neurogenesis, in which this pathway has been studied
in most detail, it has been demonstrated that Notch sig¬
nalling regulates ceil differentiation through a cell contact
dependent mechanism, termed lateral inhibition [14]. This
mechanism involves the receptor Notch 1 binding to the lig-
and Delta 1. This prompted us to investigate whether
Notch 1/Deltal interactions between T cells contribute to
peripheral tolerance and mediated linked suppression.
Materials and Methods
In brief, two experimental protocols have been used in the experi¬
ments reported here. Firstly, the expression of Deital-specific tran¬
scripts, which are measured by in situ hyridization. in sections pre¬
pared from draining lymph nodes isolated from tolerant, immunized
and unprimed H-2b (C57BL/6J) mice at different time points. Toler¬
ance is induced as previously described [2]. Briefly, peptide p 1,
110-131 (100 pg), dissolved in phosphate-buffered saline is adminis¬
tered intranasally over 3 consecutive days. The draining cervical
lymph nodes and spleens are removed at selected times and T cell re¬
sponses measured in vitro. To assess responses in the rechallenge
phase of tolerance, peptide-pretreated and control mice are immu¬
nized with Der p 1 (50 pg) 2 weeks after treatment and responses
measured in vitro [2]. The second protocol* involves the adoptive
transfer of p 1, 110-131-specific CD4+ T cells transfected with
Deltal into naive mice. The mice are then immunized with Der p 1 in
adjuvant, and the proliferative response and cytokine production are
measured for splenic and draining lymph node T cells restimulated
with antigen in vitro.
Results and Discussion
Tolerance induced, by peptide delivered via the respira¬
tory mucosa resulted in a marked increase in the number of
Deltal-expressing cells as determined by in situ hyridiza¬
tion. The expression of Deltal was maximal at 2 days, but,
although still detectable on day 8, had declined.to approxi¬
mately 50% of peak levels. In contrast, Deltal transcripts in
uprimed mice were barely detectable. Rechallenging toler¬
ant mice with an immunogenic dose of Der p 1 in adjuvant
resulted in Deltal expression at levels higher than those
observed following tolerance induction. However, in¬
creased expression of Deltal was not seen following active
immunization of non-tolerant (naive) mice with Der p 1 in
adjuvant. These results demonstrate that Deltal expression
is transiently upregulated as a consequence of peptide-in-
duced tolerance. Furthermore. Delta 1 is re-expressed when
tolerant mice are exposed to antigen rechallenge under con¬
ditions that normally prime, and. therefore, this suggests
that Notch/Deltal signaling may be important in the main¬
tenance as well as in the induction of peripheral tolerance.
In order to further investigate the function of
Notch/Deltal signaling in T cell tolerance, the Deltal gene
was expressed in p 1, 110-131 reactive CD4+ T cells. The
Delta 1+ or control infected T cells were irradiated and
injected into naive mice which were subsequendy immu¬
nized with Der p 1 or ovalbumin in adjuvant. Lymph node
T cells from the mice that had received the Deltal+T ceils
and had been immunized with Der p 1 failed to proliferate
when rechallenged with Der p 1 in vitro. In contrast, T cell
responses in the mice that were primed with ovalbumin
remained intact. These studies were extended, and the T cell
recognition of minor (e.g.. residues 81-102) as well as the
dominant T cell epitope in Der p 1 was examined. We
observed that the adoptive transfer of the Deltal-t- T cells,
reactive with p 1, 110-131, inhibited responses to both the
dominant and minor determinants. The results of these
experiments suggest that CD4+ T cells expressing Deltal
mediate similar effects to regulatory T cells selected by
high doses of peptide in that they induce antigen-specific
peripheral T cell tolerance and mediate linked suppression.
Dunng the induction of tolerance, transient activation
and expansion of T cells occurs initially [e.g., 5, 6] which
suggests that tolerance does not occur as the result of defec¬
tive T cell receptor or costimuiatory receptor mediated sig¬
nalling. However, since the final functional outcome is un¬
responsiveness, other negative signals must override
costimulation which together with antigen recognition is re¬
quired for productive immunity. Our results suggest that in
peripheral tolerance Deltal transiently expressed on in-
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hibitory T cells may ligate Notch which is constitutively ex- Acknowledgements
pressed on naive T cells. These T cell populations cluster at
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presents both the major and minor T cell epitopes, allowing
ceil contact to occur and negative signals to be transmitted.
Thus, the outcome of Notch signalling in this instance is to
prevent clonal expansion and to mediate linked suppres¬
sion.
References
1 Weiner HL. Friedman A, MillerA. Khoury SJ,
al-Sabbagh A. Santos L, Sayegh M. Nussen-
biart RB: Trentham DE, Hafler DA: Oral toler¬
ance: Immunologic mechanisms and treatment
of animals and organ-specific autoimmune dis¬
eases by oral administration of autoantigens.
Annu Rev Immunol 1994:12:809-837.
2 Hoyne GF, O'Hehir RE. Wraith DG. Thomas
WR. Lamb JR: Inhibition of T cell and anti¬
body responses to house dust mite allergen by
inhalation of the dominant T cell epitope in
naive and sensitised mice. J Exp Med 1993:
178:1783-1788.
3 Metzier B. Wraith DC: Inhibition of experi¬
mental autoimmune encephalomyelitis by in¬
halation but not oral administration of the en-
cephaiitogenic peptide: Influence of MHC
binding affinity. Int Immunol 1993:5:1159—
1165.
4 Chen Y, Kuchroo VK. Inobe J-i. Hafler DA.
Weiner HL: Regulatory T cell clones induced
by oral tolerance: Suppression of autoimmune
encephalomyelitis. Science 1994:265:1237-
1240.
5 Hoyne GF. Askonas BA, Hetzel C. Thomas
WR, Lamb JR: Regulation of house dust mite
responses by inhaled peptide: Transient activa¬
tion of CD4+T cells precedes the development
of tolerance in vivo. Int Immunol 1996:8:335-
342.
6 Hoyne GF. Jamicki AG. Thomas WR. Lamb
JR: Characterisation of the specificity and du¬
ration ofT cell tolerance to intranasally admin¬
istered peptides in mice: A role for intramolec¬
ular epitope suppression. Int Immunol 1997;
9:1165-1173.
7 Qin SX. Cobbold SP. Pope H. Elliot J. Koussis
D. Davies J. Waldmann H: 'Infectious' trans¬
plantation tolerance. Science 1993:259:974-
977.
8 Andenon SM. Wraith DC: Hierarchy in the
ability of T cell epitopes to induce peripheral
tolerance to antigens from myelin. Eur J Im¬
munol 1998:28:1251-1261.
9 Davies JD, Leong LYM. Mellor A, Cobbold
SP. Waldmann H: T cell suppression in trans¬
plantation tolerance through linked recogni¬
tion. J Immunol 1996:156:3602-3607.
10 Lamb JR. Skidmore BJ. Green N. Chiller J.
Feldmann M: Induction of tolerance in in¬
fluenza vims immune T lymphocyte clones
with synthetic peptides of influenza haemag-
glutinin. J Exp Med 1983:157:1434-1447.
11 Lornbardi G. Sidhu S. Batchelor R. Lechler R:
Anergic T ceils as suppressor cells in vitro.
Science 1994:264:1587-1589.
12 Artavanis-Tsakonas S. Matsuno F. Fortini M:
Notch signalling. Science 1995:268:225-232.
13 Robey E. Chang D. Itano A, Cado D. Alexan¬
der H. Lans D. Weinmaster G, Salmon P: An
activated form of Notch influences the choice
between CD4 and CD8 T cell lineages. Cell
1996:87:483-492.
14 Chitinis AB: The role of Notch in lateral inhi¬
bition and cell fate specification. Mol Cell
Neurosic 1995:6:311-321.
124 IiuArch Allergy Immunol 1999:118:122-124 Hoyne/Dallman/Lamb
2.3 ANTIGEN MEDIATED MODULATION OF T CELL FUNCTION
2.3.5 SELECTIVE ANTIGEN PRESENTATION BY VACCINE
VECTORS
Harris SJ et al: Int Immunol 1997, 9:273-280.
Lamb JR: Res Immunol 1998, 1 49:235-240
Hetzel C et al: Infect Immun 1998, 6 6:3643-3648
International Immunology, Vol. 9, No. 2. pp. 273-280 © 1997 Oxford University Press
Prediction of murine MHC class I epitopes in
a major house dust mite allergen and
induction of T1-type CD8+ T cell responses
Stephen J. Harris, Jeanne-Franpoise Roth, Nigel Savage, Sarah A. Woodrow, Ian
K. Hemingway, Gerard F. Hoyne1, Jonathan R. Lamb1 and Guy T. Layton
British Biotech Pharmaceuticals Ltd. Watlington Road, Oxford 0X4 5LY, UK
'Department of Biology, Imperial College of Science. Technology and Medicine, Prince Consort Road.
London SW7 2BB, UK
Keywords: allergen presentation, allergen-specific CD8+ T cells, Th1/T1 T cell priming
Abstract
The group I (Der p 1) allergen of Oermatophagoides pteronyssinus (house dust mite, HDM) contains
several T helper (Th) epitopes recognized by C57BL/6 mice, with the peptide (111-139) containing a
dominant MHC class ll-restricted epitope (113-127). Since CD8+ T cells are thought to play a role in
the regulation of allergic disease, we examined the Der p 1 sequence for potential MHC class l-binding
motifs and observed that residues 111-119 (FGISNYCQI) contain motifs for H-2D0 and Kb.
Furthermore, immunization of C57BL/6 mice with unadjuvanted Ty virus-like particles (VLP) carrying
□er p 1 (111-139), a method known to induce murine cytotoxic T lymphocyte (CTL) responses, primed
□er p 1 (111-119)-specific Db-restricted CTL which produce high levels of IFN-yand low levels of IL-5
and IL-6 in vitro (T1 -type CTL). VLP carrying the minimal epitope (FGiSNYCQI) also induced a CTL
response following immunization without adjuvant by various routes. Der p 1 (111-139)-VLP
adjuvanted with alum did not prime CTL in C57BL/6 mice but were found to prime Th1-type CD4+ T
cells that recognize the overlapping peptide (113-127) and native protein. The ability to successfully
predict allergen-specific CD8+ T cell epitopes and prime CD8 + and/or CD4+ T cell responses
provides an opportunity to dissect the relative roles of these T ceils in the regulation of allergic
responses and may offer therapeutic potential for reprogramming Th2-type allergic responses.
Introduction
The production of specific IgE antibodies predisposes indi¬
viduals to become sensitized to environmental allergens and
plays an important role in mediating the allergic inflammatory
response. The synthesis of IgE by B cells is dependent on the
cognate interactions ofCD4'r T cells of the Th2-type producing
IL-4, and other inflammatory cytokines IL-5 and IL-6 (1-3).
Studies in rodents have demonstrated that following allergen
inhalation, CD4^ Th2-type cells are activated and can promote
a transient production of allergen-specific IgE (4,5). However,
this antibody production is short lived and CD4+ Th2 cells are
replaced in time by CD4+ Thl-type cells which block further
expansion of Th2 cells by secretion of cytokines such as IFN-y
(6,7). A similar series of events is thought to occur in normal
human responses to respiratory and dietary antigens, whereas
in the atopic individual IgE antibody levels persists, driven by
a dominant Th2-type CD4+ T cell response.
House dust mite (HDM, Dermatophagoides pteronyssinus)
allergy represents a significant problem in the population and
-10% of people suffer with allergic symptoms following expo¬
sure to house dust (8). Although both non-atopic and atopic
individuals produce immune responses to HDM allergens, the
atopic patients display a Th2-dominant phenotype (9). There
are several possible therapeutic approaches to down-regulate
allergic T cell responses in vivo. For example, it is possible to
functionally inactivate allergen-specific Th ceils by the tolerog¬
enic administration of allergen-derived peptides (10-13).
Alternatively, immune deviation may be provoked by shifting
the balance of cytokine production from Th2- to Th1-type and
this may be accomplished by priming Th1-type ceils (14), by
inhibiting Th2 cytokines using mAb (15) or by providing Th1-
type cytokines (7,16),
A potentially novel approach would be to activate allergen-
specific CDS'' T cells. The benefit of such an approach is
supported by rodent studies which have shown that CD8T
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T cells become activated following allergen exposure, and
can down-regulate the IgE response and normalize airway
responsiveness in sensitized.animals (17,18). Furthermore,
recent studies have shown that allergen-specific CD8"r T cells
can be induced following injection of mice with an allergen-
based naked DNA vaccine (19). Although CD8T T cells have
been studied in various animal models of allergy, a common
deficit of all the studies has been the failure to characterize
the allergen epitope specificity of the CD8+ T cells.
In this report we describe the identification of a CD8* T cell
epitope derived from the HDM allergen Der p 1, which is a
major target antigen for the allergic immune response in
humans (20). The sequence 111-119 of Der p 1 was identified
as a possible D°- or KD-restricted epitope based on putative
MHC class l-binding motifs (21,22). The region (111-139) is
of significance in that it represents an immunodominant region
which is recognized by CD4+ T cells in both humans (13)
and C56BLV6 mice (12). Furthermore, intranasal immunization
with Der p 1 (111-139) peptide tolerized mice to subsequent
challenge with the native Der p 1 protein (11).
To characterize responses to this region we produced
recombinant hyorid Ty virus-like particles (VLP), an antigen
presentation system known to induce strong cell-mediated
immune responses (23,24.25), carrying the sequences 111—
139 and 111-119 of Der p 1. We show that both of these
constructions, when injected without adjuvant, prime classical
H-2D°-restricted cytotoxic T lymphocytes (CTL) in C57BL/6
mice which kill target cells pulsed with peptide 111-119. In
addition, the CTL secreted Tl-type cytokines when activated
in vitro and could be induced when the VLP were administered
through different routes. When injected with alum adjuvant,
the Der p 1 (111—139)-VLP primed Th1-type proliferative T cells
against the 113-127 MHC class ll-restricted epitope but did
not prime CTL to the overlapping epitope.
Methods
Immunization of mice
Female C57BL/6 mice, 6-8 weeks old. were obtained from
Charles River (Margate, UK). Mice were immunized by the
subcutaneous route (s.c.) at the base of the tail for investi¬
gation of proliferative T cell responses in draining lymph
nodes (DLN) and the intramuscular (i.m.), intraperitoneal (i.p.)
or intranasal (i.n.) routes were used for the generation of CTL
responses in the spleen.
Preparation of VLP and peptides
Hybrid Ty-VLP were constructed and purified as previously
described (26.27). Briefly. TYA:Der p 1 fusion genes were
constructed by inserting synthetic oligomers encoding the
Der p 1 sequences (22) into a yeast expression vector
(pOGS40) that contains a truncated TYA gene encoding
amino acids 1-381 of protein p 1. The resulting plasmids
produce self-assembling hybrid Der p 1-VLP. These were
purified by sucrose density gradient followed by size exclusion
chromatography. The Th epitope in 111-139 is predicted to
be 113-127 based on the known l-A° motif (28). Peptides
were dissolved in 5% DMSO and PBS. and stored at -70°C
in aliquots. Native Der p 1 protein was extracted and purified
from spent HDM medium, as previously described (11,12).
The following VLP were produced:
Der p 1 (111-139)-VLP FGISNYCQIYPPNANKIREA-
LAQPQRYCR
Der p 1 (111—119)-VLP FGISNYCQI
Der p 1 (113-127)-VLP ISNYCQIYPPNANKI
The following synthetic peptides were made by Genosys
(Cambridge. UK)
Der p 1 T helper ( l-A") epitope ISNYCQIYPPNANKI
(113-127)
IgGVH control (l-A°) epitope (21) HNADFKTPATLTVDK
(59-74)
Der p 1 CTL (H-2°) epitope FGISNYCQI
(111-119)
VSV NP CTL (H-2°) epitope RGYVYQGL
(53-60)
INP CTL(H-2b) epitope ASNENMETM
(366-374)
Proliferation and cytokine assays
The methods were as previously described (23). Inguinal
DLN nodes were removed 7 days after immunization and
expressed through 100 pm mesh (Falcon 2350: Becton
Dickinson, Franklin Lakes, NJ). The cells were cultured at
5x105/100 pi of RPMI 1640 supplemented with 5% FCS, i-
glutamine and antibiotics in U-well microtitre plates. Stimulat¬
ing peptides and proteins were added in a further 100 pi.
The cells were cultured for 5 days and 0.5 pCi [3H)thymidine/
well was added during the final 4 h. The cells were harvested
onto glass fibre and counted in aWallac Microbeta scintillation
counter. Results are expressed as stimulation indices (SI),
where SI = c.p.m. in stimulated cultures/c.p.m. in control
cultures. Suoernatants for cytokine assays were obtained by
culturing 107 lymph node or spleen cells in 2 ml wells with
the appropriate peptide for 48 h. Supernatants were stored
at -70°C prior to assay. IL-5. IL-6 and IFN-y assays were
performed using murine ELISA kits (Endogen, Boston, MA)
according to the manufacturers instructions. Each culture
supernatant and standard was assayed in duplicate. The
results are expressed in pg/ml.
Cytotoxicity assay as a functional readout for CD8* T cells
We have previously shown that the CTL primed by hybrid
Ty-VLP are CD8~ and MHC class i-restricted. and CTL assays
were performed as described previously (24.25). Splenocytes
were prepared from two mice per group. The pooled cells
were cultured in 10 ml of RPMI-1640 medium supplemented
with 10% FCS, 5xlO~5M 2-mercaptoethanol, L-glutamine,
antibiotics and 10 ng Der p 1 (111-119) peptide. After 6-7
days, the effector cells were incubated for 4-5 h with Der p 1
(111-119) peptide-pulsed or control 5,Cr-labelled EL-4 target
cells at effector:target ratios as shown. The 51Cr released
into the supernatant was measured in a Wallac Microbeta
scintillation counter. The percent specific lysis was calculated
as 100x ((test counts - mean spontaneous count)/(mean
maximum counts - mean spontaneous counts)]. Results are
expressed as net percent specific lysis (peptide-pulsed target
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percent specific lysis - control target percent specific lysis).
Figures show the mean net percent specific lysis of quadru¬
plicate wells and standard error of the mean. In some experi¬
ments, purified CD8+ T cells were removed from splenocytes
using an anti-CD8+ affinity column (Minimacs: Miltenyi
Biotechnology, Surrey, U.K). The levels of CD8"1" and CD4-
T cells in the various cell preparations was evaluated by
FACS analysis (FACScan; Becton Dickinson, Oxford, UK).
Results
Prediction of CD8+ epitopes in Der p 1 and generation of
CTL responses with Der p 1-VLP
Given the putative role for CDS"1" T cells in the down-regulation
of allergic disease (17,18.29,30), we surveyed the Der p 1
sequence for known MHC class l-binding motifs (21,22) and
identified 11 putative epitopes, five of which were predicted
to bind to either K° or D° molecules. One of these, the Der p
1 sequence 111-119 (FGISNYCQI) conformed to the motif
described for both K° and Db molecules (D° motif, N at
position 5 and I at position 9; Kb motif, Y at position 5 and I
at position 8) and this sequence is in the previously identified
immunodominant region Der p 1 (111-139). Since we had
previously shown that hybrid VLP were potent inducers of
CD8~ T cell responses when injected into mice without any
adjuvant (24.25) we immunized C57BL/6 mice i.m. with 100.
20 or 4 pg Der p 1 (111—139)-VLP without adjuvant to look
for CTL priming to the predicted epitope. Splenocytes were
used as a source of primed CTL. because previous studies
have shown that CTL leave the DLN and accumulate in the
spleen within 7 days of priming with hybrid VLP (S. J. Harris
and G. T. Layton, unpublished observations). Splenocytes
were prepared on day 19 and re-stimulated with 1 pg/ml of
Der p 1 (111-119) peptide. The effectors were tested against
Der p 1 (111-119) peptide-pulsed and control EL-4 target
cells after 8 days. Strong lysis of peptide-pulsed target cells
was observed with effector cells from mice receiving 100 and
20 pg dose (Fig. 1). However, the response with the 4 pg
dose, representing 0.1 pg Der p 1 epitope, was much lower.
The predicted epitope, therefore, generates a H-2°-specific
CTL response when presented on hybrid VLP. The CTL
epitope (111-119) is overlapping but distinct from the CD4~
T helper epitope (113-127) and does not induce proliferation
in draining lymph node cells from mice immunized with
Der p 1 (111—139)-VLP with or without alum adjuvant (data
not shown).
Specificity and MHC restriction of CD8* CTL responses
Because the CTL epitope has both the Kb and 0° motifs, we
performed cold peptide inhibition of target cell lysis using
peptides known to bind to either K° or Db. In order to establish
the optimal and sub-optimal concentrations of Der p 1 (111-
119) peptide for labelling target cells, various concentrations
of peptide were added directly to a mixture of 5,Cr-labelled
EL-4 targets and Der p 1-specific CTL effector cells from
mice immunized with 100 pg Der p 1 (111-139)-VLP (E:T ratio
50:1). The concentration of peptide became limiting at
1 ng/ml, and was insufficient to labei target cells at 0.1 ng/ml
(Fg. 2A). This demonstrated the requirement for Der p 1
IMMUNISATION DOSE .
effector : target ratio
Fig. 1. Induction of CD8"" Der p l-specific CTL in C57BU6 mice.
Mice were immunized with ,100. . 20 or 4 ng Der p 1 (111-139)-VLP.
Spleen cells were removed after 7 days and re-stimulated in vitro for
6 days with Der p 1 (111-119) peptide prior to testing against Der p
1 (111-119) peptide-pulsed or unpulsed target cells. Non-specific
killing of unpulsed target ceils at an E:T ratio of 100:1 was 12.0%
(100 ^ig dose), 17.0% (20 jig dose) and 17.6% (4 ng dose).
peptide in target cell killing. We then tested the ability of
known Db [INP (366-374)] and K° [VSV NP (53-60)] binding
peptides to inhibit the binding of Der p 1 (111-119) to target
cells. Der p 1-specific CTL effector cells, generated as above,
and 5,Cr-labelled EL-4 target cells were plated at 50:1 cell
ratio to which was added Der p 1 (111-119) at 1 ng/ml and
either VSV NP (53-60) or INP (366-374) peptides at 100, 10.
1 or 0 ng/ml. The D°-binding sequence INP (366-374) inhib¬
ited the lysis of target cells when present at 100 ng/mi and
showed some inhibition at 10 ng/ml (Fg. 2B). However, the
K°-binding sequence showed no effect. This confirms the
MHC class l-restricted nature of the killing and indicates that
INP (366-374) and Der p 1 (111-119) are competing for the
Db molecule. The Der p 1 epitope is, therefore. Db-restricted.
Cytokine production by Der p 1-specific CD8* CTL
To further characterize the Der p 1-specific CD8* T cell
response, the production of IFN-y, IL-5 and IL-6 by spieno-
cytes from primed mice following Cer p 1 (111-119)
re-stimulation in vitro was investigated. C57BC6 mice were
immunized with 50 ug Der p 1 (111—139)-VLP with or without
alum. Splenocytes were prepared on day 6 and re-stimuiated
with the Der p 1 (111-119) peptide in vitro. After 48 h, the
supernatants were removed and assayed for cytokines as
described above. In separate cultures, following 6 days
re-stimulation, effector cells were tested for CTL activity. The
results are shown in Table 1. Only splenocytes from mice
immunized with Der p 1 (111—139)-VLP without alum adjuvant
showed significant CTL, as previously established (27). CTL
activity was associated with very high levels of IFN-y but low
levels of IL-5 and IL-6. CTL responses were not detected in
the DLN or spleens of mice immunized with adjuvanted VLP.
Having defined the Derestricted epitope as Der p 1 (1 li¬
ng) (FGISNYCQI) we investigated the ability of VLP carrying
only this sequence to induce a Der p l-specific CTL response.
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Der p I peptide concentration (ng/ml)
SO b- 0 Kb peptide: RGYVYQGL (VSV)
■ Db peotide: A S N E N M E T M (flu NP)
100 10 1 0
concentration of competing peptide (ng/ml)
Der p 1 peptide: FGISNYCQI @ Ing/ml
Fig. 2. (A) Dose response of Der p 1 (111-119) peptide for labelling
EL-4 target cells in Der p 1 CTL assay. Effector cells from C57BL'6
mice immunized with Der p 1 (111-139)-VLP and Der p 1 (111-119)
peptide were added to target cells to give an E:T ratio of 50:1 and
peotide concentrations of 0.01-100 ng/ml. Non-specific killing of
unpulsed target cells was 12.0%. (B) Ability of D°-specific flu NP(366-
374) peotide to compete with Der p 1 (111-119) peptide for binding
to the D° molecule as-observed in a Der p l-specific CTL assay. Der
p 1-specific effector cells were added to target cells at a ratio of
50:1. Der p 1 (111-119) peptide was present at 1 ng/ml and
K°-soecific VSV(53-60) or D°-specific INP(366-374) peptides were
added at 0-100 ng/ml.
Potent CTL responses were primed using 100. 20 and 4 pg
doses (all >35% net specific lysis at an E:T ratio of 33:1) and
these VLP were five to 10 times more potent than Der p 1
(111-139)-VLP. These splenocyte effector cells also produced
high levels of IFN-y. In order to confirm that it is the CD8T
T cells within the spleen cell population which produce the
IFN-y, CD8"1" T cells were isolated from the spleens of Der p
1 (111-119)-VLP-immunized (50 gg, i.m.) and control mice
by affinity purification. The cells were -90% CD8~ T cells
with 4% contaminating CD4~ T cells by FACS analysis. These
cells (2x10s) were added to Der p 1 (111-119) peptide-
pulsed normal splenocytes (1X107) in 2 ml wells and the
supernatants removed after 48 h. Unfractionated splenocytes
and the CD8" fraction from Der p 1 (111-119)-VLP-immunized
and control mice were also re-stimulated with the peptide for
48 h. The results shown in Table 2 confirm that only cultures
containing CD8^ T cells from immunized mice produced
IFN-y. Immunized splenocytes depleted of CD8~ T cells
produced 24-fold less IFN-y(520 pg/ml) compared to unfrac¬
tionated splenocytes (12,400 pg/ml). This IFN-ywas presum¬
ably produced by the residual 3% CD8^ T cells detected by
FACS analysis. The much higher levels of IFN-y produced in
this experiment compared to those in Table 1 also suggests
an increase in potency of Der p 1 (111—119)-VLP over Der p
1 (111-139)-VLP in terms of CTL induction.
Effects of route of administration on CTL induction by VLF
carrying the minimal nine amino acid epitope
C57BL/6 mice were immunized with 50 gg Der p 1 (111—119)-
VLP in PBS by either the i.m. i.p. or i.n. routes. Mice were
anaesthetized for i.n. immunization. Five days following
immunization, splenocytes were re-stimulated with Der p 1
(111-119) peptide in vitro for 6 days. A strong Der p 1-specific
CTL response was seen in all groups (Fig. 3). Twelve weeks
after immunization, a response was still present in mice
immunized by the i.m. and i.p. routes, but was greatly
diminished in the splenocytes from i.n. immunized mice
(Fig. 3).
Induction of Der p '-specific CD4+ Th1-type T cell responses
using Der p 1 (111-139)-VLP
Since the Der p 1 (111-119) sequence overlaps the previously
identified l-Ab-restricted epitope (113-127), we investigated
Table 1. Cytotoxic T cell (CTL) and cytokine responses by splenocytes 6 days following i.m. immunization with 50 ug Der p 1
(111-139)-VLP with or without alum adjuvant
In vitro In vivo
Der p 1 (111-139)-VLP in alum Der p 1 (111--139)-VLP no adjuvant

















aSDlenocytes re-stimulated with peptide (111-119) from Der p 1 for 48 h (cytokines) or 6 days (CTL).
DControl wells were unstimulated splenocytes.
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Table 2. IFN-y production by purified 0087 CD8" and
unfractionated splenooytes from Oer p 1 (111—119)-VLP-
immunized (50 ng, i.m.) mice re-stimulated in vitro with Oer
p 1 (111-119) peptide (10 (ig/ml)
Mice immunised wjch:
■ ALUM ALONE
3 Oer p 1(111-139)-VLP/ALUM
Cells3 Ceils/well lFN-y (pg/mi)
Immune splenocytes 107 12.400
Control spienocyies 107 <47
Immune CDS* ceils 2X106
plus peptide-puised control splenocytes 107 17,600
Control CD8+ cells 2X106
plus peptide-puised control splenocytes 107 <47
Immune CD8" splenocytes 107 520
Control CD8" splenocytes 107 <47
aSplenocytes removed 7 days after priming and cells re-stimulated
for 48 h (IFN-y).
intramuscular:
1 10 100
effector : targfft ratio
ng. 3. Induction of Der p 1 (111—119)-specific CTL responses
following immunization of C57BU'6 mice with 50 pg Der p 1 (111—
119)-VLP by different routes. The generation of Der p 1 (111-119)-
specific CTL responses was investigated at day 5 and week 12
following immunization by re-stimulating splenocytes for 6 days in vitro
with Oer p 1 (111-119) peptide and testing effectors against oeptide-
pulsed target cells. Non-specific killing of unpulsed target cells at an
E:T ratio of 100:1 was <5.0% in all groups.
the ability of Der p 1 (111-139)-VLP to prime CD4~ T cells
recognizing this epitope. Seven days following s.c. immuniza¬
tion of C57BL/6 mice with 60 pg Der p 1 (111-139)-VLP
prepared in 300 pg alum, marked proliferative responses
were observed to Der p 1 (113-127) peptide at 1 ug/ml and
the native Der p 1 protein at 10 pg/ml in DLN cells (Fig. 4).
The specificity of the response was corroborated by the lack
of response to the control peptide and in mice immunized
with alum alone. Strong proliferation was also observed to
the Ty protein, as previously shown (23).
In order to characterize the proliferative T cell response
further, 107 DLN cells from mice immunized with 50 pg Der
p 1 (111-139)-VLP with or without alum were cultured for 48
h in 2 ml wells and the cytokine responses to Der p 1 (113—
127) measured. Proliferative T cell responses in these DLN
Oer o 1 Oer d 1 Control Ty
lOug/ml peotide peptide protein
lug/ml lug/ml 0.1 ug/ml
stimulatory protein/peptide
Fig. 4. Proliferative T cell resoonses to Der p 1 protein. Der p 1 (113—
127) peptide. Ty protein and control l-A°-binding peptide following
immunization of C57BL/6 mice with Der p 1 (111-139)-VLP prepared
in alum, or alum alone.
cells to Der p 1 (113-127) were also measured (Table 3).
Although proliferation to Der p 1 (113-127) was not detected
in mice immunized with VLP without alum, specific peptide-
induced IFN-y production was measured. When the VLP were
injected with alum, strong T cell proliferation and high levels
of IFN-y were observed. A proportion of the IFN-y production
was due to the inflammatory action of alum. Der p 1-specific
T cells primed by alum or non-adjuvanted Der p 1 (111-139)-
VLP produced low levels of IL-5. IL-6 was only produced at
low levels by T cells primed with alum adjuvanted VLP.
Discussion
Recent studies would tend to suggest that CD8T T cells
play a role in the resolution of the allergic disease process
(17,18,29.30) but no MHC class l-restricted epitopes have so
far been identified for any allergen. Using motif prediction
methods successfully applied to defining viral CTL epitopes,
we examinea the Der p 1 protein sequence. One sequence.
111-119 (FGISNYCQI), conformed to the motif described for
both Kb and D° molecules (D° motif, N at position 5 and I at
position 9: Ka motif. Y at position 5 and I at position 8).
Furthermore, the predicted CTL epitope (111-119) is overlap¬
ping but distinct from the CD4- Th epitope (113-127). The
prediction of human class l-binding epitopes in allergenic
proteins using defined motifs may lead to the identification of
peptides which may be of therapeutic benefit.
In order to test whether the predicted MHC class l-restricteo
epitope is functional, in terms of its ability to prime CD8*
T cell responses, we produced recombinant hybrid VLF
carrying Der p 1 (111-139). We had previously shown thai
hybrid VLP were potent inducers of CD8''" T cell responses
wnen injected into mice without adjuvant (24.25) and immun¬
ization of C57BL/6 mice with Der p 1 (111—139)-VLP was
indeed found to prime a strong Der p 1 (111—119)-spectfic
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Table 3. Proliferative T cell and cytokine responses in draining lymph node cells following s.c. immunization with Der p 1
(111-139)-VLP (50 |ig) with or without alum adjuvant
In vitro In vivo
Der p 1 (111—139)-VI_P in alum Der p 1 (111-139)-VLP no adjuvant
p (113—I27)a Control0 p(113-127)a Control0
Proliferation (SI) 7.3 1.0 1.0 1.0
IFN-y (pg/mi) 5648.8 883.9 1403.2 <47
IL-5 (pg/ml) 180.2 33.8 251.9 51.7
IL-6 (pg/ml) 114.8 <20 <20 <20
aDer p 1 (113-127) peptide (10 ttg/ml) was used to re-stimuiate lymph node cells in vitro for 48 h (cytokines) or for 5 days (proliferation).
°Control wells represent unstimulated lymph node cells.
CTL response which was shown to be Derestricted. VLP
carrying the minimal epitope (111-119) also primed strong
CTL responses when injected by three different routes includ¬
ing intranasal. There was no detectable proliferative CD4- Th
ceil response but a weak IFN-y response to the overlapping
l-A°-restricted epitope (113-127) in the DLN of mice immun¬
ized with unadjuvanted Der p 1 (111-139)-VLP. This suggests
that intracellular localization of the Ty p1-Der p 1 (111-139)
fusion protein, following particle uptake by antigen-presenting
cells, favours the generation of the MHC class l-binding
peptide (111-119) but does not exclude the generation of
MHC class ll-binding (113-127) peptides. Evidence for the
dual processing of the Derp 1 (111-139) sequence presented
on VLP is supported by the greatly increased potency of
Der p 1 (111—119)-VLP over Der p 1 (111-139)-VLP for
CTL priming.
CTL activity was associated with very high levels of IFN-y,
low levels of IL-5 and no IL-6, and sucn a T^l-type response
may have a role in down-regulating igE production to the
allergen via suppression of IL-4 and IL-6 production (6.7).
This has been observed in a rat model of respiratory allergy
to ovalbumin in which tolerance to aerosolized ovalbumin can
be adoptively transferred by IFN-y-producing CD8T-enriched
splenocytes (17). These cells and similar suppressor cells in
the mouse have been shown to express y8 TCR. It is currently
not known what type of TCR (a|3 or yS) is expressed by CD8~
T cells primed by VLP. Suppression of ovaibumin-specific IgE
production and normalization of airways responsiveness was
also seen in mice following the transfer of IFN-y-producing
CD8- T cells purified from the spleens of ovalbumin-sensitized
mice (18). Recent studies in -rats have shown that DNA
immunization with another Der p allergen (Der p 5) results in
the inhibition of allergen-induced IgE synthesis and airway
hyper-responsiveness, and this effect is transferable with
CD8' T cells (19). However, the allergen epitope specificity
of the CD8~ T cells is unconfirmed. IFN-y also inhibits the
production of IL-10, a Th2 cytokine which down-regulates Th1
responses (31).
The induction of T1-type CD8^ T cells may also result in
the production of other cytokines known to down-regulate
Th2/T2-type responses, e.g. IL-12 is known to inhibit Th2-type
and promote Th1-type T cell responses probably via release
of IFN-y and also enhances the generation of CD8"r T cells
(32). Furthermore, it has been shown that CD30 ligand
expressed on CD8+ T cells may serve to,inhibit Ig switching
to IgE synthesis via interaction with CD30 on B cells (33). The
apoptosis-inducing Fas ligand is also strongly expressed on
activated CD8' T cells and can mediate the death of activated
CD4~ T cells (34). There are, therefore, several mecnanisms
whereby CD8~ T cells may down-regulate Th2-type T cell
responses. However, recent studies have also shown that
CDS"" T cells were actually required for the development of
airway responsiveness to ovalbumin in mice and that these
cells produce IL-5 (35). Furthermore. CDS' T cells may
be switched to produce T2-type cytokines if the cells are
generated in the presence of IL-4 (36-38). It will be interesting
to evaluate the effects-of Der p 1 (111-139)- or (111-119)-
VLP on mice experiencing an ongoing Th2 response to Der p 1.
It is unclear, currently, whether the regulation of allergic
responses in man is attributable to allergen-specific CD8~
T cells and it is also unknown whether their cytotoxic effector
function is important. However, mechanisms exist for the
induction of MHC class l-restricted T cell responses by
exogenous allergenic proteins, at least in rodents (39.40). It
is also conceivable that in vivo administratibn of the Der p 1
(111-139) peptide, as previously described (11,12), or even
Der p 1 (111-119) can induce Der p 1 (111—119)-specific
CD8~ T cells in vivo (41). We have previously shown that the
intact particie is critical for CTL induction to epitopes pre¬
sented on VLP (42), and that free peptides and soluble
proteins at the same epitope molar equivalent as VLP do not
prime CTL in vivo (24). It will be interesting to compare the
immunogemcity of Der p 1-VLP with native Der p 1 protein
and synthetic peptides for CTL and Th cell priming.
As anticipated from previous studies (23), alum-adjuvanted
VLP carrying Der p 1 (111-139) generated a strong (113—
127)-specific CD4+ T cell response in the DLN but did not
prime CD8+ CTL in either the lymph nodes or spleen. This is
due to the denaturation of particles and the switching of uptake
to the MHC class II processing pathway (42). Suprisingly, the
alum-adjuvanted Der p 1 (111—139)-VLP primed a strong Th1-
type CD4- T cell response rather than Th2. Alum is generally
regarded as an adjuvant which predisposes to a T„2-type
responses in rodents (43). The nature of the antigen is,
therefore, a critical factor in directing T cell responses towards
a particular polarity. VLP carrying the minimal class
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II-restricted epitope (113-127) also primed Der p 1-specific
CD4^ T cell responses (data not shown). The induction of
Der p 1-specific CD4^ Th1 ceil responses in individuals
experiencing an ongoing Th2 cell response to this allergen
may have a therapeutic benefit.
In summary, therefore, we have predicted a potential CD8~
T cell epitope, residues 111-119, within the Der p 1 sequence
III-139 and have demonstrated a Tl-type CD8^" CTL
response in C57BL/6 mice following one injection of VLP
carrying either Der p 1 (111-139) or (111-119) without adjuvant
by a variety of routes. The capacity to prime Thl/Tl-type
CD4^ and/or CDS* T cell responses to Der p 1 provides the
means to study the regulatory role of these cells in models of
HDM allergy in mice.
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of allergen-specific immune responses
J.R. Lamb
Respiratory Medicine Unit. Rayne Laboratory,
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Allergic inflammatory responses are regulated
by cytokines derived from Th2-type helper cells.
Therefore, the ability to downregulate the func¬
tion of these T cells may contribute to the
improvement of clinical symptoms. Two broadly
based approaches to CD4+ T-cell-targeted immu¬
notherapy employing peptides are under consid¬
eration, namely the inhibition of Th2-cell activity
and the induction of specific Thl immunity. Evi¬
dence acquired from clinical trials using conven¬
tional allergen immunotherapy suggests that suc¬
cessful desensitization may be accompanied by
the induction of T-cell anergy and/or a shift in the
IFNy to IL4 ratio in favour of the Thl pathway.
Introduction
The primary aim of allergen immunotherapy
(IT) is to vaccinate with allergen or its derivatives
under conditions that will inhibit only the aller¬
gen-specific response, leaving the remainder of
the immune system functionally intact. In addi¬
tion to specific IgE. a hallmark of allergic inflam¬
mation is both the presence of CD4+ T cells
expressing a Th2-dominant cytokine profile [1,2]
and eosinophil infiltration at the disease site. ThO
cells with the potential to produce both Th2 (EL4,
IL5. IL10 and IL13) and Thl (IFNy) cytokines
also form a component of the T-cell repertoire in
allergic inflammation. It is suggested that eosino¬
phils contribute to airway hyperresponsiveness in
asthma through epithelial damage by basic gran¬
ule proteins, and that similar mechanisms may
contribute to upper airway inflammation in rhin¬
itis. Eosinophil chemoattractant chemokines. in
particular eotaxin and RANTES, are now recog¬
nized as important factors leading to this eosino¬
phil response. CD4+ T cells are involved in regu¬
lating the synthesis of these chemokines, and
through their capacity to produce IL5 and other
cytokines, can facilitate the differentiation of
inflammatory cells, including eosinophils. In sub¬
jects who are not genetically susceptible to aller¬
gic disease, T cells reactive with allergen can be
identified in the peripheral repertoire but they are
representative of the Thl phenotype [3]. CD4^
T cells are therefore central in immune responses
to allergens as regards the regulation of allergic
inflammation in allergic rhinitis and asthma, and
the induction of "protective" immunity in normal
individuals. As such, CD4~ T cells provide an
obvious target for immunotherapy. Evidence
from independent clinical trials of conventional
allergen desensitization indicate that successful
immunotherapy may be accompanied by the
induction of anergy in the peripheral T-cell reper¬
toire and/or a shift in the balance of the IFNy to
Received April 1. 1998.
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IL4 ratio in favour of the Thl pathway [4-7],
Although successful for a number of allergens,
desensitization with intact native allergen carries
the risk of inducing anaphylaxis and therefore the
need to develop novel therapeutics remains.
There are two basic approaches to targeting
the CD4+ T cells, one is to render Th2-type cells
or Th2-type cytokine production by ThO cells of
the appropriate specificity anergic/tolerant to
allergen rechallenge (table I and reviewed in [8]).
From clinical investigations on IT with bee
Table I. Approaches for peptide-mediated immune
intervention.




2. Promote Thl cells
• Vaccine vectors
Virus-like particle-allergen hybnd proteins
Mycobacteria (M. vaccae, BCG)
venom, it appears that this functional state (i.e.
anergy/tolerance) can be induced in vivo as a
result of allergen desensitization [7], There are a
number of in vivo experimental animal models
demonstrating that IT with proteins and peptides
is mediated by the induction of T-cell tolerance
[8-11]. The second approach is to immunize with
peptides and select conditions of antigen presen¬
tation that will promote the induction of Thl
cytokines, one example of which is the use of
recombinant mycobacteria expressing allergen-
derived peptides [12],
Approaches that target surface proteins on a
variety of different cell types, such as coreceptors
(e.g. CD4). costimulatory receptors/ligands (e.g.
CD28, CD80 and CD86) and adhesion molecules
also offer potential ways of inhibiting allergic
inflammatory responses. Similarly, antibodies
capable of blocking IgE and mutated forms of
cytokines (e.g. IL4 and IL5) and chemokines may
have therapeutic applications in the regulation of
allergic diseases. However, these approaches lack
the unique specificity that may be possible to
achieve through regulating subpopulations of
















with peptide + APCs
Cytokines
3[H]-TdR (cpm)
C. Summary of results
Peptide stimulation can induce anergy charactensed by:
1. loss of antigen specific proliferation
2. loss of B cell help
3. modulation of functional and cell membrane phenotype
Fig. 1. In vitro modulation of allergen-specific human CD4^ T cells.
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A. Experimental Protocol
3x 100 ngpl, 111-139 i.n.
B. Induction of non-responsiveness
14 days
50 ug Der p l/CFA s.c.
10 days
in vitro stimulation of lymph nodes &
spleen with Der pi & p 1, 111-139
measure IL-2, IL-3, IL-4 & IFN-gamma
& antibody production
0.1 1 10
p 1, 111-139 [yg/ml]
0.1 1 5 20
Der p 1 [pg/ml]
PBS
pi, 111-139
C. Summary of results
Intranasal delivery of peptide containing major T-cell epitope
(residues 111-139) of Der p 1 inhibits:
1. T-cells responses to peptide and intact Der p 1 protein
independently of the induction of CD8+ T cells
2. T-cell responses in naive & sensitised mice
3. T-cell proliferation, cytokine production & antibody synthesis
Fig. 2. In vivo modulation of murine responses to HDM-derived allergens following intranasal
delivery of peptide.




























Fig. 3. Effect of peptide analogues on induction of T-cell anergy.
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Allergen-derived peptide-mediated inhibition
of Th2 cytokine production
The ability of peptide fragments of allergen to
modulate the function of CD4r T cells has been
demonstrated in vitro using human T cells ([13]
and fig. 1) and in experimental animal models in
vivo (ref. [8] and fig. 2). Information on pepude
IT is now also becoming available from clinical
trials in man and the results to date are variable
[14-16],
In addition to their ability to induce T-cell
unresponsiveness/tolerance, it has been reported
that peptide ligands in which the T-cell receptor
(TCR) contact residues have been modified by
single amino acid substitutions, termed altered
T-cell ligands [17], can modify the pattern of
cytokine production by ThO cells ([18] and fig. 3).
The alteration in the affinity of the interaction
between TCR and its ligand (MHC class II and
peptide) appears to deliver an incomplete signal
such that only selected effector function of the
T cells is induced.
The immunological changes that occur in pep¬
tide mediated anergv/tolerance are summarized in
table n.
Virus-like particle-allergen hybrid proteins
Paniculate antigen presentation based on the
Tv pi protein, which forms virus-like panicles
(VLPs) when expressed in yeast, is efficient in
generating specific CD4^ Thl-type responses
when injected with the adjuvant alum and
CD8+ cytotoxic T-cell (CTL) responses in the
absence of alum [19]. This has been demon¬
strated in human immunizing with VLP-gpl20
constructs. In order to test this approach for the
regulation of responses to allergen, H-2b mice
were immunized with VLPs expressing the
immunodominant T-cell epitope of Der p 1 (res¬
idues 111-139), a major allergen derived from
house dust mites (HDM). Immunized with p 1,
111-139-VLPs in alum induced Thl-type CD4+
cells that responded when restimulated in vitro
with either the appropriate Der p 1 peptide or
the native protein. Furthermore, immunization
with p 1, 111-139-VLPs without adjuvant
Table II. Immunomodulation by allergen-derived
peptides.
Native peptide
• Activation in vitro and in vivo
• Induction of antigen-specific unresponsiveness/
tolerance
In vitro:
Loss of antigen-specific proliferation
Loss of B-cell help
Modulation of surface phenotype
(TCRI, CD284., CD251,
CD40L<-», CD80-<-k CD86<-»)
Induction phase transient activation
(cytokine-specific mRNAt)
Modulation of cytokine production on restimulation




Inhibition of responses to all epitopes
and intact protein independent of CD8* T cells
Inhibition of responses in sensitized and naive mice
Inhibition of proliferation, cytokine production
and antibody synthesis
Repeated inhalation of peptide induces
only very low levels of peptide-specific IgM.
but not IgG2a or IgGl
Altered T-cell ligands
• Activation in vitro
• Induction of altered T-cell effector function
Dissociation of proliferation from IL4 production
by Th2 cells
Inhibition of proliferation and cytokine production
by ThO cells
Enhanced production of IFNy by ThO cells
More effective induction of anergy
induced a strong 111-119-specific Derestricted
CD8+ CTL response ([20] and fig. 4). The
VLPs also induced a long-lasting CTL response
following immunization by various routes. Both
Der-p-1-specific CTLs and T helper cells pro¬
duce high levels of IFNy. The role of specific
CD8+ T cells in the regulation of allergic
responses in man is unclear, although there are
reports that the number of CD8+ T cells in the
periphery increases following desensitization.
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A. Experimental protocol C. Induction of responses
VLP-Oer p 1 (111-139 or
111-119) i.p.











B Ob peptide: ASNENMETM (flu NP)
0 Kb peotide: RGYVQGL (VSV)
0 1 10 100
Competing peptide [ng/ml]
Der p 1 peptide: FG1SNYCQI [1 ng/ml]
in vitro stimulation of lymph nodes &
soleen with HDM derived allergens
measure cytotoxicity, proliferation,
cytokine release and antibodies
C. Summary of results
Induction of type 1;
1. Der p 1, 117-1 28 specific l-Ab restricted CD4+ T cells
2. Der p 1, 111-119 specific Db restricted CD8+ T cells
Fig. 4. Experimental animal model: immunization with Der p~l (11 l-139)-VLPs.
A. Experimental protocol C. Induction of responses
M. vaccae expressing
Der p 2
Der p 2 in CFA/alum, s.c./i.p.
□ Before Mv
E2 Mv-control
B Mv-Der p 2
B PBS
H M. vaccae
□ M. Vaccae-Der p 2
IFN-gamma
in vitro stimulation of lymph nodes &
soleen with HDM derived allergens
measure Droliferation. cytokine
release and serum antibodies
C. Summary of results
Immunisation with M. vaccae-Der p 2:
1. Induces Der p 2 specific responses
2. Downregulates Der p 2 induced Th2 cytokines
Fig. 5. Experimental animal model: immunization with M. vaccae expressing Der p 2.
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Use of mycobacteria expressing peptides and
proteins to HDM to "reprogram" specific Th2
immunity
Mycobacteria are known to be highly immu-
nostimulatory. and through their uptake and pres¬
entation by macrophages favour the stimulation
of Thl-tvpe responses by the production of IL12
and IFNy. Therefore, mycobacteria seemed an
appropriate live vaccine vector for the expression
and presentation of HDM genes for the induction
of Thl cells. Antigenic determinants from HDM
proteins have been engineered into an extended
loop of the superoxide dismutase (SOD) mole¬
cule of M. tuberculosis, and expressed in M. vac-
cae, a non-pathogenic species. Antigenic regions
as large as 30 amino acids in length can be effi¬
ciently expressed in this way.
H-2b mice were primed subcutaneously with
heat-killed recombinant (r) M. vaccae expressing
(SOD-pl) or without (SOD), the immunodomi¬
nant peptide of the Der p 1 (residues 111-139).
Immunization with rM. vaccae SOD-pl induced
recall responses to specific peptide that were pre¬
dominantly of the Thl phenotype, with little or no
IL5 detectable. These experiments were extended
and mice were injected with tM. vaccae SOD-pl
or rM. vaccae SOD and subsequently immunized
with peptide to induce a specific Th2-dominant
response. Enhanced levels of IFNy together with a
marked reduction in IL5 synthesis were observed
in rM. vaccae SOD-p 1-immunized mice but not
the rM. vaccae SOD or PBS control groups [12].
In another construct, the gene for the entire
Der p 2 protein has been expressed in M. vaccae
under the regulation of the 19-kDa promoter. Pre¬
liminary studies have shown that mice with an
ongoing Th2-dominant response specific for Der
p 2 exhibit an upregulation of of specific IFNy in
vitro following subcutaneous immunization with
heat-killed M. vaccae expressing intact Der p 2
(fig. 5). In addition, in these mice, the decline in
IgGl antibodies was more rapid than in control
mice.
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We have developed a novel epitope delivery system based on the insertion of peptides within a permissive
loop of a bacterial superoxide dismutase molecule. This system allowed high-level expression of heterologous
peptides in two mycobacterial vaccine strains, Mycobacterium bovis bacille Cairaette-Guerin (BCG) and Myco¬
bacterium vaccae. The broader application of the system was analyzed by preparation of constructs containing
peptide epitopes from a range of infectious agents and allergens. We report detailed characterization of the
immunogenicity of one such construct, in which an epitope from the Der pi house dust mite allergen was
expressed in M. vaccae. The construct was able to stimulate T-cell hybridomas specific for Der pi, and it
induced peptide-specific gamma interferon responses when used to immunize naive mice. This novel expression
system demonstrates new possibilities for the use of mycobacteria as vaccine delivery vehicles.
Mycobacteria are potent immunogens, inducing both anti¬
body and cell-mediated immune responses. BCG, an attenu¬
ated strain of Mycobacterium bovis, is the most widely used
vaccine worldwide; Mycobacterium tuberculosis is routinely
used for preparation of complete Freund's adjuvant; and com¬
ponents of the mycobacterial cell wall have been exploited in
development of alternative adjuvant systems (4, 13, 23). With
the advent of tools for genetic manipulation of mycobacteria,
several reports have described the use of recombinant BCG as
a potential vaccine vector (2. 19, 31, 32). A strain of BCG
expressing the ospA antigen of Borrelia burgdorferi has been
shown to induce protective immunity in animal models, for
example (31).
With the aim of understanding factors underlying the im¬
munogenicity of mycobacteria, and the eventual construction
of improved mycobacterial vaccines, we wished to analyze the
ability of mycobacteria to present a series of well-defined an¬
tigens to the immune system in experimental models. We have
chosen initially to compare the immunogenicity of BCG, de¬
livered as a live vaccine, with that of Mycobacterium vaccae, a
soil organism that has been used as a killed preparation in
human immunotherapy (9, 30). In initial experiments with a
range of antigens, we were able to obtain only low-level ex¬
pression and observed a tendency for decreased expression
during subculture of recombinants. To obtain a high-level ex¬
pression system suitable for use with different antigens, we
have developed an epitope expression system based on the
iron-containing superoxide dismutase (SOD) of M. tuberculo¬
sis.
M. tuberculosis SOD is a multimeric protein formed by the
tight association of four 23-kDa subunits. SOD is located pre¬
dominantly in the cytoplasm of mycobacteria but is also found
* Corresponding author. Present address: TNO Prevention and
Health. Zernikedreef 9. P.O. Box 2215. 2301 CE Leiden. The Neth¬
erlands. Phone: 3171-5181276. Fax: 3171-5181901. E-mail: j.thole@pg
.tno.nl.
t Present address: Respiratory Medicine Unit, University of Edin¬
burgh Medical School. Edinburgh. United Kingdom.
in the extracellular fluid of cultures of slowly growing myco¬
bacteria such as M. tuberculosis (3) and Mycobacterium avium
(8). It was initially identified as a major target of the immune
response in mice immunized with mycobacteria. The gene en¬
coding the M. tuberculosis enzyme can be expressed at high
levels in recombinant mycobacterial systems, accounting for as
much as 10% of the total cell protein (11). High-level expres¬
sion in M. vaccae has been exploited for protein purification,
allowing establishment of the complete three-dimensional
structure of the protein (6). Analysis of this structure identified
an outward-extending loop which is distal from the reactive site
of the enzyme and is not involved in subunit interactions. In
the present study, we describe a strategy for epitope expression
in mycobacteria which is based on targeting of this loop as an
insertion site for foreign peptides.
MATERIALS AND METHODS
Epitope carrier vector construction. A BamHI site was created in the sodA
gene, present on plasmid pl6Rl/SOD (11). using two-step PCR-directed mu¬
tagenesis. The resulting plasmid. designated p23.1. contains a unique BamOl site
between codons 51 and 53 of the sodA gene. Complementary oligonucleotides
flanked by BamHI sites were subsequently used to introduce immunodominant
peptides from various antigens (Table I). In each case, codon usage was opti¬
mized for that of known M. tuberculosis proteins. Constructs were routinely
checked by DNA sequence analysis.
Bacterial cultures and transformation. Escherichia coli DH5a was grown at
37°C in LB medium. M. vaccae NCTC 11659 (supplied by John Stanford. Uni¬
versity College and Middlesex Hospital School of Medicine. London. United
Kingdom) was grown in Middlebrook 7H9 medium supplemented with 2%
glucose. M. bovis BCG (strain P3) was grown in Middlebrook 7H9 medium
supplemented with albumin, dextrose, and catalase as recommended by the
manufacturer (Difco, West Molesey, United Kingdom). When appropriate, hv-
gromycin B (Sigma. Northampton. United Kingdom) was added at 200 jxg/ml for
£. coli or at 50 p-g/ml for M. vaccae and BCG (13). Transformation of mycobac¬
teria was carried out by electroporation (11), whereas E. coli was transformed by
using standard procedures (27). For immunization purposes. M. vaccae recom¬
binants expressing chimeric SOD proteins were grown on 7H11 plates supple¬
mented with 2% glucose and 50 ug of hygromvein per mi.
Analysis of expression of chimeric SOD proteins. For analysis of protein
expression, sonicated extracts of recombinant M. vaccae or BCG were analyzed
by polyacrylamtde gel electrophoresis in the presence of sodium dodecyl sulfate
(SDS-PAGE) (22) and Western blotting. Blots were developed with a monoclo¬
nal antibody (D2D) against mycobacterial SOD (34) and visualized by chemiiu-
mtnesccnce (Amersham International. Amersham. United Kingdom). The en-
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TABLE 1. Constructs used
Construct Peptide sequence Origin Rcference(s) Length(residues) Expression
SOD +
SOD-pl 111-139 of Der pi House dust mite 16. 20 29 4-
SOD-p2 87-105 of Der p2 House dust mite 17 14 4-4-
SOD-OVA 323-339 of ovalbumin 29 17 4-4-
SOD-HA 126-138 of hemagglutinin Influenza virus 28 22 4-4-4-
SOD-NP 366-374 of nucleoprotein Influenza virus 33 9 4-4-4-
SOD-M2 58-66 of matrix protein Influenza virus 1 9 4-4-4-
SOD-48 307-319 of hemagglutinin Influenza virus 26 13 4-4-
SOD-3.20 335-349 of nucleoprotein Influenza virus 33 15 4-4-
SOD-45.1 380-391 of nucleoprotein Influenza virus 18 12 4- 4-
SOD-65 1-20 of Hsp65 M. tuberculosis 12 20 4-
SOD-40.6 Various epitopes" Plasmodium 15 30 4-
SOD-36.8 Various epitopes* Plasmodium 15 60 r
SOD-RSV 82-90 of 22-kDa protein Respiratory syncytial virus 21 9 4-4-4-
a CD8 epitopes of STARP and LSA-1 and a CD4 epitope of CS protein (15).
b CD8 epitopes of STARP, TRAP, CS protein, and LSA-1 and a CD4 epitope of CS protein (15).
zymatic aaivity of recombinant SOD proteins was examined by activity staining
of gels run under nondenaturing conditions (36).
Preparation of antigens. Aliquots of 100 mg/ml of recombinant mycobacterial
suspensions were frozen at -70*C in 15% glycerol. For immunization, the glyc¬
erol was washed away, the bacteria were heat-killed (20 mm. 80°C) where
necessary, and the preparations were resuspended at the appropriate concentra¬
tion in phosphate-buffered saiine-0.05% Tween 80. Soluble native M. vaccae
antigens for in vitro stimulation were prepared by sonicating the bacterial sus¬
pensions in phosphate-buffered saline and filtering them through a 0.22-u.m-
pore-size filter. Peptide 111-139 of Der pi (sequence, FGISNYCQIYPPNANK
IREALAOTHSAIA (5)) and peptide 111-119 were made on an ABIMED 422
synthesizer (ABIMED. Langenfeld, Germany) by the simultaneous peptide syn¬
thesis method. The purity of the peptide was verified by reverse-phase C,8
high-pressure liquid chromatography (Lichrosphen Merck. Darmstadt, Ger¬
many) and was shown to be routinely over 75%.
Animals and immunization protocols. Female C57BL/6J (H-2") mice (6 to 8
weeks old) from Harlan-Olac (Bicester. United Kingdom) were used in the
study. Mice, usually in groups of four, were immunized subcutaneously (s.c.) in
the flank with preparations of 1 to 1,000 p.g of M. vaccae (corresponding to 10°
to 10v organisms) in a 200-p.l volume.
Cell culture. Single-cell suspensions of splenocytes or lymph node cells were
cultured in 96-flat-well raicrotiter plates (Nunc, Roskilde. Denmark) at 2 x 10°
cells/ml in RPMI 1640 supplemented with 5% fetal calf serum. 2 mM u-glu-
t aminc. 20 IU of penicillin and 20 p.g of streptomycin (Gibco, Grand Island.
N.Y.) per ml. and 0.05 m-M 2-mercaptoethanol (Sigma. St. Louis, Mo.) (200
mJAvcIJ) at 37°C in humidified air containing 5% CO=. Cells were incubated in
triplicate wells alone or with various concentrations of antigens for the assess¬
ment of gamma interferon (IFN-y) in supernatants at 72 h. Proliferation was
measured by pulsing for the last 6 h with [3H)thyrnidine (0.5 jiCiAvell: Amer-
sham). harvesting the contents of each well onto glass fiber mats, and determin¬
ing the incorporation of 3H in a Betapiate liquid scintillation counter (Waliac,
Turku. Finland).
The isolation of Der pi-specific T-cell hybridomas has been previously de¬
scribed (20). Briefly, the hybridomas were generated by polyethylene glycol
(Sigma (-induced fusion of Der pl-specific CD4~ T-cell lines derived from H-2?
mice with the BW 5147 fusion partner (a kind gift from H. Bodmer. Nuffield
Department of Ginicai Medicine. Oxford, United Kingdom) and selection with
hypoxanthine-aminopterin-thymidine medium (Sigma). Hvbndoraas recognizing
epitopes between residues 111 and 139 of Der pi were used in this study.
Activation of the hybridomas was measured by culturing them at 5 x 104
cells/well with appropriate antigens and 10s irradiated (2^00 rads) syngeneic
splenocytes as antigen-presenting cells (APC) for 20 h and assaying the inter-
leukin-2 (1L-2) content of the culture supernatants.
Cytokine assays. IFN-y was measured by enzyme-linked immunosorbent
(ELISA) using the rat anti-mouse coating antibody R4-6A2 and biotinylated
detector antibody XMG12 pair (PharMingen. San Diego. Calif.). The binding of
bionnvlated antibody was detected with alkaline phosphatase-conjugated
streptavidin (Amersham) followed by p-mtropnenylphosphate (Sigma) at 1
mg/ml in Tris HQ buffer (pH 9.6) as the substrate. Optical density at 405 nm of
the product was measured with a Bio-rad ELISA reader. Recombinant murine
IFN-y (PharMingen) was used to construct a standard curve.
IL-2 was measured in supernatants from the IL-2-dependent cell line CTLL-2.
Briefly. 5 x 103 CTLL-2 (American Type Culture Collection) cells in 50 m-1 were
incubated with 50 pJ of test supernatant in triplicate for 24 h. and proliferation
was measured over the last 6 h by pulsing with [3H)thymidine (0.5 p.Ci/well;
Amersham), harvesting the contents of each well onto glass fiber mats, and
determining the incorporation of 3H in a Betapiate liquid scintillation counter
(Wailac).
ELISA for specific antibodies. Der pi peptide 111-139 (5 p-g/ml) was coated
onto Maxisorp microtiter plates (Nunc) in bicarbonate coaung buffer (Sigma)
overnight at 4°G After blocking (1 h, Tris-buffered saiine-1% bovine serum
albumin) and washing, serum dilutions were incubated in duplicate for 2 h at
37"C. After washing, the amount of specific immunoglobulin (IgG) isotypes
bound was detected with alkaline phosphatase-conjugated rat anti-mouse IgGl
and lgG2a (PharMingen) for 1 h at 37°C. The enzyme substrate p-nitrophe-
nylphosphate was added, and the soluble product was measured as described for
the cytokine ELISAs.
Isolation of CD4" and CD8"*" cells. CD4" and CD8* T cells were isolated
from lymph node cells from immunized mice by immunomagnetic selection.
After incubation with biotinylated anti-CD4 (GK1.5; PharMingen) or anti-CD8
(clone SKI; Becton Dickinson, Oxford. United Kingdom), cells were incubated
with streptavidin-conjugated microbeads (Miltenyi Biotec) (25) and selected by
using the MACS system (Miltenyi Biotec). Positively isolated fractions were
collected, and the efficiency of the separation was cross-checked by staining with
rat anti-mouse CD4 conjugated to phycoerythrin (CT-CD4; Caltag, Buriingame,
Calif.), rat anti-mouse CD8 conjugated to phycoerythrin (clone 53-6.7; Sigma),
or fluorescein isothiocyanate-conjugated streptavidin (Amersham). Samples con¬
taining 10s cells from each of the stained fractions were analyzed on a Becton
Dickinson FACScan flow cytometer.
RESULTS
Construction and expression of chimeric SOD proteins. To
exploit the adjuvant activities of mycobacteria, a mycobacterial
antigen delivery system for high-level expression of epitopes
was developed by using the tetrameric SOD protein of M.
tuberculosis as a carrier. To incorporate short peptide se¬
quences into SOD. we targeted an outward-extending loop
(positions 52 to 59 [Fig. 1)) between two alpha helices in the
N-terminal domain (7) for several reasons. First, this domain
does not seem to be involved in the enzymatic activity or in the
interaction between the SOD monomers: second, the region
around amino acid 53 appears to be particularly variable be¬
tween different mycobacterial species, suggesting that variation
in amino acid sequence in this region does not influence the
structural and functional properties of the SOD molecule. We
constructed a plasmid (p23.1) in which a unique BamHl site
was introduced between codons 51 and 53 of M. tuberculosis
SOD. Expression of SOD was under the control of its native M.
tuberculosis promoter, and the plasmid contained a mycobac¬
terial origin of replication. This vector was subsequently used
for the insertion of a variety of peptides derived from heter¬
ologous antigens listed in Table 1.
Constructs were introduced into M. vaccae or BCG. and
expression was monitored by Coomassie brilliant blue staining,
I
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FIG. 2. Expression of chimeric SOD molecules. (A) Total protein analysis.
Sonicates fromM. vaccae recombinants expressingwild-type SOD (wt-SOD: lane
1), SOD-pl (lane 2), and SOD-p2 (lane 3) were fractionated by SDS-PAGE and
the gel was stained with Coomassie brilliant blue. Recombinant (r) SOD proteins
are seen as major bands. (B and CI Western blot analysis. Extracts from BCG (B)
and M. vaccae recombinants (C) were separated by SDS-PAGE transferred to
nitrocellulose, and stained with a monoclonal antibody to SOD. Lane 1, wild-type
SOD; lane 2. SOD-pl; lane 3, SOD-p2; lane 4, SOD-HA. The endogenous SOD
from BCG and M. vaccae SOD is seen in ail lanes (lower band). Sizes are
indicated in kilodaltons.
FIG. 1. Identification of a permissive loop in M. tuberculosis SOD. Inspection
of the crystal structure of the tetrameric M. tuberculosis SOD (A) identifies an
outward-extending loop centered on ammo acid residue 53. For epitope expres¬
sion. this region of the gene was engineered to contain a BamHl site. Oligonu¬
cleotides encoding appropriate epitopes were inserted at this site to construct a
series of chimeric SOD molecules. The structure of the one of the chimeric SOD
proteins, SOD-HA. containing peptide 126-138 of inriuenza virus HA. was
predicted via computer modelling (B) using the known structure of SOD and the
known structure of HA. The modelling was done with QUANTA (Molecular
Simulations Incorporated), using conventional loop-database search to find ho¬
mologous fragmentswith the appropriate distance-geometry to fit the framework
of the protein. The core SOD protein (Fig. 1A) is also present in the predicted
chimeric SOD-HA protein (Fig. IB), and the inserted epitope is in an extended
loop far from functional sites of the protein.
Western blotting, and enzyme activity. Figure 2A illustrates
expression of two chimeric SOD proteins in M. vaccae extracts
stained for total protein. The chimeric SOD proteins are
among the most prominent bands in the extracts, although the
expression levels are lower than that of the wild-type SOD
protein (lane 1). Densitometric scanning of gels after SDS-
PAGE indicated that the bands representing the chimeric
SOD proteins correspond to 2 to 10% of the total protein in M.
vaccae extracts.
The level of expression of recombinant proteins in BCG was
lower than that in M. vaccae and was visualized by Western
blot analysis using a monoclonal anybody specific for SOD.
Figures 2B and C compare the level of expression of control
SOD and three chimeric constructs in BCG and in M. vaccae.
In each case, the amount of recombinant protein was approx¬
imately fivefold higher in M. vaccae. The 23-kDa protein seen
in all lanes of Fig. 2B and C corresponds to the native SOD
enzyme present in BCG and in M. vaccae. respectively. Intro-
r SOD
M.vaccae SOD
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FIG. 3. SOD activity in nondenaturing gels. Sonicates from M. vaccae re¬
combinants were run on nondenaturing gels and stained for SOD enzyme activ¬
ity. Native SOD activity from M. vaccae is seen as the two lower bands present
in ail lanes. The variable upper bands represent a series of hybrid tetramers
formed by the recombinant (r) SOD. Lane 1. wild-type SOD; lane 2, SOD-OVA;
lane 3, SOD-pl; lane 4, SOD-p2; lane 5, SOD-HA.
duction of the same constructs into another rapidly growing
mycobacterium, the laboratory strain ofM. smegmatis. resulted
in levels of expression similar to those observed in BCG (data
not shown).
Assay of SOD activity in nondenaturing gels revealed that
the chimeric proteins were expressed as functional enzymes
(Fig. 3). As reported previously (35), expression of the wild-
type M. tuberculosis SOD in M. vaccae generated the M. tuber¬
culosis tetramer (the predominant top band seen in lane 1) as
well as a series of hybrid enzymes containing different combi¬
nations of M. tuberculosis and V. vaccae subunits. A similar
pattern was seen with the chimeric proteins, although differ¬
ences in size and charge led to altered mobility of the tetramers
during gel electrophoresis. These data suggest that the incor¬
poration of epitopes in the extended loop of SOD is tolerated
without having a major effect on enzyme activity or on the
ability to form tetramers. The structure of one of the SOD
chimera was predicted by computer modelling. Since the crys¬
tal structure of hemagglutinin (HA) of influenza virus is
known, the SOD-HA protein was chosen. Consistent with the
experimental data, comparison of the known structure of SOD
(Fig. 1A) with the predicted structure of SOD-HA (Fig. IB)
revealed that the folding of the active SOD core of the
SOD-HA protein is identical to that of the wild-type protein.
Antigenicity of the recombinant M. vaccae. Since mycobac¬
teria are potent inducers of cell-mediated immunity, we wished
to study T-cell responses to epitopes delivered by mycobacteria
as chimeric SOD proteins. Therefore, we focused on a con¬
struct that contains an immunodominant region from Der pi
(residues 111 to 139), one of the major allergens of house dust
mites, which encompasses well-characterized murine major
histocompatibility complex (MHC) class I- and class Il-re-
stricted T-cell epitopes (residues 111 to 1 IS and 113 to 127.
respectively) (14. 16. 17, 20). The antigenicity of the chimeric
SOD protein containing Der pi (111-139) expressed in M.
vaccae (Mv-pl) was examined by measuring its ability to stim¬
ulate two different murine CD4~ T-cell hybridomas recogniz¬
ing epitopes within the region from residues 111 to 139 of Der
pi. Both hybridoma 1BB8 (Fig. 4) and hybridoma AD2 (results
not shown) were activated by the presence of intact Mv-pl and.
to an even greater extent, by sonicated Mv-pl. In contrast,
preparations of control M. vaccae expressing wild-type SOD
(Mv-SOD) failed to stimulate any IL-2 production. These find¬
ings confirmed that the peptide expressed by Mv-pl was in a
form that could be recognized by peptide 111-139-specific
murine T cells. Comparison of the response to sonicated
Mv-pl and to peptide and estimation of the amount of peptide
in such a sonicate revealed that the antigenicity of a peptide
delivered by M. vaccae is similar to that of the peptide itself.
Immunogenicity of recombinant M. vaccae. The immunoge-
nicity of Mv-pl was tested by s.c. immunization of C57BL/6J









FIG. 4. Recognition ofM. vaccae recombinants by T-cell hybridoraa. Murine
T-cell hybridoma 1BB8 specific for Der pi(l 11—139) was cultured in the pres¬
ence of APC with sonicated or intact heat-killed Mv-pl (filled and open circles,
respectively) and sonicated Mv-SOD (open triangles), and supernatants were
tested for IL-2, using the CTTL-2 cell line. Only the recombinant expressing the
specific peptide stimulated the cells. For comparison, supernatant from the same
hybridoma stimulated with 0.1 plM synthetic peptide produced 93 x 103 cpm in
the IL-2 assay.
mice with 5 x 108 (500 q.g) heat-killed Mv-pl bacilli without
adjuvant. A heat-killed preparation was used for two reasons.
First, heat-killed M. vaccae is clinically applicable in humans,
and second, M. vaccae is not believed to survive after immu¬
nization, suggesting no extra benefit for the use of viable bac¬
teria. Five days later, draining lymph nodes were isolated and
T-cell responses were evaluated by measuring IFN-y produc¬
tion and proliferation in response to in vitro stimulation with
peptide 111-139. Immunization with Mv-pl resulted in the
production of high levels of peptide-specific IFN-y by lymph
node cells in culture (Fig. 5A) and peptide-specific prolifera¬
tion (data not shown). This finding demonstrates that the pep¬
tide is immunogenic when presented in vivo as an SOD chi¬
mera delivered by M. vaccae. A control immunization with 5 x
10® heat-killed Mv-SOD did not result in peptide-specific
IFN-y responses. However, when a soluble extract ofM. vaccae
was used as an antigen, an equally strong IFN-y response was
observed in mice immunized with either Mv-pl or Mv-SOD.
Peptide 111-139 of Der pi can also be recognized by B cells.
Therefore, mice were immunized twice with a 3-week interval
with 5 x 108 heat-killed or Mv-pl or with control Mv-SOD.
Serum samples were collected 10 days after boost and tested
for the presence of peptide 111-139-specific IgGl and IgG2a.
No IgGl was detectable. IgG2a titers between 30 and 100 were
measured in mice that received Mv-pl. No peptide-specific
antibodies were detectable in sera derived from control immu¬
nized mice. This finding indicates that it is possible to induce
antibody responses by using the mycobacterial system for the
delivery of this particular peptide, although this induction is
very inefficient.
CD4+ versus CD8"*" T cells as the source of IFN-y. Since
peptide 111-139 of Der pi contains both a CD4 and a CD8
epitope, the cell type responsible for peptide-induced IFN-y
production was studied in more detail. CD4- and CD8-en-
riched cell populations were prepared by immunomagnetic
fractionation of lymph node cells from mice inoculated 5 days
previously with 5 x 108 heat-killed Mv-pl. By flow cytometry,
the proportion of CD4"*" cells in the CD8"" fraction and the
proportion of CD8~ cells in the CD4^ fraction were routinely
less than 2%. As shown in Fig. 5B, culture with Der pi peptide
resulted in production of IFN-y by unfractionated lymph node
ceils and by CD4^ cells (in the presence of syngeneic APC).
No IFN-y was produced by CD8"'" ceils incubated with Der pi
peptide 111-139 or with peptide 111-119, which encompasses
the CD8 epitope.
DISCUSSION
The expression of foreign antigens in recombinant mycobac¬
teria is attractive as a strategy for vaccine production and more
generally as an approach to probing mycobacterial interactions
with the immune system. The fact that exogenous proteins are
often expressed at low levels in mycobacteria imposes an im¬
portant limitation on development of this approach. We have














FIG. 5. Immunogenicity of M. vaccae recombinants. Mice were immunized s.c. once with Mv-pl or Mv-SOD, and antigen-specific cytokine responses were
monitored 5 days later in inguinal lymph node cells. (A) Lymph node cells (4 x 1CP ceils/well) from mice immunized with Mv-pl produced IFN-y when incubated with
specific peptide or with M. vaccae extract (2.5 wg protein/well). Ceils from mice immunized with control Mv-SOD responded only to ihe M. vaccae antigen. (8) Lymph
node cells were fractionated into CD4* and CD8~ populations and incubated (2 x 10s cells/well plus 3 x 103 irradiated APOwell) in the presence or absence of specific
peptide. IFN-y production was observed only with the CD4" population.
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repertoire of epitopes that can be delivered by mycobacteria.
We selected a native mycobacterial protein, SOD from M.
tuberculosis, as a carrier protein based on its high level of
expression and known crystal structure. While differences were
observed in the level of expression of different peptides (Table
1), the SOD expression system was found to be broadly appli¬
cable to a wide range of epitopes, and we have been able to
express chimeric SOD proteins containing as many as 60 amino
acids. The success of this expression system is probably due to
the inherent high level of expression and stability of the SOD
molecule and the fact that the point of peptide insertion does
not significantly disrupt assembly of the functionally active
tetrameric enzyme. Expression of all tested chimeric proteins
was higher in M. vaccae than in BCG, an effect that could be
due to differences in promoter activity, plasmid copy number,
or proteolytic activity between the two strains. In addition,
expression of the endogenous M. vaccae and BCG SOD pro¬
teins in the two strains might interfere with expression of the
plasmid-encoded chimeric SOD to differing extents.
A construct in which an immunodominant peptide from a
major house dust mite allergen (Der pi) was expressed as a
chimeric SOD protein in M. vaccae was selected for detailed
immunological characterization. Intact or sonicated bacteria
were recognized by murine T-ceil hybridomas specific for the
peptide, demonstrating that the chimeric SOD is available for
antigen processing and presentation. More efficient recogni¬
tion of sonicated extracts suggests that there may be differ¬
ences in processing between the intact and disintegrated my¬
cobacteria. These differences could be related to an inability of
irradiated spleen cells to process intact mycobacteria, or per¬
haps to a difference in kinetics of processing. Immunization
experiments demonstrated that recombinant mycobacteria
were also able to induce a specific T-cell response to the Der
pi peptide in vivo, as assessed by IFN-y production by lymph
node cells. Since peptide 111-139 contains both a CD4 and a
CD8 epitope (14), T-cell separation experiments were per¬
formed to determine the phenotype of the responding ceils.
These experiments, together with aytotoxicity assays (not
shown), demonstrated the response to be exclusively attribut¬
able to CD4"** T cells, suggesting that antigen presentation
occurs only via MHC class II molecules.
Experiments with transgenic mice lacking the ^-micro¬
globulin gene have demonstrated that T-cell responses re¬
stricted by MHC class I molecules play an important role in
protection against M. tuberculosis infection (10), and recent in
vitro experiments suggest that mycobacterial species differ in
the ability to deliver antigens by this route (24). .An important
application of the expression system described here is that it
will allow us to compare the ability of different mycobacteria to
deliver the same antigen to the immune system. We are cur¬
rently evaluating the immunogenicity of the recombinant BCG
constructs with a view to comparison with M. vaccae and in
some cases with virulent M. tuberculosis. This strategy provides
an approach to identifying microbial factors involved in immu¬
nogenicity and may also allow us to select vaccine candidates
with particular immunological profiles. We are also using a
peptide approach to analyze the immunogenicity of an identi¬
cal epitope expressed in a cytoplasmic (SOD) compared to a
membrane-associated carrier protein in mycobacteria. An¬
other application of this mycobacterial expression system is the
use of such recombinants for immunomodulation. As myco¬
bacteria are especially capable of inducing Thl cell develop¬
ment. characterized by the production of high levels of IFN-y
and IL-2. it may be possible to use constructs expressing
epitopes of allergens for modulation of allergen-specific Th2
ceil responses, characterized by the production of high levels of
IL-4 and IL-5. However, for this purpose the exact nature of
T-ceil responses raised with recombinant mycobacteria ex¬
pressing epitopes of allergens has to be evaluated in more
detail.
Diversity in the repertoire of peptides presented by differ¬
ent MHC molecules represents an obvious limitation to an
epitope-based approach to therapeutic vaccine development.
In the SOD expression system, it may be possible to address
this problem in part by insertion of multiple epitopes within a
single chimeric construct. The repertoire could be expanded
further by expressing tetrameric proteins comprised of differ¬
ent recombinant monomers. For broader application, the
epitope system could be used for initial experimental identifi¬
cation of a mycobacterial host strain with appropriate immu¬
nogenic properties, with a view to subsequent optimization of
specific strategies for stable expression of each whole antigen
molecule.
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